<SEC-DOCUMENT>0001683168-24-007103.txt : 20241011
<SEC-HEADER>0001683168-24-007103.hdr.sgml : 20241011
<ACCEPTANCE-DATETIME>20241011163619
ACCESSION NUMBER:		0001683168-24-007103
CONFORMED SUBMISSION TYPE:	POS AM
PUBLIC DOCUMENT COUNT:		71
FILED AS OF DATE:		20241011
DATE AS OF CHANGE:		20241011

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aclarion, Inc.
		CENTRAL INDEX KEY:			0001635077
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				473324725
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		POS AM
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-276648
		FILM NUMBER:		241367948

	BUSINESS ADDRESS:	
		STREET 1:		8181 ARISTA PLACE
		STREET 2:		STE 100
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		833 275 2266

	MAIL ADDRESS:	
		STREET 1:		8181 ARISTA PLACE
		STREET 2:		STE 100
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nocimed, Inc.
		DATE OF NAME CHANGE:	20150226
</SEC-HEADER>
<DOCUMENT>
<TYPE>POS AM
<SEQUENCE>1
<FILENAME>aclarion_posam2.htm
<DESCRIPTION>POST EFFECTIVE AMENDMENT NO. 2 TO FORM S-1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:ACON="http://aclarion.com/20240630">
<head>
     <title>Aclarion POS AM</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_033_ACON_aclarion.com_20240630 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20240101_20240630 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DAmendmentDescription_Updated S%2D1 -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DDocumentFiscalYearFocus_2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DDocumentFiscalPeriodFocus_Q2 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DAmendmentFlag_true -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DEntityCentralIndexKey_0001635077 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000003" name="dei:AmendmentDescription">Updated S-1</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000004" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000005" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000006" name="dei:AmendmentFlag">true</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000007" name="dei:EntityCentralIndexKey">0001635077</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesA1A2A3A4Member" id="xdx2ixbrl0280" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesBB1Member" id="xdx2ixbrl0281" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesB2B3Member" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:ProceedsFromSaleOfSeriesPreferredStock" contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesA1A2A3A4Member" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:ProceedsFromSaleOfSeriesPreferredStock" contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesBB1Member" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:ProceedsFromSaleOfSeriesPreferredStock" contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesB2B3Member" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:RedemptionOfSeriesPreferredStock" contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesA1A2A3A4Member" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:RedemptionOfSeriesPreferredStock" contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesBB1Member" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:RedemptionOfSeriesPreferredStock" contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesB2B3Member" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesA1A2A3A4Member" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesBB1Member" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesB2B3Member" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesA1A2A3A4Member" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesBB1Member" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesB2B3Member" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:CommitmentSharesNoteFinancing" contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:CommitmentSharesNoteFinancing" contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesA1A2A3A4Member" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:CommitmentSharesNoteFinancing" contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesBB1Member" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:CommitmentSharesNoteFinancing" contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesB2B3Member" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:CommitmentSharesNoteFinancingShares" contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0326" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfWarrantsNoteFinancing" contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfWarrantsNoteFinancing" contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesA1A2A3A4Member" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfWarrantsNoteFinancing" contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesBB1Member" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfWarrantsNoteFinancing" contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesB2B3Member" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesA1A2A3A4Member" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesBB1Member" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesB2B3Member" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesA1A2A3A4Member" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesBB1Member" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesB2B3Member" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0369" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesA1A2A3A4Member" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesBB1Member" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesB2B3Member" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0374" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommonSharesEquityLineOfCredit" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0376" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommonSharesEquityLineOfCredit" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesA1A2A3A4Member" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommonSharesEquityLineOfCredit" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesBB1Member" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommonSharesEquityLineOfCredit" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesB2B3Member" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommonSharesEquityLineOfCreditShares" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0381" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommitmentSharesNoteFinancing" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommitmentSharesNoteFinancing" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesA1A2A3A4Member" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommitmentSharesNoteFinancing" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesBB1Member" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommitmentSharesNoteFinancing" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesB2B3Member" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommitmentSharesNoteFinancingShares" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0388" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="ACON:CashlessExerciseOfPrefundedWarrant" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:CashlessExerciseOfPrefundedWarrant" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesA1A2A3A4Member" id="xdx2ixbrl0391" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:CashlessExerciseOfPrefundedWarrant" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesBB1Member" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:CashlessExerciseOfPrefundedWarrant" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesB2B3Member" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:CashlessExerciseOfPrefundedWarrantsShares" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0395" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesA1A2A3A4Member" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesBB1Member" id="xdx2ixbrl0399" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesB2B3Member" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0402" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="ACON:PublicOfferingAndLineOfCreditIssuanceCosts" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:PublicOfferingAndLineOfCreditIssuanceCosts" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesA1A2A3A4Member" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:PublicOfferingAndLineOfCreditIssuanceCosts" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesBB1Member" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:PublicOfferingAndLineOfCreditIssuanceCosts" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesB2B3Member" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommonSharesDebtForEquityExchange" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommonSharesDebtForEquityExchange" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesA1A2A3A4Member" id="xdx2ixbrl0410" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommonSharesDebtForEquityExchange" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesBB1Member" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommonSharesDebtForEquityExchange" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesB2B3Member" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommonSharesDebtForEquityExchangeShares" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0414" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="ACON:RoundUpConversionRelatedToReverseStockSplit" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:RoundUpConversionRelatedToReverseStockSplit" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesA1A2A3A4Member" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:RoundUpConversionRelatedToReverseStockSplit" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesBB1Member" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:RoundUpConversionRelatedToReverseStockSplit" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesB2B3Member" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:RoundUpConventionRelatedToReverseStockSplitShares" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0421" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesA1A2A3A4Member" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesBB1Member" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesB2B3Member" id="xdx2ixbrl0426" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0441" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesA1A2A3A4Member" id="xdx2ixbrl0442" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesBB1Member" id="xdx2ixbrl0443" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesB2B3Member" id="xdx2ixbrl0444" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesA1A2A3A4Member" id="xdx2ixbrl0447" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesBB1Member" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesB2B3Member" id="xdx2ixbrl0449" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommonSharesEquityLineOfCredit" contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommonSharesEquityLineOfCredit" contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesA1A2A3A4Member" id="xdx2ixbrl0452" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommonSharesEquityLineOfCredit" contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesBB1Member" id="xdx2ixbrl0453" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommonSharesEquityLineOfCredit" contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesB2B3Member" id="xdx2ixbrl0454" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesAMember" id="xdx2ixbrl0456" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesA1A2A3A4Member" id="xdx2ixbrl0457" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesBB1Member" id="xdx2ixbrl0458" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesB2B3Member" id="xdx2ixbrl0459" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0481" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:ProceedsFromSaleOfSeriesPreferredStock" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0486" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:ProceedsFromSaleOfSeriesPreferredStock" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0487" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:ProceedsFromSaleOfSeriesPreferredStock" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0488" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:RedemptionOfSeriesPreferredStock" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0491" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:RedemptionOfSeriesPreferredStock" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0492" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:RedemptionOfSeriesPreferredStock" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0493" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0497" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0508" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0510" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:CommitmentSharesNoteFinancing" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0513" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:CommitmentSharesNoteFinancing" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0515" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfWarrantsNoteFinancing" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0520" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfWarrantsNoteFinancing" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0522" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0525" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0526" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0544" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0546" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0549" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0550" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0551" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0552" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommonSharesEquityLineOfCredit" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommitmentSharesNoteFinancing" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0563" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommitmentSharesNoteFinancing" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0565" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:CashlessExerciseOfPrefundedWarrant" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0570" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:CashlessExerciseOfPrefundedWarrant" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0571" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:CashlessExerciseOfPrefundedWarrant" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0572" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:CashlessExerciseOfPrefundedWarrant" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0573" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0579" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:PublicOfferingAndLineOfCreditIssuanceCosts" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0584" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:PublicOfferingAndLineOfCreditIssuanceCosts" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0586" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommonSharesDebtForEquityExchange" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0591" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:RoundUpConversionRelatedToReverseStockSplit" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0596" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:RoundUpConversionRelatedToReverseStockSplit" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0597" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:RoundUpConversionRelatedToReverseStockSplit" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0598" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:RoundUpConversionRelatedToReverseStockSplit" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0599" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0603" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0604" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0615" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0617" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0620" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0621" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0622" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-012024-06-30" id="xdx2ixbrl0623" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ACON:IssuanceOfCommonSharesEquityLineOfCredit" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0629" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0634" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0635" unitRef="USD" xs:nil="true"/>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="acon-20240630.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PreferredStockSeriesAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PreferredStockSeriesA1A2A3A4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesA1A2A3A4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PreferredStockSeriesBB1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesBB1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PreferredStockSeriesB2B3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesB2B3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_PreferredStockSeriesAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_PreferredStockSeriesA1A2A3A4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesA1A2A3A4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_PreferredStockSeriesBB1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesBB1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_PreferredStockSeriesB2B3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesB2B3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PreferredStockSeriesAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PreferredStockSeriesA1A2A3A4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesA1A2A3A4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PreferredStockSeriesBB1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesBB1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PreferredStockSeriesB2B3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesB2B3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_PreferredStockSeriesAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_PreferredStockSeriesA1A2A3A4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesA1A2A3A4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_PreferredStockSeriesBB1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesBB1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_PreferredStockSeriesB2B3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesB2B3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_PreferredStockSeriesAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_PreferredStockSeriesA1A2A3A4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesA1A2A3A4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_PreferredStockSeriesBB1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesBB1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_PreferredStockSeriesB2B3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesB2B3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_PreferredStockSeriesAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_PreferredStockSeriesA1A2A3A4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesA1A2A3A4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_PreferredStockSeriesBB1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesBB1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_PreferredStockSeriesB2B3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesB2B3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_PreferredStockSeriesA1A2A3A4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesA1A2A3A4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_PreferredStockSeriesBB1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesBB1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_PreferredStockSeriesB2B3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesB2B3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_custom_PreferredStockSeriesAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_custom_PreferredStockSeriesA1A2A3A4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesA1A2A3A4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_custom_PreferredStockSeriesBB1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesBB1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_custom_PreferredStockSeriesB2B3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesB2B3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_PreferredStockSeriesAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_PreferredStockSeriesA1A2A3A4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesA1A2A3A4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_PreferredStockSeriesBB1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesBB1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_PreferredStockSeriesB2B3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesB2B3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_PreferredStockSeriesAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_PreferredStockSeriesA1A2A3A4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesA1A2A3A4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_PreferredStockSeriesBB1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesBB1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_PreferredStockSeriesB2B3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesB2B3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-01-31_custom_StockSplit2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ACON:StockSplit2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_Pre2024SplitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ACON:Pre2024SplitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_Post2024SplitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ACON:Post2024SplitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PreSplitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ACON:PreSplitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PostSplitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ACON:PostSplitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-012024-02-29_us-gaap_IPOMember_custom_CompletionOfPublicOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ACON:CompletionOfPublicOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-01</xbrli:startDate>
        <xbrli:endDate>2024-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_IPOMember_custom_CompletionOfIssuanceOfSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ACON:CompletionOfIssuanceOfSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_WarrantLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:WarrantLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_custom_WarrantLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:WarrantLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_custom_WarrantLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:WarrantLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:WarrantLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_DerivativeLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:DerivativeLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_custom_DerivativeLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:DerivativeLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_custom_DerivativeLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:DerivativeLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_custom_DerivativeLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:DerivativeLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_WarrantLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:WarrantLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_DerivativeLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:DerivativeLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_WarrantLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:WarrantLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_DerivativeLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:DerivativeLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_WarrantLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:WarrantLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_WarrantLiabilityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:WarrantLiabilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_WarrantLiabilityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:WarrantLiabilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_ShortTermDepositsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:ShortTermDepositsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ShortTermDepositsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:ShortTermDepositsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_DeferredOfferingCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:DeferredOfferingCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_DeferredOfferingCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:DeferredOfferingCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_PrepaidInsuranceDAndOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:PrepaidInsuranceDAndOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PrepaidInsuranceDAndOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:PrepaidInsuranceDAndOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_PrepaidInsuranceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:PrepaidInsuranceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PrepaidInsuranceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:PrepaidInsuranceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_PrepaidClinicalCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:PrepaidClinicalCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PrepaidClinicalCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:PrepaidClinicalCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_PrepaidExchangeFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:PrepaidExchangeFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PrepaidExchangeFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:PrepaidExchangeFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_PrepaidOtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:PrepaidOtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PrepaidOtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:PrepaidOtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_OtherReceivablesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:OtherReceivablesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_OtherReceivablesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:OtherReceivablesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AccountsPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AccountsPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_CreditCardsPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:CreditCardsPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CreditCardsPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:CreditCardsPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_AccruedPayrollMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:AccruedPayrollMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AccruedPayrollMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:AccruedPayrollMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_AccruedBonusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:AccruedBonusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AccruedBonusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:AccruedBonusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_DAndOFinancingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:DAndOFinancingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_DAndOFinancingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:DAndOFinancingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_AccruedAuditAndLegalExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:AccruedAuditAndLegalExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AccruedAuditAndLegalExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:AccruedAuditAndLegalExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_AccruedInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:AccruedInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AccruedInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:AccruedInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_AccruedBoardCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:AccruedBoardCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AccruedBoardCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:AccruedBoardCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_OtherAccruedLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:OtherAccruedLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_OtherAccruedLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:OtherAccruedLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_PatentsAndLicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ACON:PatentsAndLicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PatentsAndLicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ACON:PatentsAndLicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_OtherIntangibleAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_OtherIntangibleAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_custom_SeniorNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ACON:SeniorNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-012023-05-31_custom_SeniorNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ACON:SeniorNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_SeriesBNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ACON:SeriesBNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-012023-09-30_custom_SeriesBNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ACON:SeriesBNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-30_custom_SeriesCNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ACON:SeriesCNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-012023-11-30_custom_SeriesCNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ACON:SeriesCNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-01</xbrli:startDate>
        <xbrli:endDate>2023-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-012023-11-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-01</xbrli:startDate>
        <xbrli:endDate>2023-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_custom_SeniorNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ACON:SeniorNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_SeniorNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ACON:SeniorNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-222024-01-29_custom_ExchangeAgreementsMember_custom_AccreditedInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ACON:ExchangeAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ACON:AccreditedInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-22</xbrli:startDate>
        <xbrli:endDate>2024-01-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-01-31_custom_ExchangeAgreementsMember_custom_AccreditedInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ACON:ExchangeAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ACON:AccreditedInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-052024-03-06_custom_UnsecuredNonConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">ACON:UnsecuredNonConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-05</xbrli:startDate>
        <xbrli:endDate>2024-03-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-06_custom_UnsecuredNonConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">ACON:UnsecuredNonConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_UnsecuredNonConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">ACON:UnsecuredNonConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_RegentsOfTheUniversityOfCaliforniaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ACON:RegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_custom_RegentsOfTheUniversityOfCaliforniaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ACON:RegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_RegentsOfTheUniversityOfCaliforniaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ACON:RegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_RegentsOfTheUniversityOfCaliforniaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ACON:RegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_RegentsOfTheUniversityOfCaliforniaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ACON:RegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-232024-03-24_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-23</xbrli:startDate>
        <xbrli:endDate>2024-03-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-232024-03-24_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-23</xbrli:startDate>
        <xbrli:endDate>2024-03-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012023-02-28_custom_ExecutiveChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ACON:ExecutiveChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2023-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-262024-02-27_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-26</xbrli:startDate>
        <xbrli:endDate>2024-02-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-27_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-082023-10-09_custom_WhiteLionEquityLineAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ACON:WhiteLionEquityLineAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-08</xbrli:startDate>
        <xbrli:endDate>2023-10-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-242024-04-26_custom_WhiteLionEquityLineAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ACON:WhiteLionEquityLineAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-24</xbrli:startDate>
        <xbrli:endDate>2024-04-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_WhiteLionEquityLineAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ACON:WhiteLionEquityLineAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_WarrantStrikePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_WarrantStrikePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_WarrantStrikePrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_WarrantStrikePrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_WarrantStrikePrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePrice2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_WarrantStrikePrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePrice2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_WarrantStrikePrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePrice3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_WarrantStrikePrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePrice3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_WarrantStrikePrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePrice4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_WarrantStrikePrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePrice4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_WarrantStrikePrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePrice5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_WarrantStrikePrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePrice5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_WarrantStrikePrice6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePrice6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_WarrantStrikePrice6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePrice6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ACON:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ACON:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_RestrictedStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ACON:RestrictedStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_RestrictedStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ACON:RestrictedStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ACON:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ACON:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-21_custom_AclarionEquityIncentivePlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ACON:AclarionEquityIncentivePlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AclarionEquityIncentivePlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ACON:AclarionEquityIncentivePlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_NonVestedStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:NonVestedStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_NonVestedStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:NonVestedStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_SellingAndMarketingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_SellingAndMarketingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_SellingAndMarketingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_SellingAndMarketingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact001238" toRefs="Footnote001291"/>
  <ix:relationship fromRefs="Fact001240" toRefs="Footnote001291"/>
  <ix:relationship fromRefs="Fact001242" toRefs="Footnote001291"/>
  <ix:relationship fromRefs="Fact001244" toRefs="Footnote001291"/>
  <ix:relationship fromRefs="Fact001261" toRefs="Footnote001292"/>
  <ix:relationship fromRefs="Fact001263" toRefs="Footnote001292"/>
  <ix:relationship fromRefs="Fact001265" toRefs="Footnote001292"/>
  <ix:relationship fromRefs="Fact001267" toRefs="Footnote001292"/>
  <ix:relationship fromRefs="Fact001268" toRefs="Footnote001292"/>
  <ix:relationship fromRefs="Fact001270" toRefs="Footnote001292"/>
  <ix:relationship fromRefs="Fact001272" toRefs="Footnote001292"/>
  <ix:relationship fromRefs="Fact001274" toRefs="Footnote001292"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><a href="#s_001"><span style="font-size: 7pt">Table of Contents</span></a></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As filed with the Securities and Exchange
Commission on October 11, 2024</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Registration No. 333-276648</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">FORM <b>S-1/A</b> <b style="display: none"><span id="xdx_90A_edei--DocumentType_c20240101__20240630_zSNAu5zRzbDe"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000013" name="dei:DocumentType">POS AM</ix:nonNumeric></span></b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Post-Effective
Amendment No. 2</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>REGISTRATION STATEMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b><i>UNDER</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b><i>THE SECURITIES ACT
OF 1933</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-size: 12pt"><b><span id="xdx_90E_edei--EntityRegistrantName_c20240101__20240630_zmDltxFwS2Qf"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000014" name="dei:EntityRegistrantName">Aclarion,
Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">(Exact name of registrant
as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 32%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20240101__20240630_z2YFnJajz3Vk"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" format="ixt-sec:stateprovnameen" id="Fact000015" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 1%; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; width: 34%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8071</b></span></td>
    <td style="vertical-align: bottom; width: 1%; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; width: 32%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20240101__20240630_zGpeV3TZPtM6"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000016" name="dei:EntityTaxIdentificationNumber">47-3324725</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(State or other jurisdiction of</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">incorporation or organization)</p></td>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Primary Standard Industrial</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Classification Code Number)</p></td>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(I.R.S. Employer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Identification Number)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b><span id="xdx_906_edei--EntityAddressAddressLine1_c20240101__20240630_zZNvgqVNOuJ7"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000017" name="dei:EntityAddressAddressLine1">8181 Arista Place</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressAddressLine2_c20240101__20240630_z0U033Ng1NOh"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000018" name="dei:EntityAddressAddressLine2">Suite
100</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b><span id="xdx_908_edei--EntityAddressCityOrTown_c20240101__20240630_zTbhzCVWHZni"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000019" name="dei:EntityAddressCityOrTown">Broomfield</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressStateOrProvince_c20240101__20240630_zlRC3YPtuow"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" format="ixt-sec:stateprovnameen" id="Fact000020" name="dei:EntityAddressStateOrProvince">Colorado</ix:nonNumeric></span> <span id="xdx_909_edei--EntityAddressPostalZipCode_c20240101__20240630_zDAH88045CHd"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000021" name="dei:EntityAddressPostalZipCode">80021</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>(<span id="xdx_905_edei--CityAreaCode_c20240101__20240630_zeZud3WMq4Z5"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000022" name="dei:CityAreaCode">833</ix:nonNumeric></span>) <span id="xdx_90A_edei--LocalPhoneNumber_c20240101__20240630_z26tWkKrIURc"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000023" name="dei:LocalPhoneNumber">275-2266</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">(Address, including zip code,
and telephone number, including area code, of registrant&#8217;s principal executive offices)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>John Lorbiecki</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>Chief Financial Officer</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>Aclarion, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>8181 Arista Place, Suite
100</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>Broomfield, Colorado 80021</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>(833) 275-2266</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">(Name, address, including
zip code, and telephone number, including area code, of agent for service)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b><i>Copies to:</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: middle">
    <td style="text-align: center; width: 50%">James H. Carroll, Esq.</td>
    <td style="text-align: center; width: 50%">Rachael M. Bushey, Esq.</td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: center">Carroll Legal LLC</td>
    <td style="text-align: center">Jennifer L. Porter, Esq.</td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: center">1449 Wynkoop Street, Suite 507</td>
    <td style="text-align: center">Justin S. Platt, Esq.</td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: center">Denver, CO 80202</td>
    <td style="text-align: center">Goodwin Procter LLP</td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: center">(303) 888-4859</td>
    <td style="text-align: center">2005 Market St, 32<span style="font: normal 400 10pt Times New Roman, Times, Serif"><sup>nd</sup> Floor,</span></td></tr>
  <tr>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: middle">Philadelphia, PA 19103</td></tr>
  <tr>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: middle">(445) 207-7805</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Approximate date of commencement of proposed sale
to the public: As soon as practicable after the effective date of this Registration Statement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">If any of the securities
being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, check
the following box.&#160;&#160;&#9746;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">If this Form is filed to
register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">If this Form is a post-effective
amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">If this Form is a post-effective
amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a&#160;non-accelerated&#160;filer, a smaller reporting company or
an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large&#160;accelerated&#160;filer</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 42%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated&#160;filer</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntityFilerCategory_c20240101__20240630_zOTJyG7cLBn1"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" format="ixt-sec:entityfilercategoryen" id="Fact000024" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller&#160;reporting&#160;company</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--EntitySmallBusiness_c20240101__20240630_zsBeJQXvPS83"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" format="ixt:booleantrue" id="Fact000025" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging&#160;growth&#160;company</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--EntityEmergingGrowthCompany_c20240101__20240630_zEKjC78zhBC"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" format="ixt:booleantrue" id="Fact000026" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 26.6pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.&#160;&#160;<span id="xdx_906_edei--EntityExTransitionPeriod_c20240101__20240630_zjdgAPYPM3A2"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" format="ixt:booleanfalse" id="Fact000027" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>The Registrant
hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant
shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in
accordance with Section 8(a) of the Securities Act of 1933, as amended, or until this Registration Statement shall become effective
on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red; text-align: justify"><b>The information contained in this preliminary
prospectus is not complete and may be changed. Neither we nor the selling securityholder may sell these securities until the registration
statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities
and is not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 50%; font-size: 10pt"><span style="font-size: 10pt; color: Red"><b>Preliminary Prospectus</b></span></td>
    <td style="width: 50%; font-size: 10pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red">Subject
                                            to Completion, dated October 11, 2024</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ACLARION, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>Up to 1,450,000
Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This prospectus
relates to the offering and resale by White Lion Capital LLC (&#8220;White Lion&#8221; or the &#8220;Selling Securityholder&#8221;) of
up to 1,450,000 shares of our common stock, par value $0.00001 per share. This registration statement does not register additional shares
of our common stock. This registration statement, initially filed with the Securities and Exchange Commission on January 22, 2024, registered
up to 2,500,000 shares of common stock. As of the date of this registration statement amendment, 1,050,000 of such shares of common stock
have been sold under this registration statement and 1,450,000 shares remain unsold. As of the date of this filing, a total of 1,800,000
shares of common stock have been sold under the Purchase Agreement (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares of common stock being offered by the
Selling Securityholder have been or may be issued and sold to the Selling Securityholder pursuant to the purchase agreement (the &#8220;Purchase
Agreement&#8221;) effective as of October 9, 2023, that we entered into with White Lion. See &#8220;<a href="#s_007">The White Lion Transaction</a>&#8221;
for a description of the Purchase Agreement and &#8220;Selling Securityholder&#8221; for additional information regarding White Lion.
The prices at which White Lion may resell the shares offered hereby will be determined by the prevailing market price for the shares
or in negotiated transactions. We are not selling any securities under this prospectus and will not receive any of the proceeds from
the sale of shares of common stock by the Selling Securityholder. However, we may receive proceeds of up to $7.1 million from the sale
of our common stock to the Selling Securityholder pursuant to the Purchase Agreement, once the registration statement that includes this
prospectus is declared effective.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Securityholder may sell or otherwise
dispose of the shares of common stock described in this prospectus in a number of different ways and at varying prices. See &#8220;<a href="#s_018">Plan of Distribution</a>&#8221; for more information about how the Selling Securityholder may sell or otherwise dispose of the shares of common
stock being registered pursuant to this prospectus. The Selling Securityholder is an &#8220;underwriter&#8221; within the meaning of
Section&#160;2(a)(11) of the Securities Act of 1933, as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Securityholder will pay all brokerage
fees and commissions and similar expenses. We will pay the expenses (except brokerage fees and commissions and similar expenses) incurred
in registering the shares of common stock offered hereby, including legal and accounting fees. See &#8220;<a href="#s_018">Plan of Distribution</a>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our common stock
is listed on the Nasdaq Capital Market under the symbol &#8220;ACON.&#8221; On October 9, 2024 the closing price for our common stock,
as reported on the Nasdaq Capital Market, was $0.1746 per share. Our warrants offered in connection with our initial public offering
(the &#8220;IPO Warrants&#8221;) are quoted on the Nasdaq Capital Market under the symbol &#8220;ACONW.&#8221; The last reported sale
price of our IPO Warrants on the Nasdaq Capital Market on October 9, 2024 was $0.03 per IPO Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have received deficiency letters from The Nasdaq
Stock Market LLC (&#8220;Nasdaq&#8221;) that we are not in compliance with Nasdaq&#8217;s (i)&#160;minimum bid price requirement of at
least $1.00 per share (the &#8220;Bid Price Requirement&#8221;) and (ii) requirement to have at least $2,500,000 in stockholders&#8217;
equity (the &#8220;Stockholders&#8217; Equity Requirement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 8, 2024,
we received a written notice from Nasdaq indicating that the Company was not in compliance with the Bid Price Requirement set forth in
Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the &#8220;Bid Price Notice&#8221;). The Bid Price
Notice did not result in the immediate delisting of the Company&#8217;s common stock from the Nasdaq Capital Market. The Bid Price Notice
indicated that the Company will be provided 180 calendar days (or until October 7, 2024) in which to regain compliance. We did not regain
compliance with Rule 5550(a)(2) prior to the expiration of the initial 180 calendar day period on October 7, 2024. On October 8, 2024,
we received from the Nasdaq staff (the &#8220;Staff&#8221;) written notification that our securities are subject to delisting from the
Nasdaq Capital Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Company&#8217;s
special stockholders&#8217; meeting on September 23, 2024, the Company&#8217;s stockholders approved a proposal to grant discretionary
authority to our board of directors to (i) amend our certificate of incorporation to combine outstanding shares of our common stock into
a lesser number of outstanding shares, or a &#8220;reverse stock split,&#8221; at a specific ratio within a range of one-for-five (1-for-5)
to a maximum of a one-for-fifty (1-for-50) split, with the exact ratio to be determined by our board of directors in its sole discretion;
and (ii) effect the reverse stock split, if at all, within one year of the date the proposal was approved by stockholders. The Company
intends to implement a reverse stock split in the near future in order to assist with the Company&#8217;s compliance with Nasdaq&#8217;s
Bid Price Requirement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August
22, 2024, the Company received a letter from Nasdaq indicating that it was not in compliance with the Stockholders&#8217; Equity Requirement.
In its quarterly report on Form 10-Q for the period ended June 30, 2024, the Company reported stockholders&#8217; equity of $1,642,177,
and, as a result, did not satisfy Listing Rule 5550(b)(1). Accordingly, the Staff had determined to delist the Company&#8217;s common
stock from Nasdaq. Nasdaq&#8217;s letter provided us until August 29, 2024 to request an appeal of this determination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have appealed
both of these matters to a Nasdaq hearing panel (the &#8220;Panel&#8221;). The hearing request stays any suspension or delisting action
pending the conclusion of the hearing process and the expiration of any additional extension period granted by the Panel following the
hearing. We had an appeal hearing on October 10, 2024 before the Panel to appeal the delisting notices from the Staff. While the appeal
process is pending, the suspension of trading of the Company&#8217;s common stock will be stayed. Our common stock will continue to trade
on Nasdaq until the hearing process concludes and the Panel issues a written decision.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company
intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. The
Company is currently evaluating its available options to resolve the deficiency and regain compliance with the Stockholders&#8217; Equity
Requirement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The
Company&#8217;s receipt of these letters from Nasdaq does not affect the Company&#8217;s business, operations or reporting requirements
with the Securities and Exchange Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should read this prospectus, together with
additional information described under the headings &#8220;<a href="#s_021">Where You Can Find More Information</a>&#8221; carefully before you invest in
any of our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>INVESTING IN OUR SECURITIES INVOLVES RISKS.
SEE THE &#8220;<a href="#s_005">RISK FACTORS</a>&#8221; ON PAGE 18 OF THIS PROSPECTUS AND ANY SIMILAR SECTION CONTAINED IN ANY DOCUMENT INCORPORATED BY REFERENCE
HEREIN CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR SECURITIES.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Prospectus dated&#8195;&#8195;&#8195; &#8195;, 2024</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b><span id="s_001"></span>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Page</span></td></tr>
  <tr>
    <td style="vertical-align: top; width: 90%"><span style="font-size: 10pt"><a href="#s_002">Prospectus Summary</a></span></td>
    <td style="vertical-align: bottom; width: 10%; text-align: center"><span style="font-size: 10pt">1</span></td></tr>
  <tr>
    <td><span style="font-size: 10pt"><a href="#s_003">Market and Industry Data</a></span></td>
    <td style="text-align: center"><span style="font-size: 10pt">16</span></td></tr>
  <tr>
    <td><span style="font-size: 10pt"><a href="#s_004">The Offering</a></span></td>
    <td style="text-align: center"><span style="font-size: 10pt">17</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#s_005">Risk Factors</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">18</span></td></tr>
  <tr>
    <td><span style="font-size: 10pt"><a href="#s_006">Information Regarding Forward-Looking Statements</a></span></td>
    <td style="vertical-align: bottom; text-align: center">62</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#s_007">The White Lion Transaction</a></span></td>
    <td style="vertical-align: bottom; text-align: center">63</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#s_008">Use of Proceeds</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">64</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#s_009">Dividend Policy</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">65</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#s_010">Market Price of and Dividends on Common Equity and Related Stockholder Matters</a></span></td>
    <td style="vertical-align: bottom; text-align: center">65</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#s_011">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="vertical-align: bottom; text-align: center">66</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#s_012">Business</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">77</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#s_013">Management, Governance, Director Compensation, Executive Compensation</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">105</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#s_014">Certain Relationships and Related Party Transactions</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">116</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#s_015">Principal Stockholders</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">117</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#s_016">Description of Capital Stock</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">118</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#s_017">Selling Securityholder</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">123</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#s_018">Plan of Distribution</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">124</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#s_019">Legal Matters</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">126</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#s_020">Experts</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">126</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#s_021">Where You Can Find More Information</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">126</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#s_022">Index to Financial Statements</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-1</span></td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ABOUT THIS PROSPECTUS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The registration statement we filed with the
Securities and Exchange Commission (the &#8220;SEC&#8221;) includes exhibits that provide more detail of the matters discussed in this
prospectus. You should read this prospectus, the related exhibits filed with the SEC, and the documents incorporated by reference herein
before making your investment decision. You should rely only on the information provided in this prospectus and the documents incorporated
by reference herein or any amendment thereto. You should not assume that the information contained in this prospectus or any related
free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information
we have incorporated by reference herein is correct on any date subsequent to the date of the document incorporated by reference, even
though this prospectus or any related free writing prospectus is delivered, or securities are sold, on a later date. This prospectus
contains or incorporates by reference summaries of certain provisions contained in some of the documents described herein, but reference
is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents.
Copies of some of the documents referred to herein have been filed or have been incorporated by reference as exhibits to the registration
statement of which this prospectus forms a part, and you may obtain copies of those documents as described in this prospectus under the
heading &#8220;<a href="#s_021">Where You Can Find More Information</a>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on the information that we
have included or incorporated by reference in this prospectus and any related free writing prospectus that we may authorize to be provided
to you. Neither we, nor the Selling Securityholder, have authorized any dealer, salesman or other person to give any information or to
make any representation other than those contained or incorporated by reference in this prospectus or any related free writing prospectus
that we may authorize to be provided to you. You must not rely upon any information or representation not contained or incorporated by
reference in this prospectus or any related free writing prospectus. This prospectus and any related free writing prospectus do not constitute
an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor
does this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities
in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company was originally formed in Delaware
as Nocimed, LLC in January 2008. Nocimed, LLC, was converted to Nocimed, Inc., a Delaware corporation in February 2015&#160;. Our company
name was changed from &#8220;Nocimed, Inc.&#8221;, to &#8220;Aclarion, Inc.&#8221; on December 3, 2021. NOCIMED&#8482; -, NOCISCAN&#174;
-, NOCIGRAM&#8482; , NOCISCORE&#8482; -, NOCICALC&#8482; - MRS NOCI+&#8482; - NOCI-&#8482; -, NOCImild&#8482; -NOCIWEB&#8482; - SI-SCORE&#8482;,
VIRTUAL DISCOGRAM&#8482; - and the Nocimed logo are our trademarks. All other service marks, trademarks and trade names appearing in this
prospectus are the property of their respective owners. We do not intend our use or display of other companies&#8217; trade names, trademarks
or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies. When we refer to &#8220;Aclarion,&#8221;
&#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and the &#8220;Company&#8221; in this prospectus, we mean Aclarion, Inc., unless
otherwise specified. When we refer to &#8220;you,&#8221; we mean the potential holders of the applicable series of securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Solely for convenience, tradenames referred to
in this prospectus appear without the <sup>&#174;</sup> and <sup>&#8482;</sup> symbols, but those references are not intended to indicate,
in any way, that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert
its rights, to these tradenames.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>GLOSSARY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Unless otherwise indicated or the context otherwise requires, references
in this prospectus to the term:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#8220;AI&#8221; </b>means Artificial Intelligence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#8220;Category I Codes</b>&#8221; means numeric
codes that identify a procedure or service that is approved by the Food and Drug Administration (FDA), performed by healthcare professionals
nationwide, and is proven and documented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#8220;Category III Codes&#8221; are </b>CPT Category III codes that
are a set of temporary codes assigned to emerging technologies, services, and procedures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>CE mark&#8221;</b> is an administrative
marking with which a manufacturer or importer affirms its products are in conformity with European health, safety, and environmental
protection standards for products sold within the European Economic Area (EEA).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>"Covered Entity&#8221; </b>is a health care
provider or other person or entity who acquires and transmits private health information of patients, as covered under HIPAA and GDPR
regulations (see e.g. 45 CFR &#167;160.103).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#8220;CPT&#8221; </b>means &#8220;Current Procedural
Terminology&#8221;, and refers to a medical code set created and maintained by the American Medical Association (&#8220;AMA&#8221;) and
used by providers of healthcare services to bill insurance companies for their work. All new medical devices and services are required
to secure CPT codes to receive payment from government and private commercial payers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#8220;CT-Scan&#8221; </b>means a computerized
tomography (CT) scan combines a series of X-ray images taken from different angles around the body and uses computer processing to create
cross-sectional images (slices) of the bones, blood vessels and soft tissues inside the body. CT scan images provide more-detailed information
than plain X-rays do.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#8220;Cures Act&#8221; </b>means the 21<sup>st</sup> Century Cures
Act, signed into law on December 13, 2016, as Public Law No: 114-255.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify"><b>&#8220;DICOM&#8221; </b>means an acronym
for digital image communication, typically referring to standardized data architecture formats for managing, storing, and communicating
or transferring MRI images and other associated data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify"><b>&#8220;Disc&#8221; </b>means intervertebral
disc that is located between two vertebral body bones of the spine, where it is bordered by superior and inferior disc end-plate structures,
and comprises an inner disc nucleus between the two end-plates and that is a circumferentially surrounded by, and normally contained by,
and outer disc annulus that is normally a fibrous collagen-based connective tissue structure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#8220;DLBP&#8221; </b>means Discogenic Low Back Pain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#8220;DOC&#8221; </b>means &#8220;Declaration
of Conformity,&#8221; a document signed by us that declares that we have self-complied with applicable regulations for self-certifying
our CE Marking for our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#8220;Fusion&#8221; </b>means &#8220;Spinal Fusion&#8221;
which is surgery to permanently connect two or more vertebrae in the spine, eliminating motion between them.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#8220;GDPR&#8221; </b>means the General Data Protection
Regulation in the EU, originally effective May 25, 2018 and implemented in all local privacy laws across the EU and EEA region, to protect
a patient&#8217;s personally identifiable information (PII) and regulate how it must be collected, stored, and used by others, and in
certain situations applies concurrently with HIPAA requirements with respect to PII that is PHI for persons located in the EU and received
by companies or other persons or entities in the US.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#8220;IRB&#8221; </b>means Institutional Review
Board, which is typically an appointed board for reviewing and approving investigational clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#8220;Indications for Use&#8221; </b>means the
limited scope of the intended uses and related medical indications for appropriately using our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#8220;LBP&#8221; </b>means Lower Back Pain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#8220;Labeling&#8221; </b>means the scope of
intended &#8220;Indications for Use&#8221; that is identified with the commercial sale and use of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#8220;Lumbar Spine&#8221; </b>means the five
(5) lower vertebrae, L-1 to L-5.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#8220;<b>MR</b>&#8221; means Magnetic Resonance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#8220;<b>MRI</b>&#8221; means Magnetic Resonance Imaging.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8220;<b>MRS</b>&#8221; means Magnetic Resonance
Spectroscopy and is a type of pulse sequence used by MR scanners that, unlike MRI pulse sequences which generate images of tissue structures,
generates a &#8216;spectrum&#8217; with various peaks that represent different chemicals in the body tissue being examined, and which
allows for the quantitative measurement of the relative amounts of those chemicals in the examined tissues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#8220;Notified Body&#8221; </b>means an organization
designated by an EU country to assess the conformity of certain products before being placed on the market, as is required for certain
medical products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#8220;NIH&#8221; </b>means the United States
National Institutes of Health.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify"><b>&#8220;PD TEST&#8221; </b>means a Provocation
Discogram test which is a diagnostic test meant to confirm or exclude the intervertebral disc(s) as a source of back pain. This technique
involves puncture of the disc with a fine-gauge needle under fluoroscopic guidance and pressurization of the disc via the injection of
contrast media.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#8220;<b>PMA</b>&#8221; means Premarket Approval by the FDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify">&#8220;<b>QMS</b>&#8221; means Quality Management
System, which is a formalized system that documents processes, procedures, and responsibilities for achieving quality policies and objectives,
in particular to meet customer and regulatory requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#8220;Spectroscopy&#8221; </b>means the science
of deriving and evaluating a multi-peak spectrum for a material and in which different molecular bonds representing different components
of the material are represented by unique respective peaks at particular locations along the spectra, and with the different peaks typically
reflecting different resonant frequencies of the different components when subjected to a pulsed magnetic field; and in our current product,
relates to producing and evaluating spectra for the different chemical constituents of disc tissue as derived from MR pulse sequences
applied to those tissues for that chemical analysis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b><span id="s_002"></span>PROSPECTUS SUMMARY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The following summary highlights information
contained elsewhere in this prospectus. This summary is not complete and may not contain all the information you should consider before
investing in our common stock. You should read this entire prospectus carefully, especially the risks of investing in our common stock
discussed under the heading &#8220;<a href="#s_005">Risk Factors</a>,&#8221; and our financial statements and related notes in this prospectus
before making an investment decision. This prospectus includes forward-looking statements that involve risks and uncertainties. See &#8220;<a href="#s_006">Information
Regarding Forward-Looking Statements</a>.&#8221;</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Aclarion is a healthcare
technology company that leverages Magnetic Resonance Spectroscopy (&#8220;MRS&#8221;), and a proprietary biomarker to optimize clinical
treatments. Aclarion&#8217;s technology addresses the $134.5B U.S. low back and neck pain market, which according to a 2020 JAMA (Journal
of the American Medical Association) article is now the most costly healthcare condition in the United States. The Company is currently
utilizing Artificial Intelligence (&#8220;AI&#8221;) to assist in quality control processes that flag spectroscopy data indicative of
a poor MRS study. The use of AI in this application is early in its development cycle and is expected to evolve with further research
and development. The Company is also researching the application of AI and machine learning platforms to analyze both the raw spectroscopy
data and the post-processed signal to evaluate whether AI platforms can more efficiently and more effectively associate MRS data with
clinical outcomes. The use of AI in this application is aspirational and we intend this type of AI research and development to be an
ongoing process applied not only to the various treatment paths associated with back pain, such as conservative therapies, regenerative
and cell therapies and surgical intervention, but also to potentially expand into other clinical explorations involving the diagnosis
of brain, breast and prostate tumors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company, which has
limited sales to date, is addressing this market by initially focusing on improving the outcomes of surgical interventions to treat low
back pain. In this initial application, Aclarion technology is intended to assist surgeons in determining the optimal surgical procedure
for a patient undergoing surgery for pain isolated to their lumbar spine (the &#8220;lumbar spine&#8221; is comprised of the five (5)
lower vertebrae, L-1 to L-5). We then intend to add additional applications of our technology targeting the management of large segments
of low back pain patients from the point of initial Magnetic Resonance Imaging (&#8220;MRI&#8221;) through to episode resolution. We believe
this will expand the use of our technology to low back pain patients undergoing conservative therapies such as physical therapy or biologic
and cell therapies aimed at regenerating the lumbar discs. We plan to expand the application of our technology beyond the lumbar spine
to address neck pain populations in addition to low back pain populations. To expand the application of our technology for use in neck
pain populations, we will need to overcome technical changes associated with securing adequate MRS data from the cervical disc, which
is significantly smaller than the lumbar disc, and there can be no assurance the Company will be able to overcome these challenges.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The core technology
Aclarion employs is MRS. The patient experience when undergoing an MRS exam is exactly like that of a standard MRI, with the exception
of an additional 3-5 minutes for each disc undergoing a spectroscopy exam. Whereas a standard MRI produces a signal that is converted
into anatomical images, an MRS produces a signal that is converted into a waveform that identifies the chemical composition of tissues.
Just like with standard MRI&#8217;s, the data from spectroscopy is useless without technologies that can process the data. Aclarion has
developed proprietary signal processing software that transforms spectroscopy data into clear biomarkers. These biomarkers, which are
exclusively licensed from the Regents of University of California, San Francisco (&#8220;UCSF&#8221;), are the key data inputs for our
proprietary algorithms that, when applied, determine if an intervertebral disc is consistent with pain. Our patent portfolio includes
23 U.S. Patents, 17 Foreign Patents, 6 pending U.S. patent applications, and 7 pending Foreign patent applications, including
patents and patent applications exclusively licensed from Regents of the University of California.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We believe one of the biggest
issues driving the cost of treating low back and neck pain patients to the top of the list for healthcare spending is that there is no
objective, cost effective and noninvasive diagnostics to reliably identify the source of a patient&#8217;s pain. We believe the poor
surgical outcomes for Discogenic Low Back Pain (&#8220;DLBP&#8221;) are largely due to difficulties in reliably and accurately diagnosing
the specific spinal discs that are causing pain. The current primary diagnostic standard is the MRI, which is useful for showing abnormal
structures and tissue dehydration, but, we believe, cannot reliably identify specific discs that are causing pain. To diagnose specific
discs that are causing pain, a needle-based Provocation Discogram test (&#8220;PD Test&#8221;) has been developed. PD Tests have been
shown to be highly accurate when performed properly. However, a PD Test is invasive, subjective and unpleasant for the patient as the
patient needs to be awake in order to tell the physician if the pain the physician is purposefully causing in the disc is the same as
the pain the patient feels when they are experiencing a back pain episode. In addition, recent evidence has shown that the action of
inserting a needle into a normal disc during a discogram procedure leads to an increased rate of degeneration in these previously normal
discs. Based on the limitations and concerns of the PD Test, we believe there is a significant need for an objective, accurate, personalized
and noninvasive diagnostic test that can reliably determine if an individual disc is a pain generator. By providing physicians information
about whether a disc has the chemical and structural makeup consistent with pain or not, we believe the treatment plan for each patient
will lead to more efficient and targeted care that, will in turn, result in lower costs and healthier patient outcomes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Aclarion has taken the
first steps to demonstrate the potential use of our technology in helping to improve the outcome of surgical intervention for DLBP patients
by publishing a clinical study (Gornet et al) in the European Spine Journal in April 2019. The study illustrated that when all discs identified
as consistent with pain by our technology were included in a surgical treatment, 97% of the patients met the criteria for &#8220;clinical
improvement&#8221;. This compared to only 54% of patients meeting the criteria for clinical improvement if a disc that our technology
identified as consistent with pain, was not included in the surgical treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The results of this clinical
study led the CPT committee to approve four Category III codes for our technology in January 2021. The NIH also included our technology
as one of the handful of technologies selected to participate in their $150 million Back Pain Consortium (BACPAC) Research Program, an
NIH translational, patient-centered effort to address the need for effective and personalized therapies for chronic low back pain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In April 2023, Aclarion
advanced the evidence of our technology with a peer-reviewed journal article detailing the Gornet 2-year outcomes, published in the European
Spine Journal. The 2-year outcomes were durable with 1-year outcomes previously published in 2019. At 2-years follow-up, 85% of patients
improved when disc(s) identified as consistent with pain by our technology were included in a surgical treatment, compared to only 63%
of patients when disc(s) identified as consistent with pain were not treated or disc(s) identified as consistent without pain were treated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Aclarion Solution</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Evolving science coupled
with the understanding of degenerative painful discs has suggested that lumbar discs may become painful due to certain chemical changes,
which changes cannot be identified using standard lumbar MRI imaging. However, an application of MRI scanners Magnetic Resonance Spectroscopy
has been developed by manufacturers of MRI equipment. MRSs are different than MRIs. An MRI generates images of body structures, while
an MRS analyzes the relative amounts of various chemicals in body tissues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Aclarion has developed a
software application called NOCISCAN-LS&#174; which uses the existing MRS capabilities of many commercially available scanners to non-invasively
analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence
of chemical biomarkers that we, in conjunction with spine researchers at UCSF, have demonstrated to be associated with degenerative pain
and structural integrity of the lumbar discs. After processing the MRS exam data, we send the ordering clinician a report that details
how to interpret the results of the MRS exam. We believe these results help clinicians make quicker and more informed decisions about
which lumbar discs are painful, and which are not. We believe the ordering clinician can use this information to determine the optimal
treatment plan for an individual patient.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">NOCISCAN is entirely
non-invasive and only briefly extends an otherwise standard MRI exam. The MRI scan is the most frequently used type of pulse sequence
for operating Nuclear Magnetic Resonance (NMR) scanners. It uses a powerful magnet to apply a pulsed magnetic field to a patient, sensors
to detect radio waves that emanate from the resonant vibrations of different chemicals in the body in response to that pulsed magnetic
field and a computer to create detailed images of tissue structures in the patient based on those detected chemical signals. Because water
and fat are the most prevalent chemicals in the body, standard MRI images are typically based on the different levels of water and fat
between different tissues. MRS, however, is another type of pulse sequence that uses NMR scanners in a similar way as an MRI, but instead
of using the chemical resonances to create an image, MRS creates a spectrum for a tissue with different peaks that represent many different
chemicals, in addition to water and fat, in that tissue. The relative amounts of those chemicals can be calculated by measuring their
respective spectral peaks. While MRS has been used previously for diagnosing certain cancers (e.g. brain, breast, prostate) by measuring
unique chemical biomarkers for tumors, NOCISCAN uses MRS for measuring the relative levels of degenerative pain and structural integrity
biomarkers in discs. The relative levels of degenerative pain and structural integrity biomarkers are derived through the use of proprietary
post processing technologies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The platform used to
conduct a NOCISCAN involves: (i) an MRS exam of an intervertebral disc performed according to a proprietary protocol, (ii) a data transfer
portal to securely transfer data from the MRS exam to Aclarion&#8217;s cloud based post-processer technology, (iii) post-processor technology
that identifies biomarker peaks and leverages calculation tables that evaluate a number of ratios of biomarker peaks, where pain biomarkers
are in the numerator and structural biomarkers are in the denominator, and (iv) a final diagnostic report called a Nocigram that identifies
discs as painful or not.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="text-decoration: underline">NOCISCAN MRS Exam
Protocol.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We have developed a custom
software protocol and technique for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the
time of a standard lumbar MRI exam by an average of about 30 minutes for 5 lumbar discs. The custom protocol is a proprietary series of
settings and instructions for MRS to conduct the NOCISCAN exam to obtain optimal and reliable MRS data. This protocol is not a product
sold by the Company. The software protocol was created by Aclarion for insertion within a pre-existing software file format and is downloaded
onto the MRS by the MRS owner, for use within the MRS&#8217;s operating system environment. Currently, our software protocol is compatible
with only certain MRS models and operating systems available from SIEMENS, as those SIEMENS models specifically provide for user-defined
customizations available for running our custom pulse sequences on SIEMENS MRS equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="text-decoration: underline">Data Transfer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Data is routinely transferred
from MR scanners to externally hosted cloud post-processors in many settings and applications, with an existing market of products and
protocols for doing so. Aclarion provides MR imaging providers two options for data transfer: (1) a licensed proprietary imaging data
transfer platform provided by AMBRA&#174; Health, and (2) NOCIWEB&#174;, a custom developed web-interface developed and offered by Aclarion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">NOCISCAN-LS Post-Processor
Suite.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The NOCISCAN-LS Post Processor
Suite is comprised of the products that Aclarion currently markets and sells. The post-processor technology requires MRS exam data acquired
only according to Aclarion&#8217;s proprietary MRS exam protocols. The Suite is comprised of two software products that interact with
each other:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOCICALC-LS&#174; receives
    the raw un-processed NOCISCAN-LS MRS exam data and post-processes that raw data into final spectra, and performs various degenerative
    pain biomarker calculations from those spectra, for each disc examined. NOCICALC-LS is Registered as a Class I Medical Device with
    the FDA.</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOCIGRAM&#174; further processes
    the NOCICALC-LS results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative
    pain biomarkers the various discs examined in the patient. High/low NOCISCORE ranges are also correlated to painful (indicated as
    &#8220;NOCI+&#8221; result) versus non-painful (indicated as a &#8220;NOCI-&#8220; result). The NOCISCORE scale was developed according
    to a reference PD TEST that was used as a standard control in a peer reviewed clinical development trial for our technology. The
    post-processed MRS results are shown in an intuitive NOCIGRAM-LS report with reference to certain MRI images of the related patient&#8217;s
    lumbar spine. The NOCIGRAM-LS report is provided to the physician to aid in the physician&#8217;s diagnosis and treatment planning.
    NOCIGRAM is commercially available in the United States as &#8220;Clinical Decision Support Software&#8221; under the 21st Century
    Cures Act, and as such is not considered a medical device nor regulated by the FDA.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Clinical Evidence</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We have pursued a clinical
study (the &#8220;Gornet Study&#8221;) to demonstrate the benefits of our technology to surgeons, imaging centers, third party payers,
and patients. Without strong clinical data in support of our technology to improve clinical outcomes, the opportunity to secure new reimbursement
codes and change existing treatment pathways would be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In a clinical study sponsored
by us, and authored by, among others, a spine surgeon who has a financial interest in the Company. and published in the European Spine
Journal in April 2019, it was shown that 97% of the treated patients met the criteria for significant clinical improvement, where all
discs identified as painful by NOCISCAN-LS were included in the surgical treatment. This compared to 54% of surgical patients achieving
clinically significant improvement when discs identified as painful by NOCISCAN-LS were omitted from the surgical treatment, or discs
identified as not painful by NOCISCAN-LS were included in the treatment. Some authors of this study had a financial relationship with
Aclarion, who sponsored the study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">This clinical study included
139 chronic low back pain patients who collectively underwent a NOCISCAN-LS exam across 623 lumbar discs. Seventy-three patients underwent
surgical intervention, consisting of fusion or disc replacement, and reached six months follow up. Clinical improvement post surgically
was evaluated using the industry standard Oswestry Disability Index (&#8220;ODI&#8221;), and the Visual Analog Scale (&#8220;VAS&#8221;).
ODI evaluates patient disability on a scale of 1-100 with a higher score indicating less impairment. VAS evaluates subjective pain on
a scale of 1-10 with a lower score indicating less pain. Significant clinical improvement in the study was defined as a 15-point improvement
in ODI and a 2-point improvement in VAS. NOCISCAN-LS data was not used in surgical decision making.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Post-operatively, patients
were separated into various groups for analysis. One group consisted of patients where the surgical intervention included every disc
that was identified by NOCISCAN-LS as painful. This group consisted of 36 patients with 26 undergoing a one-level surgical procedure
and 10 undergoing a two-level surgical procedure. 97% (35 of 36) of the patients in this category met the criteria for significant clinical
improvement. The one failure in this group did meet the VAS requirement and missed the ODI cutoff of 15 by only one point.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In another group consisting
of 13 patients, a disc identified as painful by NOCISCAN-LS was not included in the surgical intervention. In this group only 54% (7
of 13) of patients met the criteria for clinically significant improvement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In April 2023, Aclarion
advanced the evidence of our technology with a peer-reviewed journal article detailing the Gornet 2-year outcomes, published in the European
Spine Journal. The 2-year outcomes were durable with 1-year outcomes previously published in 2019. At 2-years follow-up, 85% of patients
improved when disc(s) identified as consistent with pain by our technology were included in a surgical treatment, compared to only 63%
of patients when disc(s) identified as consistent with pain were not treated or disc(s) identified as consistent without pain were treated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We believe the results of
this study indicate that using NOCISCAN-LS data to help determine the appropriate level for surgical intervention will significantly
improve the outcomes for patients undergoing spine surgery for back pain. However, the Gornet Study was a single, relatively small, clinical
study at a single clinical center sponsored by us, and authored by, among others, a spine surgeon who has a financial interest in the
Company, and there can be no assurance that the results of such study accurately support our conclusions related to the market opportunity
of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Competitive Landscape</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We believe our main competition
for diagnosing disc pain are the PD Test and SPECT &#8211; CT.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Since MRIs are considered
the current standard for lumbar imaging, &#8220;SPECT &#8211; CT&#8221; requires an MRI, a CT-Scan, and an injection of a radioactive
dye followed by a period of time for circulation of the dye. We believe the radioactive dye that is injected is aimed at binding to inflammatory
markers that make the inflammation markers visible to the CT-Scan. However, we believe the inflammation markers have not been shown to
specifically correlate with pain. Because of the extra cost, time and radiation exposure when compared to MRS and our belief that SPECT
&#8211; CT does not bind to specific known pain biomarkers, we do not believe that SPECT &#8211; CT will play a major role in diagnosing
DLBP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As set forth above, a PD
Test has many issues. We believe the most significant issue impacting the future use of the PD Test is the growing evidence that the
PD Test causes long term harm to the patient by accelerating degeneration of the normal control discs that are a required component of
the PD Test. We believe this issue will create significant hesitation for spine surgeons to use a PD Test which will leave them, and
other clinicians, with a void in information about whether a disc is painful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We believe the advantages
NOCISCAN-LS delivers against this competitive landscape to address the needs of the marketplace are significant and include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published clinical trial
    indicating improved surgical outcomes when surgically treated discs were identified as consistent with pain by our technology;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noninvasive study that
    is delivered with minimal risk and no pain;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Objective results that
    are quantifiable;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Core technology that identifies
    biomarkers shown to be linked to pain and structural integrity of intervertebral discs;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Software product that leverages
    the ubiquitous install base of compatible MRI scanners so that no new hardware is required; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential diagnostic to
    evaluate the efficacy of regenerative therapies to treat degenerative discs with conservative measures such as PT, chiropractic interventions,
    steroid injections, etc., to impact outcomes.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Because of the advantages
of Aclarion&#8217;s solution as well as the issues associated with the limited availability of alternatives for patients and clinicians,
we believe NOCISCAN-LS can become the standard of care in diagnosing DLBP prior to a surgical intervention. We will continue to expand
clinical registries and data in support of the efficacy of our product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Patents</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Aclarion has an intellectual
property portfolio consisting of 23 U.S. Patents, 17 Foreign Patents, 6 pending U.S. patent applications, and 7 pending Foreign
patent applications. This portfolio includes patents assigned to Aclarion and patents exclusively licensed from the Regents of the University
of California. Many of the patents in our patent portfolio relate to aspects of our NOCISCAN-LS product suite and the related disc MRS
exam itself, as well as to broader applications of our technologies to other applications for MRS. We may expand our portfolio into alternative
approaches for pain diagnosis, in particular DLBP diagnosis, such as including using labeled molecular antibodies for imaging localized
pain. The Company is not aware of any third-party intellectual property rights that might threaten or prevent our ability to market products
or services without infringing such third-party intellectual property rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Trademarks</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company holds multiple
trademarks for its previous corporate brand name as well as for its key products and brands (&#8220;&#174;&#8221; designates registered
trademark, &#8220;&#8482;&#8221; designates unregistered trademark under common law protection). With respect to involved meanings, the
recurrent prefix term &#8220;NOCI&#8221; is derived from Latin origins for &#8220;pain&#8221; e.g. nerves that report pain are called
&#8220;nociceptors. These marks include: NOCIMED&#174;, NOCISCAN&#174;, NOCIGRAM&#174;, NOCISCORE&#174;, NOCICALC&#8482;, NOCI+&#8482;, NOCI-&#8482;,
NOCImild&#8482;, NOCIWEB&#8482;, SI-SCORE&#8482;, VIRTUAL DISCOGRAM&#8482;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Market Opportunity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The current NOCISCAN-LS product
addresses the $10 billion that is spent in the U.S. on spine fusion procedures annually. Our early clinical evidence points to a marked
improvement in surgical outcomes when discs identified as consistent with pain by our technology are included in the surgical treatment.
We believe this market is actionable now, and a significant portion of the proceeds of this offering will be directed towards commercializing
this market opportunity. However, our early clinical evidence is supported by a single (relatively small) clinical study at a single clinical
center sponsored by us, and authored by, among others, a spine surgeon who has a financial interest in the Company, and there can be no
assurance that the results of such study accurately support our conclusions related to the market opportunity of our products (See &#8220;Clinical
Evidence&#8221; above.)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As the commercialization
process progresses, Aclarion plans to track patients through clinical registries in order to build on our early clinical evidence. We
expect to use these registries to track NOCISCAN-LS patients regardless of what treatment path they may follow. Presently, NOCISCAN-LS
has only been evaluated in formal clinical studies for patients primarily undergoing surgical interventions for fusion or disc replacement.
The Company plans on expanding clinical registries to capture patients undergoing surgical interventions for back pain that includes
all surgical interventions, not just fusion and disc replacement procedures. We believe that if we are able to correlate specific MRS
findings to improved surgical outcomes for all spine surgeries, this will expand the size of the market opportunity in the U.S. from
$10 billion to roughly $40 billion, inclusive of pre-surgical conservative therapy costs. However, there can be no assurance that we
will be able to correlate specific MRS findings on all spine surgeries, or even if we do, that we would be successful in expanding our
market to all spine surgeries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Our objective for NOCISCAN-LS
is to address the entire low back and neck pain market which at $134.5 billion annually, represents the largest amount of healthcare
dollars spent to treat any disease. To address this market, our current algorithms will need to expand to include advanced machine learning
techniques that incorporate multiple data inputs in addition to the chemical composition of discs. These additional inputs will need
to be correlated to clinical outcomes for treatments ranging from physical therapy to regenerative therapies to surgical interventions.
This process is already underway as we have been selected as a participant in a $150 million, NIH funded study (the &#8220;Study&#8221;),
which is focused on evaluating the most promising data inputs for predicting the optimal treatment path for back pain patients. The Study
will cover a number of protocols for the treatment of LBP, including NOCISCAN-LS. We will derive no revenue from the Study, but all results
will be available to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In addition to participation
in major external studies such as the NIH BACPAC initiative, we expect to create our own internal data by adding patients undergoing
conservative and regenerative treatment plans to our clinical registries, and then correlating NOCISCAN-LS results to outcomes in order
to leverage AI to associate spectroscopy signals with the optimal treatment pathway. If our internal data demonstrates what we believe
to be clinical effectiveness of our technology, we intend to expand our marketing opportunity to the management of all low back and neck
pain patients, thereby increasing our potential market to $134.5 billion in the United States. However, there can be no assurance that
our internal data will demonstrate the clinical effectiveness of our technology on all back and neck pain patients, or even if we do,
that we will be successful in marketing our technology to such patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Current Market Limitation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Because we believe that
spectroscopy is not widely used for any clinical purposes today, there are practical limitations to the market opportunity that must
be addressed. We believe the two biggest limitations may be the lack of deployment of spectroscopy software across the installed base
of existing MRIs worldwide, and the fact that only certain MR scanner models are compatible with our technology. For compatible MRI sites
that do not currently have spectroscopy software installed, the onetime cost of the software ranges from $25,000 to $50,000. Currently,
our NOCISCAN-LS platform is only compatible with certain MRI scanner models provided by SIEMENS, of which there are an estimated 1,500
in the United States, and 4,320 worldwide. We plan to collaborate with other MRI scanner vendors, as well as SIEMENS, to establish compatibility
with their respective scanners and MRS capabilities for use with our products. That allows us to include discounted pricing on spectroscopy
software for MRI sites interested in providing DLBP patients with the Nociscan-LS offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Reimbursement by Third
Party Payers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#8220;Current Procedural
Terminology&#8221;, more commonly known as CPT&#174; (&#8220;CPT&#8221;), refers to a medical code set created and maintained by the American
Medical Association (&#8220;AMA&#8221;) and used by providers of healthcare services to bill insurance companies for their work. All
new medical devices and services are required to secure CPT codes to receive payment from government and private commercial payers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Based on the strength of
the improvement in surgical outcomes from the Gornet study (see &#8220;Overview&#8221;, &#8220;Clinical Evidence&#8221; above), we applied
to the CPT committee for Category III codes to cover Nociscan reimbursement. On January 1, 2021, Category III CPT Codes became effective.
CPT code 609T was established to cover payment to the imaging center and CPT code 611T was established to cover payment to us for the
use of NOCISCAN-LS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Category III codes represent
the first step in the reimbursement process. It also starts a five-year period in which we are required to demonstrate that the medical
community needs (&#8220;Clinical Needs&#8221;) the NOCISCAN-LS product. Clinical Needs would be demonstrated to the CPT Committee based
on the volume at which our codes are billed by imaging centers and physicians. In addition to demonstrating that there is a Clinical
Need, we also are required to show that NOCISCAN-LS is clinically effective as indicated by patients having better outcomes when NOCISCAN-LS
reports are used to help guide surgical treatments. We expect to show clinical effectiveness through a combination of clinical registries
and clinical studies that build upon our published clinical study the CPT committee used to create our Category III CPT codes. There
can be no assurance that we will be able to demonstrate Clinical Needs, and if we do not, our business would be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In addition to the core
CPT codes that provide payment to the imaging center and to us, the AMA has approved two additional Category III codes. The first is
CPT code 610T which covers the process of transmitting the raw spectroscopy biomarker data from the MRI scanner to our software for analysis.
This code is for payment to the imaging center and is bundled with CPT code 609T, which means the code can be billed but no additional
payments beyond 609T will be made by government payers. Although additional payment by commercial payers is possible, we believe it is
unlikely. The second is CPT code 612T, which is billed by the ordering physician and paid to the ordering physician for interpreting
the report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The 611T Code is the sole
Code under which we will derive revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Regulatory Filings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The NOCISCAN-LS Post-Processor
Suite consists of two software products that interact with each other, NOCICALC-LS&#174; and NOCIGRAM-LS&#174;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">NOCICALC-LS receives and
processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers. In conjunction with our regulatory consultants,
we determined NOCICALC-LS to be a &#8220;Class I 510(k)-exempt&#8221; medical device subject only to registration listing requirements
with no pre-market review required by the FDA for clearance or approval. As such, in accordance with FDA regulations, NOCICALC-LS is
registered with the FDA as an exempt Class I device.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The process to determine
whether a product can be considered a Class I &#8220;exempt&#8221; medical device consists of self-determining whether the product is
adequately described by one of the existing categories classified by the FDA. In consultation with our regulatory consultants, we determined
that the product Classification &#8220;Calculator/Data Processing Module, for Clinical Use,&#8221; adequately described our NOCICALC-LS
product. Our registration filing is available for review at this link; Establishment Registration and Device Listing (fda.gov).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We believe NOCIGRAM is not
considered a medical device as it meets the exclusion criteria of the 21st Century Cures Act for Clinical Support Software. Under the
Cures Act provision, a software product is not considered a device if it meets the following four elements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not intended to acquire,
    process, or analyze a medical image or a signal from an in vitro diagnostic device or a pattern or signal from a signal acquisition
    system;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intended for the purpose
    of displaying, analyzing, or printing medical information about a patient or other medical information (such as peer-reviewed clinical
    studies and clinical practice guidelines);</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intended for the purpose
    of supporting or providing recommendations to a health care professional about prevention, diagnosis, or treatment of a disease or
    condition; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intended for the purpose
    of enabling such health care professional to independently review the basis for such recommendations that such software presents
    so that it is not the intent that such health care professional rely primarily on any of such recommendations to make a clinical
    diagnosis or treatment decision regarding an individual patient.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Management has evaluated
NOCIGRAM-LS against these four elements and believes NOCIGRAM meets each of the four criteria.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">However, although we believe
our analysis is reasonable, whenever a company self classifies, there is a risk that FDA could disagree with the classification. Accordingly,
in that context, it is possible that FDA could potentially disagree that the NOCIGRAM-LS falls under the CDS software exemption to the
definition of a device and there can be no assurance that the FDA will agree with our conclusion and in the event the FDA does not agree,
our business would be severely negatively impacted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For commercialization
outside the United States, in particular the EU and UK, the Company, in conjunction with our regulatory consultants, determined NOCISCAN-LS
to be a Class I medical device, for which we secured a CE mark via self-certification. Since self-certification, the EU adopted Regulation
(EU) 2019/1020 that went into effect on July 16, 2021. Under these new regulations, we believe NOCISCAN-LS to be considered a Class II(a)
device that requires re-certification for CE mark by a Notified Body prior to May 2024. The EU Parliament has voted to extend the Medical
Device Regulation (MDR 2017/745) transition period. The extension will see the May 2024 deadline postponed until 2027 for higher-risk
Class III and implantable IIb devices, and May 2028 for lower-risk Class I, IIa and other IIb devices. A &#8220;Notified Body&#8221; is
an organization designated by an EU country to assess the conformity of certain products before being placed on the market, as is required
for certain medical products. The Company is in the process of re-certifying our CE mark.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In conjunction with Brexit,
medical devices in the UK are no longer governed by CE regulations. The UK has introduced the UKCA marking system, which largely follows
the CE marking regulations to include permitting use of the same submissions for approval. The major difference post-Brexit is that CE
marking is regulated by the EU and UKCA marking is regulated by the UK. The only practical implication to the Company is requiring a
Notifying Body within both the EU and the UK. The Company expects to meet all requirements for UKCA marking.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Commercialization</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The issuance of Category
III codes and satisfaction of regulatory requirements for marketing starts the commercialization phase which will be the primary use
of proceeds from this offering. The commercialization process in support of moving temporary Category III codes to permanent Category
I codes consists of the following key activities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying and supporting
    Key Opinion Leader (&#8220;KOL&#8221;) spine surgeons and radiologists to help secure local payer coverage decisions and surgical
    society support for our technology;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expanding the network of
    imaging centers and surgeons using NOCISCAN-LS in each market such that the technology is widely available to patients covered by
    payers;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supporting surgeons, radiologists,
    Physical Medicine and Rehabilitation physicians, physical therapists, regenerative therapy physicians and medical device companies
    that address low back pain to initiate studies and report results;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building and expanding
    clinical registries to provide real world evidence of better outcomes when using Nociscan to help determine which discs to treat;
    and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuing value-based care
    contracts to share in the profits that result from the improved surgical outcomes we believe our technology enables in DLBP patients.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Our primary near-term growth
strategy is to secure payer contracts (including insurance companies, self- insured employers, Medicare, Medicaid, workmen&#8217;s compensation
boards et. al.) to cover our Category III CPT codes. We believe that with favorable payer coverage, the Company has the opportunity to
more efficiently engage spine surgeons and imaging centers that will adopt our technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company currently
generates the vast majority of its revenue directly from patients paying out of pocket.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In order to effectively
commercialize our technology, the Company has completed its initial plan to gain the support of up to ten leading spine surgeons as Key
Opinion Leaders (KOL) who believe Nociscan technology will help them with surgical decisions in their practices. These KOL surgeons are
leaders in their field and will be assisting the Company in generating important clinical data in support of Nociscan, and using that
data to help the Company in discussions with payers to secure positive payment decisions for our Category III CPT codes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Based primarily on our
KOL surgeons and the strength of physician engagement in markets, the Company is prioritizing the following markets:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYC Metropolitan Area</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">San Francisco, CA</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chicago, IL</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phoenix, AZ</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miami, FL</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denver and Colorado Springs, CO</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Detroit, MI</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indianapolis</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Once a positive local
payment decision is secured in a geographical area, we intend to place a market manager and a team of business development professionals
into each market to focus on expanding physician support and securing favorable coverage decisions from additional payers in the market.
The objective in each market is to expand the provider network to include additional imaging centers and surgeons so there is increasing
geographical coverage. We believe increasing our footprint in each market will grow volume and revenue through increased pressure on payers
to expand positive coverage decisions across all of the varied plans associated with each payer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Recent Developments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Publication of
Gornet Study</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As discussed above, in
April 2019, the initial results of the clinical Gornet Study were published in the European Spine journal. We have pursued the Gornet
Study to demonstrate the benefits of our technology to surgeons, imaging centers, third party payers, and patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On April 24, 2023, the
Company announced the publication in the European Spine Journal of two-year durability data as a follow up to the initial Gornet Study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The multi-year, single
site clinical trial comprised 78 patients who received surgery for DLBP following standard clinical work-up including MRI and provocative
discography. Nociscan was performed on all patients but was not available in the surgical decision-making process. The patient outcomes
were evaluated using the Oswestry Disability Index (ODI) scoring scale (100 points), a common clinical outcomes measure for low back pain,
where surgical success was defined using an industry-standard improvement of 15 points or more between surgeries that were concordant
versus discordant with Nociscan results. Surgical success rates at 2 years illustrates a 22 percentage point improvement between the two
groups. The results suggest that Nociscan provides valuable new information that can help physicians successfully treat DLBP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Both clinical studies
were study sponsored by us. The principal author of these studies is a spine surgeon who has a financial interest in the Company. Other
authors of these studies also have a financial relationship with Aclarion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Alphatec Strategic Partnership</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 8, 2024, we announced that we had executed
a strategic partnership agreement solidifying our previously signed non-binding letter of intent with ATEC Spine, Inc., the wholly owned
operating subsidiary of Alphatec Holdings, Inc. (&#8220;ATEC&#8221;). ATEC is a medical device company dedicated to revolutionizing the
approach to spine surgery through clinical distinction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The agreement contemplates a multi-step strategic
partnership. Under the agreement, ATEC and Aclarion will work together to identify Key Opinion Leader (KOL) surgeons to evaluate our Nociscan
technology. Feedback from these surgeons will inform clinical evaluations designed to assess the utility of Nociscan in conjunction with
EOS imaging, the foundation of ATEC&#8217;s AlphaInformatiX platform. Assuming positive synergies, ATEC and Aclarion will co-market Nociscan
in targeted markets. In exchange for select access to ATEC&#8217;s surgeon network for the evaluation and advancement of Nociscan, Aclarion
will provide ATEC with certain exclusive distribution rights to include Nociscan as part of an integrated procedural solution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Nasdaq Bid Price Notice</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On April 8, 2024, we
received a written notice (the &#8220;Bid Price Notice&#8221;) from the Listing Qualifications Department of The Nasdaq Stock Market (&#8220;Nasdaq&#8221;)
indicating that the Company was not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2)
for continued listing on The Nasdaq Capital Market (the &#8220;Bid Price Requirement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Bid Price Notice
did not result in the immediate delisting of the Company&#8217;s common stock from The Nasdaq Capital Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Nasdaq Listing Rules
require listed securities to maintain a minimum bid price of $1.00 per share and, based upon the closing bid price of the Company&#8217;s
common stock for the 30 consecutive business days for the period ending April 5, 2024, the Company no longer met this requirement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The
Notice indicated that the Company will be provided 180 calendar days (or until October 7, 2024) in which to regain compliance. We did
not regain compliance with Rule 5550(a)(2) prior to the expiration of the initial 180 calendar day period on October 7, 2024. On October
8, 2024, we received from the Nasdaq staff (the &#8220;Staff&#8221;) written notification that our securities are subject to delisting
from the Nasdaq Capital Market. We had an appeal hearing on October 10, 2024 before a Nasdaq hearings panel (the &#8220;Panel&#8221;)
appeal the delisting notice from the Staff. While the appeal process is pending, the suspension of trading of our common stock will be
stayed. Our common stock will continue to trade on Nasdaq until the hearing process concludes and the Panel issues a written decision.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">At
the Company&#8217;s special stockholders&#8217; meeting on September 23, 2024, the Company&#8217;s stockholders approved a proposal to
grant discretionary authority to our board of directors to (i) amend our certificate of incorporation to combine outstanding shares of
our common stock into a lesser number of outstanding shares, or a &#8220;reverse stock split,&#8221; at a specific ratio within a range
of one-for-five (1-for-5) to a maximum of a one-for-fifty (1-for-50) split, with the exact ratio to be determined by our board of directors
in its sole discretion; and (ii) effect the reverse stock split, if at all, within one year of the date the proposal was approved by
stockholders. The Company intends to implement a reverse stock split in the near future in order to assist with the Company&#8217;s compliance
with Nasdaq&#8217;s Bid Price Requirement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Nasdaq Stockholder
Equity Notice</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On March 3, 2023, the
Company received a written notice (the &#8220;Stockholder Equity Notice&#8221;) from Nasdaq indicating that it is not in compliance with
Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Stock Market to maintain a minimum of $2,500,000 in stockholders&#8217;
equity for continued listing. In its annual report on Form 10-K filed on February 27, 2023 for the period ended December 31, 2022, the
Company reported stockholders&#8217; equity of $1,787,751, and, as a result, does not currently satisfy Listing Rule 5550(b)(1).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Stockholder Equity
Notice also indicated that the Company had a period of 45 calendar days from the date of the Stockholder Equity Notice, or until April
17, 2023, to submit a plan to regain compliance with the stockholders&#8217; equity requirement under Nasdaq Listing Rule 5550(b)(1).
The Company submitted such a plan to Nasdaq on April 12, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On April 20, 2023, the
Company received a letter (the &#8220;Extension Notice&#8221;) from Nasdaq notifying the Company that it has been granted an additional
180-day period, or until August 30, 2023, to regain compliance with Nasdaq Listing Rule 5550(b)(1).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On
August 31, 2023, the Staff notified the Company that it had not met the terms of the Extension Notice. Accordingly, the Staff had determined
to delist the Company&#8217;s common stock from Nasdaq, unless the Company timely requests an appeal of the Staff&#8217;s determination
to the Panel, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The
Company requested a hearing before the Panel to appeal the delisting notice from the Staff. The Company's hearing with the Panel occurred
on October 19, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On November 7, 2023,
we were notified by the Panel that the Company&#8217;s request for continued listing on Nasdaq was granted, subject to the Company demonstrating
compliance with the stockholders&#8217; equity requirement and bid price requirement on or before January 31, 2024. The Panel subsequently
extended this compliance date to February 27, 2024. On February 27, 2024, the Company completed a public offering of 5,175,000 units (&#8220;Units&#8221;)
at a price of $0.58 per Unit, for gross proceeds of approximately $3.0 million, before deducting offering expenses. Each Unit was comprised
of (i) one share of common stock or, in lieu of common stock, one prefunded warrant to purchase a share of common stock, and (ii) two
common warrants, each common warrant to purchase a share of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As a result of the public
offering described above, the Company received confirmation from Nasdaq on February 29, 2024, stating that the Company has regained compliance
with the equity requirement, as required by the Panel&#8217;s decision dated November 7, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On August 22, 2024, the
Company received a letter from The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) indicating that it was not in compliance with the equity
requirement. In its quarterly report on Form 10-Q for the period ended June 30, 2024, the Company reported stockholders&#8217; equity
of $1,642,177, and, as a result, did not satisfy Listing Rule 5550(b)(1).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Accordingly,
the Staff determined to delist our common stock from Nasdaq. Nasdaq&#8217;s letter provided the Company until August 29, 2024 to request
an appeal of this determination. The Company requested a hearing before the Panel to appeal the delisting notice from the Staff. The
hearing request stays any suspension or delisting action pending the conclusion of the hearing process and the expiration of any additional
extension period granted by the Panel following the hearing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We
had an appeal hearing on October 10, 2024 before the Panel to appeal the delisting notice from the Staff. While the appeal process is
pending, the suspension of trading of our common stock will be stayed. Our common stock will continue to trade on Nasdaq until the hearing
process concludes and the Panel issues a written decision.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The
Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq.
The Company is currently evaluating its available options to resolve the deficiency and regain compliance with the Nasdaq minimum stockholders&#8217;
equity requirement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Going Concern Opinion</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Our working capital deficiency,
stockholders&#8217; deficit, and recurring losses from operations raise substantial doubt about our ability to continue as a going concern.
As a result, our independent registered public accounting firm included an explanatory paragraph in its report dated February 20, 2024,
on our financial statements for the year ended December 31, 2023, with respect to this uncertainty. Our ability to continue as a going
concern will require us to obtain additional funding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of June 30, 2024, we
had cash of approximately $1.2 million. We believe our cash on hand will be sufficient to fund current operating plans into the fourth
quarter of 2024. The Company has based these estimates, however, on assumptions that may prove to be wrong, and could spend available
financial resources much faster than we currently expect. The Company will need to raise additional funds to continue funding our technology
development and commercialization efforts over the following twelve months. Management has plans to secure such additional funding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As a result of the Company&#8217;s
recurring losses from operations, and the need for additional financing to fund its operating and capital requirements, there is uncertainty
regarding the Company&#8217;s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial
doubt as to the Company&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Assuming
the receipt of the maximum amount of net proceeds from this offering, we believe our cash resources would be sufficient to fund our current
operating plans into the fourth quarter of 2024. We have based these estimates, however, on assumptions that may prove to be wrong, and
we could spend our available financial resources much faster than we currently expect and need to raise additional funds sooner than
we anticipate. If we are unable to raise additional capital when needed or on acceptable terms, we would be forced to delay, reduce,
or eliminate our technology development and commercialization efforts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Reverse Stock Split</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As previously announced,
in March 2023 the Company&#8217;s stockholders approved a reverse stock split proposal at a ratio in the range of one-for-five to one-for-fifty,
with the final ratio to be determined by the Company's board in its discretion without further approval from the Company's stockholders.
In January 2024, the Company's board subsequently approved the final reverse stock split ratio of one-for-sixteen, which resulted in
a reduction in the number of outstanding shares of common stock and a proportionate increase in the value of each share. The common stock
began trading on a reverse split-adjusted basis on the NASDAQ on January 4, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The following table presents
selected share information reflecting on a retroactive basis the reverse stock splits for the years ended December 31, 2023 and 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Common shares issued and outstanding - pre-2024 split, 13,206,229 and 7,861,515 shares</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">132</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">79</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common shares issued and outstanding - post-2024 split, 825,459 and 491,345 shares</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Additional paid-in capital - pre-2024 split</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">43,553,399</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">41,596,032</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additional paid-in capital - post-2024 split</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">43,553,523</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">41,596,106</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Weighted average shares outstanding, basic and diluted - pre-2024 split</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">8,908,934</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">6,105,569</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average shares outstanding, basic and diluted - post-2024 split</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">556,808</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">381,598</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Basic and diluted net loss per shares attributable to common stockholders - pre-2024 split</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.55</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1.23</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Basic and diluted net loss per shares attributable to common stockholders - post-2024 split</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(8.82</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(19.61</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Exchange Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May, September and November 2023 the Company issued $2,550,000
aggregate principal amount of unsecured non-convertible notes to certain accredited investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Between January 22 and
January 29, 2024, the Company entered into a series of exchange agreements with the accredited investors to exchange principal and accrued
interest on these notes for shares of common stock. Pursuant to the exchange agreements, the Company issued an aggregate of 644,142 shares
of common stock in exchange for $1,519,779 principal and accrued interest on the notes. Following these exchanges, the remaining outstanding
balance of principal and interest on the notes is $1,145,037.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On August 14, 2024, the
Company entered into an exchange agreement with the note holders accredited investors to exchange approximately $930,000 of principal
and accrued interest on the notes for 930 shares of newly issued Series B convertible preferred stock (&#8220;Series B Preferred Stock&#8221;)
at a purchase price of $1,000 per share. The Series B Preferred Stock is convertible into Common Stock at an initial conversion price
(&#8220;Conversion Price&#8221;) of $0.234 per share of Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Series
C Preferred Stock Financing</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On
September 30, 2024, the Company entered into a securities purchase agreement with accredited investors for a convertible preferred stock
and warrants financing. The Company has received $1,000,000 of gross proceeds in connection with the closing of this financing. The Company
issued 1,000 shares of Series C convertible preferred stock (&#8220;Series C Preferred Stock&#8221;) at a purchase price of $1,000 per
share of Series C Preferred Stock. The Series C Preferred Stock is convertible into Common Stock at an initial conversion price (&#8220;Conversion
Price&#8221;) of $0.1759 per share of Common Stock. The Company also issued warrants exercisable for 5,685,049 shares of Common Stock
with a 5.5 year term and an initial exercise price of $0.1759 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 12; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Summary of Risk Factors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Investing in our
securities involves a high degree of risk. You should carefully consider the risks described in &#8220;<a href="#s_005">Risk Factors</a>&#8221; beginning on page 18  before making a decision to invest in our common stock. If any of these risks actually
occurs, our business, financial condition, results of operations and prospects would likely be materially, adversely affected. In
that event, the trading price of our common stock could decline, and you could lose part or all of your investment. Below is a
summary of some of the principal risks we face:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are not currently in compliance with the minimum bid price rule or
the minimum stockholders&#8217; equity rule of the Nasdaq Capital Market and a delisting could limit the liquidity of our stock, increase
its volatility and hinder our ability to raise capital.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have a history of net
    losses, and we expect to continue to incur losses for the foreseeable future. If we do achieve profitability, we may not be able
    to sustain it.</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>

<tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px; text-align: left"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td><span style="font-size: 10pt">We, as well as the auditors of our financial statements, have previously
expressed substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain further financing;
have previously expressed substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain further
financing.</span></td>
</tr>
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Following
    the receipt of the net proceeds from this offering, we believe our cash resources would be sufficient to fund our current operating
    plans into the fourth quarter of 2024. We have based these estimates, however, on assumptions that may prove to be wrong, and we
    could spend our available financial resources much faster than we currently expect and need to raise additional funds sooner than
    we anticipate. If we are unable to raise additional capital when needed or on acceptable terms, we would be forced to delay, reduce,
    or eliminate our technology development and commercialization efforts.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have identified  material
    weaknesses in our internal control over financial reporting. Failure to maintain effective internal controls could cause our investors
    to lose confidence in us and adversely affect the market price of our common stock. If our internal controls are not effective, we
    may not be able to accurately report our financial results or prevent fraud.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The COVID-19 pandemic or
    other epidemic disease may have a material adverse effect on our business, financial condition and operating results, as well as on
    the operations and financial performance of our customers and suppliers. We are unable to predict the extent to which the pandemic
    and related restrictions will impact our business, operations, financial performance and the achievement of our strategic
    objectives.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently rely on our
    technology for use in assisting doctors to diagnose chemically painful discs causing discogenic low back pain, as well for supporting
    other diagnoses, treatments, and research related to lumbar disc chemistry. If we are not successful in marketing and enhancing awareness
    of our technology, driving adoption across our current target population, increasing referrals, and expanding the population of eligible
    patients, our sales, business, financial condition and results of operations will be negatively affected.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently, we can only
    market our product in the United States and certain countries observing CE mark regulations. Regulatory approvals that currently
    apply to our products include assessments where we determine the appropriate regulatory pathway for our products. Although we use
    regulatory consultants to assist in the self-registration processes and determinations, it is possible a regulator could disagree
    with our analysis. It is also possible that regulations relating to how we market our products may change. In addition, to maintain
    our ability to market our products under the approved regulations, we are required to adhere to multiple protocols in order to maintain
    regulatory approvals. The Company has failed to adequately follow protocols in the past and it is possible this may happen again
    in the future. If there is a change in our ability to market our products it may harm our sales, business, financial condition and
    results of operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our commercial success
    will depend on attaining significant market acceptance of our technology among patients, clinicians (primarily spine surgeons and
    pain management physicians) and imaging facilities, as well as increasing the number of patients who are prescribed for use of our
    diagnostic technology. If we are unable to successfully achieve substantial market acceptance and adoption of our technology, our
    sales, business, financial condition and results of operations would be harmed.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our commercial software
    products currently depend on compatible use with a limited number of MR scanners that are provided by one MR scanner vendor, SIEMENS,
    which limits our ability to address the total potential patient population that our products could otherwise address in commercial
    sales. There are risks related to the on-going compatibility, shortages, price fluctuations, and ability to grow the number of compatible
    MR scanner platforms that, if realized, could harm our sales, business, financial condition, and results of operations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to obtain,
    maintain, protect, enforce and defend patent or other intellectual property protection for our technology, or if the scope of our
    patents and other intellectual property protections is not sufficiently broad, or as a result of our existing or any future out-licenses
    of our intellectual property, our competitors could develop and commercialize products similar to or competitive with our products
    and services, our ability to continue to commercialize our technology, or our other products and services, may be harmed.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be unable to compete
    successfully with other available alternatives for diagnosing low back pain, including, in particular, identifying painful discs
    causing discogenic low back pain, which could harm our sales, business, financial condition and results of operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If adequate reimbursement
    becomes unavailable for the procedures that use, or could use, our diagnostic technology, or becomes unavailable for providing other
    ongoing care for patients diagnosed with the assistance of our technology, it could diminish our sales, affect our ability to sell
    our technology profitably, or could otherwise harm our business, financial condition, and results of operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our collection, use, storage,
    disclosure, transfer and other processing of sensitive and personal information could give rise to significant costs, liabilities
    and other risks, including, as a result of investigations, inquiries, litigation, fines, legislative and regulatory action and negative
    press about our privacy and data protection practices, which may harm our business, financial conditions, results of operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our current product is
    supported by a single clinical study at a single clinical center involving one spine surgeon who has a financial interest in the
    Company. If we are unable to replicate the success of our initial clinical trial, the efficacy of our product may be in question
    and our sales, business, financial condition and results of operations will be harmed.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To reach the full market
    potential of our product, we will need to leverage advanced machine learning and artificial intelligence technologies (&#8220;AI&#8221;)
    to a larger degree than we do today. Introducing new technologies into our products require that we secure new regulatory approvals
    and demonstrate additional clinical success. If we are unable to secure regulatory approvals for our new products, or if they prove
    incapable of demonstrating clinical success, our market opportunity will be reduced and our sales, business, financial condition
    and results of operations may be harmed.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our current product is
    dependent on certain processes that are not optimized to support the scaling of our technology. If we are not able to efficiently
    automate these processes, the Company will not be able to grow and our sales, business, financial condition and results of operations
    will be harmed.</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="width: 24px"/><td style="width: 24px; text-align: left"><span style="font-family: Symbol">&#183;</span></td><td>We may fail to continue to meet the listing standards of The Nasdaq
Capital Market whether or not this offering occurs. Even if this offering occurs, this offering could cause our stock price to fall,
which could result in us being delisted from The Nasdaq Capital Market. Failure to maintain the listing of our common stock with a U.S.
national securities exchange could adversely effect the liquidity of our common stock.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Implications of Being
an Emerging Growth Company and a Smaller Reporting Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We qualify as an &#8220;emerging growth company&#8221;
as defined in the Jumpstart our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). An emerging growth company may take advantage
of specified reduced reporting and other burdens that are otherwise applicable generally to public companies. These provisions include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inclusion
    of only two years, as compared to three years, of audited financial statements in addition to any required unaudited interim financial
    statements with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;
    disclosure;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to
    the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;);</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    exemption from compliance with any new requirements adopted by the Public Company Accounting Oversight Board (the &#8220;PCAOB&#8221;)
    requiring mandatory audit firm rotation;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    disclosure about executive compensation arrangements; and</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    exemption from the requirement to seek non-binding advisory votes on executive compensation or golden parachute arrangements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may take advantage of these provisions until
we are no longer an emerging growth company. We will remain an emerging growth company until the earliest of (1) the last day of the fiscal
year (a) following the fifth anniversary of the completion of our April 2022 IPO, (b) in which we have total annual gross revenue of at
least $1.235 billion or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that
is held by non-affiliates exceeds $700 million as of the prior December 31st, and (2) the date on which we have issued more than $1.0
billion in non-convertible debt during the prior three-year period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We have taken advantage
of the reduced reporting requirements in this prospectus and in the documents incorporated by reference into this prospectus. Accordingly,
the information contained herein may be different from the information you receive from other public companies that are not emerging
growth companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The JOBS Act permits an
emerging growth company such as us to take advantage of an extended transition period to comply with new or revised accounting standards
applicable to public companies until those standards would otherwise apply to private companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We are also a &#8220;smaller reporting company&#8221;
meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual revenue was less than $100
million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value
of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently
completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting
company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements
that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two
most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies,
smaller reporting companies have reduced disclosure obligations regarding executive compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Our Corporate Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We were formed under the
name Nocimed, LLC, a limited liability company in January 2008, under the laws of the State of Delaware. In February 2015, Nocimed, LLC
was converted into Nocimed, Inc. a Delaware corporation. On December 3, 2021, we changed our name to Aclarion, Inc. Our principal executive
offices are located at 8181 Arista Place, Suite 100, Broomfield, Colorado 80021. Our main telephone number is (833) 275-2266. Our internet
website is www.aclarion.com. The information contained in, or that can be accessed through, our website is not incorporated by reference
and is not a part of this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="s_003"></span>MARKET AND INDUSTRY DATA</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise indicated, information contained
(or incorporated by reference) in this prospectus concerning our industry and the markets in which we operate is based on information
from independent industry and research organizations, other third-party sources and management estimates. Management estimates are derived
from publicly available information released by independent industry analysts and third-party sources, as well as data from our internal
research, and are based on assumptions made by us upon reviewing such data and our knowledge of such industry and markets which we believe
to be reasonable. Although we believe the data from these third-party sources is reliable, we have not independently verified any third-party
information. In addition, projections, assumptions and estimates of the future performance of the industry in which we operate and our
future performance are necessarily subject to uncertainty and risk due to a variety of factors, including those described in &#8220;<a href="#s_005">Risk Factors</a>&#8221; and &#8220;<a href="#s_006">Information Regarding Forward-Looking Statements</a>.&#8221; These and other factors could cause results to differ
materially from those expressed in the estimates made by the independent parties and by us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b><span id="s_004"></span>THE OFFERING</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 40%"><span style="font-size: 10pt">Securities Offered by the Selling Securityholder</span></td>
    <td style="width: 60%; text-align: justify"><span style="font-size: 10pt;">This prospectus covers the resale
    of a total of up to 1,450,000 shares of our common stock that we may sell to White Lion pursuant to the Purchase Agreement from time
    to time after the registration statement that includes this prospectus is declared effective. This registration statement does not
    register any additional shares of our common stock. This registration statement, initially filed with the Securities and Exchange
    Commission on January 22, 2024, registered up to 2,500,000 shares of common stock. As of the date of this registration statement
    amendment, 1,050,000 of such shares of common stock have been sold under this registration statement and 1,450,000 shares remain
    unsold. As of the date of this filing, a total of 1,800,000 shares of common stock have been sold under the Purchase Agreement.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Common Stock Outstanding Prior to this Offering</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">10,044,728</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Common Stock to be Outstanding After this Offering</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Up to 11,494,728 shares</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>

<tr style="vertical-align: top">
    <td style="width: 40%"><span style="font-size: 10pt">Use of Proceeds</span></td>
    <td style="width: 60%; text-align: justify"><span style="font-size: 10pt">The Selling Securityholder will receive all of the proceeds
    from the sale of the shares offered for sale by it under this prospectus. We will not receive proceeds from the sale of the shares
    by the Selling Securityholder. However, we may receive proceeds of up to $250,000 from the sale of our common stock to the
    Selling Securityholder under the Purchase Agreement described above, other than the Commitment Shares. Any proceeds from the Selling
    Securityholder that we receive under the Purchase Agreement are expected to be used for general corporate purposes, including working
    capital. See &#8220;<a href="#s_008">Use of Proceeds</a>&#8221; on page 64 of this prospectus.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Nasdaq Capital Market Symbols</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Common Stock &#8220;ACON&#8221;. IPO Warrants &#8220;ACONW&#8221;.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Risk Factors</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Investing in our securities involves a high degree of risk. See &#8220;<a href="#s_005">Risk Factors</a>&#8221; beginning on page 18 of this prospectus for a discussion of factors you should carefully consider before deciding to invest in our securities. </span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares outstanding after this
offering is based on 10,044,728 shares of our common stock outstanding as of October 2, 2024, and excludes as of such date:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%">&#160;</td>
    <td style="width: 5%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 90%; text-align: justify"><span style="font-size: 10pt">136,123</span><span style="font-size: 10pt"> shares
    of our common stock issuable upon the exercise of outstanding stock options granted under our 2015 Stock Plan,</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">33,334 shares of our common stock issuable upon the exercise of outstanding stock options granted under our 2022 Stock Plan,</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify">130,093 shares of our common stock reserved for future grant
    under our 2022 Stock Plan,</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0">10,350,000 shares of our common stock issuable upon the exercise
                                    of our outstanding February 2024 public offering warrants,</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify">5,685,049 shares of our common stock issuable upon the exercise of our outstanding September 2024
    warrants,</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">155,610 shares of common stock issuable upon the exercise of our outstanding  IPO Warrants,</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">551,815</span><span style="font-size: 10pt"> shares of common
    stock issuable upon the exercise of outstanding privately placed warrants, </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">10,825 shares of common stock reserved for issuance upon the exercise of an outstanding IPO underwriter representative common stock warrant.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">approximately 3,974,581 shares of common stock
which may be issued upon conversion of our outstanding Series B Convertible Preferred Stock at the current conversion price of $0.234,
</p>
</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify">approximately 5,685,049 shares of common stock which may be issued upon conversion of our outstanding
    Series C Convertible Preferred Stock at the current conversion price of $0.1759, and</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify">up to $6.8 million worth of common stock that may be sold in the future by us to White Lion from
    time to time pursuant to the Equity Line Purchase Agreement.</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b><span id="s_005"></span>RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Risk Factors.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Investing in our securities involves a high
degree of risk. You should carefully consider the risks and uncertainties described below, together with the other information contained
in this prospectus, before making a decision to invest in our securities. If any of the following events occur, our business, financial
condition and operating results may be materially adversely affected. In that event, the trading price of our securities could decline,
and you could lose all or part of your investment. The risks included here are not exhaustive or exclusive. Other sections of this prospectus
may include additional factors which could adversely affect our business, results of operations and financial performance. We operate
in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for management
to predict all such risk factors, nor can it assess the impact of all such risk factors on our business or the extent to which any factor,
or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks relating to this offering</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>It is not possible to predict the actual number
of shares we will sell under the Purchase Agreement to the Selling Securityholder, or the actual gross proceeds resulting from those sales.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to certain limitations in the Purchase
Agreement and compliance with applicable law, we have the discretion to deliver notices to the Selling Securityholder at any time throughout
the term of the Purchase Agreement. It is anticipated that shares offered to the Selling Securityholder in this offering will be sold
over a period until December 31, 2024, at the latest. The number of shares ultimately offered for sale to the Selling Securityholder under
this prospectus is dependent upon the number of shares we elect to sell to Selling Securityholder under the Purchase Agreement. The actual
number of shares of common stock that are sold to the Selling Securityholder may depend based on a number of factors, including the market
price of our common stock during the sales period. Actual gross proceeds may be less than $7.1&#160;million, which may impact our future
liquidity. Because the price per share of each share sold to the Selling Securityholder will fluctuate during the sales period, it is
not currently possible to predict the number of shares that will be sold or the actual gross proceeds to be raised in connection with
those sales, if any.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Investors who buy shares in this offering at
different times will likely pay different prices.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors who purchase shares of common stock
in this offering at different times will likely pay different prices, and so may experience different levels of dilution and different
outcomes in their investment results. In connection with the White Lion Transaction, we will have discretion, subject to market demand,
to vary the timing, prices, and numbers of shares of common stock sold to White Lion. Similarly, may sell such shares at different times
and at different prices. Investors may experience a decline in the value of the shares they purchase from the Selling Securityholder in
this offering as a result of sales made by us in future transactions to White Lion at prices lower than the prices they paid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The issuance of common stock to the Selling
Securityholder may cause substantial dilution to our existing shareholders, and the sale of such shares acquired by the Selling Securityholder
could cause the price of our common stock to decline.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are registering for resale by the Selling Securityholder
up to 1,450,000 shares of common stock. The Selling Securityholder may ultimately purchase all, some or none of the shares of common stock
that are the subject of this prospectus. After the Selling Securityholder has acquired shares under the Purchase Agreement, it may sell
all, some or none of those shares. Sales to the Selling Securityholder by us pursuant to the Purchase Agreement under this prospectus
may result in substantial dilution to the interests of other holders of our common stock. We have already issued 1,800,000 shares of common
stock to the Selling Securityholder under the Equity Line Purchase Agreement and had an effective registration statement that registers
the resale by the Selling Securityholder of these shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The sale of a substantial number of shares to
the Selling Securityholder in this offering, or anticipation of such sales, could make it more difficult for us to sell equity or equity-related
securities in the future at a time and at a price that we might otherwise desire. The number of shares of our common stock ultimately
offered for resale by the Selling Securityholder under this prospectus is dependent upon the number of shares of common stock issued to
the Selling Securityholder pursuant to the Purchase Agreement. Depending on a variety of factors, including market liquidity of our common
stock, the issuance of shares to the Selling Securityholder may cause the trading price of our common stock to decline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We have broad discretion in the use of the
net proceeds we receive from the sale of shares to the Selling Securityholder and may not use them effectively.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management will have broad discretion in the
application of the proceeds we receive from the Selling Securityholder, if any, including for any of the purposes described in the section
entitled &#8220;<span style="text-decoration: underline">Use of Proceeds</span>,&#8221; and you will not have the opportunity as part of your investment decision to assess whether
our management is using the proceeds appropriately. Because of the number and variability of factors that will determine our use of our
proceeds from the Selling Securityholder, their ultimate use may vary substantially from their currently intended use. The failure by
our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business
and cause the price of our common stock to decline. Pending their use, we may invest the proceeds from the Selling Securityholder in short-term,
investment-grade, interest-bearing securities. These investments may not yield a favorable return to our shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks related to our Nasdaq listing</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We are not currently in compliance with
the minimum bid price requirement and minimum stockholders&#8217; equity requirement of the Nasdaq Capital Market and a delisting could limit
the liquidity of our stock, increase its volatility and hinder our ability to raise capital.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have received deficiency letters from The
Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) that we are not in compliance with Nasdaq&#8217;s (i)&#160;minimum bid price
requirement of at least $1.00 per share (the &#8220;Bid Price Requirement&#8221;) and (ii) requirement to have at least
$2,500,000 in stockholders&#8217; equity (the &#8220;Stockholders&#8217; Equity Requirement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 8, 2024, we received a written notice
(the &#8220;Bid Price Notice&#8221;) from Nasdaq indicating that the Company was not in compliance with the Bid Price Requirement
set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. The Bid Price Notice did not result in
the immediate delisting of the Company&#8217;s common stock from the Nasdaq Capital Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Notice indicated
that the Company will be provided 180 calendar days (or until October 7, 2024) in which to regain compliance. We did not regain compliance
with Rule 5550(a)(2) prior to the expiration of the initial 180 calendar day period on October 7, 2024. On October 8, 2024, we received
from the Nasdaq staff (the &#8220;Staff&#8221;) written notification that our securities are subject to delisting from the Nasdaq Capital
Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At the Company&#8217;s
special stockholders&#8217; meeting on September 23, 2024, the Company&#8217;s stockholders approved a proposal to grant discretionary
authority to our board of directors to (i) amend our certificate of incorporation to combine outstanding shares of our common stock into
a lesser number of outstanding shares, or a &#8220;reverse stock split,&#8221; at a specific ratio within a range of one-for-five (1-for-5)
to a maximum of a one-for-fifty (1-for-50) split, with the exact ratio to be determined by our board of directors in its sole discretion;
and (ii) effect the reverse stock split, if at all, within one year of the date the proposal was approved by stockholders. The Company
intends to implement a reverse stock split in the near future in order to assist with the Company&#8217;s compliance with Nasdaq&#8217;s
Bid Price Requirement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 22,
2024, the Company received a letter from Nasdaq indicating that it was not in compliance with the Stockholders&#8217; Equity Requirement.
In its quarterly report on Form 10-Q for the period ended June 30, 2024, the Company reported stockholders&#8217; equity of $1,642,177,
and, as a result, did not satisfy Listing Rule 5550(b)(1). Accordingly, the Staff had determined to delist our common stock from Nasdaq.
Nasdaq&#8217;s letter provided us until August 29, 2024 to request an appeal of this determination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have appealed
both of these matters to the Panel. The hearing request stays any suspension or delisting action pending the conclusion of the hearing
process and the expiration of any additional extension period granted by the Panel following the hearing.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 10pt;">We
had an appeal hearing on October 10, 2024 before the Panel to appeal the delisting notices from the Staff. While the appeal process is
pending, the suspension of trading of our common stock will be stayed. Our common stock will continue to trade on Nasdaq until the hearing
process concludes and the Panel issues a written decision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The
Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq.
The Company is currently evaluating its available options to regain compliance with the Stockholders&#8217; Equity Requirement and the
Bid Price Requirement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If our common stock is delisted by Nasdaq, our common stock may be eligible for quotation on an over-the-counter
quotation system or on the pink sheets. Upon any such delisting, our common stock would become subject to the regulations of the SEC
relating to the market for penny stocks. A penny stock is any equity security not traded on a national securities exchange that has a
market price of less than $5.00 per share. The regulations applicable to penny stocks may severely affect the market liquidity for our
common stock and could limit the ability of shareholders to sell securities in the secondary market. In such a case, an investor may
find it more difficult to dispose of or obtain accurate quotations as to the market value of our common stock, and there can be no assurance
that our common stock will be eligible for trading or quotation on any alternative exchanges or markets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Delisting from Nasdaq
could adversely affect our ability to raise additional financing through public or private sales of equity securities, would significantly
affect the ability of investors to trade our securities and would negatively affect the value and liquidity of our common stock. Delisting
could also have other negative results, including the potential loss of confidence by employees, the loss of institutional investor interest
and fewer business development opportunities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks related to financial, operational, commercial and manufacturing
matters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>The auditors of our
December 31, 2023 and 2022 financial statements have expressed substantial doubt about our ability to continue as a going concern,
which may hinder our ability to obtain further financing.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our
                                            past working capital deficiency, stockholders&#8217; deficit and recurring losses from operations
                                            raised substantial doubt about our ability to continue as a going concern. As a result, our
                                            independent registered public accounting firm included an explanatory paragraph in its report
                                            on our financial statements for the year ended December 31, 2023, with respect to this uncertainty.
                                            Our existing cash will be sufficient to fund our current operating plans into the fourth
                                            quarter of 2024. If we are unable to raise capital when needed or on acceptable terms, we
                                            would be forced to delay, reduce, or eliminate our technology development and commercialization
                                            efforts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>We have incurred significant
net losses since inception and anticipate that we will continue to incur net losses for the foreseeable future and may never achieve or
maintain profitability.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since our inception, we have incurred significant
net losses. Our net losses were $4,911,374 and $7,068,593 for the years ended December&#160;31, 2023, and 2022, respectively. As of June
30, 2024, we had an accumulated deficit of $47,918,705. To date, we have devoted our efforts toward securing financing, building and evolving
our technology platform, and complying with regulatory requirements as well as initiating marketing efforts for our products. We expect
to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase
substantially if, and as, we:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">hire and retain additional sales, accounting and finance, marketing and engineering personnel;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">build out our product pipeline;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">add operational, financial and management information systems and personnel; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">maintain, expand, protect and enforce our intellectual property portfolio.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To become and remain profitable, we must enhance
the marketing and commercial acceptance of our products. This will require us to be successful in a range of challenging activities, and
our expenses will increase substantially as we bring these products to market. We may never succeed in any or all of these activities
and, even if we do, we may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability,
we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would
decrease the value of our company and could impair our ability to raise capital, develop new products, expand our business or continue
our operations. A decline in the value of our company also could cause stockholders to lose all or part of their investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i>We
have identified a material weakness in our internal control over financial reporting. Failure to maintain effective internal controls
could cause our investors to lose confidence in us and adversely affect the market price of our common stock. If our internal controls
are not effective, we may not be able to accurately report our financial results or prevent fraud.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160; </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 404 of the Sarbanes-Oxley Act of 2002,
or Section 404, requires that we maintain internal control over financial reporting that meets applicable standards. We may err in the
design or operation of our controls, and all internal control systems, no matter how well designed and operated, can provide only reasonable
assurance that the objectives of the control system are met. Because there are inherent limitations in all control systems, there can
be no assurance that all control issues have been or will be detected. If we are unable, or are perceived as unable, to produce reliable
financial reports due to internal control deficiencies, investors could lose confidence in our reported financial information and operating
results, which could result in a negative market reaction and a decrease in our stock price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will be required, pursuant to Section
404, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. Such
report will not be required until our second annual report filed on Form 10-K. We will need to disclose any material weaknesses identified
by our management in our internal control over financial reporting. As an &#8220;emerging growth company,&#8221; we will avail ourselves
of the exemption from the requirement that our independent registered public accounting firm attest to the effectiveness of our internal
control over financial reporting under Section 404. However, we may no longer avail ourselves of this exemption when we cease to be an
&#8220;emerging growth company.&#8221; When our independent registered public accounting firm is required to undertake an assessment
of our internal control over financial reporting, the cost of our compliance with Section 404 will correspondingly increase. Our compliance
with applicable provisions of Section 404 will require that we incur substantial accounting expense and expend significant management
time on compliance-related issues as we implement additional corporate governance practices and comply with reporting requirements. Moreover,
if we are not able to comply with the requirements of Section 404 applicable to us in a timely manner, or if we or our independent registered
public accounting firm identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses,
the market price of our stock could decline and we could be subject to sanctions or investigations by the U.S. Securities and Exchange
Commission, or SEC, or other regulatory authorities, which would require additional financial and management resources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we continue to have material weaknesses in
our internal control over financial reporting, if we are unable to comply with the requirements of Section 404 in a timely manner, if
we are unable to assert that our internal control over financial reporting is effective, or if our independent registered public accounting
firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting, we may be late with the
filing of our periodic reports, investors may lose confidence in the accuracy and completeness of our financial reports and the market
price of our common stock could be negatively affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>We will need additional
funding, which may not be available on acceptable terms, or at all. Failure to obtain this capital when needed may force us to delay,
limit or terminate our product development efforts or other operations.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We
                                            believe our current cash resources will be sufficient to fund our current operating plans
                                            into the fourth quarter of 2024. We expect our expenses to increase in connection
                                            with our ongoing activities, particularly as we continue to invest in sales, marketing and
                                            engineering resources and bring our products to market. Furthermore, since the closing of
                                            our IPO, we have incurred additional costs associated with operating as a public company.
                                            We will need additional funding to complete the development of our full product line and
                                            scale products with a demonstrated market fit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Building and scaling
technology products is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary
user experience required to obtain market acceptance and achieve meaningful product sales. In addition, our product candidates, once developed,
may not achieve commercial success. The majority of revenue will be derived from or based on sales of software products that may not be
commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our
business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Raising additional
capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies
and product candidates.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We may seek additional
capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing
arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership
interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder.
The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations
on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating
restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships
and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, or our other
product candidates, or grant licenses on terms unfavorable to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We are highly dependent on our senior management
team and key personnel, and our business could be harmed if we are unable to attract and retain personnel necessary for our success.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are highly dependent on our senior management
and key personnel. Our success will depend on our ability to retain senior management and to attract and retain qualified personnel in
the future, including sales and marketing professionals, engineers, scientists, clinical trial specialists and other highly skilled personnel
and to integrate current and additional personnel in all departments. The loss of members of our senior management, marketing professionals,
engineers, scientists and clinical trial specialists could result in delays in product development and harm our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Competition for skilled personnel in our market
is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms, or at all. To induce valuable
employees to remain at our company, in addition to salary and cash incentives, we have issued stock options that vest over time. The value
to employees of stock options that vest over time may be significantly affected by fluctuations in our stock price that are beyond our
control, and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable
employees, members of our management and other key personnel may terminate their employment with us on short notice. Our employment arrangements
with our employees provide for at-will employment, which means that any of our employees could leave our employment at any time, with
or without notice. We also do not maintain &#8220;key man&#8221; insurance policies on the lives of these individuals or the lives of
any of our other employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our MR data post-processing products currently
depend on compatible use with only a limited number of MR scanners that are provided only by one manufacturer of MR devices.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our MR data post-processing software products
are only compatible for post-processing disc MRS data acquired via certain scanner models and operating configurations provided only by
one, third-party scanner vendor - SIEMENS. There are risks associated with our reliance on SIEMENS, and/or the MR service providers who
own and operate the SIEMENS scanners, to maintain those scanners and their operating configurations in a manner that continues to support
compatibility with our products. There are also risks that current compatible scanner platforms may become incompatible as a result of
changes made to those scanners by SIEMENS, or by the scanner owner or related service provider, which would frustrate our ability to continue
supporting that MR provider customer with our products. There are also risks that these SIEMENS scanners do not perform reliably as intended
or expected in performing data acquisition exams as required by our post-processing products, which would also frustrate the ability for
our products to perform as intended. There is also a risk that SIEMENS loses its install base of compatible MR Scanners due to cannibalization
by other non-compatible replacement scanner sales or fails to grow its install base of those compatible scanners, which could adversely
affect the number and locations of compatible scanners for our own market share and penetration. Manifestations of these risks becoming
actually realized in the marketplace could harm our business, financial condition, and results of operations. We are not subject to any
exclusivity agreement or obligations with SIEMENS, nor do we have any fee sharing, royalty, or other exchange of moneys or payments between
us and Siemens. The nexus for our focused relationship with Siemens resulted from our determination that SIEMENS scanner models were optimally
positioned to support our product. We have had a collaborative relationship with Siemens since 2011 and have been party to a Collaborative
Agreement with Siemens since October of 2017, The Collaborative Agreement is terminable.at any time by either party if such party is of
the opinion that the goals of the Collaborative Agreement cannot be achieved for technical, economic and/or clinical reasons. If Siemens
were to terminate its relationship with the Company, it would have a material adverse effect on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>If we are not successful in enhancing awareness
of our technology, driving adoption across our current target population, increasing referrals from surgeons and clinicians, and expanding
the population of eligible patients, our sales, business, financial condition and results of operations will be negatively affected.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business depends on our ability to successfully
market our technology, which includes increasing the number of patients scanned with our technology, increasing adoption of our technology
and driving utilization of our technology by surgeons and clinicians. Additionally, our technology is primarily recommended and implemented
to provide advanced diagnosis and management of spine and back pain, in particular, for diagnosing painful discs causing discogenic low
back pain. Therefore, we are dependent on widespread market adoption of our technology. While we intend to expand the population of patients
we can provide with our diagnostic technology as well as increase the number of physicians, surgeons and clinicians that can prescribe
technology, there can be no assurance that we will succeed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The commercial success of
our technology will continue to depend on a number of factors, including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the actual and perceived effectiveness, safety and reliability, and clinical
        benefit, of our technology, especially relative to alternative diagnostic systems and devices;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the prevalence and severity of any adverse patient events involving the use
        of our technology;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the degree to which physicians, surgeons and clinicians, patients and imaging
        centers adopt our technology;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the continued effects of the COVID-19 pandemic;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the availability, relative cost and perceived advantages and disadvantages of
        alternative technologies, or other diagnostic or treatment methods, for spine and back pain;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the results of additional clinical and other studies relating to the health,
        safety, economic or other benefits of our technology;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">whether key thought leaders in the medical community accept that our clinical
        efficacy and safety results are sufficiently meaningful to influence their decision to adopt our technology over other spine and back
        pain diagnostics;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the extent to which we are successful in educating physicians, surgeons, clinicians,
        patients, and imaging facilities about the appropriate (and inappropriate) uses and benefits of our technology;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the strength of our marketing and distribution infrastructure, including our
        ability to drive adoption and utilization of our technology, as well as our ability to develop and maintain relationships with MRI manufacturers
        and imaging centers;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to obtain, maintain, protect, enforce and defend our intellectual
        property rights, in and to our technology;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to maintain compliance with all legal and regulatory requirements,
        including those applicable to our technology;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to maintain our contractual relationships with our vendors and component
        suppliers, including single-source vendors and suppliers through which we obtain critical components for (or compatible use with) our
        technology;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the establishment and continued reimbursement coverage of and adequate payment
        for the use of our technology and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to continue to attract and retain key personnel.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we fail to successfully market and sell our
technology cost-effectively and maintain and expand our market share, our sales, business, financial condition and results of operations
will be negatively affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our commercial success will continue to depend
on attaining significant market acceptance of our technology among physicians, surgeons, patients, clinicians and imaging facilities,
and increasing the number of patients diagnosed by our technology. </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our commercial success will depend, in large part,
on the further acceptance by surgeons, physicians, clinicians, patients and imaging facilities of our technology as safe, useful, cost-effective,
and that it can increase the number of patients that are diagnosed. We cannot predict how quickly, or if at all, additional surgeons,
physicians, clinicians, patients and imaging facilities will adopt our technology over competing diagnostic platforms for support in on-going
care and treatment options that are expected to be supported by the intended diagnostic uses of our technology. For example, surgeons,
other physicians, clinicians, patients, and imaging facilities may be reluctant to use our technology due to familiarity with pre-existing
diagnostic systems that are more established or an otherwise resistance to adopt new technologies or change current practices. Our ability
to grow sales of our technology and drive market acceptance will depend on successfully educating surgeons, physicians, clinicians, patients
and MR imaging facilities on the relative benefits of our Technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We may be unable to compete successfully with
other diagnostic options for low back pain, or may be unable to continue providing value for supporting new treatments that may not need
the diagnostic information our products provide.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The medical device industry is intensely competitive,
subject to rapid change and significantly affected by new product introductions and other market activities of industry participants.
Our current competition primarily resides with the diagnostic standards over which our products are intended to improve &#8211; in particular,
X-ray, lumbar MRI, and PD. Our products are positioned for synergistic use with lumbar MRI, and to enhance the diagnostic value of lumbar
MR exams. However, the existing reliance on lumbar MRI as a standard of care for our DLBP indication, and on PD in some medical practices,
and the potential for other enhancements to those platforms and techniques, nonetheless also represents a competitive threat. To the extent
that these other platforms represent our primary competitors, they are mainly provided by large, well-capitalized companies with significant
market share and resources. Most of our competitors have more established sales and marketing programs than us and have greater name recognition.
These competitors also have long operating histories and may have more established relationships with potential customers. Also, there
can be no assurance that other companies or institutions will not succeed in developing or marketing devices and products that are more
accurate, useful, effective or safer than our technology or that would render our technology obsolete or noncompetitive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Adoption of our technology depends on positive
clinical data as well as clinician acceptance of the data and our products, and negative clinical data or perceptions among these clinicians
would harm our sales, business, financial condition, and results of operations.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The rate of adoption and sales of our products
are heavily influenced by clinical data. We have published positive clinical data from an Institutional Review Board (&#8220;IRB&#8221;),
approved more than 100 patient single center trial in a major peer-reviewed spine journal which showed both: (a) high diagnostic accuracy
against provocation discography controls, and (b) much higher patient success outcomes for surgeries that treated discs identified as
painful using our products, versus much lower success rates when discs diagnosed as painful with our products were left untreated. However,
there can be no assurance that our clinical data will continue to be positive for our ongoing or future clinical studies. Additionally,
there can be no assurance that future clinical studies, including those to continue demonstrating the diagnostic accuracy and value of
our products in currently approved patient populations and those to support label retention and expansion for our products, will demonstrate
diagnostic acuity or value. Unfavorable or inconsistent clinical data from ongoing or future clinical studies conducted by us, our competitors,
or third parties, or the potential for negative interpretation of our clinical data by customers, competitors, patients, and regulators,
or the potential for finding new or more frequent adverse events related to the use of our products could harm our sales, business, financial
condition, and results of operations<i>.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>If adequate reimbursement is not available
for the procedures implementing our technology, or for clinicians to provide ongoing care for patients diagnosed with our technology,
it could diminish our sales or affect our ability to sell our technology.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ability to increase sales of our technology
depends, in significant part, on the availability of adequate financial coverage and reimbursement from third-party payors, which include:
(i) governmental payors such as the Medicare and Medicaid programs in the United States; (ii) private managed care organizations; and
(iii) private health insurers. Third-party payers determine which services and treatments they will cover and establish reimbursement
rates for those treatments. While we have secured certain reimbursement codes against which the use of our products can potentially be
billed, we do not yet currently bill any third-party payers directly for our technology. The cost of our customers using our technology
is currently being paid for by either: (i) billing patients to pay directly (ii) allocation at least in part against payments received
by healthcare providers for other procedures conducted in association with the use of our technology, or (c) third-party payer reimbursement
payments to a several of our customers for less than 10 patients through the date of this prospectus. A failure to obtain wide coverage
and adequate reimbursement for using our technology in conducting our new diagnostic procedures, or for clinicians providing ongoing patient
care based on or related to our diagnostic results could diminish our sales and affect our ability to sell our technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>If adequate reimbursement for our temporary
Category III CMS Code designation for our products cannot be obtained or we are not successful in obtaining conversion to permanent Category
I codes at an adequate reimbursement level, it would diminish our sales and would affect our ability to market our technology.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2021, our Category III CPT Codes
became effective. Category III codes represent the first step in the reimbursement process. The effectiveness of our Category III codes
commenced a five-year period in which, in order to maintain our Category III status, we are required to demonstrate that the medical community
needs (&#8220;Clinical Needs&#8221;) the NOCISCAN product. Clinical Needs would be demonstrated to the CPT Committee based on the volume
at which our Category III codes are billed by imaging centers and physicians. In addition to demonstrating that there is Clinical Needs,
we also are required to show that NOCISCAN is clinically effective as indicated by patients having better outcomes when NOCISCAN reports
are used to help guide surgical treatments. We expect to show clinical effectiveness through a combination of clinical registries and
clinical studies that build upon our published clinical study the CPT committee used to create our Category III CPT codes. However, if
we are not able to demonstrate Clinical Needs, nor that NOCISCAN is clinically effective, our revenue would be limited to a direct patient
payment model, which will severely limit our ability to market our products and generate sufficient revenue to continue market our technology.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, for us to obtain a conversion from of
our CPT codes from Category III to Category I, we will need to attract a significant larger number of surgeons and imaging centers to
adopt our technology and thereby increase the volume of reimbursement claims data needed for the CPT committee to determine that our product
is needed in the healthcare marketplace. In addition to generating clinical use volume, we will also need to demonstrate the ongoing clinical
efficacy of our products to secure adequate reimbursement from payers. A failure to convert Category III codes to Category I codes will
ultimately make us more dependent on a patient pay model which will significantly diminish our sales and affect our ability to market
our technology<i>.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Use of our technology requires appropriate
training for proper use of our products, and inadequate training may lead to negative patient outcomes, which could harm our business,
financial condition, and results of operations.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The successful use of our technology depends,
in part, on the training and skill of referring doctors and other healthcare providers for appropriately prescribing our diagnostic exam
for the correctly indicated patients and anatomy, and properly interpreting the results from using our product as indicated under our
related IFUs. It also depends upon MR technicians and operators appropriately implementing and using our technology as indicated under
our related IFUs. MR technicians and operators could also experience difficulty with the steps and techniques necessary to successfully
implement and use our technology protocols. We cannot guarantee that all medical and MR technician professionals will have the necessary
skills and training, according to our instructions for use, or will sufficiently comply with that training and instructions for use in
order to properly prescribe and interpret the results of our diagnostic imaging platform. We cannot be certain that surgeons, other physicians,
MRI technicians or operators, or other healthcare providers that use our technology will have received sufficient training or will continue
to comply with that training in their on-going practice in using our technology. If physicians and surgeons utilize our technology incorrectly
or, without adhering to or completing all relevant training according to our instructions, the utility and value of our diagnostic products
and their related patient outcomes from on-going care following that diagnostic work-up may not be consistent with the outcomes achieved
in our clinical studies or otherwise expected or desired by such care providers or the patients themselves. Adverse treatment outcomes
that could potentially arise from improper or incorrect use of our technology may negatively impact the perception of patient benefit
and safety of our technology, notwithstanding results from our clinical studies. These results could limit adoption of our technology,
which would harm our sales, business, financial condition, and results of operations.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We expect to increase the size of our organization
in the future, and we may experience difficulties in managing this growth. If we are unable to manage the anticipated growth of our business,
our future revenue and operating results may be harmed.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As
                                            of October 2, 2024 we had 4 full-time employees, 2 part-time employees, 1 full-time
                                            consultant, and 3 part-time consultants. As our sales and marketing strategies develop, and
                                            as we transition into operating as a public company, we expect to need additional managerial,
                                            operational, sales, marketing, financial and other personnel. Future growth would impose
                                            significant added responsibilities on members of management, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">identifying, recruiting, integrating, maintaining and motivating additional
        employees;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">managing our internal development efforts effectively, while complying with
        our contractual obligations to contractors and other third parties; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">improving our operational, financial and management controls, reporting systems
        and procedures.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our future financial performance and our ability
to successfully market and sell our technology will depend, in part, on our ability to effectively manage any future growth, and our management
may also have to divert a disproportionate amount of attention away from day-to-day activities in order to devote a substantial amount
of time to managing these growth activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We may not be able to achieve or maintain satisfactory
pricing and margins for our NOCISCAN disc MRS diagnostic software products and related services, which could harm our business and
results of operations.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Software products classified as medical devices
have a history of price competition and we can give no assurance that we will be able to maintain satisfactory prices for our technology.
The pricing of our technology could be impacted by several factors, including pressure to reduce prices by our customers due to a decline
in the amount that third-party payers reimburse for diagnostic procedures using our technology or for clinicians providing ongoing patient
care related to the diagnostic information we provide. A decline in the amount that third-party payers reimburse our customers for ongoing
patient care could also make it difficult for us to maintain procedural volume without a corresponding reduction in prices for our products.
If we are forced to lower the price we charge for our technology, our gross margins will decrease, which, will harm our ability to invest
in and grow our business. If we are unable to maintain our prices or if our costs increase and we are unable to offset such increase with
an increase in our prices, our margins would erode and could harm our business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our results of operations may be harmed if
we are unable to accurately forecast customer demand for our technology</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ability to accurately forecast demand for
our products could be negatively affected by many factors, including (i) our potential failure to accurately manage or execute our expansion
strategy, (ii) new product introductions by competitors, (iii) an increase or decrease in customer demand for our products or for other
competing products, (iv) our failure to accurately forecast customer adoption of new products, (v) unanticipated changes in general market
conditions or regulatory matters, (vi) weakening of economic conditions or consumer confidence in future economic conditions, and (vii)
the ongoing COVID-19 pandemic. Software processing capacity, data storage, and related computer hosting resources in excess of customer
demand may result in financial write-downs or write-offs, which would cause our gross margin to be adversely affected and could impair
the strength of our brand. Conversely, if we underestimate customer demand for our products, our technical and IT resource support team,
software processing and storage resources, and computing architectures may not be able to support sufficient processing requirements
to meet the demand for our products; and, this could result in lost sales and damage to our reputation and customer relationships. In
addition, if we experience a significant increase in demand, additional computing and storage capacity and resources, and additional
technical support personnel required to support the increased demand may not be available when required or on terms that are acceptable
to us, or at all, which may negatively affect our sales, business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks related to government regulation and
our industry</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our operations and technology are subject to
pervasive and continuing FDA regulatory requirements, and failure to comply with these requirements could harm our business, financial
condition and results of operations.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before a regulated new medical device or service,
or a new intended use for an existing device or service, can be marketed in the United States, a company must first receive either 510(k)
clearance, or a PMA from the FDA, unless an exemption applies. In the 510(k) clearance process, before a device may be marketed, the FDA
must determine that: (i) a proposed device is substantially equivalent to a legally-marketed predicate device, which includes a legal
marketed device that has been previously cleared through the 510(k) process, (ii) was legally marketed prior to May 28, 1976 (pre-amendments
device), (iii) was legally marketed pursuant to an approved PMA and later down-classified, or (iv) is covered by a classification regulation
created through the de novo review process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the process of obtaining PMA approval, which
the FDA could potentially require in the future for our products, the FDA must determine that a proposed device is safe and effective
for its intended use based, in part, on extensive data, including, but not limited to, technical, preclinical, clinical study, manufacturing
and labeling data. The PMA process is typically required for devices that are deemed to pose the greatest risk, such as life-sustaining,
life-supporting or implantable devices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that one of our products under the
NOCISCAN Suite, NOCICALC, is a Class I 510(k)-exempt medical device, which only requires registration and no pre-market review with
the FDA, and which we registered as such with the FDA. We also believe the other of our products in the suite, NOCIGRAM, is &#8220;Clinical
Decision Support Software&#8221; under the 21<sup>st</sup> Century Cures Act and as such, is not considered a medical device, and thus
is not regulated by the FDA. Accordingly, we believe that our current products do not require FDA clearance or approval under either 510(k)
or PMA approval pathways. However, there can be no assurance that in the future, the FDA will not determine that PMA approval, de novo
classification, or 510(k) clearance is required for our products. If the FDA were to make such a determination, we would not be able to
sell or market our products without or until securing such approval or clearance and may be subject to potential fines and other penalties
or remedial actions for illegally marketing or selling an unapproved medical device, which would affect our sales, business, financial
condition, and results of operation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>If we are unable to expand the labeling claims
for using our technology to include additional indications, our growth potential could be harmed.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to seek expanded labeling claims for
our technology in the future, including for example: (i) extending the intended indications for use to include disc MRS along the thoracic
or cervical spine, (ii) incorporating certain MRI image post-processing along with MRS data post-processing, and (iii) real-time post-processing
of MRS exam data during the exam itself via our software installed and operated within the MR scanner software environment (vs. our current
products which are for cloud-hosted post-processing of MRS data that is transferred to us, following the MRS exams, via our own remote
computing resources). If regulatory clearance or approval is required to expand the use of our technology, and which clearance and approval
may require clinical trial results, we could incur substantial costs and the attention of management could be diverted throughout this
process. However, there can be no assurance we will be able to obtain and maintain necessary clearance or approvals for additional uses
of our technology, or even if obtained, that the broadened use of our technology would be accepted or adopted by intended users, thus
limiting the growth potential of our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our medical device products may be subject
to recalls, which could divert managerial and financial resources, harm our reputation and our business.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA has the authority to require the recall
of medical device products in certain circumstances. A government mandated or voluntary product recall by us could occur because of device
malfunctions or other adverse events, such as quality-related issues resulting from product operating malfunctions or defects. Any future
recalls of our products could divert managerial and financial resources, harm our reputation and negatively impact our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we initiate a correction or removal of certain
of our products from the market to reduce a risk to health posed by the device, we would be required to submit a Correction and Removal
report to the FDA and, in many cases, similar reports to other regulatory agencies. This report could be classified by the FDA as a device
recall which could lead to increased scrutiny by the FDA and our customers regarding the quality and safety of our products. Furthermore,
the submission of these reports could be used by competitors against us and could harm our reputation, which could cause customers to
delay purchase decisions, cancel orders or decide not to purchase our products and could cause patients to lose trust in our technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We may experience difficulties outside the
US in obtaining or maintaining regulatory clearance or approval, or exemptions therefrom, or in successfully gaining third-party reimbursement
or marketing our technology, even if approved or otherwise legally marketed. </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our NOCISCAN product suite was initially commercialized
as a Class I medical device under European Commission regulations. The process did not require pre-market submission, review, or certification
by a Notified Body in order to be CE marked. A &#8220;Notified Body&#8221; is an organization designated by an EU country to assess the
conformity of certain products before being placed on the market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For commercialization outside the United States,
in particular the European Union (&#8220;EU&#8221;) and United Kingdom (&#8220;UK&#8221;), the Company, in conjunction with our regulatory
consultants, determined NOCISCAN to be a Class I medical device, for which we secured a CE mark via self-certification. As such, we self-certified
our product for the CE mark under a Declaration of Continuity (&#8220;DOC&#8221;) filed by us as part of a dossier with a qualified EU
Representative. Since self-certification was completed by the Company, the EU adopted Medical Device Regulation (EU) 2019/1020, known
as MDR, that went into effect on July 16, 2021. Under these new regulations, we believe NOCISCAN to be considered a Class II(a) device
that requires re-certification for CE mark by a Notified Body prior to May 2024. Notified Bodies carry out tasks related to conformity
assessment procedures set out in the applicable legislation, when a third party is required. Class II(a) device certification is subject
to additional requirements for approval beyond our existing submissions, including requiring pre-market review and CE mark approval by
a Notified Body, and which may require submission and approval of supportive clinical data. We are currently seeking to identify, but
have not yet engaged, a Notified Body for this purpose. The available number of Notified Bodies, and those engaging new company applicants,
has been significantly reduced in recent years and the ability for conducting a Notified Body review and CE mark approval can typically
take more than a year. Certain aspects of the new MDR also place new requirements on Class I medical devices that are not subject to the
extended 2024 grace period and became effective as of May 2021. This applies to new required policies and practices for post-market surveillance
of our products. While we are not currently compliant with these new requirements, we are in the process of updating our policies and
practices and taking the corrective actions to achieve and maintain ongoing compliance. We believe the actions we are taking are sufficient
to support the continuance of our commercial activities in the EU under our CE mark without adverse penalties or other consequences. However,
there is a risk that one or more regulatory body or agency in the EU may determine otherwise, either with respect to our prior non-compliance
that has since been corrected or with respect to the sufficiency of our corrective actions, and which could result in us incurring certain
penalties or other consequences.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are unable to engage or receive CE mark
approval from a Notified Body under the MDR by the May 2024 grace period deadline, or are determined to be non-compliant with MDR regulations
not subject to the grace period and therefore applicable to us as of May 2021, we could lose our CE mark, and may become unable to continue
promoting or selling our products for commercial use in the EU, UK, or other countries that relate their medical device regulations to
a CE mark.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In conjunction with Brexit, medical devices in
the UK are no longer governed by CE regulations. As such, the UK has introduced the UKCA marking system which largely follows the CE marking
regulations to include permitting use of the same submissions for approval. The major difference post-Brexit is that CE marking is regulated
by the EU and UKCA marking is regulated by the UK. The only practical implication to the Company is the requirement of a Notifying Body
within both the EU and the UK. If the Company is successful in meeting all requirements of the CE mark under MDR set forth above, the
company believes it will meet all requirements for UKCA marking. While we are not currently compliant with new requirements in the UK,
we are in the process of updating our policies and practices and taking what we believe are corrective actions to achieve and maintain
ongoing compliance in the UK. We believe our activities are sufficient to support the continuance of our commercial activities in the
UK under our CE mark without adverse penalties or other consequences. However, there is a risk that one or more regulatory body or agency
in the UK may determine otherwise, either with respect to our prior non-compliance that we believe has been corrected or with respect
to the sufficiency of those corrective actions and which could result in us incurring certain penalties or other adverse consequences
to our business. There can be no assurance that we can obtain a UKCA mark and if we are not able to secure a UKCA mark, we will lose our
ability to conduct business in the UK.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of our technology outside of the United
States will be subject to foreign regulatory requirements governing clinical studies and marketing approval, as well as additional post-market
requirements. We would incur substantial expenses in connection with any international expansion. Additional risks related to operating
in foreign countries include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">differing, and potential changes in, regulatory requirements in foreign countries,
        including with respect to data privacy and security;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">differing, and potential changes in, reimbursement regimes in foreign countries,
        including price controls;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">unexpected changes in tariffs, trade barriers, price and exchange controls and
        other regulatory requirements;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">economic weakness, including inflation, or political instability in particular
        foreign economies and markets;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">compliance with tax, employment, immigration and labor laws for employees living
        or traveling abroad;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">foreign taxes, including withholding of payroll taxes;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">foreign currency fluctuations, which could result in increased operating expenses
        or reduced revenue;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">difficulties staffing and managing foreign operations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">workforce uncertainty in countries where labor unrest is more common than in
        the United States;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">potential liability under the U.S. Foreign Corrupt Practices Act of 1977, as
        amended, or the FCPA, or comparable foreign regulations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">challenges enforcing our contractual and intellectual property rights as well
        as intellectual property theft or compulsory licensing, especially in those foreign countries that do not respect and protect intellectual
        property rights to the same extent as the United States; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">business interruptions resulting from geopolitical actions, including war and
        terrorism.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These and other risks associated with international
operations that may harm our ability to attain or maintain profitable operations internationally, which would harm our growth potential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, there are foreign privacy laws and
regulations that impose restrictions on the collection, use, storage, disclosure, transfer and other processing of personal data, including
health information. For example, the European Union General Data Protection Regulation (&#8220;GDPR&#8221;), imposes stringent data protection
requirements, including, for example, more robust disclosures to individuals, a strengthened individual data rights regime, shortened
timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to special categories
of data, such as health data, and additional obligations regarding third-party processors in connection with the processing of the personal
data. Our failure to comply with the GDPR or other applicable foreign privacy laws or regulations or significant changes in the laws and
regulations restricting our ability to obtain or use required patient information could significantly impact our business and our future
business plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>If we fail to comply with fraud and abuse and
other healthcare laws and regulations in the U.S. and internationally including those relating to kickbacks and false claims for reimbursement,
we could face substantial penalties and our business, financial condition and results of operations could be harmed.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Healthcare providers play a primary role in the
distribution, recommendation, ordering and purchasing of any of our products. Through our arrangements with healthcare professionals and
hospital facilities, we are exposed to broadly applicable anti-fraud and abuse, anti-kickback, false claims and other healthcare laws
and regulations that may constrain our business, our arrangements and relationships with customers, and how we market, sell and distribute
our marketed medical devices. We have a compliance program, code of conduct and associated policies and procedures, but it is not always
possible to identify and deter misconduct by our employees, contractors, and other third parties, including our customers, and the precautions
we take to detect and prevent noncompliance may not be effective in protecting us from governmental investigations for failure to comply
with applicable fraud and abuse or other healthcare laws and regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, we are subject to various
state and federal anti-fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and federal civil False
Claims Act, or the FCA. Our relationships with physicians, other health care professionals and hospitals are subject to scrutiny under
these laws. There are also similar laws in other countries that we may become subject to if we expand internationally.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The laws that may affect our ability to operate
include, among others:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Anti-Kickback Statute, which prohibits, among other things, knowingly and
        willingly soliciting, offering, receiving or paying remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to
        induce or reward either the referral of an individual, or the purchase, order or recommendation of, items or services for which payment
        may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The federal civil and criminal false claims laws, including the FCA, and civil
        monetary penalties laws, which prohibits, among other things, persons or entities from knowingly presenting, or causing to be presented,
        a false or fraudulent claim for payment of government funds and knowingly making, using or causing to be made or used, a false record
        or statement to get a false claim paid or to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Health Insurance Portability and Accountability Act of 1996, or HIPAA, which
        applies to our customers and some of their downstream vendors and contractors, imposes criminal and civil liability for, among other actions,
        knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party
        payers, or knowingly and willfully falsifying, concealing or covering up a material fact or making a materially false, fictitious or fraudulent
        statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious
        or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Various state laws governing the privacy and security of personal information,
        including the California Consumer Privacy Act (&#8220;CCPA"), which became effective on January 1, 2020, which regulates the processing
        of personal information of California residents and increases the privacy and security obligations of covered companies handling such
        personal information. The CCPA requires covered companies to, amongst other things, provide new and additional disclosures to California
        residents, and affords such residents new abilities to access their personal information and opt out of certain sales of personal information;
        and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The federal Physician Payments Sunshine Act, also known as Open Payments, requires
        manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s
        Health Insurance Program to report annually, with certain exceptions to the Centers for Medicare and Medicaid Services, or CMS, information
        related to payments or other &#8220;transfers of value&#8221; made to certain physicians or other healthcare providers, as defined by
        such law, and teaching hospitals, and requires applicable manufacturers and group purchasing organizations to report annually to CMS ownership
        and investment interests held by physicians and their immediate family members.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">State and federal regulatory and enforcement agencies
continue to actively investigate violations of healthcare laws and regulations, and the U.S. Congress continues to strengthen the arsenal
of enforcement tools. Enforcement agencies also continue to pursue novel theories of liability under these laws. In particular, government
agencies have increased regulatory scrutiny and enforcement activity with respect to manufacturer reimbursement support activities and
patient care programs, including bringing criminal charges or civil enforcement actions under the Anti-Kickback Statute, the FCA and HIPAA&#8217;s
healthcare fraud and privacy provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Achieving and sustaining compliance with applicable
federal and state anti-fraud and abuse laws may prove costly. If we, or our employees, are found to have violated any of the above laws
we may be subjected to substantial criminal, civil and administrative penalties, including imprisonment, exclusion from participation
in federal healthcare programs, such as Medicare and Medicaid, and significant fines, monetary penalties, forfeiture, disgorgement and
damages, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings and the curtailment or
restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results. Any
action or investigation against us for the violation of these healthcare fraud and abuse laws, even if successfully defended, could result
in significant legal expenses and could divert our management&#8217;s attention from the operation of our business. Companies settling
FCA, Anti-Kickback Statute or civil monetary penalties law cases also may be required to enter into a Corporate Integrity Agreement with
the OIG, in order to avoid exclusion from participation (which results in a loss of coverage for their products) in federal healthcare
programs such as Medicare and Medicaid. Corporate Integrity Agreements typically impose substantial costs and operational burdens on companies
to ensure compliance. Defending against any such actions can be detrimental to our reputation and brand and can otherwise be costly, time-consuming
and may require significant personnel resources, and may harm our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We have financial relationships with certain
physicians and health care providers, research investigators, and authors for our clinical or scientific publications that may be deemed
a conflict of interest and may be subject to certain statutory or regulatory requirements, under which a failure to comply could lead
to enforcement actions against us and other negative consequences for our business.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have certain financial relationships with medical
doctors and other healthcare providers who are investors and shareholders in our Company and/or paid consultants, clinical investigators,
or speakers promoting our products and clinical results, some of whom are also our customers who pay us for patients receiving a NOCISCAN
exam, or otherwise prescribe and get paid for interpreting a NOCISCAN exam. There are risks that one or more of these relationships
may be determined to be a conflict of interest and be in violation of applicable laws, regulations, or guidelines, which could potentially
subject us to significant fines or curtailment of our active commercial operations, and which could also potentially harm our reputation
in the marketplace. If we are deemed to not comply with requirements governing the industry&#8217;s relationships with physicians or there
is an investigation into our compliance by the Office of the Inspector General, the Department of Justice, states&#8217; attorney generals
or other government agencies, it could harm our sales, business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Regulatory compliance is expensive, complex
and uncertain, and a failure to comply could lead to enforcement actions against us and other negative consequences for our business.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA, EU, and other foreign regulatory agencies
or governing bodies, regulate certain of our products as medical devices. Complying with these regulations is costly, time-consuming,
complex and uncertain. For instance, before a new medical device, or a new intended use for an existing device, can be marketed in the
United States, a company must first submit and receive either 510(k) clearance, de novo approval, or approval of a PMA from the FDA, unless
an exemption applies. FDA regulations and regulations of similar agencies are wide-ranging and include, among other things, oversight
of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">product design, development, manufacturing (including suppliers) and testing;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">laboratory, preclinical and clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">product safety and effectiveness;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">product labeling;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">product storage and shipping;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">quality assurance policies, practices, and record keeping;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">pre-market clearance or approval;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">marketing, advertising and promotion;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">product sales and distribution;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">product changes;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">product recalls; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">post-market surveillance and reporting of deaths, serious injuries, certain
        malfunctions, and related corrective actions.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, improvements of our existing technology,
any potential new technology, and new indications for use of our current technology may be subject to extensive regulation, and we may
require permission from regulatory agencies and ethics boards to conduct clinical studies, as well as clearance or approval from the FDA,
or other such foreign regulatory agencies or governing bodies, prior to commercial sale. In order to commercialize and distribute our
products in markets outside of the United States, it will require approval from, or otherwise meeting the requirements of, non-U.S. regulatory
agencies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 38 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA and foreign regulatory bodies can delay,
limit or deny clearance or approval (or otherwise a related &#8220;exemption&#8221;) for a device for many reasons, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our inability to demonstrate to the satisfaction of the FDA or the applicable
        regulatory entity or notified body that our products are safe or effective for their intended uses;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">disagreement of the FDA or the applicable foreign regulatory body with the design
        or implementation of our clinical studies or the interpretation of data from clinical studies, or with the regulatory classification or
        related pre-market regulatory pathway pursued by the Company for our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">adverse device effects experienced by participants in our clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the insufficiency of data from our preclinical studies and clinical studies
        to support clearance or approval, where required;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our inability to demonstrate that the clinical and other benefits of our products
        outweigh the risks;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">failure of our manufacturing process or facilities to meet applicable requirements;
        and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">significant changes to the policies or regulations of the FDA or applicable
        foreign regulatory bodies that render our clinical data or regulatory classifications, pre-market review pathways, or related filings
        insufficient for approval or that otherwise prevent us from legally marketing our products.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Future clinical studies may be delayed, suspended
or terminated for many reasons, including to support reimbursement coverage and certain potential label expansions for additional indications,
which will increase our expenses and delay the time it takes to secure reimbursement coverage or support label expansion for additional
indications.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to continue to develop and execute clinical
studies to support reimbursement coverage for using our products, label retention for our products, label expansion for our products into
additional claims for diagnosing painful discs and improving patient outcomes and additional thoracic and cervical discogenic back pain
patient populations. We may also develop and execute clinical studies for new products or for label expansion for our current products
into patient populations suffering from other pain or tissue chemistry-mediated conditions. We may also develop modifications to our products,
and conduct related clinical studies, related to expanding indications for post-processing data from other MRS applications in the body.
We do not know whether future clinical studies will begin on time, will need to be redesigned, have an adequate number of patients enrolled
or be completed on schedule, if at all. The commencement and completion of clinical studies to support label retention and expansion for
additional indications or for new products may be delayed, suspended or terminated as a result of many factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the delay or refusal of regulators or Institutional Review Boards, or IRBs,
        to authorize us to commence a clinical study at a prospective trial site;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">changes in regulatory requirements, policies and guidelines;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delays or failure to reach agreement on acceptable terms with prospective clinical
        research organizations, or CROs, and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly
        among different CROs and trial sites;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delays in patient enrollment and variability in the number and types of patients
        available for clinical studies, including due to COVID-19 or other disease outbreak, and delays in or the inability to monitor enrolled
        patients, including due to COVID-19 or other disease outbreak;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the inability to recruit, enroll, or retain a sufficient number of patients;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">deviations by our CROs or clinical sites from the trial protocol or study discontinuation
        by participants, investigators, or study sites;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">safety or tolerability concerns that could cause us to suspend or terminate
        a trial if we find that the participants are being exposed to unacceptable health risks;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulators, Institutional Review Boards (&#8220;IRBs&#8221;), Ethics Committees
        or Data Safety Monitoring Boards requiring that we or our investigators or study sites suspend or terminate clinical studies for various
        reasons, including noncompliance with GCP or other regulatory requirements or safety concerns;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">lower than anticipated retention rates of patients and volunteers in clinical
        studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">failure of our CROs or clinical studies sites to comply with regulatory requirements
        or meet their contractual obligations to us in a timely manner, or at all;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delays relating to identifying and engaging with and adding new clinical study
        site that have access to compatible MR scanners for using our products; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">exceeding budgeted costs.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 39 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, if the FDA concludes that we have
not adequately disclosed financial interests of our investigators or if our disclosed financial relationships with investigators result
in a perceived or actual conflict of interest that may have affected the interpretation of a study, the integrity of the data generated
at the applicable clinical study site or the utility of the clinical study itself, FDA may refuse to consider data from the study. This
could result in the delay or rejection by the FDA. Any such delay or rejection could prevent us from supporting label retention and expansion
for our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>A failure to comply with governmental regulatory
requirements would have a negative impact upon our business.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Failure to comply with applicable U.S. requirements
regarding promoting, manufacturing, labeling, and establishing and complying with appropriate quality assurance policies, systems, and
practices for our products may subject us to a variety of administrative or judicial actions and sanctions. We currently offer the NOCISCAN
product suite via two interactive products, NOCICALC, which is listed with the FDA as a Class I, 510(k)-exempt product, and NOCIGRAM,
a type of medical software that we have concluded is exempt from medical device regulation by the FDA pursuant to the 21<sup>st</sup>
Century Cures Act. This product suite is also self-certified and CE Marked as a Class I medical device under MDD requirements, while we
believe it is considered a Class II medical device and requiring Notified Body review and certification under newer MDR regulations (subject
to a grace period until May 2024). These products are marketed and sold with certain labeling and related instructions for use and are
promoted by various marketing and sales materials and related human interactions via our personnel and our target customers. We have also
established, and operate under, certain quality assurance systems, policies, and procedures under our QMS intended to be compliant with
applicable requirements for all relevant territories and jurisdictions related to our commercial activities. In the event that our establishment,
maintenance, marketing, promotion, labeling, or execution of these products, or these systems, policies, practices, or procedures, are
determined to be inadequate or non-compliant with applicable regulatory requirements, such defect could result in certain potential enforcement
actions or other adverse consequences, and our business would be negatively affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>If we become subject to enforcement action
by governmental regulatory agencies, our business would be negatively affected. </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our failure to comply with applicable regulatory
requirements could result in enforcement action by the FDA or other governmental regulatory agencies, which enforcement actions may include
the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">untitled letters, warning letters, fines, injunctions, consent decrees and civil
        penalties;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">unanticipated expenditures to address or defend such actions;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">issuance of form 483s, or other compliance or enforcement notices, communications
        or correspondence from regulatory bodies;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">recall, detention or seizure of our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">operating restrictions or partial suspension or total shutdown of marketing,
        sales and production or offering of product-related services;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">refusing or delaying our requests for 510(k) clearance or de novo classification
        or PMA approval of new products or modified products;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">requiring products that we determined to be classified and listed with the FDA
        as a Class I, 510(k)-exempt medical device, or that we determined not to be a medical device and thus unregulated by the FDA, instead
        to be submitted for marketing authorization (510(k) clearance, de novo classification, or PMA approval); </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">operating restrictions;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">withdrawing market authorizations that have already been granted; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">refusal to grant any export approval that might be required for our NOCISCAN
        product suite; or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">criminal prosecution</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of these events were to occur, it would
have a negative impact on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p>

<!-- Field: Page; Sequence: 40 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>If certain of our medical device products cause
or contribute to a death or a serious injury or malfunction in certain ways, we will be required to report under applicable medical device
reporting regulations, or MDRs, which can result in voluntary corrective actions or agency enforcement actions and harm our reputation,
business, financial condition and results of operations.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FDA&#8217;s Medical Device Reporting (&#8220;MDR&#8221;)
regulation requires, medical device manufacturers to report to the FDA information of which the manufacturer becomes aware that a device
has or may have caused or contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute
to death or serious injury if the malfunction of the device or a similar device marketed by the manufacturer were to recur. If we fail
to report events required to be reported to the FDA within the required timeframes, or at all, the FDA could take enforcement action and
impose sanctions against us. Any such adverse event involving our products also could result in the need to take corrective and preventative
actions, such as changes to design or manufacturing processes, corrections, removals, or recalls or customer notifications, or agency
action, such as inspection or enforcement action. Risk of harm to patients, including without limitation serious injury or death, associated
with using our products could also result in product liability actions against us. Any corrective action, whether voluntary or involuntary,
as well as defending ourselves in a lawsuit, would be costly, distract management from operating our business, could be used by competitors
against us, and may harm our reputation, business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>From time to time, we engage outside parties
to perform services related to certain of our clinical studies. If these third parties do not successfully carry out their contractual
duties or meet expected deadlines, we may not be able to complete our clinical studies on our planned timelines, or at all, and may incur
significant additional costs.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA&#8217;s investigational device exemption
(&#8220;IDE&#8221;) regulations impose requirements on the conduct of certain clinical investigations conducted with medical devices.
The requirements depend on whether the study is considered to be exempt, a nonsignificant risk or a significant risk. In general, clinical
investigations with medical devices, including those that are IDE exempt, must comply with requirements for the protection of human subjects,
which include review and approval by an institutional review board (&#8220;IRB&#8221;) and informed consent of subject participants. Significant
risk device studies also must submit an IDE to FDA for approval. The IDE regulations specify the responsibilities of sponsors and investigators
to ensure compliance with IDE requirements, including compliance with Good Clinical Practice (&#8220;GCP&#8221;) requirements. Failure
to comply may result in FDA placing a temporary or permanent clinical hold on the study, issuance of warning letters, or other regulatory
actions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, we engage consultants to help
design, monitor and analyze the results of certain clinical studies and trials that we sponsor. The consultants we engage may interact
with clinical investigators to enroll patients in our clinical studies. We depend on these consultants and clinical investigators to conduct
clinical studies and trials and monitor and analyze data from these studies and trials under the investigational plan and protocol for
the study or trial and in compliance with applicable regulations and standards. We may face delays in, or be prevented from, completing
our clinical studies if these parties do not perform their obligations in a timely, compliant or competent manner. Such roles, functions,
and related risks, also apply to certain employees of the Company. If these third parties or employees do not successfully carry out their
duties, comply with Good Clinical Practice (GCP) guidelines and other applicable requirements, or meet expected deadlines, or if the quality,
completeness or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical study protocols or for other
reasons, our clinical studies or trials may need to be extended, delayed or terminated by us or be placed on clinical hold by FDA, or
may otherwise prove to be unsuccessful, and we may have to conduct additional studies, which would significantly increase our costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Healthcare reform initiatives and other administrative
and legislative proposals may harm our business, financial condition, results of operations and cash flows in our key markets.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have been, and continue to be, proposals
by the federal government, state governments, regulators and third-party payers to control or manage the increased costs of healthcare
and, more generally, to reform the U.S. healthcare system. Certain of these proposals could limit the prices we are able to charge for
our products or the coverage and reimbursement available for our products and could limit the acceptance and availability of our products.
The adoption of proposals to control costs could harm our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 41 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There likely will continue to be legislative and
regulatory proposals at the federal and state levels directed at containing or lowering the cost of healthcare. We cannot predict the
initiatives that may be adopted in the future or their full impact. The continuing efforts of the government, insurance companies, managed
care organizations and other payers of healthcare services to contain or reduce costs of healthcare may harm:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to set a price that we believe is fair for our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to generate revenue and achieve or maintain profitability; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the availability of capital.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recently there has been heightened governmental
scrutiny over the manner in which companies set prices for their marketed products, which has resulted in several U.S. Congressional inquiries
and proposed and enacted federal legislation designed to bring transparency to product pricing and reduce the cost of products and services
under government healthcare programs. Additionally, individual states in the United States have also increasingly passed legislation and
implemented regulations designed to control product pricing, including price or patient reimbursement constraints, discounts, restrictions
on certain product access and marketing cost disclosure and transparency measures. Moreover, regional healthcare authorities and individual
hospitals are increasingly using bidding procedures to determine what products to purchase and which suppliers will be included in their
healthcare programs. Adoption of price controls and other cost-containment measures, and adoption of more restrictive policies in jurisdictions
with existing controls and measures may prevent or limit our ability to generate revenue and attain profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Various new healthcare reform proposals are emerging
at the federal and state level. It is also possible that additional governmental action will be taken in response to the COVID-19 pandemic.
Any new federal and state healthcare initiatives that may be adopted could limit the amounts that federal and state governments will pay
for healthcare products and services, and could harm our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our collection, use, storage, disclosure, transfer
and other processing of sensitive and personal information could give rise to significant costs, liabilities and other risks, including
as a result of investigations, inquiries, litigation, fines, legislative and regulatory action and negative press about our privacy and
data protection practices, which may harm our business, financial conditions, results of operations and prospects.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the course of our operations, we collect, use,
store, disclose, transfer and otherwise process an increasing volume of sensitive, and personal information including detailed recordings
of MRI and MRS results from patients as well as information from our employees and third parties with whom we conduct business. The collection,
use, storage, disclosure, transfer and other processing of personal information is increasingly subject to a wide array of federal, state
and foreign laws, rules, regulations, and standards regarding data privacy and security including comprehensive laws of broad application,
such as the CCPA and the GDPR, that are intended to protect the privacy of personal information that is collected, used, stored, disclosed,
transferred or otherwise processed in or from the governing jurisdiction. As we seek to expand our business, we are, and may increasingly
become, subject to various laws, rules, regulations and standards, as well as contractual obligations, relating to data privacy and security
in the jurisdictions in which we operate or in the jurisdictions where our patients may be. When conducting clinical studies, we face
risks associated with collecting trial participants&#8217; data, especially health data, in a manner consistent with applicable laws and
regulations, such as GCP guidelines or FDA human subject protection regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In many cases, these laws, rules, regulations
and standards apply not only to third-party transactions, but also to transfers of information between or among us, any of our affiliates
and other parties with whom we conduct business. These laws, rules, regulations and standards may be interpreted and applied differently
over time and from jurisdiction to jurisdiction, and it is possible that they will be interpreted and applied in ways that may harm our
business, financial condition and results of operations. The regulatory framework for data privacy and security worldwide is continuously
evolving and developing and, as a result, interpretation and implementation standards and enforcement practices are likely to remain uncertain
for the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 42 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to many diverse laws and regulations
relating to data privacy and security. In the United States, various federal and state regulators have adopted, or are considering adopting,
laws and regulations concerning personal information and data security. Additionally, our customers may be subject to additional federal
and state privacy and security laws, rules, regulations and standards, including HIPAA, that they may require us to comply with through
contractual obligations. This patchwork of legislation and regulation may give rise to conflicts or differing views of personal privacy
rights. For example, certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to
personal information than federal, foreign or other state laws, and such laws may differ from each other, all of which may complicate
compliance efforts. Additionally, new privacy rules are being enacted in the United States and globally, and existing ones are being updated
and strengthened. The CCPA regulates the processing of personal information of California residents and increases the privacy and security
obligations of covered companies handling such personal information. The CCPA requires covered companies to, amongst other things, provide
new and additional disclosures to California consumers and provide such consumers new data protection and privacy rights, including the
ability to access their personal information and opt out of certain sales of personal information. The CCPA provides for civil penalties
for violations, as well as a private right of action for certain data breaches that result in the loss of personal information. This private
right of action may increase the likelihood of, and risks associated with, data breach litigation. The CCPA was amended in September 2018
and November 2019, and it is possible that further amendments will be enacted, but even in its current form it remains unclear how various
provisions of the CCPA will be interpreted and enforced. Moreover, a new privacy law, the California Privacy Rights Act, (&#8220;CPRA&#8221;)
a consumer privacy ballot initiative that amends and expands the CCPA, was recently passed. The CPRA affords California residents significantly
more control over their personal information, imposes heightened compliance obligations on covered companies, and establishes a new enforcement
agency dedicated to consumer privacy. The CPRA&#8217;s substantive provisions become effective January 1, 2023, and new regulations are
expected to be introduced by July 1, 2022. While aspects of the CPRA and its interpretation remain to be determined in practice, they
create further uncertainty and may result in additional costs and expenses in an effort to comply. Further, all 50 states have passed
laws regulating the actions that a business must take if it experiences a data breach, such as prompt disclosure to affected customers.
In addition to data breach notification laws, some states have enacted statutes and rules requiring businesses to reasonably protect certain
types of personal information they hold or to otherwise comply with certain specified data security requirements for personal information.
We are also subject to the supervisory and enforcement authority of the Federal Trade Commission with regard to the collection, use, sharing,
and disclosure of certain data collected from or about individuals. State laws are changing rapidly and there is discussion in Congress
of a new federal data protection and privacy law to which we would become subject if it is enacted. All of these evolving compliance and
operational requirements impose significant costs that are likely to increase over time, may require us to modify our data processing
practices and policies, divert resources from other initiatives and projects, and could restrict the way products and services involving
data are offered, all of which may harm our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event we expand our operations internationally,
we may become subject to additional foreign data privacy and security laws, rules, regulations, requirements, and standards, which in
the European Union, for instance, have been significantly reformed. On May 25, 2018, the General Data Protection Regulation (&#8220;GDPR&#8221;)
entered into force and became directly applicable in all European Union member states. The GDPR implements more stringent operational
requirements than its predecessor legislation. For example, the GDPR requires companies to make more detailed disclosures to data subjects,
requires disclosure of the legal basis on which companies can process personal data, makes it harder for companies to obtain valid consent
for processing, requires the appointment of data protection officers when sensitive personal data, such as health data, is processed on
a large scale, provides more robust rights for data subjects, introduces mandatory data breach notification through the European Union,
imposes additional obligations on companies when contracting with service providers and requires companies to adopt appropriate privacy
governance including policies, procedures, training and data audits. The GDPR permits data protection authorities to impose large penalties
for violations of the GDPR, including potential fines of up to &#8364;20 million or four percent of annual global revenues, whichever
is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory
authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. If we become subject to
the GDPR and do not comply with our obligations under the GDPR, we could be exposed to significant fines. Compliance with the GDPR will
be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices,
and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection
with our European activities. In addition, we may be the subject of litigation or adverse publicity, which could negatively affect our
business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 43 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect that there will continue to be new proposed
laws and regulations concerning data privacy and security, and we cannot yet determine the impact such future laws, rules, regulations
and standards may have on our business. New laws, amendments to or re-interpretations of existing laws, regulations, standards and other
obligations may require us to incur additional costs and restrict our business operations. Because the interpretation, scope, and application
of laws, regulations, standards and other obligations relating to data privacy and security are still uncertain, it is possible that these
laws, regulations, standards and other obligations may be interpreted and applied in a manner that is inconsistent with our data processing
practices and policies or the features of our products and services. If so, in addition to the possibility of fines, lawsuits, regulatory
investigations, public censure, other claims and penalties, and significant costs for remediation and damage to our reputation, we could
be materially and adversely affected if legislation or regulations are expanded to require changes in our data processing practices and
policies or if governing jurisdictions interpret or implement their legislation or regulations in ways that negatively impact our business,
financial condition and results of operations. We may be unable to make such changes and modifications in a commercially reasonable manner,
or at all. In addition to government regulation, privacy advocates and industry groups have and may in the future propose self-regulatory
standards from time to time. These and other industry standards may legally or contractually apply to us, or we may elect to comply with
such standards. Any inability to adequately address data privacy or security-related concerns, even if unfounded, or to comply with applicable
laws, regulations, standards and other obligations relating to data privacy and security, could result in additional cost and liability
to us, harm our reputation and brand, damage our relationships with consumers and harm our business, financial condition and results of
operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We make public statements about our use and disclosure
of personal information through our privacy policies, information provided on our website and press statements. Although we endeavor to
comply with our public statements and documentation, we may at times fail to do so or be alleged to have failed to do so. The publication
of our privacy policies and other statements that provide promises and assurances about data privacy and security can subject us to potential
government or legal action if they are found to be deceptive, unfair or misrepresentative of our actual practices. Any concerns about
our data privacy and security practices, even if unfounded, could damage the reputation of our business and harm our business, financial
condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Complying with these numerous, complex and often
changing laws, rules, regulations, and standards is expensive and difficult. Any failure or perceived failure by us or our service providers
to comply with our posted privacy policies or with any applicable or potentially applicable federal or state laws, rules, regulations,
standards, certifications or orders relating to data privacy, security or consumer protection, or any compromise of security that results
in the theft, unauthorized access, acquisition, use, disclosure, or misappropriation of personal information or other user data, could
result in significant fines or penalties, negative publicity or proceedings or litigation by governmental agencies or consumers, including
class action privacy litigation in certain jurisdictions, which would subject us to significant awards, penalties or judgments, one or
all of which could require us to change our business practices or increase our costs and could materially and adversely affect our business,
financial condition and results of operations. In addition, if our practices are not consistent, or viewed as not consistent, with applicable
legal and regulatory requirements, including changes in laws, regulations and standards or new interpretations or applications of existing
laws, regulations and standards, we may also become subject to audits, inquiries, whistleblower complaints, adverse media coverage, investigations,
criminal or civil sanctions, all of which may harm our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our employees, independent contractors, consultants,
commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards
and requirements, which could harm our business, financial condition and results of operations.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are exposed to the risk that our employees,
independent contractors, consultants, commercial partners and vendors may engage in fraudulent or illegal activity. Misconduct by these
parties could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violates: (i) the
laws of the FDA and other similar state or foreign regulatory bodies, including those laws requiring the reporting of true, complete and
accurate information to such regulators, (ii) manufacturing standards, (iii) healthcare fraud and abuse laws in the United States and
similar foreign fraudulent misconduct laws, (iv) laws related to discrimination, harassment, or other conduct relating to a hostile work
environment, or (v) laws that require the true, complete and accurate reporting of financial information or data. These laws may impact,
among other things, future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items
and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud,
kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing arrangements,
discounting, marketing and promotion, structuring and commissions, certain customer incentive programs and other business arrangements
generally. These laws also address the improper use of information obtained in the course of patient recruitment for clinical studies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 44 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have adopted a code of conduct, employee handbook,
and compliance policies, but it is not always possible to identify and deter misconduct by our employees and other third parties, and
the precautions we take to detect and prevent these activities may not be effective in controlling unknown or unmanaged risks or losses
or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such
laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights,
those actions could result in the imposition of significant fines or other sanctions, including the imposition of civil, criminal and
administrative penalties, damages, monetary fines, disgorgement, imprisonment, reporting and oversight obligations, possible exclusion
from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, diminished profits and future earnings
and curtailment of operations, any of which could adversely affect our ability to operate our business and our results of operations.
If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions
could result in integrity issues, or a negative impact to our reputation or brand. Whether or not we are successful in defending against
any such actions or investigations, we could incur substantial costs, including legal fees, and divert the attention of management in
defending ourselves against any of these claims or investigations, which could harm our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Significant disruptions in our information
technology systems, whether through breaches or failures of our technology, unauthorized access or otherwise, may result in both an adverse
impact to our products, as well as the unauthorized use, disclosure, modification or misappropriation of patient personal information,
the occurrence of fraudulent activity, or other data security-related incidents, all of which could have a material and adverse impact
on our business, financial condition and results of operations.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are increasingly dependent on complex information
technology systems for the efficient functioning of our business, including the manufacture, distribution and maintenance of our products,
as well as for accounting, data storage, compliance, purchasing and inventory management purposes. Further, our products collect, use,
store, disclose, transfer, and otherwise process sensitive patient data, such as detailed recordings of MRIs to help clinicians make more
informed treatment decisions and optimize their patients&#8217; care. These data are recorded by our technology and can be viewed by the
physician during regular patient visits using the Physician Tablet or on demand through a secure website. We also collect, use, store,
disclose, transfer, and otherwise process a growing volume of other personal information and confidential, proprietary and sensitive data,
which may include procedure-based information and sensitive healthcare data, credit card, and other financial information, insurance information,
and other potentially personally identifiable information. Our information technology systems or those of our service providers may be
subject to computer viruses, phishing, social engineering, denial or degradation of service attacks, ransomware, malware attacks or other
threats, cyberattacks, or dishonest acts by computer hackers or terrorists, failures during the process of upgrading or replacing software,
databases or components thereof, power outages, damage or interruption from fires or other natural disasters, hardware failures, telecommunication
failures and user errors, among other malfunctions. Technological interruptions or threats would disrupt our operations, including the
ability of our clinicians to use our products as intended to treat patients, the ability of patients to safely and securely upload their
data using and into our products, as well as our ability to adequately manufacture our products, timely ship and track product orders,
project inventory requirements, manage our supply chain and otherwise adequately service our customers. Additionally, any of these incidents
could result in the theft, unauthorized access, acquisition, use, disclosure, modification, or misappropriation of personal information
of patients that use our products, trial participants, employees, third parties with whom we conduct business, as well as other confidential,
proprietary, and sensitive data, and can also result in fraudulent activity, system disruptions or shutdowns.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The occurrence of any actual or attempted breach,
failure of security or fraudulent activity, the reporting of such an incident, whether accurate or not, or our failure to make adequate
or timely disclosures to the public or law enforcement agencies following any such event, whether due to delayed discovery or a failure
to follow existing protocols, could result in claims made against us or our service providers, which could result in state and/or federal
litigation and related financial liabilities, as well as criminal penalties or civil liabilities, regulatory actions from state and/or
federal governmental authorities, and significant fines, orders, sanctions, litigation and claims against us by consumers or third parties
and related indemnification obligations. Actual or perceived security breaches or failures could also cause financial losses, increased
costs, interruptions in the operations of our businesses, misappropriation of assets, significant damage to our brand and reputation with
customers, patients, employees, and third parties with whom we do business, and result in adverse publicity, loss of consumer confidence,
distraction to our management, and reduced sales and profits, any or all of which could harm our business, financial condition and results
of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 45 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our technology is also subject to compromise from
internal threats, such as theft, misuse, unauthorized access or other improper actions by employees, service providers and other third
parties with otherwise legitimate access to our systems and website. Data security-related incidents and fraudulent activity are increasing
in frequency and evolving in nature. We rely on a framework of security processes, procedures, tools, and controls designed to protect
our information and assets but, given the unpredictability of the timing, nature and scope of data security-related incidents and fraudulent
activity, there can be no assurance that any security procedures and controls that we or our service providers have implemented will be
sufficient to prevent data security-related incidents or other fraudulent activity from occurring. Furthermore, because the methods of
attack and deception change frequently, are increasingly complex and sophisticated, and can originate from a wide variety of sources,
including third parties such as service providers and even nation-state actors, despite our reasonable efforts to ensure the integrity
of our systems and website, it is possible that we may not be able to anticipate, detect, appropriately react and respond to, or implement
effective preventative measures against, all security breaches and failures and fraudulent activity. In the event we experience significant
disruptions, we may be unable to repair our systems in an efficient and timely manner.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also face risks associated with security breaches
affecting third parties with whom we are affiliated or otherwise conduct business. Due to applicable laws and regulations or contractual
obligations, we may be held responsible for any breach, failure or fraudulent activity attributed to our service providers as they relate
to the information we share with them. In addition, while we take precautions in selecting service providers, because we do not control
our service providers and our ability to monitor their data security is limited, we cannot ensure the security measures they take will
be sufficient to protect our information. Any of the foregoing could harm our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As data security-related threats continue to evolve,
we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate
and remediate any information security vulnerabilities, or to protect against, respond to and recover from any potential, attempted, or
existing security breaches. In addition, our remediation efforts may not be successful. The inability to implement, maintain and upgrade
adequate safeguards could have a material and adverse impact on our business, financial condition and results of operations. Moreover,
there could be public announcements regarding any data security-related incidents and any steps we take to respond to or remediate such
incidents, and if securities analysts or investors perceive these announcements to be negative, it could, among other things, have a substantial
adverse effect on the price of our common stock. Any of the foregoing could harm our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently maintain a cybersecurity insurance
policy and business interruption coverage in order to mitigate certain potential losses but this insurance is limited in amount, and we
cannot be certain that such potential losses will not exceed our policy limits, or will cover all potential claims to which we are exposed
and may not be adequate to indemnify us for all liability that may be imposed. Therefore, failure to maintain or protect our information
systems and data integrity effectively could harm our business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We face potential liability related to the
privacy of health information we obtain.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may maintain, use, and share sensitive health
information that we receive directly from patients that use our technology, throughout the clinical study process, in the course of our
research collaborations, and from healthcare providers in the course of using our products and systems. Most healthcare providers, including
hospitals from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as
amended by the HITECH, and also under GDPR. We believe that we are not currently classified or regulated under HIPAA or GDPR as a Covered
Entity, but we believe we are considered and regulated as a Business Associate. Accordingly, we are subject to HIPAA and GDPR requirements
or penalties as applied to Business Associates. However, in certain situations, any person may be prosecuted under HIPAA&#8217;s criminal
provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances,
we could face substantial criminal penalties if we knowingly receive, maintain, use, or transfer individually identifiable health information
from a Covered Entity, as defined under HIPAA, that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable
health information. Furthermore, certain health privacy laws, data breach notification laws, consumer protection laws and genetic testing
laws may apply directly to our operations or those of our collaborators and may impose restrictions on our collection, use and dissemination
of individuals&#8217; health information As such, we may be subject to state laws requiring notification of affected individuals and state
regulators in the event of a breach of personal information, including certain health information, which is a broader class of information
than the health information protected by HIPAA. To the extent we engage in clinical studies and commercial uses of our products outside
the United States, we may implicate foreign data privacy and security laws and regulations, including the GDPR and legislation of the
European Union member states implementing it.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 46 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent we do business in international
markets now, and in the future, any failure by us or our third-party contractors to comply with the strict rules on the transfer of personal
data from outside of the European Union, the United Kingdom, or other foreign country or territory into the United States in accordance
with such laws and regulations may result in the imposition of criminal and administrative sanctions on such contractors, which could
adversely affect our sales, business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, patients about whom we or our contractors
or collaborators obtain or share health information, as well as the providers who share this information with us or whom we share this
data with, may have statutory or contractual rights that limit our ability to use and disclose the information. We may be required to
expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Potential
claims alleging that we have violated individuals&#8217; privacy rights or breached our contractual obligations, even if we are not found
liable, could be expensive and time consuming to defend and could result in adverse publicity that could negatively affect our business,
financial condition and results of operations. If we or third-party contractors or consultants fail to comply with applicable federal,
state or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our contractors&#8217;
ability to develop and commercialize our products and could harm or prevent sales of our technology, or could substantially increase the
costs and expenses of developing, commercializing and marketing our products. Any threatened or actual government enforcement action could
also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our
business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, data collection, privacy and security
have become the subject of increasing public concern and changing preferences towards data collection, privacy and security could adversely
affect patient willingness to consent to our collection of their health information. Patients may be reluctant or unwilling to consent
to the collecting of their health information, and patients that have opted-in to the collection of their health information may revoke
their consent at any time, including as a result of these concerns or as a result of changes to our data policies that we have implemented
or may implement in the future. In particular, the success of our business depends in part on our ability to lawfully obtain health information
from our patients. If patients choose not to consent to the collection of their health information as a result of these concerns, or our
customers who transfer patient data to us via the use of our products refuse to do so due to concerns for data privacy or potential related
liabilities, or our consent or data privacy protection and management policies or practices are found to be unlawful, this could negatively
impact the growth potential for our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have encountered potential customers in the
EU who have been reluctant, and indeed refused, to become customers due to concerns about transferring of any private patient information
from their practice in the EU into the United States. Certain such customers have indicated their opinion that such a transfer is, on
its face, non-compliant with GDPR requirements due to certain rights of the US Federal Government to seize such data from US domiciled
companies or storage facilities. We may need to expand our operations to host at least one foreign instance of our cloud-based post-processing
software products within a foreign country, such as within the European Union, in order to overcome such concerns and reach and engage
more customers to grow our business in the related territory. If we are unable to sufficiently dissuade these concerns held by certain
potential customers outside of the United States, or do not establish certain changes in our private patient health information data privacy
practices, such as moving the hosting of EU-based information to an EU-based instance of our products and storage of related patient health
information we receive via use of our products, our sales, business, financial condition, and results of operations could be harmed. We
could also encounter delays if a clinical study is suspended or terminated by us, by the IRBs or the Ethics Committees of institutions
at which such studies are being conducted, by the Data Safety Monitoring Board for such trial or by the FDA or other regulatory authorities.
Such authorities may suspend or terminate a clinical study due to a number of factors, including failure to conduct the clinical study
in accordance with regulatory requirements, including GC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 47 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks related to our intellectual property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>If we are unable to obtain, maintain, protect,
enforce and defend patents or other intellectual property protection for our technology, or if the scope of our patents and other intellectual
property protections is not sufficiently broad, or as a result of our existing or any future out-licenses of our intellectual property,
our competitors could develop and commercialize products similar to or competitive with our products and services, our ability to continue
to commercialize our technology, or our other products and services, may be harmed.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As with other medical device companies, our success
depends, in large part, on our ability to obtain, maintain, protect, enforce and defend a proprietary position for our products and services,
which will depend upon our success in obtaining and maintaining effective patent and other intellectual property protection in the United
States and other countries into which we may expand our business in the future that relate to our technology and any other products, their
manufacturing processes and their intended methods of use. Furthermore, our success will also depend on our ability to enforce and defend
those patents, as well as our other intellectual property. In some cases, we may not be able to obtain patents relating to our products
and services which are sufficient to prevent third parties, such as our competitors, from copying and competing with other products or
services that are the same, similar, or otherwise competitive with our products and services. Or, our competitors may have rights under
current or future out-licenses of our intellectual property which could result in our competitors developing and commercializing products
similar to or competitive with our products and services. Any failure to obtain, maintain, protect, enforce or defend patent and other
intellectual property protection with respect to our NOCISCAN product suite and related services, or other aspects of our business,
could harm our business, competitive position, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Changes in the patent or other intellectual property
laws, or their interpretation, in the United States and other countries may diminish our ability to protect our inventions or to obtain,
maintain, protect, enforce, and defend our patents and other intellectual property rights, and could affect the value of our intellectual
property or narrow the scope of our patents. Additionally, we cannot predict whether the patent applications we are currently pursuing
will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from
competitors or other third parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patent prosecution process is expensive, time-consuming
and complex and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patents or patent applications
at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development
output in time to obtain patent protection in one, several, or all geographies. Although we enter into non-disclosure and confidentiality
agreements with parties who have access to our confidential information or patentable aspects of our research and development output,
such as our employees, corporate collaborators, outside scientific collaborators, suppliers, consultants, advisors and other third parties,
any of these parties may breach the agreements and publicly disclose such confidential information or research and development output.
If such unauthorized public disclosure occurs before a patent application is filed, it could compromise or diminish our ability to seek
patent protection. Such third parties could also breach obligations with respect to limited uses of our confidential information, which
may include (i) breaching restrictions against making or inventing improvements or modifications to, or derivations of, our confidential
technologies, and (ii) further separately applying, on their own behalf, for patent protections for such improvements, modifications,
or derivations. Such breaches may compromise our ability to obtain or enforce our own patent protections for such improvements, modifications,
or derivations. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between
our inventions and the prior art allow our inventions to be patentable over the prior art. Furthermore, the publication of discoveries
in scientific literature often lags behind the actual discoveries, and patent applications in the United States and other jurisdictions
are typically not published until 18 months after filing, or in some cases not at all. As such, we cannot be certain that we were the
first to make the inventions claimed in any of our patents or pending patent applications, or that we were the first to file for patent
protection of such inventions. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution
of patent applications, or to maintain the patents, relating to technology that we license from or license to third parties, including
by way of our license from the Board of Regents of the University of California, and we are therefore reliant on our licensors or licensees.
Therefore, these and any of our patents and patent applications may not be prosecuted and enforced in a manner consistent with the best
interests of our business. Furthermore, our license agreements may be terminated by the licensor. Defects of form in the preparation or
filing of our patents or patent applications may exist, or may arise in the future, for example, with respect to proper priority claims,
inventorship and the like, although we are unaware of any such defects that we believe are of importance. If we or any of our current
or future licensors or licensees fail to obtain, maintain, protect, enforce or defend such patents and other intellectual property rights,
such rights may be reduced or eliminated. If any of our current or future licensors or licensees are not fully cooperative or disagree
with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are
material defects in the form, preparation or prosecution of our patents or patent applications, such patents or applications may be invalid
and/or unenforceable. Any of these outcomes could impair our ability to prevent competition from third parties, which may harm our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 48 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The strength of patent rights generally, and particularly
the patent position of medical device companies, involves complex legal and scientific questions, can be uncertain, and has been the subject
of much litigation in recent years. This uncertainty includes changes to the patent laws through either legislative action to change statutory
patent law or court action that may reinterpret existing law or rules in ways affecting the scope or validity of issued patents. Our current
or future patent applications may fail to result in issued patents in the United States or foreign countries with claims that cover our
products, including our technology. Even if patents do successfully issue from our patent applications, third parties may challenge the
validity, enforceability or scope of such patents, which may result in such patents being narrowed, invalidated or held unenforceable.
Any successful challenge to our patents could deprive us of exclusive rights necessary for the successful commercialization of our products,
including our NOCISCAN product suite. Furthermore, even if they are unchallenged, our patents may not adequately protect our technology
or any other products we develop, provide exclusivity for these products or prevent others from designing around our claims. If the scope
of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors
from commercializing similar or identical products could be adversely affected. If the breadth or strength of protection provided by the
patents we hold or pursue with respect to our products is challenged, it could dissuade companies from collaborating with us to develop,
or threaten our ability to commercialize, our technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patents have a limited lifespan. In the United
States, the natural expiration of a utility patent is generally 20 years after its effective filing date and the natural expiration of
a design patent is generally 14 years after its issue date, unless the filing date occurred on or after May 13, 2015, in which case the
natural expiration of a design patent is generally 15 years after its issue date. However, the actual protection afforded by a patent
varies from country to country, and depends upon many factors, including the type of patent, the scope of its coverage, any terminal disclaimers
filed or to be filed, overlap in claimed subject matter with other patents in the portfolio, the availability of regulatory-related extensions,
the availability of legal remedies in a particular country and the validity and enforceability of the patent. Various extensions may be
available; however, the life of a patent, and the protection it affords, is limited. Without patent protection for our technology, we
may be open to competition. Further, if we encounter delays in our development efforts, the period of time during which we could market
our technology under patent protection would be reduced and, given the amount of time required for the development, testing and regulatory
review of planned or future technology and products, patents protecting such technology and products might expire before or shortly after
such products are commercialized. For information regarding the expiration dates of patents in our patent portfolio, see &#8220;Business&#8212;Intellectual
Property.&#8221; Our U.S. issued patents are expected to expire between January 3, 2026 and March 15, 2033, without taking into account
all possible patent term adjustments, extensions, or abandonments, and assuming payment of all appropriate maintenance, renewal, annuity,
and other governmental fees. As our patents expire, the scope of our patent protection will be reduced, which may reduce or eliminate
any competitive advantage afforded by our patent portfolio. As a result, our patent portfolio may not provide us with sufficient rights
to exclude others from commercializing products similar or identical to ours.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, the coverage claimed in a patent application
can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications
licensed to us or assigned to us, currently or in the future, issue as patents, they may not issue in a form that will provide us with
any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive
advantage. Any patents assigned to us may be challenged, narrowed, circumvented or invalidated by third parties. Consequently, we do not
know whether our NOCISCAN product suite or our other products will be protectable or remain protected by valid and enforceable patents.
Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative products in a non-infringing
manner, which could harm our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of our patents and patent applications may
be co-owned or cross-licensed with third parties. If we give up, do not pursue, or are unable to obtain an exclusive license to any such
third-party co-owners&#8217; or licensee&#8217;s interest in such patents or patent applications, such co-owners or cross-licensees may
be able to license or sub-license, respectively, their rights to other third parties, including our competitors, and our competitors could
market competing products and technology. In addition, we may need the cooperation of any such co-owners or co-licensees of our patents
in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could harm
our sales, business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 49 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on a License from the Regents of the University
of California, as well as other aspects of our own patented technology and intellectual property, in order to be able to use and sell
various proprietary technologies that are material to our business, as well as technologies which we intend to use in our future commercial
activities. Our rights to use these licensed technologies and the inventions claimed in the licensed patents, are subject to the continuation
of, and our compliance with the terms of the license. The License provides that for so long as we pay patent prosecution costs, the Regents
of the University of California will diligently prosecute and maintain the United States and foreign patents comprising the Patent Rights
using counsel of its choice, and the UCSF Regents' counsel will take instructions only from The Regents of the University of California
has the right to terminate the agreement upon advanced notice in the event of a default by us. The agreement will expire upon the expiration
or abandonment of the last of the licensed patents. The patents subject to the agreement expire between 2025 and 2029. The loss of this
license would materially negatively affect our ability to pursue our business objectives and result in material harm to our business operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We may not be successful in obtaining or maintaining
necessary rights to any products or processes we may have or develop through acquisitions and in-licenses.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may find it necessary or prudent to acquire,
obtain, or maintain licenses to intellectual property or proprietary rights held by third parties that we may identify as necessary or
important to our business operations. However, we may be unable to acquire, secure, or maintain such licenses to any intellectual property
or proprietary rights from third parties that we identify as necessary for our technology or any future products we may develop. The acquisition
or licensing of third-party intellectual property or proprietary rights is a competitive area, and our competitors may pursue strategies
to acquire or license third party intellectual property or proprietary rights that we may consider attractive or necessary. Our competitors
may have a competitive advantage over us due to their size, capital resources and greater development and commercialization capabilities.
In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to
acquire or license third party intellectual property or proprietary rights on terms that would allow us to make an appropriate return
on our investment or at all. We have an existing license with the Board of Regents of the University of California, and which covers multiple
patents and patent applications for inventions that are incorporated into our products, and if we are unable to maintain this license,
we may not be able to legally market or sell our current or future products, which would harm our sales, business, financial condition,
and results of operations. If we are unable to successfully acquire or license third-party intellectual property or proprietary rights
that we require for making, using, or selling our products or services, or to maintain the existing licenses to intellectual property
rights we have, we may have to abandon the development, manufacturing, marketing, or selling of our related products that require those
rights, which could harm our sales, business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Patents directing to our technology could be
found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, which could harm
our business, financial condition and results of operations.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The issuance of a patent is not conclusive as
to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United
States and abroad. We may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;),
or become involved in opposition, derivation, revocation, reexamination, post-grant and inter partes review, or IPR, or interference proceedings
or other similar proceedings challenging our patent rights. An adverse determination in any such submission, proceeding or litigation
could reduce the scope of, or invalidate or render unenforceable, such patent rights, allow third parties to commercialize our products
and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing
third-party patent rights. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority
of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our priority of invention
or other features of patentability with respect to our patents and patent applications. Such challenges may result in loss of patent rights,
in loss of exclusivity, or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others
from using or commercializing similar or identical products or limit the duration of the patent protection of our products. Such proceedings
also may result in substantial cost and require significant time from our management, even if the eventual outcome is favorable to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 50 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, if we initiate legal proceedings
against a third party to enforce a patent relating to our products, the defendant could counterclaim that such patent is invalid or unenforceable.
In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for
a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness
or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent
withheld relevant information from the USPTO, or made a false or misleading statement, or otherwise committed inequitable conduct, during
prosecution. Defenses of these types of claims, regardless of their merit, would involve substantial litigation expense, would result
in reputational harm, and would be a substantial diversion of employee resources from our business. Third parties may also raise claims
challenging the validity or enforceability of our patents before administrative bodies in the United States or abroad, even outside the
context of litigation, including through re-examination, post-grant review, IPR, interference proceedings, derivation proceedings and
equivalent or similar proceedings in foreign jurisdictions (such as opposition proceedings). Such proceedings could result in the revocation
of, cancellation of or amendment to our patents in such a way that they no longer relate to our products. The outcome for any particular
patent following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example,
we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. Moreover,
potential third-party claims that are validated in a final ruling or determination regarding inequitable conduct with respect to securing
or enforcing a patent could also potentially give rise to other adverse claims, which may include business torts or other causes of action
regarding our enforcement of that patent, and could also potentially carry over and apply downstream to other patents that are related
to (e.g. claim of priority) the instant patent. If a defendant or other third party were to prevail on a legal assertion of invalidity
or unenforceability, we would lose at least part, and potentially all, of the patent protection for the patents raised in such a claim.
Such a loss of patent protection would harm our sales, business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The medical device industry is characterized
by patent litigation and in the future we could become subject to actual or threatened patent or other intellectual property litigation
alleging our products or services infringe or misappropriate third party rights, which could be costly to address and defend, result in
the diversion of management&#8217;s time and efforts, require us to pay damages, or prevent us from making, using, or selling our existing
or future products.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patent litigation is prevalent in the medical
device and diagnostic sectors. Our commercial success depends, in part, upon our ability and that of our suppliers to manufacture, market,
sell, and use our proprietary technology without infringing, misappropriating or otherwise violating the intellectual property or proprietary
rights of third parties. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding
intellectual property rights with respect to our products. Third parties may assert infringement claims against us based on existing or
future intellectual property rights, regardless of merit. If we are found to infringe a third party&#8217;s intellectual property rights,
we could be required to incur costs to obtain a license from such third party to continue developing, making, using, or selling our products
and services. We may also elect to enter into such a license in order to settle pending or threatened litigation. However, we may not
be able to obtain any required license on commercially reasonable terms, or at all. Even if we were able to obtain a license, it could
be non-exclusive, thereby giving our competitors access to the same technologies or methods licensed to us and could require us to pay
significant royalties and other fees. We could be forced, including by court order, to cease commercializing the infringing product or
service. In addition, we could be found liable for monetary damages, which may be significant. If we are found to have willfully infringed
a third-party patent, we could be required to pay treble damages and attorneys&#8217; fees. A finding of infringement could prevent us
from commercializing our planned products in commercially important territories or force us to cease some of our business operations,
which could harm our business and cause brand and reputational harm. An adverse infringement determination in one territory where such
a claim might be brought could also potentially carry over to influence other similarly adverse claims being brought, and/or adverse results
of those additional claims, in other territories where we have or seek a commercial presence. We could also be forced to redesign or otherwise
change those products or services that use or implicate the allegedly infringing intellectual property, which could be costly, disruptive
and infeasible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many of our employees were previously employed
at, and many of our current advisors and consultants are employed by, universities or other biotechnology, medical device, healthcare,
or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, advisors
and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we,
or these employees, have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such
employee&#8217;s former employer. Furthermore, although these agreements may be difficult to enforce, we may in the future be subject
to claims that these individuals are violating non-compete agreements with their former employers. These and other claims that we have
misappropriated the confidential information or trade secrets of third parties can have a similar negative impact on our business, including
with respect to the infringement claims discussed above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 51 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if we are successful in defending against
intellectual property claims, litigation or other legal proceedings relating to such claims, the claims and related defense may still
cause us to incur significant expenses, cause reputational harm, and could distract our technical and management personnel from their
normal responsibilities. If we fail in defending any such claims, in addition to paying monetary damages or other settlements, we may
lose valuable intellectual property rights or personnel, which could harm our business, financial condition and results of operations.
We could potentially be required, or be forced or choose among other options, to negotiate a settlement of third party infringement claims
that may include cross-licensing of our own patent or other intellectual property rights with the third party bringing the initial adverse
claim against us. This could result in our inability to protect our products and services as exclusively proprietary only to us, and allow
the third party to compete against us, with respect to the inventions or technologies related to those out-licensed rights, and which
could also diminish the value of our products, services, and overall business and company, and harm our sales, business, financial condition,
and results of operations. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings
or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial negative impact
on the price of our shares of common stock. Such litigation or proceedings could substantially increase our operating losses and reduce
our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such
litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively
than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of
litigation or other intellectual property related proceedings could harm our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Obtaining and maintaining our patent protection
depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies,
and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Obtaining and maintaining our patent protection
depends on compliance with various procedural measures, document submissions, fee payments and other requirements imposed by government
patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Periodic maintenance fees, renewal fees, annuity
fees and various other government fees on patents and patent applications will be due to be paid to the USPTO and various government patent
agencies outside of the United States over the lifetime of our patents and applications. The USPTO and various non-U.S. government agencies
require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process.
In some cases, an intentional lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There
are situations, however, in which non-compliance can result in the abandonment or lapse of the patent or patent application, resulting
in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to
enter the market with similar or identical products or technology, which could harm our business, financial condition and results of operations.
Certain legal or contractual requirements, and/or rights of others involved in our development or products, may permit the U.S. government
to disclose our confidential information to third parties. To the extent any of our current or future intellectual property is generated
through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. For example, the National Institute
of Health and the Regents of the University of California have limited rights to use certain of our patents and patent applications for
research. Any exercise by the government of any of the foregoing rights could harm our business, financial condition, results of operations
and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>If we fail to comply with our obligations in
any current or future agreements under which we license intellectual property rights from third parties or otherwise experience disruptions
to our business relationships with our licensors, we could lose license rights that are important to our business.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are, and may become, party to license or collaboration
agreements with third parties to advance our research or allow commercialization of our products. Such agreements may impose numerous
obligations, such as development, diligence, payment, commercialization, funding, milestone, royalty, sublicensing, insurance, patent
prosecution, enforcement and other obligations on us and may require us to meet development timelines, or to exercise certain efforts
to develop and commercialize licensed products, in order to maintain the licenses. In spite of our best efforts, our licensors might conclude
that we have materially breached such license agreements and might therefore terminate the license agreements, thereby removing or limiting
our ability to develop and commercialize products and technologies covered by these license agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 52 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have an existing license with the Regents of
the University of California which covers multiple patents and patent applications for inventions that are incorporated into our products.
Any termination of this or other licenses could result in the loss of significant rights and could harm our ability to commercialize our
products and competitors or other third parties may have the freedom to seek regulatory approval of, and to market, products identical
to ours, at least to the extent of products and services that incorporate the features captured by those previously licensed patent rights
and assuming our licensor permits such competitive activities, either passively or via further out licensing, under their remaining patent
rights. If we lose our licensed patent rights, we may also be required to cease our development and commercialization of certain of our
products. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results
of operations, and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Disputes may also arise between us and our licensors
regarding intellectual property subject to a license agreement, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the scope of rights granted under the license agreement and other interpretation-related
        issues;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">whether and the extent to which our technology and processes infringe, misappropriate
        or otherwise violate intellectual property rights of the licensor that are not subject to the license agreement;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our right to sublicense patent and other rights to third parties under collaborative
        development relationships;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our diligence obligations with respect to the use of the licensed technology
        in relation to our development and commercialization of our products, and what activities satisfy those diligence obligations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the priority of invention of any patented technology; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the ownership of inventions and know-how resulting from the joint creation or
        use of intellectual property by our future licensors and us and our partners.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the agreements under which we may
license intellectual property or technology from third parties are likely to be complex and certain provisions in such agreements may
be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what
we believe to be the scope of our rights to the relevant intellectual property, or increase what we believe to be our financial or other
obligations under the relevant agreement, either of which could have a material adverse effect on our sales, business, financial condition
or results of operations. Moreover, if disputes over intellectual property that we may license prevent or impair our ability to maintain
future license agreements on acceptable terms, we may be unable to successfully develop and commercialize the affected products, which
could have a material adverse effect on our sales, business, financial conditions or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our existing license with the Regents of the University
of California, in particular, includes both exclusive rights, as applied to certain aspects of their patent rights under the license,
and partial-exclusive and co-exclusive rights as applied to certain other aspects of the Licensor&#8217;s patent rights, under which we
have rights for diagnostic-related patent claims. The balance of remaining rights for therapy-related claims are exclusively licensed
to another third-party company. There are risks that the interpretation of which patent rights apply to us under our license, versus which
patent rights apply to the other third-party company under their license, could be the subject of disagreement or dispute, the existence
of which, and potential adverse result from which, could diminish the scope of rights we actually have. This could also be the subject
of disagreement or dispute with respect to patent prosecution matters along the examination path of applications toward seeking issued
patents. Any of the above could diminish, or prevent, our ability to commercialize all aspects of our products as intended, and which
could result in harm to our sales, business, financial condition, or result of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our existing license also includes exclusive rights
to certain patents which are co-owned by us and the Board of Regents of the University of California, in relation to inventions that have
been determined to be jointly invented by separate but joint inventors that are under different obligation of assignment to us and them.
If we fail to maintain and/or lose those license rights to one or more of these co-owned patents and patent applications, others would
have the ability to commercialize, or license the ability to commercialize, products or services covered by those patents competitively
against us. This would result in us losing exclusive proprietary advantage with respect to technologies and methods relating to those
patents, which could harm our sales, business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 53 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>If we are unable to obtain patent term extension
under the Hatch-Waxman Amendments, our business may be materially harmed.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depending upon the timing, duration and specifics
of FDA marketing approval of our products, one or more of the U.S. patents assigned or licensed to us may be eligible for limited patent
term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments.
The Hatch-Waxman Amendments permit a patent restoration term of up to five years for a patent covering an approved product as compensation
for effective patent term lost during product development and the FDA regulatory review process. However, even if, at the relevant time,
we have an issued patent covering our product, we may not be granted an extension if we were, for example, to fail to exercise due diligence
during the testing phase or regulatory review process, to fail to apply within applicable deadlines or prior to expiration of relevant
patents or otherwise to fail to satisfy applicable requirements. Moreover, the time period of the extension or the scope of patent protection
afforded could be less than we request. Only one patent per approved product can be extended, the extension cannot extend the total patent
term beyond 14 years from approval and only those claims covering the approved product, a method for using it or a method for manufacturing
it may be extended. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we
request, the period during which we can enforce our patent rights for the applicable product will be shortened and our competitors may
obtain approval of competing products following our patent expiration. As a result, our ability to generate revenues could be adversely
affected. Further, if this occurs, our competitors may take advantage of our investment in development and studies by referencing our
clinical and preclinical data and launch their product earlier than might otherwise be the case. If we do not have adequate patent protection
or other exclusivity for our products, our business, financial condition or results of operations could be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We have limited foreign intellectual property
rights and may not be able to protect our intellectual property and proprietary rights throughout the world, which could harm our business,
financial condition and results of operations.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have limited intellectual property rights outside
the United States. Filing, prosecuting and defending patents on our products in all countries throughout the world would be prohibitively
expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Consequently,
we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling
or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies
in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing
products to territories where we have patent protection but enforcement is not as strong as in the United States. While we do not currently
operate or sell our products outside of the United States, these products may compete with our products, and our patents or other intellectual
property rights may not be effective or sufficient to prevent them from competing. Patent protection must ultimately be sought on a country-by-country
basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection
in certain countries, and we will not have the benefit of patent protection in such countries, which may impede on our ability to grow
outside of the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many companies have encountered significant problems
in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly
certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which
could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual
property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions
could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk
of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties
to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may
not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world
may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many countries have compulsory licensing laws
under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of
patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could
materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant
to our business, our competitive position may be impaired, and our business, financial condition and results of operations may be harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p>

<!-- Field: Page; Sequence: 54 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Changes in U.S. patent laws, or patent laws
in other countries and jurisdictions, could diminish the value of patents in general, thereby impairing our ability to protect our products.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Changes in either the patent laws or interpretation
of the patent laws in the United States, or elsewhere, could increase the uncertainties and costs surrounding the prosecution of patent
applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March
2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, generally
the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act, or the
America Invents Act, enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that
other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention
regardless of whether a third party, who may have filed a patent application later, was the first to actually invent the claimed invention.
A third party that files a patent application in the USPTO after March 2013, but before we filed a patent application for the same invention
(as defined by claims), could therefore be awarded a patent covering an invention of ours even if we had made the invention before it
was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Since
patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance,
we could continue incurring costs without being certain that we were the first to file any patent application related to our products
or the first to invent any of the inventions claimed in our patents or patent applications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The America Invents Act also includes a number
of significant changes that affect the way patent applications are prosecuted and also may affect patent litigation. These include allowing
third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent
by USPTO administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. Because of
a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate
a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid
even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly,
a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged
by the third party as a defendant in a district court action. Additionally, USPTO proceedings provide a venue for challenging the validity
of patents at a cost must lower than district court litigation and on much faster timelines. This lower-cost, faster and potentially more
potent tribunal for challenging patents could itself increase the likelihood that our own patents will be challenged. Therefore, the America
Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and
the enforcement or defense of our issued patents. In addition, future actions by the U.S. Congress, the federal courts and the USPTO could
cause the laws and regulations governing patents to change in unpredictable ways. Any of the foregoing could harm our business, financial
condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, recent U.S. Supreme Court rulings
have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations.
In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created
uncertainty with respect to the validity and enforceability of patents, once obtained. For example, after the filing of our earlier filed
patent applications, from which we have received granted patents and also continue to prosecute additional patent applications under priority
filing claims, certain laws and interpretation of those laws changed. This includes, in particular, new changes that diminish or make
it more difficult to obtain, enforce, or defend as valid, claims related to medical diagnostics, any methods, and in particular any methods
involving the human body or medical procedures. Our patent portfolio is principally related to medical diagnostic methods, which in many
cases merge these multiple areas of patent laws that have since been changed. Some of our patents were issued prior to certain such changes
in the laws occurring, which could potentially result in certain risks that the patents which were initially valid when granted, under
the laws at that time, had become invalid due to the later changes in the laws. Moreover, some of our patents were granted after these
changes in the laws, but these may still be subject to risk of challenge due to uncertainty in interpreting and applying these newer changes
in the laws related to medical diagnostic methods to our issued patent claims. Depending on future actions by the U.S. Congress, the federal
courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to
obtain new patents or to enforce our existing patents and patents that we might obtain in the future. We cannot predict how this and future
decisions laws or regulations by the courts, the U.S. Congress or the USPTO may impact the value of our patents. Any similar adverse changes
in the patent laws of other jurisdictions could also harm our business, financial condition, results of operations and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p>

<!-- Field: Page; Sequence: 55 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We may be subject to claims, including third-party
claims of intellectual property infringement, misappropriation or other violations against us or our collaborators, challenging the ownership
or inventorship of our intellectual property and, if unsuccessful in any of these proceedings, we may be required to obtain licenses from
third parties, which may not be available on commercially reasonable terms, or at all, or to cease the development, manufacture and commercialization
of one or more of our products.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The medical device industry is highly competitive
and dynamic. Due to the focused research and development that is taking place by several companies, including us and our competitors in
this field, the intellectual property landscape is in flux and it may remain uncertain in the future. As such, we may be subject to claims
that current or former employees, collaborators or other third parties have an interest, either as an owner, co-owner, or otherwise, in
our patents, trade secrets or other intellectual property as an inventor or co-inventor. Additionally, we could become subject to significant
intellectual property-related litigation and proceedings relating to our or third-party intellectual property and proprietary rights.
For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved
in developing our products, or could face third-party claims of intellectual property infringement, misappropriation or other violations,
including by a licensor from whom we&#8217;ve licensed certain intellectual property. These risks apply to our existing license from the
Regents of the University of California, both in relation to patent rights we co-own with them as a result of joint invention between
our and their respective inventors, and in relation to co-existent license rights that we share with another third-party company in some
of those patent rights, as further summarized above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Litigation may be necessary to defend against
these and other claims challenging inventorship of our patents, trade secrets or other intellectual property. If we fail in defending
any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership
of, or right to use, intellectual property that is important to our products. If we were to lose exclusive ownership of such intellectual
property, other owners may be able to license their rights to other third parties, including our competitors. We also may be required
to obtain and maintain licenses from third parties, including parties involved in any such disputes. Such licenses may not be available
on commercially reasonable terms, or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need
to cease the development, manufacture and commercialization of one or more of our products. The loss of exclusivity or the narrowing of
our patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Even
if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management
and other employees. Any of the foregoing could harm our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, our commercial success depends,
in part, on our and any potential future collaborators&#8217; ability to develop, manufacture, market and sell any products that we may
develop and use our proprietary technologies without infringing, misappropriating or otherwise violating the patents and other intellectual
property or proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us or any
potential collaborators to alter our development or commercial strategies, obtain licenses or cease certain activities. The medical device
industry is characterized by extensive litigation regarding patents and other intellectual property rights, as well as administrative
proceedings for challenging patents, including interference, inter partes or post-grant review, derivation and reexamination proceedings
before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Third parties, including our competitors, may
currently have patents or obtain patents in the future and claim that the manufacture, use or sale of our products infringes upon these
patents. We have not conducted an extensive search of patents issued or assigned to other parties, including our competitors, and no assurance
can be given that patents containing claims relating to our products, parts of our products, technology or methods do not exist, have
not been filed or could not be filed or issued. In addition, because patent applications can take many years to issue and because publication
schedules for pending patent applications vary by jurisdiction, there may be applications now pending of which we are unaware and which
may result in issued patents which our current or future products infringe. Also, because the claims of published patent applications
can change between publication and patent grant, there may be published patent applications that may ultimately issue with claims that
we infringe. Unintentionally abandoned patents or applications can also be revived, so there may be recently revived patents or applications
of which we are unaware. As the number of competitors in our market grows and the number of patents issued in this area increases, the
possibility of patent infringement claims against us escalates. Moreover, we may face claims from non-practicing entities, or NPEs, which
have no relevant product revenue and against whom our own patent portfolio may have no deterrent effect. Third parties may in the future
claim that our products infringe or violate their patents or other intellectual property rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 56 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Defense of infringement claims, regardless of
their merit or outcome, would involve substantial litigation expense and would be a substantial diversion of management and other employee
resources from our business, and may impact our reputation. In the event of a successful claim of infringement against us, we may be enjoined
from further developing or commercializing the infringing products and/or have to pay substantial damages for use of the asserted intellectual
property, including treble damages and attorneys&#8217; fees were we found to willfully infringe such intellectual property. Claims that
we have misappropriated the confidential information or trade secrets of third parties could harm our business, financial condition and
results of operations. We also might have to redesign any our allegedly infringing products or technologies, which may be impossible or
require substantial time and monetary expenditure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Engaging in litigation, including to defend against
third-party infringement claims is very expensive, particularly for a company of our size, and time-consuming. In addition, there could
be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or
investors perceive these results to be negative, it could have a substantial negative impact on our common stock price. Such litigation
or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any
future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation
or proceedings adequately. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively
than we can because of greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting
from the initiation and continuation of patent litigation or other proceedings against us could impair our ability to compete in the marketplace.
The occurrence of any of the foregoing could harm our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We may become involved in lawsuits to protect
or enforce our patents and other intellectual property rights, which could be expensive, time-consuming and unsuccessful.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Competitors may infringe our patents, or the patents
of any current or future licensing partners, or we may be required to defend against claims of infringement. Our ability to enforce our
patent rights against competitors who infringe our patents depends on our ability to detect such infringement. It may be difficult to
detect infringers who do not advertise the components or processes that are used in their products or services. Moreover, it may be difficult
or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product. For example, many of
our patents relate to methods and related computer processing architectures and structures for post-processing data. The use of these
methods and structures may not be obvious or certain to assess, and may not be possible or at least may be challenging to reveal or confirm
by reverse engineering, based on limited evidence that might be available to us, such as for example from only being able to observe the
results of using those methods or architectures. We may not prevail in any lawsuits that we initiate and the damages or other remedies
awarded if we were to prevail may not be commercially meaningful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, our patents or the patents of our
licensing partners also may become involved in inventorship, priority or validity disputes. For example, although we try to ensure that
our employees, consultants and advisors are not in breach of any past contractual obligations and do not use the proprietary information
or know-how of others in the work that they do for us, we may in the future become subject to claims that we or these individuals have,
inadvertently or otherwise, used or disclosed intellectual property, including trade secrets or other proprietary information, of their
former university or employer. Additionally, we may be subject to claims from third parties challenging intellectual property rights we
regard as our own, based on claims that our agreements with employees or consultants obligating them to assign intellectual property to
us are ineffective or in conflict with prior or competing contractual obligations to assign inventions to a previous employer, or to another
person or entity. Furthermore, while it is our policy to require all employees and contractors to execute agreements assigning relevant
intellectual property to us, we may also be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops
intellectual property that we regard as our own. These assignment agreements may not be self-executing or adequate in scope, and may be
breached or challenged, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to
determine the ownership of what we regard as our intellectual property. We may not have adequate remedies for any such breaches, and such
claims could harm our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To counter or defend against such claims can be
expensive and time-consuming and it may be necessary or we may desire to enter into a license to settle any such claims; however, there
can be no assurance that we would be able to obtain a license on commercially reasonable terms, if at all. In an infringement proceeding,
a court may decide that our patent is invalid or unenforceable or may refuse to stop the other party from using the technology at issue
on the grounds that our patents do not cover such technology. An adverse result in any litigation proceeding could put one or more of
our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required
in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by
disclosure during litigation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if resolved in our favor, litigation or other
legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our management
and other personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions
or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could
have a substantial negative impact on our common stock price. Such litigation or proceedings could substantially increase our operating
losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may
not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be
able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources
and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent
litigation or other proceedings could harm our ability to compete in the marketplace, including ability to hire new employees or contract
with independent sales representatives. Additionally, we may lose valuable intellectual property rights or personnel. Any of the foregoing
could harm our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>If our trademarks and trade names are not adequately
protected, then we may not be able to build name recognition in our markets of interest and our business may be harmed.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our registered and unregistered trademarks or
trade names may be challenged, infringed, circumvented, declared generic or determined to be violating or infringing on marks held by
others. We may not be able to protect our rights to these trademarks and trade names, which we need to build or sustain name recognition
among potential partners, customers and patients in our markets of interest. At times, competitors or other third parties may adopt trade
names or trademarks similar to ours, thereby impeding our ability to continue to build brand identity and possibly leading to market confusion.
In fact, a practice exists with international scope, and which may become manifest in a given case in any or only certain territories,
in which certain third parties will deliberately secure or allege they own trademarks or tradenames that are specifically being first
used by another party in order to extort license fees or damages in those territories in which the original user of the mark had not filed
or perfected its rights to the mark. In addition, there could be potential trade name or trademark infringement, or dilution claims brought
by owners of other trademarks. Over the long term, if we are unable to establish name recognition based on our trademarks, trade names,
domain names or other intellectual property, then we may not be able to compete effectively, and our business may be adversely affected.
Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names or other intellectual property
may be ineffective, could result in substantial costs, diversion of resources, or adverse impact to our brand and could harm our sales,
business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 58 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Intellectual property rights do not necessarily
address all potential threats, and limitations in intellectual property rights could harm our business, financial condition and results
of operations.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The degree of future protection afforded by our
intellectual property rights is uncertain because intellectual property rights have limitations, may evolve, and may not adequately protect
our business or permit us to maintain our competitive advantage. For example:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">others may be able to make products that are similar to our products or utilize
        similar technology but that are not covered by the claims of our patents or that incorporate certain technology in our products that is
        in the public domain;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our intellectual property strategy may be limited, we may not seek protection
        for intellectual property that may ultimately become relevant to our business or our invention disclosure process may prove insufficient
        to encourage inventors to come forward with protectable intellectual property;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we, or our current or future licensors or collaborators, might not have been
        the first to make the inventions related to the applicable issued patent or pending patent application assigned or licensed to us now
        or in the future;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we, or our current or future licensors or collaborators, might not have been
        the first to file patent applications covering certain of our or their inventions;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we, or our current or future licensors or collaborators, may fail to meet our
        obligations to the U.S. government regarding any future patents and patent applications funded by U.S. government grants, leading to the
        loss or unenforceability of patent rights;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">others may independently develop similar or alternative technologies or duplicate
        any of our technologies without infringing our intellectual property rights;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">it is possible that our current or future pending patent applications will not
        lead to issued patents;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">it is possible that there are prior public disclosures that could invalidate
        our patents, or parts of our patents;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">it is possible that there are unpublished applications or patent applications
        maintained in secrecy that may later issue with claims related to our products or technology similar to ours;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">it is possible that our patents or patent applications omit individuals that
        should be listed as inventors or include individuals that should not be listed as inventors, which may cause these patents or patents
        issuing from these patent applications to be held invalid or unenforceable;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">issued patents that we hold rights to may be held invalid or unenforceable,
        including as a result of legal challenges by our competitors or other third parties;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the claims of our patents or patent applications, if and when issued, may not
        cover our products or technologies;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the laws of foreign countries may not protect our proprietary rights or the
        rights of current or future licensors or collaborators to the same extent as the laws of the United States;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the inventors of our patents or patent applications may become involved with
        competitors, develop products or processes that design around our patents, or become hostile to us or the patents or patent applications
        on which they are named as inventors;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our competitors or other third parties might conduct research and development
        activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive
        products for sale in our major commercial markets;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we have engaged in scientific collaborations in the past and will continue to
        do so in the future and our collaborators may develop adjacent or competing products that are outside the scope of our patents;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we may not develop additional proprietary technologies that are patentable;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our trade secrets may be misappropriated, without an ability to know or reverse
        engineer the misappropriation, or we may lose trade secret protections based on a failure to properly establish or maintain them;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">certain employees, consultants, or other collaborators may be engaged on terms
        that do not prevent them from inventing improvements, modifications, alterations, derivations of our technologies and methods, or otherwise
        from inventing alternative or new technologies or methods and pursuing them outside of and competitive with the company;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the patents of others may harm our business; or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we may choose not to file a patent in order to maintain certain trade secrets
        or know-how, and a third party may subsequently file a patent covering such intellectual property, and thereby potentially preventing
        us from continuing to use those related technologies or practice those related methods.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any of the foregoing could harm our business,
financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 59 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>If we are unable to protect the confidentiality
of our other proprietary information, our business and competitive position may be harmed.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to patent protection, we also rely
on other proprietary rights, including protection of trade secrets, know-how and other confidential or proprietary information that is
not patentable or that we elect not to patent. However, such information can be difficult to protect, and some courts, for instance, are
less willing or unwilling to protect trade secrets. To maintain the confidentiality of our trade secrets and proprietary information,
we rely heavily on confidentiality provisions that we have in contracts with our employees, consultants, collaborators, suppliers, customers,
and others upon the commencement of their relationship with us. We cannot guarantee that we have entered into such agreements with each
party that may have or have had access to our trade secrets or proprietary technology and processes. Furthermore, we may not be able to
prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by such third parties, despite the existence
generally of these confidentiality restrictions. These contracts may not provide meaningful protection or equitable remedies for our trade
secrets, know-how, or other proprietary information in the event of any unauthorized use, misappropriation, or disclosure of such trade
secrets, know-how, or other proprietary information. There can be no assurance that such third parties will not breach their agreements
with us, that we will have adequate remedies for any breach, or that our trade secrets will not otherwise become known or independently
developed by competitors. Despite the protections we do place on our intellectual property or other proprietary rights, monitoring unauthorized
use and disclosure of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual
property or other proprietary rights have or will be adequate. Trade secret violations are often a matter of state law, and the criteria
for protection of trade secrets can vary among different jurisdictions. In addition, the laws of many foreign countries will not protect
our intellectual property or other proprietary rights to the same extent as the laws of the United States. Consequently, we may be unable
to prevent our proprietary technology from being exploited abroad, which could affect our ability to expand to foreign markets or require
costly efforts to protect our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also license rights to use certain proprietary
information and technology from third parties. The use of such proprietary information and technology is therefore subject to the obligations
of the applicable license agreement between us and the owner. For example, the software we developed for our technology includes the use
of open source software that is subject to the terms and conditions of the applicable open source software licenses that grant us permission
to use such software. The owner of any such proprietary information or technology also might not enforce or otherwise protect its rights
in the proprietary information or technology with the same vigilance that we would, which would allow competitors to use such proprietary
information and technology without having to adhere to a license agreement with the owner.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent our intellectual property or other
proprietary information protection is incomplete, we are exposed to a greater risk of direct competition. A third party could, without
authorization, copy or otherwise obtain and use our products or technology, or develop similar products or technology. Our competitors
could purchase our products and attempt to reverse engineer or replicate some or all of the competitive advantages we derive from our
development efforts or design around our protected products or technology. Our failure to secure, protect and enforce our intellectual
property rights could substantially harm the value of our products, brand and business. The theft or unauthorized use or publication of
our trade secrets and other confidential business information could reduce the differentiation of our products, substantially and adversely
impact our sales and commercial operations and harm our business. Additionally, the value of our investment in development or business
acquisitions could be reduced and third parties might make claims against us related to losses of their confidential or proprietary information.
Any of the foregoing could materially and adversely affect our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, it is possible that others will independently
develop the same or similar technology or product or otherwise obtain access to our unpatented technology, and in such cases, we could
not assert any trade secret rights against such parties. Costly and time-consuming litigation could be necessary to enforce and determine
the scope of our trade secret rights and related confidentiality and nondisclosure provisions. If we fail to obtain or maintain trade
secret protection, or if our competitors otherwise obtain our trade secrets or independently develop technology or products similar to
and potentially competing with our products, our competitive market position could be materially and adversely affected. In addition,
some courts are less willing or unwilling to protect trade secrets and agreement terms that address non-competition are difficult to enforce
in many jurisdictions and might not be enforceable in certain cases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also seek to preserve the integrity and confidentiality
of our data and other confidential information by maintaining physical security of our premises and physical and electronic security of
our information technology systems. While we have confidence in these individuals, organizations, systems and tools, agreements or security
measures may be breached, whereby detecting the disclosure or misappropriation of confidential information and enforcing a claim that
a party illegally disclosed or misappropriated confidential information is difficult, expensive and time-consuming, and the outcome is
unpredictable. Further, we may not be able to obtain adequate remedies for any breach.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p>

<!-- Field: Page; Sequence: 60 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our inability to use software licensed from
third parties, or our use of open source software under license terms that interfere with our proprietary rights, could disrupt our business.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our products, including our technology and methods
used, include the use of open source software that is subject to the terms and conditions of the applicable open source software licenses
that grant us permission to use such software. Although we monitor our use of open source software, the terms of many open source licenses
to which we are subject have not been interpreted by U.S. or foreign courts, and there is a risk that such licenses could be construed
in a manner that imposes unanticipated conditions or restrictions on our ability to provide our technology to our customers. Moreover,
we cannot ensure that we have not incorporated additional open source software in our products in a manner that is inconsistent with the
terms of the applicable license or our current policies and procedures. In the future, we could be required to seek licenses from third
parties in order to continue offering our solutions, which licenses may not be available on terms that are acceptable to us, or at all.
Claims related to our use of open source software could also result in litigation, require us to purchase costly licenses or require us
to devote additional research and development resources to change the software underlying our technology, any of which would have a negative
effect on our business, financial condition and operating results and may not be possible in a timely manner. We and our customers may
also be subject to suits by parties claiming infringement due to the reliance by our products on certain open source software, and such
litigation could be costly for us to defend or subject us to injunctions enjoining us from the sale of our products that contain open
source software.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alternatively, we may need to re-engineer our
products or discontinue using portions of the functionality provided by our products. In addition, the terms of open source software licenses
may require us to provide software that we develop using such software to others on unfavorable terms, such as by precluding us from charging
license fees, requiring us to disclose our source code, requiring us to license certain of our own source code under the terms of the
applicable open source license or requiring us to provide notice on our products using such code. Any such restriction on the use of our
own software, or our inability to use open source or third-party software, could result in disruptions to our business or operations,
or delays in our development of future products or enhancements of our existing products, such as our RNS System, which could impair our
business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Public health crises may have an adverse effect
on certain aspects of our business, results of operations, financial condition, and cash flows. The nature and extent of future impacts
are highly uncertain and unpredictable.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business is subject to risks associated with
public health crises, including epidemics and pandemics such as COVID-19. In particular, the preventative and precautionary measures that
we and other businesses, communities, and governments may take to mitigate the spread of the disease could lead to restrictions on, and
disruptions in, business and personal activities that reduce the demand for deferrable and emergent medical procedures such as surgical
interventions to treat low back pain. It is not possible to predict the timing of deferrable medical procedures and, to the extent individuals
and hospital systems de-prioritize, delay or cancel these procedures, our business, results of operations, financial condition, and cash
flows could be negatively affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date we have not experienced material disruptions
in our business operations. However, while it is not possible at this time to estimate the impact that COVID-19 or other epidemic disease
could have on our business in the future, particularly as we advance our product development and marketing, the measures taken by the
governmental authorities, and any future epidemic disease outbreaks could: (i) disrupt our operations and the manufacture or shipment
of MRIs and MRSs used with our products and in our research, preclinical studies and clinical trials (ii) delay, limit or prevent our
employees and consultants from continuing research and development activities (iii) impede our clinical trial initiation and recruitment
(iv) impede the ability of patients to continue in clinical trials, including the risk that participants enrolled in our clinical trials
will contract COVID-19 or other epidemic disease while the clinical trials are ongoing, which could impact the results of clinical trials,
and impede testing, monitoring, data collection and analysis and other related activities, any of which could delay our studies and clinical
trials and increase our development costs, and have a material adverse effect on our business, financial condition and results of operations.
The COVID-19 pandemic and any future epidemic disease could also potentially affect the business of the FDA or comparable foreign regulatory
authorities, which could result in delays in meetings related to planned clinical trials. The COVID-19 pandemic and mitigation measures
have had and may continue to have, and any future epidemic disease outbreak may have, an adverse impact on global economic conditions
which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed.
While the direct effects of the pandemic on our business have significantly lessened since the beginning of 2022 as a result of declining
infection rates and the normalization of living with COVID-19 following the increase in accessibility to COVID-19 vaccines and antiviral
treatments, a resurgence of the pandemic and reinstatement of mitigation measures could delay our studies and clinical trials and increase
our development costs, so the extent to which the COVID-19 pandemic impacts our results will depend on future developments that are highly
uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain
its impact.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 61 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other risks facing our company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>If product liability lawsuits are brought against
us, we may incur substantial liabilities and may be required to limit or halt the marketing and sale of our technology. The expense and
potential unavailability of insurance coverage for liabilities resulting from our technology could harm our business and our ability to
sell our technology.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We face an inherent risk of product liability
as a result of the marketing and sale of our technology. Although we have established internal procedures designed to minimize risks that
may arise from quality issues, there can be no assurance that we will eliminate or mitigate occurrences of these issues and associated
liabilities. Our products and services are diagnostic in nature and involve an exam that is non-invasive using other third-party MR scanner
products and technologies. Those exams are also conducted by other third party MR service providers. The results of using our products
are also intended to provide information to doctors that help them perform a diagnosis for their patient, using all other diagnostic information
that is available to them. The downstream results from those diagnoses may also lead to certain treatments being performed, which are
decided upon between that treating doctor and the patient (and related payers), and which are conducted by that treating doctor on the
patient. We are not responsible for the performance of those MR scanners, nor for the performance of the MR service providers for conducting
those patient exams using the MR scanners, nor for the final diagnosis performed by a doctor as assisted via the results of our products
in combination with other available information, nor for the decisions and performance on conducting treatments or other on-going patient
care, or the patient outcomes from that care, following the use of our diagnostic assistance product. However, there are risks that certain
liability exposures or claims could be threatened or actually filed against us with respect to the performance or results of these other
activities around and relating to, but not directly caused by, the use of our products, including with respect to the use of our products
in the overall patient care regimen that might result in adverse patient outcomes. Even if we successfully defend any such allegation
or claim, this could involve significant risk of liability exposure and significant cost and diversion of resources and focus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we cannot successfully defend ourselves against
product liability claims, we may incur substantial liabilities or be required to limit or halt commercialization of our products. Regardless
of the merits or eventual outcome, liability claims may result in:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">decreased demand for our technology;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">injury to our brand or reputation;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">initiation of investigations by regulators;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">costs to defend the related litigation;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">increased insurance premiums;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a diversion of management&#8217;s time and our resources;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">substantial monetary awards to trial participants or patients;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulatory investigations, product recalls, withdrawals or labeling, marketing
        or promotional restrictions;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">loss of revenue;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">exhaustion of any available insurance and our capital resources; and </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the inability to market and sell our products.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe we have adequate product liability
insurance, but it may not prove to be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive.
We currently carry product liability insurance in the amount of $5 million in the aggregate. In the future, we may not be able to maintain
or obtain insurance at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Our insurance policy contains
various exclusions, and we may be subject to a product liability claim for which we have no coverage. The potential inability to obtain
sufficient product liability insurance at an acceptable cost to protect against product liability claims could prevent or inhibit the
marketing and sale of products we may develop. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed
our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay
such amounts, which would harm our business, financial condition and results of operations. In addition, any product liability claims
brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing continuing
coverage, harm our patient-focused brand, negatively impact our reputation in the industry, significantly increase our expenses and reduce
product sales.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 62 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of our customers may also have difficulty
in procuring or maintaining liability insurance to cover their operations, including their use of our products. Medical malpractice carriers
are withdrawing coverage in certain states or substantially increasing premiums. If this trend continues or worsens, our customers may
discontinue using our products and potential additional customers may opt against purchasing our products due to the cost or inability
to procure insurance coverage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The failure of third parties to meet their
contractual, regulatory and other obligations could adversely affect our business.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on licensors, suppliers, vendors, partners,
consultants, and other third parties to research, develop, and partake in both the commercialization of our technology, as well as manage
certain parts of our business. Using these third parties poses a number of risks, such as:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">they may not perform to our standards or legal requirements;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">they may not produce reliable results;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">they may not perform in a timely manner;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">they may not maintain confidentiality of our proprietary information;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">disputes may arise with respect to ownership of rights to products developed
        with our partners; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">disagreements could cause delays in, or termination of, the research, development
        or commercialization of our products or result in litigation or arbitration.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If and as any of one or more of these identified
parties might be replaced in the future by another party with whom we might engage or rely upon for similar technological or business
purposes, or to the extent we may expand our business to involve and rely on still more additional parties for similar purposes as those
listed (e.g. additional MR scanner vendors), similar risks would apply to those other parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, some third parties may be located in
markets subject to political and social risk, corruption, infrastructure problems and natural disasters, in addition to country-specific
privacy and data security risk given current legal and regulatory environments. Failure of third parties to meet their contractual, regulatory
and other obligations may materially affect our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Litigation and other legal proceedings may
harm our business.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time in the future we may become
involved in legal proceedings relating to patent and other intellectual property matters, product liability claims, employee matters,
tort or contract claims, federal regulatory investigations, private rights of action, securities class action and other legal proceedings
or investigations, which could have a negative impact on our reputation, business and financial condition and divert the attention of
our management from the operation of our business.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Litigation is inherently unpredictable and can
result in excessive or unanticipated verdicts, judgements, and/or injunctive relief that affect how we operate our business. We could
incur judgments or enter into settlements of claims for monetary damages or for agreements to change the way we operate our business,
or both. There may be an increase in the scope of these or other matters or there may be additional lawsuits, claims, proceedings or investigations
in the future, which could harm our business, financial condition and results of operations. Adverse publicity about regulatory or legal
action against us, irrespective of outcome, could damage our reputation and brand image, undermine our customers&#8217; confidence and
reduce long-term demand for our products, even if the regulatory or legal action is unfounded or not material to our operations.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our operating results may fluctuate across
periods, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations
or any guidance we may provide.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our quarterly and annual operating results may
fluctuate across periods, which makes it difficult for us to predict our future operating results. Accordingly, the results of any one
quarter or period should not be relied upon as an indication of future performance. Our quarterly and annual operating results may fluctuate
due to a variety of factors, many of which are outside of our control, including, but not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The level of demand for our technology and any future technology, which may
        vary significantly from period to period;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Expenditures that we may incur to acquire, develop or commercialize additional
        technology;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The timing and cost of obtaining regulatory approvals or clearances to expand
        our indications and get future approvals of any future technology or features;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pricing pressures;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our ability to expand the geographic reach of our commercial efforts;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The degree of competition in our industry and any change in the competitive
        landscape of our industry, including consolidation among our competitors or future partners;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 63 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Coverage and reimbursement policies with respect to our technology, and potential
        future technology that compete with our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The timing and success or failure of preclinical or clinical studies for expanding
        the indications of our technology or any future technology we develop or competing technology;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Positive or negative coverage in the media or clinical publications of our technology
        or technology of our competitors or our industry; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The impact of COVID-19 on procedure volume or otherwise;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The timing and cost of, and level of investment in, research, development, licenses,
        regulatory approval, commercialization activities, acquisitions and other strategic transactions, or other significant events relating
        to our technology, which may change from time to time;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The cost of developing our technology, which may vary depending on the terms
        of our agreements with third-party; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Future accounting pronouncements or changes in our accounting policies.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cumulative effects of these factors could
result in fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results
on a period-to-period basis may not be meaningful. Further, our historical results are not necessarily indicative of results expected
for any future period, and quarterly results are not necessarily indicative of the results to be expected for the full year or any other
period. Investors should not rely on our past results as an indication of our future performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This variability and unpredictability could also
result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating
results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, it could harm our business,
financial condition, and results or operations.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We will incur increased costs as a result of
operating as a public company, and our management and board of directors will be required to devote substantial time to compliance with
our public company responsibilities and corporate governance practices.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a public company, we will incur significant
legal, accounting and other expenses that we did not incur as a private company. We expect such expenses to further increase after we
are no longer an emerging growth company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing
requirements of the Nasdaq Capital Market, and other applicable securities rules and regulations impose various requirements on public
companies. Furthermore, most senior members of our management team as well as our board of directors do not have significant experience
with operating a public company. As a result, our management, board of directors, and other personnel will have to devote a substantial
amount of time to compliance with these requirements. Moreover, these rules and regulations will increase our legal and financial compliance
costs and will make some activities more time-consuming and costly. We cannot predict or estimate the amount of additional costs we will
incur as a public company or the timing of such costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks related to the ownership of our common stock and IPO Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our stock price may be volatile, and the value
of our common stock and IPO Warrants may decline.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market price of our common stock and IPO Warrants
may be highly volatile and may fluctuate or decline substantially as a result of a variety of factors, some of which are beyond our control
or are related in complex ways, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#8226;</td><td>Actual or anticipated fluctuations in our financial condition
and results of operations;</td>
</tr>
<tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#8226;</td><td>Variance in our financial performance from expectations of securities
analysts or investors;</td>
</tr>
<tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#8226;</td><td>Changes in the coverage decisions, reimbursement or pricing of
our technology;</td>
</tr>
<tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#8226;</td><td>Changes in our projected operating and financial results;</td>
</tr>
<tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#8226;</td><td>Changes in laws or regulations applicable to our technology;</td>
</tr>
<tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#8226;</td><td>Announcements by us or our competitors of significant business
developments, acquisitions, or new offerings;</td>
</tr>
<tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#8226;</td><td>Publicity associated with issues related to our technology;</td>
</tr>
<tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#8226;</td><td>Our involvement in regulatory investigations or litigation;</td>
</tr>
<tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#8226;</td><td>Future sales of our common stock or other securities, by us or
our stockholders, as well as the anticipation of lock-up releases;</td>
</tr>
<tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#8226;</td><td>Changes in senior management or key personnel;</td>
</tr>
<tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#8226;</td><td>The trading volume of our common stock;</td>
</tr>
<tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#8226;</td><td>Changes in the anticipated future size and growth rate of our
market;</td>
</tr>
<tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#8226;</td><td>General economic, regulatory, and market conditions, including
economic recessions or slowdowns;</td>
</tr>
<tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#8226;</td><td>The impact of the COVID-19 pandemic;</td>
</tr>
<tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#8226;</td><td>Changes in the structure of healthcare payment systems; and</td>
</tr>
<tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#8226;</td><td>Developments or disputes concerning our intellectual property
or other proprietary rights.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 64 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Broad market and industry fluctuations, as well
as general economic, political, regulatory, and market conditions, may negatively impact the market price of our common stock. In addition,
given the relatively small expected public float of shares of our common stock on the Nasdaq Capital Market, the trading market for our
shares may be subject to increased volatility. In the past, securities class action litigation has often been brought against a company
following a decline in the market price of its securities. This risk is especially relevant for us, because medical device companies have
experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a
diversion of management&#8217;s attention and resources, which could harm our reputation and our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>A significant portion of our total outstanding
shares may be sold into the market, which could cause the market price of our common stock to drop significantly, even if our business
is performing well.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of a substantial number of shares of our
common stock in the public market could occur at any time. These sales, or the perception in the market that holders of a large number
of shares intend to sell shares, could reduce the market price of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>You may experience
additional dilution if any of our outstanding common stock warrants are exercised or any of our outstanding shares of convertible preferred
stock are converted.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the holders
of any of our outstanding common stock warrants exercise their warrants, you will experience dilution at the time they exercise their
warrants. If the holders of any of our outstanding shares of convertible preferred stock convert their preferred shares, you will experience
dilution at the time they convert their preferred shares.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The price of our common stock may be volatile
and fluctuate substantially, which could result in substantial losses for investors in our common stock.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock price is likely to be volatile.
The stock market in general and the market for bio-technology companies in particular, has experienced extreme volatility that has often
been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your
common stock at or above your investment price. The market price for our common stock may be influenced by many factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 24px">&#160;</td>
    <td style="vertical-align: top; width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">the success of competitive products or technologies;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">regulatory or legal developments in the United States, </span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">the recruitment or departure of key personnel;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">the level of expenses related to any of our product candidates, and our commercialization
        efforts;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">actual or anticipated changes in our development timelines;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">our ability to raise additional capital;</span></td></tr>

<tr>
    <td style="width: 24px">&#160;</td>
    <td style="vertical-align: top; width: 24px">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify; vertical-align: top"><span style="font-size: 10pt">disputes or other developments relating to proprietary rights, including patents,
        litigation matters and our ability to obtain patent protection for our product candidates;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">significant lawsuits, including patent or stockholder litigation;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">variations in our financial results or those of companies that are perceived
        to be similar to us;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">general economic, industry and market conditions; and</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">the other factors described in this &#8220;<a href="#s_005">Risk Factors</a>&#8221; section.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If our quarterly operating
results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore,
any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe
that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our
future performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In the past, following
periods of volatility in the market price of a company&#8217;s securities, securities class-action litigation often has been instituted
against that company. Such litigation, if instituted against us, could cause us to incur substantial costs to defend such claims and divert
management&#8217;s attention and resources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Because we do not
expect to pay dividends for the foreseeable future, investors seeking cash dividends should not purchase shares of our common stock. </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never declared or paid any cash dividends
on our common stock. We currently intend to retain future earnings, if any, to finance the expansion of our business. As a result, we
do not anticipate paying any cash dividends in the foreseeable future. Our payment of any future dividends will be at the discretion of
our Board of Directors after taking into account various factors, including but not limited to our financial condition, operating results,
cash needs, growth plans and the terms of any credit agreements that we may be a party to at the time. Accordingly, investors seeking
cash dividends should not purchase our shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>If securities analysts
do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could
decline.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The trading market for
our common stock will rely, in part, on the research and reports that industry or financial analysts publish about us or our business.
We do not currently have, and may never obtain, research coverage by industry or financial analysts. If no, or few, analysts commence
coverage of us, the trading price of our stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts
covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts
cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We are an emerging growth company and a smaller
reporting company, and our compliance with the reduced reporting and disclosure requirements applicable to emerging growth companies and
smaller reporting companies could make our common stock less attractive to investors.</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an emerging growth company, as defined
in the JOBS Act, and we expect to take advantage of certain exemptions from various reporting requirements that are applicable to other
public companies that are not emerging growth companies, including the auditor attestation requirements of Section 404, reduced disclosure
obligations regarding executive compensation in our periodic reports and proxy statements, exemptions from the requirements of holding
a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved
and extended adoption period for accounting pronouncements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even after we no longer qualify as an emerging
growth company, we may still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to continue to take advantage
of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements
of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in this prospectus and our
periodic reports and proxy statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 66 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot predict whether investors will find
our common stock less attractive as a result of our reliance on these exemptions. If some investors find our common stock less attractive
as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will remain an emerging growth company until
the earliest of (i) the end of the fiscal year following the fifth anniversary of the completion of our IPO, (ii) the first fiscal year
after our annual gross revenues exceed $1.235 billion, (iii) the date on which we have, during the immediately preceding three-year period,
issued more than $1.00 billion in non-convertible debt securities, or (iv) the end of any fiscal year in which the market value of our
common stock held by non-affiliates exceeds $700 million as of the end of the second quarter of that fiscal year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Provisions in our corporate charter and our
bylaws and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent
attempts by our stockholders to replace or remove our current management.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The anti-takeover provisions of the Delaware General
Corporation Law (the &#8220;DGCL&#8221;) may discourage, delay or prevent a change in control by prohibiting us from engaging in a business
combination with an interested stockholder for a period of three years after the person becomes an interested stockholder, even if a change
in control would be beneficial to our existing stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions in our corporate charter and our bylaws
discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including
transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors
might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition,
because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent
any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members
of our board of directors. Among other things, these provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 24px">&#160;</td>
    <td style="vertical-align: top; width: 24px"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify; vertical-align: top"><span style="font-size: 10pt">allow the authorized number of our directors to be changed
        only by resolution of our board of directors;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify; vertical-align: top"><span style="font-size: 10pt">limit the manner in which stockholders can remove directors
        from the board;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify; vertical-align: top"><span style="font-size: 10pt">establish advance notice requirements for stockholder proposals
        that can be acted on at stockholder meetings and nominations to our board of directors;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify; vertical-align: top"><span style="font-size: 10pt">require that stockholder actions must be effected at a
        duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify; vertical-align: top"><span style="font-size: 10pt">limit who may call stockholder meetings;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify; vertical-align: top"><span style="font-size: 10pt">authorize our board of directors to issue preferred stock
        without stockholder approval, which could be used to institute a stockholder rights plan, or&#160;so-called &#8220;poison pill,&#8221;
        that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been
        approved by our board of directors; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, because we are incorporated in Delaware,
we are governed by the provisions of Section&#160;203 of the DGCL, which prohibits a person who owns in excess of 15% of our outstanding
voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired
in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 67 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our amended and restated certificate of incorporation
provides that the Court of Chancery of the State of Delaware or, under certain circumstances, the federal district courts of the United
States of America will be the exclusive forums for certain types of actions and proceedings that may be initiated by our stockholders,
which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers,
employees or agents.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our amended and restated certificate of incorporation
provides that the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware lacks subject matter
jurisdiction, any state court located within the State of Delaware or, if all such state courts lack subject matter jurisdiction, the
federal district court for the District of Delaware) is the sole and exclusive forum for the following types of actions or proceedings
under Delaware statutory or common law for:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any derivative action or proceeding brought on our behalf;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any action asserting a breach of fiduciary duty;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any action arising pursuant to the Delaware General Corporation Law, our amended
        and restated certificate of incorporation, or our amended and restated bylaws; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any action asserting a claim against us that is governed by the internal-affairs
        doctrine.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These provisions would not apply to suits brought
to enforce a duty or liability created by the Exchange Act or any claim for which the federal district courts of the United States of
America have exclusive jurisdiction. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state
courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our stockholders cannot waive compliance with
the federal securities laws and the rules and regulations thereunder. Any person or entity purchasing or otherwise acquiring any interest
in shares of our capital stock will be deemed to have notice of, and consented to, the provisions of our amended and restated certificate
of incorporation described in the preceding sentences.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To prevent having to litigate claims in multiple
jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated
certificate of provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint
asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions
are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum
provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of
our amended and restated certificate of incorporation in effect upon the effectiveness of our IPO. This may require significant additional
costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced
by a court in those other jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These exclusive forum provisions may limit a stockholder&#8217;s
ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees,
which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum
provision in our amended and restated certificate of incorporation in effect upon the effectiveness of our IPO to be inapplicable or unenforceable
in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which
could harm our business and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<!-- Field: Page; Sequence: 68 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="s_006"></span>INFORMATION REGARDING FORWARD-LOOKING STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus and the documents incorporated
by reference in this prospectus include forward-looking statements, which involve risks and uncertainties. These forward-looking statements
can be identified by the use of forward-looking terminology, including the terms &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221;
&#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;seek,&#8221; &#8220;predict,&#8221; &#8220;continue,&#8221; &#8220;possible,&#8221;
&#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; would&#8221; or &#8220;should&#8221;
or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters
that are not historical facts. They appear in a number of places throughout this prospectus and the documents incorporated by reference
in this prospectus, and include statements regarding our intentions, beliefs or current expectations concerning, among other things, our
product candidates, research and development, commercialization objectives, prospects, strategies, the industry in which we operate and
potential collaborations. We derive many of our forward-looking statements from our operating budgets and forecasts, which are based upon
many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact
of known factors, and, of course, it is impossible for us to anticipate all factors that could affect our actual results. Forward-looking
statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance
or results will be achieved. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this
prospectus may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forward-looking statements speak only as of the
date of this prospectus. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking
statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, except
to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will
make additional updates with respect to those or other forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should read this prospectus, the documents
incorporated by reference in this prospectus, and the documents that we reference in this prospectus and have filed with the SEC as exhibits
to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity,
performance and events and circumstances may be materially different from what we expect. All forward-looking statements are based upon
information available to us on the date of this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By their nature, forward-looking statements involve
risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution
you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition,
business and prospects may differ materially from those made in or suggested by the forward-looking statements contained in this prospectus.
In addition, even if our results of operations, financial condition, business and prospects are consistent with the forward-looking statements
contained in this prospectus, those results may not be indicative of results in subsequent periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forward-looking statements necessarily involve
risks and uncertainties, and our actual results could differ materially from those anticipated in the forward-looking statements due to
a number of factors, including those set forth below under &#8220;Risk Factors&#8221; and elsewhere in this prospectus. The factors set
forth below under &#8220;Risk Factors&#8221; and other cautionary statements made in this prospectus should be read and understood as
being applicable to all related forward-looking statements wherever they appear in this prospectus. The forward-looking statements contained
in this prospectus represent our judgment as of the date of this prospectus. We caution readers not to place undue reliance on such statements.
Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, even if new information
becomes available or other events occur in the future. All subsequent written and oral forward-looking statements attributable to us or
persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained above and throughout this
prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should read this prospectus and the documents
that we reference in this prospectus and have filed as exhibits to the registration statement of which this prospectus is a part completely
and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking
statements by these cautionary statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<!-- Field: Page; Sequence: 69 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="s_007"></span>THE WHITE LION TRANSACTION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 9, 2023, the Company and White Lion
entered into the Purchase Agreement and concurrently with the Purchase Agreement, the Company and White Lion entered into a Registration
Rights Agreement (the &#8220;White Lion RRA&#8221;), pursuant to which we agreed to file with the SEC the registration statement of which
this prospectus is a part to register for resale under the Securities Act the shares of stock issuable under the Purchase Agreement.
Pursuant to the Purchase Agreement, the Company has the right, but not the obligation, to require White Lion to purchase, from time to
time, up to $10,000,000 in aggregate gross purchase price (the &#8220;Purchase Price&#8221;) of newly issued shares (the &#8220;Purchase
Notice Shares&#8221;) of the Company&#8217;s common stock, subject to certain limitations and conditions set forth in the Purchase Agreement.
As of the date hereof, the Company has sold a total of $3,216,981 worth of shares of common stock to White Lion: (i) $2,912,481 worth
of shares were registered under a previously filed registration statement (No. 333-274914), which was declared effective on October 20,
2023 (the &#8220;Initial Registration Statement&#8221;), and (ii) $304,500 worth of shares were sold pursuant to this registration
statement. Capitalized terms used but not otherwise defined in this section shall have the meanings given to such terms by the Purchase
Agreement and the White Lion RRA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the satisfaction of certain customary
conditions including, without limitation, the effectiveness of this registration statement registering the shares issuable pursuant to
the Purchase Agreement, the Company&#8217;s right to sell shares registered hereby to White Lion will commence on the effective date of
the registration statement and extend until December 31, 2024 (the &#8220;Commitment Period&#8221;). During such term, subject to the
terms and conditions of the Purchase Agreement, the Company may notify White Lion when the Company exercises its right to sell shares.
The Purchase Notice may be for a fixed purchase, rapid purchase or VWAP purchase, each as described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares sold pursuant to any such
notice may not exceed the lesser of (i) 30% of the Average Daily Trading Volume (as defined in the Purchase Agreement) (the &#8220;Percentage
Limit&#8221;) for the common stock traded on Nasdaq and (ii) $1,000,000 divided by the highest closing price of the common stock over
the most recent five business days immediately preceding receipt of the notice from the Company (the &#8220;Purchase Notice Date&#8221;),
and can be increased at any time at the sole discretion of White Lion, up to 9.99% of the outstanding shares of the Company,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under a fixed Purchase Notice mechanism, the Purchase
Price to be paid by White Lion for any such Purchase Notice Shares will equal 85% of lowest daily volume-weighted average price (&#8220;VWAP&#8221;)
of common stock during a period of five consecutive business days prior to, ending on and including the applicable Purchase Notice Date.
Under a VWAP Purchase Notice mechanism, the Purchase Price to be paid by White Lion will equal 95% of the lowest daily VWAP of common
stock during a period of two consecutive Trading Days beginning on and including the applicable Purchase Notice Date. Under a rapid Purchase
Notice mechanism, the Purchase Price to be paid by White Lion will equal 85% of the lowest daily VWAP of common stock on the Purchase
Notice Date, unless notice is provided after 9:00 a.m. New York time on any business day, in which case the Purchase Price to be paid
by White Lion will equal the lowest traded price of the Company&#8217;s common stock on the Purchase Notice Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In consideration for the commitments of White
Lion, as described above, the Company agreed that it would issue to White Lion shares of common stock having a value of $75,000 based
upon the closing sale price of common stock (the &#8220;Closing Sale Price&#8221;) on the earlier of (i) the business day prior to the
filing of the Initial Registration Statement and (ii) the business day prior to the date that White Lion delivers a written request to
the Company for the Commitment Shares. The Company issued the Commitment Shares of 187,500 shares (11,719 post-split shares after giving
effect to our reverse stock split effective January 3, 2024) of common stock to White Lion, based upon the Closing Sale Price of our common
stock of $0.40 per share on October 6, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have already
issued 1,800,000 shares of common stock to White Lion under the Equity Line Purchase Agreement for proceeds of $3,216,981. As a result,
we may sell up to an additional $6,783,019 of shares of our common stock pursuant to the Equity Line Purchase Agreement. This registration
statement does not register additional shares of our common stock. This registration statement, initially filed with the Securities and
Exchange Commission on January 22, 2024, registered up to 2,500,000 shares of common stock. As of the date of this registration statement
amendment, 1,050,000 of such shares of common stock have been sold under this registration statement and 1,450,000 shares remain unsold.
As of the date of this filing, a total of 1,800,000 shares of common stock have been sold under the Purchase Agreement.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may terminate the Purchase Agreement
at any time in the event of a material breach of the Agreement by the Investor, which shall be effected by written notice being sent by
the Company to White Lion, provided, however, that the Company shall have delivered the Commitment Shares to White Lion prior to such
termination. In addition, the Agreement shall automatically terminate on the earlier of (i) the end of the Commitment Period or (ii) the
date that, pursuant to or within the meaning of any Bankruptcy Law (as defined in the Purchase Agreement), the Company commences a voluntary
case or any person commences a proceeding against the Company, a custodian is appointed for the Company or for all or substantially all
of its property or the Company makes a general assignment for the benefit of its creditors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Purchase Agreement and the White Lion RRA
contain customary representations, warranties, conditions and indemnification obligations of the parties. The representations, warranties
and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the
benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b><span id="s_008"></span>USE OF PROCEEDS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus relates to shares of common stock
that may be offered and sold from time to time by White Lion. We will not receive any proceeds from the resale of shares of common stock
by White Lion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may receive up to $250,000 in gross
proceeds if we sell to White Lion shares issuable pursuant to the Purchase Agreement and registered hereby. We estimate that the net
proceeds to us from the sale of our common stock to White Lion pursuant to the Purchase Agreement would be up to $250,000, assuming
that we sell the full amount of our common stock that we have the right, but not the obligation, to sell to White Lion under the Purchase
Agreement and registered hereby, and after other estimated fees and expenses. See &#8220;<a href="#s_018">Plan of Distribution</a>&#8221;
elsewhere in this prospectus for more information. We have already issued 1,800,000 shares of common stock to White Lion for total proceeds
of $3,216,981.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any proceeds from the Selling Securityholder that
we receive under the Purchase Agreement are currently expected to be used for general corporate purposes, including working capital. The
amounts and timing of our actual expenditures may vary significantly depending on numerous factors. As a result, our management will have
broad discretion in the application of the net proceeds from this offering, and the investors will be relying on the judgment of our management
regarding the application of the net proceeds from this offering. As we are unable to predict the timing or amount of potential issuances
of all of the additional shares of common stock issuable purchase to the Purchase Agreement, we cannot specify with certainty all of the
particular uses for the net proceeds that we will have from the sale of such additional shares. We may use the proceeds for purposes that
are not contemplated at the time of this offering. It is possible that no shares will be issued under the Purchase Agreement other than
the Commitment Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will incur all costs associated with this prospectus and the registration
statement of which it is a part.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<!-- Field: Page; Sequence: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b><span id="s_009"></span>DIVIDEND POLICY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We have not declared or
paid any cash dividends on our capital stock since our inception. We intend to retain future earnings, if any, to finance the operation
and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><span style="text-transform: uppercase"><b><span id="s_010"></span>Market
Price of and Dividends on Common Equity and Related Stockholder Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock has been traded on the Nasdaq
Stock Market under the symbol &#8220;ACON&#8221; since our IPO on April 21, 2022. Our IPO Warrants have been traded on the Nasdaq Stock
Market under the symbol &#8220;ACONW&#8221; since our IPO on April 21, 2022. As of October 2, 2024, there were approximately 145 holders
of record of our common stock and 1 holder of record of our IPO Warrants. These numbers are based on the actual number of holders
registered at such date and do not include holders whose shares are held in &#8220;street name&#8221; by brokers and other nominees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Dividends</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We have never paid any
cash dividends on our common stock. We currently intend to retain all available funds and any future earnings for use in the operation
of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future. Any future determination
to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results,
capital requirements, general business conditions and other factors that our board of directors may deem relevant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><span style="text-transform: uppercase"><b><span id="s_011"></span>Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>You should read the following discussion and
analysis of our financial condition and results of operations in conjunction with the audited and unaudited financial statements (prepared
in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) and related notes included
elsewhere in this prospectus. The following discussion contains forward-looking statements that are subject to risks and uncertainties.
See &#8220;Information Regarding Forward-Looking Statements&#8221; for a discussion of the uncertainties, risks, and assumptions associated
with those statements. Actual results could differ materially from those discussed in or implied by forward-looking statements as a result
of various factors, including those discussed below and elsewhere in this prospectus, particularly in the section entitled &#8220;<a href="#s_005">Risk Factors</a>.&#8221; Unless we state otherwise or the context otherwise requires, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221;
and the &#8220;Company&#8221; refer to Aclarion, Inc. </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Aclarion is a healthcare
technology company that leverages Magnetic Resonance Spectroscopy (&#8220;MRS&#8221;), proprietary signal processing techniques, biomarkers,
and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market
with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful
discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine
for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers
demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source
of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient&#8217;s low back pain,
giving physicians clarity to optimize treatment strategies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">To
                                            date, we have financed our operations primarily through private placements of preferred shares
                                            and debt financing, PPP loans that were forgiven, an equity line, an initial public offering
                                            on April 21, 2022, and a secondary public offering on February 27, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Since our inception we
have incurred significant operating losses. As of June 30, 2024, we had an accumulated deficit of approximately $47.9 million. Our ability
to generate product revenue sufficient to achieve profitability will depend heavily on the successful commercialization and continued
development of our SaaS platform. We expect that our expenses and capital requirements will increase substantially in connection with
our ongoing activities, particularly if and as we:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">identify and support Key Opinion Leader (&#8220;KOL&#8221;)
    physicians and radiologists to help secure local payer coverage decisions and spine society support for our technology;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">expand the network of imaging centers and physicians
    using NOCISCAN in each market such that the technology is widely available to patients covered by payers;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">support surgeons, radiologists, Physical Medicine
    and Rehabilitation physicians, chiropractors, physical therapists, regenerative therapy physicians and medical device companies that
    address low back pain to initiate studies and report results;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">build and expand clinical trials and registries to
    provide real world evidence of better outcomes when using Nociscan to help determine which discs to treat;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><p style="font: 10pt Symbol; margin: 0pt 0">&#183;</p></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">pursue value-based care contracts to
        share in the profits that result from the improved surgical outcomes we believe our technology enables in DLBP patients;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">hire additional business development,
        product management, operational and marketing personnel;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify">&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">add operational and general administrative personnel
    which will support our product development programs, commercialization efforts, and our transition to operating as a public company.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our primary near-term
growth strategy is to secure payer contracts (including insurance companies, self- insured employers, Medicare, Medicaid, workmen&#8217;s
compensation boards et. al.) to cover our Category III CPT codes. We believe that with favorable payer coverage, the Company has the
opportunity to more efficiently engage physicians and imaging centers that will adopt our technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As a result, we may need
substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate
significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other
capital sources, which may include collaborations with other companies or other strategic transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We
                                            believe our current cash resources will be sufficient to fund current operating plans into
                                            the fourth quarter of 2024. We have based this estimate on assumptions that may
                                            prove to be wrong, and we could exhaust our available capital resources sooner than we expect.
                                            See &#8220;Liquidity and capital resources&#8221; below. To finance our operations beyond
                                            that point, we will need to raise additional capital, which cannot be assured. If we are
                                            unable to raise additional capital in sufficient amounts or on terms acceptable to us, we
                                            may have to significantly delay, scale back, or discontinue the commercialization or further
                                            development of our SaaS platform.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 73 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Corporate Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We were formed under
the name Nocimed, LLC, a limited liability company in January 2008, under the laws of the State of Delaware. In February 2015, Nocimed,
LLC was converted into Nocimed, Inc. a Delaware corporation. On December 3, 2021, we changed our name to Aclarion, Inc. Our principal
executive offices are located at 8181 Arista Place, Suite 100, Broomfield, Colorado 80021. Our main telephone number is (833) 275-2266.
Our internet website is www.aclarion.com. The information contained in, or that can be accessed through, our website is not incorporated
by reference and is not a part of this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Effect of COVID-19
Pandemic on business operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The COVID-19 Pandemic is not currently impacting
plans for marketing our products or our continuing development efforts, as all such activities have been conducted by us using remote
work strategies. The Company cannot accurately predict the longer-term impact of the COVID-19 Pandemic on its business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Results of operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>Operating activities:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The following table summarizes
our results of operations for the twelve months ended December 31, 2023, and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022 to 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(restated)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$ Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-decoration: underline; font-weight: bold">Revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 55%">Revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">75,404</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">60,444</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">14,960</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Cost of revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">75,728</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">65,298</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,430</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Gross profit (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(324</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,854</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,530</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-weight: bold; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Sales and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">757,004</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">498,003</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">259,001</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">873,336</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,067,992</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(194,656</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,245,317</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,990,719</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(745,402</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,875,657</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,556,714</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(681,057</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-weight: bold; text-align: left; padding-bottom: 1pt">Income (loss) from operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,875,981</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,561,568</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">685,587</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(608,288</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,507,546</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">899,258</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Changes in fair value of warrant and derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">646,319</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">646,319</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Loss on issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(72,862</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(72,862</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(562</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">521</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,083</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total other income (expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(35,393</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,507,025</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,471,632</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Income (loss) before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,911,374</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,068,593</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,157,219</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Income tax provision</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net income (loss)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,911,374</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(7,068,593</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,157,219</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Dividends accrued for preferred stockholders</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(415,523</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">415,523</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net income (loss) allocable to common stockholders</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(4,911,374</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(7,484,116</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,572,742</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Net income (loss) per share allocable to common shareholders</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(8.82</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(19.61</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10.79</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average shares of common stock outstanding, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">556,808</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">381,598</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">175,210</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b></b></p>

<!-- Field: Page; Sequence: 74 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Years ended December 31, 2023, and 2022</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Total revenues.</i> Total revenue for the year
ended December 31, 2023, was $75,404, which was an increase of $14,960 from $60,444 for the year ended December 31, 2022. This increase
was primarily due to growing utilization of Nociscan in third-party clinical studies. Volumes and pricing were generally consistent in
each year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Cost of Revenue.&#160;</i>Cost of Revenue is
comprised of hosting and software costs, field support, UCSF royalty cost, NuVasive commission of 6%, partner fees (Radnet), and credit
card fees. Total Cost of Revenue was $75,728 for the year ended December 31, 2023, compared to $65,298 for the year ended December 31,
2022, an increase of 16.0%. This increase was primarily due to higher year-over-year scan volumes and related Nociscan report output.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Sales and Marketing.</i> Sales and marketing
expenses were $757,004 for the year ended December 31, 2023, compared to $498,003 for the year ended December 31, 2022, an increase of
$259,001 or 52.0%. This increase was driven primarily by additional vesting of restricted stock units to our increased number of Key
Opinion Leaders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Research and Development.</i>&#160;Research
and development expenses were $873,336 for the year ended December 31, 2023, compared to $1,067,992 for the year ended December 31, 2022,
a decrease of $194,656 or 18.2%. This decrease was primarily due to a $123,828 contract milestone payment to UCSF in April 2022, related
to the initial public offering, and reduced expense in 2023 clinical services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>General and Administrative</i>. General and
administrative expenses were $3,245,317 for the year ended December 31, 2023, a decrease of $745,402 or 18.7%, from $3,990,719 for the
year ended December 31, 2022. This decrease in general and administrative expenses was driven primarily by a higher 2022 compensation
expense related to the vesting of the Executive Chairman&#8217;s and executive&#8217;s outstanding common stock options, offset in part
by higher legal and accounting fees in 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Interest Expense.</i>&#160;Total Interest expense
was $608,288 for the year ended December 31, 2023, a decrease of $899,258, from the $1,507,546 for the year ended December 31, 2022.
This decrease was driven primarily by the $1.3 million beneficial conversion rate charged to interest expense in 2022 for the conversion
of all accrued interest on the Company's outstanding secured promissory notes into common shares and common stock warrants in connection
with the April 2022, initial public offering. The 2023 interest expense was primarily due to the amortization of the note discount associated
with the unsecured non-convertible promissory notes described in Note 11 to our financial statements -- Short Term Notes, Convertible
Debt, and Derivative Liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Changes in Fair Value of Warrant and Derivative
Liabilities.</i> In the year ended December 31, 2023, the Company recorded $646,319 of changes in the fair value of the warrant and derivative
liabilities associated with unsecured non-convertible promissory notes described in Note 4 -- Fair Value Measurements and Note 11 --
Short Term Notes, Convertible Debt, and Derivative Liabilities to our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Other Net Expenses</i>.&#160;During the year
ended December 31, 2023, Other Net expenses were $562, which included bank interest, government fees, and realized exchange rate gain
(losses).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Net income (loss).</i>&#160; The Company experienced
a net loss of $4,911,374 for the year ended December 31, 2023, compared to a net loss of $7,068,593 for the year ended December 31, 2022.
In general, the year ended December 31, 2023 excluded two significant expenses that were present during the year 2022, that being the
compensation expense related to the vesting of the Executive Chairman&#8217;s and other executive&#8217;s outstanding common stock options,
and the $1.3 million beneficial conversion rate charged to interest expense for the conversion of all accrued interest on the Company's
outstanding secured promissory notes into common shares and common stock warrants in connection with the April, 2022, initial public
offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 75 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>For the Three Months Ended June 30, 2024,
and 2023:</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes our results of
operations for the three months ended June 30, 2024, and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$ Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="text-decoration: underline">Revenue</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; width: 55%">Revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">10,971</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">17,072</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(6,101</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Cost of revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">23,294</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">19,301</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,993</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left">Gross profit (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,323</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,229</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,094</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-decoration: underline; font-weight: bold; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Sales and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">225,037</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">207,790</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,247</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">202,102</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,006</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(47,904</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">696,099</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">946,175</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(250,076</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,123,238</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,403,971</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(280,733</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-decoration: underline; font-weight: bold; text-align: left; padding-bottom: 1pt">(Loss) from operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,135,561</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,406,200</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">270,639</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loss on exchange of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Loss on extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(127,848</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(47,139</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(80,709</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Changes in fair value of warrant and derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,357</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,800</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,157</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(25</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">583</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(608</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total other (expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(102,516</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(58,356</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(44,160</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">(Loss) before income taxes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,238,077</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,464,557</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">226,480</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income tax provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: 10pt">Net income (loss)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,238,077</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,464,557</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">226,480</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Net (loss) allocable to common stockholders</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,238,077</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,464,557</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">226,480</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net (loss) per share allocable to common stockholders</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.15</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.83</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.68</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Weighted average shares of common stock outstanding, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,217,024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">517,979</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,699,045</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Total revenues</span></i>. Total revenues for
the quarter ended June 30, 2024 were $10,971, which was a decrease of $6,101, or 36%, from $17,072 for the quarter ended June 30, 2023.
The decrease in revenues was driven primarily by the conclusion of certain clinical activity at customer sites utilizing NOCISCAN &#174;
reports.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Cost of Revenue</span></i>. Direct cost of
revenue is comprised of hosting and software costs, field support, UCSF royalty cost, partner fees (Radnet), and credit card fees. Total
cost of revenue was $23,294 for the quarter ended June 30, 2024, compared to $19,301 for the quarter ended June 30, 2023, an increase
of 21%. This increase was primarily due to a change in revenue mix that increased partner fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Sales and Marketing</span></i>. Marketing expenses
include post-market clinical and reimbursement consulting, salaries, website support, press releases, conferences, travel, and shared-based
compensation for Key Opinion Leaders. Sales and marketing expenses were $225,037 for the quarter ended June 30, 2024, compared to $207,790
for the quarter ended June 30, 2023, an increase of $17,247, or 8%. Post-market clinical expenses increased as the Company focused on
the initiation of the Clarity trial. Marketing expenses also increased with the number of press releases year-over-year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 76 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Research and Development</span></i>. Research
and development expenses were $202,102 for the quarter ended June 30, 2024, compared to $250,006 for the quarter ended June 30, 2023,
a decrease of $47,904, or 19%. There was no accrued bonus expense in the quarter ended June 30, 2024, along with a general decrease in
required regulatory and quality system work.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">General and Administrative</span></i>. General
and administrative expenses were $696,099 for the quarter ended June 30, 2024, a decrease of $250,076 or 26%, from $946,175 for the quarter
ended June 30, 2023. For the quarter ended June 30, 2024, there was no accrued bonus expense, D&amp;O insurance premiums were reduced,
and legal fees were less compared to the quarter ended June 30, 2023, when the Company issued debt. These reductions in expense were
somewhat offset by increased investment in investor relations during the quarter ended June 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Other Income (Expense)</span></i>. Interest
expense was $127,848 for the quarter ended June 30, 2024, an increase of $80,709 from the $47,139 incurred during the quarter ended June
30, 2023. This increase in interest expense was due to the increase in debt taken on by the Company in 2023. In May, September and November
2023 the Company issued $2,594,118 aggregate principal amount of unsecured non-convertible notes to certain accredited investors. (see
Note 9 to the condensed financial statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s warrant and derivative liabilities
are recorded at fair value as of each reporting date (see Note 3 to the condensed financial statements). For the quarter ended June 30,
2024, the Company recorded a favorable adjustment in fair value of $25,357.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>For the Six Months Ended June 30, 2024,
and 2023:</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes our results of
operations for the six months ended June 30, 2024, and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$ Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold"><span style="text-decoration: underline">Revenue</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; width: 55%">Revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">21,085</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">42,542</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(21,457</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Cost of revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">42,770</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">36,754</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,016</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left">Gross profit (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,685</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,788</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27,473</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-decoration: underline; font-weight: bold; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Sales and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">406,094</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">385,074</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,020</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">441,143</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">454,405</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,262</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,541,947</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,753,774</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(211,827</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,389,184</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,593,253</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(204,069</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-decoration: underline; font-weight: bold; text-align: left; padding-bottom: 1pt">(Loss) from operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,410,869</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,587,464</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">176,596</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loss on exchange of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,066,732</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,066,732</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Loss on extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(111,928</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(111,928</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(463,672</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(48,519</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(415,153</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Changes in fair value of warrant and derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">323,041</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,800</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">334,841</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">92,980</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(234</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">93,213</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total other (expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,226,311</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(60,552</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,165,759</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">(Loss) before income taxes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,637,180</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,648,017</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(989,163</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income tax provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: 9pt">Net income (loss)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,637,180</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,648,017</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(989,163</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Net (loss) allocable to common stockholders</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,637,180</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,648,017</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(989,163</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net (loss) per share allocable to common stockholders</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.53</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5.22</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.69</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Weighted average shares of common stock outstanding, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,829,825</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">507,499</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,322,326</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 77 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Total revenues</span></i>. Total revenues for
the six months ended June 30, 2024 were $21,085, which was a decrease of $21,457, or 50%, from $42,542 for the six months ended June
30, 2023. The decrease in revenues was driven primarily by the conclusion of certain clinical activity at customer sites utilizing NOCISCAN
&#174; reports.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Cost of Revenue</span></i>. Direct cost of
revenue is comprised of hosting and software costs, field support, UCSF royalty cost, partner fees (Radnet), and credit card fees. Total
cost of revenue was $42,770 for the six months ended June 30, 2024, compared to $36,754 for the six months ended June 30, 2023, an increase
of 16%, was driven by a price increase related to hosting costs and a change in revenue mix that increased partner fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Sales and Marketing</span></i>. Marketing expenses
include post-market clinical and reimbursement consulting, salaries, website support, press releases, conferences, travel, and shared-based
compensation for Key Opinion Leaders. Sales and marketing expenses were $406,093 for the six months ended June 30, 2024, compared to
$385,074 for the six months ended June 30, 2023, an increase of $21,020, or 6%. Increased post-market clinical expense related to the
Clarity trial, greater marketing expense, and increased benefits costs were offset in part by a reduction in restricted stock vesting
expense related to the Company&#8217;s engagement of Key Opinion Leaders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Research and Development</span></i>. Research
and development expenses were $441,143 for the six months ended June 30, 2024, compared to $454,405 for the six months ended June 30,
2023, a decrease of $13,262, or 3%. There was no accrued bonus expense in the six month period ended June 30, 2024, along with a general
decrease in required regulatory and quality system work.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">General and Administrative</span></i>. General
and administrative expenses were $1,541,947 for the six months ended June 30, 2024, a decrease of $211,827 or 12%, from $1,753,774 for
the six months ended June 30, 2023. The decrease was driven by reduced bonus accruals, lower personnel expense, and decreased D&amp;O
insurance premiums, offset in part by higher legal and audit costs related to the February 2024 public offering and increased investment
in investor relations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Other Income (Expense)</span></i>. Interest
expense was $463,672 for the six months ended June 30, 2024, an increase of $415,153 from the $48,519 incurred during the six months
ended June 30, 2023. This increase in interest expense was due to the increase in debt taken on by the Company in 2023. In May, September
and November 2023 the Company issued $2,594,118 aggregate principal amount of unsecured non-convertible notes to certain accredited investors.
(see Note 9 to the condensed financial statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company incurred losses for the six months
ended June 30, 2024, on two transactions to reduce debt. The first transaction took place between January 22 and January 29, 2024, whereby
the Company entered into a series of exchange agreements with investors to issue an aggregate of 644,142 post-split shares of common
stock in exchange for $1,519,779 principal and accrued interest on the notes. This transaction accelerated the recognition of the related
note discounts and resulted in a $1,066,732 charge. The second transaction was on March 6, 2024, whereby the Company paid $300,974 of
principal and accrued interest on the notes. This transaction accelerated the recognition of the related note discounts and resulted
in a $111,928 charge.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s warrant and derivative liabilities
are recorded at fair value as of each reporting date (see Note 3 to the condensed financial statements). For the six months ended June
30, 2024, the Company recorded a favorable adjustment in fair value of $323,041.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other net income of $92,980 for the six months
ended June 30, 2024, included a favorable discount to accounts payable of $117,985, offset in part by a $25,000 penalty paid to investors
related to a failure to timely register certain commitment shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 78 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical accounting estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations is based on our financial statements, which have been prepared in accordance with generally
accepted accounting principles in the United States. The preparation of our financial statements and related disclosures requires us to
make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent
assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various
other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the
carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions
on an ongoing basis. Our actual results may differ from these estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While our significant accounting policies are
described in more detail in the notes to our financial statements, we believe that the following accounting policies are those most critical
to the judgments and estimates used in the preparation of our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company derives its revenues from one source,
the delivery of Nociscan reports to medical professionals. Revenues are recognized when a contract with a customer exists, and the control
of the promised services are transferred to our customers. The amount of revenue recognized reflects the consideration we expect to receive
in exchange for those services. Substantially all of our revenues are generated from contracts with customers in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Equity-Based Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain of our employees and consultants have
received grants of common stock options and RSUs in our company. These awards are accounted for in accordance with guidance prescribed
for accounting for equity-based compensation. Based on this guidance and the terms of the awards, the awards are equity classified.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until our April 2022 IPO, we were a private company
with no active public market for our common equity. Therefore, we had periodically determined the overall value of our company and the
estimated per share fair value of our common equity at their various dates using contemporaneous valuations performed in accordance with
the guidance outlined in the American Institute of CPA&#8217;s Practice Aid. Since a public trading market for our common stock has been
established in connection with the completion of our IPO, it will no longer be necessary for us to estimate the fair value of our common
stock in connection with our accounting for equity awards we may grant, as the fair value of our common stock will be its public market
trading price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For financial reporting purposes, we performed
common stock valuations as a private company with the assistance of a third-party specialist. Subsequent to the initial public offering,
the fair value of the Company&#8217;s common stock underlying its equity awards is based on the quoted market price of the Company&#8217;s
common stock on the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Going Concern</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company believes that the net proceeds from
the February 2024 public offering, and subsequent funding from the April 2024 equity line agreement described in Note 11, will be sufficient
to fund current operating plans into the fourth quarter of 2024. The Company has based these estimates, however, on assumptions
that may prove to be wrong, and could spend available financial resources much faster than we currently expect. The Company will need
to raise additional funds to continue funding our technology development. Management plans to secure such additional funding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of the Company&#8217;s recurring losses
from operations and the need for additional financing to fund its operating and capital requirements, there is uncertainty regarding
the Company&#8217;s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to
the Company&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 79 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Liquidity and capital resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Sources of liquidity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To date, the Company has financed operations primarily
through private placements of preferred shares and debt financing, PPP loans that were forgiven, an equity line, an initial public offering
on April 21, 2022, and a secondary public offering on February 27, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2024, the
Company completed a public offering of 5,175,000 units (&#8220;Units&#8221;) at a price of $0.58 per Unit, for gross proceeds of approximately
$3.0 million, before deducting offering expenses. Additionally, the Company raised approximately $1.4M of net proceeds from an equity
line in January 2024 and $0.3M in April 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2024, the Company had cash, including
$10,000 of restricted cash, of $1,182,687. The Company believes that this cash will be sufficient to fund current operating plans into
the fourth quarter of 2024. The Company has based these estimates, however, on assumptions that may prove to be wrong, and could
spend available financial resources much faster than we currently expect. The Company will need to raise additional funds to continue
funding our technology development. Management plans to secure such additional funding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Cash flows</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The following table summarizes
our sources and uses of cash for each of the periods presented:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(restated)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify">Cash used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(3,646,947</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(4,949,112</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(119,522</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(207,870</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,314,732</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,187,258</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net increase (decrease) in cash and cash equivalents</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(451,737</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,030,276</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><i>Operating activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2023, net cash
used in operating activities was $3,646,947. This use of cash consisted primarily of compensation and benefit expense, officers&#8217;
liability insurance, consulting, tax and audit fees, and maintain our quality system. Cash outlays in the year 2023 were relatively lower
than the year 2022 due to longer procure-to-pay cycles. During the twelve months ended December 31, 2022, operating activities used $4,949,112,
consisting primarily of compensation and benefit expense, consulting, and professional fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><i>Investing activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2023, and 2022,
investing activities used $119,522 and $207,870 of cash, respectively. These investing activities consisted almost entirely of patent
and license maintenance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 80 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><i>Financing activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2023, net cash
provided by financing activities was $3,314,732, which included $2,250,000 of proceeds from unsecured non-convertible note financings,
1,462,949 of proceeds from an equity line, and $398,217 of cash issuance costs related to both the equity line and debt. During the year
ended December 31, 2022, net cash provided by financing activities was $6,187,258, which included $8,552,318 of initial public offering
proceeds (net of underwriter compensation and deductions but excluding $25,000 pre-payment in 2021), $2,000,000 repayment of promissory
notes, and $365,060 of IPO issuance costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cash flows</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes our sources and
uses of cash for each of the periods presented:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Cash used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(3,293,096</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(1,960,653</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(157,523</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(72,634</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,602,237</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,165,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net increase (decrease) in cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">151,618</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(868,287</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Operating activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2024, operating
activities used $3,293,096 of cash. The Company significantly reduced accounts payable, primarily legal expenses that had accrued over
time, and significantly reduced accrued expenses including payroll, bonuses, board compensation, and audit fees. During the six months
ended June 30, 2023, operating activities used $1,960,653 of cash. This use of cash consisted primarily of employee compensation and
benefit expense, general liability insurance, contractor compensation, and audit and legal fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Investing activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2024, and
2023, investing activities used $157,523 and $72,634 of cash, respectively. These investing activities consisted almost entirely of patent
and license maintenance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Financing activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2024, the
Company completed a public offering of 5,175,000 units (&#8220;Units&#8221;) at a price of $0.58 per Unit, for gross proceeds of approximately
$3.0 million, before deducting offering expenses. Each Unit was comprised of (i) one share of common stock or, in lieu of common stock,
one prefunded warrant to purchase a share of common stock, and (ii) two common warrants, each common warrant to purchase a share of common
stock. The prefunded warrants are immediately exercisable at a price of $0.00001 per share of common stock and only expire when such
prefunded warrants are fully exercised. The common warrants are immediately exercisable at a price of $0.58 per share of common stock
and will expire five years from the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2024, and
pursuant to the Equity Line Purchase Agreement, the Company issued to White Lion 452,343 newly issued common shares for proceeds of $1,449,532
between January 4 and January 8, 2024, and 1,050,000 newly issued common shares for proceeds of $304,500 on April 26, 2024. Equity line
issuance costs were $262,744.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 81 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2024, the
Company paid $300,973 of principal and accrued interest on certain unsecured non-convertible notes. Following this payment, the remaining
outstanding balance of principal and interest on the notes was $898,380.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2024, the
Company entered into a series of exchange agreements (the &#8220;Exchange Agreements&#8221;) with accredited investors to exchange principal
and accrued interest on these notes for shares of common stock. Pursuant to the Exchange Agreements, the Company issued an aggregate
of 644,142 post-split shares of common stock in exchange for $1,519,779 principal and accrued interest on the notes. Following these
exchanges, the remaining outstanding balance of principal and interest on the notes was $1,145,037.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2023, the
Company sold one (1) share of the Company&#8217;s newly designated Series A preferred stock to Jeffrey Thramann, the Company&#8217;s
Executive Chairman, for a purchase price of $1,000. The share of Series A preferred stock had proportional voting rights that were limited
to the proposal to approve a reverse stock split of the Company&#8217;s common stock. Following the March 24, 2023, special meeting,
the Company redeemed the one outstanding share of Series A preferred stock on March 28, 2023, in accordance with its terms. The redemption
price was $1,000. No Series A preferred stock remains outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2023, the
Company issued an unsecured promissory note in the amount $1,250,000, net of $203,576 of issuance costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Funding requirements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Developing medical technology products is a time-consuming,
expensive and uncertain process that takes years to complete, and we may never generate meaningful revenues. Accordingly, we may need
to obtain substantial additional funds to achieve our business objectives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adequate additional funds may not be available
to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity securities, the ownership
interest of existing stockholders may be diluted. Any debt or preferred equity financing, if available, may involve agreements that include
restrictive covenants that may limit our ability to take specific actions, such as incurring additional debt, making capital expenditures
or declaring dividends, which could adversely impact our ability to conduct our business, and may require the issuance of warrants, which
could potentially dilute existing stockholders&#8217; ownership interests.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we raise additional funds through licensing
agreements and strategic collaborations with third parties, we may have to relinquish valuable rights to our technology, future revenue
streams, research programs, or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise
additional funds, we may be required to delay, limit, reduce and/or terminate development of our product candidates or any future commercialization
efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Contractual obligations and commitments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company does not have any contractual obligations
not otherwise on our balance sheet as of June 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Off-balance sheet arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company did not have, during the periods presented,
and we do not currently have any off-balance sheet arrangements as defined in the rules and regulations of the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 82 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recently issued accounting pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviewed all recently issued standards
and has determined that, as disclosed in Note 4 to our condensed financial statements appearing in this quarterly report, there have
been no recent accounting pronouncements not yet effective that have significance, or potential significance, to our Consolidated Financial
Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Emerging growth company and smaller reporting
company status</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The JOBS Act permits an emerging growth company
such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public
companies until those standards would otherwise apply to private companies. We have elected not to &#8220;opt out&#8221; of this extended
transition period and, as a result, we will not adopt new or revised accounting standards on the relevant dates on which adoption of such
standards is required for public entities. Accordingly, our financial statements may not be comparable to other public companies that
do not elect the extended transition period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also a &#8220;smaller reporting company&#8221;
meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual revenue was less than $100
million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value
of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently
completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting
company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements
that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two
most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies,
smaller reporting companies have reduced disclosure obligations regarding executive compensation.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 83 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><span style="text-transform: uppercase"><b><span id="s_012"></span>Business</b></span><br/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aclarion is a healthcare technology company that
leverages Magnetic Resonance Spectroscopy (&#8220;MRS&#8221;), and proprietary biomarkers to optimize clinical treatments. Aclarion&#8217;s
technology addresses the $134.5B U.S. low back and neck pain market, which according to a 2020 JAMA (Journal of the American Medical Association)
article is now the most costly healthcare condition in the United States. The Company is currently utilizing Artificial Intelligence (&#8220;AI&#8221;)
to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. The use of AI in this application is
early in its development cycle and is expected to evolve with further research and development. The Company is capturing in databases
both the raw spectroscopy data and the post-processed spectral data from every Nociscan completed in order to utilize this data as future
training data to teach a machine learning algorithms to associate MRS data with clinical outcomes. The use of AI in this application is
aspirational and we intend this type of AI research and development to be an ongoing process applied not only to the various treatment
paths associated with back pain, such as conservative therapies, regenerative and cell therapies and surgical intervention, but also to
potentially expand into other clinical explorations involving the diagnosis of brain, breast and prostate tumors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, which has limited sales to date, is
addressing the chronic low back pain market by initially focusing on improving the outcomes of surgical interventions to treat chronic
discogenic low back pain. In this initial application, Aclarion technology is intended to assist surgeons in determining the optimal surgical
procedure for a patient undergoing surgery for pain isolated to their lumbar spine (the &#8220;lumbar spine&#8221; is comprised of the
five (5) lower vertebrae, L-1 to L-5). Through clinical studies we intend to extend the application of our technology beyond surgical
decisioning to help with managing large segments of low back pain patients from the point of initial MRI through to episode resolution.
We believe this will expand the use of our technology to supporting treatment decisions for chronic low back pain patients undergoing
conservative therapies such as physical therapy or biologic and cell therapies aimed at regenerating the lumbar discs. We plan to expand
the application of our technology beyond the lumbar spine to address neck pain populations in addition to low back pain populations. To
expand the application of our technology for use in neck pain populations, we will need to overcome technical changes associated with
securing adequate MRS data from the cervical disc, which is significantly smaller than the lumbar disc, and there can be no assurance
the Company will be able to overcome these challenges.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The core technology Aclarion employs is MR Spectroscopy.
The patient experience when undergoing an MRS exam is exactly like that of a standard MRI, with the exception of an additional 3-5 minutes
for each disc undergoing a spectroscopy exam. Whereas a standard MRI produces a signal that is converted into anatomical images, an MRS
produces a signal that is converted into a waveform that identifies the chemical composition of tissues. Just like with standard MRIs,
the data from spectroscopy is useless without technologies that can process the data. Aclarion has developed proprietary signal processing
software that transforms spectroscopy data into clear biomarkers. These biomarkers, which are exclusively licensed from the Regents of
University of California, San Francisco (&#8220;UCSF&#8221;), are the key data inputs for our proprietary algorithms that, when applied,
determine if an intervertebral disc is consistent with pain. Our patent portfolio includes 22 U.S. Patents, 17 Foreign Patents, 6 pending
U.S. patent applications, and 7 pending Foreign patent applications, including patents and patent applications exclusively licensed from
Regents of the University of California.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe one of the biggest issues driving the
cost of treating low back and neck pain patients to the top of the list for healthcare spending is that there is no objective, cost effective
and noninvasive diagnostics to reliably identify the source of a patient&#8217;s pain. We believe the poor surgical outcomes for chronic
DLBP are largely due to difficulties in reliably and accurately diagnosing the specific spinal discs that are causing pain. The current
primary diagnostic standard is the MRI, which is useful for showing abnormal structures and tissue dehydration, but, we believe, cannot
reliably identify specific discs that are causing pain. To diagnose specific discs that are causing pain, a needle-based Provocation Discogram
test (&#8220;PD Test&#8221;) has been developed. PD Tests have been shown to be highly accurate when performed properly. However, a PD
Test is invasive, subjective, and unpleasant for the patient as the patient needs to be awake in order to tell the physician if the pain
the physician is purposefully causing in the disc is the same as the pain the patient feels when they are experiencing a back pain episode.
In addition, recent evidence has shown that the action of inserting a needle into a normal disc during a discogram procedure leads to
an increased rate of degeneration in these previously normal discs. Based on the limitations and concerns of the PD Test, we believe there
is a significant need for an objective, accurate, personalized, and noninvasive diagnostic test that can reliably determine if an individual
disc is a pain generator. By providing physicians information about whether a disc has the chemical and structural makeup consistent with
pain or not, we believe the treatment plan for each patient will lead to more efficient and targeted care that, will in turn, result in
lower costs and healthier patient outcomes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aclarion has taken the first steps to demonstrate
the potential use of our technology in helping to improve the outcome of surgical intervention for discogenic low back pain patients by
publishing a clinical study in the European Spine Journal in April 2019. The study illustrated that when all discs identified as consistent
with pain by our technology were included in a surgical treatment, 97% of the patients met the criteria for &#8220;clinical improvement&#8221;.
This compared to only 54% of patients meeting the criteria for clinical improvement if a disc that our technology identified as consistent
with pain, was not included in the surgical treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2023, Aclarion advanced the evidence
of our technology with a peer-reviewed journal article detailing the Gornet 2-year outcomes published in the European Spine Journal. The
2-year outcomes were durable with 1-year outcomes previously published in 2019. At 2-years follow-up, 85% of patients improved when disc(s)
identified as consistent with pain by our technology were included in a surgical treatment, compared to only 63% of patients when disc(s)
identified as consistent with pain were not treated or disc(s) identified as consistent without pain were treated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The results of the 2019 published study led the
CPT committee to approve four Category III codes for our technology in January 2021. The NIH also included our technology as one of the
handful of technologies selected to participate in their $150 million Back Pain Consortium (BACPAC) Research Program, an NIH translational,
patient-centered effort to address the need for effective and personalized therapies for chronic low back pain. In 2022, the NIH subsequently
selected our technology to be included in their prospective randomized follow-on study that resulted from BACPAC. This new study is called
Biomarkers for the Evaluation of Spinal Treatments (BEST) and is designed to evaluate several technologies that provide data about a patient
to see if these technologies can identify subgroups of chronic LBP patients that do better with one of four treatments being evaluated
in the study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Evolving science coupled with the understanding of
degenerative painful discs has suggested that lumbar discs may become painful due to certain chemical changes, which changes cannot be
identified using standard lumbar MRI imaging. However, an application of MRI scanners called Magnetic Resonance Spectroscopy has been
developed by manufacturers of MRI equipment. MRSs are different than MRIs. An MRI generates images of body structures, while an MRS analyzes
the relative amounts of various chemicals in body tissues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aclarion has developed a software application called
NOCISCAN&#174; which uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical
makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers
that we, in conjunction with spine researchers at UCSF, have demonstrated to be associated with degenerative pain and structural integrity
of the lumbar discs. After processing the MRS exam data, we send the ordering clinician a report that details how to interpret the results
of the MRS exam. We believe these results help clinicians make quicker and more informed decisions about which lumbar discs are painful,
and which are not. We believe the ordering clinician can use this information to determine the optimal treatment plan for an individual
patient.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because we believe that spectroscopy is not widely
used for any clinical purposes today, there are practical limitations to the market opportunity that must be addressed. We believe the
two biggest limitations may be the lack of deployment of spectroscopy software across the installed base of existing MRIs worldwide, and
the fact that only certain MR scanner models are compatible with our technology. For compatible MRI sites that do not currently have spectroscopy
software installed, the onetime cost of the software ranges from $25,000 to $50,000. Currently, our NOCISCAN platform is only compatible
with certain MR scanner models provided by SIEMENS, of which there are an estimated 1,500 in the United States, and 4,320 worldwide. We
plan to collaborate with other MRI scanner vendors, as well as SIEMENS, to establish compatibility with their respective scanners and
MRS capabilities for use with our products. That may allow us to include discounted pricing on spectroscopy software for MRI sites interested
in providing DLBP patients with the NOCISCAN offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The first application of Aclarion&#8217;s technology
is focused on improving surgical decision making when surgical intervention is being contemplated for patients with low back pain. The
Company&#8217;s first commercial product, which we have named &#8220;NOCISCAN&#8221;, utilizes our proprietary biomarkers and algorithms
to provide surgeons with information about which intervertebral discs are determined to be consistent with generating pain, and which
are not. We believe that surgeons can use this information to better plan their surgical treatments and improve outcomes in their patients.
In a clinical study published in the European Spine Journal in April 2019 it was shown that in patients where all discs identified as
painful by NOCISCAN were included in the surgical treatment that 97% of those patients met the criteria for significant clinical improvement.
This compared to only 54% of surgical patients meeting the criteria for significant clinical improvement when discs identified as painful
by NOCISCAN were omitted from the surgical treatment, or discs identified as not painful by NOCISCAN were included in the treatment. Some
authors of this study had a financial relationship with Aclarion, who sponsored the study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 85 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2023, Aclarion advanced the evidence
of our technology with a peer-reviewed journal article detailing the Gornet 2-year outcomes published in the European Spine Journal. The
2-year outcomes were durable with 1-year outcomes previously published in 2019. At 2-years follow-up, 85% of patients improved when disc(s)
identified as consistent with pain by our technology were included in a surgical treatment, compared to only 63% of patients when disc(s)
identified as consistent with pain were not treated or disc(s) identified as consistent without pain were treated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on the results of this clinical study, the
Company believes that use of NOCISCAN could become the standard protocol for assisting in the treatment plan of patients with low back
pain undergoing surgical intervention. Utilizing the results of our European Spine Journal Study, we applied to the American Medical Association
for CPT codes to begin the process of securing insurance coverage to pay for NOCISCAN. On January 1, 2021, Category III CPT codes became
effective. The Company is now executing its plan to commercialize NOCISCAN. See &#8220;Reimbursement&#8221; below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The core technology underlying NOCISCAN is the
use of MR spectroscopy to identify the chemical makeup of intervertebral discs with a focus on identifying specific proprietary biomarkers
known to be correlated to pain and to the structural degradation of discs. We believe this technology, in combination with advanced machine
learning and AI platforms, has the potential to not only become included in the standard of care for patients undergoing surgical intervention
for low back pain, but to become a core data input for optimally managing entire segments of patients suffering from low back and neck
pain.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Industry Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Low Back Pain</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the Global Burden of Disease Study
2017, low back pain (LBP) is among the top three causes for years lived with disability. A 2020 JAMA (Journal of the American Medical
Association) article established the cost of low back and neck pain at $134.5B in the U.S, making it the most costly healthcare condition
in the United States, surpassing cardiac disease, diabetes and cancer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Low back pain (LBP) can
be caused by many different problems and abnormalities along and around the spine, other than DLBP, including conditions such as spondylolisthesis
or instability of the vertebral bodies, vertebral body fractures, facet pathologies, central canal and foraminal stenosis, disc herniations,
pars fracture, congenital abnormalities and tumors. Many of the causes of low back pain are readily detected by standard MRI imaging of
the spine, which reveals clear structural abnormalities, i.e., fractures and tumors. However, in many cases the source of the pain is
not clear. As a result, the success rates of surgical care for LBP ranges from 41 to 57%, with 5-16% early complication and reoperation
rates also reported.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We believe that poor
surgical outcomes for discogenic LBP are largely due to difficulties in reliably and accurately diagnosing the specific spinal discs that
are causing pain. The current primary diagnostic standard, lumbar MRI, is useful for showing abnormal structures and tissue dehydration,
but, we believe, cannot reliably identify specific discs that are causing pain. To diagnose specific discs that are causing pain, a needle-based
Provocation Discogram test (&#8220;PD Test&#8221;) has been developed. A PD Test has been shown to be highly accurate when performed properly.
However, a PD Test is invasive, subjective and unpleasant for the patient, as the patient is required to be awake in order to tell the
physician if the pain the physician is purposefully causing in the disc is the same as the pain the patient feels when they are experiencing
a back pain episode. In addition, recent evidence has shown that the action of inserting a needle into a normal disc during PD Test, leads
to an increased rate of degeneration in these previously normal discs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Due to the current lack
of uniform acceptance of a diagnostic platform to safely and reliably diagnose the specific discs that cause DLBP, patients with DLBP
are faced with the options of surgical intervention with a risk of a poor surgical outcomes, or, non-surgical treatment with powerful
pain killing drugs, such as opiates and synthetic opiates. Those patients who choose surgery and have a poor surgical outcome with no
surgical alternatives will be faced with the possibility of enduring disabling, intractable pain, and often extended dangerous pain medication
use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 86 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Diagnostic Imaging</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Diagnostic imaging involves
the use of non-invasive procedures to generate representations of internal anatomy and function that can be recorded on film or digitized
for display on a video monitor. Diagnostic imaging procedures facilitate the early diagnosis and treatment of diseases and disorders and
may reduce unnecessary invasive procedures, often minimizing the cost and amount of care for patients. Diagnostic imaging procedures include
MRI, CT, PET, nuclear medicine, ultrasound, mammography, X-ray and fluoroscopy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">While X-ray remains the
most commonly performed diagnostic imaging procedure, one of the fastest growing procedures is the MRI. The number of MRI scans performed
annually in the United States continues to grow due to its wider acceptance by physicians and third party payers, an increasing number
of applications for their use and a general increase in demand due to the aging population. MRI has long been a widely accepted diagnostic
standard of care for spine and low back pain, including discogenic low back pain patients, which is the target medical condition for our
diagnostic products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Diagnostic Imaging
Settings</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Diagnostic imaging services
are typically provided in one of the following settings:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Fixed-site,
freestanding outpatient diagnostic facilities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">These facilities range
from single-modality to multi-modality facilities and are generally not owned by hospitals or clinics. These facilities depend upon physician
referrals for their patients and generally (although not always) do not maintain dedicated, contractual relationships with hospitals or
clinics. In fact, these facilities may compete with hospitals or clinics that have their own imaging systems to provide services to patients.
These facilities bill third-party payers, such as managed care organizations, insurance companies, Medicare or Medicaid, and workers&#8217;
compensation providers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Hospitals</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many hospitals provide both inpatient and outpatient
diagnostic imaging services, typically on site or at a dedicated center located on or nearby the hospital campus. These can be owned and
operated by the hospital and provide imaging services to inpatients as ordered or outpatients through physician referrals. The hospital
normally bills third-party payors such as managed care organizations, insurance companies, Medicare or Medicaid, and workers&#8217; compensation
providers. We have entered into joint ventures with certain hospitals both provide and manage their diagnostic imaging services, allowing
them to leverage our industry expertise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Mobile
Imaging</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">While many hospitals
own or lease their own equipment, certain hospitals provide diagnostic imaging services by contracting with providers of mobile imaging
services. Using specially designed trailers, mobile imaging service providers transport imaging equipment and provide services to hospitals
and clinics on a part-time or full-time basis, thus allowing small to mid-size hospitals and clinics that do not have the patient demand
to justify fixed on-site access to advanced diagnostic imaging technology. Diagnostic imaging providers contract directly with the hospital
or clinic and are typically reimbursed directly by them. We do not provide mobile imaging services. The cloud-based software products
and services we do provide, however, are compatible for use for post-processing data that may be acquired by certain MR scanners that
are deployed in a mobile imaging setting and model.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 87 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Company History</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aclarion&#8217;s technology was originally invented,
and initially tested, via successful proof of concept by Aclarion co-Founder and head of our Scientific Advisory Board, Jeffrey Lotz,
PhD, at the University of California San Francisco (&#8220;UCSF&#8221;). Early research, which was published in a major peer-reviewed
journal in 2005, was premised upon a growing suspicion and interest that discs may become painful due to chemical changes, in particular
elevated acidity related to hypoxia, that are not tested using a standard MRI. With that theory in mind, Dr. Lotz&#8217;s initial study
looked to identify chemical biomarkers for painful discs using MRS, which applies a pulsed magnetic field to tissues in order to vibrate
the different chemicals in that tissue and generate a spectrum that allows for measuring those different chemicals based on their different
peaks along that spectrum. NMR equipment was used to conduct MRS chemical analysis of painful discs that were surgically removed for DLBP
fusion surgery versus normal, non-painful discs that were surgically removed from spinal deformity (i.e. scoliosis) patients for lumbar
spine reconstruction. Those ex vivo 11T MRS spectral measurement results showed that all (n=9) of the painful discs were distinguished
from all of the non-painful discs based on the highly repeatable (100%) differences in their ratios between lactic acid, a painful chemical
resulting from hypoxia, and proteoglycan, a structural chemical of the disc that holds water for hydration. It was observed that with
degenerative painful discs, proteoglycan reduces with the degeneration, and lactic acid elevates with the pain. Hence, the MRS-based test
and identifiable structural and degenerative pain biomarkers were able to be identified.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This work became the subject of the first patent granted
to the Regents of the University of California and exclusively licensed to Aclarion. Thereafter, a strategic collaboration with SIEMENS,
a major MRI equipment manufacturer, was initiated and a clinical study, the Gornet Study, involving 73 surgical patients was published
in the European Spine Journal, a major peer-reviewed publication (See &#8220;Clinical Evidence&#8221; below). Our NOCICALC and NOCOGRAM
products were subsequently registered with the FDA, CE marked and launched in the US, EU, and UK markets through a customer pay model
since insurance codes were not yet in existence.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>License Agreement with the Regents of the University of California
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 8, 2008, the Company entered into an
Exclusive License Agreement which was amended and restated on December 9, 2014, (the &#8220;License Agreement&#8221;) with the Regents
of the University of California<span style="color: #2A2A2A">, </span>and was further amended on March 31, 2017. The License Agreement
encompassed certain intellectual property and patents covering inventions generally characterized as systems, materials, and methods to
localize and evaluate pain and degenerative properties of tissue, molecular markers that differentiate painful from non-painful discs;
and MR Spectroscopy System and Method for diagnosing painful and non-painful intervertebral discs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the License Agreement, the Company
obtained a worldwide, exclusive license to intellectual property including certain patent rights related to the patents and technology
which the Company utilizes. Under the License Agreement, we agreed to pay a royalty fee of 4% (subject to reduction to a minimum of 2%
of net sales, in the event the Company pays a royalty on revenues to a third party) of net sales of the licensed products or technology
and 10% of gross revenues we may receive from possible sub-licensees, affiliates or joint venture partners. Additionally, we agreed to
pay a minimum annual royalty fee of $50,000, accountable against actual earned royalties, plus other costs and expenses related to the
prosecution of existing or future patents related to the technology, and certain additional one-time fees that were contingent upon the
occurrence of certain defined milestones.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The License Agreement also provides that for so
long as we pay patent prosecution costs, the Regents of the University of California will diligently prosecute and maintain the United
States and foreign patents comprising the Patent Rights using counsel of its choice, and the UC Regents' counsel will take instructions
only from The Regents of the University of California.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 88 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon completion of our April 2022 IPO, we were
required to pay the Regents of the University of California a contingent one-time &#8220;Indexed Milestone Payment&#8221; of an amount
of cash determined by multiplying the amount of shares outstanding at such time the Company raises $1 million in capital, by 3% and then
multiplying the 3% number by the IPO price. On May 2, 2022, we paid the amount of $123,828 to satisfy the Indexed Milestone Payment obligation
included within the license agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Regents of the University of California has
the right to terminate the License Agreement upon advanced notice in the event of a default by us. The License Agreement will expire upon
the expiration or abandonment of the last of the licensed patents. The patents subject to the License Agreement expire between 2025 and
2029.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on this license, as well as other aspects
of our own patented technology and intellectual property, in order to be able to use and sell various proprietary technologies that are
material to our business, as well as technologies which we intend to use in our future commercial activities. Our rights to use these
licensed technologies and the inventions claimed in the licensed patents, are subject to the continuation of, and our compliance with
the terms of the license. The loss of this license would materially negatively affect our ability to pursue our business objectives and
result in material harm to our business operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Transactions with NuVasive, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2015, NuVasive, Inc. (&#8220;NuVasive&#8221;)
purchased approximately $2.0 million of the Company&#8217;s Series B preferred shares. NuVasive and the Company also entered into a marketing
agreement pursuant to which NuVasive would be the exclusive, other than the Company, marketing provider for the Company&#8217;s technology
and NuVasive would receive a commission (the &#8220;Commission&#8221;) of all sales of the technology made by NuVasive. In conjunction
with the marketing agreement, the Company entered into a Right of First Offer (&#8220;ROFO&#8221;) Agreement pursuant to which the Company
agreed that in the event that the Company determined to enter into a sale event (defined to include a sale of 50% or more of the Company&#8217;s
outstanding voting securities, a sale of substantially all of the Company&#8217;s assets, or a sale or exclusive license of substantially
all of the Company&#8217;s intellectual property) NuVasive would have the right to receive notice (&#8220;ROFO Notice&#8221;), and NuVasive
would have a 60-day period to determine whether it wanted to acquire the Company on terms set forth in the ROFO Notice. The ROFO obligations
will expire 42 months after the FDA issues its first regulatory clearance of a Company product or service. The ROFO obligations do not
apply to any proposed sale event in which the acquisition price is $40 million or more.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2020, NuVasive agreed to purchase
$308,720 of convertible notes, convertible into Series B-1 preferred shares and in connection with such purchase, was issued a warrant
to purchase 171,511 shares of common stock at an exercise price of $.18 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2020, NuVasive and the Company also
entered into an amended and restated commission agreement (the &#8220;Commission Agreement&#8221;), pursuant to which the Company agreed
to pay NuVasive a commission of 6% of certain revenues of the Company related to Aclarion&#8217;s Nociscan technology through December
31, 2023, and issued to NuVasive the right to receive the Company&#8217;s preferred shares subject to the terms of a $2 million &#8220;SAFE&#8221;
(Simple Agreement for Future Equity). The SAFE provided that NuVasive would receive $2 million of capital stock if the Company would raise
a minimum of $10.0 million of new capital on or before December 31, 2020, which was later extended to June 30, 2021. If the $10.0 million
was not raised, the Company would issue to NuVasive 1,584,660 Series B-2 preferred shares. The $10.0 million was not raised and the Company
issued 1,584,660 Series B-2 preferred shares to NuVasive in December 2021. In connection with the Commission Agreement, NuVasive agreed
that: (i) NuVasive would cease to market the Company&#8217;s technology, (ii) NuVasive would reduce their Commission to 6%, and (iii)
Commissions to NuVasive would terminate on December 31, 2023. In December 2021, NuVasive&#8217;s convertible notes were converted into
Series B-3 preferred shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 89 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Products and Solutions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Aclarion has developed a software application called
NOCISCAN&#174;. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical
makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers
that Aclarion, in conjunction with spine researchers at UCSF, have demonstrated to be associated with degenerative pain and structural
integrity of the lumbar discs. After processing the MRS exam data, Aclarion sends the ordering clinician a report that details how to
interpret the results of the MRS exam. We believe these results help clinicians make faster and more informed decisions about which lumbar
discs are painful, and which are not. We believe the ordering clinician can then use this information to determine the optimal treatment
plan for an individual patient.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOCISCAN is entirely non-invasive and only briefly
extends an otherwise standard MRI exam. The MRI scan is the most frequently used type of pulse sequence for operating Nuclear Magnetic
Resonance (NMR) scanners. It uses a powerful magnet to apply a pulsed magnetic field to a patient, sensors to detect radio waves that
emanate from the resonant vibrations of different chemicals in the body in response to that pulsed magnetic field and a computer to create
detailed images of tissue structures in the patient based on those detected chemical signals. Because water and fat are the most prevalent
chemicals in the body, standard MRI images are typically based on the different levels of water and fat between different tissues. MRS,
however, is another type of pulse sequence that uses NMR scanners in a similar way as an MRI, but instead of using the chemical resonances
to create an image, MRS creates a spectrum for a tissue with different peaks that represent many different chemicals, in addition to water
and fat, in that tissue. The relative amounts of those chemicals can be calculated by measuring their respective spectral peaks. While
MRS has been used previously for diagnosing certain cancers (e.g. brain, breast, prostate) by measuring unique chemical biomarkers for
tumors, NOCISCAN uses MRS for measuring the relative levels of degenerative pain and structural integrity biomarkers in discs. The relative
levels of degenerative pain and structural integrity biomarkers are derived through the use of proprietary post processing technologies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The platform used to conduct
a NOCISCAN involves: (i) an MRS exam of an intervertebral disc performed according to a proprietary protocol, (ii) a data transfer portal
to securely transfer data from the MRS exam to Aclarion&#8217;s cloud based post-processer technology, (iii) post-processor technology
that identifies biomarker peaks and leverages calculation tables that evaluate a number of ratios of biomarker peaks, where pain biomarkers
are in the numerator and structural biomarkers are in the denominator, and (iv) a final diagnostic report called a Nocigram that identifies
discs as painful or not.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">(a)&#160;&#160;&#160;&#160;<span style="text-decoration: underline">NOCISCAN
MRS Exam Protocol</span>: We have developed a custom software protocol and technique for using commercially available MRS pulse sequences
in scanning intervertebral discs which extends the time of a standard lumbar MRI exam by an average of about 30 minutes for 5 lumbar discs.
The custom protocol is a proprietary series of settings and instructions for MRS to conduct the NOCISCAN exam to obtain optimal and
reliable MRS data. This protocol is not a product sold by the Company. The software protocol was created by Aclarion for insertion within
a pre-existing software file format and is downloaded onto the MRS by the MRS owner, for use within the MRS&#8217;s operating system environment.
Currently, our software protocol is compatible with only certain MRS models and operating systems available from SIEMENS, as those SIEMENS
models specifically provide for user-defined customizations available for running our custom pulse sequences on SIEMENS MRS equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">(b)&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline">Data
Transfer</span>: Data is routinely transferred from MR scanners to externally hosted cloud post-processors in many settings and applications,
with an existing market of products and protocols for doing so. Aclarion provides MR imaging providers two options for data transfer:
(1) a licensed proprietary imaging data transfer platform provided by AMBRA&#174; Health, and (2) NOCIWEB&#174;, a custom developed web-interface
developed and offered by Aclarion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">(c)&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline">The
NOCISCAN Post-Processor Suite</span>: This comprises the products that Aclarion currently markets and sells. The post-processor technology
requires MRS exam data acquired only according to Aclarion&#8217;s proprietary MRS exam protocols described in (a) above. The NOCISCAN
Post-Processor Suite comprises of two software products that interact with each other:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">NOCICALC&#174; receives the raw un-processed NOCISCAN
        MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from
        those spectra, for each disc examined. NOCICALC is Registered as a Class I Medical Device with the FDA. </span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">NOCIGRAM&#174; further processes the NOCICALC results into
        individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs
        examined in the patient. High/low NOCISCORE ranges are also correlated to painful (indicated as &#8220;NOCI+&#8221; result) versus non-painful
        (indicated as a &#8220;NOCI-result). The NOCISCORE scale was developed according to a reference PD TEST that was used as a standard control
        in a peer reviewed clinical development trial for our technology. The post-processed MRS results are shown in an intuitive NOCIGRAM
        report with reference to certain MRI images of the related patient&#8217;s lumbar spine. The NOCIGRAM report is provided to the physician
        to aide in the physician&#8217;s diagnosis and treatment planning. NOCIGRAM is commercially available in the United States as &#8220;Clinical
        Decision Support Software&#8221; under the 21<sup>st</sup> Century Cures Act, and as such is not considered a medical device nor regulated
        by the FDA.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #0070C0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Advantages over current technology and procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOCISCAN provides new information to help doctors
better diagnose which intervertebral discs may contribute to patients back pain and thereby assist in treatment planning and potentially
improve patient outcomes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">More specifically, current standards of care for
the diagnostic workup of LBP include lumbar X-Ray and MRI and less prevalently, needle-based provocative discography testing (PD Tests).
While lumbar X-Ray and MRI can show various pathologic structural abnormalities and degeneration and can be helpful for diagnosing certain
non-discogenic sources of pain, these techniques are unreliable for identifying painful discs in LBP patients. The PD TEST is another
test that typically follows MRI for the purpose of identifying painful discs. PD Tests have been shown to be highly accurate when performed
properly, however, a PD Test is invasive, subjective and unpleasant for the patient as the patient needs to be awake in order to tell
the physician if the pain the physician is purposefully causing in the disc is the same as the pain the patient feels when they are experiencing
a back pain episode. In addition, recent evidence has shown that the action of inserting a needle into a normal disc during a discogram
procedure leads to an increased rate of degeneration in these previously normal discs. We believe NOCISCAN advantages include: (a)
enhancing the ability and value of otherwise standard lumbar MRI exams to, for the first time, reliably identify chemically painful discs
causing DLBP; and (b) providing a &#8220;Virtual Discogram&#8482;&#8221; as an entirely non-invasive, objectively quantitative, pain-free,
non-significant risk, and more widely adoptable alternative to needle-based PD exams (which share none of those advantages).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">More specifically, NOCISCAN offers many specific
advantages to the marketplace, from a diagnostic point of view, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">1)</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Readily and widely adoptable;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">2)</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Non-invasive;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">3)</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Non-painful;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">4)</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Nonsignificant risk to patients;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">5)</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Objective, quantitative diagnostic information;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">6)</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Enhances the diagnostic value of MR exams for painful disc diagnosis in DLBP patients;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">7)</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Correlative to the modern standard and accurate technique of PD diagnostic exams
        for DLBP diagnosis - but without the invasive, painful, subjective, potentially harmful, and limited adoptability shortcomings of PD;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 91 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">8)</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">First and only known ability to non-invasively assess degenerative painful disc
        chemistry;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">9)</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">More informed ability to reliably diagnose painful vs. non-painful discs;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">10)</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">More informed ability to predict the potential for ASD to develop or advance in
        discs next to neighboring discs that are initial surgical targets;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">11)</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">More informed ability to reliably diagnose actual ASD in discs following a prior
        surgery in neighboring discs;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">12)</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Potential for improved patient outcomes in DLBP patients resulting from more informed
        diagnostic acuity for painful vs. non-painful discs and related targeted treatment planning; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">13)</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">The only known non-invasive disc chemistry measurement and monitoring tool to support
        clinical research, development, and evaluation of new therapies, e.g. injectable biologics/cell therapies, that have therapeutic mechanisms
        of action related to disc chemistry interactions and changes.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOCISCAN incorporates many patented technologies
and features that we believe provide several technical advantages to the MRS field in general. Prior applications of MRS, e.g. for brain,
prostate, or breast cancer diagnosis encountered technical challenges related to acquiring reliably robust spectra for making accurate
quantitative chemical measurements. These technical challenges resulted in poor sensitivity and specificity for prior MRS products addressing
clinical applications. The novel features and advantages provided in the NOCISCAN platform are designed to address the technical and
diagnostic challenges of MRS in the past. Accordingly, we believe Aclarion improvements do not only propose benefits for disc MRS, but
potentially for other MRS applications more broadly. Improvements in processing raw MRS data incorporated in Aclarion IP are summarized
below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">1)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Introducing novel signal processing approaches for enhanced
        reliability of the underlying spectra and related chemical biomarker &#8216;peak&#8217; measurements:</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">a)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">increased signal noise ratio or &#8220;SNR&#8221; for more
        reliably identifying and measuring chemical peaks - in particular, by averaging spectra from multiple acquisitions using (i) only strong
        acquired signals and filtering out weak ones (&#8220;frame editing&#8221;), and (ii) a &#8220;smart&#8221; form of frequency shift correction
        to align multiple acquisitions for &#8220;coherent&#8221; averaging; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">b)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">detecting spectral artifacts that might compromise the reliability
        of spectral peak measurements and related chemical measurements, and which can occasionally result from technical issues during MRS exams
        in the scanner (generally observed in &lt;10% of discs), and then either: (i) correct for the artifact (e.g. patient motion artifact correction),
        or (ii) identify the compromised MRS acquisition as a technical failure and unable to perform reliable spectroscopic measurement (i.e.,
        occasionally supplanting a risk for inaccurate diagnosis instead of a technical failure and indeterminate diagnostic result).</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">2)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Basing diagnostic results on relative, normalized comparisons
        of the differences between chemical biomarkers for multiple different disc tissues in the same patient vs. assigning diagnostic thresholds
        for chemical measurements that are empirically derived from a separate clinical trial patient population and are not patient specific.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">3)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Evaluating only multi-chemical &#8220;degenerative pain&#8221;
        biomarkers that use ratios between spectral peaks for chemicals associated with (i) pain and (ii) structural degeneration, thus providing
        for: (a) a two-fold and bi-directional sensitivity in the combined biomarker from both the ratio&#8217;s numerator (pain biomarker) and
        its denominator (structural degeneration biomarker), and (b) reduction of patient anatomy-dependent variables in the MRS data to thereby
        enhance the personalization of the data and increase the generalizability of the diagnostic algorithms across diverse populations.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">4)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Using multi-peak spectral ranges, representing multiple different
        painful acids, as a single pain biomarker used in the combined ratios for degenerative pain biomarkers (e.g. &#8220;LAAL&#8221; painful
        chemical biomarker range combining adjacent <span style="text-decoration: underline">L</span>actic <span style="text-decoration: underline">A</span>cid
        and <span style="text-decoration: underline">AL</span>anine peaks, and &#8220;ALPA&#8221; combining <span style="text-decoration: underline">A</span>lanine,
        <span style="text-decoration: underline">L</span>actic acid, and <span style="text-decoration: underline">P</span>ropionic <span style="text-decoration: underline">A</span>cid
        peaks) &#8211; thereby removing the need for accurately differentiating each individual peak, and thus reducing the risk for inaccuracy
        in the spectral measurements and diagnostic interpretations.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 92 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Clinical Evidence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have pursued a clinical study (the &#8220;Gornet
Study&#8221;) to demonstrate the benefits of our technology to surgeons, imaging centers, third party payers, and patients. Without strong
clinical data in support of our technology to improve clinical outcomes, the opportunity to secure new reimbursement codes and change
existing treatment pathways would be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In a clinical study sponsored by us, and authored
by, among others, a spine surgeon who has a financial interest in the Company. and published in the European Spine Journal in April 2019,
it was shown that 97% of the treated patients met the criteria for significant clinical improvement, where all discs identified as painful
by NOCISCAN were included in the surgical treatment. This compared to 54% of surgical patients achieving clinically significant improvement
when discs identified as painful by NOCISCAN were omitted from the surgical treatment, or discs identified as not painful by NOCISCAN
were included in the treatment. Some authors of this study had a financial relationship with Aclarion, who sponsored the study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This clinical study included 139 chronic low back
pain patients who collectively underwent a NOCISCAN exam across 623 lumbar discs. Seventy-three patients underwent surgical intervention,
consisting of fusion or disc replacement, and reached six months follow up. Clinical improvement post surgically was evaluated using the
industry standard Oswestry Disability Index (ODI), and the Visual Analog Scale (VAS). ODI evaluates patient disability on a scale of 1-100
with a higher score indicating less impairment. VAS evaluates subjective pain on a scale of 1-10 with a lower score indicating less pain.
Significant clinical improvement in the study was defined as a 15-point improvement in ODI and a 2-point improvement in VAS. NOCISCAN
data was not used in surgical decision making.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Post-operatively, patients were separated into
various groups for analysis. One group consisted of patients where the surgical intervention included every disc that was identified by
NOCISCAN as painful. This group consisted of 36 patients with 26 undergoing a one-level surgical procedure and 10 undergoing a two-level
surgical procedure. 97% (35 of 36) of the patients in this category met the criteria for significant clinical improvement. The one failure
in this group did meet the VAS requirement and missed the ODI cutoff of 15 by only one point.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In another group consisting of 13 patients, a
disc identified as painful by NOCISCAN was not included in the surgical intervention. In this group only 54% (7 of 13) of patients
met the criteria for clinically significant improvement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April 2023, Aclarion advanced the evidence of our technology with
a peer-reviewed journal article detailing the Gornet 2-year outcomes published in the European Spine Journal. The 2-year outcomes were
durable with 1-year outcomes previously published in 2019. At 2-years follow-up, 85% of patients improved when disc(s) identified as consistent
with pain by our technology were included in a surgical treatment, compared to only 63% of patients when disc(s) identified as consistent
with pain were not treated or disc(s) identified as consistent without pain were treated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe the results of this study indicates
that using NOCISCAN data to help determine the appropriate level for surgical intervention will significantly improve the outcomes
for patients undergoing spine surgery for back pain. However, the Gornet Study was a single (relatively small) clinical study at a single
clinical center sponsored by us, and authored by, among others, a spine surgeon who has a financial interest in the Company, and there
can be no assurance that the results of such study accurately support our conclusions related to the market opportunity of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 93 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market Opportunity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The current NOCISCAN product addresses the $10B
that is spent in the U.S. on spine fusion procedures annually. Our early clinical evidence points to a marked improvement in surgical
outcomes when discs identified as painful by our technology are included in the surgical treatment. We believe this market is actionable
now and a significant portion of the proceeds of our IPO will be directed towards commercializing this market opportunity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we continue our commercialization efforts,
we plan to track patients through clinical registries in order to build on our early clinical evidence. We expect to use these registries
to track NOCISCAN patients regardless of what treatment path they may follow. Through the date of this prospectus, NOCISCAN has
only been evaluated in formal clinical studies for patients primarily undergoing surgical interventions for fusion or disc replacement.
The Company plans on expanding clinical registries to capture patients undergoing surgical interventions for back pain that include all
surgical interventions, not just fusion and disc replacement procedures. If we are able to correlate specific MRS findings to improved
surgical outcomes for all spine surgeries, we believe this would expand the size of our market opportunity in the U.S. from what we believe
is $10B, to an estimated $40B, inclusive of pre-surgical conservative therapy costs. However, there can be no assurance that we will be
successful in marketing our products, regardless of the size of the estimated market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our ultimate objective for NOCISCAN is to address
the entire low back and neck pain market which at $134.5B annually represents the largest amount of healthcare dollars spent to treat
any disease. To address this market, our current algorithms will need to expand to include advanced machine learning techniques that incorporate
multiple data inputs besides the chemical composition of discs. These additional inputs will all need to be correlated to clinical outcomes
for treatments ranging from physical therapy to regenerative therapies, and surgical interventions. To further this process, we have been
selected as a participant in a $150M NIH funded study (the NIH BACPAC Initiative&#8221;) focused on evaluating the most promising data
inputs for predicting the optimal treatment path for back pain patients and in the NIH&#8217;s follow on BEST study to evaluate the clinical
efficacy of using these data inputs for improving clinical results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to participation in external studies such
as the NIH BACPAC and BEST initiatives, we expect to create our own internal data by adding patients undergoing conservative and regenerative
treatment plans to our clinical registries correlating NOCISCAN results to outcomes in order to utilize AI to associate spectroscopy signals
with the optimal treatment pathway. If we are successful in demonstrating the clinical effectiveness of these associations, we intend
to expand our market opportunity to the management of entire segments of low back and neck pain patients, thereby, we believe, increasing
the size of our addressable market. However, there can be no assurance that we will be successful in marketing our products, regardless
of the size of the estimated market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although we believe that we are addressing a large
U.S. and European market, there are practical limitations to the market opportunity that must be overcome by us. We believe the two biggest
limitations are the lack of deployment of spectroscopy software across the install base of existing MRI&#8217;s worldwide and the fact
that only certain MR scanner models are compatible with our technology. For compatible MRI machines, that do not have spectroscopy hardware
and software installed, the onetime cost of the hardware and software ranges from $25,000 to $50,000. Currently, our NOCISCAN platform
is only compatible with certain MR scanner models provided by SIEMENS, of which there are an estimated 1,500 in the United States, and
4,320 worldwide. We plan to collaborate with other MRI scanner vendors to establish compatibility of their respective scanners and MRS
capabilities for use with our products, to include discounted pricing on spectroscopy software for MRI sites interested in providing DLBP
patients with the NOCISCAN offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Plan of Operation and Growth Strategies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our primary near-term growth strategy is to secure
payer contracts to cover our Category III CPT codes. We believe that with favorable payer coverage decisions comes the opportunity to
more efficiently market to spine surgeons and imaging centers to adopt our technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is currently generating the vast majority
of its revenue directly from patients paying out of pocket. With the introduction of Category III CPT codes and the proceeds of our IPO,
the Company is transitioning to full commercial operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 94 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to effectively commercialize our technology,
the Company has completed its initial plan to gain the support of up to ten leading spine surgeons as Key Opinion Leaders (KOL) who believe
Nociscan technology will help them with surgical decisions in their practices. These KOL surgeons are leaders in their field and will
be assisting the Company in generating important clinical data in support of Nociscan, and using that data to help the Company in discussions
with payers to secure positive payment decisions for our Category III CPT codes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based primarily on our KOL surgeons and the
strength of physician engagement in markets, the Company is prioritizing the following markets:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">1.</td><td style="text-align: justify">NYC Metropolitan Area</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">2.</td><td style="text-align: justify">San Francisco, CA</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">3.</td><td style="text-align: justify">Chicago, IL</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">4.</td><td style="text-align: justify">Phoenix, AZ</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">5.</td><td style="text-align: justify">Miami, FL</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">6.</td><td style="text-align: justify">Denver &amp; Colorado Springs, CO</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">7.</td><td style="text-align: justify">Detroit, MI</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">8.</td><td style="text-align: justify">Indianapolis</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once a positive local payment decision is secured
in a geographical area, we intend to place a market manager and a team of business development professionals into each market to focus
on expanding physician support and securing favorable coverage decisions from additional payers in the market. The objective in each market
is to expand the provider network to include additional imaging centers and surgeons so there is increasing geographical coverage. We
believe increasing our footprint in each market will grow volume and revenue through increased pressure on payers to expand positive coverage
decisions across all of the varied plans associated with each payer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe the following strategies will contribute
to growth in the prescription and use of NOCISCAN.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Enhance our multi-tiered sales/marketing/branding campaign
        targeted at (i) referring physicians, (ii) MR imaging providers, (iii) DLBP patients, (iv) spine implant equipment suppliers, (v) injectable
        biologics and cell therapy providers, (vi) MR scanner vendors, (vii) third party payors, and (viii) employers, all to grow awareness and
        demand for NOCISCAN;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Increase third party payer reimbursement coverage via reimbursement
        code utilization, payer negotiations, growing clinical evidence dossier via published registry studies and Randomized Control Trials (&#8220;RCT&#8221;),
        and converting temporary Category III CPT codes into permanent CPT Category I codes see &#8220;Third Party Reimbursement &#8221; below;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Expand MR scanner compatibility to additional scanner models,
        including within the Siemens product lines and other manufacturers/vendors;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Expand into international markets; </span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Evolve the adaptations and positioning of our products to support
        new emerging technologies, and clinical trials, in particular for injectable biologic and cell therapies; </span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Continue to conduct clinical trials, and publish clinical trial
        results in peer-reviewed journals in relevant fields to our business (e.g. MR/radiology, spine, and pain);</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Continue to engage and expand Key Opinion Leader (&#8220;KOL&#8221;)
        advisory boards and specialty medical society support for supporting and driving awareness of our products and services to wider audiences
        of potential customers and other stakeholders; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Pursue additional applications of our technology, including other regions
of the spine (e.g., thoracic, cervical), areas of the anatomy outside of the spine, and integrative use of our diagnostic platform with
other diagnostic platforms and tests to potentially improve the management and outcomes of populations of low back and neck pain patients.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 95 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Strategic Relationships</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Siemens</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The NOCISCAN product suite is currently compatible
for use only with certain MR scanner models and configurations provided by SIEMENS. We are not subject to any exclusivity agreement or
obligations with SIEMENS, nor do we have any fee sharing, royalty, or other exchange of moneys or payments between us and Siemens. The
nexus for our focused relationship with Siemens resulted from our determination that Siemens scanner models were optimally positioned
to support our product. We have had a collaborative relationship with Siemens since 2011.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 2, 2012, following a prior period of informal
collaboration, we entered a Memorandum of Understanding (&#8220;MOU&#8221;) with SIEMENS, under which SIEMENS agreed to support Aclarion&#8217;s
research and development of what later became the NOCISCAN product suite for compatible use with SIEMENS scanners. The MOU included
the development of certain custom features and technical support that SIEMENS would make available to support the development effort by
Aclarion. The relationship was non-exclusive. The MOU was replaced by a Strategic Collaboration Agreement for Phased Commercialization
of the SIEMENS-compatible NOCISCAN Product of Aclarion, Inc. (the &#8220;SIEMENS Agreement&#8221;) that we entered into with SIEMENS
Healthcare GmbH on December 31, 2017. This agreement comprised a collaboration to identify, onboard and provide technical support for
the SIEMENS-compatible NOCISCAN platform with early commercial users in the European Union, including a free trial period for those
initial commercial users to activate and use the SIEMENS SVS pulse sequence option package that is required to be purchased by our customers
in order to perform disc MRS according to the specifications for compatible use with our products. The SIEMENS Agreement also provided
for plans for global joint marketing, potential business model/fee agreement and a potential integration of the NOCISCAN product suite
into the SIEMENS Next Generation Frontier App Store model. While these plans have not yet been realized, the agreement still remains in
effect through automatic extensions and we are in on-going dialogue and negotiations toward some, or possibly all, of these objectives.
The Siemens Agreement is terminable.at any time by either party if such party is of the opinion that the goals of the Collaborative Agreement
cannot be achieved for technical, economic and/or clinical reasons. If Siemens were to terminate its relationship with the Company, it
would have a material adverse effect on our business. Further, there can be no assurance that there will be any joint marketing or that
future financial arrangements between us and SIEMENs will be established, and even if established, that such agreements will be successful
or profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>RadNet</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Two of the Company&#8217;s imaging centers that
are fully operational to perform NOCISCAN&#8217;s are owned by RadNet, Inc., (&#8220;RadNet&#8221;) a leading provider of outpatient imaging
centers in the United States. RadNet currently own 357 outpatient imaging centers across seven states. Larry Tannenbaum is one of our
former board members and leads the radiology section of our Medical Advisory Board. The New York/New Jersey area is one of our top targets
for early commercialization post IPO and we expect to leverage RadNet&#8217;s extensive relationship with commercial payers to secure
introductions that we believe will lead to early coverage decisions from payers in support of our growth plans. Although we have ambitions
to grow the RadNet relationship, the current arrangement is limited to the flow of revenue between Aclarion and RadNet for the performance
of an MRS exam by RadNet and the subsequent generation of a Nociscan report by Aclarion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 96 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Reimbursement </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Current Procedural Terminology or &#8220;CPT&#8221;
codes are developed by the American Medical Association (&#8220;AMA&#8221;) to describe a wide range of health care services provided
by physicians, hospitals and other health care professionals. These codes are utilized to communicate with: other physicians, hospitals,
and insurers for claims processing. There are three categories of CPT Codes: Category I, Category II, and Category III (also often referred
to interchangeably as &#8220;Levels&#8221;):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Category I CPT codes are used for reporting devices and drugs
        (including vaccines) required for the performance of a service or procedure, services or procedures performed by physicians and other
        health care providers, services or procedures performed intended for clinical use, services or procedures performed according to current
        medical practice, and services or procedures that meet CPT requirements. These codes are billable for reimbursement. </span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Category II CPT Codes are used for reporting performance measures
        reducing the necessity for chart review and medical records abstraction. </span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Category III CPT codes are used for reporting emerging technology
        in a number of capacities including services or procedures recently performed on humans, clinical trials and etc. These codes are temporary
        codes and must be accepted for placement in Level I by the CPT committee within five years, be renewed for another five more years, or
        be removed from the book.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our NOCISCAN product suite was initially commercialized
without existing CPT codes or other pathways for seeking reimbursement coverage from third party payers. Accordingly, to date, the commercial
uses of our products have been principally paid for directly by patients or their spine surgery care provider. The first third party payer
reimbursement occurred in May 2021 via the payment of a Workman&#8217;s Compensation claim in Colorado.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective January 1, 2021, a previously retired
Category I CPT Code 76390 for MR Spectroscopy was reinstated and reactivated by the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;).
This resulted from our own direct efforts with CMS in hopes of achieving this result. In addition, also effective January 1, 2021, the
AMA approved four new Category III CPT Codes for performing MRS exams specifically on intervertebral discs. More specifically, these codes
were assigned respectively to: (i) determine and localize discogenic pain via SVS (0609T), (ii) transmit the MRS derived biomarker data
for software analysis (0610T), (iii) post-process the biomarker data for algorithmic analysis to determine relative chemical differences
between discs (0611T), and (iv) interpret and report those results. Ambulatory Payment Classification (&#8220;APC&#8221;) pricing assignments
were also made by CMS for three of these Level 1 T-codes, while the fourth (0612T) was not priced and left for us, or interpreting doctors,
to negotiate payment pricing amounts with Medicare Administrative Contractors (MACs) and third-party payers. The creation, activation,
and APC pricing assignment of these four new Level 3 codes was also the result of our Company directly pursuing and negotiating with the
AMA toward these interim objectives. We intend to further explore APC assignments such as a New Technology APC to ensure our NOCISCAN
product suite is assigned an APC that is appropriate in terms of clinical characteristics and resource costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 97 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below further explains these four new
Level III CPT Codes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: #4F81BD">
    <td style="border-top: white 1pt solid; border-right: white 1pt solid; border-bottom: white 3pt solid; border-left: white 1pt solid; width: 8%; font-size: 10pt"><span style="font-size: 10pt; color: white">CPT
        Code</span></td>
    <td style="border-top: white 1pt solid; border-right: white 1pt solid; border-bottom: white 3pt solid; width: 92%; font-size: 10pt"><span style="font-size: 10pt; color: white">Description</span></td></tr>
  <tr style="vertical-align: top; background-color: #D0D8E8">
    <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; border-left: white 1pt solid; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">0609T</span></td>
    <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; font-size: 10pt"><span style="font-size: 10pt">MRS, determination
        and localization of discogenic pain (cervical, thoracic, or lumbar); acquisition of single voxel data, per disc, in &#8805;3 discs</span></td></tr>
  <tr style="vertical-align: top; background-color: #E9EDF4">
    <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; border-left: white 1pt solid; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">0610T</span></td>
    <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; font-size: 10pt"><span style="font-size: 10pt">MRS, determination
        and localization of discogenic pain (cervical, thoracic, or lumbar); transmit biomarker data for software analysis</span></td></tr>
  <tr style="vertical-align: top; background-color: #D0D8E8">
    <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; border-left: white 1pt solid; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">0611T</span></td>
    <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; font-size: 10pt"><span style="font-size: 10pt">MRS, determination
        and localization of discogenic pain (cervical, thoracic, or lumbar); postprocessing for algorithmic analysis of biomarker data for determination
        of relative chemical differences between discs</span></td></tr>
  <tr style="vertical-align: top; background-color: #E9EDF4">
    <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; border-left: white 1pt solid; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">0612T</span></td>
    <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; font-size: 10pt"><span style="font-size: 10pt">MRS, determination
        and localization of discogenic pain (cervical, thoracic, or lumbar); interpretation and report</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to a lack of operating capital, we have
not yet begun to seek reimbursement coverage or promote or suggest our customers use these codes. However, we plan to use the
proceeds of our IPO to hire the personnel and expend our financial resources do so. The Category III Codes become more valuable and
useful upon being converted into Level I, when widespread reimbursement coverage is expected to be achievable. We plan to support
conversion of codes from Category III to Category I by advancing multiple clinical studies and related peer-reviewed clinical
publications intended to further support improved patient outcomes (such as success rates following DLBP surgeries), and various
economic advantages to be achieved by incorporating the use of our NOCISCAN platform into the DLBP patient&#8217;s healthcare
journey. However, there can be no assurance that the Category III codes will be converted and replaced with corresponding Level I
Codes, and if there is a delay in the conversion of the Codes to Level 1 or there is ultimately no conversion of Codes to Level I,
our business will be materially adversely affected. Further, even if the Codes are converted to Level 1, there can be no assurance
that we will be successful in increasing the use of our technology by patients and health care professionals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property - Licenses, Patents and
Trademarks</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on a combination of licenses, patents,
trade secrets, copyrights and trademarks, as well as contractual protections to establish and protect our intellectual property rights.
Our success depends in part on our ability to obtain and maintain intellectual property protection for our technology. We seek to protect
our technology and any potential future technology related to our NOCISCAN platform through a variety of methods, including seeking
and maintaining patents intended to cover current and future technology, their methods of use and processes, and any other inventions
that are commercially important to the development of our business. We seek to obtain domestic and foreign patent protection which includes,
in addition to filing and prosecuting patent applications in the United States, typically filing counterpart patent applications in additional
countries where we believe such foreign filing is likely to be beneficial, including Europe, Australia, Canada, China, Japan, India and
South Africa.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 9, 2014, the Company entered into
an amended and restated exclusive license agreement (the &#8220;License Agreement&#8221;) with the Regents of the University of California
<span style="color: #2A2A2A">for certain</span> <span style="color: #161616">inventions</span><span style="color: #3F3F3F">, </span><span style="color: #2A2A2A">generally
characterized as</span> systems, materials, and methods to localize and evaluate pain and degenerative properties of tissue, molecular
markers that differentiate painful from non-painful discs; and MR Spectroscopy System and Method for diagnosing painful and non-painful
intervertebral discs <span style="color: #3F3F3F">(collect</span><span style="color: #161616">i</span><span style="color: #3F3F3F">ve</span><span style="color: #161616">ly
the </span><span style="color: #2A2A2A">&#8220;Invention&#8221;). </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the License Agreement, the Company
obtained a royalty-bearing, worldwide, exclusive license to the Invention, including certain patent rights related to the patents and
technology the Company uses. Under the agreement, we agreed to pay a royalty of 4% of net sales of the licensed products. Additionally,
we agreed to pay a minimum annual royalty fee starting on the third anniversary of the effective date of the agreement, which escalates
each anniversary and is currently $50,000. UCSF has the right to terminate the agreement upon advanced notice in the event of a default
by us. The agreement will expire upon the expiration or abandonment of the last of the licensed patents. The U.S. patents subject to the
agreement expire between 2026 and 2029, without considering any possible patent term adjustment or extensions and assuming payment of
all appropriate maintenance, renewal, annuity, or other governmental fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 98 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 1, 2023, our intellectual property
portfolio has 22 issued patent and 6 pending patent applications in the U.S., and 17 patent grants and 7 pending patent applications outside
the United States. The overall patent portfolio includes patents and patent applications that are (i) assigned exclusively to the Company,
(ii) assigned exclusively to the Regents of the University of California but exclusively licensed to the Company, and (iii) assigned to
both the Company and the Regents of the University of California (also exclusively licensed to the Company). Many of these patents relate
to, inventions involved in, the Company&#8217;s first product, the NOCISCAN product suite for post-processing disc MRS exam data. Others
relate to potential enhancements of the NOCISCAN disc MRS exam (as conducted at the MR scanner) and also other alternative diagnostic
approaches (e.g. molecular imaging and gene expression testing). Our portfolio of patents and patent applications, if issued, are expected
to expire between January 30, 2026 and June 16, 2037 in the U.S., in each case without considering any possible patent term adjustments
or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our intellectual property portfolio includes four
patent families (each reflecting multiple families, if based on different original applications), that relate to our NOCISCAN technology&#8201;and/or
to other potential future pipeline products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The first patent family is directed to inventions
for signal processing techniques to include leveraging artificial intelligence technologies for improving the quality, reliability, and
accuracy of MRS-based chemical biomarker measurements and related diagnostic interpretations. Many of these patented inventions are included
in our NOCICALC product under the NOCISCAN Suite and cover uses specifically for disc MRS, and for MRS in any other tissues. This first
family includes 8 issued patents and 1 pending patent application assigned to the Company in the US, and 3 issued patents and 1 pending
patent application outside the U.S. (Europe and Australia). All of these are assigned to the Company. The U.S. granted patents and pending
patent applications, if issued, are expected to expire between October 14, 2029 and March 15, 2033, without considering any possible patent
term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The second patent family relates to inventions for
novel diagnostic systems and methods for providing diagnostically useful information based on MRS-based chemical biomarkers. Many of these
patented inventions are incorporated in our NOCIGRAM product and related diagnostic report under the NOCISCAN Suite and relate to uses
specifically for discogenic pain, conditions related to discs more generally, and more broadly any degenerative pain-related diagnosis
in any tissue. This family includes patents relating to diagnosing degenerative painful discs (and other tissues) using the primary degenerative
pain biomarkers evaluated by our NOCIGRAM product. The second patent family includes 6 issued patents and 3 pending patent applications
in the US, and 9 patent grants and 6 pending patent applications outside the U.S. (Europe, Australia, Canada, China, Japan, India, South
Africa). These are either assigned to the Regents of the University of California or assigned to both the Regents of the University of
California and the Company, in all cases with the UC&#8217;s rights exclusively licensed to the Company. The U.S. granted patents and
pending patent applications, if issued, are expected to expire between January 30, 2026 and June 16, 2037, without considering any possible
patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our third patent family relates to inventions that
enhance the efficiency and reliability of certain aspects related to conducting MRS exams at the MR scanner. This includes enhancing the
efficiency and quality of NOCISCAN disc MRS exams and other applications of MRS in general. These patented inventions are not currently
incorporated into our commercial products but are in the research and development phase for potential pipeline products. This third patent
family includes 3 issued US patents that are expected to expire on November 23, 2031, without considering any possible patent term adjustment
or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. These patents are all
assigned to the Company. This patent family also includes a pending U.S. patent application that relates to the use of Artificial Intelligence
for enhancing MRS exams, which is in the research and development phase for potential pipeline products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our fourth patent family relates to inventions for
other novel diagnostic systems and methods that represent potential future pipeline products, or otherwise provide potential exclusionary
rights against related potential competitive threats. This includes patents related to discogenic pain diagnosis using molecular imaging
and/or gene expression testing. The fourth patent family includes 4 issued patents and 1 pending patent application in the US, and 5 patent
grants outside the U.S. (Europe, Canada, China). These patents are assigned to the Regents of the University of California and exclusively
licensed to the Company (and in certain aspects, co-exclusively licensed under which the Company has exclusive rights to diagnostic aspects
and another third-party licensee has limited exclusive rights to only certain treatment aspects). The U.S. granted patents and pending
patent applications, if issued, are expected to expire between September 21, 2026 and May 29, 2029, without considering any possible patent
term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 99 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot be sure that patents will be granted
with respect to any of our pending patent applications or with respect to any patent applications we may own or license in the future.
We cannot be sure that any of our existing patents or any patents we may own or license in the future will be useful in protecting our
technology. Please see &#8220;<i>Risk Factors&#8201;&#8212;&#8201;Risks Related to Our Intellectual Property</i>&#8221; for additional
information on the risks associated with our intellectual property strategy and portfolio.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We continually assess and refine our intellectual
property strategies to fortify our position. We file additional patent applications when our intellectual property strategy warrants such
filings. We intend to pursue additional intellectual property protection to the extent that we believe it would be beneficial and cost-effective.
Our ability to stop third parties from making, using, selling, offering to sell, importing or otherwise commercializing any of our patented
inventions, either directly or indirectly, will depend in part on our success in obtaining, defending and enforcing patent claims that
relate to our technology, inventions, and improvements. With respect to our intellectual property, we cannot provide any assurance that
any of our current or future patent applications will result in the issuance of patents in any particular jurisdiction, or that any of
our current or future issued patents will effectively protect any of our tests or technology from infringement or prevent others from
commercializing infringing tests or technology. Even if our pending patent applications are granted as issued patents, those patents may
be challenged, circumvented or invalidated by third parties. Consequently, we may not obtain or maintain adequate patent protection for
any of our tests or technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to our reliance on patent protection
for our inventions and technology, we also rely on trade secrets, know-how, confidentiality agreements and continuing technological innovation
to develop and maintain our competitive position. For example, some elements of our analytics techniques and processes, computational-biological
algorithms and related processes and software are based on unpatented trade secrets and know-how that are not publicly disclosed. Although
we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees, advisors
and consultants, these agreements may be breached, and we may not have adequate remedies for any breach. In addition, third parties may
independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or
disclose our technology. As a result, we may not be able to meaningfully protect our trade secrets. For further discussion of the risks
relating to intellectual property, see the section titled &#8220;Risk Factors&#8201;&#8212;&#8201;Risks Related to our Intellectual Property.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company holds the following trademarks for
its previous corporate brand name as well as for its key products and brands (&#8220;&#174;&#8221; designates registered trademark, &#8220;&#8482;&#8221;
designates unregistered trademark under common law protection):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOCIMED&#174;Corporate brand name</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOCISCAN&#174; - Primary data acquisition exam
(procedure) and software-based post-processing suite (product)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOCIGRAM&#174; - Post-processed report, one of
two products in the NOCISCAN product suite</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOCISCORE&#174; - Feature of NOCIGRAM Report</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOCICALC&#8482; - MRS spectral processor and biomarker
calculator, one of two products in the NOCISCAN suite</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOCI+&#8482; - Feature of NOCIGRAM Report</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOCI-&#8482; - Feature of NOCIGRAM Report</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOCImild&#8482; - Feature of NOCIGRAM Report</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOCIWEB&#8482; - Web-hosted user interface</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SI-SCORE&#8482; - Feature of NOCIGRAM Report</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">VIRTUAL DISCOGRAM&#8482; - Additional name associated
with NOCIGRAM</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">With respect to involved
meanings, the recurrent prefix term &#8220;NOCI&#8221; among these marks is derived from Latin origins for &#8220;<i>pain</i>&#8221; (e.g.
nerves that report pain are called &#8220;<i>noci</i>ceptors&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 100 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and Development (&#8220;R&amp;D&#8221;)
activities at Aclarion primarily explore the use of AI, our post-processing technologies and clinical registry data to expand the use
of our technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is researching the application of
AI and machine learning platforms to analyze both the raw spectroscopy data and the post-processed signal to evaluate whether AI platforms
can more efficiently and more effectively associate MRS data with clinical outcomes. We expect this type of AI research and development
to be an ongoing process applied not only to the various treatment paths associated with back pain, i.e., conservative therapies, regenerative
and cell therapies and surgical intervention, but to potentially expand into other clinical explorations involving the diagnosis of brain,
breast and prostate tumors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical research at Aclarion includes the building
of clinical registries that provide the data inputs required to train the AI models to improve the efficiency and effectiveness of our
technology for surgical decisioning as well as extend the use of our technology for potentially optimizing the treatment of neck and low
back pain through other interventions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical registries track the MRS results for
each disc being evaluated and correlates the MRS signature of the disc to patient specific data such as MRI imaging, Oswestry Disability
Index (ODI) and Visual Analog Scores (VAS). These methods are proven tools to assess low back pain, clinical treatments performed and
to identify conservative therapies such as physical therapy and chiropractic intervention, regenerative and cell therapies or surgical
interventions. By tracking specific treatments applied to each patient over time and correlating the effectiveness of those treatments
to the MRS data of each disc, we expect to create a large repository of clinical data that can be used to train advanced machine learning
algorithms that correlate MRS signatures from specific discs to improved outcomes from conservative and regenerative therapies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Government Regulation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>United States FDA.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, the FDA has broad regulatory
powers with respect to pre-clinical and clinical testing of new medical devices and the designing, manufacturing, labeling, storage, record
keeping, marketing, advertising, promotion, distribution, post-approval monitoring and reporting and import and export of medical devices.
Unless an exemption applies, federal law and FDA regulations require that all new or significantly modified medical devices introduced
into the market be preceded either by a pre-market notification clearance order under section&#160;510(k)&#160;of the Federal Food, Drug
and Cosmetic Act (FDCA), or an approved Denovo or pre-market approval (PMA) application. Under the FDCA, medical devices are classified
into one of three classes&#8212;Class&#160;I, Class&#160;II or Class&#160;III&#8212;depending on the degree of risk associated with each
medical device and the extent of control needed to provide reasonable assurances with respect to safety and effectiveness. Class&#160;I
devices are those for which safety and effectiveness can be reasonably assured by adherence to a set of regulations, referred to as General
Controls, which require compliance with the applicable portions of the FDA&#8217;s Quality System Regulation (QSR) facility registration
and product listing, reporting of adverse events and malfunctions and appropriate, truthful and non-misleading labeling, advertising and
promotional materials. Some Class&#160;I devices, also called Class&#160;I reserved devices, also require premarket clearance by the FDA
through the 510(k)&#160;premarket notification process described below. Most Class&#160;I products are exempt from the premarket notification
requirements, and subject only to registration requirements (which the FDA does not typically review, thus determined and submitted solely
by the applicant product owner).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Class&#160;II devices are those that are subject
to the General Controls, as well as Special Controls as deemed necessary by the FDA, which can include performance standards, guidelines
and post-market surveillance. Most Class&#160;II devices are subject to premarket review and clearance by the FDA. Premarket review and
clearance by the FDA for Class&#160;II devices is accomplished through the 510(k) premarket notification process. Under the 510(k) process,
the manufacturer must submit to the FDA a premarket notification, demonstrating that the product for which clearance has been sought is
substantially equivalent to a previously cleared 510(k)&#160;device or a device that was in commercial distribution before May&#160;28,
1976 for which the FDA had not yet called for the submission of pre-market approval applications. To be substantially equivalent, the
proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the
predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the
predicate device. Clinical data is sometimes required to support substantial equivalence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 101 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After a 510(k)&#160;notice is submitted, the FDA
determines whether to accept it for substantive review. If it lacks necessary information for substantive review, the FDA will refuse
to accept the 510(k)&#160;notification. If it is accepted for filing, the FDA begins a substantive review. By statute, the FDA is required
to complete its review of, and clear or deny, a 510(k)&#160;notification within 90&#160;days of receiving the 510(k)&#160;notification.
As a practical matter, clearance often takes longer, and clearance is never assured. Although many 510(k)&#160;premarket notifications
are cleared without clinical data, the FDA may require further information, including clinical data, to make a determination regarding
substantial equivalence, which may significantly prolong the review process. If the FDA agrees that the device is substantially equivalent,
it will grant clearance to commercially market the device.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After a device receives 510(k)&#160;clearance,
any modification that could significantly affect its safety or effectiveness, or that would constitute a new or major change in its intended
use, will require a new 510(k)&#160;clearance or, depending on the modification, could require a De Novo or PMA application. The FDA requires
each manufacturer to make this determination initially, but the FDA can review any such decision and can disagree with a manufacturer&#8217;s
determination. If the FDA disagrees with a manufacturer&#8217;s determination regarding whether a new premarket submission is required
for the modification of an existing device, the FDA can require the manufacturer to cease marketing and/or recall the modified device
until 510(k)&#160;clearance or approval of a De Novo or PMA application is obtained. If the FDA requires us to seek 510(k)&#160;clearance
or approval of a De Novo or PMA application for any modifications to a previously cleared product, we may be required to cease marketing
or recall the modified device until we obtain this clearance or approval. In addition, in these circumstances, we may be subject to significant
regulatory fines or penalties for failure to submit the requisite PMA application(s). In addition, the FDA is currently evaluating the
510(k) process and may make substantial changes to industry requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Class&#160;III devices include devices deemed
by the FDA to pose the greatest risk such as life-supporting or life-sustaining devices, or implantable devices, in addition to those
deemed not substantially equivalent following the 510(k)&#160;process. The safety and effectiveness of Class&#160;III devices cannot be
reasonably assured solely by the General Controls and Special Controls described above. Therefore, these devices are subject to the PMA
application process, which is generally more costly and time consuming than the 510(k)&#160;process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event a device might be considered Class
III due to lack of an equivalent predicate device, but which does not pose a significant risk to patients, it may be &#8216;down-classified&#8217;
to a relatively newer De Novo pathway for pre-market notification review and approval, which typically involves burdens and review cycle
times between what are typical for 510(k) and PMA pathways. In addition to the above classifications and related FDA regulatory pathways
in the United States, certain technologies that were previously considered medical devices have recently been reclassified and not considered
a medical device, and thus not regulated by the FDA. On December 13, 2016 the 21<sup>st</sup> Century Cures Act (&#8220;Cures Act&#8221;)
was signed into law (Public Law 114-255, 130 STAT. 1033), and was designed to help accelerate medical product development and bring new
innovations and advances to patients who need them faster and more efficiently. Section 3060 of the Cures Act was created as an amendment
to section 520 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), which addressed how medical devices are defined. This outlined
software functions that would be exempt from FDA regulation, such as those used for administrative purposes, encouraging a healthy lifestyle,
electronic health records, clinical laboratory test results and related information, and clinical decision tools.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, the NOCISCAN product
suite is only partially regulated as a medical device by the FDA. The NOCICALC product is considered a Class I &#8220;exempt&#8221;
medical device and is registered as such with the FDA under product Classification &#8220;Calculator/Data Processing Module, for Clinical
Use,&#8221; Product Code &#8220;JQP,&#8221; Regulation Number 862.2100, and Registration Number 3015426626.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The process to determine whether a product can
be considered a Class I &#8220;exempt&#8221; medical device consists of self-determining whether the product is adequately described by
one of the existing categories classified by the FDA. In conjunction with our regulatory consultants, we determined that the product Classification
&#8220;Calculator/Data Processing Module, for Clinical Use,&#8221; adequately described our NOCICALC product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In contrast, we believe the NOCIGRAM product
is considered Clinical Decision Support software (CDS) under the 21<sup>st </sup>Century Cures Act and not a medical device. As such,
we believe NOCIGRAM is not regulated by the FDA. Our conclusion that NOCISCAN would be considered Clinical Decision Support software
(&#8220;CDS&#8221;), which under the 21st Century Cures Act&#8217; is not a device and therefore exempted from medical device regulation,&#8221;
is based upon the following analysis:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 102 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Cures Act provision, a software product
is not considered a device if it meets the following four elements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 32px">&#160;</td>
    <td style="width: 23px; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">"[Not] intended to acquire, process, or analyze a medical
        image or a signal from an in vitro diagnostic device or a pattern or signal from a signal acquisition system;"</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 32px">&#160;</td>
    <td style="width: 23px; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">"[I]ntended ... for the purpose of... displaying, analyzing,
        or printing medical information about a patient or other medical information (such as peer-reviewed clinical studies and clinical practice
        guidelines);"</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 32px">&#160;</td>
    <td style="width: 23px; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">"[I]ntended ... for the purpose of... supporting or providing
        recommendations to a health care professional about prevention, diagnosis, or treatment of a disease or condition;" and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 32px">&#160;</td>
    <td style="width: 23px; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">"[I]ntended ... for the purpose of... enabling such health
        care professional to independently review the basis for such recommendations that such software presents so that it is not the intent
        that such health care professional rely primarily on any of such recommendations to make a clinical diagnosis or treatment decision regarding
        an individual patient."<sup>4</sup></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since December 13, 2016, the FDA has issued draft
guidance which provides further insight into the interpretation of the above four elements. The draft guidance, entitled &#8220;Clinical
and Patient Decision Support Software&#8221; (Dec. 2017) (&#8220;Draft Guidance&#8221;), reviews section 520(o)(l)(E) of the FDC Act and provides
additional clarity on each element.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to the last element listed above,
the Draft Guidance elaborates on what is meant by allowing health professionals to "independently" review the basis for recommendations
such that the CDS software is not intended to be "primarily" relied upon in a diagnosis or treatment decision. To that end, according
to the Draft Guidance, the user must be told: "(I) The purpose or intended use of the software function; (2) The intended user (e.g.,
ultrasound technicians, vascular surgeons); (3) The inputs used to generate the recommendation (e.g., patient age and gender); and (4)
The rationale or support for the recommendation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As described above, FDA will not regulate software
that meets the four requirements in the Cures Act as a medical device. Although there are some ambiguities as to the meaning of the relevant
statutory terms, we believe NOCIGRAM meets all four of these requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">First, the NOCIGRAM is not intended to acquire,
process, or analyze a medical image or a signal from an in vitro diagnostic device or a pattern or signal from a signal acquisition system.
Rather, it receives information from the NOCICALC, which separately performs such operations and produces a table of calculated disc
chemistry ratio values for each disc examined. It is this table that the NOCIGRAM references in performing its analysis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Second, NOCIGRAM is intended for the purpose
of displaying, analyzing, or printing medical information about a patient or other medical information. The NOCISCORE Table and graphical
plots provide medical information about the patient and analyze the data into classifications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Third, NOCIGRAM is intended for the purpose
of supporting or providing recommendations to a health care professional about prevention, diagnosis, or treatment of a disease or condition.
The information generated by the product is intended to support recommendations on how to manage patients presenting with low back pain
that may be discogenic in nature. It does this by providing additional disc chemistry-based information to be considered by the physician
in combination with other available patient information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 103 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fourth element of the statute is also met
by NOCIGRAM, although the requirements for this element are more involved than the other three elements. This element requires a means
for the health care professional to independently review the basis for any recommendation to prevent primary reliance on the software.
In its recent Draft Guidance, FDA provides four elements that can be used to determine whether the CDS software allows for independent
review: whether it explains (1) the purpose or intended use; (2) the intended user; (3) the inputs used to generate the recommendation;
and (4) the rationale for the recommendation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The NOCIGRAM explains the purpose of the intended
use. It instructs the user that it is intended to provide analyses of chemical ratio information obtained from the NOCICALC product,
which was separately derived from data via an MRS device, for the purpose of supporting recommendations about diagnosing and/or treating
patients with certain back conditions. This information is explained in the product labeling. The product labeling also explicitly states
that the intended user is a professional medical healthcare provider trained and skilled in diagnosing and recommending treatment options
for low back pain and related lumbar spine disorders. Thus, both the first and second elements set forth in the Draft Guidance are satisfied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As to the third element, the inputs used to generate
any calculations for the health care professional consist of the chemical ratio information obtained from the NOCICALC device, and
also the adjustment and analysis factors (e.g. weighting and thresholding/ranges) for analyzing that disc chemistry data. The labeling
for NOCIGRAM will describe the NOCICALC outputs as the source disc chemistry data, and will also reference the published clinical
trial results (i.e. correlations to discogram results) and related adjustment and analysis factors. This satisfies the third element.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fourth element requires that the health care
professional is able to independently review the rationale for the CDS software recommendation. FDA's Draft Guidance indicates that the
sources supporting a recommendation should, among other things, be publicly available. Tracking the statute, FDA suggests that clinical
practice guidelines and published literature would fit this description. The Company intends to publish the various factors (i.e. weighting
and thresholds) applied to adjusting and analyzing the various input chemical ratios, and the correlative analysis to the PD reference
test (as well as certain related treatment outcomes), in medical literature in marketing NOCIGRAM. The user is informed of the medical
literature in the instructions for use of NOCIGRAM.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Moreover, the physician-user will have three means
to independently verify the results of the NOCIGRAM. First, the user can manually input the adjustment factors and thresholding of
the ratios as custom inputs for the NOCICALC product to derive the same custom output results from NOCICALC as those results provided
by NOCIGRAM. Second, the user can independently (apart from NOCICALC) perform these same factor-adjusted and threshold classifier calculations
based on the values obtained from NOCICALC using the methods described in publicly available literature. Third, the user can further verify
the NOCI+/- results of the NOCIGRAM, which are correlated to discogram as a reference test based on clinical trial data, by conducting
a discogram on the same discs in the patient. This will either confirm or disprove the correlation of NOCI+/ - to discogram results in
those particular discs in that specific patient. These three verification options sufficiently address the issue of a proprietary database
or algorithm that is essentially a "black box" to users, creating primary reliance on the CDS software rather than aiding informed
decision making.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, although we believe the above analysis
is reasonable, whenever a company self classifies, there is a risk that FDA could disagree with the classification. Accordingly, in that
context, it is possible that FDA could potentially disagree that the NOCIGRAM falls under the CDS software exemption to the definition
of a device and there can be no assurance that the FDA will agree with our conclusion and in the event the FDA does not agree, our business
would be severely negatively impacted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 104 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FDA clearance or approval, when granted, may entail
limitations on the indicated uses for which a product may be marketed, and such product approvals, once granted, may be withdrawn if problems
occur after initial marketing. Manufacturers of FDA-regulated products are subject to pervasive and continuing post-approval governmental
regulation, including, but not limited to: (i) the registration and listing regulation, which requires manufacturers to register all manufacturing
facilities and list all medical devices placed into commercial distribution, (ii) the QSR, which requires manufacturers, including third
party manufacturers, to follow stringent design, validation, testing, production, control, supplier/contractor selection, complaint handling,
documentation and other quality assurance procedures during the manufacturing process, (iii) labeling regulations and unique device identification
requirements, (iv) advertising and promotion requirements, (v) restrictions on sale, distribution or use of a device, (vi) PMA annual
reporting requirements, (vii) the FDA&#8217;s general prohibition against promoting products for unapproved or &#8220;off-label&#8221;
uses, (viii) the Medical Device Reporting (MDR) regulation, which requires that manufacturers report to the FDA if their device may have
caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious
injury if it were to reoccur, (ix) medical device correction and removal reporting regulations, which require that manufacturers report
to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy
a violation of the FDCA that may present a risk to health; recall requirements, including a mandatory recall if there is a reasonable
probability that the device would cause serious adverse health consequences or death; an order of repair, replacement or refund, (x) device
tracking requirements, and (xi) post-approval study and post-market surveillance requirements. The FDA has also established a Unique Device
Identification (&#8220;UDI&#8221;) system that was phased in over a period of years. The UDI system requires manufacturers to mark certain
medical devices distributed in the United States with unique device identifiers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA recently finalized its guidance for managing
post-market cybersecurity for connected medical devices. This guidance places additional expectations on our technology to build in cybersecurity
controls when we design and develop our devices to assure safe performance in the face of cyber threats. It is also incumbent on us to
monitor third party software for new vulnerabilities and verify and validate any software updates or patches meant to address vulnerabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our facilities, records and manufacturing processes
are subject to periodic unscheduled inspections by the FDA. Failure to comply with the applicable United States medical device regulatory
requirements could result in, among other things, warning letters, untitled letters, fines, injunctions, consent decrees, civil penalties,
unanticipated expenditures, repairs, replacements, refunds, recalls or seizures of products, operating restrictions, total or partial
suspension of production, the FDA&#8217;s refusal to issue certificates to foreign governments needed to export products for sale in other
countries, the FDA&#8217;s refusal to grant future premarket clearances or approvals, withdrawals or suspensions of current product clearances
or approvals and criminal prosecution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Coverage and Reimbursement.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Government and private sector initiatives to limit
the growth of healthcare costs, including price regulation and competitive pricing, coverage and payment policies, comparative effectiveness
therapies, technology assessments and managed care arrangements, are continuing in many countries where we do business, including the
United States, Europe and Asia. As a result of these changes, the marketplace has placed increased emphasis on the delivery of more cost-effective
medical therapies. In addition, because there is generally no separate reimbursement from third-party payers to our customers for many
of our products, the additional costs associated with the use of our products can impact the profit margin of our customers. Accordingly,
these various initiatives have created increased price sensitivity over healthcare products generally and may impact demand for our products
and technologies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Healthcare cost containment efforts have also
prompted domestic hospitals and other customers of medical devices to consolidate into larger purchasing groups to enhance purchasing
power, and this trend is expected to continue. The medical device industry has also experienced some consolidation, partly in order to
offer a broader range of products to large purchasers. As a result, transactions with customers are larger, more complex and tend to involve
more long-term contracts than in the past. These larger customers, due to their enhanced purchasing power, may attempt to increase the
pressure on product pricing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 105 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant healthcare reforms have had an impact
on medical device manufacturer and hospital revenues. The Patient Protection and Affordable Care Act as amended by the Health Care and
Education and Reconciliation Act of 2010, collectively referred to as the Affordable Care Act, is a sweeping measure designed to expand
access to affordable health insurance, control healthcare spending and improve healthcare quality. Many states have also adopted or are
considering changes in healthcare policies, in part due to state budgetary pressures. Ongoing uncertainty regarding implementation of
certain aspects of the Affordable Care Act makes it difficult to predict the impact the Affordable Care Act or state law proposals may
have on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Other Healthcare Laws.&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to FDA restrictions on marketing and
promotion of drugs and devices, other federal and state laws restrict our business practices. These laws include, without limitation,
data privacy and security laws, anti-kickback and false claims laws, and transparency laws regarding payments or other items of value
provided to healthcare providers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a participant in the healthcare industry, we
are subject to extensive regulations protecting the privacy and security of patient health information that we receive, including the
Health Insurance Portability and Accountability Act of 1996 (HIPAA), as amended by the Health Information Technology for Economic and
Clinical Health Act of 2009 (HITECH), which was enacted as part of the American Recovery and Reinvestment Act of 2009. Among other things,
these regulations impose extensive requirements for maintaining the privacy and security of individually identifiable health information,
known as &#8220;protected health information.&#8221; The HIPAA privacy regulations do not preempt state laws and regulations relating
to personal information that may also apply to us. Our failure to comply with these regulations could expose us to civil and criminal
sanctions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The HIPAA provisions also created federal criminal
statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare
benefit program, including private third-party payers, knowingly and willfully embezzling or stealing from a healthcare benefit program,
willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering
up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for
healthcare benefits, items or services. A person or entity does not need to have actual knowledge of the statutes or specific intent to
violate them in order to have committed a violation. Also, many states have similar fraud and abuse statutes or regulations that may be
broader in scope and may apply regardless of payer, in addition to items and services reimbursed under Medicaid and other state programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The federal Anti-Kickback Statute prohibits, among
other things, knowingly and willfully offering, paying, soliciting or receiving any remuneration (including any kickback, bribe or rebate),
directly or indirectly, overtly or covertly, to induce or in return for the purchasing, leasing, ordering, or arranging for or recommending
the purchase, lease or order of items or services for which payment may be made, in whole or in part, under Medicare, Medicaid or other
federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. Although there
are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and
safe harbors are drawn narrowly. Further, a claim including items or services resulting from a violation of the federal Anti-Kickback
Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The federal False Claims Act prohibits, among
other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment or approval
to the federal government, or knowingly making, using or causing to be made or used a false record or statement material to a false or
fraudulent claim to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the
U.S. Government. Medical device manufacturers have been held liable under these laws if they are deemed to cause the submission of false
or fraudulent claims by, for example, providing customers with inaccurate billing or coding information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These laws impact the kinds of financial arrangements
we may have with potential users of our technology. They particularly impact how we structure our marketing, including discount practices,
customer support, education and training programs, physician consulting, research grants and other service arrangements. If our operations
are found to be in violation of any of the health regulatory laws described above or any other laws that apply to us, we may be subject
to penalties, including potentially significant criminal and civil and administrative penalties, damages, fines, disgorgement, imprisonment,
exclusion from participation in government healthcare programs, contractual damages, reputational harm, and the curtailment or restructuring
of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 106 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, there has been a trend towards increased
federal and state regulation of payments and other transfers of value provided to healthcare professionals or entities. The federal Physician
Payment Sunshine Act requires that certain device manufacturers track and report to the government information regarding payments and
other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their
family members. A manufacturer&#8217;s failure to submit timely, accurately and completely the required information for all payments,
transfers of value or ownership or investment interests may result in civil monetary penalties of up to an aggregate of $150,000 per&#160;year,
and up to an aggregate of $1&#160;million per&#160;year for &#8220;knowing failures.&#8221; Certain states also mandate implementation
of compliance programs, impose restrictions on device manufacturer marketing practices and/or require the tracking and reporting of gifts,
compensation and other remuneration to healthcare professionals and entities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to similar laws in foreign countries
where we conduct business. For example, within the EU, the control of unlawful marketing activities is a matter of national law in each
of the member states. The member states of the EU closely monitor perceived unlawful marketing activity by companies. We could face civil,
criminal, and administrative sanctions if any member state determines that we have breached our obligations under its national laws. Industry
associations also closely monitor the activities of member companies. If these organizations or authorities name us as having breached
our obligations under their regulations, rules&#160;or standards, our reputation would suffer and our business and financial condition
could be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Other Foreign Healthcare Regulations </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also subject to regulation in the foreign
countries in which we manufacture and market our products. For example, the commercialization of certain products, including certain medical
devices, in the EU is regulated under a system that presently requires all such products sold in the EU to bear the CE mark&#8212;an international
symbol of adherence to quality assurance standards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The International Medical Device Regulators Forum
has implemented a global approach to auditing manufacturers of medical devices. This audit system, called the Medical Device Single Audit
Program (&#8220;MDSAP&#8221;), provides for an annual audit of a medical device manufacturer by a certified body on behalf of various
regulatory authorities. Current authorities participating in MDSAP include the Therapeutic Goods Administration of Australia, Brazil&#8217;s
Agencia Nacional de Vigilancia Sanitaria, Health Canada, Japan&#8217;s Ministry of Health, Labour and Welfare, and the Japanese Pharmaceuticals
and Medical Devices Agency and the FDA. It is expected that more regulatory authorities will participate in MDSAP in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We, and other medical device manufacturers, are
currently adjusting to major changes in the EU&#8217;s decades-old regulatory framework which governs market access to the EU. The Medical
Devices Regulation (&#8220;MDR&#8221;) went into effect on May 26, 2021 and replaces the EU&#8217;s prior Medical Device Directive (93/42/EEC).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our NOCISCAN product suite is subject to these
EU regulations, and is CE Marked via self-certification as a Class I medical device. However, this was secured prior to enactment of the
MDR. Under the MDR, we expect to be considered a Class II medical device and subject to stricter requirements for pre-market review and
certification for CE Marking by a Notified Body, including with respect to clinical data that must be submitted in support of our claimed
indications and labeling. However, manufacturers of certain classes of currently approved medical devices will have a transition time
to meet certain aspects of the new requirements under the MDR.&#160;A grace period until May 2024 is provided for Class I medical devices
that were self-certified for CE Marking prior to the MDR conversion to become CE Mark certified as a Class II medical device by a Notified
Body. We are still, however, required to continue monitoring and ensuring our on-going compliance with certain other provisions under
the new MDR requirements with respect to post-market surveillance of our products, as of May 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The EU Parliament has voted to extend the Medical Device Regulation
(MDR 2017/745) transition period. The extension will see the May 2024 deadline postponed until 2027 for higher-risk Class III and implantable
IIb devices, and May 2028 for lower-risk Class I, IIa, and other IIb devices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 107 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The MDR differs in several important ways from
the EU&#8217;s prior MDD directives for medical devices and active implantable medical devices. The most significant changes in the regulation
include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The definition of medical devices covered under the MDR will
        be significantly expanded to include devices that may not have a medical intended purpose, such as colored contact lenses. Also included
        in the scope of the regulation are devices designed for the purpose of &#8220;prediction and prognosis&#8221; of a disease or other health
        condition;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Device manufacturers will be required to identify at least
        one person within their organization who is ultimately responsible for all aspects of compliance with the requirements of the new MDR.
        The organization must document the specific qualifications of this individual relative to the required tasks;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The MDR requires rigorous post-market oversight of medical
        devices;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The MDR will allow the EU Commission or expert panels to publish
        &#8220;Common Specifications&#8221;, such as requirements for technical documentation, risk management, or clinical evaluation, which
        devices shall be required to meet;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Devices will be reclassified according to risk, contact, duration,
        and invasiveness;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Systematic clinical evaluation will be required for Class&#160;IIa
        and Class&#160;IIb medical devices; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">All currently approved devices must be recertified in accordance
        with the new MDR requirements.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75pt; text-align: justify">Following Brexit, certain medical devices,
including our products, are also required to meet the local regulatory requirements within the U.K., separate and apart from EU regulations
that previously also covered commercial practices in the U.K. While our CE Mark still applies for the U.K., other U.K. requirements for
regulatory monitoring and compliance must also be met. Our quality and regulatory compliance systems and practices are currently in the
process of being updated for ensuring compliance with the applicable U.K. regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>General Data Protection Regulation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The implementation on May&#160;25, 2018 of
the General Data Protection Regulation (&#8220;GDPR&#8221;), a regulation in the EU on data protection and privacy for all
individuals in the EU and the European Economic Area (&#8220;EEA&#8221;), applies to all enterprises, regardless of location, that
are doing business in the EU or that collect and analyze data tied to EU and EEA residents. GDPR creates a range of new compliance
obligations, including stringent technical and security controls surrounding the storage, use, and disclosure of personal
information, and significantly increases financial penalties for noncompliance (including possible fines of up to 4% of global
annual turnover for the preceding financial year or &#8364;20 million (whichever is higher) for the most serious
infringements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July&#160;2020, the European Commission invalidated
the EU.-U.S. Privacy Shield framework, of which we were registrants. This has resulted in some uncertainty related to continuing obligations
and future data transfer compliance obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 108 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>California Consumer Privacy Act</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The California Consumer Privacy Act, &#8220;CCPA&#8221;,
became effective on January&#160;1, 2020 along with a number of complex privacy regulations affecting the processing of personal information
of California residents. If we fail to comply with the CCPA, we may be subject to significant financial penalties or adverse regulatory
actions. In addition to the CCPA, the California legislature is exploring additional regulations to expand the scope and depth of the
state&#8217;s data protection controls.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Competition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the diagnostic and connected care markets,
competition is also based on a variety of factors including product performance, functionality, value and breadth of sales and service
organization. We believe that currently, there is a scarcity of new diagnostic platforms on the market, or otherwise proposed and approaching
the market, that are competitive with our products for our primary intended discogenic low back pain indication. Accordingly, our primary
competition resides with the current diagnostic standards over which our products are intended to improve &#8211; in particular, X-ray,
lumbar MRI, and provocative discography (PD). While we believe our products are positioned for synergistic use with lumbar MRI, and to
enhance the diagnostic value of lumbar MR exams, the existing reliance on MRI as a standard of care for our indication, and other potential
enhancements to those platforms and techniques, nonetheless also represent competition. To the extent these other platforms represent
our primary competitors, they are mainly provided by large, well-capitalized companies with significant market share and resources. Our
competitors have more established sales and marketing programs than we do and have greater name recognition. These competitors also have
long operating histories and may have more established relationships with our potential customers. In addition to competing for market
share, competitors may develop or acquire patents or other rights that may limit our ability to compete.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Competition could result
in price reductions, reduced margins and loss of our potential market share. We believe that our NOCISCAN product suite is superior
to currently known competition in this market as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 27px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We believe we are superior to standard lumbar MRI because:</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 75px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">o</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Standard lumbar MRI only indicates structural defects, degeneration,
        and hydration, which have not been well correlated to identifying painful discs in DLBP patients, whereas our products have been highly
        correlated to pain as indicated by positive Provocation Discogram results in a clinical trial published in a major peer-reviewed spine
        journal;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td></tr>

<tr style="vertical-align: top">
    <td style="width: 75px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">o</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Standard lumbar MRI does not identify nor allow for measuring
        levels of acidic chemicals, such as lactic acid, that have been identified as a source of causing discs to become painful, and which we
        both identify and measure objectively and quantitatively; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td></tr>

<tr style="vertical-align: top">
    <td style="width: 75px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">o</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Patient outcomes from surgeries following standard lumbar MRI
        diagnosis, but without the benefit of or following our diagnosis, have resulted in a much lower &lt;60% success rate versus much higher
        &gt;90% success rates shown for patient outcomes following surgeries that treat painful discs identified via our diagnostic products,
        as also demonstrated in the same published clinical trial referenced above.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 27px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We believe we are superior to standard Provocation Discogram
        (PD) because:</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 75px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">o</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">PD is highly invasive, whereas our test is entirely non-invasive;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td></tr>

<tr style="vertical-align: top">
    <td style="width: 75px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">o</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">PD is painful by deliberate design, whereas our test is entirely
        pain-free;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td></tr>

<tr style="vertical-align: top">
    <td style="width: 75px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">o</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">PD has certain risks of harm, including certain reports of
        &gt;1% risk of infection and increased risks of accelerating degeneration and/or herniation rates in discs after receiving needle injections
        form PD, whereas our test is non-significant risk and no more risky that standard lumbar MRI or other applications of MRS;</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 75px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">o</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">PD is subjective, based both on patient reporting of subjective
        pain and physician subjectivity in interpreting results, whereas our test is entirely objective; and</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 75px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">o</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">PD is often performed, for optimal reliability and accuracy,
        with a CT scan to evaluate the distribution of injected dye in and around the disc, which requires a second diagnostic imaging exam and
        additional related costs, and which also exposes the patient to radiation, whereas our test is only a single exam, is more cost effective,
        and is entirely radiation free.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 109 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of October 2, 2024, we had 7 total employees,
3 of whom were engaged in research and development activities, 1 engaged in strategy and business development, and 3 of whom were
engaged in general administration. We believe that we maintain good relations with our employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Legal Proceedings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, we may be involved in litigation
relating to claims arising out of our operations in the normal course of business. We are not currently a party to any material legal
proceedings, the adverse outcome of which, in our management&#8217;s opinion, individually or in the aggregate, could have a material
adverse effect on the results of our operations or financial position. There are no material proceedings in which any of our directors,
officers or affiliates or any registered or beneficial stockholder of more than 5% of our common stock is an adverse party or has a material
interest adverse to our interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Segment Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We operate in a single operating segment and a
single reporting segment. Operating segments are defined as components of an enterprise about which separate financial information is
regularly evaluated by the chief operating decision maker function (which is fulfilled by our chief executive officer) in deciding how
to allocate resources and in assessing performance. Our chief executive officer allocates resources and assesses performance based upon
financial information at the level. Since we operate in one operating segment, all required financial segment information is presented
in the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our corporate information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were formed under the name Nocimed, LLC, a
limited liability company in January 2008, under the laws of the State of Delaware. In February 2015, Nocimed, LLC was converted into
Nocimed, Inc. a Delaware corporation. On December 3, 2021, we changed our name to Aclarion, Inc. Our principal executive offices are located
at 8181 Arista Place, Suite 100, Broomfield, Colorado 80021. Our main telephone number is (833) 275-2266. Our internet website is www.aclarion.com.
The information contained in or accessible from our website is not incorporated into this Annual Report, and you should not consider it
part of this Annual Report. We have included our website address in this Annual Report solely as an inactive textual reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Implications of being an emerging growth company and a smaller
reporting company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We qualify as an &#8220;emerging growth company&#8221;
as defined in the Jumpstart our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). An emerging growth company may take advantage
of specified reduced reporting and other burdens that are otherwise applicable generally to public companies. These provisions include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; width: 24px; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify; vertical-align: top; font-size: 10pt"><span style="font-size: 10pt">inclusion of only two years, as compared
        to three years, of audited financial statements in addition to any required unaudited interim financial statements with correspondingly
        reduced Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations
        disclosure;</span></td></tr>
  <tr>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt">&#160;</td></tr>
  <tr>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify; vertical-align: top; font-size: 10pt"><span style="font-size: 10pt">an exemption from the auditor attestation
        requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley
        Act&#8221;);</span></td></tr>
  <tr>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt">&#160;</td></tr>
  <tr>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify; vertical-align: top; font-size: 10pt"><span style="font-size: 10pt">an exemption from compliance with any
        new requirements adopted by the Public Company Accounting Oversight Board (the &#8220;PCAOB&#8221;) requiring mandatory audit firm rotation;</span></td></tr>
  <tr>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt">&#160;</td></tr>
  <tr>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify; vertical-align: top; font-size: 10pt"><span style="font-size: 10pt">reduced disclosure about executive compensation
        arrangements; and</span></td></tr>
  <tr>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt">&#160;</td></tr>
  <tr>
    <td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify; vertical-align: top; font-size: 10pt"><span style="font-size: 10pt">an exemption from the requirement to seek
        non-binding advisory votes on executive compensation or golden parachute arrangements.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 110 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may take advantage of these provisions until
we are no longer an emerging growth company. We will remain an emerging growth company until the earliest of (1) the last day of the fiscal
year (a) following the fifth anniversary of the completion of our IPO, (b)&#160;in which we have total annual gross revenue of at least
$1.235 billion or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is
held by non-affiliates exceeds $700 million as of the prior December 31st, and (2) the date on which we have issued more than $1.0 billion
in non-convertible debt during the prior three-year period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have taken advantage of the reduced reporting
requirements in this Annual Report. Accordingly, the information contained herein may be different from the information you receive from
other public companies that are not emerging growth companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The JOBS Act permits an emerging growth company
such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public
companies until those standards would otherwise apply to private companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also a &#8220;smaller reporting company&#8221;
meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual revenue was less than $100
million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value
of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently
completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting
company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements
that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two
most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies,
smaller reporting companies have reduced disclosure obligations regarding executive compensation.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Available Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our internet address is www.aclarion.com. Our
Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports can be found
on our investor relations website, free of charge, as soon as reasonably practicable after we electronically file such material with,
or furnish it to, the SEC. Information contained on our website is not incorporated by reference into this prospectus. The SEC maintains
a public website, www.sec.gov, which includes information about and the filings of issuers that file electronically with the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left; background-color: white">&#160;<br/></p>

<!-- Field: Page; Sequence: 111 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><span style="text-transform: uppercase"><b><span id="s_013"></span>Management,
Governance, Director Compensation, Executive Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Executive officers and directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Set forth below are the names, ages and positions of our executive
officers and directors as of October 2, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position(s) held</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Served as a Director</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>and/or Officer Since</b></p></td></tr>
  <tr style="vertical-align: bottom">
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Executive Officers</b></p></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeff Thramann, M.D.</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 42%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Chairman and Director</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 21%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020(1)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brent Ness</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, President and Director</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021(2)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Lorbiecki</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021(3)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ryan Bond</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Strategy Officer</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021(4)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Employee Directors</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scott Breidbart, M.D.</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve Deitsch</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Neal</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">William Wesemann</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amanda Williams</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_______________</p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 4%">(1)</td>
    <td style="width: 96%">Dr. Thramann has been a director since 2020. He was appointed Executive Director as of March 2021, and became Executive
        Chairman as of April 21, 2022.</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 4%">(2)</td>
    <td style="width: 96%">Mr. Ness was appointed CEO and a director on September 15, 2021.</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 4%">(3)</td>
    <td style="width: 96%">Mr. Lorbiecki was appointed Chief Financial Officer on October 1, 2021.</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 4%">(4)</td>
    <td style="width: 96%">Mr. Bond was appointed Chief Strategy Officer on September 15, 2021.</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 4%">(5)</td>
    <td style="width: 96%">Ms. Williams, Mr. Deitsch, and Dr. Breidbart have been directors since April 21, 2022.</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 4%">(6)</td>
    <td style="width: 96%">Mr. Wesemann and Mr. Neal have been directors since 2016.</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Executive Officers&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Jeff Thramann, M.D., Executive Chairman
and Director: </i></b>Jeff Thramann has been a director since September, 2020. He was also an executive Director since March 2021, which
is an executive officer of the Company. He transitioned to Executive Chairman at the time of our April 2022 IPO. He oversees strategic
initiatives, capitalization and governance at the company. This includes day-to-day involvement in working with senior management to establish
the strategic vision of the Company, assist in KOL development, work with the Chief Executive Officer and Chief Financial Officer on financial
plans, clinical reimbursement and product strategies, and assisting the Chief Executive Officer in recruitment and hiring of senior executives
and the pursuit of business development activities. His responsibilities also include leading investor relations efforts, building the
board of directors and leading board meetings. Dr. Thramann is currently the founder and Executive Chairman of Auddia Inc. (NASDAQ: AUUD),
a technology company that is reinventing how consumers interact with audio through an AI platform that enables unique consumer experiences
across radio and podcast listening. Dr. Thramann founded Auddia Inc. in January 2012. In 2002, Dr. Thramann was the founder (and became
the chairman) of Lanx, LLC (&#8220;Lanx&#8221;). Lanx was an innovative medical device company focused on the spinal implant market that
created the interspinous process fusion space with the introduction of its patented Aspen product. Lanx was sold to Biomet, Inc., an international
orthopedic conglomerate, in November, 2013. Concurrent with Lanx, in July, 2006 Dr. Thramann was the founder and chairman of ProNerve,
LLC (&#8220;ProNerve&#8221;). ProNerve was a healthcare services company that provided monitoring of nerve function during high-risk surgical
procedures affecting the brain and spinal cord. ProNerve was sold to Waud Capital Partners, a private equity firm, in 2012. Prior to ProNerve
and concurrent with Lanx, Dr. Thramann was the founder and chairman of U.S. Radiosurgery (&#8220;USR&#8221;). USR is a healthcare services
company that provides advanced radiosurgical treatments for tumors throughout the body. USR became the largest provider of robotic guided
CyberKnife treatments of such tumors in the U.S. and was sold to Alliance Healthcare Services (NASDAQ: AIQ) in April, 2011. From July,
2001 through April, 2008, Dr. Thramann was the founder and senior partner of Boulder Neurosurgical Associates, a neurosurgical practice
serving Boulder County, Colorado. Dr. Thramann is the named inventor on over 100 U.S. and international issued and pending patents. He
completed his neurosurgical residency and complex spinal reconstruction fellowship at the Barrow Neurological Institute in Phoenix, AZ,
in June, 2001. He is a graduate of Cornell University Medical College in New York City and earned his Bachelor of Science degree in electrical
engineering management at the U. S. Military Academy in West Point, NY.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 112 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Brent Ness, Chief Executive Officer. </i></b>Mr.
Ness became our Chief Executive Officer on September 15, 2021. From December 2019 through April 2021, he was a consultant and then became
President and Chief Commercial Officer of Cleerly, Inc. (&#8220;Cleerly&#8221;). Cleerly is a developer of an AI enabled non-invasive
digital care pathway aimed at improving clinicians understanding of their patients&#8217; risk of sudden coronary death. At Cleerly, Mr.
Ness co-led efforts to create a partnership with Canon, Inc. who co-markets Cleerly solutions as part of their offerings. From March 2016
to December 2019, Mr. Ness was the Chief Operating Officer of Mighty Oak Medical (&#8220;Mighty Oak&#8221;) whose principal products progressed
from pre-FDA clearance through an international full market launch of their platform called FIREFLY.&#160; FIREFLY is a 3D Printed patient
specific solution that is intended to provide spine surgeons with a highly accurate alternative to navigation and robotic applications
in the spinal navigation space. FIREFLY involves the use of CT scans as the core data upon which sophisticated pre-surgical plans are
created along with guides and bone models. From 2014 through 2016, Mr. Ness was the Chief Commercial Officer of HeartFlow, Inc. (&#8220;Heartflow&#8221;).
HeartFlow is a medical technology company that created and developed a non-invasive cardiac test enabling physicians to make more informed
decisions for their patients with suspected coronary heart disease. Mr. Ness led the business from pre-FDA clearance through a global
expansion of early adopter sites. Along with the senior leadership team at HeartFlow, he deployed a strong clinical evidence-based approach
in the early launch of the SaaS platform to engage Key Opinion Leader Physicians and the third-party payer community. This resulted in
the issuance of Category III CPT Codes and multiple private payer coverage decisions. From 2008 through 2013, he was President of ProNerve,
LLC, (&#8220;ProNerve"). ProNerve is a provider of intraoperative neuromonitoring services which involves the use of a variety of
electro-physiological monitoring procedures during spine and brain surgery, to allow early warning and avoidance of injury to nervous
system structures. As President of ProNerve, Mr. Ness presided over a roll up of the highly fragmented Interoperative Nerve Monitoring
Industry. From 2004 to 2008, Mr. Ness served as Vice President- Global Sales and Marketing for Medtronic Navigation, a division of Medtronic,
Inc. Earlier in his career he was employed by GE Healthcare as Director of Corporate Accounts and for Philips North America as Vice President
of Sales Operations, which companies are suppliers of diagnostic imaging equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Ness currently serves as an advisor to Mighty
Oak Medical, K2 Capital and Cleerly. Mr. Ness has a Bachelor&#8217;s Degree in Marketing from the University of North Dakota and an MBA
from the University of Colorado.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>John Lorbiecki, Chief Financial Officer:</i></b>
Mr. Lorbiecki became our Chief Financial Officer on October 1, 2021. He has over 25 years of financial management and operational experience
which includes serving as the divisional CFO for two business units within Medtronic, Inc. From January 2019 through October 1, 2021,
Mr. Lorbiecki was a principal of Strategic Finance Solutions LLC, a financial consulting company. From April 2021 to October 2021, he
also advised Fusion Robotics LLC through their merger with Integrity Implants Inc., now doing business as Accelus Inc. From January 2020
through April 2021, Mr. Lorbiecki held the lead finance role at Honeybee Robotics, an aerospace company that designs and builds advanced
robotic systems. He led the financial dimensions of the strategic planning process, managed monthly project reviews to measure progress
and ensure economic targets were met, and oversaw monthly accounting activities. From March 2017 through July 2018, he served as Chief
Operating Officer at Colorado Therapeutics LLC, a medical startup focused on innovative biologic soft tissue repair products where he
was instrumental in completing the relocation of the company headquarters and increasing manufacturing capacity. From 1991 through 2017
he was with Medtronic, among the largest medical device companies in the world. He led sales operations, including pricing and contracting,
for the Cardiac Surgery Division, and moved through other business unit and corporate financial leadership roles. Mr. Lorbiecki has a
Bachelor&#8217;s Degree in Economics from the University of St. Thomas where he graduated magna cum laude and an MBA from the University
of Chicago Booth School of Business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Ryan Bond, Chief Strategy Officer: </i></b>Mr.
Bond became our Chief Strategy Officer in September 2021. From December 2018 to August 2021, he has been our Vice President, Business
Development, where he led business development, sales and marketing including a limited commercial launch of Aclarion&#8217;s cloud-based
SaaS with early adopters in the US, EU, and UK, Mr. Bond coordinated multiple research trials sponsored by our customers, where Aclarion&#8217;s
proprietary, adjunctive diagnostic technology is employed. Mr. Bond was instrumental in working with reimbursement consultants to gain
Category III CPT Codes for Aclarion with assigned APC rates and advocating to CMS for the removal of a long-standing non-coverage policy
for magnetic resonance spectroscopy (MRS, CPT Code 76390). From November 2014 to September 2018 Mr. Bond was Director, Healthcare Solutions
at NuVasive, a company in the global spine market. While at NuVasive, he led several strategic initiatives involving strategic partnerships,
channel development, pricing, contracting, and sales training. From 2005 to 2014, Mr. Bond was with Accelero Health Partners (&#8220;Accelero&#8221;),
a consulting firm focused on musculoskeletal service line development using a combination of strategic organizational development programs
and a proprietary cloud-based business intelligence tool that discretely measured a cadre of clinical, functional, operational, and volume-based
metrics, while simultaneously illustrating the interrelated cause-effect of each. In 2006, Accelero was acquired by Zimmer Holdings. Mr.
Bond serves on an Advisory Board to the College of Business at Ohio University, where he earned a Bachelor&#8217;s of Science Degree in
Engineering from the Russ College of Engineering and Technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 113 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Non-employee directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Scott Breidbart, M.D., Director: </i></b>Dr.
Scott Breidbart has been consulting in the healthcare industry since November 2021. Before that, he was the Chief Medical Officer of Affinity
Health Plans from January 2018 until its purchase in November 2021. From October 2016 to January 2018, he was Chief Medical Officer of
Solera Health and from October 2015 to September 2016, he was the Chief Clinical Officer of Emblem Health. From November 2008 to October
2015, Mr. Breidbart served as the Chief Medical Officer of Empire BlueCross BlueShield, and from May 1998 to August 2008 he had various
roles in medical management for HealthNet. Dr. Breidbart practiced pediatric endocrinology for ten years on the faculty of New York Medical
College. He is Board Certified in Pediatrics and Pediatric Endocrinology and is licensed to practice medicine in NY. He holds a BA in
Mathematics from Yale, an MD from Columbia, and an MBA from Pace University. We believe Dr. Breidbart&#8217;s experience with medical management and medical reimbursement matters provides
him with the appropriate set of skills to serve as a member of our board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Steve Deitsch,
Director:</i></b> Steve Deitsch is currently the CFO of OrganOx, a medical device company which is changing the paradigm in liver transplantation.
He has extensive strategic, operational, and financial leadership experience at both publicly traded and privately held companies. From
September 2020 to April 2024, Mr. Deitsch served as Chief Financial Officer at Paragon 28, a medical device company focused on surgical
implants for the foot and ankle. From April 2017 to August 2019, Mr. Deitsch served as Senior Vice President and Chief Financial Officer
of BioScrip, Inc., which is now part of Option Care Health, Inc. (NASDAQ: BIOS). From August&#160;2015 to April 2017, Mr. Deitsch served
as Executive Vice President, Chief Financial Officer and Corporate Secretary of Coalfire, Inc., a leading cyber-security firm owned by
The Carlyle Group. He served as the Chief Financial Officer of the Zimmer Biomet Spine, Bone Healing, and Microfixation business from
July 2014 to July 2015 and as Vice President Finance, Biomet Corporate Controller from February 2014 to July&#160;2014. Mr. Deitsch was
the Chief Financial Officer of Lanx from September 2009 until it was acquired by Biomet in October 2013. From 2002 to 2009, Mr. Deitsch
also served in various senior financial leadership roles at Zimmer Holdings, Inc. (now part of Zimmer Biomet, Inc.), including Vice President
Finance, Reconstructive and Operations, and Vice President Finance, Europe. He is a director and audit committee chair of Auddia Inc.
(NASDAQ: AUUD), since February of 2021. Mr. Deitsch holds a B.S. in Accounting from Ball State University and has an in-active CPA license.
We believe Mr. Deitsch&#8217;s financial, management and healthcare experience provides him with the appropriate set of skills to serve
as a member of our board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>David Neal, Director:</i></b> Mr. Neal
has been a director since September 2016. He is the founder and a current member of SC Capital 1 LLC which was formed in 2016. SC
Capital 1 LLC is a securitized LLC formed to invest in breakthrough medical technologies and therapies. Also, from April 2015 to the
present, he has been a partner of Frontier Wealth Enterprises, LLC a financial services firm providing advice-based financial
services to high-net worth families. From 2000 to 2015, he held various positions with UBS, including Portfolio Manager and manager
of a Regional Office in Wichita Kansas. He was on the Hutchinson Regional Medical Center board of directors for 9 years and
currently is a member of the board of the Hutchinson Community Foundation. He holds a Bachelor of Sport Science degree from the
University of Kansas and a Master of Management Science degree from the John Cook School of Business at Saint Louis University. We
believe Mr. Neal&#8217;s experience in medical technology investment provides him with the appropriate set of skills to serve as a
member of our board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>William (Bill) Wesemann, Director: </i></b>Mr.
Wesemann has been a director since 2016. Mr. Wesemann has been an independent businessman and investor since June 2002. Prior to 2002
his experience included serving in chief executive, sales leadership, and advisory roles at technology companies. Since 2004, he has been
a director of LivePerson (Nasdaq: LPSN), a global technology company that develops conversational commerce and AI software. He is also
a director of Stationhead, Inc. (commencing in 2019), a consumer social audio platform; and a director of Mylio, Inc (commencing in 2013)
a photo management company. Mr. Wesemann received a B.A. from Glassboro State College (Rowan University). We believe Mr. Wesemann&#8217;s experience in technology investing provides him with the appropriate set of skills
to serve as a member of our board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Amanda Williams, Director:</i></b> Ms. Williams
has been Senior Vice President for Clinical and Regulatory at MedAlliance, a Cordis company, which is a healthcare company focused on
treating peripheral and coronary artery disease with the Selution drug coated balloon, since August 2023. From September 2018 to May 2023,
she was the Senior Vice President of Clinical, Quality and Regulatory at ViewRay, Inc. (Nasdaq: VRAY), a healthcare company that integrates
real time MRI imaging of tumors with the delivery of high dose radiation for improved treatment accuracy. From December, 2017, to September,
2018, she was the Head of Regulatory with the Image Guided Therapy Devices and Systems divisions of Philips. From July, 2010 to December,
2017 Ms. Sequira was the Senior Director (2010-2013) and Vice President (2013-2017) of Clinical and Regulatory with The Spectranetics
Corp., (now part of Philips), and from 2003 to 2010 she was Manager, and then Director of Regulatory of AGA Medical Corp (now part of
Abbott). Prior to these roles, she worked as a Regulatory Specialist with Vascular Solutions and as a Chemist with GE &#8211; Osmonics.
In these positions, she worked on a diverse range of products, including cardiovascular treatment, implantable heart defect device, combination
drug/device and large capital equipment (both imaging and treatment) devices.&#160; At Spectranetics, she led teams that completed multiple
global randomized clinical studies. She holds a Master of Science in Regulatory from Northeastern University and a Bachelor of Science
in Chemistry from the University of Minnesota. We believe Ms. Williams&#8217; medical clinical and regulatory matters provides her with
the appropriate set of skills to serve as a member of our board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 114 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Section 16(a) Beneficial Ownership Reporting Compliance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following our IPO, Section 16(a) of the Exchange
Act requires our directors, executive officers, and persons holding more than 10% of our common stock to report their initial ownership
of the common stock and other equity securities and any changes in that ownership in reports that must be filed with the SEC. The SEC
has designated specific deadlines for these reports, and we must identify in our Annual Report on Form 10-K those persons who did not
file these reports when due.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based solely on a review of reports furnished
to us, or written representations from reporting persons, we believe all directors, executive officers, and 10% owners timely filed all
reports regarding transactions in our securities required to be filed in 2023 by Section 16(a) under the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Election of Officers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our executive officers are appointed by, and serve
at the discretion of, our board of directors. There are no family relationships among any of our directors or executive officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Composition of the Board of Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors currently consists of seven
members. Four of our directors are independent within the meaning of the independent director guidelines of the Nasdaq Stock Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each director&#8217;s term continues until the
election and qualification of his successor, or his earlier death, resignation or removal. Our restated certificate of incorporation and
restated bylaws authorize only our board of directors to fill vacancies on our board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board Leadership Structure and Role in Risk
Oversight</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our corporate governance guidelines provide that
unless the board chair is an independent director, the board shall appoint a Lead Independent Director. The Lead Independent Director
chairs the executive sessions of the independent directors, coordinates the activities of the other independent directors and performs
such other duties as deemed necessary by the board from time to time. Because our Executive Chairman Dr. Thramann is not independent,
the board has appointed William Wesemann to serve as our Lead Independent Director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risk is inherent with every business, and how
well a business manages risk can ultimately determine its success. We face a number of risks, including credit risk, interest rate risk,
liquidity risk, operational risk, strategic risk and reputation risk. Management is responsible for the day-to-day management of risks
we face, while the board, as a whole and through its committees, has responsibility for the oversight of risk management. In its risk
oversight role, the board has the responsibility to satisfy itself that the risk management processes designed and implemented by management
are adequate and functioning as designed. To do this, the board meets regularly with management to discuss strategy and the risks we face.
In addition, the Audit Committee regularly monitors our enterprise risk, including financial risks, through reports from management. Senior
management attends the board meetings and is available to address any questions or concerns raised by the board on risk management and
any other matters. The Lead Independent Director and the independent board members work together to provide strong, independent oversight
of our management and affairs through the board&#8217;s standing committees and, when necessary, executive sessions of the independent
directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Director Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the rules of Nasdaq, independent directors
must comprise a majority of a listed company&#8217;s board of directors within a specified period following the completion of its IPO.
In addition, the rules of Nasdaq require that, subject to specified exceptions, each member of a listed company&#8217;s audit, compensation
and nominating and governance committees be independent. Under the rules of Nasdaq, a director will only qualify as an &#8220;independent
director&#8221; if, in the opinion of that company&#8217;s board of directors, that person does not have a relationship that would interfere
with the exercise of independent judgment in carrying out the responsibilities of a director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 115 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Audit committee members must also satisfy the
independence criteria set forth in Rule 10A-3 under the Exchange Act. In order to be considered independent for purposes of Rule 10A-3,
a member of an audit committee of a listed company may not, other than in his capacity as a member of the audit committee, the board of
directors or any other board committee: (i) accept, directly or indirectly, any consulting, advisory or other compensatory fee from the
listed company or any of its subsidiaries; or (ii) be an affiliated person of the listed company or any of its subsidiaries. We currently
satisfy the audit committee independence requirements of Rule 10A-3. Additionally, compensation committee members must not have a relationship
with us that is material to the director&#8217;s ability to be independent from management in connection with the duties of a compensation
committee member.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors has undertaken a review
of the independence of each director and considered whether each director has a material relationship with us that could compromise his
ability to exercise independent judgment in carrying out his responsibilities. As a result of this review, our board of directors determined
that all of our directors, except for Jeffrey Thramann, Brent Ness and David Neal are &#8220;independent directors&#8221; as defined under
the applicable rules and regulations of the Securities and Exchange Commission, or SEC, and the listing requirements and rules of Nasdaq.
In making these determinations, our board of directors reviewed and discussed information provided by the directors and us with regard
to each director&#8217;s business and personal activities and relationships as they may relate to us and our management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Committees of Our Board of Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Audit Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audit committee is comprised of Bill Wesemann,
Scott Breidbart and Steve Deitsch, with Steve Deitsch serving as its chairman The composition of our audit committee meets the requirements
for independence under the current Nasdaq and SEC rules and regulations. Each member of our audit committee is financially literate. In
addition, our board of directors has determined that Stephen Deitsch is an &#8220;audit committee financial expert&#8221; as defined in
Item 407(d)(5)(ii) of Regulation S-K promulgated under the Securities Act. This designation does not impose on Mr. Deitsch any duties,
obligations or liabilities that are greater than are generally imposed on members of our audit committee and our board of directors. Our
audit committee is directly responsible for, among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting and hiring our independent
        registered public accounting firm;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the qualifications, independence
        and performance of our registered public accounting firm;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the preparation of the audit committee
        report to be included in our annual proxy statement;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our compliance with legal and regulatory
        requirements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our accounting and financial reporting
        processes, including our financial statement audits and the integrity of our financial statements; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving related-person
        transactions.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compensation Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our compensation committee is comprised of Amanda
Williams, Scott Breidbart, and Bill Wesemann, with Mr. Wesemann serving as chairman. Each member of our compensation committee is a non-employee
director, as defined by Rule 16b-3 promulgated under the Exchange Act and meets the requirements for independence under the current Nasdaq
listing standards and SEC rules and regulations. Our compensation committee is responsible for, among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating, recommending, approving
        and reviewing executive officer compensation arrangements, plans, policies and programs;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating and recommending non-employee
        director compensation arrangements for determination by our board of directors;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">administering our cash-based and
        equity-based compensation plans; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing our compliance with regulatory
        requirements associated with the compensation of directors, officers and employees.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 116 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nominating and Governance Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our nominating and governance committee is comprised
of Bill Wesemann, Scott Breidbart, and Amanda Williams, with Amanda Williams serving as its chairman. Each member of our nominating and
governance committee meets the requirements for independence under the current Nasdaq listing standards. Our nominating and governance
committee is responsible for, among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying, considering and recommending
        candidates for membership on our board of directors;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing the process of evaluating
        the performance of our board of directors; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advising our board of directors
        on other corporate governance matters.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Consideration of Director Nominees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Director Qualifications</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no specific minimum qualifications that
the Board requires to be met by a director nominee recommended for a position on our board, nor are there any specific qualities or skills
that are necessary for one or more members of our board to possess, other than as are necessary to meet the requirements of the rules
and regulations applicable to us. The Nominating and Governance Committee considers a potential director candidate&#8217;s experience,
areas of expertise and other factors relative to the overall composition of our board and its committees, including the following characteristics:
experience, judgment, commitment (including having sufficient time to devote to the Company), skills, diversity, and expertise appropriate
for the Company. In assessing potential directors, the Nominating and Governance Committee may consider the current needs of the board
and the Company to maintain a balance of knowledge, experience and capability in various areas.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stockholder Nominations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with our bylaws, a stockholder wishing
to nominate a director for election at an annual meeting of stockholders must timely submit a written proposal of nomination to us at
our executive offices. To be timely, a written proposal of nomination for an annual meeting of stockholders must be received at least
90 calendar days but no more than 120 calendar days before the first anniversary of the date on which we held our annual meeting of stockholders
in the immediately preceding year;&#160;<i>provided</i>,&#160;<i>however</i>, that in the event that the date of the annual meeting is
advanced or delayed more than 30 calendar days from the anniversary of the annual meeting of stockholders in the immediately preceding
year, the written proposal must be received: (i) at least 90 calendar days but no more than 120 calendar days prior to the date of the
annual meeting; or (ii) no more than 10 days after the date we first publicly announce the date of the annual meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each written proposal for a nominee must contain:
(1) the name, age, business address and residence address of such nominee, (2) the principal occupation or employment of such nominee,
(3) the class and number of shares of each class of capital stock of the Company which are owned of record and beneficially by such nominee,
(4) the date or dates on which such shares were acquired and the investment intent of such acquisition, (5) a statement whether such nominee,
if elected, intends to tender, promptly following such person's failure to receive the required vote for election or reelection at the
next meeting at which such person would face election or re-election, an irrevocable resignation effective upon acceptance of such resignation
by the board, and (6) such other information concerning such nominee as would be required to be disclosed in a proxy statement soliciting
proxies for the election of such nominee as a director in an election contest (even if an election contest is not involved), or that is
otherwise required to be disclosed pursuant to Section 14 of the 1934 Act and the rules and regulations promulgated thereunder (including
such person&#8217;s written consent to being named as a nominee and to serving as a director if elected).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A stockholder interested in submitting a nominee
for election to the board should refer to our bylaws for additional requirements. Upon receipt of a written proposal of nomination meeting
these requirements, the Nominating and Governance Committee of the Board will evaluate the nominee in accordance with its charter and
the characteristics listed above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 117 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Evaluating Nominees for Director</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Nominating and Corporate Governance Committee
considers director candidates that are suggested by members of the committee, other members of our Board, members of management, advisors
and our stockholders who submit recommendations in accordance with the requirements set forth in our Bylaws, as described above. Our Board
has in the past engaged a third-party search firm to identify potential candidates for consideration by the Nominating and Governance
Committee and election to our Board. The Nominating and Corporate Governance Committee may, in the future, retain third-party search firms
to identify Board candidates on terms and conditions acceptable to the Nominating and Corporate Governance Committee to assist in the
process of identifying or evaluating director candidates. The Nominating and Corporate Governance Committee evaluates all nominees for
director using the same approach whether they are recommended by stockholders or other sources. The Nominating and Corporate Governance
Committee reviews candidates for director nominees in the context of the current composition of our Board and committees, the operating
requirements of the Company and the long-term interests of our stockholders. In conducting this assessment, the Nominating and Corporate
Governance Committee considers the director nominee&#8217;s qualifications, diversity, skills and such other factors as it deems appropriate
given the current needs of the Board, the committees and the Company, to maintain a balance of knowledge, experience, diversity and capability.
In the case of incumbent directors whose terms of office are set to expire, the Nominating and Corporate Governance Committee reviews
such directors&#8217; overall service to the Board, the committees and the Company during their term, including the number of meetings
attended, level of participation, quality of performance and any other relationships and transactions that might impair such directors&#8217;
independence. In the case of new director candidates, the Nominating and Corporate Governance Committee will also determine whether the
nominee must be independent for Nasdaq purposes, which determination will be based upon applicable Nasdaq listing standards and applicable
SEC rules and regulations. Although we do not have a formal diversity policy, when considering diversity in evaluating director nominees,
the Nominating and Corporate Governance Committee focuses on whether the nominees can contribute varied perspectives, skills, experiences
and expertise to the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Nominating and Corporate Governance Committee
will evaluate the proposed director&#8217;s candidacy, including proposed candidates recommended by stockholders, and recommend whether
the Board should nominate the proposed director candidate for election by our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Stockholder Communications with the Board</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any stockholder or interested party who desires
to contact our board, or specific members of our board, may do so electronically by sending an email to our CFO at the following address:
jlorbiecki@aclarion.com. Alternatively, a stockholder may contact our board, or specific members of our board, by writing to: Aclarion,
Inc., 8181 Arista Place, Suite 100, Broomfield, Colorado, 80021, Attn: CFO. All such communications will be initially received and processed
by the office of our CFO. Communications concerning accounting, audit, internal accounting controls and other financial matters will be
referred to the Chair of the Audit Committee. Other matters will be referred to the board, the non-employee directors or individual directors,
as appropriate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board has instructed the CFO to review all
communications so received and to exercise his discretion not to forward to the board correspondence that is inappropriate such as business
solicitations, frivolous communications and advertising, routine business matters and personal grievances. However, any director may at
any time request the CFO to forward any and all communications received by the CFO but not forwarded to the directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Compensation Committee Interlocks and Insider
Participation </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of the current members of our compensation
committee has ever been an executive officer or employee of ours. None of our executive officers currently serves, or has served during
the last completed fiscal year, on the compensation committee or board of directors of any other entity that has one or more executive
officers serving as a member of our board of directors or compensation committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 118 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Code of Business Conduct and Ethics</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors has adopted a code of business
conduct and ethics that applies to all of our employees, officers and directors, including our Chief Executive Officer and other executive
and senior officers. The full text of our code of business conduct and ethics is posted on the investor relations section of our website.
The reference to our website address in this prospectus does not include or incorporate by reference the information on our website into
this prospectus. We intend to disclose future amendments to certain provisions of our code of business conduct and ethics, or waivers
of these provisions, on our website or in public filings to the extent required by the applicable rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Number of Meetings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2023,
the board held a total of nine meetings. Our Audit Committee held seven meetings in 2023, our Compensation Committee held five meetings
in 2023, and our Nominating and Governance Committee held one meeting. Each director attended at least 75% of the aggregate of the total
number of meetings of the board and the board committees on which he or she served during 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Board Member Attendance at Annual Stockholder Meetings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we do not have a formal policy regarding
director attendance at annual stockholder meetings, directors are encouraged to attend these annual meetings absent extenuating circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Non-Employee Director Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our non-employee directors began serving on our
board following our April 2022 IPO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Executive Chairman, Dr. Thramann, and our
President and Chief Executive Officer, Mr. Ness, do not receive compensation for their services as a director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors approved the following
compensation for our non-employee directors in 2023. Our non-employee directors receive annual cash compensation of (i) $25,000 for service
on the board (ii) $15,000 for service as the Audit Committee chair, and (iii) $5,000 for service on each board committee. All cash payments
will be made quarterly in arrears, and pro-rated for any partial quarters of service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following Director Compensation Table summarizes
the compensation of each of our non-employee directors for services rendered to us during the year ended December 31, 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; width: 25%">
    <p style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Name </b></p></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fees
    Earned or Paid in Cash ($)</b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 14%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Stock Awards<br/>
    ($)</b></p></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 14%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Option Awards<br/>
    ($) </b></p></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 13%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All Other Compensation<br/>
($)</b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 11%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Total </b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>($)</b></p></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scott Breidbart</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve Deitsch</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45,000</span></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Neal</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">William Wesemann</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000</span></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amanda Williams</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,000</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 119 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Executive Compensation Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As an &#8220;emerging growth company,&#8221; we
have opted to comply with the executive compensation disclosure rules applicable to &#8220;smaller reporting companies,&#8221; as such
term is defined in the rules promulgated under the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This section provides an overview of the compensation
awarded to, earned by, or paid to each individual who served as our principal executive officer during our fiscal year 2023, and
our next three most highly compensated executive officers in respect of their service to our company for fiscal year 2023. Our named
executive officers, or the Named Executive Officers, for the year ended December&#160;31, 2023, are:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey Thramann,
        Executive Chairman; </span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brent Ness,
        Chief Executive Officer; </span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Lorbiecki,
        Chief Financial Officer; and</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ryan Bond,
        Chief Strategy Officer.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Summary Compensation Table Year Ended December
31, 2023</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table contains information about
the compensation paid to or earned by each of our Named Executive Officers during the two most recently completed fiscal years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    and Principal Position</b></span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary<br/>
    ($)</b></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Bonus<br/>
    ($)(1)(2)<sup></sup></b></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Stock</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Awards</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>($)</b></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Option</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Awards<br/>
($)(3)</b></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>All Other Compensation</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>($)</b></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total<br/>
    ($)</b></span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom; width: 33%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeff
    Thramann, Executive Director</span></td>
    <td style="vertical-align: bottom; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">300,000</span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 11%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">300,000</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">300,000</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,750</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">252,369</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">571,119</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brent Ness, Chief
    Executive Officer</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">300,000</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#8211;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">300,000</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">300,000</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118,750<sup>(4)</sup></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90,704</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">509,454</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ryan Bond, Chief
    Strategy Officer</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,000</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,000</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,000</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,532<sup>(5)</sup></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">219,532</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Lorbiecki, Chief
    Financial Officer</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">225,000</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">225,000</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">225,000</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89,871<sup>(6)</sup></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,747</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">334,618</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">____________________</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-size: 10pt">(1)</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-size: 10pt">The Company has a discretionary annual cash bonus program.
    The Company has not yet determined and approved annual cash bonuses for the year 2023.</span>
    </td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Except for the amounts described below in notes
    4, 5, and 6, the 2022 bonus amounts reflect cash bonus amounts earned in the 2022 year (as determined and approved by our compensation
    committee in March 2023) but which amounts have not been paid to date. Such bonus amounts will not be paid until the Company has
    additional funding and cash liquidity.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Represents the grant date fair value of stock option awards computed in accordance with FASB ASC Topic 718, excluding the effect of estimated forfeitures. For information regarding assumptions underlying the valuation of equity awards, see Note 15 to our financial statements in the Annual Report on Form 10-K/A filed June 12, 2023.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Under the terms of his employment agreement, Mr. Ness received a bonus payment of $100,000 upon the IPO completed in April 2022.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Company implemented a cash bonus plan related to the temporary
    deferral of all employees&#8217; base salaries by 50% effective as of October 16, 2020. Under this program, $8,594 was paid to Mr.
    Bond</span> <span style="font-size: 10pt">in 2022.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Under the terms of his employment agreement, Mr. Lorbiecki received a bonus payment of $28,125 upon the IPO completed in April 2022.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 120 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employment Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Dr. Jeff Thramann</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 15, 2021, we entered into an employment agreement with Dr.
Jeff Thramann. The employment agreement was retroactively made effective to March 1, 2021. The employment agreement provides that Dr.
Thramann will:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.25pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receive a salary of $25,000 per
        month.;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Be appointed as Executive Director
        (an executive officer position with the Company), as an &#8220;at will&#8221; employee, until the date of the IPO, at which time he transitioned
        from Executive Director to Executive Chairman, an executive officer of the Company.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.25pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Be issued
    options (the &#8220;Thramann Options&#8221;) to purchase 1,204,820 shares (75,302 shares after
    our January 3, 2024 &#160;reverse stock split) of common stock (the &#8220;Thramann Option Shares&#8221;) of the Company
    subject to the terms and conditions set forth in the Company&#8217;s equity incentive plan, at an exercise price of $1.94 ($31.04
    after our January 3, 2024 reverse stock split) per share. The options have a 10-year term. The vesting of the Thramann
    Options occurred on the date of the IPO, April 21, 2022.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.25pt"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Brent Ness</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 15, 2021, we entered into an Employment
Agreement with Brent Ness. The employment agreement provides that Mr. Ness would:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Be appointed Chief Executive Officer
        of the Company.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receive an annual base salary of
        $300,000, plus an additional $100,000 if the Company completes an initial public offering and its securities are listed for trading on
        Nasdaq or the NYSE.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing in 2022, Mr. Ness will
        be eligible to receive, upon certain conditions, an annual incentive bonus up to 50% of Mr. Ness&#8217; base salary</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Ness&#8217; employment agreement
        is terminable &#8216;at will&#8217; by the Company. If the Company terminates Mr. Ness&#8217; employment without cause or Mr. Ness terminates
        for good reason, he is entitled to receive twelve months of base salary, (ii) up to nine months of paid health insurance under COBRA,
        and (iii) any earned but unpaid bonus for a prior completed fiscal year. </span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Be
    issued options to purchase 341,365 shares (21,337 shares after our January 3, 2024 reverse stock split) of common stock of the
    Company, subject to the terms and conditions set forth in the Company&#8217;s equity incentive plan, at an exercise price of $1.94
    ($31.04 after our January 3, 2024  &#160;reverse stock split) per share. The stock options have a 10-year term. The stock
    options will vest in 48 equal installments on each monthly anniversary of the date of grant, such that the grant will become fully
    vested and exercisable on the four-year anniversary of the date of grant.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>John Lorbiecki </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 22, 2021, we entered into an Employment
Agreement with John Lorbiecki. The employment agreement provides that Mr. Lorbiecki would:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Be appointed Chief Financial Officer
        of the Company as an &#8220;at will&#8221; employee.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receive an annual base salary of
        $225,000.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing in 2022, Mr. Lorbiecki
        will be eligible to receive, upon certain conditions, an annual incentive bonus up to 50% of Mr. Lorbiecki&#8217;s base salary.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p>

<!-- Field: Page; Sequence: 121 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Lorbiecki&#8217;s employment
        agreement is terminable &#8216;at will&#8217; by the Company. If the Company terminates Mr. Lorbiecki&#8217;s employment without cause
        or Mr. Lorbiecki terminates for good reason, he is entitled to receive twelve months of base salary, (ii) up to nine months of paid health
        insurance under COBRA, and (iii) any earned but unpaid bonus for a prior completed fiscal year. </span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Be issued
    options to purchase 66,934 shares (4,185 shares after our January 3, 2024 reverse stock
    split) of common stock of the Company subject to the terms and conditions set forth in the Company&#8217;s equity incentive
    plan, at an exercise price of $1.94 ($31.04 after our January 3, 2024 reverse stock
    split) per share. The stock options have a 10-year term. The stock options will vest in 48 equal installments on each monthly
    anniversary of the date of grant, such that the grant will become fully vested and exercisable on the four-year anniversary of the
    date of grant.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Outstanding Equity Awards at December 31, 2023</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information regarding
equity awards held by our Named Executive Officers as of December 31, 2023. Information in this table
has been adjusted for our January 3, 2024 reverse stock split.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center">&#160;</td>
    <td colspan="13" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option Awards</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center">&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Awards</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares or</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value of</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underlying</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underlying</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Units of</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares or</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unexercised</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unexercised</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock That</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Units That</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Have Not</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Have Not</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grant</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(#)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(#)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Vested</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Vested</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unexercisable</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(#)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Jeffrey Thramann</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/27/2021</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75,302</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$31.04</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/27/2031</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/14/2022</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,581</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$31.04</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/14/2032</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brent Ness</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/27/2021</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,002</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,335</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$31.04</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/27/2031</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/14/2022</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,658</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,067</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$31.04</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/14/2032</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ryan Bond</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/19/2019</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,339</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$21.44</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/19/2029</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/4/2021</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">382</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$31.04</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/4/2031</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Lorbiecki</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/27/2021</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,267</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,918</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$31.04</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/27/2031</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/14/2022</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">558</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">472</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$31.04</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/14/2032</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 122 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><span style="text-transform: uppercase"><b><span id="s_014"></span>Certain
Relationships and Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the executive officer and director
compensation arrangements discussed above, below we describe transactions since January 1, 2019 to which we have been or will be a participant,
in which the amount involved in the transaction exceeds or will exceed $120,000 and in which any of our directors, executive officers
or beneficial holders of more than 5% of any class of our capital stock, or 5% security holders, or any immediate family member of, or
person sharing the household with, any of these individuals, had or will have a direct or indirect material interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Commencing January 2020 and through the date of
the filing of this annual report, we paid a total of $125,324 to the Regents of the University of California pursuant to our License Agreement
with them Professor Jeffrey Lotz, PhD. who was a director of the Company prior to our IPO is a Director of the Company, is the Vice Chair
of Orthopedic Research at UCSF. Dr. Lotz continues to serve as a member of our Scientific Advisory Board. We will continue to make payments
to&#160;the Regents of the University of California&#160;for the duration of our License Agreement with UCSF (See &#8220;Business- License
Agreement with the Regents of the University of California&#8221; above).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into a number of investment and
commercial transactions with Nuvasive. See &#8220;Business &#8211; Transactions with Nuvasive.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since January 2019, SC Capital 1 LLC and Clark
Gunderson, M.D. have invested in (i) our Series B-1 preferred stock financing and (ii) our 6% convertible preferred note financing. Such
investments were made on the same terms offered to other investors. David Neal, one of our directors, is the founder and a current member
of SC Capital 1, LLC. Until December 2022, SC Capital 1 LLC owned more than 10% of our outstanding common shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 16, 2023, we entered into a securities
purchase agreement with Jeffrey Thramann, our Executive Chairman pursuant to which we issued and sold one (1) share of the Company&#8217;s
newly designated Series A Preferred Stock for an aggregate purchase price of $1,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The share of Series A Preferred Stock will have
15,000,000 votes and will vote together with the outstanding shares of the Company&#8217;s common stock as a single class exclusively
with respect to any proposal to amend the Company&#8217;s Certificate of Incorporation to effect a reverse stock split of the Company&#8217;s
common stock. The share of Series A Preferred Stock will be voted, without action by the holder, on any such reverse stock split proposal
in the same proportion as shares of common stock are voted on such proposal (excluding any common shares that are not voted).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series A Preferred Stock otherwise has no
voting rights, except as may otherwise be required by the General Corporation Law of the State of Delaware. The share of Series A Preferred
Stock is not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. The
share of Series A Preferred Stock has no rights with respect to any distribution of assets of the Company, including upon a liquidation,
bankruptcy, reorganization, merger, acquisition, sale, dissolution or winding up of the Company, whether voluntarily or involuntarily.
The holder of the Share of Series A Preferred Stock will not be entitled to receive dividends of any kind. The share of Series A Preferred
Stock shall be redeemed in whole, but not in part, at any time (i) if such redemption is ordered by our board in its sole discretion or
(ii) automatically upon the effectiveness of the amendment to the Certificate of Incorporation implementing a reverse stock split. Upon
such redemption, the holder of the Series A Preferred Stock will receive consideration of $1,000.00 in cash. We redeemed the one outstanding
share of Series A preferred stock on March 28, 2023.<b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Policy for Approval of Related-Person Transactions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have adopted a related-person transaction policy
that requires audit committee review and approval of any transaction, arrangement or relationship in which we are a participant and one
of our executive officers, directors, director nominees or each person whom we know to beneficially own more than 5% of our outstanding
common stock (a &#8220;5% stockholder&#8221;) (or their immediate family members), each of whom we refer to as a &#8220;related person,&#8221;
has a direct or indirect material interest.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 123 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><span style="text-transform: uppercase"><b><span id="s_015"></span>Principal
Stockholders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><span style="text-transform: uppercase"></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The
                                            following table sets forth information regarding the beneficial ownership of our common stock
                                            as of October 2, 2024 by (i) each person who beneficially owned more than 5% of our
                                            outstanding shares of common stock, (ii) each director, (iii) each Named Executive Officer
                                            and (iv) all of our directors and executive officers as a group. Unless otherwise indicated,
                                            the address of each executive officer and director is c/o listed below is c/o Aclarion, Inc.,
                                            8181 Arista Place, Suite 100, Broomfield, Colorado 80021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares of common stock &#8220;beneficially
owned&#8221; by each stockholder is determined under rules issued by the SEC regarding the beneficial ownership of securities. This information
is not necessarily indicative of beneficial ownership for any other purpose. Under these rules, beneficial ownership of shares of our
common stock includes (1) any shares as to which the person or entity has sole or shared voting power or investment power, and (2) any
shares as to which the person or entity has the right to acquire beneficial ownership within 60 days after October 2, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The calculations set forth below are based upon
10,044,728 shares of common stock outstanding at October 2, 2024. Unless otherwise indicated below, and subject to community
property laws where applicable, to our knowledge, all persons named in the table have sole voting and investment power with respect to
their shares of common stock. The After Offering column below has been calculated assuming that we will offer and sell 1,450,000 shares
of common stock pursuant to the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Prior to Offering</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">After Offering</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Name of Beneficial Owner</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Amount and</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Nature of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Beneficial</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Ownership</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Approximate</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Percentage</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of Outstanding</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Shares of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Common Stock</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Amount and</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Nature of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Beneficial</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Ownership</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Approximate Percentage</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of Outstanding Shares of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Common Stock</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold">5% Stockholders:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>None</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Executive Officers and Directors:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 44%; text-align: left">Jeff Thramann (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">86,882</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">86,882</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Brent Ness (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,517</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,517</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">John Lorbiecki (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,526</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,526</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Ryan Bond (4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,284</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,284</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">David Neal (5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,201</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,201</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">William Wesemann (6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,793</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,793</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Amanda Williams (7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,391</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,391</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stephen Deitsch (7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,391</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,391</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Scott Breidbart (7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,391</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,391</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">All directors and executive officers as a group (9 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">155,376</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.7%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">155,376</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.3%</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">________________________</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">*</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td>
    <td style="width: 97%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Represents beneficial ownership of less
    than 1%.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Represents outstanding stock options held
    by Dr. Thramann.</p></td></tr>

<tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Ness&#8217; beneficial ownership includes 1,281 common shares, 21,173 vested options, and 63 IPO Warrants, and excludes 4,886 unvested options.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Lorbiecki&#8217;s beneficial
    ownership includes 1,400 common shares and 4,126 vested options, and excludes 1,086 unvested options.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Bond&#8217;s beneficial ownership includes 1,250 common shares, 1,721 vested options, and 1,313 IPO Warrants.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr, Neal&#8217;s beneficial ownership includes 11,658 common shares, 2,150 IPO Warrants, and 4,393 vested options.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Wesemann&#8217;s beneficial
    ownership includes 3,296 common shares, 3,809 vested stock options, and 688 IPO Warrants, and excludes 756 unvested
    stock options.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 3,391 vested
    stock options and excludes 547 unvested stock options.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 124 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="s_016"></span>DESCRIPTION OF CAPITAL STOCK</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The following description is intended as a
summary of our certificate of incorporation (which we refer to as our &#8220;charter&#8221;) and our bylaws, each of which is filed as
an exhibit to the registration statement of which this prospectus forms a part, and to the applicable provisions of the Delaware General
Corporation Law. Because the following is only a summary, it does not contain all of the information that may be important to you. For
a complete description, you should refer to our charter and bylaws.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have two classes of securities registered under
Section 12 of the Exchange Act. Our shares of common stock are listed on The Nasdaq Stock Market under the trading symbol &#8220;ACON.&#8221;
Our IPO Warrants are listed on the Nasdaq Stock Market under the trading symbol &#8220;ACONW.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Authorized Capital Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized capital stock consists of 200,000,000
shares of common stock, par value $0.00001 per share, and 20,000,000 shares of preferred stock, par value $0.00001 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of our common stock are entitled to
one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative
voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds
legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has
no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of our liquidation, dissolution or
winding up, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all debts and other
liabilities and any liquidation preference of any outstanding preferred stock. Each outstanding share of common stock is duly and validly
issued, fully paid and non-assessable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board will have the authority, without further
action by our stockholders, to issue up to 20,000,000 shares of preferred stock in one or more series and to fix the rights, preferences,
privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting
rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of,
such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect
the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our
liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control
of our company or other corporate action.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We issued 930 shares of newly issued Series
B convertible preferred stock on August 14, 2024. The Series B Preferred Stock is convertible into common stock at an initial conversion
price of $0.234 per share of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We issued 1,000 shares of newly issued Series
C convertible preferred stock on September 30, 2024. The Series C Preferred Stock is convertible into common stock at an initial conversion
price of $0.1759 per share of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Anti-Takeover Effects of Delaware Law and Provisions
of Our Charter and Our Bylaws</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain provisions of the DGCL and of our charter
and our bylaws could have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons
considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue
non-negotiated takeover attempts. These provisions include the items described below.</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 125 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Delaware Anti-Takeover
Statute</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We are subject to the provisions
of Section 203 of the DGCL. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business
combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes
an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section 203, a business combination
between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">before the
    stockholder became interested, our Board approved either the business combination or the transaction which resulted in the stockholder
    becoming an interested stockholder;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon consummation of the
    transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of
    the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the
    voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances,
    but not the outstanding voting stock owned by the interested stockholder; or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at or after the time the
    stockholder became interested, the business combination was approved by our Board and authorized at an annual or special meeting
    of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested
    stockholder.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Section 203 defines a business
combination to include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any merger
    or consolidation involving the corporation and the interested stockholder;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any sale, transfer, lease,
    pledge, exchange, mortgage or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to exceptions,
    any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;
    or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the receipt by the interested
    stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In general, Section 203
defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation
and any entity or person affiliated with or controlling or controlled by the entity or person.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Board Composition and
Filling Vacancies</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Our charter provides that
stockholders may remove directors only for cause and only by the affirmative vote of the holders of at least two-thirds of our outstanding
common stock. Our charter and bylaws authorize only our board of directors to fill vacant directorships, including newly created seats.
In addition, the number of directors constituting our board of directors may only be set by a resolution adopted by a majority vote of
our entire board of directors. These provisions would prevent a stockholder from increasing the size of our board of directors and then
gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more difficult to change
the composition of our board of directors but promotes continuity of management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 126 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>No Written Consent of
Stockholders</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Our charter and bylaws provide
that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting, and that stockholders
may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder
actions and would prevent the amendment of our bylaws or removal of directors by our stockholders without holding a meeting of stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Meetings of Stockholders</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Our charter and bylaws provide
that only a majority of the members of our Board then in office, our Executive Chairman or our Chief Executive Officer may call special
meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special
meeting of stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Advance Notice Requirements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Our bylaws provide advance
notice procedures for stockholders seeking to bring matters before our annual meeting of stockholders or to nominate candidates for election
as directors at our annual meeting of stockholders. Our bylaws also specify certain requirements regarding the form and content of a
stockholder&#8217;s notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders
or from making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that
these provisions might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s
own slate of directors or otherwise attempting to obtain control of our company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Amendment to Our Charter
and Bylaws</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The DGCL, provides, generally,
that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#8217;s certificate
of incorporation or bylaws, unless a corporation&#8217;s certificate of incorporation or bylaws, as the case may be, requires a greater
percentage. Our bylaws may be amended or repealed by a majority vote of our board of directors or the affirmative vote of the holders
of at least two-thirds of the votes that all our stockholders would be entitled to cast in an annual election of directors. In addition,
the affirmative vote of the holders of at least two-thirds of the votes that all our stockholders would be entitled to cast in an election
of directors is required to amend or repeal or to adopt certain provisions of our charter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Undesignated Preferred
Stock</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Our charter provides for
20,000,000 authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board
to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the
due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests
of our stockholders, our board could cause shares of convertible preferred stock to be issued without stockholder approval in one or
more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder
or stockholder group. In this regard, our charter grants our board broad power to establish the rights and preferences of authorized
and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available
for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting
rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 127 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Choice of Forum</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Our charter provides that
the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings: any derivative
action or proceeding brought on behalf of the Company, any action asserting a claim of breach of a fiduciary duty owed by any director,
officer or other employee of the Company to the Company or the Company&#8217;s stockholders, any action asserting a claim against the
Company arising pursuant to any provision of the DGCL or the Company&#8217;s certificate of incorporation or bylaws, or any action asserting
a claim against the Company governed by the internal affairs doctrine. Our charter also provides that unless the Company consents in
writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the exclusive
forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Despite the fact that the certificate
of incorporation provides for this exclusive forum provision to be applicable to the fullest extent permitted by applicable law, Section
27 of the Exchange Act, creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the
Exchange Act or the rules and regulations thereunder and Section 22 of the Securities Act, creates concurrent jurisdiction for federal
and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.
As a result, this provision of the Company&#8217;s certificate of incorporation would not apply to claims brought to enforce a duty or
liability created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction. However, there is
uncertainty as to whether a Delaware court would enforce the exclusive federal forum provisions for Securities Act claims and that investors
cannot waive compliance with the federal securities laws and rules and regulations thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Unless the Company consents
in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the exclusive
forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Nasdaq-Listed IPO Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Each IPO Warrant represents
the right to purchase one share of common stock at an exercise price of $4.35 (pre-split),
or $69.60 (after giving effect to our January 3, 2024 reverse stock split). The IPO Warrants are exercisable
beginning April 21, 2022, will terminate on the 5th anniversary date the IPO Warrants are first exercisable. The exercise price and number
of shares for which each IPO Warrant may be exercised is subject to adjustment in the event of stock dividends, stock splits, reorganizations
or similar events affecting our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Holders of the IPO Warrants
may exercise their IPO Warrants to purchase shares of our common stock on or before the termination date by delivering an exercise notice,
appropriately completed and duly signed. Payment of the exercise price for the number of shares for which the IPO Warrants is being exercised
must be made within two trading days following such exercise. In the event that the registration statement relating to the IPO Warrant
shares (the &#8220;IPO Warrant Shares&#8221;) is not effective, a holder of IPO Warrants may only exercise its IPO Warrants for a net
number of IPO Warrant Shares pursuant to the cashless exercise procedures specified in the IPO Warrants. IPO Warrants may be exercised
in whole or in part, and any portion of an IPO Warrant not exercised prior to the termination date shall be and become void and of no
value. The absence of an effective registration statement or applicable exemption from registration does not alleviate our obligation
to deliver common stock issuable upon exercise of an IPO Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Upon the holder&#8217;s
exercise of an IPO Warrant, we will issue the shares of common stock issuable upon exercise of the IPO Warrant within three trading days
of our receipt of notice of exercise, subject to timely payment of the aggregate exercise price therefor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The shares of common stock
issuable on exercise of the IPO Warrants will be, when issued in accordance with the IPO Warrants, duly and validly authorized, issued
and fully paid and non-assessable. We will authorize and reserve at least that number of shares of common stock equal to the number of
shares of common stock issuable upon exercise of all outstanding warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">If, at any time an IPO Warrant
is outstanding, we consummate any fundamental transaction, as described in the IPO Warrants and generally including any consolidation
or merger into another corporation, the consummation of a transaction whereby another entity acquires more than 50% of our outstanding
common stock, or the sale of all or substantially all of our assets, or other transaction in which our common stock is converted into
or exchanged for other securities or other consideration, the holder of any IPO Warrants will thereafter receive upon exercise of the
IPO Warrants, the securities or other consideration to which a holder of the number of shares of common stock then deliverable upon the
exercise or conversion of such IPO Warrants would have been entitled upon such consolidation or merger or other transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 128 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The IPO Warrants are not
exercisable by their holder to the extent (but only to the extent) that such holder or any of its affiliates would beneficially own in
excess of 4.99% of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Amendments and waivers of
the terms of the IPO Warrants require the written consent of the holder of such IPO Warrants and us. The IPO Warrants were issued in
book-entry form under a warrant agent agreement between V-Stock Transfer Company, Inc. as warrant agent, and us, and shall initially
be represented by one or more book-entry certificates deposited with The Depository Trust Company, or DTC, and registered in the name
of Cede &amp; Co., a nominee of DTC, or as otherwise directed by DTC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">You should review a copy
of the warrant agent agreement and the form of the IPO Warrants, each of which are included as exhibits to the registration statement
of which this prospectus is a part.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Transfer Agent, Registrar,
Warrant Agent</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The transfer agent and
registrar for our common stock and the warrant agent for our IPO Warrants is VStock Transfer LLC, 18 Lafayette Place, Woodmere, NY 11598.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of October 2, 2024, there were 10,044,728
shares of our common stock outstanding, and approximately 145 stockholders of record. 1,930 shares of our preferred stock are outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other Outstanding Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of October
2, 2024, after giving effect to our January 3, 2024 reverse stock split, we had 16,597,689 other outstanding common stock warrants (in
addition to our IPO Warrants described above). The terms of these warrants are (i) 123,566 warrants with a per share exercise price of
$0.29 and expiring 2028,   (ii) 26,673 warrants with a per share exercise price of $69.60 and expiring 2027, (iii) 1,576 warrants
with a per share exercise price of $0.0002 and expiring 2028, (iv) 400,000 warrants with a per share exercise price of $0.1759 and expiring
2029, (v) 10,350,000 warrants issued as part of a February 2024 public offering, with a per share exercise price of $0.58 and expiring
2029, and (vi) 5,685,049 warrants issued as part of a September 2024 private placement, with a per share exercise price of $0.1759 and
expiring 2030.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The per share exercise price of the warrants described
in clause (i) and (ii) above is subject to a &#8220;full ratchet&#8221; adjustment if the Company issues securities at an effective per
share price lower than the then effective warrant exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These warrants have a net exercise provision under
which its holder may, in lieu of payment of the exercise price in cash, surrender the warrant and receive a net amount of shares based
on the fair market value of the underlying shares at the time of exercise of the warrant after deduction of a number of shares equal in
value to the aggregate exercise price. The warrants contain provisions for the adjustment of the exercise price and the number of shares
issuable upon the exercise of the warrant in the event of certain stock dividends, stock splits, reorganizations, reclassifications and
consolidations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with our April 2022 IPO, we issued
a warrant (the &#8220;IPO Representative&#8217;s Warrant&#8221;), which enables our IPO underwriter to purchase up to an aggregate of
10,825 post-split shares of Common Stock, at an exercise price equal to $87.04 per share. The IPO Representative&#8217;s Warrant may be
exercised beginning on October 26, 2022 until April 26, 2027.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 129 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="s_017"></span>SELLING SECURITYHOLDER</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">White Lion (as a Selling Securityholder) may from
time to time offer and sell any or all of the shares of common stock that may be issued by us to White Lion under the Purchase Agreement.
We are registering the shares of common stock pursuant to the provisions of the White Lion RRA in order to permit White Lion to offer
the shares for resale from time to time. Except for the transactions contemplated by the Purchase Agreement and the White Lion RRA, White
Lion has not had any material relationship with us within the past three years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below presents information regarding
White Lion (as a Selling Securityholder) and the shares of common stock that it may offer from time to time under this prospectus. This
table is prepared based on information supplied to us by White Lion, and reflects holdings as of October 2, 2024. The number of
shares in the column &#8220;Maximum Number of Shares of Common Stock to be Offered Pursuant to this Prospectus&#8221; represents all
of the shares of Common Stock that White Lion may offer under this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beneficial ownership is determined in accordance
with Rule 13d-3(d) promulgated by the SEC under the Exchange Act, and includes shares of common stock with respect to which the Selling
Securityholder has voting and investment power. The percentage of shares of common stock beneficially owned by the Selling Securityholder
prior to the offering shown in the table below is based on an aggregate of 10,044,728 shares of our common stock outstanding on
October 2, 2024. Because the purchase price of the shares of common stock issuable under the Purchase Agreement is determined
on the date of each purchase, the number of shares that may actually be sold by the Company under the Purchase Agreement may be fewer
than the number of shares being offered by this prospectus. The fourth column assumes the sale of all of the shares offered by the Selling
Securityholder pursuant to this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><b>Name of Selling Securityholder</b></span></td>
    <td>&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Number of Shares of<br/>
Common Stock<br/>
Owned Prior to<br/>
Offering</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Maximum Number of Shares of Common Stock<br/>
to be Offered Pursuant to<br/>
this Prospectus</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Number of Shares of<br/>
Common Stock<br/>
Owned After Offering</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Number<sup>(1)</sup></b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Percent<sup>(2)</sup></b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Number<sup>(3)</sup></b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Percent<sup>(2)</sup></b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 32%"><span style="font-size: 10pt">White Lion Capital, LLC<sup>(4)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center"><span style="font-size: 10pt">0</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center">1,450<span style="font-size: 10pt">,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center"><span style="font-size: 10pt">0</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center"><span style="font-size: 10pt">*</span></td>
    <td style="width: 1%">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%"><span style="font-size: 10pt">*</span></td>
    <td style="width: 95%; text-align: justify"><span style="font-size: 10pt">Represents beneficial ownership of less than 1% of the outstanding shares of our common stock.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">In accordance with Rule&#160;13d-3(d)&#160;under the Exchange Act, we have excluded from the number of shares beneficially owned prior to the offering all of the shares that White Lion may be required to purchase under the Purchase Agreement, because the issuance of such shares is solely at our discretion and is subject to conditions contained in the Purchase Agreement, the satisfaction of which are entirely outside of White Lion&#8217;s control, including the registration statement that includes this prospectus becoming and remaining effective. Furthermore, the purchase of common stock is subject to certain agreed upon maximum amount limitations set forth in the Purchase Agreement. Also, the Purchase Agreement prohibits us from issuing and selling any shares of our common stock to White Lion to the extent such shares, when aggregated with all other shares of our common stock then beneficially owned by White Lion, would cause White Lion&#8217;s beneficial ownership of our common stock to exceed 9.99% (the &#8220;Beneficial Ownership Cap&#8221;). The Beneficial Ownership Cap (to the extent applicable under Nasdaq rules) may not be amended or waived under the Purchase Agreement.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Applicable percentage ownership is based on 10,044,728 shares
    of our common stock outstanding as of October 2, 2024.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Assumes the sale of all shares being offered pursuant to this prospectus.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The business address of White Lion Capital, LLC (&#8220;WLC&#8221;), is 17631 Ventura Blvd., Suite 1008, Encino, CA 91316. WLC&#8217;s principal business is that of a private investor. Dmitriy Slobodskiy Jr., Yash Thukral, Sam Yaffa, and Nathan Yee are the managing principals of WLC. Therefore, each of Slobodskiy Jr., Thukral, Yaffa, and Yee may be deemed to have sole voting control and investment discretion over securities beneficially owned directly by WLC and, indirectly, by WLC. We have been advised that WLC is not a member of the Financial Industry Regulatory Authority or an independent broker-dealer. The foregoing should not be construed in and of itself as an admission by Slobodskiy Jr., Thukral, Yaffa, and Yee as to beneficial ownership of the securities beneficially owned directly by WLC and, indirectly, by WLC.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 130 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="s_018"></span>PLAN OF DISTRIBUTION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 1,450,000 shares of common stock being registered
by this prospectus are being offered by White Lion. The shares may be sold or distributed from time to time by White Lion directly to
one or more purchasers or through brokers, dealers, or underwriters who may act solely as agents at market prices prevailing at the time
of sale, at prices related to the prevailing market prices, at negotiated prices, or at fixed prices, which may be changed. The sale of
the shares of our common stock offered by this prospectus could be effected in one or more of the following methods:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 5%; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; width: 93%; text-align: justify"><span style="font-size: 10pt">ordinary brokers&#8217; transactions;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">transactions involving cross or block trades;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">through brokers, dealers, or underwriters who may act solely as agents;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#8220;at the market&#8221; into an existing market for our common stock;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">in other ways not involving market makers or established business markets, including direct sales to purchasers or sales effected through agents;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">in privately negotiated transactions; or</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">any combination of the foregoing.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to comply with the securities laws of
certain states, if applicable, the shares of common stock may be sold only through registered or licensed brokers or dealers. In addition,
in certain states, the shares may not be sold unless they have been registered or qualified for sale in the state or an exemption from
the state&#8217;s registration or qualification requirement is available and complied with.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">White Lion is an &#8220;underwriter&#8221; within
the meaning of Section&#160;2(a)(11) of the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">White Lion has informed us that it intends to
use one or more registered broker-dealers to effectuate all sales, if any, of our common stock that it has acquired and may in the future
acquire from us pursuant to the Purchase Agreement. Such sales will be made at prices and at terms then prevailing or at prices related
to the then current market price. Each such registered broker-dealer will be an underwriter within the meaning of Section&#160;2(a)(11)
of the Securities Act. White Lion has informed us that each such broker-dealer will receive commissions from White Lion that will not
exceed customary brokerage commissions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Brokers, dealers, underwriters or agents participating
in the distribution of the shares of our common stock offered by this prospectus may receive compensation in the form of commissions,
discounts, or concessions from the purchasers, for whom the broker-dealers may act as agent, of the shares sold by White Lion through
this prospectus. The compensation paid to any such particular broker-dealer by any such purchasers of shares of our common stock sold
by White Lion may be less than or in excess of customary commissions. Neither we nor White Lion can presently estimate the amount of compensation
that any agent will receive from any purchasers of shares of our common stock sold by White Lion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We know of no existing arrangements between White
Lion or any other stockholder, broker, dealer, underwriter or agent relating to the sale or distribution of the shares of our common stock
offered by this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may from time to time file with the SEC one
or more supplements to this prospectus or amendments to the registration statement of which this prospectus forms a part to amend, supplement
or update information contained in this prospectus, including, if and when required under the Securities Act, to disclose certain information
relating to a particular sale of shares offered by this prospectus by the Selling Securityholder, including the names of any brokers,
dealers, underwriters or agents participating in the distribution of such shares by White Lion, any compensation paid by White Lion to
any such brokers, dealers, underwriters or agents, and any other required information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 131 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will pay the expenses incident to the registration
under the Securities Act of the offer and sale of the shares of our common stock covered by this prospectus by White Lion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also have agreed to indemnify White Lion against
certain liabilities in connection with the offering of shares of our common stock offered hereby, including liabilities arising under
the Securities Act or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. White
Lion has agreed to indemnify us against liabilities under the Securities Act that may arise from certain written information furnished
to us by White Lion specifically for use in this prospectus or, if such indemnity is unavailable, to contribute amounts required to be
paid in respect of such liabilities. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our
directors, officers, and controlling persons, we have been advised that in the opinion of the SEC this indemnification is against public
policy as expressed in the Securities Act and is therefore, unenforceable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate that the total expenses for the offering
will be approximately $65,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">White Lion has represented to us that at no time
prior to the date of the Purchase Agreement has White Lion or its agents, representatives or affiliates engaged in or effected, in any
manner whatsoever, directly or indirectly, any short sale (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act)
of our common stock, which establishes a net short position with respect to our common stock. White Lion has agreed that during the term
of the Purchase Agreement, neither White Lion, nor any of its agents, representatives or affiliates will enter into or effect, directly
or indirectly, any of the foregoing transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have advised White Lion that it is required
to comply with Regulation M promulgated under the Exchange Act. With certain exceptions, Regulation M precludes White Lion, any affiliated
purchasers, and any broker-dealer or other person who participates in the distribution from bidding for or purchasing, or attempting to
induce any person to bid for or purchase any security which is the subject of the distribution until the entire distribution is complete.
Regulation M also prohibits any bids or purchases made in order to stabilize the price of a security in connection with the distribution
of that security. All of the foregoing may affect the marketability of the securities offered by this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This offering will terminate on the date that
all shares of our common stock offered by this prospectus have been sold by White Lion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed on the Nasdaq Capital
Market under the symbol &#8220;ACON&#8221;, and our IPO Warrants offered in connection with our initial public offering are quoted on
the Nasdaq Capital Market under the symbol &#8220;ACONW.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 132 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b><span id="s_019"></span>LEGAL MATTERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Carroll Legal LLC, Denver, CO will pass upon the
validity of the shares of common stock offered hereby.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b><span id="s_020"></span>EXPERTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Haynie &amp; Company,
independent registered public accounting firm, has audited the financial statements of the Company as of December 31, 2023 and for the
year ended December 31, 2023, as set forth in their report included herein. The report of Haynie &amp; Company contains an explanatory
paragraph about the ability of the Company to continue as a going concern. The 2023 financial statements of the Company are included in
this prospectus and elsewhere in this registration statement in reliance of Haynie &amp; Company&#8217;s report, given on their authority
as experts in accounting and auditing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CohnReznick LLP, independent registered public accounting firm, has
audited the restated financial statements of the Company as of December 31, 2022 and for the year ended December 31, 2022, as set forth
in their report included herein. The report of CohnReznick LLP contains an explanatory paragraph about the ability of the Company to continue
as a going concern. The restated 2022 financial statements of the Company are included in this prospectus and elsewhere in this registration
statement in reliance of CohnReznick LLP&#8217;s report, given on their authority as experts in accounting and auditing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b><span id="s_021"></span>WHERE YOU CAN FIND MORE
INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We have filed with the SEC
a registration statement on Form S-1 under the Securities Act with respect to the shares of our common stock being offered by this prospectus.
This prospectus, which constitutes part of that registration statement, does not contain all of the information set forth in the registration
statement or the exhibits and schedules that are part of the registration statement. Some items included in the registration statement
are omitted from the prospectus in accordance with the rules and regulations of the SEC. For further information with respect to us and
the common stock offered in this prospectus, we refer you to the registration statement and the accompanying exhibits and schedules filed
therewith. Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit
to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the
full text of such contract or other document filed as an exhibit to the registration statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We are subject to the information
and periodic reporting requirements of the Exchange Act, and we file periodic reports, proxy statements and other information with the
SEC. These periodic reports, proxy statements and other information are available for inspection and copying at the public reference
room of the SEC. The SEC also maintains a website that contains reports, proxy and information statements and other information regarding
registrants that file electronically with the SEC. The address of the SEC website is www.sec.gov.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">You may access our annual
reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished
pursuant to Section 13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after
such material is electronically filed with, or furnished to, the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Our website address is www.aclarion.com.
The reference to our website address does not constitute incorporation by reference of the information contained on our website, and
you should not consider information on our website to be part of this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">You may also request a copy
of these filings, at no cost to you, by writing or telephoning us at the following address:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">Aclarion, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">Attn: Investor Relations</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">8181 Arista Place, Suite
100</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">Broomfield, Colorado 80021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">Telephone: (833) 275-2266</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></p>

<!-- Field: Page; Sequence: 133 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="text-transform: uppercase"><b><span id="s_022"></span>Index
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aclarion, Inc.</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financial Statements</i></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#k_report">Report of Independent Registered Public Accounting Firm - Haynie &amp; Company LLP</a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ID#
457)</span></td>
    <td style="text-align: center">F-2</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 95%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_015">Report of Independent Registered Public Accounting Firm CohnReznick LLP</a></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ID# 596)</span></td>
    <td style="width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: center"/></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_017">Balance Sheets at December 31, 2023 and 2022</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_018">Statements of Operations for the Years Ended December 31, 2023 and 2022</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_019">Statements of Changes in
    Stockholders&#8217; Equity (deficit) for the Years Ended December 31, 2023 and 2022</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_020">Statements of Cash Flows for the Years Ended December 31, 2023 and 2022</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_021">Notes to Financial Statements</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-9</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>

<tr style="vertical-align: bottom">
    <td style="width: 95%"><a href="#q2_004"><span style="font-size: 10pt">Balance Sheets at June 30, 2024 and December 31, 2023</span></a></td>
    <td style="text-align: center; width: 5%"><span style="font-size: 10pt">F-32</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#q2_005"><span style="font-size: 10pt">Statements of Operations for the Three and Six Months Ended June 30, 2024 and 2023</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-33</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#q2_006"><span style="font-size: 10pt">Statements of Changes in Stockholders&#8217; Equity (deficit) for the Six Months Ended June 30, 2024 and 2023</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-34</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#q2_008"><span style="font-size: 10pt">Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-36</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#q2_009"><span style="font-size: 10pt">Notes to Financial Statements</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-37</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 134; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span id="k_report"></span>Report of Independent
Registered Public Accounting Firm</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 244.7pt 0pt 0; background-color: white">To the Board of Directors and<br/>
Stockholders</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 244.7pt 0pt 0; background-color: white">of Aclarion, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.95pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Opinion on the
Financial Statements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We have audited the accompanying
balance sheet of Aclarion, Inc. (the Company) as of December 31, 2023, and the related statements of operations, changes in stockholders&#8217;
equity (deficit), and cash flows for the year then ended, and the related notes (collectively referred to as the financial statements).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2023, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally
accepted in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Substantial Doubt
about the Company&#8217;s Ability to Continue as a <i>Going Concern</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The accompanying financial
statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements,
<span style="background-color: white">the Company has suffered recurring losses from operations and has a deficiency in shareholders&#8217;
equity that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are
also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Basis for Opinion</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">These financial statements
are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial
statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States)
(PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We conducted our audit
in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to
have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required
to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness
of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our audit included performing
procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our
opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>/s/ Haynie &amp; Company</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Haynie &amp; Company</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Salt
Lake City, Utah</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">February 20, 2024, except
for Notes 2 and 17, as to which the date is March 28, 2024</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We have served as the
Company&#8217;s auditor since 2023</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PCAOB ID 0457</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 135; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span id="k_015"></span><span style="font-family: Times New Roman, Times, Serif">Report
of Independent Registered Public Accounting Firm</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 244.7pt 0pt 0; background-color: white">To the Board of Directors and
Stockholders</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 244.7pt 0pt 0; background-color: white">Aclarion, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Broomfield, Colorado</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.95pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Opinion on the Financial Statements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We have audited the accompanying
balance sheet of Aclarion, Inc. (the &#8220;Company&#8221;) as of December 31, 2022, and the related statements of operations, changes
in stockholders&#8217; equity (deficit) and cash flows for the year then ended, and the related notes (collectively referred to as the
financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the
Company at December 31, 2022, and the results of its operations and its cash flows for the year then ended, in conformity with accounting
principles generally accepted in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Restatement to correct the 2022 financial statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As discussed in Note 3 to the financial statements,
the 2022 financial statements have been&#160;restated&#160;to correct misstatements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements of the Company as of
December 31, 2022, before the effects of the adjustments for the correction of the errors described in Note 3, were audited by Daszkal
Bolton LLP who issued an unqualified opinion on those statements in their report, containing explanatory language that substantial doubt
exists about the entity&#8217;s ability to continue as a going concern, dated February 27, 2023. Effective March 1, 2023, CohnReznick
LLP acquired certain people and assets of Daszkal Bolton LLP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Going Concern Uncertainty</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has
suffered recurring losses from operations and an accumulated deficit that raise substantial doubt about its ability to continue as a going
concern. Management's plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Basis for Opinion</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">These financial statements
are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial
statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States)
(PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audit in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding
of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s
internal control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audit included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>/s/ CohnReznick LLP</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">CohnReznick
LLP</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Sunrise, Florida</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">June 12, 2023, except for Note 1, 2024 Reverse Stock Split, Note 7,
SUPPLEMENTAL FINANCIAL INFORMATION, Prepaids and other current assets and Accrued and other liabilities, and Note 14, Net Loss Per Share
of Common Stock, as to which the date is February 21, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We have served
as the Company&#8217;s auditor from 2021 (such date takes into account the acquisition of certain people and assets of Daszkal Bolton
LLP by CohnReznick LLP effective March 1, 2023) to 2023</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 136; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Aclarion, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="k_017"></span><b>Balance Sheets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31, 2023 and 2022</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(restated)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-decoration: underline; font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; width: 66%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,021,069</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,472,806</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,270</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,569</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Prepaids &amp; other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">245,030</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">199,701</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,289,369</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,701,076</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-decoration: underline; text-align: left">Non-current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,782</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,346</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Intangible assets, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,168,623</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,210,207</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total non-current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,170,405</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,213,553</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,459,774</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,914,629</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">760,535</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">462,202</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued and other liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">857,722</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">226,469</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Note payable, net of discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,125,724</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">289,165</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,326</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Liability to issue equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">33,297</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total current liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,187,769</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">688,671</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-decoration: underline; text-align: left">Commitments and contingencies (See Note 12)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><b style="display: none">&#8211;</b></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><b style="display: none">&#8211;</b></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; text-align: left">Stockholders' equity (deficit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Common stock - $0.00001 par value, 200,000,000 authorized and 825,459 and 491,345 shares issued and outstanding (see Note 13)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,553,523</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,596,106</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(44,281,526</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(39,370,153</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total stockholders&#8217; equity (deficit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(727,995</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,225,958</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; equity (deficit)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,459,774</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,914,629</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See Accompanying Notes to Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<!-- Field: Page; Sequence: 137; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Aclarion, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="k_018"></span>Statements of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Years Ended December 31, 2023, and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(restated)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-decoration: underline; font-weight: bold">Revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 66%">Revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">75,404</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">60,444</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Cost of revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">75,728</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">65,298</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Gross profit (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(324</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,854</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-weight: bold; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Sales and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">757,004</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">498,003</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">873,336</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,067,992</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,245,317</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,990,719</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,875,657</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,556,714</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-weight: bold; text-align: left; padding-bottom: 1pt">Income (loss) from operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,875,981</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,561,568</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(608,288</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,507,546</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Changes in fair value of warrant and derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">646,319</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Loss on issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(72,862</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(562</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">521</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total other income (expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(35,393</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,507,025</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Income (loss) before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,911,374</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,068,593</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Income tax provision</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net income (loss)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,911,374</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(7,068,593</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Dividends accrued for preferred stockholders</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(415,523</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net income (loss) allocable to common stockholders</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(4,911,374</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(7,484,116</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Net income (loss) per share allocable to common stockholders</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(8.82</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(19.61</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average shares of common stock outstanding, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">556,808</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">381,598</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See Accompanying Notes to Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 138; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Aclarion,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="k_019"></span><b>Statements of Changes in Stockholders' Equity
(Deficit)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Years Ended December 31, 2023
and 2022 (restated)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 5pt; padding-bottom: 1pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt">Series A</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt">Series A-1, A-2, A-3, A-4</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt">Series B, B-1</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt">Preferred Stock</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt">Preferred Stock</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt">Preferred Stock</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt">Value</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt">Value</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt">Value</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 40%; padding-bottom: 1pt"><span style="font-size: 8pt">Balance, December 31, 2021</span></td><td style="width: 1%; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><span style="font-size: 8pt">6,247,695</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><span style="font-size: 8pt">62</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><span style="font-size: 8pt">12,434,500</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><span style="font-size: 8pt">124</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -5pt; padding-left: 5pt; padding-bottom: 1pt"><span style="font-size: 8pt">Share-based compensation</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt; padding-bottom: 1pt"><span style="font-size: 8pt">Preferred stock dividend payable</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -5pt; padding-left: 5pt; padding-bottom: 1pt"><span style="font-size: 8pt">Conversion of preferred stock
    to common stock</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(6,247,695</span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(62</span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(12,434,500</span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(124</span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt; padding-bottom: 1pt"><span style="font-size: 8pt">Conversion of preferred dividends
    payable to common stock</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -5pt; padding-left: 5pt; padding-bottom: 1pt"><span style="font-size: 8pt">Conversion of accrued interest
    on promissory notes</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt; padding-bottom: 1pt"><span style="font-size: 8pt">Issuance of common stock and warrants
    related to IPO, net issuance costs</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">Issuance of common shares</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 8pt">Issuance of warrants</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -5pt; padding-left: 5pt; padding-bottom: 1pt"><span style="font-size: 8pt">IPO issuance costs</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt; padding-bottom: 1pt"><span style="font-size: 8pt">Exercise of convertible note warrants</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 8pt">Net income (loss)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt; padding-bottom: 1pt"><span style="font-size: 8pt">Balance, December 31, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>

<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -5pt; padding-left: 5pt"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>

<tr style="vertical-align: bottom">
    <td style="text-indent: -5pt; padding-left: 5pt"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -5pt; padding-left: 5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt; padding-bottom: 1pt"><span style="font-size: 8pt">Balance, December 31, 2022</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>

<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 8pt">Share-based compensation</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 8pt">Issuance of common shares</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 8pt">Proceeds from sale of Series A preferred stock</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">1</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">1,000</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><span style="font-size: 8pt">Redemption of Series A preferred stock</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(1</span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(1,000</span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 8pt">Commitment shares - note financing</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><span style="font-size: 8pt">Issuance of warrants - note financing</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 8pt">Issuance of common shares - equity line</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><span style="font-size: 8pt">Commitment common shares - equity line</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -5pt; padding-left: 5pt; padding-bottom: 1pt"><span style="font-size: 8pt">Common share issuance costs -
    equity line</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 8pt">Cashless exercise of pre-funded warrants</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 8pt">Conversion of vested restricted stock units to common shares</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><span style="font-size: 8pt">Common share - stock split round up</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 8pt">Net income (loss)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">Balance, December 31, 2023</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 139; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt">Series B-2, B-3</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt">Additional</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt">Preferred Stock</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt">Common Stock</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt">Paid-In</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt">Accumulated</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt">Value</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt">Value</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt">Capital</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt">Deficit</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt">Total</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 30%; padding-bottom: 1pt"><span style="font-size: 8pt">Balance, December 31, 2021</span></td><td style="width: 1%; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><span style="font-size: 8pt">5,812,809</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><span style="font-size: 8pt">56,605</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><span style="font-size: 8pt">1</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><span style="font-size: 8pt">19,054,243</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><span style="font-size: 8pt">(31,886,036</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="width: 1%; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><span style="font-size: 8pt">(12,831,606</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 8pt">Share-based compensation</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">1,186,658</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">1,186,658</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt; padding-bottom: 1pt"><span style="font-size: 8pt">Preferred stock dividend payable</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(415,523</span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(415,523</span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -5pt; padding-left: 5pt; padding-bottom: 1pt"><span style="font-size: 8pt">Conversion of preferred stock
    to common stock</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(5,812,809</span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">204,945</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">2</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">7,102,472</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">7,102,287</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt; padding-bottom: 1pt"><span style="font-size: 8pt">Conversion of preferred dividends
    payable to common stock</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">61,534</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">1</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">4,272,420</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">4,272,421</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -5pt; padding-left: 5pt; padding-bottom: 1pt"><span style="font-size: 8pt">Conversion of accrued interest
    on promissory notes</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">26,673</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">1,855,158</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">1,855,158</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt; padding-bottom: 1pt"><span style="font-size: 8pt">Issuance of common stock and warrants
    related to IPO, net issuance costs</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">135,313</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">1</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">8,552,338</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">8,552,340</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">Issuance of common shares</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right">&#8211;</td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">2,500</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">102,000</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">102,000</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 8pt">Issuance of warrants</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">1,280</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">1,280</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 8pt">IPO issuance costs</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(530,463</span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(530,463</span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><span style="font-size: 8pt">Exercise of convertible note warrants</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">3,776</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 8pt">Net income (loss)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">(7,068,593</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">(7,068,593</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">Balance, December 31, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">491,345</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">5</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">41,596,106</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">(39,370,153</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">2,225,958</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">Balance, December 31, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">491,345</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">5</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">41,596,106</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">(39,370,153</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">2,225,958</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 8pt">Share-based compensation</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">456,000</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">456,000</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 8pt">Issuance of common shares</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">1,852</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 8pt">Proceeds from sale of Series A preferred stock</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">1,000</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><span style="font-size: 8pt">Redemption of Series A Preferred stock</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(1,000</span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 8pt">Commitment shares - note financing</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">21,210</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">175,619</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">175,619</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><span style="font-size: 8pt">Issuance of warrants - note financing</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">67,500</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">67,500</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -5pt; padding-left: 5pt; padding-bottom: 1pt"><span style="font-size: 8pt">Commitment common shares - equity
    line</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">11,719</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt; padding-bottom: 1pt"><span style="font-size: 8pt">Common share issuance costs -
    equity line</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(204,647</span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(204,647</span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -5pt; padding-left: 5pt; padding-bottom: 1pt"><span style="font-size: 8pt">Issuance of common shares - equity
    line</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">285,938</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">3</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">1,462,946</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">1,462,949</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt; padding-bottom: 1pt"><span style="font-size: 8pt">Cashless exercise of pre-funded
    warrants</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">3,396</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -5pt; padding-left: 5pt; padding-bottom: 1pt"><span style="font-size: 8pt">Conversion of vested restricted
    stock units to common shares</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">9,930</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt; padding-bottom: 1pt"><span style="font-size: 8pt">Common share - stock split round
    up</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">70</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 8pt">Net income (loss)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">(4,911,374</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">(4,911,374</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">Balance, December 31, 2023</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">825,459</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">8</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">43,553,523</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">(44,281,526</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">(727,995</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See Accompanying Notes to Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 140; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Aclarion, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="k_020"></span>Statements of Cash Flows</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Years Ended December 31, 2023, and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Year Ended
    December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 9pt">(restated)</span></td><td style="font-weight: bold"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 9pt">Cash flows from operating activities</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left"><span style="font-size: 9pt">Net income (loss)</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt">(4,911,374</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">)</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt">(7,068,593</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><span style="font-size: 9pt">Adjustments to reconcile net income (loss) to net cash used in operation
    activities:</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Depreciation and amortization</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">162,670</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">143,622</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Share-based compensation</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">456,001</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">1,186,658</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Amortization of deferred issuance costs</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">497,656</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Changes in fair value of warrants and derivative</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(646,319</span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Non-cash interest related to bridge funding</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">98,685</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Warrants issued as non- cash finance charge</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">72,862</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Share-based vendor payments</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">102,000</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Loss on disposal of furniture and equipment</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">3,789</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Interest conversion discount settled in equity</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">1,299,507</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Change in assets and liabilities</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Accounts receivable</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(1,491</span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(12,290</span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Prepaids and other current assets</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(38,539</span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(87,522</span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Accounts payable</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">220,633</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(603,102</span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Accrued and other liabilities</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">448,459</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(113,893</span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">Accrued interest on promissory
    and convertible notes</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(6,190</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">200,712</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">Net cash (used in) operations</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(3,646,947</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(4,949,112</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 9pt">Investing Activities</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Proceeds from sale of furniture</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">1,000</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">Intangible assets - Patents</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(119,522</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(208,870</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">Net cash (used in) investing activities</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(119,522</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(207,870</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 9pt">Financing Activities</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Bridge funding issuance costs</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(323,301</span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Equity line issuance costs</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(74,916</span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Proceeds from equity line</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">1,462,949</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Proceeds from issuance of promissory notes</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">2,250,000</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Proceeds from sale of Series A preferred stock</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">1,000</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Redemption of Series A Preferred stock</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(1,000</span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">IPO cash issuance costs</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(365,060</span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Repayment of promissory notes</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(2,000,000</span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">Issuance of common stock and warrants
    related to IPO, net deductions</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">8,552,318</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">Net cash provided by financing
    activities</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">3,314,732</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">6,187,258</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 9pt">Net increase (decrease) in cash and cash equivalents</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(451,737</span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">1,030,276</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">Cash, cash equivalents, and restricted cash, beginning
    of period</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">1,482,806</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">452,530</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 9pt">Cash, cash equivalents, and restricted cash, end
    of period</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">1,031,069</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">1,482,806</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 9pt">Non- cash activities</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left"><span style="font-size: 9pt">Accrued debt issuance costs related
    to bridge funding</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">22,150</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Accrued debt issuance costs related to equity line</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">129,731</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Issuance of warrants related to bridge funding</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">67,500</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Original issuance discount (15%) related to bridge
    funding</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">344,118</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Liability to issue common shares</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">33,297</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Issuance of commitment shares related to bridge funding</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">175,619</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Fair value of warrants and derivative related to first
    tranche bridge funding</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">742,988</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Fair value of warrants and derivative related to second
    tranche bridge funding</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">153,810</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Fair value of warrants and derivative related to third
    tranche bridge funding</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">160,012</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Dividends accrued on preferred shares</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">415,523</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Conversion of preferred stock to common stock</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">25,754,379</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Conversion of preferred stock dividends to common stock</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">4,272,421</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Conversion of accrued interest on promissory notes
    to common stock and warrants</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">1,856,438</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Issuance of underwriter's warrants related to IPO</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">199,246</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Designation of prepaid expenses to IPO issuance costs</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">165,403</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See Accompanying Notes to Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 141; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Aclarion, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="k_021"></span>Notes to Financial Statements </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Year Ended December 31, 2023</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1. THE COMPANY AND BASIS OF PRESENTATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aclarion, Inc., formerly Nocimed, Inc., (the &#8220;Company&#8221;
or &#8220;Aclarion&#8221;) is a healthcare technology company that leverages magnetic resonance spectroscopy (&#8220;MRS&#8221;), and
a proprietary biomarker to optimize clinical treatments. The Company was formed in February 2015, is incorporated in Delaware, and has
its principal place of business in Broomfield, Colorado.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks and Uncertainties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to various risks and uncertainties
frequently encountered by companies in the early stages of development. Such risks and uncertainties include, but are not limited to,
its limited operating history, competition from other companies, limited access to additional funds, dependence on key personnel, and
management of potential rapid growth. To address these risks, the Company must, among other things, develop its customer base&#894; implement
and successfully execute its business and marketing strategy&#894; develop follow-on products&#894; provide superior customer service&#894;
and attract, retain, and motivate qualified personnel. There can be no guarantee that the Company will be successful in addressing these
or other such risks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Initial Public Offering</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 21, 2022, the registration statement
for our initial public offering (&#8220;IPO&#8221;) was declared effective. In connection with the effectiveness of the IPO registration
statement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr>
    <td style="width: 24pt">&#160;</td>
    <td style="vertical-align: top; width: 24pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    effected a 1-for-7.47
    reverse stock split of our outstanding common stock (2022 Stock Split)&#894;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">accordingly, all common share amounts and per share data presented in our condensed financial statements have been retrospectively adjusted to reflect the reverse stock split for all periods presented&#894;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we filed a restated Certificate of Incorporation with the State of Delaware and we adopted new restated Bylaws&#894;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
    outstanding common stock warrants were exercised on a net share basis
for 60,408 common shares (3,776 shares after giving effect to the 2024 Stock Split)&#894;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,495,004
    outstanding shares of our preferred stock were converted into 3,279,117 common shares (204,945 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">common
    shares after giving effect to the 2024 Stock Split)&#894;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    accrued dividends on our outstanding Series B, B-1, B-2 and B-3 preferred stock were converted to 984,429 common shares (61,527
    common shares after giving effect to the 2024 Stock Split)&#894; and</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    accrued interest on the Company's outstanding secured promissory notes was converted into (i) 426,768 c</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ommon
    shares (26,673
    common shares after giving effect to the 2024 Stock Split) and (ii) warrants to purchase 426,768 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
    of  common stock  (26,673
    common shares after giving effect to the 2024 Stock Split), with beneficial conversion rates charged to interest expense upon
    conversion.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 26, 2022, the Company completed its
IPO of 2,165,000 units at a public offering price of $4.35 per unit. Each unit consisted of (i) one share of common stock (equivalent
to 0.0625 of a common share following the 2024 Split) and (ii) one warrant to purchase one share of common stock (adjusted to 0.0625
of a common share following the 2024 Split) with a per share exercise price of $4.35 (adjusted to $69.60 following the 2024 Split). Following
the commencement of the IPO, the underwriters partially exercised their over-allotment option and purchased additional common stock warrants
to purchase 324,750 common shares (adjusted to 20,297
common shares following the 2024 Split). After deducting underwriter's commissions and expenses, we received net proceeds of approximately
$8.6
million and our common stock and warrants started trading on Nasdaq under the ticker symbols &#8220;ACON&#8221; and &#8220;ACONW&#8221;,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 142; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the IPO, we issued to the
representative of the underwriters a common stock warrant to purchase 173,200 shares of common stock (10,825
shares after giving effect to the 2024 Stock Split) with an exercise price of $5.44 ($87.04 on a post-2024 Split basis) per share.
The representative's warrants are exercisable commencing October 26, 2022 and will expire on April 26, 2027.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 21, 2022, options to purchase
1,204,819 shares of common stock (75,301
common shares after giving effect to the 2024 Stock Split) previously awarded to the Company's Executive Chairman, Dr. Jeffrey
Thramann, vested in connection with the completion of the IPO pursuant to the terms of such options. The per share exercise price of
these options is $1.94 ($31.04 on a post-2024 Split basis) per share. The options have a 10-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 21, 2022, in connection with the IPO,
the Company&#8217;s 2022 Aclarion Equity Incentive Plan, or &#8220;2022 Plan&#8221;, became effective. Our board of directors has appointed
the compensation committee of our board of directors as the committee under the 2022 Plan with the authority to administer the 2022 Plan.
At the 2022 Plan effective date, the aggregate number of our shares of common stock that could be issued or used for reference purposes
under the 2022 Plan could not exceed 2,000,000 shares (125,000 shares after giving effect to the 2024 Stock Split), subject to adjustments
as described in the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 29, 2022, in connection with the IPO,
a bonus was paid to David Neal and Brent Ness of $100,000 each. On May 13, 2022, in connection with the IPO, a bonus of $130,000 was paid
to James Peacock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 2, 2022, in connection with the IPO, the
Company paid the University of California - San Francisco the amount of $123,828 to satisfy the Indexed Milestone Payment obligation included
within the exclusive license agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2022 Reverse Stock Split</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 21, 2022, the Company effected a 1-for-7.47
reverse stock split (the &#8220;2022 Stock Split&#8221;) of its issued and outstanding common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2024 Reverse Stock Split</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2023 the Company&#8217;s
stockholders approved a reverse stock split proposal at a ratio in the range of one-for-five to one-for-fifty, with the final ratio
to be determined by the Company's board in its discretion without further approval from the Company's stockholders. In January 2024,
the Company's board subsequently approved the final reverse stock split ratio of one-for-sixteen
(the &#8220;2024 Stock Split&#8221;), which resulted in a reduction in the number of outstanding shares of common stock,
warrants, stock options and restricted share units and a proportionate increase in the value of each share or strike price of the
warrants and stock options. The common stock began trading on a reverse split-adjusted basis on the NASDAQ on January 4, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the 2022 Stock Split and the 2024
Stock Split, unless described otherwise, all references to common stock, share data, per share data and related information contained
in these financial statements have been retrospectively adjusted to reflect the effect of the stock splits for all periods presented.
In addition, any fractional shares that would otherwise be issued as a result of the stock splits were rounded up to the nearest whole
share. Further, the number of shares issuable and exercise prices of stock options and warrants have been retrospectively adjusted in
these financial statements for all periods presented to reflect the 2022 Stock Split and the 2024 Stock Split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables present selected share information
reflecting on a retroactive basis the reverse stock splits as of and for the years ended December 31, 2023 and 2022:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt"><b style="display: none">Equity statement information</b></td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; font-size: 10pt; text-align: left">Common shares issued and outstanding - pre-2024 split, 13,206,229 and 7,861,515 shares</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">132</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">79</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Common shares issued and outstanding - post-2024 split, 825,459 and 491,345 shares</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">8</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">5</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt; text-align: left">Additional paid-in capital - pre-2024 split</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">43,553,399</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">41,596,032</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Additional paid-in capital - post-2024 split</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">43,553,523</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">41,596,106</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="display: none; text-align: left">Schedule of share information
reflecting on a retroactive basis the reverse stock splits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Year ended December 31</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Weighted average shares outstanding, basic and diluted - pre-2024 split</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">8,908,934</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">6,105,569</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average shares outstanding, basic and diluted - post-2024 split</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">556,808</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">381,598</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Basic and diluted net loss per shares attributable to common stockholders - pre-2024 split</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.55</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1.23</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Basic and diluted net loss per shares attributable to common stockholders - post-2024 split</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(8.82</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(19.61</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been
prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;).</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 143; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements include some amounts
that are based on management's best estimates and judgments. The most significant estimates relate to depreciation, amortization, valuation
of capital stock, and valuation of warrants and options to purchase shares of the Company's preferred and common stock. These estimates
may be adjusted as more current information becomes available, and any adjustment could be significant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Valuation
of Derivative Instruments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial Accounting Standards Board (&#8220;FASB&#8221;)
Accounting Standards Codification (&#8220;ASC&#8221;) 815-40, <i>Derivatives and Hedging: Contracts on an Entity&#8217;s Own Equity</i>,
addresses whether an equity-linked contract qualifies as equity in the entity&#8217;s financial statements. Agreements where an entity
has insufficient authorized and unissued shares to settle the contract generally are accounted for as a liability and marked to fair value
through earnings each reporting period. The Company evaluates its financial instruments to determine if such instruments are liabilities
or contain features that qualify as embedded derivatives. For financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then revalued at each reporting date, with changes in the fair value reported
as charges or credits to income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fair Value of Financial Instruments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820, Fair Value Measurements, provides guidance
on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price,
representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market
participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions
that market participants would use in pricing an asset or a liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accounting guidance classifies fair value
measurements in one of the following three categories for disclosure purposes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Level 1</i> - Unadjusted quoted prices
in active markets for identical instruments that are accessible by the Company on the measurement date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Level 2</i> - Quoted prices in markets
that are not active or inputs which are either directly or indirectly observable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Level 3</i> - Unobservable inputs
for the instrument requiring the development of assumptions by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company analyzes all financial instruments
with features of both liabilities and equity under the Financial Accounting Standard Board&#8217;s (&#8220;FASB&#8221;) accounting standard
for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level
of input that is significant to the fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying values of the Company&#8217;s financial
instruments including cash equivalents, restricted cash, accounts receivable, and accounts payable are approximately equal to their respective
fair values due to the relatively short-term nature of these instruments. The Company&#8217;s warrant liabilities and derivative liabilities
are estimated using level 3 inputs (see Note 4).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 144; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Derivative Financial Instruments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has derivative financial instruments
that are not hedges and do not qualify for hedge accounting. Changes in the fair value of these instruments are recorded in other income
(expenses), on a net basis in the Consolidated Statements of Operations and Comprehensive Loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash and Cash Equivalents</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid instruments
purchased with an original maturity of three months or less to be cash equivalents. The Company had no
cash equivalents for all periods
presented. The Company maintains cash deposits at several financial institutions, which are insured by the Federal Deposit Insurance Corporation
up to $250,000. The Company&#8217;s cash balance may at times exceed these limits. On December 31, 2023, and 2022, the Company had approximately
$761,800 and $1,229,000, respectively, in excess of federally insured limits. The Company continually monitors its positions with, and
the credit quality of, the financial institutions with which it invests. The Company maintains no international bank accounts. As of December
31, 2023, $10,000 of the Company&#8217;s cash was restricted as collateral related to the credit card program offered by our bank.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Accounts Receivable, Less Allowance for Doubtful
Accounts</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company estimates an allowance for doubtful
accounts based upon an evaluation of the current status of receivables, historical experience, and other factors as necessary. It is reasonably
possible that the Company&#8217;s estimate of the allowance for doubtful accounts will change. The allowance for doubtful accounts was
$0
on December 31, 2023, and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenue
Recognition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues are recognized when a contract with a
customer exists, and at that point in time when we have delivered a Nociscan report to our customer. Revenue is recognized in the amount
that reflects the negotiated consideration expected to be received in exchange for those reports. Following the delivery of the report,
the company has no ongoing obligations or services to provide to the customer. Customers pay no other upfront, licensing, or other fees.
To date, our reports are not reimbursable under any third-party payment arrangements, The Company invoices its customers based on the
billing schedules in its sales arrangements. Payment terms range generally from 30 to 90 days, from the date of invoice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Geographic Locations &amp; Segments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 16.05pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approximately 13% and 9% of the Company&#8217;s
revenues were generated from contracts with customers outside the United States in the years ended December 31, 2023, and 2022, respectively.
All invoices are billed in the currency of the customers and are recorded in US Dollars at the then spot rate, which automatically is
converted to dollars upon receipt and deposited in the Company&#8217;s bank. Differences between the amounts received and the amounts
initially recorded are reflected in Other Income (Expense).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Segment Disclosure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
has&#160;a single&#160;operating and reporting segment, which is the delivery of Nociscan reports to our customers. The Company&#8217;s
Chief Executive Officer reviews financial information for purposes of making operating decisions and assessing financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Property and Equipment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost and
are depreciated using the straight-line method over the estimated useful lives of the related assets. Furniture and fixtures are depreciated
over&#160;seven years. Computer and office equipment and computer software are depreciated over five years. Repairs and maintenance costs,
which are not considered improvements and do not extend the useful life of the property and equipment, are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 145; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Impairment of Long-Lived Assets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
reviews long-lived assets, including intangible assets, property and equipment, for impairment whenever events or changes in business
circumstances indicate that the carrying amount of the assets may not be fully recoverable using pre-tax undiscounted cash flows. Impairment,
if any, is measured as the amount by which the carrying value of a long-lived asset exceeds its fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Sales and Marketing Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expenses the costs of sales and marketing
its products and services as incurred. The primary drivers of cost have been employee payroll, website and branding development, press
releases, attendance at various industry conferences, Key Opinion Leader consulting fees in the form of restricted stock grants, and travel
expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Research and Development Costs</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Costs related
to research, design and development of products are charged to research and development expense as incurred. These costs include direct
compensation, benefits, and other headcount related costs for research and development personnel; costs for materials used in research
and development activities; costs for outside services and allocated portions of facilities and other corporate costs. The Company has
entered into research and clinical study arrangements with selected hospitals, cancer treatment centers, academic institutions and research
institutions worldwide. These agreements support the Company&#8217;s internal research and development capabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>General
&amp; Administrative</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">General
and administrative expenses primarily consist of personnel and related costs, including stock-based compensation, legal fees relating
to both intellectual property and corporate matters, accounting and audit related costs, insurance, corporate communications and public
company expenses, information technology, depreciation, amortization and maintenance, and fees for consulting, business development and
other professional services.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity, Capital Resources and Going Concern</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, we had cash of
approximately $1.0 million. Subsequent to December 31, 2023, the Company raised capital using an
equity line and a secondary public offering (refer to Note 17 &#8211; Subsequent Events to our financial statements). We believe our current
cash will fund our operating expenses and capital expenditure requirements into the third quarter of 2024, approaching our final maturity
repayment of our unsecured non-convertible note, which is due in September 2024. The Company has based these estimates, however, on assumptions that may prove to be wrong, and could spend available financial
resources much faster than we currently expect. The Company will need to raise additional funds to continue funding our technology
development and commercialization efforts over the following twelve months. Management has plans to secure such additional
funding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the Company&#8217;s recurring losses
from operations, and the need for additional financing to fund its operating and capital requirements, there is uncertainty regarding
the Company&#8217;s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to
the Company&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 146; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Share-Based Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock-based awards in
accordance with provisions of ASC Topic 718, <i>Compensation&#8212;Stock Compensation</i>, under which the Company recognizes the grant-date
fair value of stock-based awards issued to employees and nonemployee board members as compensation expense on a straight-line basis over
the vesting period of the award, while awards containing a performance condition are recognized as expense when the achievement of the
performance criteria is achieved. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock
options. The Company records expense for forfeitures in the periods they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The exercise or strike price of each option is
not less than 100% of the fair market value of the Common Stock subject to the option on the date the option is granted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issues restricted stock unit awards
to non-employee consultants who are providing various services. The awards are valued at the market price on the date of the grant. The
awards vest over the contract life and based on achievement of targeted performance milestones.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On occasion, the Company grants common stock to
compensate vendors for services rendered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Deferred Financing Costs</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company capitalizes certain legal, accounting,
and other fees and costs that are directly attributable to in-process equity financings as deferred offering costs until such financings
are completed. Upon the completion of an equity financing, these costs are recorded as a reduction of additional paid-in capital of the
related offering. Upon the completion of the IPO in April 2022, approximately $1.5 million of offering costs related to the IPO were reclassified
to additional paid-in capital. Upon the completion of the issuance of shares pursuant to the equity line in the fourth quarter
of 2023, $204,647 of offering costs were reclassified to additional paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Emerging Growth Company Status</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is an emerging growth company, as
defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies
can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those
standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or
revised accounting standards that have different effective dates for public and private companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Income Taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the asset and liability method
of accounting for income taxes under ASC 740, &#8220;Income Taxes.&#8221; Deferred tax assets and liabilities are recognized for the estimated
future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable
income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and
liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are
established, when necessary, to reduce deferred tax assets to the amount expected to be realized. As of December 31, 2023, the Company
had deferred tax assets related to certain net operating losses. A valuation allowance was established against these deferred tax assets
at their full amount, resulting in a zero balance of deferred tax assets on the consolidated balance sheets as of December 31, 2023 and
2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 147; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3. 2022 RESTATEMENT OF PREVIOUSLY ISSUED
FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The full details of the restatement to the financial
statements for the year ended December 31, 2022, are reported in Note 4 to the financial statements as of December 31, 2022 that were
included by the Company in its amended annual report on Form 10-K/A filed with the Securities and Exchange Commission on June 12, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4. FAIR VALUE MEASUREMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 820 (Fair Value Measurements
and Disclosures), the Company uses various inputs to measure the outstanding warrants, certain embedded redemption features associated
with the senior note to Aclarion, Inc. on a recurring basis to determine the fair value of the liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="display: none">Schedule of recurring basis to determine the fair value of the liability</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value measured as of December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value on December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Quoted prices in active markets</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Level 1)</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Significant other observable inputs</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Level 2)</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Significant unobservable inputs</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Level 3)</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 40%; text-align: justify">Warrant liability</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">289,165</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">289,165</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Derivative Liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">121,326</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">121,326</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total Fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">410,491</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">410,491</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no transfers between Level 1, 2, and
3 during the year ended December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents changes in Level
3 liabilities measures at fair value for the year ended December 31, 2023. Both observable and unobservable inputs were used to determine
the fair value positions that the Company has classified within the Level 3 category.</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="display: none">Schedule of liabilities measures at fair value</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrant Liability</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Derivative Liability</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Balance - January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 49%; text-align: left; text-indent: 9pt">Additional warrant and derivative liability</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">736,249</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">320,561</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">1,056,810</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 9pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(447,084</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(199,235</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(646,319</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance &#8211; December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">289,165</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">121,326</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">410,491</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the embedded derivative liabilities
associated with the Senior Notes Payable was estimated using a probability weighted discounted cash flow model to measure the fair value.
This involves significant Level 3 inputs and assumptions including an (i) estimated probability and timing of certain financing events
and event of default, and (ii) the Company&#8217;s risk-adjusted discount rate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the warrants to purchase shares
of common stock was estimated using a Monte Carlo simulation using the following assumptions.</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="display: none">&#160;Schedule of assumptions</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of Issuance</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of Dec 31, 2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrant Liability</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrant Liability</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%">Strike Price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">0.63</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">0.27</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Contractual term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Volatility (annual)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80.0%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80.0%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.52%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.89%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Floor Financing price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.14</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 148; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5. RECENT ACCOUNTING PRONOUNCEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2020, the FASB issued ASU No. 2020-06,
<i>Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own </i>Equity (Subtopic
815-40) (&#8220;ASU 2020-06&#8221;), which simplifies the accounting for convertible instruments. The guidance removes certain accounting
models that separate the embedded conversion features from the host contract for convertible instruments. The guidance also modifies how
certain convertible instruments, that may be settled in cash or shares, impact the calculation of diluted earnings per share. ASU 2020-06
allows for a modified or full retrospective method of transition. This update is effective for emerging growth companies following private
company adoption dates in fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, and early
adoption is permitted. The Company adopted this standard as of April 1, 2022, using the modified retrospective approach. The adoption
of this standard did not have a material impact on the Company's consolidated financial statements and related disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2023, the Company adopted ASU 2016-13,
<i>Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>, as amended, which
replaces the incurred loss methodology with an expected loss methodology, that is referred to as a current expected loss methodology (CECL).
CECL was required to be implemented for small business reporting companies after December 31, 2022. The measurement of expected losses
under the CECL methodology is applicable to financial assets measured at amortized cost, including trade receivables, loan receivables
and held-to-maturity debt securities. It also applies to off balance sheet credit exposures not accounted for as insurance, loan commitments,
standby letters of credit, financial guarantees, and similar instruments and net investment in leases, as accounted for by the lessor
under ASC 842. In addition, ASC 326 made changes to the available for-sale debt securities. One such change is to require credit losses
be accounted for as an allowance instead of a write-down on available for-sale securities that management does not intend to sell, or
believes it is more likely than not that they will be required to sell.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has adopted ASC 326 using the retrospective
approach for all financial assets measured at amortized cost, which consists of trade receivables. The Company estimates the likelihood
of collection considering trade receivables-based factors such as the creditworthiness of its customers. There are no off-balance sheet
assets or guarantees. The Company recorded no change to retained earnings due to the adoption of ASC 326.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of this date, the Company has not purchased,
nor does it intend to purchase, debt securities, eroded or financial assets, or leases within the scope of the pronouncement. If it does,
it will use the prospective transition approach.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6. REVENUE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Contract Balances</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The timing of revenue recognition, billings, and
cash collections may result in trade, unbilled receivables, and deferred revenues on the balance sheets. At times, revenue recognition
may occur before the billing, resulting in an unbilled receivable, which would represent a contract asset. The contract asset would be
a component of accounts receivable and other assets for the current and non-current portions, respectively. In the event the Company receives
advances or deposits from customers before revenue is recognized, this would result in a contract liability. In years ending December
31, 2023, and 2022, the Company invoiced as services were performed and did not invoice in advance; the company has no contract balances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 149; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7. SUPPLEMENTAL FINANCIAL INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Balance Sheets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>Accounts receivable, net</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 16.05pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white">Accounts receivable, net consisted
of the following:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="display: none">Schedule of accounts receivable</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Accounts receivable (1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">13,270</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">18,569</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: Allowance for doubtful accounts</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Accounts receivable, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,270</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,569</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">(</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td>
    <td style="width: 98%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable denominated in foreign currencies represent less than 15% of accounts receivable in all periods.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white"><b>Prepaids and other current assets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><b style="display: none">Schedule of prepaids and other current assets</b></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Short term deposits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">50,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">50,100</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,588</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Prepaid insurance D &amp; O</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,769</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,478</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid insurance other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,884</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,475</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Prepaid, other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,635</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,564</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other receivables</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">154</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">84</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">245,030</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">199,701</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>Accounts payable</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="display: none">Schedule of accounts payable</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Accounts payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">758,821</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">457,558</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Credit cards payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,714</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,644</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">760,535</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">462,202</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Accrued and other liabilities</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><b style="display: none">Schedule of accrued and other liabilities</b></td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Accrued payroll</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">162,887</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued bonus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">262,580</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134,704</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Accrued board compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued committee compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Accrued audit and legal expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,082</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,919</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investment banking and related fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">139,906</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98,685</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">12,082</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,596</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">857,722</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">226,469</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 150; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>Statements of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white">Other expense, net consisted
of the following:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="display: none">Schedule of other expense</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">Income/(Expense)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Bank Interest</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">172</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2,511</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,144</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(800</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Foreign Currency Gain (Loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,190</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">265</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(562</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">521</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
8. LEASES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rent expense for the year ended December 31,
2023, and 2022 was $0 and $36,070,
respectively. The Company entered into a subleasing agreement in 2021 and realized $0
and $26,340
of sublease income for the year ended December 31, 2023, and 2022. Both the lease and sublease are netted within the general
&amp; administrative line item in the Statements of Operations. Our prior office lease and sublease expired on June 30, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9. PROPERTY, PLANT, AND EQUIPMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost and
are depreciated using the straight-line method over the estimated useful lives of the related assets. Furniture and fixtures are depreciated
over seven years. Computer and office equipment and computer software are depreciated over five years. Repairs and maintenance costs,
which are not considered improvements and do not extend the useful life of the property and equipment, are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s property and equipment are
as follows:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="display: none">Schedule of&#160;property and equipment</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Computer and office equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">13,032</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">13,032</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Software</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,150</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other Equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,190</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,182</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,372</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(53,400</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(70,026</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,782</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,346</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense related to property and equipment
were $1,564 and $4,500 for the years ended December 31, 2023, and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2022 the company received proceeds of $1,000 from the sale of
property and equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Future depreciation and amortization of property,
equipment, and software is as follows:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%">
  <tr style="vertical-align: bottom">
    <td><span style="display: none">Schedule of future depreciation of property
and equipment</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 33%; text-align: left">2024</td><td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,186</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">2025</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">596</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,782</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 151; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10. INTANGIBLE ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s intangible assets are as follows:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="display: none">Schedule of intangible assets</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2022</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Patents and licenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2,267,251</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2,147,728</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,017</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,017</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><b style="display: none">Total intangible assets gross&#160;</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,272,268</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,152,745</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: accumulated amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,103,645</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(942,538</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Intangible assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,168,623</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,210,207</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amortization expense related to purchased intangible
assets was $161,107 and $139,121 for the years ended December 31, 2023, and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">UC royalties are paid annually, amortized over
twelve months, and charged to cost of revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patents and trademarks are reviewed at least annually
for impairment. No impairment was recorded through December 31, 2023, and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Future amortization of intangible assets is as
follows:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%">
  <tr style="vertical-align: bottom">
    <td><span style="display: none">Schedule of future amortization of intangible assets</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 33%; text-align: left">2024</td><td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">169,002</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">168,951</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">2026</td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">168,951</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">168,951</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2028 and beyond</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">492,768</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,168,623</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11. SHORT TERM NOTES, CONVERTIBLE DEBT,
AND DERIVATIVE LIABILITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Convertible Notes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, there were no Convertible
Notes payable and outstanding. There was no convertible note activity in the year ended December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Senior Notes Payable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2023, the Company issued $1,437,500 unsecured senior notes that
mature on May 16, 2024 (&#8220;the Senior Notes Payable&#8221;), for cash proceeds of $1,250,000. The Senior Notes Payable contain an
original issue discount of 15.0% and accrue interest at an annual rate of 8.0%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2023, as agreed to during the issuance of the Senior Notes
Payable, the Company exercised their right to an additional financing, issuing $862,500 unsecured senior notes that mature on September
1, 2024 ("the Series B Notes Payable) for cash proceeds of $750,000. The Series B Notes Payable contain an original issue discount
of 15.0% and accrue interest at an annual rate of 8.0%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 152; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2023, the Company issued $294,118 unsecured senior notes
that mature on April 19, 2024 (&#8220;the Series C Notes Payable&#8221;), for cash proceeds of $250,000. The Senior Notes Payable contain
an original issue discount of 15.0% and accrue interest at an annual rate of 8.0%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company incurred issuance costs, recorded as deferred financing
costs, of $296,313 relating to due diligence and legal costs associated with the issuance of the notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluated the embedded redemption and contingent interest
features in the notes to determine if such features were required to be bifurcated as an embedded derivative liability. In accordance
with ASC 815-40, Derivatives and Hedging Activities, the embedded redemption features and contingent interest feature were accounted for
as derivative liabilities at the date of issuance and shall be adjusted to fair value at each reporting date. The Company fair valued
such derivative liabilities and recorded a debt discount at issuance of the notes of $320,561.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issued warrants to purchase 1,232,156
and 744,890 shares of common stock (77,010 and 46,556 shares, respectively, after giving effect to the 2024 Stock Split) to the holders
of the Senior Notes Payable and Series C Notes Payable (collectively the &#8220;Senior Notes Warrants&#8221;) with an exercise price of
$0.6262 and $0.2856 per share ($10.02 and $4.58 post-2024 split), respectively. The Company accounted for the warrants in accordance with
the guidance contained in ASC 815 &#8220;Derivatives and Hedging&#8221; whereby under that provision these warrants did not meet the criteria
for equity treatment and were recorded as a liability. As such, these warrants are recorded at fair value as of each reporting date with
the change in fair value reported within other income in the accompanying consolidated statements of operations as &#8220;Change in fair
value of warrant liability&#8221; until the warrants are exercised, expired or other facts and circumstances lead the warrant liability
to be reclassified to stockholders&#8217; equity. The fair value of the Senior Notes Warrants at issuance was $736,249 and was recorded
as a debt discount. The Company incurred issuance costs of $72,862 relating to the Senior Notes Warrants which was recorded as a day 1
expense due to the liability classification of such warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the issuance of the Senior
Notes Payable and Series C Notes Payable, the Company paid a commitment fee in the form of 339,360 and 148,978 shares (21,210 and 9,311
shares after giving effect to the 2024 Stock Split) of unregistered common stock to the holders, respectively. The aggregate commitment
fees had a fair value at issuance of $208,916 and are recorded as a deferred financing cost.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The resulting debt discounts from the derivative liabilities, warrant
liabilities and deferred financing costs were presented as a direct deduction from the carrying amount of that debt liability and amortized
to interest expense using the effective interest rate method. For the year ended December 31, 2023, the Company recognized $497,763 in
amortization of debt discounts and deferred financing costs which is recorded in interest expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table reconciles the aggregate
amount for the Senior Notes Payable, Series B Notes Payable, and Series C Notes Payable as well as the unamortized deferred financing
costs and debt discounts relating to the derivative liabilities and warrant liabilities.</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="display: none; text-align: left">Schedule of derivative liabilities and warrant
liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2022</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Note Payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2,594,118</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: Unamortized Discounts and Deferred Financing Costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: 9pt">Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(557,582</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 9pt">Derivative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(235,628</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 9pt">Deferred financing costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(675,184</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><b></b></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,468,394</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt; text-indent: 9pt"><b>&#160;</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,125,724</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 153; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Secured Promissory Notes Payable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2021, the Company issued $2.0 million
of promissory notes that matured at the earlier of the consummation of a Qualified Financing or May 31, 2022. The promissory notes incorporated
the following major attributes: secured by a lien and security interest on substantially all of the Company&#8217;s assets&#894; interest
accrues at 33%&#894; holder option to convert the accrued interest into the Company securities being offered in a Qualified Financing
at 30% (i.e. 70% discount) of the price being paid by other investors in the Qualified Financing&#894; and automatic conversion in the
case of a Qualifying IPO of the accrued interest into the Company securities being offered in the Qualifying IPO at 30% (70% discount)
of the price being paid by other investors in the Qualifying IPO. If the promissory notes remained outstanding after May 31, 2022, the
Company had the option to extend the promissory notes upon the payment of an extension fee, which consisted of warrants to purchase 150,000
shares (1,255 shares after giving effect to the 2022 and 2024 Stock Splits) with a five-year term, to purchase shares of the Company&#8217;s
common stock at a price of $ 0.01 per share ($1.20 post-2022 and 2024 splits).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 21, 2022, the registration statement
for our IPO was declared effective. In connection with the effectiveness of the IPO registration statement, all accrued interest on the
Company's outstanding secured promissory notes were converted into (i) 426,768 (26,673 after giving effect to the 2024 Stock Split) common
shares and (ii) warrants to purchase 426,768 shares of common stock (26,673 common shares after giving effect to the 2024 Stock Split)
with a $1,299,507 beneficial conversion rate charged to interest expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 27, 2022, the Company used $2 million
of the IPO proceeds to retire all outstanding secured promissory notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 12. COMMITMENTS AND CONTINGENCIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Royalty Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has an exclusive license agreement
with the Regents of the University of California to make, use, sell and otherwise distribute products under certain of the Regents of
the University of California&#8217;s patents anywhere in the world. The Company is obligated to pay a minimum annual royalty of $50,000,
and an earned royalty of 4% of net sales. The minimum annual royalty will be applied against the earned royalty due for the calendar year
in which the minimum payment was made. The license agreements expire upon expiration of the patents and may be terminated earlier if the
Company so elects. The U.S. licensed patents that are currently issued expire between 2026 and 2029, without considering any possible
patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees.
The Company recorded royalty costs of $50,000 for each of the years ended December 31, 2023, and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, the Company was obligated to make
a cash Indexed Milestone Payment to the Regents of the University of California in the event of either a change of control or an IPO.
This cash payment was calculated as follows: 28,532 (1,783 shares after giving effect to the 2024 Stock Split) of Company common stock
times the IPO price of $4.34 ($69.44 post-2024 Stock Split). On May 2, 2022, in connection with the IPO, the Company paid the University
of California - San Francisco the amount of $123,828 to satisfy the Indexed Milestone Payment obligation included within the exclusive
license agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Litigation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, the Company has not been involved in
legal proceedings arising in the ordinary course of its business. If any legal proceeding occurs, the Company would record a provision
for a loss when it believes that it is both probable that a loss has been incurred and the amount can be reasonably estimated, although
litigation is inherently unpredictable and is subject to significant uncertainties, some of which are beyond the Company&#8217;s control.
Should any of these estimates and assumptions change or prove to have been incorrect, the Company could incur significant charges related
to legal matters that could have a material impact on its results of operations, financial position and cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 154; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock Option Grant to our Executive Chairman</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2021, the Board of Directors approved
a stock option grant of 1,204,819 shares (75,301 after giving effect to the 2024 Stock Split) to Dr. Jeffrey Thramann, our Executive Chairman.
These options were conditional, such that they vested only upon the occurrence of certain specified events, including an IPO, a next round
financing, the merger of the Company with a SPAC, or the sale of the Company. The amount of stock options that would vest upon such specified
events depended upon the terms and timing of the applicable event.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 21, 2022, options to purchase 1,204,819
shares of common stock (75,301 shares post-2024 Stock Split) previously awarded to Dr. Jeffrey Thramann vested in connection with the
completion of the IPO pursuant to the terms of such options. The exercise price of these options is $1.94 ($31.04 post-2024 Stock Split)
per share. The options have a 10-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 15, 2022, the Board of Directors approved a stock option
grant to purchase an additional 185,285 (11,580 post-2024 Stock Split) shares of common stock to Dr. Thramann. The exercise price of the
options is $1.94 ($31.04 post-2024 Stock Split) per share, they are fully vested, and they have a 10-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
13. STOCKHOLDERS&#8217; EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company filed an Amended and Restated Certificate
of Incorporation on April 21, 2022, as part of the IPO. The Company is authorized to issue two classes of stock to be designated, respectively,
&#8220;Common Stock&#8221; and &#8220;Preferred Stock.&#8221; The total number of shares which the Company is authorized to issue is two
hundred twenty million (220,000,000) shares. Two hundred million (200,000,000) shares are authorized to be Common Stock, having a par
value per share of $0.00001. Twenty million (20,000,000) shares are authorized to be Preferred Stock, having a par value per share of
$0.00001.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the IPO, the Company had authorized two
classes of shares. These classes included shares of common stock and preferred stock. There was one authorized series of shares of common
stock and eight existing authorized series of preferred stock: Series A-1, A-2, A-3, A-4, B, B-1, B-2, and B-3.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preferred shares converted to common shares
on a 1:1 pre-split basis immediately prior to the Stock Split on April 21, 2022. Those common shares were adjusted to reflect the 2022
Stock Split and 2024 Stock Split as described in Note 1 Reverse Stock Split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preference Amounts</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issue Date</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total Face Value of Investment</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issue Purchase Price/Share</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series A-1 Preferred Stock</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/31/2014</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,247,541</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.70</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="10" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Prior to its conversion to common shares, the Series A-1 had a 1x liquidation preference junior to B/B1 plus participation on an as-converted to common basis, which participation was capped at 3x, conversion into common stock at a ratio of 1:1, limited anti-dilution protection, and voting rights on an as-converted to common basis.</i></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series A-2 Preferred Stock</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/31/2014</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,114,797</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.77</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="10" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Prior to its conversion to common shares, the Series A-2 had a 1x liquidation preference junior to B/B1 plus participation on an as-converted to common basis, which participation was capped at 3x, conversion into common stock at a ratio of 1:1, limited anti-dilution protection, and voting rights on an as-converted to common basis.</i></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series A-3 Preferred Stock</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/31/2014</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">795,002</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.85</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="10" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Prior to its conversion to common shares, the Series A-3 had a 1x liquidation preference junior to B/B1 plus participation on an as-converted to common basis, which participation was capped at 3x, conversion into common stock at a ratio of 1:1, limited anti-dilution protection, and voting rights on an as-converted to common basis.</i></span></td>
    <td>&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 155; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid"><b>Preference Amounts</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>Issue Date</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Total Face Value of Investments</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Issue Purchase Price/Share</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 52%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 13%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 13%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series A-4 Preferred Stock</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/31/2014</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,965,288</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.94</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="10" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Prior to its conversion to common shares, the Series A-4 had a 1x liquidation preference junior to B/B1 plus participation on an as-converted to common basis, which participation was capped at 3x, conversion into common stock at a ratio of 1:1, limited anti-dilution protection, and voting rights on an as-converted to common basis.</i></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series B Preferred Stock</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/5/2015</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,013,579</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.00</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="10" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Prior to its conversion to common shares, the Series B had a 1x senior liquidation preference junior to B/B1 plus participation on an as-converted to common basis, which participation was capped at 3x, conversion into common stock at a ratio of 1:1, limited anti-dilution protection, and voting rights on an as-converted to common basis.</i></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="10" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The dividend rate is 6.0% Dividends are cumulative. Accrued and unpaid dividends are payable in shares of common stock in certain events (including an IPO) at the then current fair market value of the common stock.</i></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series B-1 Preferred Stock</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/27/2017</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.26</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/2/2018</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,217,698</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.26</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/1/2019</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,463,328</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.26</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td colspan="10" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Prior to its conversion to common shares, the Series B-1 had a 1x senior liquidation preference junior to B2/B3 plus participation on an as-converted to common basis, which participation was capped at 3x, conversion into common stock at a ratio of 1:1, limited anti-dilution protection, and voting rights on an as-converted to common basis.</i></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td colspan="10" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The dividend rate is 6.0%. Dividends are cumulative. Accrued and unpaid dividends are payable in shares of common stock in certain events (including an IPO) at the then current fair market value of the common stock.</i></span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 52%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series B-2 Preferred Stock</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/3/2021</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,774,819</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.12</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td colspan="10" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Prior to its conversion to common shares, the Series B-2 has a 1x senior liquidation preference plus participation on an as-converted to common basis, which participation was capped at 3x, conversion into common stock at a ratio of 1:1, limited anti-dilution protection, and voting rights on an as-converted to common basis.</i></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td colspan="10" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The dividend rate is 6.0%. Dividends are cumulative. Accrued and unpaid dividends are payable in shares of common stock in certain events (including an IPO) at the then current fair market value of the common stock. Redemption is available by a majority vote of holders commencing after fifth anniversary from issuance, payable in three annual installments.</i></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series B-3 Preferred Stock</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/3/2021</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,327,468</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.26</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td colspan="10" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Prior to its conversion to common shares, the Series B-3 has a 2x senior liquidation preference, conversion into common stock at a ratio of 1:1, limited anti-dilution protection, and voting rights on an as-converted to common basis.</i></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td colspan="10" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The dividend rate is 6.0%. Dividends are cumulative. Accrued and unpaid dividends are payable in shares of common stock in certain events (including an IPO) at the then current fair market value of the common stock. Redemption is available by a majority vote of holders commencing after fifth anniversary from issuance, payable in three annual installments.</i></span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, IPO Warrants to purchase
155,610 shares of common stock (post-split), and other warrants to purchase 165,555 shares of common stock (post-split) were outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 156; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Warrants issued in connection with the IPO</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Company&#8217;s IPO, all
accrued interest on the Company's outstanding secured promissory notes were converted into (i) 26,673 (post-2024 Stock Split) common shares
and (ii) warrants to purchase 26,673 shares of common stock (post-2024 Stock Split), with beneficial conversion rates charged to interest
expense upon conversion. These warrants have an exercise price of $69.60 (post-2024 Stock Split) per share and expiring 2027.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the IPO, the Company sold 2,165,000 units at
a public offering price of $4.35 per unit. Each unit consisted of (i) one share of common stock (equivalent to 0.0625 of a common share
following the 2024 Split) and (ii) one warrant to purchase one share of common stock (adjusted to 0.0625 of a common share following the
2024 Split) warrant with a per share exercise price of $4.35 (adjusted to $69.60 following the 2024 Split). On April 22, 2022, the underwriters
partially exercised their over-allotment option and purchased additional common stock warrants to purchase 324,750 common shares (adjusted
to 20,297 common shares following the 2024 Split). The common stock and the IPO Warrants were immediately separable and issued separately
in the offering. The IPO Warrants are listed and tradeable on the NASDAQ stock market, immediately exercisable at the option of the holder,
and expire five years from the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the IPO, we issued to the representative
of the underwriters&#8217; common stock warrants to purchase 10,825 shares of common stock (post-2024 Stock Split) with an exercise price
of $87.04 (post-2024 Stock Split) per share. The representative's warrants are exercisable commencing October 26, 2022, and will expire
on April 26, 2027.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluated the terms of all warrants
issued at the IPO and determined that they should be classified as equity instruments based upon accounting guidance provided in ASC 480,
<i>Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging</i>. Since the Company determined that the warrants were
equity classified, the Company recorded the proceeds from the IPO, net of issuance costs, within common stock at par value and the balance
of proceeds to additional paid in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other Outstanding Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, we had other
outstanding warrants to purchase 128,057
shares of common stock (post-split) (in addition to our IPO Warrants described above). The terms of these warrants are (i) warrants
to purchase 123,566
shares of common stock (post-split) with a per share exercise price of $2.315
(post split) and expiring 2028, and warrants to purchase 4,491
common shares (post split) with a per share exercise price of $0.0002
(post-split) and expiring 2028.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The per share exercise price of the warrants
described in clause (i) above is subject to a &#8220;ratchet&#8221; adjustment if the Company issues securities at an effective per share
price lower than the then effective warrant exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>White Lion Equity
Line Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 9, 2023, the Company entered into an
equity line common stock purchase agreement (the &#8220;Equity Line Purchase Agreement&#8221;) and a related registration rights agreement
with White Lion Capital, LLC (&#8220;White Lion&#8221;). Pursuant to the Equity Line Agreement, the Company has the right, but not the
obligation to require White Lion to purchase, from time to time, up to $10,000,000 in aggregate gross purchase price of newly issued shares
of the Company&#8217;s common stock, subject to certain limitations and conditions set forth in the Equity Line Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 157; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is anticipated that the Company may sell shares
of common stock to White Lion from time-to-time over a sales period that expires December 31, 2024. The number of shares ultimately offered
for sale to White Lion under the Equity Line Purchase Agreement is dependent upon the number of shares we elect to sell to White Lion
under the Equity Line Purchase Agreement. The actual number of shares of common stock that are sold to White Lion may depend based on
a number of factors, including the market price of our common stock during the time that the Equity Line Purchase Agreement in is effect.
The actual gross proceeds the Company may derive from the Equity Line Purchase Agreement may be less than $10.0&#160;million, which may
impact our future liquidity. Because the price per share of each share sold to White Lion will fluctuate during the sales period, it is
not currently possible to predict the number of shares that will be sold or the actual gross proceeds to be raised in connection with
those sales, if any.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company currently has an effective registration
statement to register for resale by White Lion 2,500,000
shares of common stock. White Lion may ultimately purchase all or some of these shares. After White Lion has acquired shares under
the Equity Line Purchase Agreement, it may sell all, some or none of those shares. Sales to the Selling Securityholder by us pursuant
to the Equity Line Purchase Agreement may result in substantial dilution to the interests of other holders of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The sale of a substantial number of shares to
White Lion, or anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future
at a time and at a price that we might otherwise desire. The number of shares of our common stock ultimately offered for resale by White
Lion is dependent upon the number of shares of common stock issued to White Lion pursuant to the Equity Line Purchase Agreement. Depending
on a variety of factors, including market liquidity of our common stock, the issuance of shares to White Lion may cause the trading price
of our common stock to decline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In consideration for the commitments of White
Lion, as described above, the Company issued to White Lion 187,500 pre-split shares (11,719 post-2024 Stock Split) of Common Stock (the
&#8220;Commitment Shares&#8221;), having a value of $75,000 based upon the closing sale price of Common Stock on October 6, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, the Company sold to White
Lion 4,575,000 newly issued pre-split common shares (285,938 post-2024 Stock Split) for proceeds of $1,462,949.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
14. NET LOSS PER SHARE OF COMMON STOCK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2024, the Company&#8217;s board approved
the final reverse stock split ratio of one-for-sixteen, which resulted in a reduction in the number of outstanding shares of common stock
and a proportionate increase in the value of each share. The common stock began trading on a reverse split-adjusted basis on the NASDAQ
on January 4, 2024. The retrospective effect of the reverse stock split has been incorporated on a retrospective basis in the tabular
disclosures of loss per share and weighted average outstanding shares for the fiscal years 2023 and 2022 herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic and diluted net loss per share is computed
by dividing net loss attributable to stockholders by the weighted average number shares of common stock outstanding, vested restricted
stock units, and pre-funded warrants during the year. Potentially dilutive outstanding shares of common stock equivalents were excluded
from the computation of diluted net loss per share for loss periods presented because including them would have been antidilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A post-split reconciliation of the numerator and
denominator used in the calculation of basic and diluted net loss per share attributable to stockholders follows:&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="display: none">Schedule of reconciliation of basic and diluted net loss per share</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(restated)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Numerator:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 5pt; width: 66%; text-align: left; text-indent: -5pt">Net loss allocable to common shareholders used to compute basic and diluted loss per common share</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(4,911,374</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(7,484,116</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Weighted average shares used to compute basic and dilutive loss per share (post-split)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">556,808</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">381,598</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 158; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following outstanding potentially dilutive
securities were excluded from the calculation of dilutive loss per share attributable to common stockholders because their impact would
have been antidilutive for the period presented:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="display: none">Schedule of anti-dilutive securities excluded from computation of earnings per share</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2022</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Shares issuable on Series A and B convertible preferred stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">51,236</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Shares issuable on warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">255,270</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145,624</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Shares issuable on restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,185</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,127</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Shares issuable on  options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">171,033</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">155,114</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">475,488</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">355,101</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 15. STOCK-BASED COMPENSATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2022 Aclarion Equity Incentive Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 21, 2022, in connection with the
IPO, the Company&#8217;s 2022 Aclarion Equity Incentive Plan, or &#8220;2022 Plan&#8221;, went into effect. Our board of directors
has appointed the compensation committee of our board of directors as the committee under the 2022 Plan with the authority to
administer the 2022 Plan. The aggregate number of our shares of common stock that may be issued or used for reference purposes under
the 2022 Plan is 2,000,000
shares (125,000 post 2024 Stock Split), with an automatic increase on January 1st of each year, for a period of not more than ten
years, commencing on January 1st of the year following the year in which the IPO Date occurs and ending on (and including) January
1, 2032, in an amount equal to 5% of the total number of shares of Capital Stock outstanding on December 31st of the preceding
calendar year. Notwithstanding the foregoing, the Board may act prior to January 1st of a given year to provide that there will be
no January 1st increase in shares for such year or that the increase in shares for such year will be a lesser number of shares of
Common Stock than would otherwise occur pursuant to the preceding sentence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the year ended December 31, 2023, the aggregate
number of our shares of common stock that may be issued or used for reference purposes under the 2022 Plan was 2,470,814 (154,426 post-split).
On January 1, 2024, the 2022 Plan had an automatic increase of 660,311 (41,270 post-split) shares which was 5% of the total number of shares
of Capital Stock outstanding on December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options granted under the 2022 Plan may be incentive
stock options or non-statutory stock options, as determined by the administrator at the time of grant of an option. Restricted stock
may also be granted under the 2022 Plan. The options vest in accordance with the grant terms and are exercisable for a period of up to
10 years from grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company did not grant any stock options for
the twelve months ended December 31, 2023. The fair value of the options granted for the&#160;twelve months ended December 31, 2022 were
estimated at the date of grant using the Black-Scholes-Merton option pricing model with the following assumptions:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="display: none">Schedule of assumptions used for valuation</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: left">Risk-free interest rate (4/2022 &#8211; 8/2022)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">1.99%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate (9/2022 &#8211; 12/2022)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.67%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-8 years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66.35%</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 159; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Nocimed, Inc. 2015 Stock Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains the Nocimed, Inc. 2015 Stock
Plan, or the &#8220;Existing Plan&#8221;, under which the Company could grant 152,558 shares (after giving effect to the 2024 Stock Split)
or options of the Company to our employees, consultants, and other service providers. The Company suspended the Existing Plan in connection
with the April 2022, initial public offering. The Company did not grant any stock options under the Existing Plan for the twelve months
ended December 31, 2022. No further awards will be granted under the Existing Plan, but awards granted prior to the suspension date will
continue in accordance with their terms and the terms of the Existing Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Determining Fair Value of Stock Options</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of each grant of stock options
was determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires
significant judgment to determine.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Valuation and Amortization Method </i>&#8212;The
Company estimates the fair value of its stock options using the Black-Scholes-Merton option-pricing model. This fair value is then amortized
over the requisite service periods of the awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Expected Term</i>&#8212;The Company estimates
the expected term of stock option by taking the average of the vesting term and the contractual term of the option, as illustrated by
the simplified method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Expected Volatility</i>&#8212;The expected
volatility is derived from the Company&#8217;s expectations of future market volatility over the expected term of the options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Risk-Free Interest Rate</i>&#8212;The risk-free
interest rate is based on the U.S. Treasury yield curve on the date of grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dividend Yield</i>&#8212;The dividend yield
assumption is based on the Company&#8217;s history and expectation of no dividend payouts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock Award Activity </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A post-split summary of option activity under
the Company&#8217;s equity incentive plans is as follows:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="display: none">Schedule of option activity</span></td><td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Options Outstanding</b></td>
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted- Average Remaining Contractual Life</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(In Years)</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; width: 55%">Balance at December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 12%">140,980</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 12%">29.47</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 12%">9.2</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">33,334</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">36.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.6</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8211;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Weighted average exercise price, Options granted" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Options forfeited/expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(3,138</td>
    <td style="padding-bottom: 1pt">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">20.32</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5.6</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold">Balance at December 31, 2022</td><td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">171,176</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.4</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8211;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Weighted average exercise price, Options granted" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8211;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Weighted average exercise price, Options granted" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Options forfeited/expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(1,720</td>
    <td style="padding-bottom: 1pt">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">23.64</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6.0</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">169,456</td>
    <td>&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31.15</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">7.5</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Weighted average exercise price, Options granted" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Exercisable at December 31, 2023</td><td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">147,977</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">30.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.4</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 160; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value in the table above
of the unexercised options reflects the total pre-tax intrinsic value (the difference between the Nasdaq closing price on December 30,
2023, and the exercise price of the options that would have been received by option holders if all options exercisable had been exercised.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value of options outstanding
at December 31, 2023 is $0. The aggregate intrinsic value of vested and exercisable options at December 31, 2022 is $0.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, there was approximately
$327,853 of total unrecognized compensation cost related to non-vested stock options, which is expected to be recognized over the next
21 months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adjusts expense for actual forfeitures
in the periods they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Restricted Stock Units </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the twelve month period ending
December 31, 2023, the Company granted RSUs under the 2022 Plan that have a combination of time-based and performance-based vesting,
contingent upon continued service with the Company. The Company granted certain consultants an aggregate of RSUs for  26,506
common shares (after giving effect to the 2024 Stock Split).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Post-split RSU activity under the 2022 Plan was
as follows for the year ended December 31, 2023:</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td><span style="display: none">Schedule of RSU activity</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>RSU&#8217;s Outstanding</b></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-Average Grant-Date Fair value per Unit</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nonvested as of December 31, 2021</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 12%">&#8211;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">30,120</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.12</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(3,864</td>
    <td>)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.92</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8211;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nonvested as of December 31, 2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">26,256</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.12</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">26,506</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.52</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(22,936</td>
    <td>)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.40</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(14,077</td>
    <td style="padding-bottom: 1pt">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nonvested as of December 31, 2023</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">15,749</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.72</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The grant date fair value for a RSU is the market
price of the common stock on the date of grant. The total fair value of RSUs vested during 2023 was $226,918.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, there was approximately
$43,468 total unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over the next nine months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Stock Subject to Vesting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company entered into a contract for consulting
services shortly after the completion of the IPO in April 2022. The contract included a fee payable in the form of 40,000 (2,500 after
giving effect to the 2024 Stock Split) restricted common shares that vested over six months. The shares were issued in November 2022
after the shares vested. Stock-based vendor payments of $102,000 were recognized on the date of grant and recorded as general and administrative
expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 161; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-based Compensation Expense</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the total stock-based
compensation expense included in the Company&#8217;s statements of operations for the periods presented:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="display: none">Schedule of stock-based compensation expense</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(restated)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Sales and marketing</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">228,437</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">57,298</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,725</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(259</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">217,839</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,129,619</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><b style="display: none">Total stock-based compensation</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">456,001</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,186,658</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 16. INCOME TAXES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes under ASC
740-10, which provides for an asset and liability approach of accounting for income taxes. Under this approach, deferred tax assets and
liabilities are recognized based on anticipated future tax consequences, using currently enacted tax laws, attributed to temporary differences
between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts calculated for income tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">A reconciliation
of the federal income tax rates to the Company&#8217;s effective tax rates for the year ended December 31, 2023 consist of
the following:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="display: none">Schedule of reconciliation
of the federal income tax rates</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    </tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td>&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 81%; text-align: justify">U.S. federal statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">21.0</td><td style="width: 2%; text-align: left">&#160;%</td>
    <td style="width: 1%">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Effects of:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">State taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.0</td><td style="text-align: left">&#160;%</td>
    <td>&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.6</td><td style="text-align: left">)%</td>
    <td>&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.3</td><td style="text-align: left">)%</td>
    <td>&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.3</td><td style="text-align: left">)%</td>
    <td>&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(26.8</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left">)%</td>
    <td>&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Effective rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8211;</td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left">&#160;%</td>
    <td>&#160;</td>
    </tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Significant
components of the Company&#8217;s deferred tax assets as of December 31, 2023 are summarized below.</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="display: none">Schedule of deferred tax assets</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    </tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Deferred tax asset:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">Net operating losses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">9,235,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Stock based compensation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">479,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total deferred tax asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">9,714,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Less valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(9,714,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred income tax liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 162; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company recognizes
deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination,
the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences,
projected future taxable income, tax-planning strategies, and results of recent operations. The Company assessed the need for a valuation
allowance of $9,714,000 required as of December
31, 2023, as the Company determined it is more likely than not the deferred tax assets will not be realized. Our net deferred tax asset
and valuation allowance increased by $1,315,000
for the year ended December 31, 2023. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during
the periods in which those temporary differences become deductible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company has evaluated
its income tax positions and has determined that it does not have any uncertain tax positions. The Company will recognize interest and
penalties related to any uncertain tax positions through its income tax expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company files income
tax returns in the U.S., Colorado, and California jurisdictions and is subject to examination by the various taxing authorities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 17. SUBSEQUENT EVENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Reverse
Stock Split</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2023 the Company&#8217;s stockholders
approved a reverse stock split proposal at a ratio in the range of one-for-five to one-for-fifty, with the final ratio to be determined
by the Company's board in its discretion without further approval from the Company's stockholders. In January 2024, the Company's board
approved the final reverse stock split ratio of one-for-sixteen, which resulted in a reduction in the number of outstanding shares of
common stock and a proportionate increase in the value of each share. The common stock began trading on a reverse split-adjusted basis
on the NASDAQ on January 4, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents selected share
information reflecting on a retroactive basis the reverse stock splits for the years ended December 31, 2023 and 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
    ended December 31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average shares
    outstanding, basic and diluted - pre-2024 split</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,908,934</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,105,569</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average shares outstanding, basic and diluted
    - post-2024 split</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">556,808</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">381,598</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net loss per shares attributable to
    common stockholders - pre-2024 split</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.55</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1.23</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net loss per shares attributable to
    common stockholders - post-2024 split</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8.82</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19.61</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>White Lion Equity
Line Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On October 9, 2023, the
Company entered into an equity line common stock purchase agreement (the &#8220;Equity Line Purchase Agreement&#8221;) and a related registration
rights agreement with White Lion Capital, LLC (&#8220;White Lion&#8221;). Pursuant to the Equity Line Agreement, the Company has the right,
but not the obligation to require White Lion to purchase, from time to time, up to $10,000,000 in aggregate gross purchase price of newly
issued shares of the Company&#8217;s common stock, subject to certain limitations and conditions set forth in the Equity Line Purchase
Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Pursuant to the Equity
Line Purchase Agreement (see Note 13: Stockholders Equity), the Company issued to White Lion 452,343 newly issued post-split common shares
for proceeds of $1,449,532, between January 4, 2024 and January 8, 2024. Through March 15, 2024, the Company has issued 750,000 shares
(after giving effect to the 2024 Stock Split) to White Lion for total proceeds of $2,912,481.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 163; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Exchange
Agreements and Repayment of Unsecured Non-Convertible Notes</i> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May, September and November 2023 the Company issued $2,594,118 aggregate
principal amount of unsecured non-convertible notes to certain accredited investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Between January 22 and
January 29, 2024, the Company entered into a series of exchange agreements (the &#8220;Exchange Agreements&#8221;) with the accredited
investors to exchange principal and accrued interest on these notes for shares of common stock. Pursuant to the Exchange Agreements, the
Company issued an aggregate of 644,142 post-split shares of common stock in exchange for $1,519,779 principal and accrued interest on
the notes. Following these exchanges, the remaining outstanding balance of principal and interest on the notes was $1,145,037.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On March 6, 2024, the
Company paid $300,973 of principal and accrued interest on certain unsecured non-convertible notes. Following this payment, the remaining
outstanding balance of principal and interest on the notes was $898,380.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company and the accredited
investors may elect in the future to effect additional exchanges of the notes for common stock. Any such future exchanges would be negotiated
and agreed to among the parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Public Offering;
Placement Agent Agreement; Warrants; Prefunded Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 26, 2024, the Company entered into a placement agency agreement
(the &#8220;Placement Agent Agreement&#8221;) with Maxim Group LLC (&#8220;Maxim&#8221; or the &#8220;Placement Agent&#8221;) pursuant
to which the Company engaged Maxim as the placement agent for a registered public offering by the Company (the &#8220;Offering&#8221;),
of an aggregate of 5,175,000 units (&#8220;Units&#8221;) at a price of $0.58 per Unit, for gross proceeds of approximately $3.0 million,
and net proceeds of $2.7M after deducting expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Unit is comprised of (i) one share of common stock or, in lieu
of common stock or one prefunded warrant to purchase a share of common stock, and (ii) two common warrants, each common warrant to purchase
a share of common stock. The prefunded warrants are immediately exercisable at a price of $0.00001 per share of common stock and only
expire when such prefunded warrants are fully exercised. The common warrants are immediately exercisable at a price of $0.58 per share
of common stock and will expire five years from the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company intends to use the proceeds from the Offering, together
with our existing cash, to fund clinical studies, repay outstanding debt, build out product platforms, expand our sales and marketing
efforts, and for general and administration expenses and other general corporate purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Offering closed on February 27, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Nasdaq Delisting Notices</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As previously disclosed, the Company received written notice from Nasdaq
on March 3, 2023, that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the &#8220;Equity Rule&#8221;), which requires
the Company to maintain a minimum of $2.5 million in stockholders&#8217; equity for continued listing on The Nasdaq Capital Market. Subsequent
to a hearing before a Nasdaq Hearings Panel, the Company was granted an extension, ultimately, through February 27, 2024, to evidence
compliance with the Rule.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the Offering described above, the Company received confirmation
from Nasdaq on February 29, 2024, stating that the Company has regained compliance with the Equity Rule, as required by the Hearing Panel&#8217;s
decision dated November 7, 2023. The Company will be subject to a Mandatory Panel Monitor for a period of one year. If, within that one-year
monitoring period, Nasdaq finds the Company again out of compliance with the Equity Rule, the Company will not be permitted to provide
the Staff with a plan of compliance with respect to that deficiency, and Staff will not be permitted to grant additional time for the
Company to regain compliance with respect to that deficiency, nor will the company be afforded an applicable cure or compliance period.
Instead, Staff will issue a Delist Determination Letter, and the Company will have an opportunity to request a new hearing with the initial
Hearings Panel, or a newly convened Hearings Panel if the initial Hearings Panel is unavailable. The Company will have the opportunity
to respond and present to the Hearings Panel. The Company&#8217;s securities may be at that time delisted from Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>




















































<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<!-- Field: Page; Sequence: 164; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Aclarion, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="q2_004"></span>Condensed Balance Sheets </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_301_111_zJFOezaBP8L6" summary="xdx: Statement - Condensed Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20240630_zYW4NQ2Ryio2" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20231231" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Jun 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Dec 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(Unaudited)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsAbstract_iB_zzs03ZIKV5e6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-decoration: underline; font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsCurrentAbstract_i01B_zHJZq7Cjten8" style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCz5JY_z0SFNbfgoyA1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; width: 66%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-06-30" id="Fact000035" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,172,687</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000036" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,021,069</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RestrictedCash_i02I_maCz5JY_zyHRgrYtigO3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2024-06-30" id="Fact000038" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2023-12-31" id="Fact000039" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccountsReceivableNetCurrent_i02I_maCz5JY_zfqzDbUnGAp8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-06-30" id="Fact000041" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,713</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-12-31" id="Fact000042" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,270</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCz5JY_zuIfWAjq4ky5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Prepaids and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-06-30" id="Fact000044" format="ixt:numdotdecimal" decimals="0" unitRef="USD">649,357</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000045" format="ixt:numdotdecimal" decimals="0" unitRef="USD">245,030</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsCurrent_i01TI_mtCz5JY_maCzqRT_zdFK7N0pRdTf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-06-30" id="Fact000047" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,851,757</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,289,369</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsNoncurrentAbstract_i01B_zjwser0r6qT7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-decoration: underline; text-align: left">Non-current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_i02I_maCzabo_z8wRlFBl1856" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-06-30" id="Fact000053" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,189</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,782</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i02I_maCzabo_zJELrKhTsjK2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Intangible assets, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2024-06-30" id="Fact000056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,235,875</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-12-31" id="Fact000057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,168,623</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetsNoncurrent_i01TI_mtCzabo_maCzqRT_zj9AKaeCAcR9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total non-current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2024-06-30" id="Fact000059" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,237,064</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2023-12-31" id="Fact000060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,170,405</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Assets_i01TI_mtCzqRT_z0QVQEuyHu0k" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-06-30" id="Fact000062" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,088,821</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000063" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,459,774</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesCurrentAbstract_i01B_zB0K1WcO2W5e" style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_i02I_maCzpT9_zKaFWJWQzTs6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-06-30" id="Fact000071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">179,123</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">760,535</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_i02I_maCzpT9_zSd7Di2PAfH2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued and other liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2024-06-30" id="Fact000074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">447,972</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2023-12-31" id="Fact000075" format="ixt:numdotdecimal" decimals="0" unitRef="USD">857,722</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherNotesPayableCurrent_i02I_maCzpT9_z3Swh58IMYkg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Note payable, net of discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNotesPayableCurrent" contextRef="AsOf2024-06-30" id="Fact000077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">777,087</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNotesPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,125,724</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--WarrantLiabilityCurrent_i02I_maCzpT9_zDZXKzbiQtV6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:WarrantLiabilityCurrent" contextRef="AsOf2024-06-30" id="Fact000080" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,861</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:WarrantLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">289,165</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DerivativeLiabilitiesCurrent_i02I_maCzpT9_zaCVZtVCMun2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2024-06-30" id="Fact000083" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,601</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000084" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,326</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--LiabilityToIssueEquity_i02I_d0_maCzpT9_zs1O1QWzq4S4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Liability to issue equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ACON:LiabilityToIssueEquity" contextRef="AsOf2024-06-30" id="Fact000086" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ACON:LiabilityToIssueEquity" contextRef="AsOf2023-12-31" id="Fact000087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,297</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrent_i01TI_mtCzpT9_maLztEx_zlZ1xumiRK6d" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total current liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-06-30" id="Fact000089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,446,644</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,187,769</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--Liabilities_iTI_mtLztEx_maLASEzrym_zr6hCgbFJm3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-06-30" id="Fact000092" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,446,644</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000093" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,187,769</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-decoration: underline; text-align: left">Stockholders' equity (deficit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CommonStockValue_i01I_maCzLZR_zLdnRJgTeS56" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Common stock - $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_c20240630_zHRPLzhnSKj4" title="Common stock, par value"><span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_c20231231_pdd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30" id="Fact000101" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000103" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></ix:nonFraction></span></span>
    par value, <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_c20240630_z8XEQRLalL82" title="Common stock, shares authorized"><span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_c20231231_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-06-30" id="Fact000105" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000107" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction></span></span>
    authorized and <span id="xdx_902_eus-gaap--CommonStockSharesIssued_c20240630_zLCH9X8uzeM4" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_c20240630_zW6V4a2W7Gpg" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-06-30" id="Fact000109" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-06-30" id="Fact000111" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,210,671</ix:nonFraction></ix:nonFraction></span></span>
    and <span id="xdx_907_eus-gaap--CommonStockSharesIssued_c20231231_pdd" title="Common stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_c20231231_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000113" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000115" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">825,459</ix:nonFraction></ix:nonFraction></span></span>
    shares issued and outstanding (see Note 11)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-06-30" id="Fact000098" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000099" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AdditionalPaidInCapital_i01I_maCzLZR_z3RmOpXVTmxb" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-06-30" id="Fact000117" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,560,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000118" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,553,523</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maCzLZR_zks3uTq1iRe1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-06-30" id="Fact000120" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">47,918,705</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000121" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,281,526</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--StockholdersEquity_i01TI_mtCzLZR_maLASEzrym_z1itf3X424Nf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total stockholders&#8217; equity (deficit)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000123" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,642,177</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000124" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">727,995</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzrym_zKyuCvLds3H1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217;
    equity (deficit)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000126" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,088,821</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000127" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,459,774</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to condensed financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 165; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Aclarion, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="q2_005"></span>Condensed Statements of Operations </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_113_za5C5bOk7pja" summary="xdx: Statement - Condensed Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20240401__20240630_zvVrtYMWmAx6" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20230401__20230630_zinttp7Tke3a" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20240101__20240630_zasu87a5UmCb" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20230101__20230630_zK4uTyaeWXak" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RevenuesAbstract_iB_zV88Ih8r1gdi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-decoration: underline; font-weight: bold">Revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Revenues_maCzbnq_zngVKviAIcw7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 44%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-04-012024-06-30" id="Fact000134" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,971</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-04-012023-06-30" id="Fact000135" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,072</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-01to2024-06-30" id="Fact000136" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,085</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-06-30" id="Fact000137" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,542</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CostOfRevenue_msCzbnq_zXKYijgXQOOi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Cost of revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-04-012024-06-30" id="Fact000139" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,294</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-04-012023-06-30" id="Fact000140" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,301</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-01to2024-06-30" id="Fact000141" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,770</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-012023-06-30" id="Fact000142" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,754</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--GrossProfit_iT_mtCzbnq_maCzhfY_zQNze5RHGMD7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Gross profit (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2024-04-012024-06-30" id="Fact000144" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,323</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-04-012023-06-30" id="Fact000145" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,229</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2024-01-01to2024-06-30" id="Fact000146" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,685</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-01-012023-06-30" id="Fact000147" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,788</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingExpensesAbstract_iB_z4T9T6wYfnwc" style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-weight: bold; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SellingAndMarketingExpense_i01_maCzagn_zJf8Uy1A2dr2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Sales and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2024-04-012024-06-30" id="Fact000154" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225,037</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2023-04-012023-06-30" id="Fact000155" format="ixt:numdotdecimal" decimals="0" unitRef="USD">207,790</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2024-01-01to2024-06-30" id="Fact000156" format="ixt:numdotdecimal" decimals="0" unitRef="USD">406,094</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2023-01-012023-06-30" id="Fact000157" format="ixt:numdotdecimal" decimals="0" unitRef="USD">385,074</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzagn_zYLHTdoN8tb6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-04-012024-06-30" id="Fact000159" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,102</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-04-012023-06-30" id="Fact000160" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,006</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-06-30" id="Fact000161" format="ixt:numdotdecimal" decimals="0" unitRef="USD">441,143</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-06-30" id="Fact000162" format="ixt:numdotdecimal" decimals="0" unitRef="USD">454,405</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzagn_zeVpSTwgwEC9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-04-012024-06-30" id="Fact000164" format="ixt:numdotdecimal" decimals="0" unitRef="USD">696,099</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-04-012023-06-30" id="Fact000165" format="ixt:numdotdecimal" decimals="0" unitRef="USD">946,175</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-06-30" id="Fact000166" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,541,947</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-06-30" id="Fact000167" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,753,774</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpenses_i01T_mtCzagn_msCzhfY_z6c6a57rXBm8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 20pt; text-align: left">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-04-012024-06-30" id="Fact000169" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,123,238</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-04-012023-06-30" id="Fact000170" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,403,971</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-01to2024-06-30" id="Fact000171" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,389,184</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-06-30" id="Fact000172" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,593,253</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingIncomeLoss_iT_mtCzhfY_maCzPhS_zVEMuGZiPcT4" style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-weight: bold; text-align: left; padding-bottom: 1pt">(Loss) from operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-04-012024-06-30" id="Fact000174" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,135,561</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-04-012023-06-30" id="Fact000175" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,406,200</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-06-30" id="Fact000176" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,410,869</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-06-30" id="Fact000177" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,587,465</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zriFqVFcHa8c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InterestExpenseOther_iN_di_msCz2XV_zMcrS1defe71" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseOther" contextRef="From2024-04-012024-06-30" id="Fact000184" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,848</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseOther" contextRef="From2023-04-012023-06-30" id="Fact000185" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,139</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseOther" contextRef="From2024-01-01to2024-06-30" id="Fact000186" format="ixt:numdotdecimal" decimals="0" unitRef="USD">463,672</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseOther" contextRef="From2023-01-012023-06-30" id="Fact000187" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,519</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--LossOnExchangeOfDebt_iN_di0_msCz2XV_zSRTLqpbqcbh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loss on exchange of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:LossOnExchangeOfDebt" contextRef="From2024-04-012024-06-30" id="Fact000189" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:LossOnExchangeOfDebt" contextRef="From2023-04-012023-06-30" id="Fact000190" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ACON:LossOnExchangeOfDebt" contextRef="From2024-01-01to2024-06-30" id="Fact000191" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,066,732</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:LossOnExchangeOfDebt" contextRef="From2023-01-012023-06-30" id="Fact000192" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_d0_maCz2XV_z64mi8pFoAs6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Loss on extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-04-012024-06-30" id="Fact000194" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-04-012023-06-30" id="Fact000195" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-01to2024-06-30" id="Fact000196" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">111,928</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-012023-06-30" id="Fact000197" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DerivativeGainLossOnDerivativeNet_d0_maCz2XV_zxDFBFj7rDz6" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Changes in fair value of warrant and derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-04-012024-06-30" id="Fact000199" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,357</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-04-012023-06-30" id="Fact000200" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,800</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-01-01to2024-06-30" id="Fact000201" format="ixt:numdotdecimal" decimals="0" unitRef="USD">323,041</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-012023-06-30" id="Fact000202" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,800</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--OtherNonoperatingIncomeExpense_maCz2XV_zhrA084IYZPa" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-04-012024-06-30" id="Fact000204" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-04-012023-06-30" id="Fact000205" format="ixt:numdotdecimal" decimals="0" unitRef="USD">583</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-01to2024-06-30" id="Fact000206" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,980</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-012023-06-30" id="Fact000207" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">234</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--NonoperatingIncomeExpense_iT_mtCz2XV_maCzPhS_zzxl5nIuo6wa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total other income (expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-04-012024-06-30" id="Fact000209" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">102,516</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-04-012023-06-30" id="Fact000210" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">58,356</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-01to2024-06-30" id="Fact000211" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,226,311</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-06-30" id="Fact000212" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">60,552</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCzPhS_maCzSwP_zf3JZoSQxVla" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income (loss) before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-04-012024-06-30" id="Fact000214" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,238,077</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-04-012023-06-30" id="Fact000215" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,464,557</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-01to2024-06-30" id="Fact000216" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,637,180</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-012023-06-30" id="Fact000217" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,648,017</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_d0_msCzSwP_zo8PmaQoSWDi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Income tax provision</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-04-012024-06-30" id="Fact000219" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-04-012023-06-30" id="Fact000220" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-06-30" id="Fact000221" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-06-30" id="Fact000222" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_iT_mtCzSwP_maCzmAn_zhLO1st5SuGb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net income (loss)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30" id="Fact000224" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,238,077</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30" id="Fact000225" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,464,557</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-06-30" id="Fact000226" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,637,180</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-06-30" id="Fact000227" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,648,017</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtCzmAn_zEscUafjFlAa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss) allocable to common stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-04-012024-06-30" id="Fact000229" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,238,077</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-04-012023-06-30" id="Fact000230" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,464,557</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-01to2024-06-30" id="Fact000231" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,637,180</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-012023-06-30" id="Fact000232" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,648,017</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss) per share allocable to common shareholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20240401__20240630_zwHN4wmGAQC2" title="Net income (loss) per share allocable to common shareholders, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_c20240401__20240630_zeJ4o27VZv3j" title="Net income (loss) per share allocable to common shareholders, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-04-012024-06-30" id="Fact000234" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-04-012024-06-30" id="Fact000236" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.15</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20230401__20230630_za23g6keR3dl" title="Net income (loss) per share allocable to common shareholders, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_900_eus-gaap--EarningsPerShareDiluted_c20230401__20230630_znPfnP8jaa15" title="Net income (loss) per share allocable to common shareholders, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-04-012023-06-30" id="Fact000238" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-04-012023-06-30" id="Fact000240" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.83</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_c20240101__20240630_z0vtfReyeLN1" title="Net income (loss) per share allocable to common shareholders, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20240101__20240630_zemCu4qT3Mc7" title="Net income (loss) per share allocable to common shareholders, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-06-30" id="Fact000242" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-06-30" id="Fact000244" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.53</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20230101__20230630_zMpd7H6B3EEf" title="Net income (loss) per share allocable to common shareholders, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20230101__20230630_zcWY54Zn60uj" title="Net income (loss) per share allocable to common shareholders, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-06-30" id="Fact000246" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-06-30" id="Fact000248" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">5.22</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Weighted average shares of common stock outstanding, basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_z92X6IQryZA6" title="Weighted average shares of common stock outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zrRED9NOofVk" title="Weighted average shares of common stock outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-04-012024-06-30" id="Fact000250" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-04-012024-06-30" id="Fact000252" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,217,024</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630_zpUbD9nkSYO8" title="Weighted average shares of common stock outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630_zNuKLb256Cdk" title="Weighted average shares of common stock outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-04-012023-06-30" id="Fact000254" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-04-012023-06-30" id="Fact000256" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">517,979</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_zUDfWibmF6me" title="Weighted average shares of common stock outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zrpZZM326Sba" title="Weighted average shares of common stock outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-06-30" id="Fact000258" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-06-30" id="Fact000260" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,829,825</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630_z46l5GsZnNh" title="Weighted average shares of common stock outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630_zE7QAD7ikgi" title="Weighted average shares of common stock outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-06-30" id="Fact000262" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-06-30" id="Fact000264" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">507,499</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to condensed financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 166; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Aclarion, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="q2_006"></span>Condensed Statements of Changes in Stockholders'
Equity (Deficit)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_114_zGNcSjEw5UQ6" summary="xdx: Statement - Condensed Statements of Changes in Stockholders' Equity (Deficit) (Unaudited)" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_custom--PreferredStockSeriesAMember_z11XptjeNSsl" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_custom--PreferredStockSeriesA1A2A3A4Member_z2kGvObNb0jj" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_custom--PreferredStockSeriesBB1Member_z6Yg7HFiAUU3" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_custom--PreferredStockSeriesB2B3Member_zCllP6ocIZyk" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Series A</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Series A-1, A-2, A-3, A-4</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Series B, B-1</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Series B-2, B-3</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Preferred Stock</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Preferred Stock</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Preferred Stock</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Preferred Stock</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Value</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Value</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Value</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Value*</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_43A_c20230101__20230331_eus-gaap--StockholdersEquity_iS_d0_z90peIXpkxcj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -5pt; padding-left: 5pt">Balance, December 31, 2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_d0_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesAMember_zAsLjv2nKxMl" title="Beginning balance, shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_custom_PreferredStockSeriesAMember" id="Fact000271" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_PreferredStockSeriesAMember" id="Fact000266" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_d0_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesA1A2A3A4Member_zBpHrwYwjWLf" title="Beginning balance, shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_custom_PreferredStockSeriesA1A2A3A4Member" id="Fact000273" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_PreferredStockSeriesA1A2A3A4Member" id="Fact000267" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_d0_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesBB1Member_zK1wUtk4s3d3" title="Beginning balance, shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_custom_PreferredStockSeriesBB1Member" id="Fact000275" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_PreferredStockSeriesBB1Member" id="Fact000268" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_d0_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesB2B3Member_zayupPYKFqx6" title="Beginning balance, shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_custom_PreferredStockSeriesB2B3Member" id="Fact000277" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_PreferredStockSeriesB2B3Member" id="Fact000269" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zH9G726zQpq" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0279">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0280">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0281">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0282">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ProceedsFromSaleOfSeriesPreferredStock_zRQRPoNAn6f3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 36%; text-align: left; text-indent: -5pt; padding-left: 5pt">Proceeds from sale of Series A preferred stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_ecustom--PreferredStockIssuedDuringPeriodSharesNewIssues_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesAMember_z8eAx3LxwWdj" title="Proceeds from sale of Series A preferred stock, shares" style="width: 5%; text-align: right"><ix:nonFraction name="ACON:PreferredStockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesAMember" id="Fact000289" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction name="ACON:ProceedsFromSaleOfSeriesPreferredStock" contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesAMember" id="Fact000284" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0285">&#8211;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0286">&#8211;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0287">&#8211;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--RedemptionOfSeriesPreferredStock_z8nsJ7uk5tRb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Redemption of Series A Preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--RedemptionOfSeriesPreferredStockShares_iN_di_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesAMember_zctEdhpHvbUd" title="Redemption of Series A Preferred stock, shares" style="text-align: right">(<ix:nonFraction name="ACON:RedemptionOfSeriesPreferredStockShares" contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesAMember" id="Fact000296" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ACON:RedemptionOfSeriesPreferredStock" contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesAMember" id="Fact000291" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0292">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0293">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0294">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_zgihrRlnL8Qc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -5pt; padding-left: 5pt">Net income (loss)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0298">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0299">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0300">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0301">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_435_c20230401__20230630_eus-gaap--StockholdersEquity_iS_d0_zMgMo62ZWcW1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -5pt; padding-left: 5pt">Balance, March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_d0_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesAMember_zCEyRl2zVvc" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_custom_PreferredStockSeriesAMember" id="Fact000308" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_custom_PreferredStockSeriesAMember" id="Fact000303" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_d0_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesA1A2A3A4Member_zSc0WbqfRo4d" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_custom_PreferredStockSeriesA1A2A3A4Member" id="Fact000310" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_custom_PreferredStockSeriesA1A2A3A4Member" id="Fact000304" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_d0_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesBB1Member_zOKuN4OSHpic" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_custom_PreferredStockSeriesBB1Member" id="Fact000312" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_custom_PreferredStockSeriesBB1Member" id="Fact000305" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_d0_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesB2B3Member_zJzb0Eek80t8" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_custom_PreferredStockSeriesB2B3Member" id="Fact000314" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_custom_PreferredStockSeriesB2B3Member" id="Fact000306" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zjGki6e4uOG6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0317">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0319">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--CommitmentSharesNoteFinancing_iP3custom--RedemptionOfSeriesPreferredStockShares_zHumzaZCWwT3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Commitment shares - note financing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--CommitmentSharesNoteFinancingShares_iP3custom--CommitmentSharesNoteFinancing_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesAMember_zeYZdbYx6zxe" title="Commitment shares - note financing, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0326">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0321">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0322">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--IssuanceOfWarrantsNoteFinancing_iP3custom--CommitmentSharesNoteFinancingShares_zPVn1rejW2y3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Issuance of warrants - note financing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0328">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0329">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0331">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_zLvtq2lAk6I3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -5pt; padding-left: 5pt">Net income (loss)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0333">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0335">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43B_c20230401__20230630_eus-gaap--StockholdersEquity_iE_d0_zH24F62ogHsl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -5pt; padding-left: 5pt">Balance, June 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_d0_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesAMember_zIsPKiClnE73" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_custom_PreferredStockSeriesAMember" id="Fact000343" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_custom_PreferredStockSeriesAMember" id="Fact000338" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_d0_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesA1A2A3A4Member_zq5vnvp0zkFf" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_custom_PreferredStockSeriesA1A2A3A4Member" id="Fact000345" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_custom_PreferredStockSeriesA1A2A3A4Member" id="Fact000339" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_d0_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesBB1Member_zYNHnm3k8ZEa" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_custom_PreferredStockSeriesBB1Member" id="Fact000347" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_custom_PreferredStockSeriesBB1Member" id="Fact000340" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_d0_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesB2B3Member_z3Sz9iA13uTg" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_custom_PreferredStockSeriesB2B3Member" id="Fact000349" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_custom_PreferredStockSeriesB2B3Member" id="Fact000341" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20240101__20240331_eus-gaap--StockholdersEquity_iS_d0_z10gF4iY5Avl" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -5pt; padding-left: 5pt">Balance, December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_d0_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesAMember_ztZM4LyhqUe1" title="Beginning balance, shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_custom_PreferredStockSeriesAMember" id="Fact000356" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_PreferredStockSeriesAMember" id="Fact000351" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_d0_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesA1A2A3A4Member_zaXRpDGIP2kh" title="Beginning balance, shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_custom_PreferredStockSeriesA1A2A3A4Member" id="Fact000358" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_PreferredStockSeriesA1A2A3A4Member" id="Fact000352" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_d0_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesBB1Member_ztf3kzeqzHXd" title="Beginning balance, shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_custom_PreferredStockSeriesBB1Member" id="Fact000360" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_PreferredStockSeriesBB1Member" id="Fact000353" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_d0_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesB2B3Member_zTxDjXQ6r0Ih" title="Beginning balance, shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_custom_PreferredStockSeriesB2B3Member" id="Fact000362" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_PreferredStockSeriesB2B3Member" id="Fact000354" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zGWvhIZa89t2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0365">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_iP3us-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z6NyT3uHPVw8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Issuance of common shares related to restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_iP3us-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesAMember_z3qKQtlQpixi" title="Issuance of common shares related to restricted stock units, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0369">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0370">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0371">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--IssuanceOfCommonSharesEquityLineOfCredit_iP3us-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_zTdDcHMbOPv7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Issuance of common shares - equity line of credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--IssuanceOfCommonSharesEquityLineOfCreditShares_iP3custom--IssuanceOfCommonSharesEquityLineOfCredit_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesAMember_zixLRXnxvlie" title="Issuance of common shares - equity line of credit, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0381">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0376">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0377">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0378">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0379">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--IssuanceOfCommitmentSharesNoteFinancing_iP3custom--IssuanceOfCommonSharesEquityLineOfCreditShares_zD0AVl2e9e1f" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Issuance of commitment shares - note financing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--IssuanceOfCommitmentSharesNoteFinancingShares_iP3custom--IssuanceOfCommitmentSharesNoteFinancing_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesAMember_zLu4mTwKkTff" title="Issuance of commitment shares - note financing, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0388">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0384">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0385">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--CashlessExerciseOfPrefundedWarrant_iP3custom--IssuanceOfCommitmentSharesNoteFinancingShares_z3rynqaHKy5j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Cashless exercise of pre-funded warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--CashlessExerciseOfPrefundedWarrantsShares_iP3custom--CashlessExerciseOfPrefundedWarrant_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesAMember_zadHhhG3fNJg" title="Cashless exercise of pre-funded warrants, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0395">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0390">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0391">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0392">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts_iP3custom--CashlessExerciseOfPrefundedWarrantsShares_zBJgRnD3bBD2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Issuance of common stock and warrants related to public offering, net issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares_iP3custom--IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesAMember_zPgvsDxOVAX2" title="Issuance of common stock and warrants related to public offering, net issuance costs, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0402">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0398">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0399">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0400">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--PublicOfferingAndLineOfCreditIssuanceCosts_iP3custom--IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares_zqp0x8BjTl5a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Public offering and line of credit issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0404">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0405">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0406">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0407">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--IssuanceOfCommonSharesDebtForEquityExchange_iP3custom--PublicOfferingAndLineOfCreditIssuanceCosts_zxtmdv1olvLf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Issuance of common shares - debt for equity exchange</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--IssuanceOfCommonSharesDebtForEquityExchangeShares_iP3custom--IssuanceOfCommonSharesDebtForEquityExchange_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesAMember_zJnf2XvkBI35" title="Issuance of common shares - debt for equity exchange, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0414">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0409">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0410">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0411">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0412">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--RoundUpConversionRelatedToReverseStockSplit_iP3custom--IssuanceOfCommonSharesDebtForEquityExchangeShares_z6RQZAWE4xfj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Round up conversion related to reverse stock split</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--RoundUpConventionRelatedToReverseStockSplitShares_iP3custom--RoundUpConversionRelatedToReverseStockSplit_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesAMember_ztE97PsT5rU6" title="Round up convention related to reverse stock split, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0418">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_zsvmDmM5e9Y1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -5pt; padding-left: 5pt">Net income (loss)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0423">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0425">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0426">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_430_c20240401__20240630_eus-gaap--StockholdersEquity_iS_d0_zfuu64d7Pprf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -5pt; padding-left: 5pt">Balance, March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_d0_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesAMember_zS28BJ6lW2kk" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_custom_PreferredStockSeriesAMember" id="Fact000433" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_custom_PreferredStockSeriesAMember" id="Fact000428" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_d0_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesA1A2A3A4Member_zg8kh3wD4l48" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_custom_PreferredStockSeriesA1A2A3A4Member" id="Fact000435" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_custom_PreferredStockSeriesA1A2A3A4Member" id="Fact000429" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_d0_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesBB1Member_zVKrUtO5vUN9" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_custom_PreferredStockSeriesBB1Member" id="Fact000437" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_custom_PreferredStockSeriesBB1Member" id="Fact000430" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_d0_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesB2B3Member_z4lCivJoTgs" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_custom_PreferredStockSeriesB2B3Member" id="Fact000439" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_custom_PreferredStockSeriesB2B3Member" id="Fact000431" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zgIx6Ib4KvA5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0441">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0442">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0443">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0444">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zcfxUwCs0NOe" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Issuance of common shares related to restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0446">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0447">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0448">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0449">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--IssuanceOfCommonSharesEquityLineOfCredit_z5cXoGtrF5x6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Issuance of common shares - equity line of credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0451">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0452">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0453">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0454">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_z1jYaOKnGe93" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -5pt; padding-left: 5pt">Net income (loss)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0456">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0457">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0458">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0459">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43C_c20240401__20240630_eus-gaap--StockholdersEquity_iE_d0_zhxysDIfurag" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -5pt; padding-left: 5pt">Balance, June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_d0_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesAMember_z1pBGyH25M03" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_custom_PreferredStockSeriesAMember" id="Fact000466" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_custom_PreferredStockSeriesAMember" id="Fact000461" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_d0_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesA1A2A3A4Member_z4zb467uXMb4" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_custom_PreferredStockSeriesA1A2A3A4Member" id="Fact000468" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_custom_PreferredStockSeriesA1A2A3A4Member" id="Fact000462" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_d0_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesBB1Member_zHHu2PdEbZaf" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_custom_PreferredStockSeriesBB1Member" id="Fact000470" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_custom_PreferredStockSeriesBB1Member" id="Fact000463" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_d0_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesB2B3Member_zDuZN2w6fbQ5" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_custom_PreferredStockSeriesB2B3Member" id="Fact000472" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_custom_PreferredStockSeriesB2B3Member" id="Fact000464" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">(continued)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 167; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Aclarion, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Statements of Changes in Stockholders'
Equity (Deficit)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(continued)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zOIXQqvRR5F" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zjgDzSzetJpe" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z6G1KYgI36wc" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B0_zVv0mYxdOZ2" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Additional</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">Paid-In</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">Accumulated</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Value</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Capital</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Deficit</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_432_c20230101__20230331_eus-gaap--StockholdersEquity_iS_zu7EE9BnN5hk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 50%; padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ze5jLZHpFqU8" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000479" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">491,345</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000474" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000475" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,596,106</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000476" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">39,370,153</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000477" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,225,958</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zQeJCi3dWVq6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0481">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000482" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,531</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0483">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31" id="Fact000484" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,531</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ProceedsFromSaleOfSeriesPreferredStock_znVqRBAlXVS8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Proceeds from sale of Series A preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0486">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0487">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0488">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:ProceedsFromSaleOfSeriesPreferredStock" contextRef="From2023-01-012023-03-31" id="Fact000489" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--RedemptionOfSeriesPreferredStock_zaK3afAShacl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Redemption of Series A Preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0491">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0492">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0493">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ACON:RedemptionOfSeriesPreferredStock" contextRef="From2023-01-012023-03-31" id="Fact000494" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_z888VPzdznBl" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Net income (loss)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0496">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0497">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="Fact000498" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,183,460</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31" id="Fact000499" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,183,460</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43D_c20230401__20230630_eus-gaap--StockholdersEquity_iS_zOLUyV7p9gFi" style="vertical-align: bottom; background-color: White">
    <td>Balance, March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOFx8ASvC0sd" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact000506" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">491,345</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact000501" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000502" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,678,637</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" id="Fact000503" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,553,613</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" id="Fact000504" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,125,029</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z9TTqWNj3tY3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0508">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000509" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136,631</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0510">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30" id="Fact000511" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136,631</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--CommitmentSharesNoteFinancing_zG7iOZZDkOk4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Commitment shares - note financing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--CommitmentSharesNoteFinancingShares_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zomwUPb5tZPd" title="Commitment shares - note financing, shares" style="text-align: right"><ix:nonFraction name="ACON:CommitmentSharesNoteFinancingShares" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="Fact000518" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,210</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0513">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:CommitmentSharesNoteFinancing" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000514" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,619</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0515">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:CommitmentSharesNoteFinancing" contextRef="From2023-04-012023-06-30" id="Fact000516" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,619</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--IssuanceOfWarrantsNoteFinancing_z7QPVisF9L3c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of warrants - note financing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0520">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfWarrantsNoteFinancing" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000521" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0522">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfWarrantsNoteFinancing" contextRef="From2023-04-012023-06-30" id="Fact000523" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_zUFuGBp2XAW2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Net income (loss)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0525">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0526">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="Fact000527" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,464,557</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30" id="Fact000528" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,464,557</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_430_c20230401__20230630_eus-gaap--StockholdersEquity_iE_z8PjDidMEzrd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance, June 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z39MQEeuiqZ1" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact000535" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">512,555</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact000530" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000531" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,028,387</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" id="Fact000532" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">42,018,169</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" id="Fact000533" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,223</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_439_c20240101__20240331_eus-gaap--StockholdersEquity_iS_zd3y9cErFWCi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt">Balance, December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFLI5abBHVU2" title="Beginning balance, shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000542" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">825,459</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000537" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000538" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,553,524</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000539" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,281,526</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000540" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">727,995</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zKDdKu1VD57c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0544">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000545" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,827</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0546">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31" id="Fact000547" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,827</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zxnTqJgA79Yh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Issuance of common shares related to restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztO2gn0yvhq3" title="Issuance of common shares related to restricted stock units, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000554" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,261</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0549">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0550">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0551">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0552">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--IssuanceOfCommonSharesEquityLineOfCredit_z284GqGKJRc5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of common shares - equity line of credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--IssuanceOfCommonSharesEquityLineOfCreditShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzeFyTUMrUEd" title="Issuance of common shares - equity line of credit, shares" style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfCommonSharesEquityLineOfCreditShares" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000561" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">452,343</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfCommonSharesEquityLineOfCredit" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000556" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfCommonSharesEquityLineOfCredit" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000557" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,449,527</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0558">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfCommonSharesEquityLineOfCredit" contextRef="From2024-01-012024-03-31" id="Fact000559" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,449,532</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--IssuanceOfCommitmentSharesNoteFinancing_z2y82OHTSPT3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Issuance of commitment shares - note financing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--IssuanceOfCommitmentSharesNoteFinancingShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zO0ZtJxmoe9i" title="Issuance of commitment shares - note financing, shares" style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfCommitmentSharesNoteFinancingShares" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000568" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,312</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0563">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfCommitmentSharesNoteFinancing" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000564" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,297</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0565">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfCommitmentSharesNoteFinancing" contextRef="From2024-01-012024-03-31" id="Fact000566" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,297</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--CashlessExerciseOfPrefundedWarrant_zsyaeb0vjQOa" style="vertical-align: bottom; background-color: White">
    <td>Cashless exercise of pre-funded warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--CashlessExerciseOfPrefundedWarrantsShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgnkcc2CTFEj" title="Cashless exercise of pre-funded warrants, shares" style="text-align: right"><ix:nonFraction name="ACON:CashlessExerciseOfPrefundedWarrantsShares" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000575" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,915</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0570">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0571">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0572">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0573">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts_zxMX4TnFMRB2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Issuance of common stock and warrants related to public offering, net issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk4ImFtPzWFb" title="Issuance of common stock and warrants related to public offering, net issuance costs, shares" style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000582" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,175,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000577" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000578" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,691,339</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0579">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts" contextRef="From2024-01-012024-03-31" id="Fact000580" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,691,391</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--PublicOfferingAndLineOfCreditIssuanceCosts_zg7ae1ZVrfJa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Public offering and line of credit issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0584">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ACON:PublicOfferingAndLineOfCreditIssuanceCosts" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000585" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">399,106</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0586">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ACON:PublicOfferingAndLineOfCreditIssuanceCosts" contextRef="From2024-01-012024-03-31" id="Fact000587" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">399,106</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--IssuanceOfCommonSharesDebtForEquityExchange_zMfbmYPEu11" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Issuance of common shares - debt for equity exchange</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--IssuanceOfCommonSharesDebtForEquityExchangeShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkQfeHrtnm8j" title="Issuance of common shares - debt for equity exchange, shares" style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfCommonSharesDebtForEquityExchangeShares" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000594" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">644,142</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfCommonSharesDebtForEquityExchange" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000589" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfCommonSharesDebtForEquityExchange" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000590" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,771,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0591">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfCommonSharesDebtForEquityExchange" contextRef="From2024-01-012024-03-31" id="Fact000592" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,771,606</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--RoundUpConversionRelatedToReverseStockSplit_z4KZOANAf2y6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Round up conversion related to reverse stock split</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--RoundUpConventionRelatedToReverseStockSplitShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXkA1cSz9HC" title="Round up convention related to reverse stock split, shares" style="text-align: right"><ix:nonFraction name="ACON:RoundUpConventionRelatedToReverseStockSplitShares" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000601" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,068</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0596">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0597">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0598">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0599">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_zjeiEkECe4C2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Net income (loss)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0603">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0604">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="Fact000605" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,399,102</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact000606" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,399,102</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43B_c20240401__20240630_eus-gaap--StockholdersEquity_iS_z354BmAjMRTa" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance, March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkbZRGdge8h3" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000613" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,153,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000608" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000609" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,186,006</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" id="Fact000610" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">46,680,628</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000611" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,505,449</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zeb2QdIa1fid" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0615">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000616" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,305</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0617">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012024-06-30" id="Fact000618" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,305</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zKja70gp3Ibb" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Issuance of common shares related to restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVBe6HvSBWcl" title="Issuance of common shares related to restricted stock units, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000625" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,171</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0620">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0621">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0622">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0623">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--IssuanceOfCommonSharesEquityLineOfCredit_zO321mE82Xf1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of common shares - equity line of credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--IssuanceOfCommonSharesEquityLineOfCreditShares_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvcnZiHnBg8c" title="Issuance of common shares - equity line of credit, shares" style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfCommonSharesEquityLineOfCreditShares" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000632" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,050,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfCommonSharesEquityLineOfCredit" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000627" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfCommonSharesEquityLineOfCredit" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000628" format="ixt:numdotdecimal" decimals="0" unitRef="USD">304,490</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0629">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfCommonSharesEquityLineOfCredit" contextRef="From2024-04-012024-06-30" id="Fact000630" format="ixt:numdotdecimal" decimals="0" unitRef="USD">304,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_z1OmS0wWTZf8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Net income (loss)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0634">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0635">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="Fact000636" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,238,077</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30" id="Fact000637" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,238,077</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_431_c20240401__20240630_eus-gaap--StockholdersEquity_iE_z4cLkkQnBRvl" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance, June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyN6DCV3P5T8" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000644" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,210,671</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000639" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000640" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,560,800</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" id="Fact000641" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">47,918,705</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000642" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,642,177</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to condensed financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 168; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Aclarion, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="q2_008"></span>Condensed Statements of Cash Flows </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_307_112_zEiN1kez3Gwe" summary="xdx: Statement - Condensed Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20240101__20240630_zxktgCZOmycl" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20230101__20230630_zKUyaSFMDOO8" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zDxQDkkpUwn" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Cash flows from operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_i01_maNCPBUzrlo_zvuIEBlIiPFj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 66%; text-align: left">Net income (loss)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-06-30" id="Fact000649" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,637,180</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-06-30" id="Fact000650" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,648,017</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_iB_z9M7D8PXVxK5" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Adjustments to reconcile net income (loss) to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DepreciationDepletionAndAmortization_i01_maNCPBUzrlo_z1qP1tN7hdBl" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2024-01-01to2024-06-30" id="Fact000655" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,864</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-01-012023-06-30" id="Fact000656" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,809</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensation_i01_maNCPBUzrlo_zP3bbmJ7ZKOb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-06-30" id="Fact000658" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,131</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-06-30" id="Fact000659" format="ixt:numdotdecimal" decimals="0" unitRef="USD">219,162</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--GainLossOnExchangeOfDebt_i01_d0_maNCPBUzrlo_z7bhoHT1QLdg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left">Loss on exchange of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:GainLossOnExchangeOfDebt" contextRef="From2024-01-01to2024-06-30" id="Fact000661" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,066,732</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:GainLossOnExchangeOfDebt" contextRef="From2023-01-012023-06-30" id="Fact000662" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--GainsLossesOnExtinguishmentOfDebts_i01_d0_maNCPBUzrlo_zyt8HQBHEtIj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Loss on extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:GainsLossesOnExtinguishmentOfDebts" contextRef="From2024-01-01to2024-06-30" id="Fact000664" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,928</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:GainsLossesOnExtinguishmentOfDebts" contextRef="From2023-01-012023-06-30" id="Fact000665" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AmortizationOfFinancingCosts_i01_d0_maNCPBUzrlo_z785AaUvvbQi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left">Amortization of deferred issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2024-01-01to2024-06-30" id="Fact000667" format="ixt:numdotdecimal" decimals="0" unitRef="USD">442,289</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2023-01-012023-06-30" id="Fact000668" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,520</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_i01_d0_maNCPBUzrlo_z4ESosPIoLkk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Change in fair value related to warrants and derivative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="From2024-01-01to2024-06-30" id="Fact000670" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">323,041</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="From2023-01-012023-06-30" id="Fact000671" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,800</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--NoncashInterestRelatedToBridgeFunding_i01_d0_maNCPBUzrlo_zyhWk6nCxTOf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left">Non-cash interest related to bridge funding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:NoncashInterestRelatedToBridgeFunding" contextRef="From2024-01-01to2024-06-30" id="Fact000673" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,116</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:NoncashInterestRelatedToBridgeFunding" contextRef="From2023-01-012023-06-30" id="Fact000674" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,346</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_iB_zP6CSS0n7MY6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in assets and liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInAccountsReceivable_i01N_di_msNCPBUzrlo_zLMxHSGgEHN1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2024-01-01to2024-06-30" id="Fact000679" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,115</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-012023-06-30" id="Fact000680" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,414</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i01N_di_msNCPBUzrlo_zKQ77vo06MSe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Prepaids and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-01to2024-06-30" id="Fact000682" format="ixt:numdotdecimal" decimals="0" unitRef="USD">405,657</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-06-30" id="Fact000683" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,287</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInAccountsPayable_i01_maNCPBUzrlo_zxzIRPs4SBJ7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-01-01to2024-06-30" id="Fact000685" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">540,710</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-012023-06-30" id="Fact000686" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,914</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i01_maNCPBUzrlo_zqDCHduOOJA7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Accrued and other liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2024-01-01to2024-06-30" id="Fact000688" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">267,325</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-01-012023-06-30" id="Fact000689" format="ixt:numdotdecimal" decimals="0" unitRef="USD">241,110</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--IncreaseDecreaseInNotePayableNetOfDiscount_i01_d0_maNCPBUzrlo_zxELxbsQl1El" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Note payable, net of discount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ACON:IncreaseDecreaseInNotePayableNetOfDiscount" contextRef="From2024-01-01to2024-06-30" id="Fact000691" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">31,129</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ACON:IncreaseDecreaseInNotePayableNetOfDiscount" contextRef="From2023-01-012023-06-30" id="Fact000692" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzrlo_maCCERCzH5D_zhvA1iHBpEhh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash (used in) operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-06-30" id="Fact000694" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,293,096</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-06-30" id="Fact000695" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,960,653</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_z0Uhf4MfOfCg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PaymentsToAcquireIntangibleAssets_iN_di_msNCPBUzjPB_zOXFw09I48S8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Intangible assets - Patents</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2024-01-01to2024-06-30" id="Fact000700" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,523</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2023-01-012023-06-30" id="Fact000701" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,634</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_mtNCPBUzjPB_maCCERCzH5D_zzYiqDK5Ctkd" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash (used in) investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-01to2024-06-30" id="Fact000703" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">157,523</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-06-30" id="Fact000704" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">72,634</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zFGDCtN7mCq8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_d0_maNCPBUzALN_zEGzbJD8uw26" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Issuance of common stock and warrants related to public offering, net deductions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-01to2024-06-30" id="Fact000709" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,691,391</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-06-30" id="Fact000710" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromLinesOfCredit_i01_d0_maNCPBUzALN_zzA3OZR8QTGc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from equity line</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2024-01-01to2024-06-30" id="Fact000712" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,754,032</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2023-01-012023-06-30" id="Fact000713" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RepaymentsOfNotesPayable_i01N_di0_msNCPBUzALN_zNPAaOOcTMe2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Repayment of promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2024-01-01to2024-06-30" id="Fact000715" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,973</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2023-01-012023-06-30" id="Fact000716" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--EquityLineOfCreditIssuanceCosts_i01N_di0_msNCPBUzALN_z4muftjZ2vdg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Equity line cash issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ACON:EquityLineOfCreditIssuanceCosts" contextRef="From2024-01-01to2024-06-30" id="Fact000718" format="ixt:numdotdecimal" decimals="0" unitRef="USD">262,744</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:EquityLineOfCreditIssuanceCosts" contextRef="From2023-01-012023-06-30" id="Fact000719" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PaymentsOfStockIssuanceCosts_i01N_di0_msNCPBUzALN_zpxqELZgrfrl" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Public offering cash issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2024-01-01to2024-06-30" id="Fact000721" format="ixt:numdotdecimal" decimals="0" unitRef="USD">256,094</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2023-01-012023-06-30" id="Fact000722" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--BridgeFundingIssuanceCosts_i01N_di0_msNCPBUzALN_zcfZRyPqVrW8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Bridge fund cash issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ACON:BridgeFundingIssuanceCosts" contextRef="From2024-01-01to2024-06-30" id="Fact000724" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,375</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ACON:BridgeFundingIssuanceCosts" contextRef="From2023-01-012023-06-30" id="Fact000725" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--ProceedsFromBridgeFunding_i01_d0_maNCPBUzALN_z0b6zUIKGz5c" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from bridge funding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:ProceedsFromBridgeFunding" contextRef="From2024-01-01to2024-06-30" id="Fact000727" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:ProceedsFromBridgeFunding" contextRef="From2023-01-012023-06-30" id="Fact000728" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_i01_d0_maNCPBUzALN_zHVnPqZ68215" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from sale of Series A preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2024-01-01to2024-06-30" id="Fact000730" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2023-01-012023-06-30" id="Fact000731" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_i01N_di0_msNCPBUzALN_zAAtoZUmkAK7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Redemption of Series A Preferred stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" contextRef="From2024-01-01to2024-06-30" id="Fact000733" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" contextRef="From2023-01-012023-06-30" id="Fact000734" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_d0_mtNCPBUzALN_maCCERCzH5D_z7UXfzkDksik" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-06-30" id="Fact000736" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,602,237</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-06-30" id="Fact000737" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,165,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCCERCzH5D_zrTelhEDCbOj" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Net increase (decrease) in cash and cash equivalents</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2024-01-01to2024-06-30" id="Fact000739" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,618</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2023-01-012023-06-30" id="Fact000740" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">868,287</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zwN4PDTxbBq7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Cash, cash equivalents and restricted cash, beginning of period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000742" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,031,069</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" id="Fact000743" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,482,806</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zBC3HLksUdfa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash, cash equivalents and restricted cash, end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-06-30" id="Fact000745" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,182,687</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-06-30" id="Fact000746" format="ixt:numdotdecimal" decimals="0" unitRef="USD">614,518</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Non-cash activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--IssuanceOfCommonSharesInExchangeForDebt_i01_d0_zdVbOrQQzcOk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Issuance of common shares in exchange for debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfCommonSharesInExchangeForDebt" contextRef="From2024-01-01to2024-06-30" id="Fact000751" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,519,779</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfCommonSharesInExchangeForDebt" contextRef="From2023-01-012023-06-30" id="Fact000752" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IssuanceOfBridgeFundCommitmentShares_i01_ztOYA98D54H1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Issuance of bridge fund commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfBridgeFundCommitmentShares" contextRef="From2024-01-01to2024-06-30" id="Fact000754" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,297</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfBridgeFundCommitmentShares" contextRef="From2023-01-012023-06-30" id="Fact000755" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,619</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--FairValueOfWarrantsAndDerivativeRelatedToBridgeFunding_i01_d0_zDg8tkDk9Jha" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Fair value of warrants and derivative related to bridge funding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:FairValueOfWarrantsAndDerivativeRelatedToBridgeFunding" contextRef="From2024-01-01to2024-06-30" id="Fact000757" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:FairValueOfWarrantsAndDerivativeRelatedToBridgeFunding" contextRef="From2023-01-012023-06-30" id="Fact000758" format="ixt:numdotdecimal" decimals="0" unitRef="USD">742,988</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--AccruedDebtIssuanceCostsRelatedToBridgeFunding_i01_d0_z8v4Zy6NkPI" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued debt issuance costs related to bridge funding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:AccruedDebtIssuanceCostsRelatedToBridgeFunding" contextRef="From2024-01-01to2024-06-30" id="Fact000760" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:AccruedDebtIssuanceCostsRelatedToBridgeFunding" contextRef="From2023-01-012023-06-30" id="Fact000761" format="ixt:numdotdecimal" decimals="0" unitRef="USD">118,575</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--IssuanceOfWarrantsRelatedToBridgeFunding_i01_d0_zIZVuROxEQe6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Issuance of warrants related to bridge funding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfWarrantsRelatedToBridgeFunding" contextRef="From2024-01-01to2024-06-30" id="Fact000763" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:IssuanceOfWarrantsRelatedToBridgeFunding" contextRef="From2023-01-012023-06-30" id="Fact000764" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--OriginalIssueDiscount15RelatedToBridgeFunding_i01_d0_zZo3YDva2ypd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Original issue discount (15%) related to bridge funding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:OriginalIssueDiscount15RelatedToBridgeFunding" contextRef="From2024-01-01to2024-06-30" id="Fact000766" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:OriginalIssueDiscount15RelatedToBridgeFunding" contextRef="From2023-01-012023-06-30" id="Fact000767" format="ixt:numdotdecimal" decimals="0" unitRef="USD">187,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to condensed financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 169; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Aclarion, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="q2_009"></span>Notes to Condensed Financial Statements </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000769" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_804_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zMtdWvT9gXrj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE</b>&#160; <b>1. <span id="xdx_822_zka55zb6zZBd">THE COMPANY AND BASIS
OF PRESENTATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aclarion, Inc., formerly Nocimed, Inc., (the &#8220;Company&#8221;
or &#8220;Aclarion&#8221;) is a healthcare technology company that leverages magnetic resonance spectroscopy (&#8220;MRS&#8221;), and
a proprietary biomarker to optimize clinical treatments. The Company was formed in February 2015, is incorporated in Delaware, and has
its principal place of business in Broomfield, Colorado.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying condensed financial statements
have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) and
pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information.
Accordingly, they do not include all of the information required by U.S. GAAP for complete financial statements. The interim condensed
financial statements reflect all adjustments that are of a normal recurring nature and that are considered necessary for a fair representation
of the results for the periods presented and should be read in conjunction with the audited financial statements and notes thereto for
the year ended December 31, 2023, which include a complete set of footnote disclosures, including our significant accounting policies.
The December 31, 2023, condensed balance sheet was derived from the December 31, 2023, audited financial statements. They should be read
in conjunction with the financial statements and notes thereto included in our Annual report on Form 10-K, filed with the SEC on March
28, 2024. The results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or
for any other future period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks and Uncertainties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to various risks and uncertainties
frequently encountered by companies in the early stages of development. Such risks and uncertainties include, but are not limited to,
its limited operating history, competition from other companies, limited access to additional funds, dependence on key personnel, and
management of potential rapid growth. To address these risks, the Company must, among other things, develop its customer base&#894; implement
and successfully execute its business and marketing strategy&#894; develop follow-on products&#894; provide superior customer service&#894;
and attract, retain, and motivate qualified personnel. There can be no guarantee that the Company will be successful in addressing these
or other such risks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2024 Reverse Stock Split</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2023 the Company&#8217;s stockholders
approved a reverse stock split proposal at a ratio in the range of one-for-five to one-for-fifty, with the final ratio to be determined
by the Company's board in its discretion without further approval from the Company's stockholders. In January 2024, the Company's board
subsequently approved the final reverse stock split ratio of <span id="xdx_90A_eus-gaap--StockholdersEquityReverseStockSplit_c20240101__20240131__us-gaap--TransactionTypeAxis__custom--StockSplit2024Member_zKdEPfaEeWA1" title="Reverse stock split"><ix:nonNumeric contextRef="From2024-01-012024-01-31_custom_StockSplit2024Member" id="Fact000771" name="us-gaap:StockholdersEquityReverseStockSplit">one-for-sixteen</ix:nonNumeric></span> (the &#8220;2024 Stock Split&#8221;), which resulted in a
reduction in the number of outstanding shares of common stock, warrants, stock options and restricted share units and a proportionate
increase in the value of each share or strike price of the warrants and stock options. The common stock began trading on a reverse split-adjusted
basis on the NASDAQ on January 4, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the 2024 Stock Split, unless described
otherwise, all references to common stock, share data, per share data and related information contained in these financial statements
have been retrospectively adjusted to reflect the effect of the stock splits for all periods presented. In addition, any fractional shares
that would otherwise be issued as a result of the stock splits were rounded up to the nearest whole share. Further, the number of shares
issuable and exercise prices of stock options and warrants have been retrospectively adjusted in these financial statements for all periods
presented to reflect the 2024 Stock Split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23D_znWIcNrcOzO" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_z7OhkbSK306b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zTgCdg2vVnD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 170; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_zm4BW15LxoT4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables present selected share information
reflecting on a retroactive basis the reverse stock splits as of and for the year ended December 31, 2023:</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000777" name="ACON:ScheduleOfChangesToEquityStatementTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfChangesToEquityStatementTableTextBlock_zZRvytdP8TH3" summary="xdx: Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details - Balance sheet changes from split)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B1_z5fsJdtzTOkc" style="display: none">Schedule of equity statement information</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_zx70AX1o1z2a" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CommonStockValue_iI_pp0p0_hus-gaap--TransactionTypeAxis__custom--Pre2024SplitMember_z00mAK4ij0Y3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: left">Common shares issued and outstanding - pre-2024 split, <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_c20231231__us-gaap--TransactionTypeAxis__custom--Pre2024SplitMember_zzbiaUSo59Pd" title="Common stock shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--TransactionTypeAxis__custom--Pre2024SplitMember_zRXG7S1lnhA3" title="Common stock shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31_custom_Pre2024SplitMember" id="Fact000781" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_Pre2024SplitMember" id="Fact000783" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,206,229</ix:nonFraction></ix:nonFraction></span></span> shares</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31_custom_Pre2024SplitMember" id="Fact000779" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">132</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CommonStockValue_iI_pp0p0_hus-gaap--TransactionTypeAxis__custom--Post2024SplitMember_zFLz567u1sZ2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common shares issued and outstanding - post-2024 split, <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20231231__us-gaap--TransactionTypeAxis__custom--Post2024SplitMember_zq5ZhNpBA2Yl" title="Common stock shares issued"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--TransactionTypeAxis__custom--Post2024SplitMember_zWAI9cspabM6" title="Common stock shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31_custom_Post2024SplitMember" id="Fact000787" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_Post2024SplitMember" id="Fact000789" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">825,459</ix:nonFraction></ix:nonFraction></span></span> shares</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31_custom_Post2024SplitMember" id="Fact000785" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_hus-gaap--TransactionTypeAxis__custom--Pre2024SplitMember_z36SUXsfVLUi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Additional paid-in capital - pre-2024 split</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31_custom_Pre2024SplitMember" id="Fact000791" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,553,399</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_hus-gaap--TransactionTypeAxis__custom--Post2024SplitMember_z03MNEEJTmcj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additional paid-in capital - post-2024 split</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31_custom_Post2024SplitMember" id="Fact000793" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,553,523</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zo2yVaKiuuzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000795" name="ACON:ScheduleOfRetroactiveBasisRreverseStockSplitsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfRetroactiveBasisRreverseStockSplitsTableTextBlock_zhBkya5ufew7" summary="xdx: Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details- Retroactive basis the reverse stock splits)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B9_zVL8x49ZagWc" style="display: none">Schedule of share information reflecting on a retroactive basis the reverse stock splits</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: left">Weighted average shares outstanding, basic and diluted - pre-2024 split</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PreSplitMember_zRCKpWECLsDk" title="Weighted average shares outstanding, basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PreSplitMember_ziZ01LCrKPSd" title="Weighted average shares outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31_custom_PreSplitMember" id="Fact000797" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31_custom_PreSplitMember" id="Fact000799" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,908,934</ix:nonFraction></ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average shares outstanding, basic and diluted - post-2024 split</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PostSplitMember_zNy0pB4jkdD" title="Weighted average shares outstanding, basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PostSplitMember_zyspSxsF3Cdd" title="Weighted average shares outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31_custom_PostSplitMember" id="Fact000801" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31_custom_PostSplitMember" id="Fact000803" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">556,808</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Basic and diluted net loss per shares attributable to common stockholders - pre-2024 split</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PreSplitMember_z9bzbcgtXBe2" title="Basic net loss per shares attributable to common stockholders"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PreSplitMember_z9zldA0n5aS8" title="Diluted net loss per shares attributable to common stockholders">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31_custom_PreSplitMember" id="Fact000805" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31_custom_PreSplitMember" id="Fact000807" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.55</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Basic and diluted net loss per shares attributable to common stockholders - post-2024 split</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PostSplitMember_zbqirK9pCUt3" title="Basic net loss per shares attributable to common stockholders"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PostSplitMember_zqys2puH9Qhd" title="Diluted net loss per shares attributable to common stockholders">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31_custom_PostSplitMember" id="Fact000809" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31_custom_PostSplitMember" id="Fact000811" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">8.82</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zveFxll1R1M5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Nasdaq notice regarding <span style="background-color: white">compliance
with the $1.00 Minimum Bid Price requirement</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="background-color: white">&#160;</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="background-color: white"></span></b>On April 8, 2024, Aclarion, Inc. (the &#8220;Company&#8221;) received a written
notice (the &#8220;Notice&#8221;) from the Listing Qualifications Department of The Nasdaq Stock Market (&#8220;Nasdaq&#8221;) indicating
that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued
listing on The Nasdaq Capital Market (the &#8220;Bid Price Requirement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Notice does not result in the immediate delisting
of the Company&#8217;s common stock from The Nasdaq Capital Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Nasdaq Listing Rules require listed securities to maintain
a minimum bid price of $1.00 per share and, based upon the closing bid price of the Company&#8217;s common stock for the 30 consecutive
business days for the period ending April 5, 2024, the Company no longer meets this requirement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Notice indicated that the
Company will be provided 180 calendar days (or until October 7, 2024) in which to regain compliance. If at any time during this 180 calendar
day period the bid price of the Company&#8217;s common stock closes at or above $1.00 per share for a minimum of ten consecutive business
days, the Nasdaq staff (the &#8220;Staff&#8221;) will provide the Company with a written confirmation of compliance and the matter will
be closed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alternatively, if the Company fails to regain compliance with Rule 5550(a)(2) prior to the expiration of the initial
180 calendar day period, the Company may be eligible for an additional 180 calendar day compliance period, provided (i) it meets the
continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The
Nasdaq Capital Market (except for the Bid Price Requirement) and (ii) it provides written notice to Nasdaq of its intention to cure this
deficiency during the second compliance period by effecting a reverse stock split, if necessary. In the event the Company does not regain
compliance with Rule 5550(a)(2) prior to the expiration of the initial 180 calendar day period, and if it appears to the Staff that the
Company will not be able to cure the deficiency, or if the Company is not otherwise eligible, the Staff will provide the Company with
written notification that its securities are subject to delisting from The Nasdaq Capital Market. At that time, the Company may appeal
the delisting determination to a Hearings Panel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company intends to monitor the closing bid price of its common stock and
is considering its options to regain compliance with the Bid Price Requirement. The Company&#8217;s receipt of the Notice does not affect
the Company&#8217;s business, operations or reporting requirements with the Securities and Exchange Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<ix:exclude><p id="xdx_23B_zh503Uvs6Zm9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zEhmQc6KOsyc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<ix:exclude><!-- Field: Page; Sequence: 171; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_z2TJ6qHtHpZ3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nasdaq Stockholder Equity Notice</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 3, 2023, the Company received a written notice (the &#8220;Stockholder Equity Notice&#8221;) from Nasdaq indicating that it
is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Stock Market to maintain a minimum
of $2,500,000 in stockholders&#8217; equity for continued listing. In its annual report on Form 10-K filed on February 27, 2023 for the
period ended December 31, 2022, the Company reported stockholders&#8217; equity of $1,787,751, and, as a result, does not currently satisfy
Listing Rule 5550(b)(1).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Stockholder Equity Notice also indicated that the Company had a period of 45 calendar days
from the date of the Stockholder Equity Notice, or until April 17, 2023, to submit a plan to regain compliance with the stockholders&#8217;
equity requirement under Nasdaq Listing Rule 5550(b)(1). The Company submitted such a plan to Nasdaq on April 12, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April
20, 2023, the Company received a letter (the &#8220;Extension Notice&#8221;) from Nasdaq notifying the Company that it has been granted
an additional 180-day period, or until August 30, 2023, to regain compliance with Nasdaq Listing Rule 5550(b)(1).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31,
2023, the Nasdaq staff notified the Company that it had not met the terms of the Extension Notice. Accordingly, the Nasdaq staff had
determined to delist the Company&#8217;s common stock from Nasdaq, unless the Company timely requests an appeal of the staff&#8217;s
determination to a hearings panel (the &#8220;Panel&#8221;), pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company requested a hearing before a hearings panel (the &#8220;Panel&#8221;) to appeal the delisting notice from the staff.
The Company's hearing with the Panel occurred on October 19, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 7, 2023, we were notified by the Panel that the
Company&#8217;s request for continued listing on Nasdaq was granted, subject to the Company demonstrating compliance with the stockholders&#8217;
equity requirement and bid price requirement on or before January 31, 2024. The Panel subsequently extended this compliance date to February
27, 2024. On February 27, 2024, the Company completed a public offering of 5,175,000 units (&#8220;Units&#8221;) at a price of $0.58
per Unit, for gross proceeds of approximately $3.0 million, before deducting offering expenses. Each Unit was comprised of (i) one share
of common stock or, in lieu of common stock, one prefunded warrant to purchase a share of common stock, and (ii) two common warrants,
each common warrant to purchase a share of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 15, 2024, the Company filed a Quarterly Report on Form 10-Q for
the three months ending March 31, 2024, and reported stockholders&#8217; equity of $2,505,450.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2024, the Company had Stockholders&#8217;
Equity of $1,642,177.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000816" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_z7gDNj0vRmL6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE</b>  <b>2. <span id="xdx_821_zZssDNNZtoL6">SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000818" name="us-gaap:UseOfEstimates"><p id="xdx_849_eus-gaap--UseOfEstimates_ziG9kpLZ5Bff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_867_zn4BPLb1gMOa">Use of Estimates</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements include some amounts
that are based on management's best estimates and judgments. The most significant estimates relate to depreciation, amortization, and
valuation of warrants, warrant and derivative liabilities, and options to purchase shares of the Company's common stock. These estimates
may be adjusted as more current information becomes available, and any adjustment could be significant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_233_zxQkupVEACYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zl6t72zXhOKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 172; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<ix:exclude><p id="xdx_238_zfbVh73Ummw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000823" name="us-gaap:DerivativesPolicyTextBlock"><p id="xdx_84B_eus-gaap--DerivativesPolicyTextBlock_zQFUWdhps961" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86B_zvGU9YFgC5dg">Valuation of Derivative Instruments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial Accounting Standards Board (&#8220;FASB&#8221;)
Accounting Standards Codification (&#8220;ASC&#8221;) 815-40, <i>Derivatives and Hedging: Contracts on an Entity&#8217;s Own Equity</i>,
addresses whether an equity-linked contract qualifies as equity in the entity&#8217;s financial statements. Agreements where an entity
has insufficient authorized and unissued shares to settle the contract generally are accounted for as a liability and marked to fair value
through earnings each reporting period. The Company evaluates its financial instruments to determine if such instruments are liabilities
or contain features that qualify as embedded derivatives. For financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then revalued at each reporting date, with changes in the fair value reported
as charges or credits to income.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000825" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zRpqL0aSezma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_862_zO4Tn9Q11Wl1">Fair Value of Financial Instruments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820, Fair Value Measurements, provides guidance
on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price,
representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market
participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions
that market participants would use in pricing an asset or a liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accounting guidance classifies fair value
measurements in one of the following three categories for disclosure purposes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Level 1</i> - Unadjusted quoted prices
in active markets for identical instruments that are accessible by the Company on the measurement date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Level 2</i> - Quoted prices in markets
that are not active or inputs which are either directly or indirectly observable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Level 3</i> - Unobservable inputs
for the instrument requiring the development of assumptions by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company analyzes all financial instruments
with features of both liabilities and equity under the Financial Accounting Standard Board&#8217;s (&#8220;FASB&#8221;) accounting standard
for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level
of input that is significant to the fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying values of the Company&#8217;s financial
instruments including cash equivalents, restricted cash, accounts receivable, and accounts payable are approximately equal to their respective
fair values due to the relatively short-term nature of these instruments. The Company&#8217;s warrant liabilities and derivative liabilities
are estimated using level 3 inputs (see Note 3).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000827" name="us-gaap:DerivativesReportingOfDerivativeActivity"><p id="xdx_841_eus-gaap--DerivativesReportingOfDerivativeActivity_zVoH8tcJ5E1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_864_z3ko8Qu0N10l">Derivative Financial Instruments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has derivative financial instruments
that are not hedges and do not qualify for hedge accounting. Changes in the fair value of these instruments are recorded in other income
(expenses), on a net basis in the Consolidated Statements of Operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000829" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zk0RdMwL3mnk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_864_zVRDtCC2yNvc">Cash and Cash Equivalents</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid
instruments purchased with an original maturity of three months or less to be cash equivalents. The Company had <span id="xdx_90F_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20240630_zJosY1pNcA8e" title="Cash equivalents"><span id="xdx_90F_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20231231_zQ3wey1WdzB5" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2024-06-30" id="Fact000831" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000833" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>
cash equivalents at June 30, 2024 and December 31, 2023. The Company maintains cash deposits at several financial institutions,
which are insured by the FDIC up to $250,000. The Company&#8217;s cash balance may at times exceed these limits. On June 30, 2024,
and December 31, 2023, the Company had $<span id="xdx_90A_eus-gaap--CashUninsuredAmount_pp0p0_c20240630_zvmXQ04QcOR4" title="Cash uninsured amount"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2024-06-30" id="Fact000835" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">818,591</ix:nonFraction> </span>and
$<span id="xdx_905_eus-gaap--CashUninsuredAmount_iI_pp0p0_c20231231_zF4ZgR3wsS2i" title="Cash uninsured amount"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2023-12-31" id="Fact000837" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">761,800</ix:nonFraction></span>,
respectively, in excess of federally insured limits. The Company continually monitors its positions with, and the credit quality of,
the financial institutions with which it invests. The Company maintains no international bank accounts. As of June 30, 2024, $<span id="xdx_90A_eus-gaap--RestrictedCash_pp0p0_c20240630_zjS4vKHk3vag" title="Restricted cash"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2024-06-30" id="Fact000839" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,000</ix:nonFraction></span>
of the Company&#8217;s cash was restricted as collateral related to the credit card program offered by our bank.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000841" name="us-gaap:ReceivablesPolicyTextBlock"><p id="xdx_84E_eus-gaap--ReceivablesPolicyTextBlock_zerACPyV9j7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86F_zcsnM77PyZQa">Accounts Receivable, Less Allowance for Doubtful
Accounts</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company estimates an allowance for doubtful
accounts based upon an evaluation of the current status of receivables, historical experience, and other factors as necessary. It is reasonably
possible that the Company&#8217;s estimate of the allowance for doubtful accounts will change. The allowance for doubtful accounts was
$<span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_c20240630_za2m8ElG0ibl" title="Allowance for doubtful accounts"><span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_c20231231_zSjpkmAhEE6k" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2024-06-30" id="Fact000843" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2023-12-31" id="Fact000845" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></ix:nonFraction></span></span> on June 30, 2024, and December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_239_zXkkK0fIcPIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_z3ELgu3JpDc4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zLfxxdiHHZC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 173; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zQK9ljxMPfgg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000851" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_84D_eus-gaap--RevenueRecognitionPolicyTextBlock_zsEL0fBsDPzh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_865_zqmMPrW88aq3">Revenue Recognition</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues are recognized when a contract with a
customer exists, and at that point in time when we have delivered a Nociscan report to our customer. Revenue is recognized in the amount
that reflects the negotiated consideration expected to be received in exchange for those reports. Following the delivery of the report,
the company has no ongoing obligations or services to provide to the customer. Customers pay no other upfront, licensing, or other fees.
To date, our reports are not reimbursable under any third-party payment arrangements, The Company invoices its customers based on the
billing schedules in its sales arrangements. Payment terms range generally from 30 to 90 days from the date of invoice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000853" name="ACON:LiquidityCapitalResourcesAndGoingConcernPolicyTextBlock"><p id="xdx_84C_ecustom--LiquidityCapitalResourcesAndGoingConcernPolicyTextBlock_z5a6J8nqvx05" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86F_zj66HsO4f93g">Liquidity, Capital Resources and Going Concern</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company believes that the net proceeds from
the February 2024 initial public offering, and subsequent funding from the April 2024 equity line agreement described in Note 11, will
be sufficient to fund current operating plans into the third quarter of 2024, approaching our final maturity repayment of our unsecured
non-convertible note, which is due in September 2024. The Company has based these estimates, however, on assumptions that may prove to
be wrong, and could spend available financial resources much faster than we currently expect. The Company will need to raise additional
funds to continue funding our technology development. Management plans to secure such additional funding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the Company&#8217;s recurring
losses from operations and the need for additional financing to fund its operating and capital requirements, there is uncertainty regarding
the Company&#8217;s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to
the Company&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000855" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_843_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zYhjdlqc7Rki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86A_zVMECq7BR5Ci">Share-Based Compensation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock-based awards in
accordance with provisions of ASC Topic 718, Compensation&#8212;Stock Compensation, under which the Company recognizes the grant-date
fair value of stock-based awards issued to employees and nonemployee board members as compensation expense on a straight-line basis over
the vesting period of the award, while awards containing a performance condition are recognized as expense when the achievement of the
performance criteria is achieved. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock
options. The Company records expense for forfeitures in the periods they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The exercise or strike price of each option is
not less than 100% of the fair market value of the Common Stock subject to the option on the date the option is granted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issues restricted stock unit awards
to non-employee consultants who are providing various services. The awards are valued at the market price on the date of the grant. The
awards vest over the contract life and based on achievement of targeted performance milestones.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On occasion, the Company grants common stock to
compensate vendors for services rendered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000857" name="us-gaap:DeferredChargesPolicyTextBlock"><p id="xdx_84B_eus-gaap--DeferredChargesPolicyTextBlock_zhAbqLlDwUt5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_865_zvEaGPLTAznc">Deferred Financing Costs</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company capitalizes certain legal, accounting,
and other fees and costs that are directly attributable to in-process equity financings as deferred offering costs until such financings
are completed. Upon the completion of an equity financing, these costs are recorded as a reduction of additional paid-in capital of the
related offering. Upon the completion of the public offering in February 2024, approximately $<span id="xdx_905_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20240201__20240229__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TransactionTypeAxis__custom--CompletionOfPublicOfferingMember_zE4lWkkHSuXd" title="Adjustment to additional paid in capital"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2024-02-012024-02-29_us-gaap_IPOMember_custom_CompletionOfPublicOfferingMember" id="Fact000859" format="ixt:numdotdecimal" decimals="0" unitRef="USD">566,200</ix:nonFraction></span> of offering costs related to the
public offering were reclassified to additional paid-in capital ($310,105 deducted from proceeds, and $256,094 paid or accrued). Upon
the completion of the issuance of shares pursuant to the equity line in the first quarter of 2024, $<span id="xdx_909_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20240101__20240331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TransactionTypeAxis__custom--CompletionOfIssuanceOfSharesMember_zZUikbr0Sf4k"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2024-01-012024-03-31_us-gaap_IPOMember_custom_CompletionOfIssuanceOfSharesMember" id="Fact000860" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133,000</ix:nonFraction></span> of offering costs were reclassified
to additional paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23A_zuQEpzPdxDy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zpWvPrPL0GF3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zZNkuPH5Rbx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 174; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zgZ4Kh401vLc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000866" name="ACON:EmergingGrowthCompanyStatusPolicyTextBlock"><p id="xdx_84D_ecustom--EmergingGrowthCompanyStatusPolicyTextBlock_zJUuI0JP9rFb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_865_zEi2eT73N822">Emerging Growth Company Status</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is an emerging growth company, as
defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies
can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those
standards apply to private companies. The Company has elected to use this extended transition period to comply with certain new or revised
accounting standards that have different effective dates for public and private companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000868" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock"><p id="xdx_803_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zgrmGCl64dOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3: <span id="xdx_822_zVDsykCc31lf">FAIR VALUE MEASUREMENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 820 (Fair Value Measurements
and Disclosures), the Company uses various inputs to measure the outstanding warrants, certain embedded redemption features associated
with the senior note to Aclarion, Inc. on a recurring basis to determine the fair value of the liability.</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000870" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_z5DHIjUGoj67" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details- Recurring basis to determine the fair value of the liability)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B8_zWsBf9xJ1UB8" style="display: none">Schedule of recurring basis to determine the fair value of the liability</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value measured as of June 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fair value on<br/> June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Quoted prices</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>in active</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>markets</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Level 1)</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Significant</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>other</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>observable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>inputs</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Level 2)</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Significant unobservable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>inputs</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Level 3)</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 40%; text-align: justify">Warrant liability</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_c20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zA998PkcuyZk" title="Total Fair value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-06-30_custom_WarrantLiabilityMember" id="Fact000872" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,861</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zoLgDjODusAg" title="Total Fair value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_custom_WarrantLiabilityMember" id="Fact000874" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zBYKvutvi8Ng" title="Total Fair value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_custom_WarrantLiabilityMember" id="Fact000876" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueNetAssetLiability_pp0p0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zLaohb2EEvqf" title="Total Fair value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityMember" id="Fact000878" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,861</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Derivative Liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_c20240630__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_zlfWBvMfTNoh" title="Total Fair value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-06-30_custom_DerivativeLiabilityMember" id="Fact000880" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,601</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_zfXnrkd37Wvl" title="Total Fair value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_custom_DerivativeLiabilityMember" id="Fact000882" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_z7h2kPtKhmVg" title="Total Fair value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_custom_DerivativeLiabilityMember" id="Fact000884" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueNetAssetLiability_pp0p0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_z0SijhPWVEma" title="Total Fair value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_custom_DerivativeLiabilityMember" id="Fact000886" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,601</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total Fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueNetAssetLiability_pp0p0_c20240630_z43pQYhHON8" title="Total Fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-06-30" id="Fact000888" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,462</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z6bJ5xowjKLc" title="Total Fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member" id="Fact000890" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zwzpmUh6TWbi" title="Total Fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member" id="Fact000892" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueNetAssetLiability_pp0p0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zM04iHzAvbXk" title="Total Fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member" id="Fact000894" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,462</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AF_z3ybJzpQPRKk" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no transfers between Level 1, 2, and
3 during the six months ended June 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents changes in Level
3 liabilities measures at fair value for the six months ended June 30, 2024. Both observable and unobservable inputs were used to determine
the fair value positions that the Company has classified within the Level 3 category.</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000896" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_ziPQmesJtQ7c" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Liabilities measures at fair value)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B0_zoX9EIuMPvmi" style="display: none">Schedule of liabilities measures at fair value</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zG0wTBSIxWt2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_zgv8BPVxntkh" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20240630_z0lU2wVoFOj5" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrant</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Liability</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Derivative</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Liability</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueHedgeLiabilitiesAtFairValue_iS_d0_zLtUPk9WPLzj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 49%">Balance &#8211; December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:FairValueHedgeLiabilitiesAtFairValue" contextRef="AsOf2023-12-31_custom_WarrantLiabilityMember" id="Fact000898" format="ixt:numdotdecimal" decimals="0" unitRef="USD">289,165</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:FairValueHedgeLiabilitiesAtFairValue" contextRef="AsOf2023-12-31_custom_DerivativeLiabilityMember" id="Fact000899" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,326</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:FairValueHedgeLiabilitiesAtFairValue" contextRef="AsOf2023-12-31" id="Fact000900" format="ixt:numdotdecimal" decimals="0" unitRef="USD">410,491</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ExchangeAndPayoffOfNotesPayable_d0_zaS5H20uttU1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 9pt">Exchange and Payoff of Notes Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ACON:ExchangeAndPayoffOfNotesPayable" contextRef="From2024-01-012024-06-30_custom_WarrantLiabilityMember" id="Fact000902" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ACON:ExchangeAndPayoffOfNotesPayable" contextRef="From2024-01-012024-06-30_custom_DerivativeLiabilityMember" id="Fact000903" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,988</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ACON:ExchangeAndPayoffOfNotesPayable" contextRef="From2024-01-01to2024-06-30" id="Fact000904" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,988</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_zoD7OVLvy4Nc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 9pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="From2024-01-012024-06-30_custom_WarrantLiabilityMember" id="Fact000906" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">265,304</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="From2024-01-012024-06-30_custom_DerivativeLiabilityMember" id="Fact000907" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">57,737</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="From2024-01-01to2024-06-30" id="Fact000908" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">323,041</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--FairValueHedgeLiabilitiesAtFairValue_iE_zBA4hafI9HUk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance &#8211; June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueHedgeLiabilitiesAtFairValue" contextRef="AsOf2024-06-30_custom_WarrantLiabilityMember" id="Fact000910" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,861</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueHedgeLiabilitiesAtFairValue" contextRef="AsOf2024-06-30_custom_DerivativeLiabilityMember" id="Fact000911" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,601</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueHedgeLiabilitiesAtFairValue" contextRef="AsOf2024-06-30" id="Fact000912" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,462</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AB_z6dYD8CMFBy3" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the embedded derivative liabilities
associated with the Senior Notes Payable was estimated using a probability weighted discounted cash flow model to measure the fair value.
This involves significant Level 3 inputs and assumptions including an (i) estimated probability and timing of certain financing events
and event of default, and (ii) the Company&#8217;s risk-adjusted discount rate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_239_z99aNusHGZZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zXhbFHMF9p6l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zMbefid6JfV7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 175; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zYXz3QCwR8E" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the warrants to purchase shares
of common stock was estimated using a Monte Carlo simulation using the following assumptions.&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000918" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zmUoad8QJIye" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details- Fair value of the warrants)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B8_zFEAOSKhbGl7" style="display: none">Schedule of assumptions</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b><b>As of</b></b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b>Dec 31, 2023</b></p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b><b>As of</b></b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b>June 30, 2024</b></p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrant Liability</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrant Liability</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%">Strike Price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_905_eus-gaap--SharePrice_iI_c20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zOAACiCYM3Mc" title="Strike Price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_custom_WarrantLiabilityMember" id="Fact000920" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.32</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_909_eus-gaap--SharePrice_c20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zxP9Y65jeFVg" title="Strike Price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-06-30_custom_WarrantLiabilityMember" id="Fact000922" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.29</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Contractual term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zaz2aQfE56f2" title="Contractual term (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_WarrantLiabilityMember" format="ixt-sec:duryear" id="Fact000924" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.0</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zhS3Y0k1tA9a" title="Contractual term (years)"><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_WarrantLiabilityMember" format="ixt-sec:duryear" id="Fact000926" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.0</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Volatility (annual)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230101__20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zIpabLWtGOf3" title="Volatility (annual)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-12-31_custom_WarrantLiabilityMember" id="Fact000928" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80.0</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zjcBHjV81VK6" title="Volatility (annual)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-06-30_custom_WarrantLiabilityMember" id="Fact000930" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80.0</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230101__20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zHhsZBfMcWsc" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-12-31_custom_WarrantLiabilityMember" id="Fact000932" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.89</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember__srt--RangeAxis__srt--MinimumMember_zLS5YTh5Wju3" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-06-30_custom_WarrantLiabilityMember_srt_MinimumMember" id="Fact000934" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.39</ix:nonFraction></span>-<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember__srt--RangeAxis__srt--MaximumMember_z6hRSb9ZgVR2" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-06-30_custom_WarrantLiabilityMember_srt_MaximumMember" id="Fact000936" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.44</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Floor Financing price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_ecustom--FloorFinancingPrice_iI_c20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zchQoQsnIuza" title="Floor Financing price"><ix:nonFraction name="ACON:FloorFinancingPrice" contextRef="AsOf2023-12-31_custom_WarrantLiabilityMember" id="Fact000938" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.24</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_ecustom--FloorFinancingPrice_c20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zySMHJETMa5f" title="Floor Financing price"><ix:nonFraction name="ACON:FloorFinancingPrice" contextRef="AsOf2024-06-30_custom_WarrantLiabilityMember" id="Fact000940" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.14</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A9_zo7snNywcdEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000942" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"><p id="xdx_808_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zSdY292RwJ19" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE</b>&#160; <b>4. <span id="xdx_828_zrzMnZQQ0LQg">RECENT ACCOUNTING PRONOUNCEMENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, there have been no recent accounting
pronouncements not yet effective that have significance, or potential significance, to our Consolidated Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000944" name="us-gaap:RevenueFromContractWithCustomerTextBlock"><p id="xdx_808_eus-gaap--RevenueFromContractWithCustomerTextBlock_zmRrrjg9Kjx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE</b>&#160; <b>5. <span id="xdx_826_z9TbXXEUwy4a">REVENUE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Contract Balances</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The timing of revenue recognition, billings, and
cash collections may result in trade, unbilled receivables, and deferred revenues on the balance sheets. At times, revenue recognition
may occur before the billing, resulting in an unbilled receivable, which would represent a contract asset. The contract asset would be
a component of accounts receivable and other assets for the current and non-current portions, respectively. In the event the Company receives
advances or deposits from customers before revenue is recognized, this would result in a contract liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000946" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock"><p id="xdx_802_eus-gaap--SupplementalBalanceSheetDisclosuresTextBlock_z38Paqrdbrtl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6. <span id="xdx_825_zc4ACJqUwL85">SUPPLEMENTAL FINANCIAL INFORMATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Balance Sheets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Prepaids and other current assets:</b></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000948" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zeNyOudskBJ1" summary="xdx: Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Prepaids and other current assets)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B5_zK2pEwT8cpR" style="display: none">Schedule of prepaid and other current assets</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Short term deposits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--ShortTermDepositsMember_zb4aN5R8jCqg" title="Prepaids and other current assets" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-06-30_custom_ShortTermDepositsMember" id="Fact000950" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--ShortTermDepositsMember_pp0p0" title="Prepaids and other current assets" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31_custom_ShortTermDepositsMember" id="Fact000952" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--DeferredOfferingCostsMember_zktWUjLur0Vi" title="Prepaids and other current assets" style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-06-30_custom_DeferredOfferingCostsMember" id="Fact000954" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">74,648</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--DeferredOfferingCostsMember_pp0p0" title="Prepaids and other current assets" style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31_custom_DeferredOfferingCostsMember" id="Fact000956" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,588</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Prepaid insurance D&amp;O</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidInsuranceDAndOMember_z0Dq6pWKqSPf" title="Prepaids and other current assets" style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-06-30_custom_PrepaidInsuranceDAndOMember" id="Fact000958" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">241,445</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidInsuranceDAndOMember_pp0p0" title="Prepaids and other current assets" style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31_custom_PrepaidInsuranceDAndOMember" id="Fact000960" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">34,769</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid insurance, other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidInsuranceMember_zQnE22F9Hp2a" title="Prepaids and other current assets" style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-06-30_custom_PrepaidInsuranceMember" id="Fact000962" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,010</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidInsuranceMember_pp0p0" title="Prepaids and other current assets" style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31_custom_PrepaidInsuranceMember" id="Fact000964" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,884</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Prepaid clinical costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Prepaids and other current assets" id="xdx_989_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidClinicalCostsMember_z4NdHg9Wvrwj" style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-06-30_custom_PrepaidClinicalCostsMember" id="Fact000966" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">165,417</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Prepaids and other current assets" id="xdx_980_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_d0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidClinicalCostsMember_zWatJ1Hu44N1" style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31_custom_PrepaidClinicalCostsMember" id="Fact000968" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid exchange fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Prepaids and other current assets" id="xdx_98C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidExchangeFeesMember_zJM5gk9Evs19" style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-06-30_custom_PrepaidExchangeFeesMember" id="Fact000970" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">53,720</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Prepaids and other current assets" id="xdx_988_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_d0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidExchangeFeesMember_zMfMHNbAAo04" style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31_custom_PrepaidExchangeFeesMember" id="Fact000972" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Prepaid other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidOtherMember_zRBV1TXD6WMb" title="Prepaids and other current assets" style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-06-30_custom_PrepaidOtherMember" id="Fact000974" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">59,117</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidOtherMember_pp0p0" title="Prepaids and other current assets" style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31_custom_PrepaidOtherMember" id="Fact000976" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">41,635</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other receivables</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_d0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--OtherReceivablesMember_z5XNvq0Z7use" title="Prepaids and other current assets" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-06-30_custom_OtherReceivablesMember" id="Fact000978" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--OtherReceivablesMember_pp0p0" title="Prepaids and other current assets" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31_custom_OtherReceivablesMember" id="Fact000980" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">154</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_pp0p0_c20240630_zkKJiSoOyZwe" title="Prepaids and other current assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-06-30" id="Fact000982" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">649,357</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231_pp0p0" title="Prepaids and other current assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000984" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">245,030</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_z7C8U8F1Mml8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b>&#160;</p>

<ix:exclude><p id="xdx_237_zO1F9WO6QUQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zItrBsD9KjRl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_z7hqscdEq8a1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 176; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zeeEK3jvS8Me" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Accounts payable&#160;</b></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000990" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zTvrYeDxelCb" summary="xdx: Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accounts payable)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B5_zSyxO9ISdGC9" style="display: none">Schedule of accounts payable</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Accounts payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableMember_zdUfHxMTEIEa" title="Accounts payable, current" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-06-30_us-gaap_AccountsPayableMember" id="Fact000992" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">177,610</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20231231__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableMember_zJoexTeiy02g" title="Accounts payable, current" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31_us-gaap_AccountsPayableMember" id="Fact000994" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">758,821</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Credit cards payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--CreditCardsPayableMember_zVaRZmq7fgMi" title="Accounts payable, current" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-06-30_custom_CreditCardsPayableMember" id="Fact000996" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,513</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--CreditCardsPayableMember_zVNBgm4lGbQ1" title="Accounts payable, current" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31_custom_CreditCardsPayableMember" id="Fact000998" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,714</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20240630_zF97TVRPQL9a" title="Accounts payable, current" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-06-30" id="Fact001000" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">179,123</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20231231_zI3iZs4JGxhk" title="Accounts payable, current" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact001002" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">760,535</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zfLnjLm6PRz2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Accrued and other liabilities:</b></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001004" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zrTml1alRrec" summary="xdx: Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accrued and other liabilities)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B0_z8XLJzLqEuCe" style="display: none">Schedule of accrued and other liabilities</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Accrued payroll</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_d0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedPayrollMember_zuUB5QnUo5Gj" title="Accrued liabilities and other liabilities" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2024-06-30_custom_AccruedPayrollMember" id="Fact001006" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedPayrollMember_pp0p0" title="Accrued liabilities and other liabilities" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2023-12-31_custom_AccruedPayrollMember" id="Fact001008" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">162,887</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued bonus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedBonusMember_zMsVY1gUUsR1" title="Accrued liabilities and other liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2024-06-30_custom_AccruedBonusMember" id="Fact001010" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">127,875</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedBonusMember_pp0p0" title="Accrued liabilities and other liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2023-12-31_custom_AccruedBonusMember" id="Fact001012" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">262,580</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">D&amp;O financing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--DAndOFinancingMember_zjLLjX2IFC2" title="Accrued liabilities and other liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2024-06-30_custom_DAndOFinancingMember" id="Fact001014" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">126,605</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_d0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--DAndOFinancingMember_zFBb4u5EQxIj" title="Accrued liabilities and other liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2023-12-31_custom_DAndOFinancingMember" id="Fact001016" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued audit and legal expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedAuditAndLegalExpensesMember_zuRK6HTESlkl" title="Accrued liabilities and other liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2024-06-30_custom_AccruedAuditAndLegalExpensesMember" id="Fact001018" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,226</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedAuditAndLegalExpensesMember_pp0p0" title="Accrued liabilities and other liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2023-12-31_custom_AccruedAuditAndLegalExpensesMember" id="Fact001020" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">89,082</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedInterestMember_z7lMRjF6iPde" title="Accrued liabilities and other liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2024-06-30_custom_AccruedInterestMember" id="Fact001022" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">58,666</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedInterestMember_pp0p0" title="Accrued liabilities and other liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2023-12-31_custom_AccruedInterestMember" id="Fact001024" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">98,685</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued board compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedBoardCompensationMember_zexcHQEREEye" title="Accrued liabilities and other liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2024-06-30_custom_AccruedBoardCompensationMember" id="Fact001026" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">46,250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedBoardCompensationMember_pp0p0" title="Accrued liabilities and other liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2023-12-31_custom_AccruedBoardCompensationMember" id="Fact001028" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">92,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--OtherAccruedLiabilitiesMember_zS0PkkCzetue" title="Accrued liabilities and other liabilities" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2024-06-30_custom_OtherAccruedLiabilitiesMember" id="Fact001030" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">48,350</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--OtherAccruedLiabilitiesMember_z8nqfOTF3aL6" title="Accrued liabilities and other liabilities" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2023-12-31_custom_OtherAccruedLiabilitiesMember" id="Fact001032" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">151,988</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_pp0p0_c20240630_zvVXBovpmAfi" title="Accrued liabilities and other liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2024-06-30" id="Fact001034" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">447,972</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231_pp0p0" title="Accrued liabilities and other liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2023-12-31" id="Fact001036" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">857,722</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zjCBivLPC25h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b>&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001038" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_804_eus-gaap--LesseeOperatingLeasesTextBlock_zGC3EjGPHWg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7. <span id="xdx_825_zTY09N13LGe1">LEASES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had <span id="xdx_905_eus-gaap--OperatingLeaseExpense_do_c20240101__20240630_zX8zSUxV5Z67" title="Office lease"><span id="xdx_909_eus-gaap--OperatingLeaseExpense_do_c20230101__20231231_zh4rWwxUDzig" title="Office lease"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-01to2024-06-30" id="Fact001040" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2023-01-012023-12-31" id="Fact001042" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> office lease for the quarter
ended June 30, 2024, and the year ended December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001044" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_800_eus-gaap--IntangibleAssetsDisclosureTextBlock_z91wxPjcXXOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8. <span id="xdx_828_zKoSPnqWrXM">INTANGIBLE ASSETS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s intangible assets are as follows:</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001046" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zhB6FjHufG38" summary="xdx: Disclosure - INTANGIBLE ASSETS (Details - Intangible assets)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B1_zYNZ7On6vOw9" style="display: none">Schedule of intangible assets</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Patents and licenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember_zfZNiqzh3foj" title="Intangible assets gross" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-06-30_custom_PatentsAndLicensesMember" id="Fact001048" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,424,773</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember_z31PDMbOROfb" title="Intangible assets gross" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_custom_PatentsAndLicensesMember" id="Fact001050" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,267,251</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zXtlrxNqIsrc" title="Intangible assets gross" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-06-30_us-gaap_OtherIntangibleAssetsMember" id="Fact001052" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,017</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zpYXKnkgRmdd" title="Intangible assets gross" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_us-gaap_OtherIntangibleAssetsMember" id="Fact001054" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,017</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20240630_znK4725Bxe74" title="Intangible assets gross" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-06-30" id="Fact001056" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,429,790</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231_zGmbyoCwOype" title="Intangible assets gross" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31" id="Fact001058" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,272,268</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: accumulated amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_pp0p0_c20240630_zW4Ue8YHjAAd" title="Less: accumulated amortization" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-06-30" id="Fact001060" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,193,915</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20231231_pp0p0" title="Less: accumulated amortization" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31" id="Fact001062" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,103,645</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Intangible assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_pp0p0_c20240630_zZgNolLTo23b" title="Intangible assets, net" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-06-30" id="Fact001064" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,235,875</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_c20231231_pp0p0" title="Intangible assets, net" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" id="Fact001066" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,168,623</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8AC_z1Zqnm8VB3Wf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patents and licenses costs are accounted for as
intangible assets and amortized over the life of the patent or license agreement and charged to research and development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amortization expense related to purchased intangible
assets was $<span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20240401__20240630_zdW8DImGUUy" title="Amortization of intangible assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-04-012024-06-30" id="Fact001068" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,458</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20230401__20230630_zissSmIK4bOd" title="Amortization of intangible assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-04-012023-06-30" id="Fact001070" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,940</ix:nonFraction></span> for the three months ended June 30, 2024, and 2023, respectively. Amortization expense related to purchased
intangible assets was $<span id="xdx_90A_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20240101__20240630_zawle9A08a0i" title="Amortization of intangible assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-01to2024-06-30" id="Fact001072" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">90,270</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20230101__20230630_zYUnuCsn9CQj" title="Amortization of intangible assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-06-30" id="Fact001074" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">78,805</ix:nonFraction></span> for the six months ended June 30, 2024, and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23A_z9L7NPwovyJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zYwZEUbl9rPi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zXeGz3O7Wt32" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 177; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_ziRI8PS04pMk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patents and trademarks are reviewed at least annually
for impairment. No impairment was recorded through June 30, 2024, and December 31, 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Future amortization of intangible assets is as
follows:</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001080" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zVjC7kro9EO5" summary="xdx: Disclosure - INTANGIBLE ASSETS (Details - Future amortization)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B9_zeB5K09APzF1" style="display: none">Schedule of future amortization of intangible assets</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20240630_zEz3tmZnbFS7" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" contextRef="AsOf2024-06-30" id="Fact001082" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">96,015</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" contextRef="AsOf2024-06-30" id="Fact001084" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">192,030</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" contextRef="AsOf2024-06-30" id="Fact001086" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">192,030</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" contextRef="AsOf2024-06-30" id="Fact001088" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">192,030</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">2028 and beyond</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" contextRef="AsOf2024-06-30" id="Fact001090" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">563,770</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherIntangibleAssetsNet_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherIntangibleAssetsNet" contextRef="AsOf2024-06-30" id="Fact001092" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,235,875</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8AF_zJmZzSpOfYo2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001094" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_801_eus-gaap--DebtDisclosureTextBlock_zlJk15fg5pm4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE</b>&#160; <b>9. <span id="xdx_827_ziIBCsPkvEGi">SHORT TERM NOTES AND CONVERTIBLE
DEBT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Convertible Notes:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, there were <span id="xdx_90D_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_do_c20231231_znzzovgCIuZ9" title="Convertible notes payable outstanding"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2023-12-31" id="Fact001096" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></span> Convertible
Notes payable and outstanding. There was <span id="xdx_90C_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_do_c20240630_zfvyuEhxsTpe" title="Convertible notes payable outstanding"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2024-06-30" id="Fact001098" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></span> convertible note activity in the three months ended June 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Senior Notes Payable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2023, the Company issued $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20230531__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesPayableMember_ziQJNjOL2sqf" title="Debt instrument face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-05-31_custom_SeniorNotesPayableMember" id="Fact001100" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,437,500</ix:nonFraction></span>
unsecured senior notes with a maturity date of <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20230501__20230531__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesPayableMember_zAgQmBQ6t3C4" title="Maturity date"><ix:nonNumeric contextRef="From2023-05-012023-05-31_custom_SeniorNotesPayableMember" format="ixt:datemonthdayyearen" id="Fact001102" name="us-gaap:DebtInstrumentMaturityDate">May
16, 2024</ix:nonNumeric></span> (&#8220;the Senior Notes Payable&#8221;), for cash proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromSecuredNotesPayable_c20230501__20230531__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesPayableMember_zzJOqzc4uGwi" title="Proceeds from secured notes payable"><ix:nonFraction name="us-gaap:ProceedsFromSecuredNotesPayable" contextRef="From2023-05-012023-05-31_custom_SeniorNotesPayableMember" id="Fact001104" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,250,000</ix:nonFraction></span>.
The Senior Notes Payable contained an original issue discount of <span id="xdx_908_ecustom--DebtOriginalIssueDiscountPercenrtage_iI_dp_c20230531__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesPayableMember_z50hrDNBIGNe" title="Original issue discount, percentage"><ix:nonFraction name="ACON:DebtOriginalIssueDiscountPercenrtage" contextRef="AsOf2023-05-31_custom_SeniorNotesPayableMember" id="Fact001106" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.0</ix:nonFraction></span>%
and accrue interest at an annual rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20230531__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesPayableMember_zqodwGe3Med4" title="Annual rate percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2023-05-31_custom_SeniorNotesPayableMember" id="Fact001108" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.0</ix:nonFraction></span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2023, as agreed to during the
issuance of the Senior Notes Payable, the Company exercised their right to an additional financing, issuing $<span id="xdx_909_eus-gaap--UnsecuredDebt_iI_c20230930__us-gaap--LongtermDebtTypeAxis__custom--SeriesBNotesPayableMember_zZWI74uySrV9" title="Issuing unsecured senior notes"><ix:nonFraction name="us-gaap:UnsecuredDebt" contextRef="AsOf2023-09-30_custom_SeriesBNotesPayableMember" id="Fact001110" format="ixt:numdotdecimal" decimals="0" unitRef="USD">862,500</ix:nonFraction></span>
unsecured senior notes that mature on <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20230901__20230930__us-gaap--LongtermDebtTypeAxis__custom--SeriesBNotesPayableMember_zX76nbvmzQRd" title="Maturity date"><ix:nonNumeric contextRef="From2023-09-012023-09-30_custom_SeriesBNotesPayableMember" format="ixt:datemonthdayyearen" id="Fact001112" name="us-gaap:DebtInstrumentMaturityDate">September
1, 2024</ix:nonNumeric></span> ("the Series B Notes Payable) for cash proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfUnsecuredDebt_c20230901__20230930__us-gaap--LongtermDebtTypeAxis__custom--SeriesBNotesPayableMember_zK65V3n7jW16" title="Cash proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfUnsecuredDebt" contextRef="From2023-09-012023-09-30_custom_SeriesBNotesPayableMember" id="Fact001114" format="ixt:numdotdecimal" decimals="0" unitRef="USD">750,000</ix:nonFraction></span>.
The Series B Notes Payable contained an original issue discount of <span id="xdx_908_ecustom--DebtOriginalIssueDiscountPercenrtage_iI_dp_c20230930__us-gaap--LongtermDebtTypeAxis__custom--SeriesBNotesPayableMember_zutrWpABSzq" title="Original issue discount, percentage"><ix:nonFraction name="ACON:DebtOriginalIssueDiscountPercenrtage" contextRef="AsOf2023-09-30_custom_SeriesBNotesPayableMember" id="Fact001116" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.0</ix:nonFraction></span>%
and accrue interest at an annual rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20230930__us-gaap--LongtermDebtTypeAxis__custom--SeriesBNotesPayableMember_zA3ejm5fWkI5" title="Annual rate percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2023-09-30_custom_SeriesBNotesPayableMember" id="Fact001118" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.0</ix:nonFraction></span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2023, the Company issued $<span id="xdx_90E_eus-gaap--UnsecuredDebt_iI_c20231130__us-gaap--LongtermDebtTypeAxis__custom--SeriesCNotesPayableMember_zWZAD6h7ABXd" title="Issuing unsecured senior notes"><ix:nonFraction name="us-gaap:UnsecuredDebt" contextRef="AsOf2023-11-30_custom_SeriesCNotesPayableMember" id="Fact001120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,118</ix:nonFraction></span>
unsecured senior notes with a maturity date of <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20231101__20231130__us-gaap--LongtermDebtTypeAxis__custom--SeriesCNotesPayableMember_zsMJjmFikEol" title="Maturity date"><ix:nonNumeric contextRef="From2023-11-012023-11-30_custom_SeriesCNotesPayableMember" format="ixt:datemonthdayyearen" id="Fact001122" name="us-gaap:DebtInstrumentMaturityDate">April
19, 2024</ix:nonNumeric></span> (&#8220;the Series C Notes Payable&#8221;), for cash proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfUnsecuredDebt_c20231101__20231130__us-gaap--LongtermDebtTypeAxis__custom--SeriesCNotesPayableMember_zhMisB3KpCIk" title="Cash proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfUnsecuredDebt" contextRef="From2023-11-012023-11-30_custom_SeriesCNotesPayableMember" id="Fact001124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>.
The Senior Notes Payable contained an original issue discount of <span id="xdx_90F_ecustom--DebtOriginalIssueDiscountPercenrtage_dp_c20231130__us-gaap--LongtermDebtTypeAxis__custom--SeriesCNotesPayableMember_zCRSv78cDYD" title="Original issue discount, percentage"><ix:nonFraction name="ACON:DebtOriginalIssueDiscountPercenrtage" contextRef="AsOf2023-11-30_custom_SeriesCNotesPayableMember" id="Fact001126" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.0</ix:nonFraction></span>%
and accrue interest at an annual rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20231130__us-gaap--LongtermDebtTypeAxis__custom--SeriesCNotesPayableMember_zU1uK2SzJKna" title="Annual rate percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2023-11-30_custom_SeriesCNotesPayableMember" id="Fact001128" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.0</ix:nonFraction></span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company incurred issuance costs, recorded
as deferred financing costs, of $<span id="xdx_909_eus-gaap--PaymentsForLegalSettlements_c20231101__20231130_zgu0H6Rz1zJb" title="Diligence and legal costs"><ix:nonFraction name="us-gaap:PaymentsForLegalSettlements" contextRef="From2023-11-012023-11-30" id="Fact001130" format="ixt:numdotdecimal" decimals="0" unitRef="USD">296,313</ix:nonFraction></span> relating to due diligence and legal costs associated with the issuance of the notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluated the embedded redemption
and contingent interest features in the notes to determine if such features were required to be bifurcated as an embedded derivative liability.
In accordance with ASC 815-40, Derivatives and Hedging Activities, the embedded redemption features and contingent interest feature were
accounted for as derivative liabilities at the date of issuance and shall be adjusted to fair value at each reporting date. The Company
fair valued such derivative liabilities and recorded a debt discount at issuance of the notes of $<span id="xdx_906_eus-gaap--PaymentsOfDebtIssuanceCosts_c20231101__20231130_zrh02kXYPJf1" title="Issuance of debt discount"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2023-11-012023-11-30" id="Fact001132" format="ixt:numdotdecimal" decimals="0" unitRef="USD">320,561</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issued warrants to purchase 77,010
and 46,556 shares of common stock (1,232,156 and 744,890 shares before giving effect to the 2024 Stock Split) to the holders of the Senior
Notes Payable and Series C Notes Payable (collectively the &#8220;Senior Notes Warrants&#8221;) with an exercise price of $10.02 and $4.58
per share ($0.6262 and $0.2856 pre-2024 split), respectively. The Company accounted for the warrants in accordance with the guidance contained
in ASC 815 &#8220;Derivatives and Hedging&#8221; whereby under that provision these warrants did not meet the criteria for equity treatment
and were recorded as a liability. As such, these warrants are recorded at fair value as of each reporting date with the change in fair
value reported within other income in the accompanying consolidated statements of operations as &#8220;Change in fair value of warrant
liability&#8221; until the warrants are exercised, expired or other facts and circumstances lead the warrant liability to be reclassified
to stockholders&#8217; equity. The fair value of the Senior Notes Warrants at issuance was $736,249 and was recorded as a debt discount.
The Company incurred issuance costs of $72,862 relating to the Senior Notes Warrants which was recorded as a day 1 expense due to the
liability classification of such warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_234_zQrsvGrDxdEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zlIikqSn3Ah" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 178; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zyfoeLReKWN7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the issuance of the Senior
Notes Payable and Series C Notes Payable, the Company paid a commitment fee in the form of 21,210 and 9,311 shares (339,360 and 148,978
shares before giving effect to the 2024 Stock Split) of unregistered common stock to the holders, respectively. The aggregate commitment
fees had a fair value at issuance of $208,916 and are recorded as a deferred financing cost.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The resulting debt discounts from the derivative
liabilities, warrant liabilities and deferred financing costs were presented as a direct deduction from the carrying amount of that debt
liability and amortized to interest expense using the effective interest rate method. For the three months ended June 30, 2024, the Company
recognized $<span id="xdx_901_eus-gaap--AmortizationOfDebtDiscountPremium_c20240401__20240630__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesPayableMember_zMPibOHoNAAk" title="Amortization of debt discounts"><span id="xdx_900_eus-gaap--DeferredCostsCurrent_iI_c20240630__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesPayableMember_zaj5CN0Rsyh8" title="Deferred financing costs"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2024-04-012024-06-30_custom_SeniorNotesPayableMember" id="Fact001137" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:DeferredCostsCurrent" contextRef="AsOf2024-06-30_custom_SeniorNotesPayableMember" id="Fact001139" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,937</ix:nonFraction></ix:nonFraction></span></span> in amortization of debt discounts and deferred financing costs which is recorded in interest expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Between January 22 and January 29, 2024, the Company
entered into a series of exchange agreements (the &#8220;Exchange Agreements&#8221;) with the accredited investors to exchange principal
and accrued interest on these notes for shares of common stock. Pursuant to the Exchange Agreements, the Company issued an aggregate of
<span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240122__20240129__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementsMember__srt--CounterpartyNameAxis__custom--AccreditedInvestorsMember_zQucwyyeJxkb" title="Number of common shares issued on exchange"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2024-01-222024-01-29_custom_ExchangeAgreementsMember_custom_AccreditedInvestorsMember" id="Fact001141" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">644,142</ix:nonFraction></span> post-split shares of common stock in exchange for $<span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20240122__20240129__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementsMember__srt--CounterpartyNameAxis__custom--AccreditedInvestorsMember_zjLwfPWqBZvi" title="Exchange of principal and accrued interest"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2024-01-222024-01-29_custom_ExchangeAgreementsMember_custom_AccreditedInvestorsMember" id="Fact001143" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,519,779</ix:nonFraction></span> principal and accrued interest on the notes. Following these exchanges,
the remaining outstanding balance of principal and interest on the notes was $<span id="xdx_90C_ecustom--RemainingOutstandingBalanceOfPrincipalAndInterest_c20240122__20240129__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementsMember__srt--CounterpartyNameAxis__custom--AccreditedInvestorsMember_zBot47Kz0uXd" title="Remaining outstanding balance of principal and interest"><ix:nonFraction name="ACON:RemainingOutstandingBalanceOfPrincipalAndInterest" contextRef="From2024-01-222024-01-29_custom_ExchangeAgreementsMember_custom_AccreditedInvestorsMember" id="Fact001145" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,145,037</ix:nonFraction></span>. This transaction accelerated the recognition
of the related note discounts and resulted in a $<span id="xdx_901_ecustom--LossOnExchangeOfDebt_c20240101__20240131__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementsMember__srt--CounterpartyNameAxis__custom--AccreditedInvestorsMember_z2DU0vT0YRSd" title="Exchange of principal and accrued interest"><ix:nonFraction name="ACON:LossOnExchangeOfDebt" contextRef="From2024-01-012024-01-31_custom_ExchangeAgreementsMember_custom_AccreditedInvestorsMember" id="Fact001147" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,066,732</ix:nonFraction></span> charge.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 6, 2024, the Company paid $<span id="xdx_904_ecustom--PrincipalAndAccruedInterestPaid_c20240305__20240306__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredNonConvertibleNotesMember_zCw1GaMARoF5" title="Principal and accrued interest paid"><ix:nonFraction name="ACON:PrincipalAndAccruedInterestPaid" contextRef="From2024-03-052024-03-06_custom_UnsecuredNonConvertibleNotesMember" id="Fact001149" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,974</ix:nonFraction></span> of
principal and accrued interest on certain unsecured non-convertible notes. Following this payment, the remaining outstanding balance of
principal and interest on the notes was $<span id="xdx_901_eus-gaap--NotesPayable_iI_c20240306__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredNonConvertibleNotesMember_ztB4KyasF758" title="Outstanding balance"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2024-03-06_custom_UnsecuredNonConvertibleNotesMember" id="Fact001151" format="ixt:numdotdecimal" decimals="0" unitRef="USD">898,380</ix:nonFraction></span>. This transaction accelerated the recognition of the related note discounts and resulted
in a $<span id="xdx_90D_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20240101__20240630__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredNonConvertibleNotesMember_zNx7AWSMcmg3" title="Principal and accrued interest paid"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-012024-06-30_custom_UnsecuredNonConvertibleNotesMember" id="Fact001153" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,928</ix:nonFraction></span> charge.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table reconciles the aggregate amount
for the Senior Notes Payable, Series B Notes Payable, and Series C Notes Payable as well as the unamortized deferred financing costs and
debt discounts relating to the derivative liabilities and warrant liabilities.</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001155" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfDerivativeInstrumentsTextBlock_z4DHNowa9Azk" summary="xdx: Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT (Details - Note payable)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BA_zxLYHvNf4Ulc" style="display: none">Schedule of derivative liabilities and warrant liabilities</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Note Payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--NotesPayable_pp0p0_c20240630_zqz3p393tW25" title="Note Payable" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2024-06-30" id="Fact001157" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">862,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--NotesPayable_c20231231_pp0p0" title="Note Payable" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-12-31" id="Fact001159" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,594,118</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: Unamortized Discounts and Deferred Financing Costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: 9pt">Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsWarrants_iI_pp0p0_d0_c20240630_zTX1z2WgTctb" title="Warrants" style="text-align: right"><ix:nonFraction name="ACON:UnamortizedDiscountsAndDeferredFinancingCostsWarrants" contextRef="AsOf2024-06-30" id="Fact001161" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsWarrants_c20231231_pp0p0" title="Warrants" style="text-align: right">(<ix:nonFraction name="ACON:UnamortizedDiscountsAndDeferredFinancingCostsWarrants" contextRef="AsOf2023-12-31" id="Fact001163" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">557,582</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 9pt">Derivative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsDerivative_iI_pp0p0_c20240630_zfU2xKExR65a" title="Derivative" style="text-align: right">(<ix:nonFraction name="ACON:UnamortizedDiscountsAndDeferredFinancingCostsDerivative" contextRef="AsOf2024-06-30" id="Fact001165" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">34,475</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsDerivative_c20231231_pp0p0" title="Derivative" style="text-align: right">(<ix:nonFraction name="ACON:UnamortizedDiscountsAndDeferredFinancingCostsDerivative" contextRef="AsOf2023-12-31" id="Fact001167" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">235,628</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; text-align: left; text-indent: 9pt">Deferred financing costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost_iI_pp0p0_c20240630_zzOeVpNyJTNk" title="Deferred financing costs" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ACON:UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost" contextRef="AsOf2024-06-30" id="Fact001169" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">50,938</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost_c20231231_pp0p0" title="Deferred financing costs" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ACON:UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost" contextRef="AsOf2023-12-31" id="Fact001171" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">675,184</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsTotal_iI_pp0p0_d0_c20240630_z5De3Php7MDe" title="Total notes payable discount" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ACON:UnamortizedDiscountsAndDeferredFinancingCostsTotal" contextRef="AsOf2024-06-30" id="Fact001173" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">85,413</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsTotal_c20231231_pp0p0" title="Total notes payable discount" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ACON:UnamortizedDiscountsAndDeferredFinancingCostsTotal" contextRef="AsOf2023-12-31" id="Fact001175" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,468,394</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt; text-indent: 9pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--OtherNotesPayableCurrent_pp0p0_c20240630_zEMiVbduCHde" title="Note payable, net of discount" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherNotesPayableCurrent" contextRef="AsOf2024-06-30" id="Fact001177" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">777,087</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--OtherNotesPayableCurrent_c20231231_pp0p0" title="Note payable, net of discount" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherNotesPayableCurrent" contextRef="AsOf2023-12-31" id="Fact001179" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,125,724</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001181" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zsZtOZEebdj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10. <span id="xdx_82F_zp5jn8mqS7zc">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Royalty Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has an exclusive license agreement
with the Regents of the University of California to make, use, sell and otherwise distribute products under certain of the Regents of
the University of California&#8217;s patents anywhere in the world. The Company is obligated to pay a minimum annual royalty of $<span id="xdx_901_ecustom--MinimumAnnualRoyaltyPayment_iI_c20240630__srt--CounterpartyNameAxis__custom--RegentsOfTheUniversityOfCaliforniaMember_z40fsnAJo1za" title="Minimum annual royalty payment"><ix:nonFraction name="ACON:MinimumAnnualRoyaltyPayment" contextRef="AsOf2024-06-30_custom_RegentsOfTheUniversityOfCaliforniaMember" id="Fact001183" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span>,
and an earned royalty of 4% of net sales. The minimum annual royalty will be applied against the earned royalty due for the calendar year
in which the minimum payment was made. The license agreements expire upon expiration of the patents and may be terminated earlier if the
Company so elects. The U.S. licensed patents that are currently issued expire between 2026 and 2029, without considering any possible
patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees.
The Company recorded royalty costs of $<span id="xdx_909_eus-gaap--RoyaltyExpense_c20240401__20240630__srt--CounterpartyNameAxis__custom--RegentsOfTheUniversityOfCaliforniaMember_z1308vfk3yNg" title="Royalty expense"><span id="xdx_908_eus-gaap--RoyaltyExpense_c20230401__20230630__srt--CounterpartyNameAxis__custom--RegentsOfTheUniversityOfCaliforniaMember_zk6I9VOeHRjf" title="Royalty expense"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2024-04-012024-06-30_custom_RegentsOfTheUniversityOfCaliforniaMember" id="Fact001185" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2023-04-012023-06-30_custom_RegentsOfTheUniversityOfCaliforniaMember" id="Fact001187" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,500</ix:nonFraction></ix:nonFraction></span></span> for the three months ended June 30, 2024, and 2023, respectively, and $<span id="xdx_906_eus-gaap--RoyaltyExpense_c20240101__20240630__srt--CounterpartyNameAxis__custom--RegentsOfTheUniversityOfCaliforniaMember_zkHrqG9SKkpg" title="Royalty expense"><span id="xdx_90C_eus-gaap--RoyaltyExpense_c20230101__20230630__srt--CounterpartyNameAxis__custom--RegentsOfTheUniversityOfCaliforniaMember_zxzBnbHfeXr2" title="Royalty expense"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2024-01-012024-06-30_custom_RegentsOfTheUniversityOfCaliforniaMember" id="Fact001189" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2023-01-012023-06-30_custom_RegentsOfTheUniversityOfCaliforniaMember" id="Fact001191" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></ix:nonFraction></span></span> for the six
months ended June 30, 2024, and 2023, respectively, as Cost of Revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_234_zg33OAxhoqpi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zvp64zJtni81" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zamWFnwUwJVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 179; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_z5f8gfLRfCl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Litigation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, the Company has not been involved in
legal proceedings arising in the ordinary course of its business. If any legal proceeding occurs, the Company will record a provision
for a loss when it believes that it is both probable that a loss has been incurred and the amount can be reasonably estimated, although
litigation is inherently unpredictable and is subject to significant uncertainties, some of which are beyond the Company&#8217;s control.
Should any of these estimates and assumptions change or prove to have been incorrect, the Company could incur significant charges related
to legal matters that could have a material impact on its results of operations, financial position and cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001197" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zmMgODpX1cmc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11. <span id="xdx_824_zHd6p14jyvC6">STOCKHOLDERS&#8217; EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company filed an Amended and Restated Certificate
of Incorporation on April 21, 2022, as part of the Company&#8217;s initial public offering. The Company was authorized to issue two classes
of stock to be designated, respectively, &#8220;common stock&#8221; and &#8220;preferred stock.&#8221; The total number of shares which
the Company was authorized to issue was two hundred twenty million (220,000,000) shares. Two hundred million (<span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20240630_zsbPAzQb1jK" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-06-30" id="Fact001199" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></span>) shares were authorized
to be common stock, having a par value per share of $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240630_zFhX2FEZluEl" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30" id="Fact001201" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></span>. Twenty million (<span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20240630_znqavJoGlk19" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-06-30" id="Fact001203" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></span>) shares were authorized to be preferred stock,
having a par value per share of $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240630_zdZL7ncqlh5l" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30" id="Fact001205" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></span>. As of June 30, 2024, the Company had <span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20240630_zuLXKsSe7bja" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-06-30" id="Fact001207" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,210,671</ix:nonFraction></span> common shares outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stockholders&#8217; Vote &#8211; Reverse stock
split</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company held a special meeting of stockholders
on March 24, 2023. At the special meeting, our stockholders approved one proposal, which was to grant discretionary authority to our board
of directors to (i) amend our certificate of incorporation to combine outstanding shares of our common stock into a lesser number of outstanding
shares, or a &#8220;reverse stock split,&#8221; at a specific ratio within a range of <span id="xdx_906_eus-gaap--StockholdersEquityReverseStockSplit_c20240323__20240324__srt--RangeAxis__srt--MinimumMember_z3nH5C4xGxg8" title="Stockholders equity, reverse stock Split"><ix:nonNumeric contextRef="From2024-03-232024-03-24_srt_MinimumMember" id="Fact001209" name="us-gaap:StockholdersEquityReverseStockSplit">one-for-five</ix:nonNumeric></span> (1-for-5) to a maximum of a <span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20240323__20240324__srt--RangeAxis__srt--MaximumMember_zPYs1eWBSEX8" title="Stockholders equity, reverse stock Split"><ix:nonNumeric contextRef="From2024-03-232024-03-24_srt_MaximumMember" id="Fact001211" name="us-gaap:StockholdersEquityReverseStockSplit">one-for-fifty</ix:nonNumeric></span>
(1-for-50) split, with the exact ratio to be determined by our board of directors in its sole discretion; and (ii) effect the reverse
stock split, if at all, within one year of the date the proposal was approved by stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2024, the Company's board subsequently
approved the final reverse stock split ratio of one-for-sixteen (the &#8220;2024 Stock Split&#8221;), which resulted in a reduction in
the number of outstanding shares of common stock, warrants, stock options and restricted share units and a proportionate increase in the
value of each share or strike price of the warrants and stock options. The common stock began trading on a reverse split-adjusted basis
on the NASDAQ on January 4, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Series A Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2023 the Company sold one (1) share
of the Company&#8217;s newly designated Series A preferred stock to Jeffrey Thramann, the Company&#8217;s Executive Chairman, for a purchase
price of $<span id="xdx_909_ecustom--PurchasePrice_c20230201__20230228__srt--TitleOfIndividualAxis__custom--ExecutiveChairmanMember_zL0NtzklOwHd" title="Purchase price"><ix:nonFraction name="ACON:PurchasePrice" contextRef="From2023-02-012023-02-28_custom_ExecutiveChairmanMember" id="Fact001213" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span>. The share of Series A preferred stock had proportional voting rights that were limited to the proposal to approve a reverse
stock split of the Company&#8217;s common stock. Following the March 24, 2023, special meeting, the Company redeemed the one outstanding
share of Series A preferred stock on March 28, 2023, in accordance with its terms. The redemption price was $<span id="xdx_907_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_c20240101__20240630_zl1w3LDReM4b" title="Redemption price"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2024-01-01to2024-06-30" id="Fact001215" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span>. No Series A preferred
stock remains outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Public Offering</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 27, 2024, the Company completed a
public offering of <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240226__20240227__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zY6NX13D0WK1" title="Issued units"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-02-262024-02-27_us-gaap_IPOMember" id="Fact001217" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,175,000</ix:nonFraction></span> units (&#8220;Units&#8221;) at a price of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20240227__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zkoFuLPx90j2" title="Price per unit"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-02-27_us-gaap_IPOMember" id="Fact001219" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.58</ix:nonFraction></span> per Unit, for gross proceeds of approximately $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn6n6_c20240226__20240227__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z56C0JMPRZok" title="Gross proceeds"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-02-262024-02-27_us-gaap_IPOMember" id="Fact001221" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">3</ix:nonFraction></span>.0 million,
before deducting offering expenses. Each Unit was comprised of (i) one share of common stock or, in lieu of common stock, one prefunded
warrant to purchase a share of common stock, and (ii) two common warrants, each common warrant to purchase a share of common stock. The
prefunded warrants were immediately exercisable at a price of $0.00001 per share of common stock and only expire when such prefunded warrants
are fully exercised. The common warrants were immediately exercisable at a price of $0.58 per share of common stock and will expire five
years from the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23E_za2gBxDJMlCk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zobKSkPKZs81" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 180; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_z6U4CtBi2wC1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>White Lion Equity Line Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 9, 2023, the Company entered into an
equity line common stock purchase agreement (the &#8220;Equity Line Purchase Agreement&#8221;) and a related registration rights agreement
with White Lion Capital, LLC (&#8220;White Lion&#8221;). Pursuant to the Equity Line Agreement, the Company has the right, but not the
obligation to require White Lion to purchase, from time to time, up to $<span id="xdx_90C_eus-gaap--PaymentsForRepurchaseOfWarrants_c20231008__20231009__us-gaap--TransactionTypeAxis__custom--WhiteLionEquityLineAgreementMember_z5JWvqdnTuFd" title="Aggregate gross purchase price"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfWarrants" contextRef="From2023-10-082023-10-09_custom_WhiteLionEquityLineAgreementMember" id="Fact001226" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000,000</ix:nonFraction></span> in aggregate gross purchase price of newly issued shares
of the Company&#8217;s common stock, subject to certain limitations and conditions set forth in the Equity Line Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Equity Line Purchase Agreement,
the Company issued to White Lion <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240424__20240426__us-gaap--TransactionTypeAxis__custom--WhiteLionEquityLineAgreementMember_zb1Wp5ZAAnTl" title="Issued shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-04-242024-04-26_custom_WhiteLionEquityLineAgreementMember" id="Fact001228" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,050,000</ix:nonFraction></span> newly issued common shares for proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240424__20240426__us-gaap--TransactionTypeAxis__custom--WhiteLionEquityLineAgreementMember_zTjpZkz2rA0c" title="Proceeds from issuance of common shares"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-04-242024-04-26_custom_WhiteLionEquityLineAgreementMember" id="Fact001230" format="ixt:numdotdecimal" decimals="0" unitRef="USD">304,500</ix:nonFraction></span> on April 26, 2024. Through June 30, 2024,
the Company has issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240630__us-gaap--TransactionTypeAxis__custom--WhiteLionEquityLineAgreementMember_zrvCiCidW0Y7" title="Issued shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-06-30_custom_WhiteLionEquityLineAgreementMember" id="Fact001232" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,800,000</ix:nonFraction></span> shares to White Lion for total proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20240630__us-gaap--TransactionTypeAxis__custom--WhiteLionEquityLineAgreementMember_zsczwgdCYrga" title="Proceeds from issuance of common shares"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-012024-06-30_custom_WhiteLionEquityLineAgreementMember" id="Fact001234" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,216,981</ix:nonFraction></span>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the
Company&#8217;s outstanding warrants as of June 30, 2024. The warrants and related strike prices have been adjusted to reflect
the 2024 Stock Split.</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001236" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellspacing="0" cellpadding="0" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details - Outstanding warrants)" id="xdx_898_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zeO8GMHB4xni" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span id="xdx_8BC_zDYQiP0cRYif" style="display: none">Schedule of warrants and related strike prices</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; width: 36%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issue Date</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 16%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Strike price</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 21%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number outstanding</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePriceMember_fKDEp_zQTeExaR3F09" title="Issue date"><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_WarrantStrikePriceMember" format="ixt:datemonthdayyearen" id="Fact001238" name="ACON:StockIssueDate">April 21, 2022</ix:nonNumeric></span> (1)</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePriceMember_fKDEp_z6lUJG3j11mb" title="Strike price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-06-30_custom_WarrantStrikePriceMember" id="Fact001240" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">69.60</ix:nonFraction></span></span></td>
    <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePriceMember_fKDEp_z9AvwNC0r9fe" title="Number of shares outstanding" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-06-30_custom_WarrantStrikePriceMember" id="Fact001242" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">155,610</ix:nonFraction></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePriceMember_fKDEp_zJ7zgL2ZelT8" title="Expiration"><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_WarrantStrikePriceMember" format="ixt:datemonthdayyearen" id="Fact001244" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">April 21, 2027</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice1Member_z9pJvj90xyok" title="Issue date"><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_WarrantStrikePrice1Member" format="ixt:datemonthdayyearen" id="Fact001246" name="ACON:StockIssueDate">April 21, 2022</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice1Member_zVRoDsbB8YYh" title="Strike price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-06-30_custom_WarrantStrikePrice1Member" id="Fact001248" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">87.04</ix:nonFraction></span></span></td>
    <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice1Member_zrK5fyXYQTMf" title="Number of shares outstanding" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-06-30_custom_WarrantStrikePrice1Member" id="Fact001250" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,825</ix:nonFraction></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice1Member_zXp7Xrmz7z28" title="Expiration"><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_WarrantStrikePrice1Member" format="ixt:datemonthdayyearen" id="Fact001252" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">April 21, 2027</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice2Member_zAL3HNZT5cwe" title="Issue date"><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_WarrantStrikePrice2Member" format="ixt:datemonthdayyearen" id="Fact001254" name="ACON:StockIssueDate">April 21, 2022</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice2Member_z6GuYgYlJZv9" title="Strike price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-06-30_custom_WarrantStrikePrice2Member" id="Fact001256" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">69.60</ix:nonFraction></span></span></td>
    <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice2Member_zCJWWiqdmGZj" title="Number of shares outstanding" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-06-30_custom_WarrantStrikePrice2Member" id="Fact001258" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,673</ix:nonFraction></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice2Member_zEbTR3XZhu5a" title="Expiration"><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_WarrantStrikePrice2Member" format="ixt:datemonthdayyearen" id="Fact001260" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">April 21, 2027</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice3Member_fKDIp_zKn3cxuZlpj2"><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_WarrantStrikePrice3Member" format="ixt:datemonthdayyearen" id="Fact001261" name="ACON:StockIssueDate">May 16, 2023</ix:nonNumeric></span> (2)</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice3Member_fKDIp_zaa23c02Ypni" title="Strike price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-06-30_custom_WarrantStrikePrice3Member" id="Fact001263" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.29</ix:nonFraction></span></span></td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice3Member_fKDIp_zfbPTWn3ixq8" title="Number of shares outstanding" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-06-30_custom_WarrantStrikePrice3Member" id="Fact001265" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,010</ix:nonFraction></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice3Member_fKDIp_zt5B26Xna7zd" title="Expiration"><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_WarrantStrikePrice3Member" format="ixt:datemonthdayyearen" id="Fact001267" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">May 16, 2028</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice4Member_fKDIp_zZKYEOaU9Dl2"><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_WarrantStrikePrice4Member" format="ixt:datemonthdayyearen" id="Fact001268" name="ACON:StockIssueDate">November 21, 2023</ix:nonNumeric></span> (2)</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice4Member_fKDIp_za5OwvRfkRjb" title="Strike price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-06-30_custom_WarrantStrikePrice4Member" id="Fact001270" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.29</ix:nonFraction></span></span></td>
    <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice4Member_fKDIp_zetOjQH87aHk" title="Number of shares outstanding" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-06-30_custom_WarrantStrikePrice4Member" id="Fact001272" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,556</ix:nonFraction></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice4Member_fKDIp_zVMslzSfPg94" title="Expiration"><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_WarrantStrikePrice4Member" format="ixt:datemonthdayyearen" id="Fact001274" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">November 21, 2028</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice5Member_zyVIuNupPfab" title="Issue date"><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_WarrantStrikePrice5Member" format="ixt:datemonthdayyearen" id="Fact001276" name="ACON:StockIssueDate">November 21, 2023</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice5Member_ze9lEuppAHH1" title="Strike price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-06-30_custom_WarrantStrikePrice5Member" id="Fact001278" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></span></span></td>
    <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice5Member_zWcXOoFlmoq4" title="Number of shares outstanding" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-06-30_custom_WarrantStrikePrice5Member" id="Fact001280" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,576</ix:nonFraction></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice5Member_zAVvgOlrmmtd" title="Expiration"><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_WarrantStrikePrice5Member" format="ixt:datemonthdayyearen" id="Fact001282" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">November 21, 2028</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice6Member_z0r4BBtZVwTb" title="Issue date"><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_WarrantStrikePrice6Member" format="ixt:datemonthdayyearen" id="Fact001284" name="ACON:StockIssueDate">February 27, 2024</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice6Member_zGxVNyRQ7IYe" title="Strike price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-06-30_custom_WarrantStrikePrice6Member" id="Fact001286" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.58</ix:nonFraction></span></span></td>
    <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice6Member_zc5Qv22unfrg" title="Number of shares outstanding" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-06-30_custom_WarrantStrikePrice6Member" id="Fact001288" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,350,000</ix:nonFraction></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice6Member_zQtn98pTlbZ3" title="Expiration"><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_WarrantStrikePrice6Member" format="ixt:datemonthdayyearen" id="Fact001290" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">February 27, 2029</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; text-align: justify"><span id="xdx_F03_znuzUtQP6ula" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F1C_zH4hCCWyNCSl"><ix:footnote id="Footnote001291" xml:lang="en-US">These
    warrants were issued as part of the Company&#8217;s initial public offering completed April 2022, and trade on Nasdaq under the
    ticker symbol &#8220;ACONW.&#8221;</ix:footnote></i></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span id="xdx_F02_zXPSiiQZe8N1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F11_zom5hNjrTiyc"><ix:footnote id="Footnote001292" xml:lang="en-US">The per share exercise price of these warrants is subject to a &#8220;ratchet&#8221; adjustment if the Company issues securities at an effective per share price lower than the then effective warrant exercise price. The strike price of $0.29 is current through the equity line activity closed April 26, 2024.</ix:footnote></i></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A9_ziLpPF7lpbv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001294" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_800_eus-gaap--EarningsPerShareTextBlock_zy0JXDs1fVDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 12. <span id="xdx_82F_zes4OZvugAGk">NET LOSS PER SHARE OF COMMON STOCK</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic and diluted net loss per share is computed
by dividing net loss attributable to stockholders by the weighted average number shares of common stock outstanding during the period
and shares issuable for vested restricted stock units. Potentially dilutive outstanding shares of common stock equivalents were excluded
from the computation of diluted net loss per share for loss periods presented because including them would have been antidilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reconciliation of the numerator and denominator
used in the calculation of basic and diluted net loss per share attributable to stockholders follows:</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001296" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zOBicJRIU8Q6" summary="xdx: Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Basic and diluted net loss per share)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BD_z4534VW0VB3b" style="display: none">Schedule of reconciliation of basic and diluted net loss per share</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left; text-indent: -10pt; padding-left: 10pt">Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ProfitLoss_c20240401__20240630_zRqXvkIA5F5g" title="Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share" style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-04-012024-06-30" id="Fact001298" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,238,077</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ProfitLoss_c20230401__20230630_zluZTpibBKI" title="Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share" style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-04-012023-06-30" id="Fact001300" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,464,557</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Weighted average shares outstanding used to compute basic and dilutive loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--WeightedAverageNumberOfSharesOutstandingBasic1_c20240401__20240630_zvbTvMv46EO1" title="Weighted average shares outstanding used to compute basic and dilutive loss per share" style="text-align: right"><ix:nonFraction name="ACON:WeightedAverageNumberOfSharesOutstandingBasic1" contextRef="From2024-04-012024-06-30" id="Fact001302" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,208,281</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--WeightedAverageNumberOfSharesOutstandingBasic1_c20230401__20230630_zHC2O3Vhjsf2" title="Weighted average shares outstanding used to compute basic and dilutive loss per share" style="text-align: right"><ix:nonFraction name="ACON:WeightedAverageNumberOfSharesOutstandingBasic1" contextRef="From2023-04-012023-06-30" id="Fact001304" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">505,485</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Weighted average shares issuable for vested restricted stock units</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c20240401__20240630_z7cyP1rhrlYj" title="Weighted average shares issuable for vested restricted stock units" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="From2024-04-012024-06-30" id="Fact001306" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,743</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c20230401__20230630_zxg6eTNXwjHg" title="Weighted average shares issuable for vested restricted stock units" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="From2023-04-012023-06-30" id="Fact001308" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,494</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_zHkoSbbSqQVl" title="Weighted average shares of common stock outstanding, basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zttpRmKIGWJb" title="Weighted average shares of common stock outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-04-012024-06-30" id="Fact001310" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-04-012024-06-30" id="Fact001312" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,217,024</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630_zL11xWBCdfef" title="Weighted average shares of common stock outstanding, basic"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630_zEanN7LkPm0i" title="Weighted average shares of common stock outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-04-012023-06-30" id="Fact001314" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-04-012023-06-30" id="Fact001316" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">517,979</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>


<p style="margin: 0">&#160;</p>

<ix:exclude><p id="xdx_23E_zjkIPmbpbYMl" style="margin: 0">&#160;</p></ix:exclude>

<p style="margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 181; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zf3abrEZigz5" style="margin: 0">&#160;</p></ix:exclude>

<table cellpadding="0" cellspacing="0" summary="xdx: Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Dilutive securities)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span></span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left; text-indent: -10pt; padding-left: 10pt">Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ProfitLoss_c20240101__20240630_zQezW8C3z1I8" title="Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share" style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-01to2024-06-30" id="Fact001320" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,637,180</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ProfitLoss_c20230101__20230630_ziLnBC20sjWj" title="Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share" style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-06-30" id="Fact001322" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,648,017</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Weighted average shares outstanding used to compute basic and dilutive loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--WeightedAverageNumberOfSharesOutstandingBasic1_c20240101__20240630_z8wEh4n4P4o6" title="Weighted average shares outstanding used to compute basic and dilutive loss per share" style="text-align: right"><ix:nonFraction name="ACON:WeightedAverageNumberOfSharesOutstandingBasic1" contextRef="From2024-01-01to2024-06-30" id="Fact001324" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,817,419</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--WeightedAverageNumberOfSharesOutstandingBasic1_c20230101__20230630_zvbL6WdrpmAg" title="Weighted average shares outstanding used to compute basic and dilutive loss per share" style="text-align: right"><ix:nonFraction name="ACON:WeightedAverageNumberOfSharesOutstandingBasic1" contextRef="From2023-01-012023-06-30" id="Fact001326" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">498,415</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Weighted average shares issuable for vested restricted stock units</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c20240101__20240630_zS2qQxKYUMik" title="Weighted average shares issuable for vested restricted stock units" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="From2024-01-01to2024-06-30" id="Fact001328" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,406</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c20230101__20230630_z2vkQKGEftQe" title="Weighted average shares issuable for vested restricted stock units" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="From2023-01-012023-06-30" id="Fact001330" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,084</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_zDW2ANguK92g" title="Weighted average shares of common stock outstanding, basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zjvrwv6h73y2" title="Weighted average shares of common stock outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-06-30" id="Fact001332" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-06-30" id="Fact001334" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,829,825</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630_zNxkDGSoU7q9" title="Weighted average shares of common stock outstanding, basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630_zuNTUzpSSISb" title="Weighted average shares of common stock outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-06-30" id="Fact001336" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-06-30" id="Fact001338" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">507,499</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_z1G6C1gFphj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following outstanding potentially dilutive
securities were excluded from the weighted average calculation of dilutive loss per share attributable to common stockholders because
their impact would have been antidilutive for the period presented:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001340" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMLYqGufMkN6" summary="xdx: Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Dilutive securities)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BC_zIU952YOod9a" style="display: none">Schedule of anti-dilutive securities excluded from computation of earnings per share</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%">Warrants</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_z6O5fIgId0sg" title="Antidilutive shares" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-06-30_custom_WarrantsMember" id="Fact001342" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,666,674</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zVoXztMvdzk7" title="Antidilutive shares" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-06-30_custom_WarrantsMember" id="Fact001344" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">219,910</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zUdurxZWOqm5" title="Antidilutive shares" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-06-30_custom_RestrictedStockUnitsMember" id="Fact001346" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,853</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zp1OkIoaM1R4" title="Antidilutive shares" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-06-30_custom_RestrictedStockUnitsMember" id="Fact001348" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">43,276</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Stock options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zqXA7perEKUd" title="Antidilutive shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-06-30_custom_StockOptionsMember" id="Fact001350" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">169,458</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zn1xY5JHgPaj" title="Antidilutive shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-06-30_custom_StockOptionsMember" id="Fact001352" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">171,176</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630_zwDiURYaUSil" title="Antidilutive shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-01to2024-06-30" id="Fact001354" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,840,985</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630_zr5181425Buk" title="Antidilutive shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-06-30" id="Fact001356" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">434,362</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001358" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_801_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zzg2XxwG8CNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 13. <span id="xdx_820_zBeXq9ZaQ4bf">STOCK BASED COMPENSATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2022 Aclarion Equity Incentive Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 21, 2022, in connection with the IPO,
the Company&#8217;s 2022 Aclarion Equity Incentive Plan, or &#8220;2022 Plan&#8221;, went into effect. Our board of directors has appointed
the compensation committee of our board of directors as the committee under the 2022 Plan with the authority to administer the 2022 Plan.
The aggregate number of our shares of common stock that may be issued or used for reference purposes under the 2022 Plan is <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20220421__us-gaap--PlanNameAxis__custom--AclarionEquityIncentivePlan2022Member_zqcgf0zFWDnf" title="Number of common shares issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2022-04-21_custom_AclarionEquityIncentivePlan2022Member" id="Fact001360" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,000</ix:nonFraction></span> shares
(2,000,000 prior to the 2024 Stock Split), with an automatic increase on January 1st of each year, for a period of not more than ten years,
commencing on January 1st of the year following the year in which the initial public offering date (April 2022) occurs and ending on (and
including) January 1, 2032, in an amount equal to 5% of the total number of shares of Capital Stock outstanding on December 31st of the
preceding calendar year. Notwithstanding the foregoing, the Board may act prior to January 1st of a given year to provide that there will
be no January 1st increase in shares for such year or that the increase in shares for such year will be a lesser number of shares of Common
Stock than would otherwise occur pursuant to the preceding sentence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the year ended December 31, 2023, the aggregate
number of our shares of common stock that may be issued or used for reference purposes under the 2022 Plan was <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20231231__us-gaap--PlanNameAxis__custom--AclarionEquityIncentivePlan2022Member_zEy7ijCE1GK" title="Number of common shares issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2023-12-31_custom_AclarionEquityIncentivePlan2022Member" id="Fact001362" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">154,426</ix:nonFraction></span> (2,470,814 pre-split).
On January 1, 2024, the 2022 Plan had an automatic increase of 41,270 (660,311 pre-split) shares which was 5% of the total number of shares
of Capital Stock outstanding on December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options granted under the 2022 Plan may be incentive
stock options or non-statutory stock options, as determined by the administrator at the time of grant of an option. Restricted stock may
also be granted under the 2022 Plan. The options vest in accordance with the grant terms and are exercisable for a period of up to 10
years from grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20240101__20240630_z2uwhkqSJq7l" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-01to2024-06-30" id="Fact001364" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">No</ix:nonFraction></span> options were granted in the six months ended
June 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_237_zM0a5Rgectcj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zNke9I0qm3Sb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 182; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_zEraDfOFCnUg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Nocimed, Inc. 2015 Stock Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains the Nocimed, Inc. 2015 Stock
Plan, or the &#8220;Existing Plan&#8221;, under which the Company could grant 152,558 shares (after giving effect to the 2024 Stock Split)
or options of the Company to our employees, consultants, and other service providers. The Company suspended the Existing Plan in connection
with the April 2022, initial public offering. The Company did not grant any stock options under the Existing Plan for the twelve months
ended December 31, 2022, and thereafter. No further awards will be granted under the Existing Plan, but awards granted prior to the suspension date will
continue in accordance with their terms and the terms of the Existing Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Determining Fair Value of Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of each grant of stock options
was determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires
significant judgment to determine.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Valuation and Amortization Method </i>&#8212;The
Company estimates the fair value of its stock options using the Black-Scholes-Merton option-pricing model. This fair value is then amortized
over the requisite service periods of the awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Expected Term</i>&#8212;The Company estimates
the expected term of stock option by taking the average of the vesting term and the contractual term of the option, as illustrated by
the simplified method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Expected Volatility</i>&#8212;The expected
volatility is derived from the Company&#8217;s expectations of future market volatility over the expected term of the options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Risk-Free Interest Rate</i>&#8212;The risk-free
interest rate is based on the 10-year U.S. Treasury yield curve on the date of grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dividend Yield</i>&#8212;The dividend yield
assumption is based on the Company&#8217;s history and expectation of no dividend payouts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock Award Activity </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of option activity under the Company&#8217;s
incentive plans is as follows:</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001369" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z0YRy0CouXe1" summary="xdx: Disclosure - STOCK BASED COMPENSATION (Details - Option activity)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BF_z5ndK5Ip9mLc" style="display: none">Schedule of option activity</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Options</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Outstanding</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (In Years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 49%">Balance at December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240630_ziEbKKlajOQ4" title="Number of share options outstanding, Beginning" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31" id="Fact001371" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">169,456</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630_ztzwJh2DJBsj" title="Weighted average exercise price, Beginning" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" id="Fact001373" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">31.15</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zhb47Tevujcl" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2023-01-012023-12-31" format="ixt-sec:duryear" id="Fact001375" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.5</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20240101__20240630_zrSY25AjPoAg" title="Options granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-01-01to2024-06-30" id="Fact001377" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20240101__20240630_zKsW4n8Ypfw6" title="Weighted average exercise price, Options granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-06-30" id="Fact001379" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_d0_c20240101__20240630_zwdp07jOO9Gf" title="Options exercised" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-01-01to2024-06-30" id="Fact001381" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20240101__20240630_z3gf1yCre7jj" title="Weighted average exercise price, Options exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-06-30" id="Fact001383" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Options forfeited/expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d0_c20240101__20240630_zRKrgkTLHmOi" title="Options forfeited or expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2024-01-01to2024-06-30" id="Fact001385" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20240101__20240630_zM9MSTKUhKPa" title="Weighted average exercise price, Options forfeited or expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-06-30" id="Fact001387" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Balance at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240630_zgGpyxoeCIuj" title="Number of share options outstanding, Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-06-30" id="Fact001389" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">169,456</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630_zmLnIcsg8aY8" title="Weighted average exercise price, Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-06-30" id="Fact001391" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">31.15</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630_zpAxW2DRAvvf" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" format="ixt-sec:duryear" id="Fact001393" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.0</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Exercisable at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231_zRQKl506Bqbd" title="Options exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-12-31" id="Fact001395" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">147,977</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231_z9oGo4nj6li1" title="Weighted average exercise price, Option exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" id="Fact001397" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.57</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_z139Zn2yr4Mg" title="weighted average remaining contractual life, Options exercisable"><ix:nonNumeric contextRef="From2023-01-012023-12-31" format="ixt-sec:duryear" id="Fact001399" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">7.4</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercisable at June 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630_z0DZmV1BTCSi" title="Options exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-06-30" id="Fact001401" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">154,971</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240630_zXshqrmyo0W8" title="Weighted average exercise price, Option exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-06-30" id="Fact001403" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.80</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240630_ztmuQ0k80rK" title="Weighted average remaining contractual life, Options exercisable"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" format="ixt-sec:duryear" id="Fact001405" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">6.9</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_231_zMobGwexRoA6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zP3W9JFdvKCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 183; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zqXGxWSCgU8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value of options outstanding
at June 30, 2024 is $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20240101__20240630_zv709ybiOnD2" title="Intrinsic value options outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2024-01-01to2024-06-30" id="Fact001410" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>. The aggregate intrinsic value of vested and exercisable options at June 30, 2024 is $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240630__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zOdKuSwKZLd" title="Intrinsic value options exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2024-01-012024-06-30_us-gaap_OptionMember" id="Fact001412" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2024, there was approximately $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20240630__us-gaap--AwardTypeAxis__custom--NonVestedStockOptionsMember_zCdAcK1Q1gKl" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2024-06-30_custom_NonVestedStockOptionsMember" id="Fact001414" format="ixt:numdotdecimal" decimals="0" unitRef="USD">212,454</ix:nonFraction></span>
of total unrecognized compensation cost related to non-vested stock options, which is expected to be recognized over the next <span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtM_c20240101__20240630__us-gaap--AwardTypeAxis__custom--NonVestedStockOptionsMember_zmtrVpzYoTUj" title="Unrecognized compensation cost, remaining term"><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_NonVestedStockOptionsMember" format="ixt-sec:durmonth" id="Fact001416" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">15</ix:nonNumeric></span> months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Restricted Stock Units</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the six months ended June 30, 2024, the Company
had <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_do_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z10gADxGBbPl" title="RSU's granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001418" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> new grants of RSUs under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Post-split RSU activity under the 2022 Plan was
as follows for the six months ended June 30, 2024:</p>


<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001420" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"><table cellspacing="0" cellpadding="0" summary="xdx: Disclosure - STOCK BASED COMPENSATION (Details - RSU activity)" id="xdx_88F_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_znkXrAaqdKi2" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B8_zlry3kkdAuRd" style="display: none">Schedule of RSU activity</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>RSU&#8217;s</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Outstanding</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-Average Grant-Date Fair value per Unit</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonvested as of December 31, 2023</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zePX4Qyrfiej" title="Number of Rsu shares outstanding, Beginning" style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001422" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,749</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjpfSHqj9crd" title="Weighted average grant date fair value per unit, Beginning" style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001424" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.72</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zahTZfqSkZq5" title="RSU's granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001426" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ziHveFgJQBjj" title="RSU's granted, weighted-average grant date fair value per unit" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001428" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zcmCPBhYXQZ" title="RSU's vested" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001430" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,953</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNdV89pR7yXl" title="RSU's vested, weighted-average grant date fair value per unit" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001432" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.30</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7U6sSahi0vf" title="RSU's forfeited" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001434" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,942</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)&#160;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMI4bZqbrpT1" title="RSU's forfeited, weighted-average grant date fair value per unit" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001436" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.42</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonvested as of June 30, 2024</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zc83dXAXOWx3" title="Number of Rsu shares outstanding, Ending" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001438" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,854</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvS4oeiGAyV8" title="Weighted average grant date fair value per unit, Ending" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001440" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.20</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The grant date fair value for a RSU is the market
price of the common stock on the date of grant. The total share-based compensation expense related to RSUs recognized during the six months
ended June 30, 2024, was $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxBXymiIEGRk" title="Share-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001442" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,733</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2024, there was approximately $<span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKOzNcOti995" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001444" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,735</ix:nonFraction></span>
total unrecognized compensation cost related to non-vested RSUs which is expected to be recognized over the next three months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2024, the Company is obligated
to issue <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCZYvGt9SpF7" title="Obligated to issue share of common stock"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001446" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,539</ix:nonFraction></span> post-split shares of common stock associated with vested Restricted Stock Units.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-based Compensation Expense</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the total stock-based
compensation expense included in the Company&#8217;s statements of operations for the periods presented:</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001448" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zJu4tEMlReM2" summary="xdx: Disclosure - STOCK BASED COMPENSATION (Details - Share based compensation)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BC_zYuwJnv8gwP5" style="display: none">Schedule of stock-based compensation expense</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 36%; text-align: left">Sales and marketing</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zLOfSKVm9H6" title="Total stock-based compensation" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_SellingAndMarketingExpenseMember" id="Fact001450" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,605</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_z3jc3MI7sEhi" title="Total stock-based compensation" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-04-012023-06-30_us-gaap_SellingAndMarketingExpenseMember" id="Fact001452" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">78,688</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zRB0FsyZiys4" title="Total stock-based compensation" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-06-30_us-gaap_SellingAndMarketingExpenseMember" id="Fact001454" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,733</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_z7yWBeNbyZm2" title="Total stock-based compensation" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-06-30_us-gaap_SellingAndMarketingExpenseMember" id="Fact001456" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">106,997</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zkdWfugvBio9" title="Total stock-based compensation" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001458" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,055</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zQ8KKpLlNz12" title="Total stock-based compensation" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-04-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001460" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,055</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z38BJhvIHmqi" title="Total stock-based compensation" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001462" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,110</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zV23PCvbPxqd" title="Total stock-based compensation" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001464" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,615</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zogvgu0lPfM" title="Total stock-based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001466" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">55,644</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zf4C6vqufR21" title="Total stock-based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-04-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001468" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">55,888</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zagqkI9NH7j8" title="Total stock-based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001470" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">111,288</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zfZPA7ZVraN4" title="Total stock-based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001472" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">106,551</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: white; text-align: left; padding-bottom: 2.5pt">Total share based compensation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630_zrS0WUsqZy2l" title="Total stock-based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-04-012024-06-30" id="Fact001474" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">70,305</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630_z4AHE4AehdS2" title="Total stock-based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-04-012023-06-30" id="Fact001476" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">136,631</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240630_z8II90fIOkr2" title="Total stock-based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-06-30" id="Fact001478" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">156,131</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230630_zZMVK0sXPuyk" title="Total stock-based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-06-30" id="Fact001480" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">219,162</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact001482" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_z3VOft7VDVoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 14. <span id="xdx_82F_zUyUP3ABlnAa">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Stock Subscription Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 12, 2024, we entered into a subscription
agreement with an institutional investor, pursuant to which the Company agreed to issue and sell to the investor 400,000 shares of Common
Stock of the Company at a price of $0.29 per share for gross proceeds to the Company of $116,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares were issued pursuant to the Company&#8217;s
Form 1-A Offering Statement initially filed by the Company with the Securities and Exchange Commission under the Securities Act of 1933,
as amended on June 11, 2024 and qualified on June 24, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Exchange Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May, September and November 2023 the Company
issued $2,594,118 aggregate principal amount of unsecured non-convertible notes to certain accredited investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Between January 22 and January 29, 2024, the Company
entered into a series of exchange agreements (the &#8220;Exchange Agreements&#8221;) with the accredited investors to exchange principal
and accrued interest on these notes for shares of common stock. Pursuant to the Exchange Agreements, the Company issued an aggregate of
644,142 post-split shares of common stock in exchange for $1,519,779 principal and accrued interest on the notes. Following these exchanges,
the remaining outstanding balance of principal and interest on the notes was $1,145,037.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On March 6, 2024, the
Company paid $300,973 of principal and accrued interest on certain unsecured non-convertible notes. Following this payment, the remaining
outstanding balance of principal and interest on the notes was $898,380.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 14, 2024, the Company entered into an
additional exchange agreement with the accredited investors to exchange $930,052 principal and accrued interest on these notes for newly
issued shares of Series B convertible preferred stock. Following this exchange, there was no remaining outstanding balance of principal
and interest on the notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><p id="xdx_811_zYsZ7MOI7nh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></p>

<!-- Field: Page; Sequence: 184; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Up to 1,450,000 Shares of Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>ACLARION, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>PROSPECTUS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 185 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>PART II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>INFORMATION NOT REQUIRED
IN PROSPECTUS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item&#160;13.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other Expenses of Issuance and Distribution.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the costs and expenses,
payable in connection with the sale of common stock being registered. All amounts shown are estimates, except the Securities and Exchange
Commission registration fee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 84%"><span style="font-size: 10pt">Securities and Exchange Commission registration fee</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right">1,118.07</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Legal fees and expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">35,000.00</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Accountants&#8217; fees and expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">10,000.00</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Printing expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">7,500.00</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Transfer agent and registrar fees and expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">7,500.00</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Miscellaneous</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">3,881.93</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Total</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">65,000.00</span></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item&#160;14.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnification of Directors
    and Officers.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We are incorporated under
the laws of the state of Delaware. Section 145 of the Delaware General Corporation Law provides that a Delaware corporation may indemnify
any persons who are, or are threatened to be made, parties to any threatened, pending or completed action, suit or proceeding, whether
civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact
that such person was an officer, director, employee or agent of such corporation, or is or was serving at the request of such person
as an officer, director, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&#8217;
fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action,
suit or proceeding, provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed
to the corporation&#8217;s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe
that his or her conduct was illegal. A Delaware corporation may indemnify any persons who are, or are threatened to be made, a party
to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person was
a director, officer, employee or agent of such corporation, or is or was serving at the request of such corporation as a director, officer,
employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&#8217; fees) actually
and reasonably incurred by such person in connection with the defense or settlement of such action or suit provided such person acted
in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation&#8217;s best interests except
that no indemnification is permitted without judicial approval if the officer or director is adjudged to be liable to the corporation.
Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation
must indemnify him or her against the expenses that such officer or director has actually and reasonably incurred. Our charter and bylaws
provide for the indemnification of our directors and officers to the fullest extent permitted under the Delaware General Corporation
Law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 186 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Section 102(b)(7) of
the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation
shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duties as a director,
except for liability for:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 2%; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    breach of the director&#8217;s duty of loyalty to the corporation or its stockholders;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    transaction from which the director derived an improper personal benefit.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">These limitations of liability
do not affect the availability of equitable remedies such as injunctive relief or rescission. Our charter also authorizes us to indemnify
our officers, directors and other agents to the fullest extent permitted under Delaware law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As permitted by Section
145 of the Delaware General Corporation Law, our bylaws provide that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 2%; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may indemnify our directors, officers and employees to the fullest extent permitted by the Delaware General Corporation Law, subject
    to limited exceptions;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may advance expenses to our directors, officers and employees in connection with a legal proceeding to the fullest extent permitted
    by the Delaware General Corporation Law, subject to limited exceptions; and</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rights provided in our bylaws are not exclusive.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Section 174 of the Delaware
General Corporation Law provides, among other things, that a director who willfully or negligently approves of an unlawful payment of
dividends or an unlawful stock purchase or redemption may be held liable for such actions. A director who was either absent when the
unlawful actions were approved, or dissented at the time, may avoid liability by causing his or her dissent to such actions to be entered
in the books containing minutes of the meetings of the board of directors at the time such action occurred or immediately after such
absent director receives notice of the unlawful acts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As permitted by the Delaware
General Corporation Law, we have entered and expect to continue to enter into agreements to indemnify our directors, executive officers
and other employees as determined by our board of directors. Under the terms of our indemnification agreements, we are required to indemnify
each of our directors and officers, to the fullest extent permitted by the laws of the state of Delaware, if the basis of the indemnitee&#8217;s
involvement was by reason of the fact that the indemnitee is or was a director, or officer, of the company or any of its subsidiaries
or was serving at the company&#8217;s request in an official capacity for another entity. We must indemnify our officers and directors
against (1) attorneys&#8217; fees and (2) all other costs of any type or nature whatsoever, including any and all expenses and obligations
paid or incurred in connection with investigating, defending, being a witness in, participating in (including on appeal) or preparing
to defend, be a witness or participate in any completed, actual, pending or threatened action, suit, claim or proceeding, whether civil,
criminal, administrative or investigative, or establishing or enforcing a right to indemnification under the indemnification agreement.
The indemnification agreements also set forth certain procedures that will apply in the event of a claim for indemnification thereunder.
These indemnification provisions and the indemnification agreements may be sufficiently broad to permit indemnification of our officers
and directors for liabilities, including reimbursement of expenses incurred, arising under the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In addition, we have purchased
a policy of directors&#8217; and officers&#8217; liability insurance that insures our directors and officers against the cost of defense,
settlement or payment of a judgment in some circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 187 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 9%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    15.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent Sales of Unregistered
    Securities.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Note: The following
sales have not been adjusted for our reverse stock split in January 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">During the three-year
period preceding the date of filing of this registration statement, we have issued securities in the transactions described below without
registration under the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In February 2020, the
Company issued to NuVasive a $2 million &#8220;SAFE&#8221; (Simple Agreement for Future Equity). In December 2021, the SAFE was converted
into shares of Series B-2 Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In February 2020 and
continuing through June 2021, the Company initiated a financing in the form of 6% Convertible Promissory Notes due June 30, 2021. This
financing raised $2,130,010 during 2020 and $814,000 during the first six months of 2021. In December 2021, all notes were converted into
shares of Series B-3 Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection with the
above-referenced note financing, the Company also issued certain common stock warrants. Such warrants were exercised immediately prior
to the Company&#8217;s April 2022 IPO, resulting in the issuance of 76,156 shares (post-reverse stock split) of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In June 2021, the Company
issued $2.0 million of Promissory Notes that mature at the earlier of the consummation of a Qualified Financing or May 31, 2022. The notes
incorporated the following major attributes; interest on the Notes accrues at 33%, and the accrued interest would automatically convert
into the securities offered in a Qualified Financing, at a per security price equal to the offering price of the Qualified Financing multiplied
by 0.30 (70% discount).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">From January 1, 2019 through
the date of the Company&#8217;s April 2022 IPO, we granted to our consultants, employees, officers and directors options to purchase
an aggregate of 16,073,154 shares (pre-reverse stock split) of Common Stock at per share exercise prices ranging from $0.18 to $0.26
(pre-reverse stock split) under our 2015 Stock Plan. Included in those totals were grants made during 2021 of options to purchase an
aggregate of 14,234,688 shares (pre-reverse stock split) of Common Stock at a per share exercise price of $0.26 (pre-reverse stock split).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">From January 1, 2019 through
the date of the Company&#8217;s April 2022 IPO, we granted to our consultants, employees, officers and directors options to purchase
an aggregate of 16,073,154 shares (pre-reverse stock split) of Common Stock at per share exercise prices ranging from $0.18 to $0.26
(pre-reverse stock split) under our 2015 Stock Plan. Included in those totals were grants made during 2021 of options to purchase an
aggregate of 14,234,688 shares (pre-reverse stock split) of Common Stock at a per share exercise price of $0.26 (pre-reverse stock split).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">From January 1, 2019 through
the date of the Company&#8217;s April 2022 IPO, we issued an aggregate of 10,000 shares of Common Stock pursuant to the exercise of options
by our consultants, employees, officers and directors.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 188 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In connection with our April
2022 IPO:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain outstanding common
    stock warrants were exercised on a net share basis for 60,408 common shares&#894;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,495,004 (pre-split)
    outstanding shares of our preferred stock were converted into 3,279,117 post-split shares of common stock&#894;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all accrued dividends on
    our outstanding Series B, B-1, B-2 and B-3 preferred stock were converted to 984,429 post-split common shares&#894;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all accrued interest on
    the Company's outstanding secured promissory notes was converted into (i) 426,768 post-split common shares and (ii) 426,768 post-split
    common stock warrants, with beneficial conversion rates charged to interest expense upon conversion; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we issued to the representative
    of the underwriters a common stock warrant for 173,200 shares with an exercise price of $5.44 per share. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In November 2022, we
issued 40,000 unregistered and restricted shares to a vendor as partial payment for services rendered by such vendor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In May and September
2023, we issued $2.3 million of unsecured non-convertible promissory notes. In connection with this note issuance, the Company issued
(x) 339,360 shares of common stock as a commitment fee, (y) 1,232,156 common stock warrants with a five-year term and an initial exercise
price of $0.6262 per share, and (z) 100,973 prefunded common stock warrants to a broker dealer firm as a commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2023, we entered into an equity line
common stock purchase agreement (the &#8220;Purchase Agreement&#8221;) with White Lion Capital LLC. Pursuant to the Purchase Agreement,
the Company has the right, but not the obligation, to require White Lion to purchase, from time to time, up to $10,000,000 in aggregate
gross purchase price of newly issued shares of the Company&#8217;s common stock, subject to certain limitations and conditions set forth
in the Purchase Agreement. This includes 187,500 shares of common stock we issued to White Lion as commitment shares. As of August 2024,
we sold 1,800,000 shares of common stock to White Lion pursuant to the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In November 2023, we
issued $294,117.65 of unsecured non-convertible promissory notes. In connection with this note issuance, the Company issued (x) 148,978
shares of common stock as a commitment fee, (y) 744,890 common stock warrants with a five-year term and an initial exercise price of $0.2865
per share, and (z) 25,210 prefunded common stock warrants to a broker dealer firm as a commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note: The following sales have been adjusted for our reverse stock
split in January 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">From January 22 through
January 29, 2024, we issued 644,142 shares of common stock in connection with a series of exchange agreements with the accredited investors
to exchange principal and accrued interest on the certain outstanding non-convertible note for shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On August 14, 2024,
we entered into an exchange agreement with certain note holders to exchange approximately $930,000 of principal and accrued interest
on the notes for 930 shares of newly issued Series B convertible preferred stock (&#8220;Series B Preferred Stock&#8221;) at a purchase
price of $1,000 per share of Series B Preferred Stock. The Series B Preferred Stock is convertible into common stock at an initial conversion
price of $0.234 per share of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 12
and 27, 2024, we entered into subscription agreements with certain accredited investors, pursuant to which the Company agreed to issue
and sell to the investors an aggregate amount of 1,825,000 shares of common stock of the Company at a price of $0.29 per share for gross
proceeds to the Company of $529,250 pursuant to the Company&#8217;s Form 1-A filed with the Securities and Exchange Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 27,
2024, we entered into a warrant purchase agreement with the accredited investors pursuant to with the Company issued warrants to purchase
up to 400,000 shares of common stock exercisable on or after February 27, 2025 with a five-year term and an initial exercise price of
$0.29 per share, subject to customary adjustments as described in the warrants. The warrants may be exercised by cashless exercise in
accordance with a formula described in the warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2024, we entered into a securities
purchase agreement with accredited investors for 1,000 shares of Series C convertible preferred stock (&#8220;Series C Preferred Stock&#8221;)
at a purchase price of $1,000 per share of Series C Preferred Stock for aggregate gross proceeds of $1,000,000. The Series C Preferred
Stock is convertible into common stock at an initial exercise price of $0.1759 per share. We also issued warrants exercisable for 5,685,049
shares of common stock with a 5.5 year term and an initial exercise price of $0.1759 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">These sales and issuances
were made in reliance upon Section 3(a)(9), Section 4(a)(2) or Regulation A of the Securities Act of 1933, as amended, and Regulation
D, Rule 506 (d), and did not involve any underwriters, underwriting discounts or commissions, or any public offering. The persons and
entities who received such securities have represented their intention to acquire these securities for investment only and not with a
view to or for sale in connection with any distribution thereof, and appropriate legends are be affixed to all share certificates issued.
All recipients have adequate access through their relationship with us to information about us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 189 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item&#160;16.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibits and Financial Statement Schedules.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><b>(a)
Exhibits</b>. The following exhibits are filed as part of this Registration Statement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 6%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Exhibit</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Number</b></p></td>
    <td style="width: 3%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 56%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description of Document</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 10%">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Incorporated by </b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>reference from Form</b></p></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 10%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Filing</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Date</b></p></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 6%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Exhibit</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Number</b></p></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 5%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Filed </b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Herewith</b></p></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822002974/aclarion_ex0301.htm">Amended
    and Restated Certificate of Incorporation of the Company</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04-27-2022</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">3.2</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1635077/000168316824000066/acon_ex0301.htm">Certificate of Amendment dated January 3, 2024 to the Amended and Restated Certificate of Incorporation</a></td>
    <td>&#160;</td>
    <td style="vertical-align: top">8-K</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">01-04-2024</td>
    <td>&#160;</td>
    <td style="vertical-align: top">3.1</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822002974/aclarion_ex0302.htm">Bylaws of the Company</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04-27-2022</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">3.4</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">Amendment to Bylaws dated June 12, 2024</td>
    <td>&#160;</td>
    <td style="vertical-align: top">8-K</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">06-18-2024</td>
    <td>&#160;</td>
    <td style="vertical-align: top">3.1</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">3.5</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">Series B Convertible Preferred Stock Certificate of Designations dated August
    14, 2024</td>
    <td>&#160;</td>
    <td style="vertical-align: top">8-K</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">08-14-2024</td>
    <td>&#160;</td>
    <td style="vertical-align: top">3.1</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">3.6</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">Series C Convertible Preferred Stock Certificate of Designations dated September
    30, 2024</td>
    <td>&#160;</td>
    <td style="vertical-align: top">8-K</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><p style="margin: 0pt 0">10-01-2024</p></td>
    <td>&#160;</td>
    <td style="vertical-align: top">3.1</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000165495422007977/aclarion_ex41.htm">Form of Common Stock Certificate</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">06-06-2022</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822002974/aclarion_ex0401.htm">Form of IPO Warrant</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04-27-2022</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822002974/aclarion_ex0402.htm">Form of IPO Representative&#8217;s Common Stock Purchase Warrant</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04-27-2022</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000165495422007977/aclarion_ex44.htm">Description of Securities</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">06-06-2022</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">5.1</td>
    <td>*</td>
    <td style="vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1635077/000168316824000371/aclarion_ex0501.htm">Opinion of Carroll Legal LLC</a></td>
    <td>&#160;</td>
    <td style="vertical-align: top">S-1</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">01-22-2024</td>
    <td>&#160;</td>
    <td style="vertical-align: top">5.1</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822001851/aclarion_ex1001.htm">Employment Agreement of Jeff Thramann</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-23-2022</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822001851/aclarion_ex1002.htm">Employment Agreement of Brent Ness</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-23-2022</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822001851/aclarion_ex1003.htm">Employment Agreement of John Lorbiecki</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-23-2022</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822000097/aclarion_ex1004.htm">Form of Aclarion, Inc. 2022 Equity Incentive Plan</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01-06-2022</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822001434/aclarion_ex1005.htm">Senior Secured Bridge Note</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-04-2022</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822000097/aclarion_ex1006.htm">License Agreement with UCSF the Regents of the University of California</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01-06-2022</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822001434/aclarion_ex1007.htm">Amendment to UC License Agreement</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-04-2022</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822001851/aclarion_ex1008.htm">NuVasive Amended and Restated Commission Agreement dated February 28, 2020</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-23-2022</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822001851/aclarion_ex1009.htm">Amended and Restated Investor Rights Agreement dated July 27, 2017</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-23-2022</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822001851/aclarion_ex1010.htm">First Amendment to Amended and Restated Investor Rights Agreement dated February 20, 2020</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-23-2022</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822001851/aclarion_ex1011.htm">NuVasive SAFE (Simple Agreement for Future Equity) dated February 28, 2020</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-23-2022</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822001851/aclarion_ex1012.htm">Right of First Offer Agreement</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-23-2022</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822001851/aclarion_ex1013.htm">First Amendment to Right of First Offer Agreement</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-23-2022</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822001851/aclarion_ex1014.htm">Second Amendment to Right of First Offer Agreement</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-23-2022</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822001851/aclarion_ex1016.htm">Convertible Note and Warrant Purchase Agreement</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-23-2022</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822002974/aclarion_ex1001.htm">Warrant Agent Agreement dated April 21, 2022</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04-27-2022</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 190 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><span style="font-size: 10pt"><b>Exhibit Number</b></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
    of Document</b></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><span style="font-size: 10pt"><b>Incorporated
    by reference from Form</b></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>Filing</b></span></p>
                                                        <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>Date</b></span></p></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><span style="font-size: 10pt"><b>Exhibit Number</b></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>Filed Herewith</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify; width: 56%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822000097/aclarion_ex1017.htm">Siemens
    Strategic Collaboration Agreement</a></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01-06-2022</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 5%"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822000097/aclarion_ex1020.htm">Aclarion,
    Inc. 2022 Equity Incentive Plan &#8211; Form of Option Grant Notice and Stock Option Agreement</a></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01-06-2022</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822000097/aclarion_ex1021.htm">Aclarion,
    Inc. 2022 Equity Incentive Plan &#8211; Form of RSU Grant Notice and RSU Agreement</a></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01-06-2022</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822004014/aclarion_ex9904.htm">Nocimed,
    Inc. 2015 Stock Plan</a></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05-26-2022</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1635077/000168316822004014/aclarion_ex9905.htm">Nocimed,
    Inc. 2015 Stock Plan &#8211; Form of Option Grant Notice and Stock Option Agreement</a></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05-26-2022</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.5</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.22</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1635077/000168316823001027/aclarion_ex1001.htm">Securities
    Purchase Agreement dated February 16, 2023 between Aclarion, Inc. and Jeffrey Thramann</a></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">02-17-2023</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">10.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.23</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><p style="margin: 0pt 0"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1635077/000168316823003484/aclarion_ex1001.htm">Form
                                            of Securities Purchase Agreement</a></span></p></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">05-17-2023</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">10.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.24</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1635077/000168316823003484/aclarion_ex1002.htm">Form
    of Unsecured Non-Convertible Note</a></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">05-17-2023</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">10.2</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.25</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1635077/000168316823003484/aclarion_ex1003.htm">Form
    of Common Stock Warrant</a></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">05-17-2023</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">10.3</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.26</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1635077/000168316823003484/aclarion_ex1004.htm">Form
    of Registration Rights Agreement</a></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">05-17-2023</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">10.4</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.27</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1635077/000168316823005758/acon_ex1001.htm">Waiver
    related to Unsecured Non-Convertible Notes</a></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">08-14-2023</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">10.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.28</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1635077/000168316823007017/aclarion_ex1001.htm">White
    Lion Purchase Agreement</a></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10-10-2023</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">10.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.29</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1635077/000168316823007017/aclarion_ex1002.htm">White
    Lion Registration Rights Agreement</a></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10-10-2023</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">10.2</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.30</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1635077/000168316823008420/acon_ex1001.htm">Form
    of Securities Purchase Agreement dated November 21, 2023</a></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">11-22-2023</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">10.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.31</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1635077/000168316823008420/acon_ex1002.htm">Form
    of Unsecured Non-Convertible Note dated November 21, 2023</a></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">11-22-2023</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">10.2</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.32</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1635077/000168316823008420/acon_ex1003.htm">Form
    of Common Stock Warrant dated November 21, 2023</a></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">11-22-2023</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">10.3</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.33</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1635077/000168316823008420/acon_ex1004.htm">Form
    of Registration Rights Agreement dated November 21, 2023</a></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">11-22-2023</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">10.4</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.34</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1635077/000168316824000377/acon_8k.htm">Form
    of Exchange Agreement</a></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">01-23-2024</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">10.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>

<tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.35</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1635077/000168316824006791/acon_ex1001.htm">Form
    of Securities Purchase Agreement dated September 30, 2024</a></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10-01-2024</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.36</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1635077/000168316824006791/acon_ex1002.htm">Form
    of Common Stock Warrant dated September 30, 2024</a></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10-01-2024</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10.2</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.37</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1635077/000168316824006791/acon_ex1003.htm">Form
    of Registration Rights Agreement dated September 30, 2024</a></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10-01-2024</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10.3</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>

  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">23.1</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="aclarion_ex2301.htm">Consent of Haynie
    &amp; Company</a></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">X</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="aclarion_ex2302.htm"><span style="font-family: Times New Roman, Times, Serif">Consent
    of CohnReznick LLP, Independent Registered Public Accounting Firm</span></a></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">X</span></td></tr>

<tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">23.3*</span></td>
    <td/>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Consent of Carroll Legal LLC (included in <a href="https://www.sec.gov/Archives/edgar/data/1635077/000168316824000371/aclarion_ex0501.htm">Exhibit
    5.1</a>)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">01/22/2024</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">5.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">24.1*</span></td>
    <td/>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1635077/000168316824000371/aclarion_s1.htm">Power
    of Attorney</a> (Included on Signature Page) </span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">01/22/2024</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">24.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">107*</span></td>
    <td/>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1635077/000168316824000371/aclarion_ex107.htm">Filing
    Fees</a></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">01/22/2024</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">107</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">____________________________</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">*</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">Previously <span style="font-family: Times New Roman, Times, Serif">filed.</span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">**</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Certain information contained
    in this Exhibit has been redacted and appears as &#8220;XXXXX&#8221; as the disclosure of same would be a disadvantage to the Registrant
    in the marketplace.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">#</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Indicates management contract
    or compensatory plan.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(b) Financial statement schedules.</b>&#160;Schedules
not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the Financial
Statements or notes thereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 191 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 9%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    17.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Undertakings.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 6%; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">(a)</span></td>
    <td style="width: 94%; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The undersigned registrant hereby undertakes:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">(1)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">i.</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-size: 10pt">To include any prospectus required by Section&#160;10(a)(3)&#160;of the Securities Act of 1933;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">ii.</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-size: 10pt">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&#160;424(b)&#160;if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">iii.&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-size: 10pt">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">(2)</span></td>
    <td colspan="3" style="text-align: justify"><span style="font-size: 10pt">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</span></td></tr>
  <tr>
    <td style="width: 5%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 87%">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 6%; text-align: justify"><span style="font-size: 10pt">(3)</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-size: 10pt">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">That for the purpose of determining any liability under the Securities Act of 1933 in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 5%; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 5%; text-align: justify"><span style="font-size: 10pt">i.</span></td>
    <td style="width: 90%; text-align: justify"><span style="font-size: 10pt">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&#160;424;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">ii.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 5%; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 5%; text-align: justify"><span style="font-size: 10pt">iii.</span></td>
    <td style="width: 90%; text-align: justify"><span style="font-size: 10pt">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">iv.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 6%; text-align: justify"><span style="font-size: 10pt">(5)</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-size: 10pt">That for the purpose of determining liability under the Securities Act of 1933 to any purchaser, if the registrant is subject to Rule&#160;430C, each prospectus filed pursuant to Rule&#160;424(b)&#160;as part of a registration statement relating to an offering, other than registration statements relying on Rule&#160;430B or other than prospectuses filed in reliance on Rule&#160;430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt"></p>

<!-- Field: Page; Sequence: 192 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Pursuant to the requirements
of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement on Form S-1 to be signed on its
behalf by the undersigned, thereunto duly authorized, in the city of Broomfield, in the State of Colorado, on this 11th day of October,
2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ACLARION, INC.</b></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="width: 51%">&#160;</td>
    <td style="vertical-align: top; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 43%">/s/ John Lorbiecki</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Lorbiecki</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span id="poa_001"></span>Pursuant to the requirements
of the Securities Act of 1933, as amended, this Registration Statement on Form S-1 has been signed by the following persons in the capacities
and on the dates indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 28%; text-align: center"><span style="font-size: 10pt"><b>Signature</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 45%; text-align: center"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 25%; text-align: center"><span style="font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">/s/ Brent Ness</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Chief Executive Officer and Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">October 11, 2024</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Brent Ness</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Principal Executive Officer)</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">President and Director</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">/s/ John Lorbiecki</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Chief Financial Officer</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">October 11, 2024</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">John Lorbiecki</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Principal Financial and Accounting Officer)</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Executive Chairman and Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">October 11, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Jeffrey Thramann</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">October 11, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">David Neal</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">October 11, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">William Wesemann</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">October 11, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Amanda Williams</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">October 11, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Stephen Deitsch</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">October 11, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Scott Breidbart</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">* <span style="text-decoration: underline">/s/ John Lorbiecki&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">John Lorbiecki</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attorney-in-Fact</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 193; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>









































































<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>aclarion_ex2301.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 23.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the use in this Registration Statement
on Form S-1/A2 of Aclarion, Inc. of our report dated February 20, 2024 and March 28, 2024, with respect to the financial statements of
Aclarion, Inc. as of December 31, 2023, and for the year then ended. Our audit report includes an explanatory paragraph relating to Aclarion,
Inc.&rsquo;s ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
We also consent to the reference to our firm under the caption &quot;Experts&quot; in such Prospectus.<BR>
<BR>
<BR>
/s/ Haynie &amp; Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Salt Lake City, Utah</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">October 11, 2024</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>aclarion_ex2302.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 23.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We consent to the inclusion in this Post-Effective Amendment No. 2
to Registration Statement on Form S-1 (No. 333-276648) and related Prospectus, of our report dated June 12, 2023, except for Note 1, 2024
Reverse Stock Split, Note 7, SUPPLEMENTAL FINANCIAL INFORMATION, Prepaids and other current assets and Accrued and other liabilities,
and Note 14, Net Loss Per Share of Common Stock, as to which the date is February 21, 2024, with respect to the restated financial statements
of Aclarion, Inc. as of December 31, 2022 and for the year then ended. Our audit report includes an explanatory paragraph relating to
Aclarion, Inc.&rsquo;s ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also consent to the reference to our firm under the caption &ldquo;Experts.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ CohnReznick LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sunrise, Florida</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">October 11, 2024</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>acon-20240630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOaSDuaPty552iYkxvmR5fWmqPyQlVKW59iPjwc2G0XoE -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ACON="http://aclarion.com/20240630" elementFormDefault="qualified" targetNamespace="http://aclarion.com/20240630">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://aclarion.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Condensed Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Condensed Statements of Operations (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit" id="StatementsOfChangesInStockholdersEquityDeficit">
          <link:definition>00000005 - Statement - Condensed Statements of Changes in Stockholders' Equity (Deficit) (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/CompanyAndBasisOfPresentation" id="CompanyAndBasisOfPresentation">
          <link:definition>00000007 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/FairValueMeasurements" id="FairValueMeasurements">
          <link:definition>00000009 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/RecentAccountingPronouncements" id="RecentAccountingPronouncements">
          <link:definition>00000010 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/Revenue" id="Revenue">
          <link:definition>00000011 - Disclosure - REVENUE</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/SupplementalFinancialInformation" id="SupplementalFinancialInformation">
          <link:definition>00000012 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/Leases" id="Leases">
          <link:definition>00000013 - Disclosure - LEASES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/IntangibleAssets" id="IntangibleAssets">
          <link:definition>00000014 - Disclosure - INTANGIBLE ASSETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/ShortTermNotesAndConvertibleDebt" id="ShortTermNotesAndConvertibleDebt">
          <link:definition>00000015 - Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>00000017 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/NetLossPerShareOfCommonStock" id="NetLossPerShareOfCommonStock">
          <link:definition>00000018 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/StockBasedCompensation" id="StockBasedCompensation">
          <link:definition>00000019 - Disclosure - STOCK BASED COMPENSATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000020 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/CompanyAndBasisOfPresentationTables" id="CompanyAndBasisOfPresentationTables">
          <link:definition>00000022 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
          <link:definition>00000023 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/SupplementalFinancialInformationTables" id="SupplementalFinancialInformationTables">
          <link:definition>00000024 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
          <link:definition>00000025 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/ShortTermNotesAndConvertibleDebtTables" id="ShortTermNotesAndConvertibleDebtTables">
          <link:definition>00000026 - Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>00000027 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/NetLossPerShareOfCommonStockTables" id="NetLossPerShareOfCommonStockTables">
          <link:definition>00000028 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
          <link:definition>00000029 - Disclosure - STOCK BASED COMPENSATION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-BalanceSheetChangesFromSplit" id="CompanyAndBasisOfPresentationDetails-BalanceSheetChangesFromSplit">
          <link:definition>00000030 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details - Balance sheet changes from split)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-RetroactiveBasisReverseStockSplits" id="CompanyAndBasisOfPresentationDetails-RetroactiveBasisReverseStockSplits">
          <link:definition>00000031 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details- Retroactive basis the reverse stock splits)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/CompanyAndBasisOfPresentationDetailsNarrative" id="CompanyAndBasisOfPresentationDetailsNarrative">
          <link:definition>00000032 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>00000033 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability" id="FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability">
          <link:definition>00000034 - Disclosure - FAIR VALUE MEASUREMENTS (Details- Recurring basis to determine the fair value of the liability)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/FairValueMeasurementsDetails-LiabilitiesMeasuresAtFairValue" id="FairValueMeasurementsDetails-LiabilitiesMeasuresAtFairValue">
          <link:definition>00000035 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Liabilities measures at fair value)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/FairValueMeasurementsDetails-FairValueOfWarrants" id="FairValueMeasurementsDetails-FairValueOfWarrants">
          <link:definition>00000036 - Disclosure - FAIR VALUE MEASUREMENTS (Details- Fair value of the warrants)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets" id="SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets">
          <link:definition>00000037 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Prepaids and other current assets)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/SupplementalFinancialInformationDetails-AccountsPayable" id="SupplementalFinancialInformationDetails-AccountsPayable">
          <link:definition>00000038 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accounts payable)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities" id="SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities">
          <link:definition>00000039 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accrued and other liabilities)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>00000040 - Disclosure - LEASES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/IntangibleAssetsDetails-IntangibleAssets" id="IntangibleAssetsDetails-IntangibleAssets">
          <link:definition>00000041 - Disclosure - INTANGIBLE ASSETS (Details - Intangible assets)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/IntangibleAssetsDetails-FutureAmortization" id="IntangibleAssetsDetails-FutureAmortization">
          <link:definition>00000042 - Disclosure - INTANGIBLE ASSETS (Details - Future amortization)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
          <link:definition>00000043 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetails-NotePayable" id="ShortTermNotesAndConvertibleDebtDetails-NotePayable">
          <link:definition>00000044 - Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT (Details - Note payable)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative" id="ShortTermNotesAndConvertibleDebtDetailsNarrative">
          <link:definition>00000045 - Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>00000046 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/StockholdersEquityDetails-OutstandingWarrants" id="StockholdersEquityDetails-OutstandingWarrants">
          <link:definition>00000047 - Disclosure - STOCKHOLDERS' EQUITY (Details - Outstanding warrants)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>00000048 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-BasicAndDilutedNetLossPerShare" id="NetLossPerShareOfCommonStockDetails-BasicAndDilutedNetLossPerShare">
          <link:definition>00000049 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Basic and diluted net loss per share)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-DilutiveSecurities" id="NetLossPerShareOfCommonStockDetails-DilutiveSecurities">
          <link:definition>00000050 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Dilutive securities)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/StockBasedCompensationDetails-OptionActivity" id="StockBasedCompensationDetails-OptionActivity">
          <link:definition>00000051 - Disclosure - STOCK BASED COMPENSATION (Details - Option activity)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/StockBasedCompensationDetails-RsuActivity" id="StockBasedCompensationDetails-RsuActivity">
          <link:definition>00000052 - Disclosure - STOCK BASED COMPENSATION (Details - RSU activity)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/StockBasedCompensationDetails-ShareBasedCompensation" id="StockBasedCompensationDetails-ShareBasedCompensation">
          <link:definition>00000053 - Disclosure - STOCK BASED COMPENSATION (Details - Share based compensation)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aclarion.com/role/StockBasedCompensationDetailsNarrative" id="StockBasedCompensationDetailsNarrative">
          <link:definition>00000054 - Disclosure - STOCK BASED COMPENSATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="acon-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="acon-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="acon-20240630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="acon-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="ACON_PreferredStockSeriesAMember" name="PreferredStockSeriesAMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_PreferredStockSeriesA1A2A3A4Member" name="PreferredStockSeriesA1A2A3A4Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_PreferredStockSeriesBB1Member" name="PreferredStockSeriesBB1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_PreferredStockSeriesB2B3Member" name="PreferredStockSeriesB2B3Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_StockSplit2024Member" name="StockSplit2024Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_Pre2024SplitMember" name="Pre2024SplitMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_Post2024SplitMember" name="Post2024SplitMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_PreSplitMember" name="PreSplitMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_PostSplitMember" name="PostSplitMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_CompletionOfPublicOfferingMember" name="CompletionOfPublicOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_CompletionOfIssuanceOfSharesMember" name="CompletionOfIssuanceOfSharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_WarrantLiabilityMember" name="WarrantLiabilityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_DerivativeLiabilityMember" name="DerivativeLiabilityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_ShortTermDepositsMember" name="ShortTermDepositsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_DeferredOfferingCostsMember" name="DeferredOfferingCostsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_PrepaidInsuranceDAndOMember" name="PrepaidInsuranceDAndOMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_PrepaidInsuranceMember" name="PrepaidInsuranceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_PrepaidClinicalCostsMember" name="PrepaidClinicalCostsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_PrepaidExchangeFeesMember" name="PrepaidExchangeFeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_PrepaidOtherMember" name="PrepaidOtherMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_OtherReceivablesMember" name="OtherReceivablesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_CreditCardsPayableMember" name="CreditCardsPayableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_AccruedPayrollMember" name="AccruedPayrollMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_AccruedBonusMember" name="AccruedBonusMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_DAndOFinancingMember" name="DAndOFinancingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_AccruedAuditAndLegalExpensesMember" name="AccruedAuditAndLegalExpensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_AccruedInterestMember" name="AccruedInterestMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_AccruedBoardCompensationMember" name="AccruedBoardCompensationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_OtherAccruedLiabilitiesMember" name="OtherAccruedLiabilitiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_PatentsAndLicensesMember" name="PatentsAndLicensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_SeniorNotesPayableMember" name="SeniorNotesPayableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_SeriesBNotesPayableMember" name="SeriesBNotesPayableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_SeriesCNotesPayableMember" name="SeriesCNotesPayableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_ExchangeAgreementsMember" name="ExchangeAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_AccreditedInvestorsMember" name="AccreditedInvestorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_UnsecuredNonConvertibleNotesMember" name="UnsecuredNonConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_RegentsOfTheUniversityOfCaliforniaMember" name="RegentsOfTheUniversityOfCaliforniaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_ExecutiveChairmanMember" name="ExecutiveChairmanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_WhiteLionEquityLineAgreementMember" name="WhiteLionEquityLineAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_WarrantStrikePriceMember" name="WarrantStrikePriceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_WarrantStrikePrice1Member" name="WarrantStrikePrice1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_WarrantStrikePrice2Member" name="WarrantStrikePrice2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_WarrantStrikePrice3Member" name="WarrantStrikePrice3Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_WarrantStrikePrice4Member" name="WarrantStrikePrice4Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_WarrantStrikePrice5Member" name="WarrantStrikePrice5Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_WarrantStrikePrice6Member" name="WarrantStrikePrice6Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_RestrictedStockUnitsMember" name="RestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_StockOptionsMember" name="StockOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_AclarionEquityIncentivePlan2022Member" name="AclarionEquityIncentivePlan2022Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_NonVestedStockOptionsMember" name="NonVestedStockOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_WarrantLiabilityCurrent" name="WarrantLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_LiabilityToIssueEquity" name="LiabilityToIssueEquity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_LossOnExchangeOfDebt" name="LossOnExchangeOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_IssuanceOfCommonSharesEquityLineOfCredit" name="IssuanceOfCommonSharesEquityLineOfCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_IssuanceOfCommonSharesEquityLineOfCreditShares" name="IssuanceOfCommonSharesEquityLineOfCreditShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_IssuanceOfCommitmentSharesNoteFinancing" name="IssuanceOfCommitmentSharesNoteFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_IssuanceOfCommitmentSharesNoteFinancingShares" name="IssuanceOfCommitmentSharesNoteFinancingShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_CashlessExerciseOfPrefundedWarrant" name="CashlessExerciseOfPrefundedWarrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_CashlessExerciseOfPrefundedWarrantsShares" name="CashlessExerciseOfPrefundedWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts" name="IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares" name="IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_PublicOfferingAndLineOfCreditIssuanceCosts" name="PublicOfferingAndLineOfCreditIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_IssuanceOfCommonSharesDebtForEquityExchange" name="IssuanceOfCommonSharesDebtForEquityExchange" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_IssuanceOfCommonSharesDebtForEquityExchangeShares" name="IssuanceOfCommonSharesDebtForEquityExchangeShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_RoundUpConversionRelatedToReverseStockSplit" name="RoundUpConversionRelatedToReverseStockSplit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_RoundUpConventionRelatedToReverseStockSplitShares" name="RoundUpConventionRelatedToReverseStockSplitShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_ProceedsFromSaleOfSeriesPreferredStock" name="ProceedsFromSaleOfSeriesPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_PreferredStockIssuedDuringPeriodSharesNewIssues" name="PreferredStockIssuedDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_RedemptionOfSeriesPreferredStock" name="RedemptionOfSeriesPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_RedemptionOfSeriesPreferredStockShares" name="RedemptionOfSeriesPreferredStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_CommitmentSharesNoteFinancing" name="CommitmentSharesNoteFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_CommitmentSharesNoteFinancingShares" name="CommitmentSharesNoteFinancingShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_IssuanceOfWarrantsNoteFinancing" name="IssuanceOfWarrantsNoteFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_GainLossOnExchangeOfDebt" name="GainLossOnExchangeOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_GainsLossesOnExtinguishmentOfDebts" name="GainsLossesOnExtinguishmentOfDebts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_NoncashInterestRelatedToBridgeFunding" name="NoncashInterestRelatedToBridgeFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_IncreaseDecreaseInNotePayableNetOfDiscount" name="IncreaseDecreaseInNotePayableNetOfDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_EquityLineOfCreditIssuanceCosts" name="EquityLineOfCreditIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_BridgeFundingIssuanceCosts" name="BridgeFundingIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_ProceedsFromBridgeFunding" name="ProceedsFromBridgeFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_IssuanceOfCommonSharesInExchangeForDebt" name="IssuanceOfCommonSharesInExchangeForDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_IssuanceOfBridgeFundCommitmentShares" name="IssuanceOfBridgeFundCommitmentShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_FairValueOfWarrantsAndDerivativeRelatedToBridgeFunding" name="FairValueOfWarrantsAndDerivativeRelatedToBridgeFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_AccruedDebtIssuanceCostsRelatedToBridgeFunding" name="AccruedDebtIssuanceCostsRelatedToBridgeFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_IssuanceOfWarrantsRelatedToBridgeFunding" name="IssuanceOfWarrantsRelatedToBridgeFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_OriginalIssueDiscount15RelatedToBridgeFunding" name="OriginalIssueDiscount15RelatedToBridgeFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_LiquidityCapitalResourcesAndGoingConcernPolicyTextBlock" name="LiquidityCapitalResourcesAndGoingConcernPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_EmergingGrowthCompanyStatusPolicyTextBlock" name="EmergingGrowthCompanyStatusPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_ScheduleOfChangesToEquityStatementTableTextBlock" name="ScheduleOfChangesToEquityStatementTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_ScheduleOfRetroactiveBasisRreverseStockSplitsTableTextBlock" name="ScheduleOfRetroactiveBasisRreverseStockSplitsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_ExchangeAndPayoffOfNotesPayable" name="ExchangeAndPayoffOfNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_FloorFinancingPrice" name="FloorFinancingPrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_UnamortizedDiscountsAndDeferredFinancingCostsWarrants" name="UnamortizedDiscountsAndDeferredFinancingCostsWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_UnamortizedDiscountsAndDeferredFinancingCostsDerivative" name="UnamortizedDiscountsAndDeferredFinancingCostsDerivative" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost" name="UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_UnamortizedDiscountsAndDeferredFinancingCostsTotal" name="UnamortizedDiscountsAndDeferredFinancingCostsTotal" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_DebtOriginalIssueDiscountPercenrtage" name="DebtOriginalIssueDiscountPercenrtage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_RemainingOutstandingBalanceOfPrincipalAndInterest" name="RemainingOutstandingBalanceOfPrincipalAndInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_PrincipalAndAccruedInterestPaid" name="PrincipalAndAccruedInterestPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_MinimumAnnualRoyaltyPayment" name="MinimumAnnualRoyaltyPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_StockIssueDate" name="StockIssueDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_PurchasePrice" name="PurchasePrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ACON_WeightedAverageNumberOfSharesOutstandingBasic1" name="WeightedAverageNumberOfSharesOutstandingBasic1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>acon-20240630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aclarion.com/role/Cover" xlink:href="acon-20240630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/BalanceSheets" xlink:href="acon-20240630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/BalanceSheetsParenthetical" xlink:href="acon-20240630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StatementsOfOperations" xlink:href="acon-20240630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:href="acon-20240630.xsd#StatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StatementsOfCashFlows" xlink:href="acon-20240630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/CompanyAndBasisOfPresentation" xlink:href="acon-20240630.xsd#CompanyAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="acon-20240630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/FairValueMeasurements" xlink:href="acon-20240630.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/RecentAccountingPronouncements" xlink:href="acon-20240630.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/Revenue" xlink:href="acon-20240630.xsd#Revenue" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SupplementalFinancialInformation" xlink:href="acon-20240630.xsd#SupplementalFinancialInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/Leases" xlink:href="acon-20240630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/IntangibleAssets" xlink:href="acon-20240630.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/ShortTermNotesAndConvertibleDebt" xlink:href="acon-20240630.xsd#ShortTermNotesAndConvertibleDebt" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/CommitmentsAndContingencies" xlink:href="acon-20240630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockholdersEquity" xlink:href="acon-20240630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/NetLossPerShareOfCommonStock" xlink:href="acon-20240630.xsd#NetLossPerShareOfCommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockBasedCompensation" xlink:href="acon-20240630.xsd#StockBasedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SubsequentEvents" xlink:href="acon-20240630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="acon-20240630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/CompanyAndBasisOfPresentationTables" xlink:href="acon-20240630.xsd#CompanyAndBasisOfPresentationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/FairValueMeasurementsTables" xlink:href="acon-20240630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SupplementalFinancialInformationTables" xlink:href="acon-20240630.xsd#SupplementalFinancialInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/IntangibleAssetsTables" xlink:href="acon-20240630.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/ShortTermNotesAndConvertibleDebtTables" xlink:href="acon-20240630.xsd#ShortTermNotesAndConvertibleDebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockholdersEquityTables" xlink:href="acon-20240630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/NetLossPerShareOfCommonStockTables" xlink:href="acon-20240630.xsd#NetLossPerShareOfCommonStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockBasedCompensationTables" xlink:href="acon-20240630.xsd#StockBasedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-BalanceSheetChangesFromSplit" xlink:href="acon-20240630.xsd#CompanyAndBasisOfPresentationDetails-BalanceSheetChangesFromSplit" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-RetroactiveBasisReverseStockSplits" xlink:href="acon-20240630.xsd#CompanyAndBasisOfPresentationDetails-RetroactiveBasisReverseStockSplits" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/CompanyAndBasisOfPresentationDetailsNarrative" xlink:href="acon-20240630.xsd#CompanyAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="acon-20240630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability" xlink:href="acon-20240630.xsd#FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/FairValueMeasurementsDetails-LiabilitiesMeasuresAtFairValue" xlink:href="acon-20240630.xsd#FairValueMeasurementsDetails-LiabilitiesMeasuresAtFairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/FairValueMeasurementsDetails-FairValueOfWarrants" xlink:href="acon-20240630.xsd#FairValueMeasurementsDetails-FairValueOfWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets" xlink:href="acon-20240630.xsd#SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SupplementalFinancialInformationDetails-AccountsPayable" xlink:href="acon-20240630.xsd#SupplementalFinancialInformationDetails-AccountsPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities" xlink:href="acon-20240630.xsd#SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/LeasesDetailsNarrative" xlink:href="acon-20240630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/IntangibleAssetsDetails-IntangibleAssets" xlink:href="acon-20240630.xsd#IntangibleAssetsDetails-IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/IntangibleAssetsDetails-FutureAmortization" xlink:href="acon-20240630.xsd#IntangibleAssetsDetails-FutureAmortization" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/IntangibleAssetsDetailsNarrative" xlink:href="acon-20240630.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetails-NotePayable" xlink:href="acon-20240630.xsd#ShortTermNotesAndConvertibleDebtDetails-NotePayable" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative" xlink:href="acon-20240630.xsd#ShortTermNotesAndConvertibleDebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="acon-20240630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockholdersEquityDetails-OutstandingWarrants" xlink:href="acon-20240630.xsd#StockholdersEquityDetails-OutstandingWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockholdersEquityDetailsNarrative" xlink:href="acon-20240630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-BasicAndDilutedNetLossPerShare" xlink:href="acon-20240630.xsd#NetLossPerShareOfCommonStockDetails-BasicAndDilutedNetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-DilutiveSecurities" xlink:href="acon-20240630.xsd#NetLossPerShareOfCommonStockDetails-DilutiveSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockBasedCompensationDetails-OptionActivity" xlink:href="acon-20240630.xsd#StockBasedCompensationDetails-OptionActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockBasedCompensationDetails-RsuActivity" xlink:href="acon-20240630.xsd#StockBasedCompensationDetails-RsuActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockBasedCompensationDetails-ShareBasedCompensation" xlink:href="acon-20240630.xsd#StockBasedCompensationDetails-ShareBasedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockBasedCompensationDetailsNarrative" xlink:href="acon-20240630.xsd#StockBasedCompensationDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="loc_us-gaapOtherNotesPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantLiabilityCurrent" xlink:label="loc_ACONWarrantLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_ACONWarrantLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_LiabilityToIssueEquity" xlink:label="loc_ACONLiabilityToIssueEquity" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_ACONLiabilityToIssueEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaapInterestExpenseOther" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpenseOther" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_LossOnExchangeOfDebt" xlink:label="loc_ACONLossOnExchangeOfDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_ACONLossOnExchangeOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000005 - Statement - Condensed Statements of Changes in Stockholders&apos; Equity (Deficit) (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_GainLossOnExchangeOfDebt" xlink:label="loc_ACONGainLossOnExchangeOfDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ACONGainLossOnExchangeOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_GainsLossesOnExtinguishmentOfDebts" xlink:label="loc_ACONGainsLossesOnExtinguishmentOfDebts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ACONGainsLossesOnExtinguishmentOfDebts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_NoncashInterestRelatedToBridgeFunding" xlink:label="loc_ACONNoncashInterestRelatedToBridgeFunding" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ACONNoncashInterestRelatedToBridgeFunding" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IncreaseDecreaseInNotePayableNetOfDiscount" xlink:label="loc_ACONIncreaseDecreaseInNotePayableNetOfDiscount" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ACONIncreaseDecreaseInNotePayableNetOfDiscount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_EquityLineOfCreditIssuanceCosts" xlink:label="loc_ACONEquityLineOfCreditIssuanceCosts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ACONEquityLineOfCreditIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_BridgeFundingIssuanceCosts" xlink:label="loc_ACONBridgeFundingIssuanceCosts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ACONBridgeFundingIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_ProceedsFromBridgeFunding" xlink:label="loc_ACONProceedsFromBridgeFunding" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ACONProceedsFromBridgeFunding" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfPreferredStockAndPreferenceStock" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/CompanyAndBasisOfPresentation" xlink:title="00000007 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/FairValueMeasurements" xlink:title="00000009 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/RecentAccountingPronouncements" xlink:title="00000010 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/Revenue" xlink:title="00000011 - Disclosure - REVENUE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/SupplementalFinancialInformation" xlink:title="00000012 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/Leases" xlink:title="00000013 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/IntangibleAssets" xlink:title="00000014 - Disclosure - INTANGIBLE ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/ShortTermNotesAndConvertibleDebt" xlink:title="00000015 - Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockholdersEquity" xlink:title="00000017 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/NetLossPerShareOfCommonStock" xlink:title="00000018 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockBasedCompensation" xlink:title="00000019 - Disclosure - STOCK BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/SubsequentEvents" xlink:title="00000020 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/CompanyAndBasisOfPresentationTables" xlink:title="00000022 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/FairValueMeasurementsTables" xlink:title="00000023 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/SupplementalFinancialInformationTables" xlink:title="00000024 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/IntangibleAssetsTables" xlink:title="00000025 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/ShortTermNotesAndConvertibleDebtTables" xlink:title="00000026 - Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockholdersEquityTables" xlink:title="00000027 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/NetLossPerShareOfCommonStockTables" xlink:title="00000028 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockBasedCompensationTables" xlink:title="00000029 - Disclosure - STOCK BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-BalanceSheetChangesFromSplit" xlink:title="00000030 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details - Balance sheet changes from split)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-RetroactiveBasisReverseStockSplits" xlink:title="00000031 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details- Retroactive basis the reverse stock splits)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/CompanyAndBasisOfPresentationDetailsNarrative" xlink:title="00000032 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000033 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability" xlink:title="00000034 - Disclosure - FAIR VALUE MEASUREMENTS (Details- Recurring basis to determine the fair value of the liability)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/FairValueMeasurementsDetails-LiabilitiesMeasuresAtFairValue" xlink:title="00000035 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Liabilities measures at fair value)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/FairValueMeasurementsDetails-FairValueOfWarrants" xlink:title="00000036 - Disclosure - FAIR VALUE MEASUREMENTS (Details- Fair value of the warrants)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets" xlink:title="00000037 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Prepaids and other current assets)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/SupplementalFinancialInformationDetails-AccountsPayable" xlink:title="00000038 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accounts payable)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities" xlink:title="00000039 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accrued and other liabilities)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/LeasesDetailsNarrative" xlink:title="00000040 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/IntangibleAssetsDetails-IntangibleAssets" xlink:title="00000041 - Disclosure - INTANGIBLE ASSETS (Details - Intangible assets)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/IntangibleAssetsDetails-FutureAmortization" xlink:title="00000042 - Disclosure - INTANGIBLE ASSETS (Details - Future amortization)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000043 - Disclosure - INTANGIBLE ASSETS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetails-NotePayable" xlink:title="00000044 - Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT (Details - Note payable)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative" xlink:title="00000045 - Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000046 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockholdersEquityDetails-OutstandingWarrants" xlink:title="00000047 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details - Outstanding warrants)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000048 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-BasicAndDilutedNetLossPerShare" xlink:title="00000049 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Basic and diluted net loss per share)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-DilutiveSecurities" xlink:title="00000050 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Dilutive securities)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockBasedCompensationDetails-OptionActivity" xlink:title="00000051 - Disclosure - STOCK BASED COMPENSATION (Details - Option activity)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockBasedCompensationDetails-RsuActivity" xlink:title="00000052 - Disclosure - STOCK BASED COMPENSATION (Details - RSU activity)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockBasedCompensationDetails-ShareBasedCompensation" xlink:title="00000053 - Disclosure - STOCK BASED COMPENSATION (Details - Share based compensation)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockBasedCompensationDetailsNarrative" xlink:title="00000054 - Disclosure - STOCK BASED COMPENSATION (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>acon-20240630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aclarion.com/role/Cover" xlink:href="acon-20240630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/BalanceSheets" xlink:href="acon-20240630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/BalanceSheetsParenthetical" xlink:href="acon-20240630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StatementsOfOperations" xlink:href="acon-20240630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:href="acon-20240630.xsd#StatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StatementsOfCashFlows" xlink:href="acon-20240630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/CompanyAndBasisOfPresentation" xlink:href="acon-20240630.xsd#CompanyAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="acon-20240630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/FairValueMeasurements" xlink:href="acon-20240630.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/RecentAccountingPronouncements" xlink:href="acon-20240630.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/Revenue" xlink:href="acon-20240630.xsd#Revenue" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SupplementalFinancialInformation" xlink:href="acon-20240630.xsd#SupplementalFinancialInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/Leases" xlink:href="acon-20240630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/IntangibleAssets" xlink:href="acon-20240630.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/ShortTermNotesAndConvertibleDebt" xlink:href="acon-20240630.xsd#ShortTermNotesAndConvertibleDebt" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/CommitmentsAndContingencies" xlink:href="acon-20240630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockholdersEquity" xlink:href="acon-20240630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/NetLossPerShareOfCommonStock" xlink:href="acon-20240630.xsd#NetLossPerShareOfCommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockBasedCompensation" xlink:href="acon-20240630.xsd#StockBasedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SubsequentEvents" xlink:href="acon-20240630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="acon-20240630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/CompanyAndBasisOfPresentationTables" xlink:href="acon-20240630.xsd#CompanyAndBasisOfPresentationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/FairValueMeasurementsTables" xlink:href="acon-20240630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SupplementalFinancialInformationTables" xlink:href="acon-20240630.xsd#SupplementalFinancialInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/IntangibleAssetsTables" xlink:href="acon-20240630.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/ShortTermNotesAndConvertibleDebtTables" xlink:href="acon-20240630.xsd#ShortTermNotesAndConvertibleDebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockholdersEquityTables" xlink:href="acon-20240630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/NetLossPerShareOfCommonStockTables" xlink:href="acon-20240630.xsd#NetLossPerShareOfCommonStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockBasedCompensationTables" xlink:href="acon-20240630.xsd#StockBasedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-BalanceSheetChangesFromSplit" xlink:href="acon-20240630.xsd#CompanyAndBasisOfPresentationDetails-BalanceSheetChangesFromSplit" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-RetroactiveBasisReverseStockSplits" xlink:href="acon-20240630.xsd#CompanyAndBasisOfPresentationDetails-RetroactiveBasisReverseStockSplits" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/CompanyAndBasisOfPresentationDetailsNarrative" xlink:href="acon-20240630.xsd#CompanyAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="acon-20240630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability" xlink:href="acon-20240630.xsd#FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/FairValueMeasurementsDetails-LiabilitiesMeasuresAtFairValue" xlink:href="acon-20240630.xsd#FairValueMeasurementsDetails-LiabilitiesMeasuresAtFairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/FairValueMeasurementsDetails-FairValueOfWarrants" xlink:href="acon-20240630.xsd#FairValueMeasurementsDetails-FairValueOfWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets" xlink:href="acon-20240630.xsd#SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SupplementalFinancialInformationDetails-AccountsPayable" xlink:href="acon-20240630.xsd#SupplementalFinancialInformationDetails-AccountsPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities" xlink:href="acon-20240630.xsd#SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/LeasesDetailsNarrative" xlink:href="acon-20240630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/IntangibleAssetsDetails-IntangibleAssets" xlink:href="acon-20240630.xsd#IntangibleAssetsDetails-IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/IntangibleAssetsDetails-FutureAmortization" xlink:href="acon-20240630.xsd#IntangibleAssetsDetails-FutureAmortization" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/IntangibleAssetsDetailsNarrative" xlink:href="acon-20240630.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetails-NotePayable" xlink:href="acon-20240630.xsd#ShortTermNotesAndConvertibleDebtDetails-NotePayable" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative" xlink:href="acon-20240630.xsd#ShortTermNotesAndConvertibleDebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="acon-20240630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockholdersEquityDetails-OutstandingWarrants" xlink:href="acon-20240630.xsd#StockholdersEquityDetails-OutstandingWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockholdersEquityDetailsNarrative" xlink:href="acon-20240630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-BasicAndDilutedNetLossPerShare" xlink:href="acon-20240630.xsd#NetLossPerShareOfCommonStockDetails-BasicAndDilutedNetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-DilutiveSecurities" xlink:href="acon-20240630.xsd#NetLossPerShareOfCommonStockDetails-DilutiveSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockBasedCompensationDetails-OptionActivity" xlink:href="acon-20240630.xsd#StockBasedCompensationDetails-OptionActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockBasedCompensationDetails-RsuActivity" xlink:href="acon-20240630.xsd#StockBasedCompensationDetails-RsuActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockBasedCompensationDetails-ShareBasedCompensation" xlink:href="acon-20240630.xsd#StockBasedCompensationDetails-ShareBasedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockBasedCompensationDetailsNarrative" xlink:href="acon-20240630.xsd#StockBasedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000005 - Statement - Condensed Statements of Changes in Stockholders&apos; Equity (Deficit) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PreferredStockSeriesAMember" xlink:label="loc_ACONPreferredStockSeriesAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ACONPreferredStockSeriesAMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PreferredStockSeriesA1A2A3A4Member" xlink:label="loc_ACONPreferredStockSeriesA1A2A3A4Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ACONPreferredStockSeriesA1A2A3A4Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PreferredStockSeriesBB1Member" xlink:label="loc_ACONPreferredStockSeriesBB1Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ACONPreferredStockSeriesBB1Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PreferredStockSeriesB2B3Member" xlink:label="loc_ACONPreferredStockSeriesB2B3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ACONPreferredStockSeriesB2B3Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_720" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_720" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_720" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_720" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_720" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommonSharesEquityLineOfCredit" xlink:label="loc_ACONIssuanceOfCommonSharesEquityLineOfCredit_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONIssuanceOfCommonSharesEquityLineOfCredit_720" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommonSharesEquityLineOfCreditShares" xlink:label="loc_ACONIssuanceOfCommonSharesEquityLineOfCreditShares_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONIssuanceOfCommonSharesEquityLineOfCreditShares_720" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommitmentSharesNoteFinancing" xlink:label="loc_ACONIssuanceOfCommitmentSharesNoteFinancing_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONIssuanceOfCommitmentSharesNoteFinancing_720" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommitmentSharesNoteFinancingShares" xlink:label="loc_ACONIssuanceOfCommitmentSharesNoteFinancingShares_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONIssuanceOfCommitmentSharesNoteFinancingShares_720" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_CashlessExerciseOfPrefundedWarrant" xlink:label="loc_ACONCashlessExerciseOfPrefundedWarrant_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONCashlessExerciseOfPrefundedWarrant_720" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_CashlessExerciseOfPrefundedWarrantsShares" xlink:label="loc_ACONCashlessExerciseOfPrefundedWarrantsShares_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONCashlessExerciseOfPrefundedWarrantsShares_720" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts" xlink:label="loc_ACONIssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONIssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts_720" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares" xlink:label="loc_ACONIssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONIssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares_720" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PublicOfferingAndLineOfCreditIssuanceCosts" xlink:label="loc_ACONPublicOfferingAndLineOfCreditIssuanceCosts_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONPublicOfferingAndLineOfCreditIssuanceCosts_720" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommonSharesDebtForEquityExchange" xlink:label="loc_ACONIssuanceOfCommonSharesDebtForEquityExchange_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONIssuanceOfCommonSharesDebtForEquityExchange_720" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommonSharesDebtForEquityExchangeShares" xlink:label="loc_ACONIssuanceOfCommonSharesDebtForEquityExchangeShares_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONIssuanceOfCommonSharesDebtForEquityExchangeShares_720" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_RoundUpConversionRelatedToReverseStockSplit" xlink:label="loc_ACONRoundUpConversionRelatedToReverseStockSplit_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONRoundUpConversionRelatedToReverseStockSplit_720" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_RoundUpConventionRelatedToReverseStockSplitShares" xlink:label="loc_ACONRoundUpConventionRelatedToReverseStockSplitShares_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONRoundUpConventionRelatedToReverseStockSplitShares_720" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_ProceedsFromSaleOfSeriesPreferredStock" xlink:label="loc_ACONProceedsFromSaleOfSeriesPreferredStock_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONProceedsFromSaleOfSeriesPreferredStock_720" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PreferredStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_ACONPreferredStockIssuedDuringPeriodSharesNewIssues_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONPreferredStockIssuedDuringPeriodSharesNewIssues_720" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_RedemptionOfSeriesPreferredStock" xlink:label="loc_ACONRedemptionOfSeriesPreferredStock_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONRedemptionOfSeriesPreferredStock_720" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_RedemptionOfSeriesPreferredStockShares" xlink:label="loc_ACONRedemptionOfSeriesPreferredStockShares_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONRedemptionOfSeriesPreferredStockShares_720" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_CommitmentSharesNoteFinancing" xlink:label="loc_ACONCommitmentSharesNoteFinancing_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONCommitmentSharesNoteFinancing_720" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_CommitmentSharesNoteFinancingShares" xlink:label="loc_ACONCommitmentSharesNoteFinancingShares_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONCommitmentSharesNoteFinancingShares_720" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfWarrantsNoteFinancing" xlink:label="loc_ACONIssuanceOfWarrantsNoteFinancing_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONIssuanceOfWarrantsNoteFinancing_720" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_720" xlink:type="arc" order="26" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/CompanyAndBasisOfPresentation" xlink:title="00000007 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/FairValueMeasurements" xlink:title="00000009 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/RecentAccountingPronouncements" xlink:title="00000010 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/Revenue" xlink:title="00000011 - Disclosure - REVENUE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/SupplementalFinancialInformation" xlink:title="00000012 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/Leases" xlink:title="00000013 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/IntangibleAssets" xlink:title="00000014 - Disclosure - INTANGIBLE ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/ShortTermNotesAndConvertibleDebt" xlink:title="00000015 - Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockholdersEquity" xlink:title="00000017 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/NetLossPerShareOfCommonStock" xlink:title="00000018 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockBasedCompensation" xlink:title="00000019 - Disclosure - STOCK BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/SubsequentEvents" xlink:title="00000020 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/CompanyAndBasisOfPresentationTables" xlink:title="00000022 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/FairValueMeasurementsTables" xlink:title="00000023 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/SupplementalFinancialInformationTables" xlink:title="00000024 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/IntangibleAssetsTables" xlink:title="00000025 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/ShortTermNotesAndConvertibleDebtTables" xlink:title="00000026 - Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockholdersEquityTables" xlink:title="00000027 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/NetLossPerShareOfCommonStockTables" xlink:title="00000028 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockBasedCompensationTables" xlink:title="00000029 - Disclosure - STOCK BASED COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-BalanceSheetChangesFromSplit" xlink:title="00000030 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details - Balance sheet changes from split)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapTransactionTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_Pre2024SplitMember" xlink:label="loc_ACONPre2024SplitMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_ACONPre2024SplitMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_Post2024SplitMember" xlink:label="loc_ACONPost2024SplitMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_ACONPost2024SplitMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapCommonStockValue_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-RetroactiveBasisReverseStockSplits" xlink:title="00000031 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details- Retroactive basis the reverse stock splits)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PreSplitMember" xlink:label="loc_ACONPreSplitMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_ACONPreSplitMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PostSplitMember" xlink:label="loc_ACONPostSplitMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_ACONPostSplitMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/CompanyAndBasisOfPresentationDetailsNarrative" xlink:title="00000032 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapTransactionTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_StockSplit2024Member" xlink:label="loc_ACONStockSplit2024Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_ACONStockSplit2024Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000033 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTransactionTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_CompletionOfPublicOfferingMember" xlink:label="loc_ACONCompletionOfPublicOfferingMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_ACONCompletionOfPublicOfferingMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_CompletionOfIssuanceOfSharesMember" xlink:label="loc_ACONCompletionOfIssuanceOfSharesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_ACONCompletionOfIssuanceOfSharesMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCashUninsuredAmount_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapRestrictedCash_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_50" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability" xlink:title="00000034 - Disclosure - FAIR VALUE MEASUREMENTS (Details- Recurring basis to determine the fair value of the liability)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantLiabilityMember" xlink:label="loc_ACONWarrantLiabilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_ACONWarrantLiabilityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_DerivativeLiabilityMember" xlink:label="loc_ACONDerivativeLiabilityMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_ACONDerivativeLiabilityMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapFairValueNetAssetLiability_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/FairValueMeasurementsDetails-LiabilitiesMeasuresAtFairValue" xlink:title="00000035 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Liabilities measures at fair value)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantLiabilityMember" xlink:label="loc_ACONWarrantLiabilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_ACONWarrantLiabilityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_DerivativeLiabilityMember" xlink:label="loc_ACONDerivativeLiabilityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_ACONDerivativeLiabilityMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueHedgeLiabilitiesAtFairValue" xlink:label="loc_us-gaapFairValueHedgeLiabilitiesAtFairValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapFairValueHedgeLiabilitiesAtFairValue_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_ExchangeAndPayoffOfNotesPayable" xlink:label="loc_ACONExchangeAndPayoffOfNotesPayable_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_ACONExchangeAndPayoffOfNotesPayable_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaapFairValueOptionChangesInFairValueGainLoss1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapFairValueOptionChangesInFairValueGainLoss1_100" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/FairValueMeasurementsDetails-FairValueOfWarrants" xlink:title="00000036 - Disclosure - FAIR VALUE MEASUREMENTS (Details- Fair value of the warrants)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantLiabilityMember" xlink:label="loc_ACONWarrantLiabilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_ACONWarrantLiabilityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapSharePrice_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_FloorFinancingPrice" xlink:label="loc_ACONFloorFinancingPrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_ACONFloorFinancingPrice_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets" xlink:title="00000037 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Prepaids and other current assets)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_ShortTermDepositsMember" xlink:label="loc_ACONShortTermDepositsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONShortTermDepositsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_DeferredOfferingCostsMember" xlink:label="loc_ACONDeferredOfferingCostsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONDeferredOfferingCostsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PrepaidInsuranceDAndOMember" xlink:label="loc_ACONPrepaidInsuranceDAndOMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONPrepaidInsuranceDAndOMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PrepaidInsuranceMember" xlink:label="loc_ACONPrepaidInsuranceMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONPrepaidInsuranceMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PrepaidClinicalCostsMember" xlink:label="loc_ACONPrepaidClinicalCostsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONPrepaidClinicalCostsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PrepaidExchangeFeesMember" xlink:label="loc_ACONPrepaidExchangeFeesMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONPrepaidExchangeFeesMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PrepaidOtherMember" xlink:label="loc_ACONPrepaidOtherMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONPrepaidOtherMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_OtherReceivablesMember" xlink:label="loc_ACONOtherReceivablesMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONOtherReceivablesMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_190" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/SupplementalFinancialInformationDetails-AccountsPayable" xlink:title="00000038 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accounts payable)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableMember" xlink:label="loc_us-gaapAccountsPayableMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_us-gaapAccountsPayableMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_CreditCardsPayableMember" xlink:label="loc_ACONCreditCardsPayableMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONCreditCardsPayableMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities" xlink:title="00000039 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accrued and other liabilities)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_AccruedPayrollMember" xlink:label="loc_ACONAccruedPayrollMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONAccruedPayrollMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_AccruedBonusMember" xlink:label="loc_ACONAccruedBonusMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONAccruedBonusMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_DAndOFinancingMember" xlink:label="loc_ACONDAndOFinancingMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONDAndOFinancingMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_AccruedAuditAndLegalExpensesMember" xlink:label="loc_ACONAccruedAuditAndLegalExpensesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONAccruedAuditAndLegalExpensesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_AccruedInterestMember" xlink:label="loc_ACONAccruedInterestMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONAccruedInterestMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_AccruedBoardCompensationMember" xlink:label="loc_ACONAccruedBoardCompensationMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONAccruedBoardCompensationMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_OtherAccruedLiabilitiesMember" xlink:label="loc_ACONOtherAccruedLiabilitiesMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONOtherAccruedLiabilitiesMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities_170" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/LeasesDetailsNarrative" xlink:title="00000040 - Disclosure - LEASES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/IntangibleAssetsDetails-IntangibleAssets" xlink:title="00000041 - Disclosure - INTANGIBLE ASSETS (Details - Intangible assets)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PatentsAndLicensesMember" xlink:label="loc_ACONPatentsAndLicensesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_ACONPatentsAndLicensesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember" xlink:label="loc_us-gaapOtherIntangibleAssetsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapOtherIntangibleAssetsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/IntangibleAssetsDetails-FutureAmortization" xlink:title="00000042 - Disclosure - INTANGIBLE ASSETS (Details - Future amortization)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000043 - Disclosure - INTANGIBLE ASSETS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetails-NotePayable" xlink:title="00000044 - Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT (Details - Note payable)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative" xlink:title="00000045 - Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_SeniorNotesPayableMember" xlink:label="loc_ACONSeniorNotesPayableMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ACONSeniorNotesPayableMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_SeriesBNotesPayableMember" xlink:label="loc_ACONSeriesBNotesPayableMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ACONSeriesBNotesPayableMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_SeriesCNotesPayableMember" xlink:label="loc_ACONSeriesCNotesPayableMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ACONSeriesCNotesPayableMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_ExchangeAgreementsMember" xlink:label="loc_ACONExchangeAgreementsMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ACONExchangeAgreementsMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_AccreditedInvestorsMember" xlink:label="loc_ACONAccreditedInvestorsMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_ACONAccreditedInvestorsMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_UnsecuredNonConvertibleNotesMember" xlink:label="loc_ACONUnsecuredNonConvertibleNotesMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_ACONUnsecuredNonConvertibleNotesMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSecuredNotesPayable" xlink:label="loc_us-gaapProceedsFromSecuredNotesPayable_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromSecuredNotesPayable_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_DebtOriginalIssueDiscountPercenrtage" xlink:label="loc_ACONDebtOriginalIssueDiscountPercenrtage_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ACONDebtOriginalIssueDiscountPercenrtage_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebt" xlink:label="loc_us-gaapUnsecuredDebt_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapUnsecuredDebt_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfUnsecuredDebt_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfUnsecuredDebt_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaapPaymentsForLegalSettlements_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapPaymentsForLegalSettlements_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts_170" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_170" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaapDeferredCostsCurrent_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDeferredCostsCurrent_170" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_170" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1_170" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_RemainingOutstandingBalanceOfPrincipalAndInterest" xlink:label="loc_ACONRemainingOutstandingBalanceOfPrincipalAndInterest_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ACONRemainingOutstandingBalanceOfPrincipalAndInterest_170" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_LossOnExchangeOfDebt" xlink:label="loc_ACONLossOnExchangeOfDebt_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ACONLossOnExchangeOfDebt_170" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PrincipalAndAccruedInterestPaid" xlink:label="loc_ACONPrincipalAndAccruedInterestPaid_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ACONPrincipalAndAccruedInterestPaid_170" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapNotesPayable_170" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_170" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000046 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_RegentsOfTheUniversityOfCaliforniaMember" xlink:label="loc_ACONRegentsOfTheUniversityOfCaliforniaMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_ACONRegentsOfTheUniversityOfCaliforniaMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_MinimumAnnualRoyaltyPayment" xlink:label="loc_ACONMinimumAnnualRoyaltyPayment_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ACONMinimumAnnualRoyaltyPayment_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRoyaltyExpense_60" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockholdersEquityDetails-OutstandingWarrants" xlink:title="00000047 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details - Outstanding warrants)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePriceMember" xlink:label="loc_ACONWarrantStrikePriceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePriceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice1Member" xlink:label="loc_ACONWarrantStrikePrice1Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePrice1Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice2Member" xlink:label="loc_ACONWarrantStrikePrice2Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePrice2Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice3Member" xlink:label="loc_ACONWarrantStrikePrice3Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePrice3Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice4Member" xlink:label="loc_ACONWarrantStrikePrice4Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePrice4Member_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice5Member" xlink:label="loc_ACONWarrantStrikePrice5Member_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePrice5Member_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice6Member" xlink:label="loc_ACONWarrantStrikePrice6Member_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePrice6Member_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_StockIssueDate" xlink:label="loc_ACONStockIssueDate_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ACONStockIssueDate_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_150" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000048 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_ExecutiveChairmanMember" xlink:label="loc_ACONExecutiveChairmanMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ACONExecutiveChairmanMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTransactionTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WhiteLionEquityLineAgreementMember" xlink:label="loc_ACONWhiteLionEquityLineAgreementMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_ACONWhiteLionEquityLineAgreementMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PurchasePrice" xlink:label="loc_ACONPurchasePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_ACONPurchasePrice_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaapPaymentsForRepurchaseOfWarrants_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfWarrants_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_110" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-BasicAndDilutedNetLossPerShare" xlink:title="00000049 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Basic and diluted net loss per share)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-DilutiveSecurities" xlink:title="00000050 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Dilutive securities)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantsMember" xlink:label="loc_ACONWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ACONWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_RestrictedStockUnitsMember" xlink:label="loc_ACONRestrictedStockUnitsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ACONRestrictedStockUnitsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_StockOptionsMember" xlink:label="loc_ACONStockOptionsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ACONStockOptionsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockBasedCompensationDetails-OptionActivity" xlink:title="00000051 - Disclosure - STOCK BASED COMPENSATION (Details - Option activity)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockBasedCompensationDetails-RsuActivity" xlink:title="00000052 - Disclosure - STOCK BASED COMPENSATION (Details - RSU activity)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockBasedCompensationDetails-ShareBasedCompensation" xlink:title="00000053 - Disclosure - STOCK BASED COMPENSATION (Details - Share based compensation)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaapSellingAndMarketingExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingAndMarketingExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation_170" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockBasedCompensationDetailsNarrative" xlink:title="00000054 - Disclosure - STOCK BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_AclarionEquityIncentivePlan2022Member" xlink:label="loc_ACONAclarionEquityIncentivePlan2022Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ACONAclarionEquityIncentivePlan2022Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapOptionMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_NonVestedStockOptionsMember" xlink:label="loc_ACONNonVestedStockOptionsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONNonVestedStockOptionsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_90" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePriceMember" xlink:label="loc_ACONWarrantStrikePriceMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePriceMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice1Member" xlink:label="loc_ACONWarrantStrikePrice1Member" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePrice1Member" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice2Member" xlink:label="loc_ACONWarrantStrikePrice2Member" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePrice2Member" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice3Member" xlink:label="loc_ACONWarrantStrikePrice3Member" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePrice3Member" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice4Member" xlink:label="loc_ACONWarrantStrikePrice4Member" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePrice4Member" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice5Member" xlink:label="loc_ACONWarrantStrikePrice5Member" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePrice5Member" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice6Member" xlink:label="loc_ACONWarrantStrikePrice6Member" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePrice6Member" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_NonVestedStockOptionsMember" xlink:label="loc_ACONNonVestedStockOptionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONNonVestedStockOptionsMember" xlink:type="arc" order="70" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>acon-20240630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PreferredStockSeriesAMember" xlink:label="ACON_PreferredStockSeriesAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_PreferredStockSeriesAMember" xlink:to="ACON_PreferredStockSeriesAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_PreferredStockSeriesAMember_lbl" xml:lang="en-US">Preferred Stock Series A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PreferredStockSeriesA1A2A3A4Member" xlink:label="ACON_PreferredStockSeriesA1A2A3A4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_PreferredStockSeriesA1A2A3A4Member" xlink:to="ACON_PreferredStockSeriesA1A2A3A4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_PreferredStockSeriesA1A2A3A4Member_lbl" xml:lang="en-US">Preferred Stock Series A 1 A 2 A 3 A 4 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PreferredStockSeriesBB1Member" xlink:label="ACON_PreferredStockSeriesBB1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_PreferredStockSeriesBB1Member" xlink:to="ACON_PreferredStockSeriesBB1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_PreferredStockSeriesBB1Member_lbl" xml:lang="en-US">Preferred Stock Series B B 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PreferredStockSeriesB2B3Member" xlink:label="ACON_PreferredStockSeriesB2B3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_PreferredStockSeriesB2B3Member" xlink:to="ACON_PreferredStockSeriesB2B3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_PreferredStockSeriesB2B3Member_lbl" xml:lang="en-US">Preferred Stock Series B 2 B 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransactionTypeAxis_lbl" xml:lang="en-US">Transaction Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_StockSplit2024Member" xlink:label="ACON_StockSplit2024Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_StockSplit2024Member" xlink:to="ACON_StockSplit2024Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_StockSplit2024Member_lbl" xml:lang="en-US">Stock Split 2024 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_Pre2024SplitMember" xlink:label="ACON_Pre2024SplitMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_Pre2024SplitMember" xlink:to="ACON_Pre2024SplitMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_Pre2024SplitMember_lbl" xml:lang="en-US">Pre 2024 Split [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_Post2024SplitMember" xlink:label="ACON_Post2024SplitMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_Post2024SplitMember" xlink:to="ACON_Post2024SplitMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_Post2024SplitMember_lbl" xml:lang="en-US">Post 2024 Split [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PreSplitMember" xlink:label="ACON_PreSplitMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_PreSplitMember" xlink:to="ACON_PreSplitMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_PreSplitMember_lbl" xml:lang="en-US">Pre Split [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PostSplitMember" xlink:label="ACON_PostSplitMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_PostSplitMember" xlink:to="ACON_PostSplitMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_PostSplitMember_lbl" xml:lang="en-US">Post Split [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_CompletionOfPublicOfferingMember" xlink:label="ACON_CompletionOfPublicOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_CompletionOfPublicOfferingMember" xlink:to="ACON_CompletionOfPublicOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_CompletionOfPublicOfferingMember_lbl" xml:lang="en-US">Completion Of Public Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_CompletionOfIssuanceOfSharesMember" xlink:label="ACON_CompletionOfIssuanceOfSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_CompletionOfIssuanceOfSharesMember" xlink:to="ACON_CompletionOfIssuanceOfSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_CompletionOfIssuanceOfSharesMember_lbl" xml:lang="en-US">Completion Of Issuance Of Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US">Liability Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantLiabilityMember" xlink:label="ACON_WarrantLiabilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_WarrantLiabilityMember" xlink:to="ACON_WarrantLiabilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_WarrantLiabilityMember_lbl" xml:lang="en-US">Warrant Liability [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_DerivativeLiabilityMember" xlink:label="ACON_DerivativeLiabilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_DerivativeLiabilityMember" xlink:to="ACON_DerivativeLiabilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_DerivativeLiabilityMember_lbl" xml:lang="en-US">Derivative Liability [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_ShortTermDepositsMember" xlink:label="ACON_ShortTermDepositsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_ShortTermDepositsMember" xlink:to="ACON_ShortTermDepositsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_ShortTermDepositsMember_lbl" xml:lang="en-US">Short Term Deposits [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_DeferredOfferingCostsMember" xlink:label="ACON_DeferredOfferingCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_DeferredOfferingCostsMember" xlink:to="ACON_DeferredOfferingCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_DeferredOfferingCostsMember_lbl" xml:lang="en-US">Deferred Offering Costs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PrepaidInsuranceDAndOMember" xlink:label="ACON_PrepaidInsuranceDAndOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_PrepaidInsuranceDAndOMember" xlink:to="ACON_PrepaidInsuranceDAndOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_PrepaidInsuranceDAndOMember_lbl" xml:lang="en-US">Prepaid Insurance D&amp;O [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PrepaidInsuranceMember" xlink:label="ACON_PrepaidInsuranceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_PrepaidInsuranceMember" xlink:to="ACON_PrepaidInsuranceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_PrepaidInsuranceMember_lbl" xml:lang="en-US">Prepaid Insurance, Other [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PrepaidClinicalCostsMember" xlink:label="ACON_PrepaidClinicalCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_PrepaidClinicalCostsMember" xlink:to="ACON_PrepaidClinicalCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_PrepaidClinicalCostsMember_lbl" xml:lang="en-US">Prepaid Clinical Costs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PrepaidExchangeFeesMember" xlink:label="ACON_PrepaidExchangeFeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_PrepaidExchangeFeesMember" xlink:to="ACON_PrepaidExchangeFeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_PrepaidExchangeFeesMember_lbl" xml:lang="en-US">Prepaid Exchange Fees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PrepaidOtherMember" xlink:label="ACON_PrepaidOtherMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_PrepaidOtherMember" xlink:to="ACON_PrepaidOtherMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_PrepaidOtherMember_lbl" xml:lang="en-US">Prepaid Other [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_OtherReceivablesMember" xlink:label="ACON_OtherReceivablesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_OtherReceivablesMember" xlink:to="ACON_OtherReceivablesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_OtherReceivablesMember_lbl" xml:lang="en-US">Other Receivables [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableMember_lbl" xml:lang="en-US">Accounts Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_CreditCardsPayableMember" xlink:label="ACON_CreditCardsPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_CreditCardsPayableMember" xlink:to="ACON_CreditCardsPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_CreditCardsPayableMember_lbl" xml:lang="en-US">Credit Cards Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_AccruedPayrollMember" xlink:label="ACON_AccruedPayrollMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_AccruedPayrollMember" xlink:to="ACON_AccruedPayrollMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_AccruedPayrollMember_lbl" xml:lang="en-US">Accrued Payroll [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_AccruedBonusMember" xlink:label="ACON_AccruedBonusMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_AccruedBonusMember" xlink:to="ACON_AccruedBonusMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_AccruedBonusMember_lbl" xml:lang="en-US">Accrued Bonus [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_DAndOFinancingMember" xlink:label="ACON_DAndOFinancingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_DAndOFinancingMember" xlink:to="ACON_DAndOFinancingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_DAndOFinancingMember_lbl" xml:lang="en-US">D&amp;O Financing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_AccruedAuditAndLegalExpensesMember" xlink:label="ACON_AccruedAuditAndLegalExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_AccruedAuditAndLegalExpensesMember" xlink:to="ACON_AccruedAuditAndLegalExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_AccruedAuditAndLegalExpensesMember_lbl" xml:lang="en-US">Accrued Audit And Legal Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_AccruedInterestMember" xlink:label="ACON_AccruedInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_AccruedInterestMember" xlink:to="ACON_AccruedInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_AccruedInterestMember_lbl" xml:lang="en-US">Accrued Interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_AccruedBoardCompensationMember" xlink:label="ACON_AccruedBoardCompensationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_AccruedBoardCompensationMember" xlink:to="ACON_AccruedBoardCompensationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_AccruedBoardCompensationMember_lbl" xml:lang="en-US">Accrued Board Compensation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_OtherAccruedLiabilitiesMember" xlink:label="ACON_OtherAccruedLiabilitiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_OtherAccruedLiabilitiesMember" xlink:to="ACON_OtherAccruedLiabilitiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_OtherAccruedLiabilitiesMember_lbl" xml:lang="en-US">Other Accrued Liabilities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PatentsAndLicensesMember" xlink:label="ACON_PatentsAndLicensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_PatentsAndLicensesMember" xlink:to="ACON_PatentsAndLicensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_PatentsAndLicensesMember_lbl" xml:lang="en-US">Patents And Licenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember" xlink:label="us-gaap_OtherIntangibleAssetsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsMember" xlink:to="us-gaap_OtherIntangibleAssetsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIntangibleAssetsMember_lbl" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_SeniorNotesPayableMember" xlink:label="ACON_SeniorNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_SeniorNotesPayableMember" xlink:to="ACON_SeniorNotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_SeniorNotesPayableMember_lbl" xml:lang="en-US">Senior Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_SeriesBNotesPayableMember" xlink:label="ACON_SeriesBNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_SeriesBNotesPayableMember" xlink:to="ACON_SeriesBNotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_SeriesBNotesPayableMember_lbl" xml:lang="en-US">Series B Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_SeriesCNotesPayableMember" xlink:label="ACON_SeriesCNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_SeriesCNotesPayableMember" xlink:to="ACON_SeriesCNotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_SeriesCNotesPayableMember_lbl" xml:lang="en-US">Series C Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_ExchangeAgreementsMember" xlink:label="ACON_ExchangeAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_ExchangeAgreementsMember" xlink:to="ACON_ExchangeAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_ExchangeAgreementsMember_lbl" xml:lang="en-US">Exchange Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_AccreditedInvestorsMember" xlink:label="ACON_AccreditedInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_AccreditedInvestorsMember" xlink:to="ACON_AccreditedInvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_AccreditedInvestorsMember_lbl" xml:lang="en-US">Accredited Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_UnsecuredNonConvertibleNotesMember" xlink:label="ACON_UnsecuredNonConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_UnsecuredNonConvertibleNotesMember" xlink:to="ACON_UnsecuredNonConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_UnsecuredNonConvertibleNotesMember_lbl" xml:lang="en-US">Unsecured Non Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_RegentsOfTheUniversityOfCaliforniaMember" xlink:label="ACON_RegentsOfTheUniversityOfCaliforniaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_RegentsOfTheUniversityOfCaliforniaMember" xlink:to="ACON_RegentsOfTheUniversityOfCaliforniaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_RegentsOfTheUniversityOfCaliforniaMember_lbl" xml:lang="en-US">Regents Of The University Of California [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_ExecutiveChairmanMember" xlink:label="ACON_ExecutiveChairmanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_ExecutiveChairmanMember" xlink:to="ACON_ExecutiveChairmanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_ExecutiveChairmanMember_lbl" xml:lang="en-US">Executive Chairman [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WhiteLionEquityLineAgreementMember" xlink:label="ACON_WhiteLionEquityLineAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_WhiteLionEquityLineAgreementMember" xlink:to="ACON_WhiteLionEquityLineAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_WhiteLionEquityLineAgreementMember_lbl" xml:lang="en-US">White Lion Equity Line Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePriceMember" xlink:label="ACON_WarrantStrikePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_WarrantStrikePriceMember" xlink:to="ACON_WarrantStrikePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_WarrantStrikePriceMember_lbl" xml:lang="en-US">Strike Price 69.60 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice1Member" xlink:label="ACON_WarrantStrikePrice1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_WarrantStrikePrice1Member" xlink:to="ACON_WarrantStrikePrice1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_WarrantStrikePrice1Member_lbl" xml:lang="en-US">Strike Price 87.04 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice2Member" xlink:label="ACON_WarrantStrikePrice2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_WarrantStrikePrice2Member" xlink:to="ACON_WarrantStrikePrice2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ACON_WarrantStrikePrice2Member_lbl" xml:lang="en-US">Strike Price 69.60 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice3Member" xlink:label="ACON_WarrantStrikePrice3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_WarrantStrikePrice3Member" xlink:to="ACON_WarrantStrikePrice3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_WarrantStrikePrice3Member_lbl" xml:lang="en-US">Strike Price 0.29 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice4Member" xlink:label="ACON_WarrantStrikePrice4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_WarrantStrikePrice4Member" xlink:to="ACON_WarrantStrikePrice4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_WarrantStrikePrice4Member_lbl" xml:lang="en-US">Strike Price 0.29 (1) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice5Member" xlink:label="ACON_WarrantStrikePrice5Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_WarrantStrikePrice5Member" xlink:to="ACON_WarrantStrikePrice5Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_WarrantStrikePrice5Member_lbl" xml:lang="en-US">Strike Price 0.00001 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice6Member" xlink:label="ACON_WarrantStrikePrice6Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_WarrantStrikePrice6Member" xlink:to="ACON_WarrantStrikePrice6Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_WarrantStrikePrice6Member_lbl" xml:lang="en-US">Strike Price 0.58 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantsMember" xlink:label="ACON_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_WarrantsMember" xlink:to="ACON_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_RestrictedStockUnitsMember" xlink:label="ACON_RestrictedStockUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_RestrictedStockUnitsMember" xlink:to="ACON_RestrictedStockUnitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_RestrictedStockUnitsMember_lbl" xml:lang="en-US">Restricted Stock Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_StockOptionsMember" xlink:label="ACON_StockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_StockOptionsMember" xlink:to="ACON_StockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_StockOptionsMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_AclarionEquityIncentivePlan2022Member" xlink:label="ACON_AclarionEquityIncentivePlan2022Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_AclarionEquityIncentivePlan2022Member" xlink:to="ACON_AclarionEquityIncentivePlan2022Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_AclarionEquityIncentivePlan2022Member_lbl" xml:lang="en-US">Aclarion Equity Incentive Plan 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionMember" xlink:label="us-gaap_OptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionMember_lbl" xml:lang="en-US">Options Held [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_NonVestedStockOptionsMember" xlink:label="ACON_NonVestedStockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_NonVestedStockOptionsMember" xlink:to="ACON_NonVestedStockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_NonVestedStockOptionsMember_lbl" xml:lang="en-US">Non Vested Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xml:lang="en-US">Selling and Marketing Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaids and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Non-current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Accrued and other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="us-gaap_OtherNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayableCurrent" xlink:to="us-gaap_OtherNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayableCurrent_lbl" xml:lang="en-US">Note payable, net of discount</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantLiabilityCurrent" xlink:label="ACON_WarrantLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_WarrantLiabilityCurrent" xlink:to="ACON_WarrantLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_WarrantLiabilityCurrent_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_LiabilityToIssueEquity" xlink:label="ACON_LiabilityToIssueEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_LiabilityToIssueEquity" xlink:to="ACON_LiabilityToIssueEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_LiabilityToIssueEquity_lbl" xml:lang="en-US">Liability to issue equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock - $0.00001 par value, 200,000,000 authorized and 8,210,671 and 825,459 shares issued and outstanding (see Note 11)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Sales and marketing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">(Loss) from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOther" xlink:label="us-gaap_InterestExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseOther_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_LossOnExchangeOfDebt" xlink:label="ACON_LossOnExchangeOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_LossOnExchangeOfDebt" xlink:to="ACON_LossOnExchangeOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ACON_LossOnExchangeOfDebt_lbl" xml:lang="en-US">Loss on exchange of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Changes in fair value of warrant and derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income (loss) before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax provision</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net income (loss) allocable to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net income (loss) per share allocable to common shareholders, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net income (loss) per share allocable to common shareholders, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares of common stock outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares of common stock outstanding, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of common shares related to restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of common shares related to restricted stock units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommonSharesEquityLineOfCredit" xlink:label="ACON_IssuanceOfCommonSharesEquityLineOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_IssuanceOfCommonSharesEquityLineOfCredit" xlink:to="ACON_IssuanceOfCommonSharesEquityLineOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_IssuanceOfCommonSharesEquityLineOfCredit_lbl" xml:lang="en-US">Issuance of common shares - equity line of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommonSharesEquityLineOfCreditShares" xlink:label="ACON_IssuanceOfCommonSharesEquityLineOfCreditShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_IssuanceOfCommonSharesEquityLineOfCreditShares" xlink:to="ACON_IssuanceOfCommonSharesEquityLineOfCreditShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_IssuanceOfCommonSharesEquityLineOfCreditShares_lbl" xml:lang="en-US">Issuance of common shares - equity line of credit, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommitmentSharesNoteFinancing" xlink:label="ACON_IssuanceOfCommitmentSharesNoteFinancing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_IssuanceOfCommitmentSharesNoteFinancing" xlink:to="ACON_IssuanceOfCommitmentSharesNoteFinancing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_IssuanceOfCommitmentSharesNoteFinancing_lbl" xml:lang="en-US">Issuance of commitment shares - note financing</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommitmentSharesNoteFinancingShares" xlink:label="ACON_IssuanceOfCommitmentSharesNoteFinancingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_IssuanceOfCommitmentSharesNoteFinancingShares" xlink:to="ACON_IssuanceOfCommitmentSharesNoteFinancingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_IssuanceOfCommitmentSharesNoteFinancingShares_lbl" xml:lang="en-US">Issuance of commitment shares - note financing, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_CashlessExerciseOfPrefundedWarrant" xlink:label="ACON_CashlessExerciseOfPrefundedWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_CashlessExerciseOfPrefundedWarrant" xlink:to="ACON_CashlessExerciseOfPrefundedWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_CashlessExerciseOfPrefundedWarrant_lbl" xml:lang="en-US">Cashless exercise of pre-funded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_CashlessExerciseOfPrefundedWarrantsShares" xlink:label="ACON_CashlessExerciseOfPrefundedWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_CashlessExerciseOfPrefundedWarrantsShares" xlink:to="ACON_CashlessExerciseOfPrefundedWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_CashlessExerciseOfPrefundedWarrantsShares_lbl" xml:lang="en-US">Cashless exercise of pre-funded warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts" xlink:label="ACON_IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts" xlink:to="ACON_IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts_lbl" xml:lang="en-US">Issuance of common stock and warrants related to public offering, net issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares" xlink:label="ACON_IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares" xlink:to="ACON_IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares_lbl" xml:lang="en-US">Issuance of common stock and warrants related to public offering, net issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PublicOfferingAndLineOfCreditIssuanceCosts" xlink:label="ACON_PublicOfferingAndLineOfCreditIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_PublicOfferingAndLineOfCreditIssuanceCosts" xlink:to="ACON_PublicOfferingAndLineOfCreditIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_PublicOfferingAndLineOfCreditIssuanceCosts_lbl" xml:lang="en-US">Public offering and line of credit issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommonSharesDebtForEquityExchange" xlink:label="ACON_IssuanceOfCommonSharesDebtForEquityExchange" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_IssuanceOfCommonSharesDebtForEquityExchange" xlink:to="ACON_IssuanceOfCommonSharesDebtForEquityExchange_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_IssuanceOfCommonSharesDebtForEquityExchange_lbl" xml:lang="en-US">Issuance of common shares - debt for equity exchange</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommonSharesDebtForEquityExchangeShares" xlink:label="ACON_IssuanceOfCommonSharesDebtForEquityExchangeShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_IssuanceOfCommonSharesDebtForEquityExchangeShares" xlink:to="ACON_IssuanceOfCommonSharesDebtForEquityExchangeShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_IssuanceOfCommonSharesDebtForEquityExchangeShares_lbl" xml:lang="en-US">Issuance of common shares - debt for equity exchange, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_RoundUpConversionRelatedToReverseStockSplit" xlink:label="ACON_RoundUpConversionRelatedToReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_RoundUpConversionRelatedToReverseStockSplit" xlink:to="ACON_RoundUpConversionRelatedToReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_RoundUpConversionRelatedToReverseStockSplit_lbl" xml:lang="en-US">Round up conversion related to reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_RoundUpConventionRelatedToReverseStockSplitShares" xlink:label="ACON_RoundUpConventionRelatedToReverseStockSplitShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_RoundUpConventionRelatedToReverseStockSplitShares" xlink:to="ACON_RoundUpConventionRelatedToReverseStockSplitShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_RoundUpConventionRelatedToReverseStockSplitShares_lbl" xml:lang="en-US">Round up convention related to reverse stock split, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_ProceedsFromSaleOfSeriesPreferredStock" xlink:label="ACON_ProceedsFromSaleOfSeriesPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_ProceedsFromSaleOfSeriesPreferredStock" xlink:to="ACON_ProceedsFromSaleOfSeriesPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_ProceedsFromSaleOfSeriesPreferredStock_lbl" xml:lang="en-US">Proceeds from sale of Series A preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PreferredStockIssuedDuringPeriodSharesNewIssues" xlink:label="ACON_PreferredStockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_PreferredStockIssuedDuringPeriodSharesNewIssues" xlink:to="ACON_PreferredStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_PreferredStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Proceeds from sale of Series A preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_RedemptionOfSeriesPreferredStock" xlink:label="ACON_RedemptionOfSeriesPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_RedemptionOfSeriesPreferredStock" xlink:to="ACON_RedemptionOfSeriesPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_RedemptionOfSeriesPreferredStock_lbl" xml:lang="en-US">Redemption of Series A Preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_RedemptionOfSeriesPreferredStockShares" xlink:label="ACON_RedemptionOfSeriesPreferredStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_RedemptionOfSeriesPreferredStockShares" xlink:to="ACON_RedemptionOfSeriesPreferredStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ACON_RedemptionOfSeriesPreferredStockShares_lbl" xml:lang="en-US">Redemption of Series A Preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_CommitmentSharesNoteFinancing" xlink:label="ACON_CommitmentSharesNoteFinancing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_CommitmentSharesNoteFinancing" xlink:to="ACON_CommitmentSharesNoteFinancing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_CommitmentSharesNoteFinancing_lbl" xml:lang="en-US">Commitment shares - note financing</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_CommitmentSharesNoteFinancingShares" xlink:label="ACON_CommitmentSharesNoteFinancingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_CommitmentSharesNoteFinancingShares" xlink:to="ACON_CommitmentSharesNoteFinancingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_CommitmentSharesNoteFinancingShares_lbl" xml:lang="en-US">Commitment shares - note financing, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfWarrantsNoteFinancing" xlink:label="ACON_IssuanceOfWarrantsNoteFinancing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_IssuanceOfWarrantsNoteFinancing" xlink:to="ACON_IssuanceOfWarrantsNoteFinancing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_IssuanceOfWarrantsNoteFinancing_lbl" xml:lang="en-US">Issuance of warrants - note financing</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net income (loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_GainLossOnExchangeOfDebt" xlink:label="ACON_GainLossOnExchangeOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_GainLossOnExchangeOfDebt" xlink:to="ACON_GainLossOnExchangeOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_GainLossOnExchangeOfDebt_lbl" xml:lang="en-US">Loss on exchange of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_GainsLossesOnExtinguishmentOfDebts" xlink:label="ACON_GainsLossesOnExtinguishmentOfDebts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_GainsLossesOnExtinguishmentOfDebts" xlink:to="ACON_GainsLossesOnExtinguishmentOfDebts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ACON_GainsLossesOnExtinguishmentOfDebts_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of deferred issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xml:lang="en-US">Change in fair value related to warrants and derivative</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_NoncashInterestRelatedToBridgeFunding" xlink:label="ACON_NoncashInterestRelatedToBridgeFunding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_NoncashInterestRelatedToBridgeFunding" xlink:to="ACON_NoncashInterestRelatedToBridgeFunding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_NoncashInterestRelatedToBridgeFunding_lbl" xml:lang="en-US">Non-cash interest related to bridge funding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in assets and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaids and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued and other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IncreaseDecreaseInNotePayableNetOfDiscount" xlink:label="ACON_IncreaseDecreaseInNotePayableNetOfDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_IncreaseDecreaseInNotePayableNetOfDiscount" xlink:to="ACON_IncreaseDecreaseInNotePayableNetOfDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ACON_IncreaseDecreaseInNotePayableNetOfDiscount_lbl" xml:lang="en-US">Note payable, net of discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash (used in) operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Intangible assets - Patents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash (used in) investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common stock and warrants related to public offering, net deductions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds from equity line</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayment of promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_EquityLineOfCreditIssuanceCosts" xlink:label="ACON_EquityLineOfCreditIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_EquityLineOfCreditIssuanceCosts" xlink:to="ACON_EquityLineOfCreditIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ACON_EquityLineOfCreditIssuanceCosts_lbl" xml:lang="en-US">Equity line cash issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Public offering cash issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_BridgeFundingIssuanceCosts" xlink:label="ACON_BridgeFundingIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_BridgeFundingIssuanceCosts" xlink:to="ACON_BridgeFundingIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ACON_BridgeFundingIssuanceCosts_lbl" xml:lang="en-US">Bridge fund cash issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_ProceedsFromBridgeFunding" xlink:label="ACON_ProceedsFromBridgeFunding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_ProceedsFromBridgeFunding" xlink:to="ACON_ProceedsFromBridgeFunding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_ProceedsFromBridgeFunding_lbl" xml:lang="en-US">Proceeds from bridge funding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Proceeds from sale of Series A preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Redemption of Series A Preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Non-cash activities</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommonSharesInExchangeForDebt" xlink:label="ACON_IssuanceOfCommonSharesInExchangeForDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_IssuanceOfCommonSharesInExchangeForDebt" xlink:to="ACON_IssuanceOfCommonSharesInExchangeForDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_IssuanceOfCommonSharesInExchangeForDebt_lbl" xml:lang="en-US">Issuance of common shares in exchange for debt</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfBridgeFundCommitmentShares" xlink:label="ACON_IssuanceOfBridgeFundCommitmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_IssuanceOfBridgeFundCommitmentShares" xlink:to="ACON_IssuanceOfBridgeFundCommitmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_IssuanceOfBridgeFundCommitmentShares_lbl" xml:lang="en-US">Issuance of bridge fund commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_FairValueOfWarrantsAndDerivativeRelatedToBridgeFunding" xlink:label="ACON_FairValueOfWarrantsAndDerivativeRelatedToBridgeFunding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_FairValueOfWarrantsAndDerivativeRelatedToBridgeFunding" xlink:to="ACON_FairValueOfWarrantsAndDerivativeRelatedToBridgeFunding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_FairValueOfWarrantsAndDerivativeRelatedToBridgeFunding_lbl" xml:lang="en-US">Fair value of warrants and derivative related to bridge funding</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_AccruedDebtIssuanceCostsRelatedToBridgeFunding" xlink:label="ACON_AccruedDebtIssuanceCostsRelatedToBridgeFunding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_AccruedDebtIssuanceCostsRelatedToBridgeFunding" xlink:to="ACON_AccruedDebtIssuanceCostsRelatedToBridgeFunding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_AccruedDebtIssuanceCostsRelatedToBridgeFunding_lbl" xml:lang="en-US">Accrued debt issuance costs related to bridge funding</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfWarrantsRelatedToBridgeFunding" xlink:label="ACON_IssuanceOfWarrantsRelatedToBridgeFunding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_IssuanceOfWarrantsRelatedToBridgeFunding" xlink:to="ACON_IssuanceOfWarrantsRelatedToBridgeFunding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_IssuanceOfWarrantsRelatedToBridgeFunding_lbl" xml:lang="en-US">Issuance of warrants related to bridge funding</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_OriginalIssueDiscount15RelatedToBridgeFunding" xlink:label="ACON_OriginalIssueDiscount15RelatedToBridgeFunding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_OriginalIssueDiscount15RelatedToBridgeFunding" xlink:to="ACON_OriginalIssueDiscount15RelatedToBridgeFunding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_OriginalIssueDiscount15RelatedToBridgeFunding_lbl" xml:lang="en-US">Original issue discount (15%) related to bridge funding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">THE COMPANY AND BASIS OF PRESENTATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">REVENUE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US">SUPPLEMENTAL FINANCIAL INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_DisclosureLeasesAbstract" xlink:label="ACON_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_DisclosureLeasesAbstract" xlink:to="ACON_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">SHORT TERM NOTES AND CONVERTIBLE DEBT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">NET LOSS PER SHARE OF COMMON STOCK</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Valuation of Derivative Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesReportingOfDerivativeActivity" xlink:label="us-gaap_DerivativesReportingOfDerivativeActivity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesReportingOfDerivativeActivity" xlink:to="us-gaap_DerivativesReportingOfDerivativeActivity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesReportingOfDerivativeActivity_lbl" xml:lang="en-US">Derivative Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US">Accounts Receivable, Less Allowance for Doubtful Accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_LiquidityCapitalResourcesAndGoingConcernPolicyTextBlock" xlink:label="ACON_LiquidityCapitalResourcesAndGoingConcernPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_LiquidityCapitalResourcesAndGoingConcernPolicyTextBlock" xlink:to="ACON_LiquidityCapitalResourcesAndGoingConcernPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_LiquidityCapitalResourcesAndGoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Liquidity, Capital Resources and Going Concern</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Share-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Financing Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="ACON_EmergingGrowthCompanyStatusPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="ACON_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xml:lang="en-US">Emerging Growth Company Status</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_ScheduleOfChangesToEquityStatementTableTextBlock" xlink:label="ACON_ScheduleOfChangesToEquityStatementTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_ScheduleOfChangesToEquityStatementTableTextBlock" xlink:to="ACON_ScheduleOfChangesToEquityStatementTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_ScheduleOfChangesToEquityStatementTableTextBlock_lbl" xml:lang="en-US">Schedule of equity statement information</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_ScheduleOfRetroactiveBasisRreverseStockSplitsTableTextBlock" xlink:label="ACON_ScheduleOfRetroactiveBasisRreverseStockSplitsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_ScheduleOfRetroactiveBasisRreverseStockSplitsTableTextBlock" xlink:to="ACON_ScheduleOfRetroactiveBasisRreverseStockSplitsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_ScheduleOfRetroactiveBasisRreverseStockSplitsTableTextBlock_lbl" xml:lang="en-US">Schedule of share information reflecting on a retroactive basis the reverse stock splits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of recurring basis to determine the fair value of the liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of liabilities measures at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl" xml:lang="en-US">Schedule of assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of prepaid and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued and other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of future amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_lbl" xml:lang="en-US">Schedule of derivative liabilities and warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of warrants and related strike prices</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of basic and diluted net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of anti-dilutive securities excluded from computation of earnings per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of RSU activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US">Schedule of stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsTable_lbl" xml:lang="en-US">Offsetting Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="us-gaap_OffsettingAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsLineItems" xlink:to="us-gaap_OffsettingAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsLineItems_lbl" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_2_lbl" xml:lang="en-US">Common shares issued and outstanding - post-2024 split, 825,459 shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Common stock shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Common stock shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_2_lbl" xml:lang="en-US">Additional paid-in capital - post-2024 split</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted average shares outstanding, basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Weighted average shares outstanding, diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Basic net loss per shares attributable to common stockholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_2_lbl" xml:lang="en-US">Diluted net loss per shares attributable to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash uninsured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Adjustment to additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xml:lang="en-US">Total Fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueHedgeLiabilitiesAtFairValue" xlink:label="us-gaap_FairValueHedgeLiabilitiesAtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueHedgeLiabilitiesAtFairValue" xlink:to="us-gaap_FairValueHedgeLiabilitiesAtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueHedgeLiabilitiesAtFairValue_lbl" xml:lang="en-US">Balance &#8211; December 31, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_ExchangeAndPayoffOfNotesPayable" xlink:label="ACON_ExchangeAndPayoffOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_ExchangeAndPayoffOfNotesPayable" xlink:to="ACON_ExchangeAndPayoffOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_ExchangeAndPayoffOfNotesPayable_lbl" xml:lang="en-US">Exchange and Payoff of Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueHedgeLiabilitiesAtFairValue" xlink:to="us-gaap_FairValueHedgeLiabilitiesAtFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueHedgeLiabilitiesAtFairValue_2_lbl" xml:lang="en-US">Balance &#8211; June 30, 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Strike Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Contractual term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility (annual)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free rate</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_FloorFinancingPrice" xlink:label="ACON_FloorFinancingPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_FloorFinancingPrice" xlink:to="ACON_FloorFinancingPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_FloorFinancingPrice_lbl" xml:lang="en-US">Floor Financing price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_2_lbl" xml:lang="en-US">Accounts payable, current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_2_lbl" xml:lang="en-US">Accrued liabilities and other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Office lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Intangible assets gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Less: accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl" xml:lang="en-US">2028 and beyond</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="us-gaap_OtherIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsNet" xlink:to="us-gaap_OtherIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Note Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_UnamortizedDiscountsAndDeferredFinancingCostsWarrants" xlink:label="ACON_UnamortizedDiscountsAndDeferredFinancingCostsWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_UnamortizedDiscountsAndDeferredFinancingCostsWarrants" xlink:to="ACON_UnamortizedDiscountsAndDeferredFinancingCostsWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_UnamortizedDiscountsAndDeferredFinancingCostsWarrants_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_UnamortizedDiscountsAndDeferredFinancingCostsDerivative" xlink:label="ACON_UnamortizedDiscountsAndDeferredFinancingCostsDerivative" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_UnamortizedDiscountsAndDeferredFinancingCostsDerivative" xlink:to="ACON_UnamortizedDiscountsAndDeferredFinancingCostsDerivative_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_UnamortizedDiscountsAndDeferredFinancingCostsDerivative_lbl" xml:lang="en-US">Derivative</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost" xlink:label="ACON_UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost" xlink:to="ACON_UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost_lbl" xml:lang="en-US">Deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_UnamortizedDiscountsAndDeferredFinancingCostsTotal" xlink:label="ACON_UnamortizedDiscountsAndDeferredFinancingCostsTotal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_UnamortizedDiscountsAndDeferredFinancingCostsTotal" xlink:to="ACON_UnamortizedDiscountsAndDeferredFinancingCostsTotal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_UnamortizedDiscountsAndDeferredFinancingCostsTotal_lbl" xml:lang="en-US">Total notes payable discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Convertible notes payable outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt instrument face amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSecuredNotesPayable" xlink:label="us-gaap_ProceedsFromSecuredNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSecuredNotesPayable" xlink:to="us-gaap_ProceedsFromSecuredNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSecuredNotesPayable_lbl" xml:lang="en-US">Proceeds from secured notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_DebtOriginalIssueDiscountPercenrtage" xlink:label="ACON_DebtOriginalIssueDiscountPercenrtage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_DebtOriginalIssueDiscountPercenrtage" xlink:to="ACON_DebtOriginalIssueDiscountPercenrtage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_DebtOriginalIssueDiscountPercenrtage_lbl" xml:lang="en-US">Original issue discount, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Annual rate percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebt" xlink:label="us-gaap_UnsecuredDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebt" xlink:to="us-gaap_UnsecuredDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnsecuredDebt_lbl" xml:lang="en-US">Issuing unsecured senior notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_lbl" xml:lang="en-US">Cash proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="us-gaap_PaymentsForLegalSettlements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLegalSettlements" xlink:to="us-gaap_PaymentsForLegalSettlements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForLegalSettlements_lbl" xml:lang="en-US">Diligence and legal costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Issuance of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US">Deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Number of common shares issued on exchange</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Exchange of principal and accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_RemainingOutstandingBalanceOfPrincipalAndInterest" xlink:label="ACON_RemainingOutstandingBalanceOfPrincipalAndInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_RemainingOutstandingBalanceOfPrincipalAndInterest" xlink:to="ACON_RemainingOutstandingBalanceOfPrincipalAndInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_RemainingOutstandingBalanceOfPrincipalAndInterest_lbl" xml:lang="en-US">Remaining outstanding balance of principal and interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_LossOnExchangeOfDebt" xlink:to="ACON_LossOnExchangeOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ACON_LossOnExchangeOfDebt_2_lbl" xml:lang="en-US">Exchange of principal and accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PrincipalAndAccruedInterestPaid" xlink:label="ACON_PrincipalAndAccruedInterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_PrincipalAndAccruedInterestPaid" xlink:to="ACON_PrincipalAndAccruedInterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_PrincipalAndAccruedInterestPaid_lbl" xml:lang="en-US">Principal and accrued interest paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayable_2_lbl" xml:lang="en-US">Outstanding balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Principal and accrued interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_MinimumAnnualRoyaltyPayment" xlink:label="ACON_MinimumAnnualRoyaltyPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_MinimumAnnualRoyaltyPayment" xlink:to="ACON_MinimumAnnualRoyaltyPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_MinimumAnnualRoyaltyPayment_lbl" xml:lang="en-US">Minimum annual royalty payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_StockIssueDate" xlink:label="ACON_StockIssueDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_StockIssueDate" xlink:to="ACON_StockIssueDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_StockIssueDate_lbl" xml:lang="en-US">Issue date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Strike price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xml:lang="en-US">Expiration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_2_lbl" xml:lang="en-US">Stockholders equity, reverse stock Split</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PurchasePrice" xlink:label="ACON_PurchasePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_PurchasePrice" xlink:to="ACON_PurchasePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_PurchasePrice_lbl" xml:lang="en-US">Purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl" xml:lang="en-US">Redemption price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Issued units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Price per unit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants_lbl" xml:lang="en-US">Aggregate gross purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issued shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from issuance of common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WeightedAverageNumberOfSharesOutstandingBasic1" xlink:label="ACON_WeightedAverageNumberOfSharesOutstandingBasic1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_WeightedAverageNumberOfSharesOutstandingBasic1" xlink:to="ACON_WeightedAverageNumberOfSharesOutstandingBasic1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_WeightedAverageNumberOfSharesOutstandingBasic1_lbl" xml:lang="en-US">Weighted average shares outstanding used to compute basic and dilutive loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US">Weighted average shares issuable for vested restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of share options outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Options forfeited or expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Options forfeited or expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of share options outstanding, Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Option exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life, Options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of Rsu shares outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value per unit, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">RSU's granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">RSU's granted, weighted-average grant date fair value per unit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">RSU's vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">RSU's vested, weighted-average grant date fair value per unit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">RSU's forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">RSU's forfeited, weighted-average grant date fair value per unit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of Rsu shares outstanding, Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted average grant date fair value per unit, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Total stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of common shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Intrinsic value options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Unrecognized compensation cost, remaining term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Obligated to issue share of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_WarrantStrikePrice2Member" xlink:to="ACON_WarrantStrikePrice2Member_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_WarrantStrikePrice2Member_2_lbl" xml:lang="en-US">Strike Price 69.60 [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOther_2_lbl" xml:lang="en-US">Interest Expense, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_LossOnExchangeOfDebt" xlink:to="ACON_LossOnExchangeOfDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_LossOnExchangeOfDebt_3_lbl" xml:lang="en-US">LossOnExchangeOfDebt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_RedemptionOfSeriesPreferredStockShares" xlink:to="ACON_RedemptionOfSeriesPreferredStockShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_RedemptionOfSeriesPreferredStockShares_2_lbl" xml:lang="en-US">RedemptionOfSeriesPreferredStockShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_GainsLossesOnExtinguishmentOfDebts" xlink:to="ACON_GainsLossesOnExtinguishmentOfDebts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_GainsLossesOnExtinguishmentOfDebts_2_lbl" xml:lang="en-US">GainsLossesOnExtinguishmentOfDebts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_IncreaseDecreaseInNotePayableNetOfDiscount" xlink:to="ACON_IncreaseDecreaseInNotePayableNetOfDiscount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_IncreaseDecreaseInNotePayableNetOfDiscount_2_lbl" xml:lang="en-US">IncreaseDecreaseInNotePayableNetOfDiscount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_EquityLineOfCreditIssuanceCosts" xlink:to="ACON_EquityLineOfCreditIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_EquityLineOfCreditIssuanceCosts_2_lbl" xml:lang="en-US">EquityLineOfCreditIssuanceCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ACON_BridgeFundingIssuanceCosts" xlink:to="ACON_BridgeFundingIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ACON_BridgeFundingIssuanceCosts_2_lbl" xml:lang="en-US">BridgeFundingIssuanceCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_2_lbl" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_2_lbl" xml:lang="en-US">Payments for Repurchase of Preferred Stock and Preference Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueHedgeLiabilitiesAtFairValue" xlink:to="us-gaap_FairValueHedgeLiabilitiesAtFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueHedgeLiabilitiesAtFairValue_3_lbl" xml:lang="en-US">Fair Value Hedge Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrent_2_lbl" xml:lang="en-US">Deferred Costs, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>acon-20240630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aclarion.com/role/Cover" xlink:href="acon-20240630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/BalanceSheets" xlink:href="acon-20240630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/BalanceSheetsParenthetical" xlink:href="acon-20240630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StatementsOfOperations" xlink:href="acon-20240630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:href="acon-20240630.xsd#StatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StatementsOfCashFlows" xlink:href="acon-20240630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/CompanyAndBasisOfPresentation" xlink:href="acon-20240630.xsd#CompanyAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="acon-20240630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/FairValueMeasurements" xlink:href="acon-20240630.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/RecentAccountingPronouncements" xlink:href="acon-20240630.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/Revenue" xlink:href="acon-20240630.xsd#Revenue" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SupplementalFinancialInformation" xlink:href="acon-20240630.xsd#SupplementalFinancialInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/Leases" xlink:href="acon-20240630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/IntangibleAssets" xlink:href="acon-20240630.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/ShortTermNotesAndConvertibleDebt" xlink:href="acon-20240630.xsd#ShortTermNotesAndConvertibleDebt" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/CommitmentsAndContingencies" xlink:href="acon-20240630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockholdersEquity" xlink:href="acon-20240630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/NetLossPerShareOfCommonStock" xlink:href="acon-20240630.xsd#NetLossPerShareOfCommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockBasedCompensation" xlink:href="acon-20240630.xsd#StockBasedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SubsequentEvents" xlink:href="acon-20240630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="acon-20240630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/CompanyAndBasisOfPresentationTables" xlink:href="acon-20240630.xsd#CompanyAndBasisOfPresentationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/FairValueMeasurementsTables" xlink:href="acon-20240630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SupplementalFinancialInformationTables" xlink:href="acon-20240630.xsd#SupplementalFinancialInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/IntangibleAssetsTables" xlink:href="acon-20240630.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/ShortTermNotesAndConvertibleDebtTables" xlink:href="acon-20240630.xsd#ShortTermNotesAndConvertibleDebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockholdersEquityTables" xlink:href="acon-20240630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/NetLossPerShareOfCommonStockTables" xlink:href="acon-20240630.xsd#NetLossPerShareOfCommonStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockBasedCompensationTables" xlink:href="acon-20240630.xsd#StockBasedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-BalanceSheetChangesFromSplit" xlink:href="acon-20240630.xsd#CompanyAndBasisOfPresentationDetails-BalanceSheetChangesFromSplit" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-RetroactiveBasisReverseStockSplits" xlink:href="acon-20240630.xsd#CompanyAndBasisOfPresentationDetails-RetroactiveBasisReverseStockSplits" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/CompanyAndBasisOfPresentationDetailsNarrative" xlink:href="acon-20240630.xsd#CompanyAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="acon-20240630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability" xlink:href="acon-20240630.xsd#FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/FairValueMeasurementsDetails-LiabilitiesMeasuresAtFairValue" xlink:href="acon-20240630.xsd#FairValueMeasurementsDetails-LiabilitiesMeasuresAtFairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/FairValueMeasurementsDetails-FairValueOfWarrants" xlink:href="acon-20240630.xsd#FairValueMeasurementsDetails-FairValueOfWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets" xlink:href="acon-20240630.xsd#SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SupplementalFinancialInformationDetails-AccountsPayable" xlink:href="acon-20240630.xsd#SupplementalFinancialInformationDetails-AccountsPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities" xlink:href="acon-20240630.xsd#SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/LeasesDetailsNarrative" xlink:href="acon-20240630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/IntangibleAssetsDetails-IntangibleAssets" xlink:href="acon-20240630.xsd#IntangibleAssetsDetails-IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/IntangibleAssetsDetails-FutureAmortization" xlink:href="acon-20240630.xsd#IntangibleAssetsDetails-FutureAmortization" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/IntangibleAssetsDetailsNarrative" xlink:href="acon-20240630.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetails-NotePayable" xlink:href="acon-20240630.xsd#ShortTermNotesAndConvertibleDebtDetails-NotePayable" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative" xlink:href="acon-20240630.xsd#ShortTermNotesAndConvertibleDebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="acon-20240630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockholdersEquityDetails-OutstandingWarrants" xlink:href="acon-20240630.xsd#StockholdersEquityDetails-OutstandingWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockholdersEquityDetailsNarrative" xlink:href="acon-20240630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-BasicAndDilutedNetLossPerShare" xlink:href="acon-20240630.xsd#NetLossPerShareOfCommonStockDetails-BasicAndDilutedNetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-DilutiveSecurities" xlink:href="acon-20240630.xsd#NetLossPerShareOfCommonStockDetails-DilutiveSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockBasedCompensationDetails-OptionActivity" xlink:href="acon-20240630.xsd#StockBasedCompensationDetails-OptionActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockBasedCompensationDetails-RsuActivity" xlink:href="acon-20240630.xsd#StockBasedCompensationDetails-RsuActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockBasedCompensationDetails-ShareBasedCompensation" xlink:href="acon-20240630.xsd#StockBasedCompensationDetails-ShareBasedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aclarion.com/role/StockBasedCompensationDetailsNarrative" xlink:href="acon-20240630.xsd#StockBasedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="loc_us-gaapOtherNotesPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantLiabilityCurrent" xlink:label="loc_ACONWarrantLiabilityCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_ACONWarrantLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_LiabilityToIssueEquity" xlink:label="loc_ACONLiabilityToIssueEquity" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_ACONLiabilityToIssueEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaapInterestExpenseOther" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpenseOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_LossOnExchangeOfDebt" xlink:label="loc_ACONLossOnExchangeOfDebt" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_ACONLossOnExchangeOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000005 - Statement - Condensed Statements of Changes in Stockholders&apos; Equity (Deficit) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="200" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PreferredStockSeriesAMember" xlink:label="loc_ACONPreferredStockSeriesAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_ACONPreferredStockSeriesAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PreferredStockSeriesA1A2A3A4Member" xlink:label="loc_ACONPreferredStockSeriesA1A2A3A4Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_ACONPreferredStockSeriesA1A2A3A4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PreferredStockSeriesBB1Member" xlink:label="loc_ACONPreferredStockSeriesBB1Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_ACONPreferredStockSeriesBB1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PreferredStockSeriesB2B3Member" xlink:label="loc_ACONPreferredStockSeriesB2B3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_ACONPreferredStockSeriesB2B3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommonSharesEquityLineOfCredit" xlink:label="loc_ACONIssuanceOfCommonSharesEquityLineOfCredit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONIssuanceOfCommonSharesEquityLineOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommonSharesEquityLineOfCreditShares" xlink:label="loc_ACONIssuanceOfCommonSharesEquityLineOfCreditShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONIssuanceOfCommonSharesEquityLineOfCreditShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommitmentSharesNoteFinancing" xlink:label="loc_ACONIssuanceOfCommitmentSharesNoteFinancing" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONIssuanceOfCommitmentSharesNoteFinancing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommitmentSharesNoteFinancingShares" xlink:label="loc_ACONIssuanceOfCommitmentSharesNoteFinancingShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONIssuanceOfCommitmentSharesNoteFinancingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_CashlessExerciseOfPrefundedWarrant" xlink:label="loc_ACONCashlessExerciseOfPrefundedWarrant" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONCashlessExerciseOfPrefundedWarrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_CashlessExerciseOfPrefundedWarrantsShares" xlink:label="loc_ACONCashlessExerciseOfPrefundedWarrantsShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONCashlessExerciseOfPrefundedWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts" xlink:label="loc_ACONIssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONIssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares" xlink:label="loc_ACONIssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONIssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PublicOfferingAndLineOfCreditIssuanceCosts" xlink:label="loc_ACONPublicOfferingAndLineOfCreditIssuanceCosts" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONPublicOfferingAndLineOfCreditIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommonSharesDebtForEquityExchange" xlink:label="loc_ACONIssuanceOfCommonSharesDebtForEquityExchange" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONIssuanceOfCommonSharesDebtForEquityExchange" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommonSharesDebtForEquityExchangeShares" xlink:label="loc_ACONIssuanceOfCommonSharesDebtForEquityExchangeShares" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONIssuanceOfCommonSharesDebtForEquityExchangeShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_RoundUpConversionRelatedToReverseStockSplit" xlink:label="loc_ACONRoundUpConversionRelatedToReverseStockSplit" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONRoundUpConversionRelatedToReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_RoundUpConventionRelatedToReverseStockSplitShares" xlink:label="loc_ACONRoundUpConventionRelatedToReverseStockSplitShares" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONRoundUpConventionRelatedToReverseStockSplitShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_ProceedsFromSaleOfSeriesPreferredStock" xlink:label="loc_ACONProceedsFromSaleOfSeriesPreferredStock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONProceedsFromSaleOfSeriesPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PreferredStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_ACONPreferredStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONPreferredStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_RedemptionOfSeriesPreferredStock" xlink:label="loc_ACONRedemptionOfSeriesPreferredStock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONRedemptionOfSeriesPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_RedemptionOfSeriesPreferredStockShares" xlink:label="loc_ACONRedemptionOfSeriesPreferredStockShares" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONRedemptionOfSeriesPreferredStockShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_CommitmentSharesNoteFinancing" xlink:label="loc_ACONCommitmentSharesNoteFinancing" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONCommitmentSharesNoteFinancing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_CommitmentSharesNoteFinancingShares" xlink:label="loc_ACONCommitmentSharesNoteFinancingShares" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONCommitmentSharesNoteFinancingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfWarrantsNoteFinancing" xlink:label="loc_ACONIssuanceOfWarrantsNoteFinancing" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ACONIssuanceOfWarrantsNoteFinancing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_GainLossOnExchangeOfDebt" xlink:label="loc_ACONGainLossOnExchangeOfDebt" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ACONGainLossOnExchangeOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_GainsLossesOnExtinguishmentOfDebts" xlink:label="loc_ACONGainsLossesOnExtinguishmentOfDebts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ACONGainsLossesOnExtinguishmentOfDebts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_NoncashInterestRelatedToBridgeFunding" xlink:label="loc_ACONNoncashInterestRelatedToBridgeFunding" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ACONNoncashInterestRelatedToBridgeFunding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IncreaseDecreaseInNotePayableNetOfDiscount" xlink:label="loc_ACONIncreaseDecreaseInNotePayableNetOfDiscount" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_ACONIncreaseDecreaseInNotePayableNetOfDiscount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_EquityLineOfCreditIssuanceCosts" xlink:label="loc_ACONEquityLineOfCreditIssuanceCosts" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ACONEquityLineOfCreditIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_BridgeFundingIssuanceCosts" xlink:label="loc_ACONBridgeFundingIssuanceCosts" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ACONBridgeFundingIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_ProceedsFromBridgeFunding" xlink:label="loc_ACONProceedsFromBridgeFunding" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ACONProceedsFromBridgeFunding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfCommonSharesInExchangeForDebt" xlink:label="loc_ACONIssuanceOfCommonSharesInExchangeForDebt" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_ACONIssuanceOfCommonSharesInExchangeForDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfBridgeFundCommitmentShares" xlink:label="loc_ACONIssuanceOfBridgeFundCommitmentShares" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_ACONIssuanceOfBridgeFundCommitmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_FairValueOfWarrantsAndDerivativeRelatedToBridgeFunding" xlink:label="loc_ACONFairValueOfWarrantsAndDerivativeRelatedToBridgeFunding" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_ACONFairValueOfWarrantsAndDerivativeRelatedToBridgeFunding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_AccruedDebtIssuanceCostsRelatedToBridgeFunding" xlink:label="loc_ACONAccruedDebtIssuanceCostsRelatedToBridgeFunding" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_ACONAccruedDebtIssuanceCostsRelatedToBridgeFunding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_IssuanceOfWarrantsRelatedToBridgeFunding" xlink:label="loc_ACONIssuanceOfWarrantsRelatedToBridgeFunding" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_ACONIssuanceOfWarrantsRelatedToBridgeFunding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_OriginalIssueDiscount15RelatedToBridgeFunding" xlink:label="loc_ACONOriginalIssueDiscount15RelatedToBridgeFunding" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_ACONOriginalIssueDiscount15RelatedToBridgeFunding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/CompanyAndBasisOfPresentation" xlink:title="00000007 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/FairValueMeasurements" xlink:title="00000009 - Disclosure - FAIR VALUE MEASUREMENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="loc_us-gaapFairValueMeasurementInputsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueMeasurementInputsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/RecentAccountingPronouncements" xlink:title="00000010 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/Revenue" xlink:title="00000011 - Disclosure - REVENUE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/SupplementalFinancialInformation" xlink:title="00000012 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaapSupplementalBalanceSheetDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/Leases" xlink:title="00000013 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_DisclosureLeasesAbstract" xlink:label="loc_ACONDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ACONDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/IntangibleAssets" xlink:title="00000014 - Disclosure - INTANGIBLE ASSETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/ShortTermNotesAndConvertibleDebt" xlink:title="00000015 - Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockholdersEquity" xlink:title="00000017 - Disclosure - STOCKHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/NetLossPerShareOfCommonStock" xlink:title="00000018 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockBasedCompensation" xlink:title="00000019 - Disclosure - STOCK BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/SubsequentEvents" xlink:title="00000020 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesReportingOfDerivativeActivity" xlink:label="loc_us-gaapDerivativesReportingOfDerivativeActivity" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesReportingOfDerivativeActivity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaapReceivablesPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReceivablesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_LiquidityCapitalResourcesAndGoingConcernPolicyTextBlock" xlink:label="loc_ACONLiquidityCapitalResourcesAndGoingConcernPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ACONLiquidityCapitalResourcesAndGoingConcernPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaapDeferredChargesPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDeferredChargesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="loc_ACONEmergingGrowthCompanyStatusPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ACONEmergingGrowthCompanyStatusPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/CompanyAndBasisOfPresentationTables" xlink:title="00000022 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_ScheduleOfChangesToEquityStatementTableTextBlock" xlink:label="loc_ACONScheduleOfChangesToEquityStatementTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_ACONScheduleOfChangesToEquityStatementTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_ScheduleOfRetroactiveBasisRreverseStockSplitsTableTextBlock" xlink:label="loc_ACONScheduleOfRetroactiveBasisRreverseStockSplitsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_ACONScheduleOfRetroactiveBasisRreverseStockSplitsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/FairValueMeasurementsTables" xlink:title="00000023 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="loc_us-gaapScheduleOfAssumptionsUsedTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/SupplementalFinancialInformationTables" xlink:title="00000024 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/IntangibleAssetsTables" xlink:title="00000025 - Disclosure - INTANGIBLE ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/ShortTermNotesAndConvertibleDebtTables" xlink:title="00000026 - Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeInstrumentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDerivativeInstrumentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockholdersEquityTables" xlink:title="00000027 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/NetLossPerShareOfCommonStockTables" xlink:title="00000028 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockBasedCompensationTables" xlink:title="00000029 - Disclosure - STOCK BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-BalanceSheetChangesFromSplit" xlink:title="00000030 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details - Balance sheet changes from split)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapTransactionTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_Pre2024SplitMember" xlink:label="loc_ACONPre2024SplitMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_ACONPre2024SplitMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_Post2024SplitMember" xlink:label="loc_ACONPost2024SplitMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_ACONPost2024SplitMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-RetroactiveBasisReverseStockSplits" xlink:title="00000031 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details- Retroactive basis the reverse stock splits)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PreSplitMember" xlink:label="loc_ACONPreSplitMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_ACONPreSplitMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PostSplitMember" xlink:label="loc_ACONPostSplitMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_ACONPostSplitMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/CompanyAndBasisOfPresentationDetailsNarrative" xlink:title="00000032 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapTransactionTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_StockSplit2024Member" xlink:label="loc_ACONStockSplit2024Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_ACONStockSplit2024Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000033 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTransactionTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_CompletionOfPublicOfferingMember" xlink:label="loc_ACONCompletionOfPublicOfferingMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_ACONCompletionOfPublicOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_CompletionOfIssuanceOfSharesMember" xlink:label="loc_ACONCompletionOfIssuanceOfSharesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_ACONCompletionOfIssuanceOfSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCashUninsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability" xlink:title="00000034 - Disclosure - FAIR VALUE MEASUREMENTS (Details- Recurring basis to determine the fair value of the liability)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantLiabilityMember" xlink:label="loc_ACONWarrantLiabilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_ACONWarrantLiabilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_DerivativeLiabilityMember" xlink:label="loc_ACONDerivativeLiabilityMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_ACONDerivativeLiabilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapFairValueNetAssetLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/FairValueMeasurementsDetails-LiabilitiesMeasuresAtFairValue" xlink:title="00000035 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Liabilities measures at fair value)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantLiabilityMember" xlink:label="loc_ACONWarrantLiabilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_ACONWarrantLiabilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_DerivativeLiabilityMember" xlink:label="loc_ACONDerivativeLiabilityMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_ACONDerivativeLiabilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueHedgeLiabilitiesAtFairValue" xlink:label="loc_us-gaapFairValueHedgeLiabilitiesAtFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapFairValueHedgeLiabilitiesAtFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_ExchangeAndPayoffOfNotesPayable" xlink:label="loc_ACONExchangeAndPayoffOfNotesPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_ACONExchangeAndPayoffOfNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaapFairValueOptionChangesInFairValueGainLoss1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapFairValueOptionChangesInFairValueGainLoss1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueHedgeLiabilitiesAtFairValue" xlink:label="loc_us-gaapFairValueHedgeLiabilitiesAtFairValue_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapFairValueHedgeLiabilitiesAtFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/FairValueMeasurementsDetails-FairValueOfWarrants" xlink:title="00000036 - Disclosure - FAIR VALUE MEASUREMENTS (Details- Fair value of the warrants)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantLiabilityMember" xlink:label="loc_ACONWarrantLiabilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_ACONWarrantLiabilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_FloorFinancingPrice" xlink:label="loc_ACONFloorFinancingPrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_ACONFloorFinancingPrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets" xlink:title="00000037 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Prepaids and other current assets)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_ShortTermDepositsMember" xlink:label="loc_ACONShortTermDepositsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONShortTermDepositsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_DeferredOfferingCostsMember" xlink:label="loc_ACONDeferredOfferingCostsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONDeferredOfferingCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PrepaidInsuranceDAndOMember" xlink:label="loc_ACONPrepaidInsuranceDAndOMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONPrepaidInsuranceDAndOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PrepaidInsuranceMember" xlink:label="loc_ACONPrepaidInsuranceMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONPrepaidInsuranceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PrepaidClinicalCostsMember" xlink:label="loc_ACONPrepaidClinicalCostsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONPrepaidClinicalCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PrepaidExchangeFeesMember" xlink:label="loc_ACONPrepaidExchangeFeesMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONPrepaidExchangeFeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PrepaidOtherMember" xlink:label="loc_ACONPrepaidOtherMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONPrepaidOtherMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_OtherReceivablesMember" xlink:label="loc_ACONOtherReceivablesMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONOtherReceivablesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/SupplementalFinancialInformationDetails-AccountsPayable" xlink:title="00000038 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accounts payable)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableMember" xlink:label="loc_us-gaapAccountsPayableMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_us-gaapAccountsPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_CreditCardsPayableMember" xlink:label="loc_ACONCreditCardsPayableMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONCreditCardsPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities" xlink:title="00000039 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accrued and other liabilities)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_AccruedPayrollMember" xlink:label="loc_ACONAccruedPayrollMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONAccruedPayrollMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_AccruedBonusMember" xlink:label="loc_ACONAccruedBonusMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONAccruedBonusMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_DAndOFinancingMember" xlink:label="loc_ACONDAndOFinancingMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONDAndOFinancingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_AccruedAuditAndLegalExpensesMember" xlink:label="loc_ACONAccruedAuditAndLegalExpensesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONAccruedAuditAndLegalExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_AccruedInterestMember" xlink:label="loc_ACONAccruedInterestMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONAccruedInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_AccruedBoardCompensationMember" xlink:label="loc_ACONAccruedBoardCompensationMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONAccruedBoardCompensationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_OtherAccruedLiabilitiesMember" xlink:label="loc_ACONOtherAccruedLiabilitiesMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_ACONOtherAccruedLiabilitiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/LeasesDetailsNarrative" xlink:title="00000040 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_DisclosureLeasesAbstract" xlink:label="loc_ACONDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ACONDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/IntangibleAssetsDetails-IntangibleAssets" xlink:title="00000041 - Disclosure - INTANGIBLE ASSETS (Details - Intangible assets)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PatentsAndLicensesMember" xlink:label="loc_ACONPatentsAndLicensesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_ACONPatentsAndLicensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember" xlink:label="loc_us-gaapOtherIntangibleAssetsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapOtherIntangibleAssetsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/IntangibleAssetsDetails-FutureAmortization" xlink:title="00000042 - Disclosure - INTANGIBLE ASSETS (Details - Future amortization)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaapOtherIntangibleAssetsNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherIntangibleAssetsNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000043 - Disclosure - INTANGIBLE ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetails-NotePayable" xlink:title="00000044 - Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT (Details - Note payable)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_UnamortizedDiscountsAndDeferredFinancingCostsWarrants" xlink:label="loc_ACONUnamortizedDiscountsAndDeferredFinancingCostsWarrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_ACONUnamortizedDiscountsAndDeferredFinancingCostsWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_UnamortizedDiscountsAndDeferredFinancingCostsDerivative" xlink:label="loc_ACONUnamortizedDiscountsAndDeferredFinancingCostsDerivative" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_ACONUnamortizedDiscountsAndDeferredFinancingCostsDerivative" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost" xlink:label="loc_ACONUnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_ACONUnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_UnamortizedDiscountsAndDeferredFinancingCostsTotal" xlink:label="loc_ACONUnamortizedDiscountsAndDeferredFinancingCostsTotal" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_ACONUnamortizedDiscountsAndDeferredFinancingCostsTotal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="loc_us-gaapOtherNotesPayableCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapOtherNotesPayableCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative" xlink:title="00000045 - Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_SeniorNotesPayableMember" xlink:label="loc_ACONSeniorNotesPayableMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ACONSeniorNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_SeriesBNotesPayableMember" xlink:label="loc_ACONSeriesBNotesPayableMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ACONSeriesBNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_SeriesCNotesPayableMember" xlink:label="loc_ACONSeriesCNotesPayableMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ACONSeriesCNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_ExchangeAgreementsMember" xlink:label="loc_ACONExchangeAgreementsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ACONExchangeAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtCounterpartyNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_AccreditedInvestorsMember" xlink:label="loc_ACONAccreditedInvestorsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_ACONAccreditedInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_UnsecuredNonConvertibleNotesMember" xlink:label="loc_ACONUnsecuredNonConvertibleNotesMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_ACONUnsecuredNonConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSecuredNotesPayable" xlink:label="loc_us-gaapProceedsFromSecuredNotesPayable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromSecuredNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_DebtOriginalIssueDiscountPercenrtage" xlink:label="loc_ACONDebtOriginalIssueDiscountPercenrtage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ACONDebtOriginalIssueDiscountPercenrtage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebt" xlink:label="loc_us-gaapUnsecuredDebt" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapUnsecuredDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfUnsecuredDebt" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfUnsecuredDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaapPaymentsForLegalSettlements" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapPaymentsForLegalSettlements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaapDeferredCostsCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDeferredCostsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_RemainingOutstandingBalanceOfPrincipalAndInterest" xlink:label="loc_ACONRemainingOutstandingBalanceOfPrincipalAndInterest" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ACONRemainingOutstandingBalanceOfPrincipalAndInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_LossOnExchangeOfDebt" xlink:label="loc_ACONLossOnExchangeOfDebt" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ACONLossOnExchangeOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PrincipalAndAccruedInterestPaid" xlink:label="loc_ACONPrincipalAndAccruedInterestPaid" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ACONPrincipalAndAccruedInterestPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000046 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_RegentsOfTheUniversityOfCaliforniaMember" xlink:label="loc_ACONRegentsOfTheUniversityOfCaliforniaMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_ACONRegentsOfTheUniversityOfCaliforniaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_MinimumAnnualRoyaltyPayment" xlink:label="loc_ACONMinimumAnnualRoyaltyPayment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ACONMinimumAnnualRoyaltyPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockholdersEquityDetails-OutstandingWarrants" xlink:title="00000047 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details - Outstanding warrants)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePriceMember" xlink:label="loc_ACONWarrantStrikePriceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice1Member" xlink:label="loc_ACONWarrantStrikePrice1Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePrice1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice2Member" xlink:label="loc_ACONWarrantStrikePrice2Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePrice2Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice3Member" xlink:label="loc_ACONWarrantStrikePrice3Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePrice3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice4Member" xlink:label="loc_ACONWarrantStrikePrice4Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePrice4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice5Member" xlink:label="loc_ACONWarrantStrikePrice5Member" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePrice5Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice6Member" xlink:label="loc_ACONWarrantStrikePrice6Member" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePrice6Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_StockIssueDate" xlink:label="loc_ACONStockIssueDate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ACONStockIssueDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000048 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_ExecutiveChairmanMember" xlink:label="loc_ACONExecutiveChairmanMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ACONExecutiveChairmanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTransactionTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WhiteLionEquityLineAgreementMember" xlink:label="loc_ACONWhiteLionEquityLineAgreementMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_ACONWhiteLionEquityLineAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_PurchasePrice" xlink:label="loc_ACONPurchasePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_ACONPurchasePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaapPaymentsForRepurchaseOfWarrants" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-BasicAndDilutedNetLossPerShare" xlink:title="00000049 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Basic and diluted net loss per share)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WeightedAverageNumberOfSharesOutstandingBasic1" xlink:label="loc_ACONWeightedAverageNumberOfSharesOutstandingBasic1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_ACONWeightedAverageNumberOfSharesOutstandingBasic1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaapIncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapIncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-DilutiveSecurities" xlink:title="00000050 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Dilutive securities)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantsMember" xlink:label="loc_ACONWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ACONWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_RestrictedStockUnitsMember" xlink:label="loc_ACONRestrictedStockUnitsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ACONRestrictedStockUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_StockOptionsMember" xlink:label="loc_ACONStockOptionsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ACONStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockBasedCompensationDetails-OptionActivity" xlink:title="00000051 - Disclosure - STOCK BASED COMPENSATION (Details - Option activity)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockBasedCompensationDetails-RsuActivity" xlink:title="00000052 - Disclosure - STOCK BASED COMPENSATION (Details - RSU activity)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockBasedCompensationDetails-ShareBasedCompensation" xlink:title="00000053 - Disclosure - STOCK BASED COMPENSATION (Details - Share based compensation)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaapSellingAndMarketingExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingAndMarketingExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aclarion.com/role/StockBasedCompensationDetailsNarrative" xlink:title="00000054 - Disclosure - STOCK BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_AclarionEquityIncentivePlan2022Member" xlink:label="loc_ACONAclarionEquityIncentivePlan2022Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ACONAclarionEquityIncentivePlan2022Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_NonVestedStockOptionsMember" xlink:label="loc_ACONNonVestedStockOptionsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONNonVestedStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePriceMember" xlink:label="loc_ACONWarrantStrikePriceMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePriceMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice1Member" xlink:label="loc_ACONWarrantStrikePrice1Member" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePrice1Member" order="100" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice2Member" xlink:label="loc_ACONWarrantStrikePrice2Member" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePrice2Member" order="200" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice3Member" xlink:label="loc_ACONWarrantStrikePrice3Member" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePrice3Member" order="300" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice4Member" xlink:label="loc_ACONWarrantStrikePrice4Member" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePrice4Member" order="400" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice5Member" xlink:label="loc_ACONWarrantStrikePrice5Member" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePrice5Member" order="500" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_WarrantStrikePrice6Member" xlink:label="loc_ACONWarrantStrikePrice6Member" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONWarrantStrikePrice6Member" order="600" />
      <link:loc xlink:type="locator" xlink:href="acon-20240630.xsd#ACON_NonVestedStockOptionsMember" xlink:label="loc_ACONNonVestedStockOptionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ACONNonVestedStockOptionsMember" order="700" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" order="800" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>64
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MK,IVQD"0B;SZ9Z\[1[PSH/2  =T94,]=?<A37C'+)B.MMD2[T:#F'OQ4O37
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MHSBEUAB:0<"8A?%0O^,CUXJ] OPME:8OG=H#TL?N6[2E-K'Y T :A,YJFP%
MG2W%B3WL(2!+0\+" 0%(+P#Q"G#QIUE8T**6JQ<9M%<'Z1-@I<$A8Y%M(D"D
MGLYZTVD+ " )U5XB2FT%("1+8AH-38+>L6*_9?V@EJ)&1367*X$NNA'P!EQ]
M\%D][%FS96?--CM7MM,^Z7TL]AO9NTH)G5>]3$BP,RAD?>*$.O,1 -(8A[;[
M 7&1MG+$'HP0,&$X'1B*O;G%?G=K)B.2E68]7_+J41BGFXL'<"'"KNL,;.*O
M0C( \@X'412'#FE?LE.^O<7%?H_;\S75=U,T2[/L>EF[WM-A_2HD R"ZEN&4
M)#9I7ZY3TKW1Q5[W-IFV7=OHBH,6O*C1EI>;MJ=WO*ZYIK]W(76Q;5=B5!;\
MH2@+50PL2S&P-H3,]F$ 3%-.W)+LXO02%U!L*_-JOE-Y>O>)_?:S+<=O427@
M_G<=H%X';*XNB"6A3=0%I21-[+T=V& X9#QZQXG]EK,S'N#2 _)V+:">IX3A
MR.8. #5Y9CM/,"$A48B=G@:04<#8P$Z>].Z3^-WG7<>[W=NB![&0M7@10_%G
M>+@3UPN:#6^B-Q66$B"21I39<R.#D&$4QM@9#1"21#0)<#R@1F]%B=^*WAV(
MFTW_MC"?T$$!7"]H5\#7(=GKD)D7<DJRMYO$;S?_$NHPW <_:1#(/\)=##I-
ML(L!Y$ 70T[3V\6]TR1>U^2R1[PLY9P_E+K?)=(/5GHQ;)2</RUEJ9< > :$
MSH>U(7D@)"P/@!R0!T#ZY>E-'_&;/E<>O2%!S9+KL@ *99YT0KTUQSS%'-1K
MWVIR_,;!);87#0A&+IUE \[&[!T[!&.79*AF]@Z1^!WB]VF4%^5&@8<FMUV[
MKZH$P""5P&RN2@#,HU+O*XG?5WYIS_5$COA6;VFUCVYE: ^DCB<9DAO5*&VW
MM/GT#2#7!"8$Q^UYRZDXP(=1'*>QO=$ <%&BO8=M9&90PB"FZ<!&@_0>E/@]
MZ#<)Y!L]KAL<D,@%PA*YN &)@(201..CL\V5J!_;0^5&L]U4:G^\=;A[.+C^
MI3VNM>[?XJLI!NYG^&JV/Y;NT^]/R=_S^K&H&E2*A6XJN(SUJ*_W!\_["R77
M[<GJ@U1*KMJ?2\'UE#4 _7PAI7JY, T<CO\G_P-02P,$%     @ AH1+62$I
MK'4$#@  X8X  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6RUG6]OV[@!
MQK^*D U;#Y@O$BG*\BT-<(U(6P-N"-K=]F+8"]5F$J&VY9.4IO?M1SF.98D4
M:?F>XI!K_CS\438?4=1#BKYY*<HOU9.4M?=ML]Y6[Z^>ZGKWT_5UM7R2FZSZ
ML=C)K?K+0U%NLEK]6#Y>5[M29JM]H<WZFOA^=+W)\NW5[<W^=_?E[4WQ7*_S
MK;POO>IYL\G*WS_(=?'R_BJX>OO%Q_SQJ6Y^<7U[L\L>Y2=9_[J[+]5/UT?*
M*M_(;9476Z^4#^^O?@Y^2J-]@;WBW[E\J4Z^]YJ7\KDHOC0_I*OW5WYS1'(M
MEW6#R-0_7^6=7*\;DCJ.WP[0JV.=3<'3[]_H8O_BU8OYG%7RKEC_)U_53^^O
MXBMO)1^RYW7]L7A9R,,+8@UO6:RK_?^]EX/6O_*6SU5=; Z%U1%L\NWKO]FW
MPQMQ4H"& P7(H0#I%0CC@0+T4(#V:Q@J$!X*A/T:AEX#.Q1@O0*$#!2(#@6B
M_B%% P6FAP+3?@W3@0+QH4#<*Q#0@0*S0X'9W@ZO[;=O_"2KL]N;LGCQRD:M
M:,TW>P?M2ZLVS[>-V3_5I?IKKLK5MW?%=J6L*U?>ISJKI;)Q77G%@W?WE&T?
M9>7E6_6'8OGEJ5BO9%G]U>._/>?U[]Z[1#[DR[S^P7OWZS9[7N6U7/W@3;Q?
M/R7>NS__<'-=JX-KJKA>'@[DP^N!D($#N5<FEV6Y/Q!5G_=)EKFJ_V?OO[_(
MS6=9_L^ O+L0&:@OHKZH^@IM%2075?!!_1?8L/Q"+%%?U 86=O!=L=D4AP:U
M8>9VS,\KU=RJI\K6WGV6KR;*(W?9+J_5SQ;HP@[]*&O5-:O7S+-RFV\?*QLK
MM;/^5:ACZ1:[5N?%\>0@QY.#[#GA .>#?,RWS<&H_G2=;9?R;][7;/TLO:SV
M$KG\T:/!WSSB$V*R^RN:[='-)>?KK7]S_?74O4Y%XE1PIT+H"M95S'5%&+!9
M%/A15[C0A1,ZHU,_8+2K3'4E(83-6'S4=1J$'AN$CFV0ZBDKU<EQ3HN\LB-+
MBS@5B5/!G0JA*\)90,-^LUC?BF80]%.URY;R_94:Y52R_"JO;O_RIR#R_VXZ
M^9"P% 3K6" \6B"T6N!3T]Z39GRS\I;%1@WZJJSIC$P-;B69C],S769 G 3$
MX2". ''FH6;HF# :]'H/4&VIJ[:.K=C15LQJJ_NR6$JYJKR'LMAX5;:6S2CH
M.&+8'2_)57/Q-)F-:5U>X/O]#L9Z$".<!.)P$$> .',09P'BI$SS6J=1.U:+
MCE:+@%9[N\*9+!?I1]?SF_5(1G;["1+&D3"!A,V1L 42EH)@'==.CZZ=6EW[
M4:[D9K</*$[=>N_N&*?ZJ-'0,UIK']$S@C@<Q!$@SAS$68 XZ53K>R;#76-\
M-%D,,)FM2XP-A]5SFO40QO:)2!A'P@02-D?"%DA8"H)U[#H[VG5FM>L_9>WE
M6W47(KUWZZ*JC+&7%3'B)@3$24 <#N(($&<.XBQFAAXDB&D8]:Y8Z1G"CJL"
MO\UD?:NO^'9E#IU^R<ICQ$&-&:OO3)W<DL0MX6Z),$CZ$<=!THE"@F@:1W3:
MNWDT*">ASQB-@G[V9) & 6$^F0VTRTE6'HQJES9[<C=,X R?W)+$+>%NB3!(
MC &4_=T8V^M#:2F*UG5"&PP'WS$9#MS1L%N2N"7<+1$&B68#8CA)C?FP03D4
M$!NDUH0X:"/BX'MFQ($[)'9+$K>$NR7"(#&?I]"D&$I+4;2N&=JP.+"GQ6>-
MT.R,D:_X#DI+H#0.I0DH;0ZE+:"T-- SYPF)PM@/I@/=59L[!_;@>7"L]X_G
MK>JJ?,N00D^<M:[**4G<$NZ6"(-$ZZ7T+#54+RVFL3;6TY43)0WB()KU+R.F
M@)80.M J;40;V#/:X9&>NUGT5%9K%J<D<4NX6R(,$J:&PDQK&VCF":6E*%K7
M"6WL&=AS3]M(SSWJU[-/S0M.2>*6<+=$&"2:#?10;^AVS!#_#=V.Z5+[[5@;
M%@;VM- ZTG.WC1X5:FWCE"1N"7=+A$%B'NE!<S@H+471NF9HH[C GL6-61=@
M1XW(Y%"@! 7B*)! @>:!GI,%-(JTY0&H"E-WA=W%8&TL1^RQ7+-\+J^;)9)O
M_<S$VQ:U]![RK>I^5$=D7 =FA8XP&PJ4H$ <!1(HT)P8LK\IBX+>N'&!JC!U
M5]@U6YLU$GO6Z#:;;1K,#A]C.F1JET!I'$H31$]%24""WJ5Z#JUT :6E*%K7
MLB>K9>VA:%I5S\TPK)F[?<G*,FO6DI_515JY8]P* B4H$$>!! HT)WKR2J>L
MOQYC@:HO==;7=5N;\Q)[SGM6M&=GC'$6")2@0!P%$BC0' 5:$#WXG@1A%#+6
MNP]-SU%V_=5&Q\0>'5\>S!W UJ7_3DGBEG"W1!@DVO)_/=P<".8,RJ%@SB"U
M!'.DC4O)N+AT1#!']*Q0:Q:G)'%+N%LB#!)C,&=_-T:/-I"T%$7K.J&-:(D]
MHCUW"M;LA<A]BCHEB5O"W1)AD,1]&^@Y;D@9HXR$_5-45T["D,0!(U'_%#5(
MIV0ZF[&!D[3-3,GHS-0\!6MN&STPU-K&*4G<$NZ6"(,D)BQDLWX#7;"LTG*>
M(FDIBM8U0YO2$GM*.R:8LZ/&#-= H 0%XBB00('F1 ^=8Q83[:(/JB]UUM<U
M6)O\$GOR>WK;N7Q]PO70VY1RG=7*=G6AOJWJ,E_6;VN(O>=M7INC$U0XC (E
M*!!'@00*-$>!%BA0"@!U'VUMXV5JCY?_@(]M4:"]UA%^O@0T' 5":1Q*$]2P
M+)5$O0F+.;3.!926HFA=*[?A-;6'U\-6GGCR=0.)ILC^SZ5<Y;71N*@,&P5*
M4"". HD#R'9[3_5<.PC#&=,N]*B#2H=JI&3@Z?\V8:;G)\QG^<K:,:)2YTM
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M)ZA)$@[WY0[#,;V&T<3/Z,?3O+U8LX/4)(J#S-)\,:J)037QH_K>;%8NUNM
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M8D]'7&).4W&[TMFJ\U5G?(M6"5HLC'%$5^3:9H6Q,(Q-PWFRE6G0^^AEJ1<
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MWW&[-NC_]"]/5MSPNB"()X@9):-N30![T;:;BE8B:2?+BLVA&"=>PKW7N2N
M\ =CA?.]\1K1S$CLMBX^KD_(7J=#'KRI&47H)&TKFLO-[E!-,4.,IN!2B$FZ
MWVQ06UB@38:\:XR9%(/:]ATTZ'LH3%DJ;QO(9+>!#"UM+D87D%,6D "QR[(=
M0S8:@POQ/G.&8OC<2_2$7.V';BX@2\DS:004"O."FSY:V^DU<-#4OB6%J'TV
M"=A$S4G'/V9?\@H'B*#R-D>SM>=,/S9&OQ-15?:=T<X%)$F820+$D#@6BZUU
MYHR^:;=*;+\X#VQWYH@F*6X!P<!MH6-*A02=F<)N1@&B.%DSQ63NT4;=S;3
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M^ O]/=%.#E315:RB%571+2QP7>U>--A]K(T&(E,Y/7;D1Y)(0VX5Q^6##KI
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M645#R5"@!-B(4*E4%<_D*%^II>M0XWP-A9-1/SBE[1#E$KJ ;7-8Z##?+3V
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MPR/AXL\GXIM@6_[)PM(&S);\<J,D,H86X/G*8LY(;^B X3<L+_\"4$L#!!0
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MRBW76&JU21GYNG2^JLS-%(+-1"'LR\";8H],J\(M_1\D[V:SUL0C18](#LN
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M=_M)-&T%^#N\'6-W3.6<'D^)&:4&@_<7'JAV-+0+(VLGQZTT)&YG%C1-4=D
M\F>26NP6MD _GZ-?4$L#!!0    ( (:$2UE(WDI9&0,  /L&   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;'U538_:,!"][Z\8I5)/E&2!_= 6D(!2
MM95VN]JO'JH>G&0@UCIV:CNP]-=W;"=95F*Y@#WQ>_/FQ3,9;Y5^-@6BA9=2
M2#.)"FNKJS@V68$E,WU5H:0G*Z5+9FFKU[&I-++<@TH1#Y+D/"X9E]%T[&.W
M>CI6M15<XJT&4Y<ET[LY"K6=1*=1&[CCZ\*Z0#P=5VR-]V@?JUM-N[ACR7F)
MTG E0>-J$LU.K^8C=]X?>.*X-7MK<)6D2CV[S?=\$B5.$ K,K&-@]+?!!0KA
MB$C&WX8SZE(ZX/ZZ9?_J:Z=:4F9PH<0OGMMB$EU&D..*U<+>J>TW;.HY<WR9
M$L;_PC:<'5U$D-7&JK(!DX*2R_#/7AH?]@"7R3N 00,8>-TAD5?YA5DV'6NU
M!>U.$YM;^%(]FL1QZ5[*O=7TE!/.3N^63\N;Q^4XMD3F0G'6 .<!.'@'> [7
M2MK"P%+FF+_%QR2B4S)HE<P'1PE_U+(/PZ0'@V0P.L(W["H;>K[A>Y7A!F6-
ML-*JA 5IU70#R%U;P,+[BAI^SU+CXW\.&1#X1X?Y7;=<F8IE.(FH'0SJ#4;3
MCQ].SY//1]2/.O6C8^S'WLM1X&%9-S\?EG#6AX;UU8XY$TQF:."A0+"<+M@:
MU(JZ+7BG,5-KR5W_]"#E@I*M30^8S$\R9@J@V]>TEZ%+N:/SAKH!N 2BS[$'
MM70HS!T3\@U+!0:\ZQS4VC_QN0Q0CUI2D09)X.^TZ</,.F$.=D#5B<NJLJRF
MWD0:41@H@M)>H\<519*8/"2G!]N"9P4-CUJXN#=-6F!47&,2,P9MWUOT-M:
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M4+BR 'R^D=(<)G:#_I]G^A]02P,$%     @ AH1+6305?.W^ 0  EP0  !D
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M2#KJ@5='X!J2->!T-^W,I3UL<6F;A,-/YEQ#R["I1(?#LM@XSY&L=^C8[]8
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M:+>0NH-51;T$SI3%E;)^3'&'YYH$\'ZAD.?Z0 ;:_PI&_P)02P,$%     @
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M?ND()66+%ULJ1;C76&B+"L6WR#0FL]\H1>AGORJ?H"!Z<(1*,J0'Z.\=F<L
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MN#T;3;UW7)A0:R:H:I7V@*9/RL&>:604;]FO*.*ILL-9.;K!<%;^O5UW/+)
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M&+H!UY<&S67\0ANT+T^>_0]02P,$%     @ AH1+6<%.AF=R P  \@@  !D
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M<\W-5]!;WL!%<ZLIM$.\CR(?YOU6=ZU+3+%<H(*XX[<HE7%K*LN2CECGC-"
M:UUCYC) K80P1,;%"LZ ?)W9U(.N"FY\Z,1^%/;\*#J'GTF(WHPCM7D!U(\2
MOYM8E'YKG&7<TJ0L5XQG9UQ RBIN2/Z> >EW8S])8C\^/_\'PY<NOUDF40Q'
M<IWL<IV\.=<N_/T3MQW4M4**WI8VR4;)IBG:OL8UF!QI]QF51LJ:3)\:GOI0
M;?P_3%J?D"E VTK@=05]="W89ILL::)L:V O\;YSD+IZR'A16^U7&>W[YR']
MXNZ_0/PNU4G2\_MAOS5YI2MH\!92:Z@HE T\,T;Q16ULTP4C(=V4M#V)7!89
MG<NA.CP)VTD"I_^MDU<U>])O]R,X/52OP=X<*E&MW+35A%P+TXRDW>YNH(^;
M.?9-O?D:N&5JQ86& I=D&K;?4<&I9L(V@I&5FVH+:6A&NF5.'R6HK *]7TII
MMH)UL/O,&?T-4$L#!!0    ( (:$2UD TFA #00  #<*   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;*U6WV_B.!!^SU\QRJY6(''D)RG=!23:4MV>
MVE6OM-V'TSV8, &KB<W93FG_^QLG$.@MI7VX!\+8GOD\X_G&GL%:JD>]1#3P
M7.1"#]VE,:NOGJ?3)19,=^4*!:UD4A7,T% M/+U2R.:549%[H>\G7L&X<$>#
M:NY&C0:R-#D7>*- ET7!U,L9YG(]= -W.W'+%TMC)[S18,46.$5SO[I1-/(:
ME#DO4&@N!2C,ANXX^'J66/U*X8'C6N_)8".92?EH!]_G0]>W#F&.J;$(C/Z>
M\!SSW *1&_]L,-UF2VNX+V_1+ZO8*989TW@N\Y]\;I9#M^_"'#-6YN96KG_'
M33P]BY?*7%=?6->Z)Y$+::F-+#;&Y$'!1?W/GC?GL&?0]]\P"#<&8>5WO5'E
MY04S;#10<@W*:A.:%:I0*VMRC@N;E*E1M,K)SHPNQ]]OX6%\=3^!Z\EX>G\[
MN9[\N)M"ZX[-<M3M@6=H%ZOKI1O$LQHQ? ,Q@6LIS%+#1,QQ_MK>(^\:%\.M
MBV?A4< _2M&%R.] Z(?Q$;RH"3FJ\**W0F9<P0/+2X0+KM-<ZE*AAK_&,VT4
ML>3O0S'7D/%A2%LY7_6*I3ATJ30TJB=T1U\^!8G_[8C#<>-P? Q]-*5*G)<Y
M@LRH#M)2*2X6EHM<@Y'$08.*J(%@E@B9C>ZIBH[4[4S.V8SGW+P<BNOHSH?C
M^K_<<2YW:P4RFX4Y,&WU*.78I'Q?C^K83L&?I32DO5(\I=3Q;7539:A'-!I:
M5_B$.01MF/*%X!E/F3 @:7\%<F8#L?0FPU6YTPY?:Y?B3<VH[?QD2EFM)ASX
M#&'4Z2<!"5\^]<,@^/9*JA>="U3\B57.7C6F0;^3^$&CO/VOIYT[:5@.>Z?P
M&>*P$R?A&SMM%H\PK]<PK_=AYFT#Y73@FW1I8&8OPX?X=13_?7Z]OVF3B-UI
M'CSBZA"=,Y8SD6)S6!>88C$C4D1!1;;()JI_V@F2'DE!&'2B,+%'&OB=^#1P
M)L_IDHD% A-SN&$O,LNLFS^(C=J.*ZYLP5MQW#GM]Z&]DYSSVIP8NU<9K3#I
M=2(_MIJ]D\Y)=&*EB!CCQP$9_=?K5^6QS[L-CSY"@:2A0/)A"C!-;_?*OJ;Z
M4*Z/ KV?ZSUT9UQ= Y2=76+&!VZ&7W/_RXQ#/O!'A!M[5=B3Z4:V;OQN>.J<
MTT-E;_R2RLM>6M!Z0:9T&WI=W_Z<!YD3CRK@%A."]-K0]VG1?IQ;KA]_RQ0B
M*&;(JV[_U,+;3TRW5BZE@DLN*'7V@EQM' B[5<[\;A ?S(^W]Y@7J!95RZ(A
ME:4P];O>S#9=T;AN!G;J=4MUS=2""PTY9F3J=T^H&E7=IM0#(U=5:S"3AAJ-
M2EQ29X?**M!Z)HG8FX'=H.D51_\"4$L#!!0    ( (:$2UD!AMK!'00  -X)
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;)56VV[C-A!]]U<0VB!H
M 2*2J*L3VX!S0U-L$B/.M@]%'VAI;!,KB2I)Q]E^?8>2K'5W'6_V12*IF3-G
MAF<HCK92?=9K $->RZ+28V=M3'WNNCI;0\GUF:RAPB]+J4IN<*I6KJX5\+QQ
M*@N7>5[LEEQ4SF34K,W49"0WIA 5S!31F[+DZLLE%'([=GQGM_ D5FMC%]S)
MJ.8KF(/Y5,\4SMP>)1<E5%K(BBA8CIVI?WX96_O&X \!6[TW)C:3A92?[>0N
M'SN>)00%9,8B<'R]P!44A05"&O]TF$X?TCKNCW?HMTWNF,N":[B2Q9\B-^NQ
MDSHDAR7?%.9);G^#+I_(XF6RT,V3;#M;SR'91AM9=L[(H!15^^:O71W>X\ Z
M!];P;@,U+*^YX9.1DENBK#6BV4&3:N.-Y$1E-V5N%'X5Z&<F\T^SV<>;^YN'
MY^E'<GOW,'VXNL/1W</MX]/]]/GN\8'\\LP7!>A?1Z[!@-;-S3KPRQ:<O0$>
MDWM9F;4F-U4.^?_]723:LV4[MI?L*.#OF^J,!!XES&/A$;R@SSYH\((W\![5
MBE?B7VX%0LF5K+0L1,Y;O50YF2G04)EV02[)K:AXE0E>D#DN HK3:/+7=*&-
M0GG]?:A"+8'P, ';<N>ZYAF,G=K&4B_@3$X_^+%W<22]L$\O/(8^F6,+YYL"
M+'6$K[G(F[2D68-"=2F%"1"N-1A]B/M1],/<?R;D +<3^NTDUY!!N4"KP&]6
M@L%\+94A!E2)C59++;#:)R3RJ.=Y_6!P#4M 6(RQQ(&H5B23&BV3D,9A2GS/
MHU&:#F8=&U'IC<)=!')]RLOZXI&PT*=A&)$@I$D\_-Z0=NPCZOD>\1.:IF%O
ME6%91(:*:(/Z<41#/R&G'U+F^Q>]&;QF:UZM@"P!-(D"FC#O.Z,NS)#ZB("D
MXB :/#9K"FLC7IH^W'D1/PH')R0.AS2($BP'"Y%@X)$CPHEZX43O%@[/,KFQ
M.J_Y%TO@D%".HOU8*-^&^*$PIM\X8/9^DM#8M[)(HI1BA097J EA2,95_M70
MIY$?X#/Q;?'\!&O- NL4HTJ"Z%CQXKYX\<\43VU@OP4*P1>B$$; P98["OVN
M2KX=[SUE;;RQ6$H6!99EIS4L5<Q0]TEOLY#5!N7.L!N2B##\&J78BUU++=N#
M$GO19S&-O:C7^LZ?;^SF6)X%K+!]X!7O&1KE'7J4L9BD0^JEK#<7%1X#H W!
MS8WCF SQE49[;'"7L05+"](>UV%,6>21(1+#0Z)MHUUY]HI"PA3[!]LZ\ND0
MCXD3$H8)'28,<TZC!/N4'12%N_?/+4&MFIN%)HTNV]]OO]I?7J;M/_NK>7OS
MN>=JA8<-%F*)KMY9@NVDVMM$.S&R;O[@"VGP/M ,UW@! V4-\/M22K.;V #]
ME6[R'U!+ P04    " "&A$M9.:J?@@(#   9!P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6R-5=^/VS8,?L]?07B'H06,\Z_83FY)@*1WZS*TW:&Y
M;0_#'A2;283*4BK)3;N_?I2<<W-#+KL72Y3(CQ])DYH<E/YD=H@6OC9"FFFP
MLW9_$T6FVF'#S+7:HZ2;C=(-LR3J;63V&EGMC1H1I7%<1 WC,IA-_-F]GDU4
M:P67>*_!M$W#]+<%"G68!DGP>/"1;W?6'42SR9YM<87V]_V])BGJ46K>H#1<
M2="XF0;SY&:1.WVO\ ?'@SG9@XMDK=0G)RSK:1 [0BBPL@Z!T?(%WZ 0#HAH
M?#YB!KU+9WBZ?T3_V<=.L:R9P3=*_,EKNYL&HP!JW+!6V(_J\ L>X_$$*R6,
M_\*AT\VS *K66-4<C8E!PV6WLJ_'/)P8C.)G#-*C0>IY=XX\RUMFV6RBU0&T
MTR8TM_&A>FLBQZ4KRLIJNN5D9V?+#P_S#V^7BW=W,%^M[AY6\.J!K06:UY/(
M$K[3BJHCUJ+#2I_!*N"]DG9GX$[66#^UCXA73RY])+=(+P+^VLIKR.(0TC@=
M7L#+^F SCY<]@_=6J?K A0 F:UA*R^264ZPP-P:M@5MN*J%,JQ'^FJ^-U?3+
M_'TN#9V7X7DOKHUNS)Y5. VH3PSJ+QC,?OPA*>*?+L0P[&,87D*?K:@MZY9(
MJPWP[R$P'\(YLA?ASI.]Z&- 5<&^*G"+%39KU) E_B0;W#.+DM+IDBQX10V,
M!JX@#8?I,"S+S._3H@S3/!G\9G=DFX=Q4G;?@=,;A^4X=EJETQP-WJ$Q-]3!
M5=NT@N!K8(W2EO_#?&N_2L)DG(7C)(?77HBSL!B2,%C^EWT(DB;=%21AFN7A
MJ,S]/BE&89%F<*$^>5^?_,7UV;36_4Q/N+ZT;!>]_'_97NIZX(MX!>."DI\[
M*8=DG(9Q%CNA.!7*4V'DZ[O&;XJ6O,BHLO'@05DFGF3W7$:CDW'5H-[ZH6R@
M4JVTW>3J3_NY/^_&W7?U[M%XS_262P,"-V0:7Y>4-MT-XDZP:N^'WUI9&J5^
MNZ.W"[53H/N-4O91< [ZUW#V+U!+ P04    " "&A$M9IT/2,?("   S!@
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MNB7C&#),HU.:0H@S*M7\U0O2Q#YX];1[ S]P^H[S"_V&0,_W/5_O]28!YY6
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MY$,YYFIF-RP9R:$0A!6(PZQC==W+)-3Q)N 7@;78&"/M9,K8HYX,LH[E:$%
M(96: :O?"A*@5!,I&4\UI]4<J8&;XU?VOO&NO$RQ@(31WR23BXYU8:$,9GA)
MY1U;_X#:3Z#Y4D:%^:)U%1NU+)0NA61Y#58*<E)4?_Q<YV$#X+X'\&J ]U&
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MK*>K&^4$STGZQ_IA7OP/4$L#!!0    ( (:$2UEBVB$_^P(  &X)   9
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M2C?#;!CK"Q$(XZ#?+SA7NXD)4%ZQ_%]02P,$%     @ AH1+65H-\&2"!@
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M!-?8CV'[<_L'P, K&7CW":6Y#J7?E6BM(Y1#]364*L)70QE\W9WJ:]"YJE*
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M6>97JCR_NO8"SX]]>=<!&9Q,H#0=2C.@-!-*LZ T&TJC*%K5Q&48IFJOU76
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MW2!Y?QZ&XGDA+;"9DF_\/U!+ P04    " "&A$M9+R].]\\#  #-#   &0
M 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6RM5]MNXS80_15"+8H$V(WN%Z>V
M@=C68MMM8B/>[3X4?: EVA8BB2Y)V=N_WR$E:VV)<8,T+S8O9PYG#H?D:'B@
M[(EO"1'H6Y&7?&1LA=C=FB9/MJ3 _(;N2 DS:\H*+*#+-B;?,8)3953DIF-9
M@5G@K#3&0S6V8.,AK42>E63!$*^* K-_)R2GAY%A&\>!QVRS%7+ ' ]W>$.6
M1'S9+1CTS)8ES0I2\HR6B)'UR+BS;^-(XA7@SXP<^$D;R4A6E#[)SF_IR+"D
M0R0GB9 ,&/[V9$KR7!*!&_\TG$:[I#0\;1_9/ZC8(985YF1*\Z]9*K8C(S)0
M2M:XRL4C/7PD33R^Y$MHSM4O.C18RT!)Q04M&F/PH,C*^A]_:W0X,0 >O8'3
M&#A= ^\9 [<Q<%^Z@M<8>"]=P6\,5.AF';L2;H8%'@\9/2 FT< F&TI]90UZ
M9:7,DZ5@,)N!G1@_Q)_1'_/E$BWB1[3\>/<8H_D'-)W?W\\?T/+S?/H)7<V(
MP%G.T7LTP3Q+$"Y3E&9Y)4B*2DCEG'*.=@2R;XL9N0;<E^4,7?U\/30%N"@7
M,I/&G4GMCO.,.RZZIZ78<A27*4DU]K/+]L$%>Q.D:?5QCOI,G(N$OU?E#7*M
M=\BQ'$_CS_3EYJXNG/^W>OSJU<_$<-MD<16?^PQ?C%F9E1N.%K#92[G9Z*^[
M%1<,COO?NLVNZ3P]G;P";_D.)V1DP!W'"=L38_S+3W9@_:I3^BW)9F])%K\1
MV=F>>.V>>)?8QP]P *_D";Q&.,]I@E<Y08*BA!8%7,1P@21/6YJGA'%4<3BQ
M]=P.3J^\83O'N3W*1W.YR;J=K9WRE5/R+=J/W]N.&UEA.#3WI[NF WJ!Y_L=
MX$P#= ,WM"/K'!AK@$[@19;]@_%,2;]5TK^HY%?UJ( (>$\8O)%U\!S!Z\H%
MB 29_U\*PIO7N0UUVM5N!"<!1(X5.9'=D:Z/\RW?B_R.<'U8$-FA9P\ZNO5Q
MWB#R;%^O6M"J%KQ*M8SS2N4BU#)H3[B$P+A@62*;*B]156:"ZR0*^A*%GMO1
MIP^R'6_@=>31HJR@(TX?-; B3R]-V$H3OBZAUF>G\S3!WM49I9,DU&2-':IW
MX4R5/LZWPT'8R899'Q9$SB!R.MD5:^BLT!L,]-)$K331VTO37%(Z<:(7BM/'
M:<7IP_3B:.ATXI@G]5E!V$85QAPBK4I1O[[M:%M[WZF2LS,^L6^GMF9\!K5Z
M75K_H*\+_7O,-EG)44[6L)1U$\(MP.KBN>X(NE/5X8H*J#55<PO?&X1) ,RO
M*17'CER@_8(9?P=02P,$%     @ AH1+6<.JDF!G P  7PX  !D   !X;"]W
M;W)K<VAE971S+W-H965T-3 N>&ULS5??;]HZ%/Y7K%QIVJ2[YB<!.D!J*=-V
M[RB(='</TQ[<< "KB9W93NG^^]E.2 E-<U<I#^4!;.><S^?[_!'YC/:,WXD=
M@$0/:4+%V-I)F9W;MHAWD&)QQC*@ZLF&\11+->5;6V0<\-HDI8GM.4YHIYA0
M:S(R:TL^&;%<)H3"DB.1IRGFORXA8?NQY5J'A179[J1>L">C#&\A ODU6W(U
MLRN4-4F!"L(HXK 96Q?N^=3U=8*)^(_ 7AR-D:9RR]B=GGQ>CRU'5P0)Q%)#
M8/5S#U-($HVDZOA9@EK5GCKQ>'Q _VC(*S*W6,"4)=_(6N[&UL!":]C@/)$K
MMO\$):&>QHM9(LPWVI>QCH7B7$B6ELFJ@I30XA<_E$(<)2B<Y@2O3/!.$X)G
M$OPRP2AG%Y496E=8XLF(LSWB.EJAZ8'1QF0K-H3J8XPD5T^)RI.3Z]D-^K*(
M(K2<K5#TZ6(U0XN/:+J8SQ?7*+I93/]%;Z] 8I((]!Y=D237LB,!<<Z))"#>
MJ66QPQS$R):J( UKQ^7FE\7FWC.;AVC.J-P)-*-K6-?S;46D8N,=V%QZK8#_
MY/0,^<[?R'.\H*&>Z9^G^RWE^)6XOL'SG\&[H)*L#Y)%E61H]A GN6*,-IRE
M:,K2+)?8N)IMT QS2NA6H"5P%&EET?<O"AA]EI"*'TTJ%U4$S57H%\&YR' ,
M8TO]TP7P>[ F;_YR0^=#DT0=@=4$"RK!@C;TNF#/NZH "0V(?D_=3UQG$#C#
M06]DWQ]S>1H8^($?>E58K<I>566OM<IOF'-,I4#?YY#> F\\DU:(EYY)1V U
MMF'%-GP5)@Z[%*PCL)I@_4JP?A<F[C>8.%2??G!BXJ>!GCL<NDZSB0=5E8/6
M*E<@)">Q5 <821;?H:^4_(^E6P%?>D(=@=6X#RONPU=AZ6&7@G4$5A/,=1ZO
M"4X7IBY1:F_<0<\_<713E._UPV9'NT=W&;>UR,+(BTP?6;N5VX%>>C1=H=5I
M>X^TO5=AY[*,KD3K"*TNVN/5S&V]R/RQH?VGK^EP&/0&IY9NB.N[[A-/VT=7
M]13XUG0P L4LI[*XYU:K59=T87J#D_5+W3V9%N 1IFB]YIAOB?)_ AL%Z9SU
MU>V!%]U,,9$L,PW!+9.JO3##G>H @>L ]7S#F#Q,] 953SGY#5!+ P04
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MK;:$.YZ3$'J67/,<V :L_J^_8-_YK0[\C90]"X-7A<$S:>\_KM,Y,$07B*N
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M;JZ 1,#4 /E]0:G8=Y2!ZH^/_G]02P,$%     @ AH1+6=M]_?QM P  PPH
M !D   !X;"]W;W)K<VAE971S+W-H965T-3(N>&ULK59M;^)&$/XK([=J[Z0$
M&YO7%"P!2=7TF@2%2^_#J1\6>X!5;"^WNX:+U!]_L[8QI#&&4^^+]\4S\SSS
M>'<\@ZV0SVJ%J.%K'"5J:*VT7E_9M@I6&#/5$&M,Z,U"R)AI6LJEK=8269@Y
MQ9'M.D['CAE/+'^0[4VE/Q"ICGB"4PDJC6,F7\88B>W0:EJ[C4>^7&FS8?N#
M-5OB#/73>BII99=10AYCHKA(0.)B:(V:5^.F9QPRB[\Y;M7!'$PJ<R&>S>(V
M'%J.8801!MJ$8#1L<()19"(1CR]%4*O$-(Z'\UWTW[/D*9DY4S@1T2<>ZM70
MZED0XH*ED7X4VS^P2*AMX@4B4MD3MH6M8T&0*BWBPID8Q#S)1_:U$.+ P7./
M.+B%@YOQSH$REM=,,W\@Q1:DL:9H9I*EFGD3.9Z8KS+3DMYR\M/^[./#Y .,
M1[.;:Y@\W$UO[F>CC[</]_#N&C7CD8)+>)P]Y>IQ_?+>K%%IR0.-(<RT")[A
M*>%:P3NR4^_A\QW&<Y3_#&Q-_ R*'11<QCD7]PB7#MR)1*\4W"0AAJ_];<JK
M3,[=)3=V:P/^F28-\)P+<!VW!3^##6K%)*IBJ$'P2OF\#,$[)I\)=#FF8Q'"
M1,1T5Q3+3MM(2I8LD<ZOAOD+'-I-V4NV/=HR&<+GOR@DW&J,5:5D.7ZK&M_<
MV2NU9@$.+;J4"N4&+?^7GYH=Y[>:[%IE=JVZZ/Y]:KXDB 4\JG2G'5UMI5D2
M\F1Y 6-<\B2A*?Q;*6J>0X[2R5!,F=CXS7:WU1_8FPIR[9)<NY;<I^S"D9YL
M@Y(*""Q)<0TATP@+QB5L6)0BK"F!E,[G:Z[[LU#%-P?N'?)U&EVWFF^GY-NI
MY4NWXU>5DR32=7)UWLCE5$-W2^CN^= 7L"V4NSQ/N9-RY>#MTWQ[)=_>&7PW
M5&9.*-5[H]2EUV][U>C]$KU_-OJ/%ZM?=;:.,&XZ^RKNG,&9?M(+Y*=$*T*]
M4JW3;QTYWLV#/TGS>SC\>.D*_%?:>8VCQ-T]<?=_EKF;;*Q7U7VC:JO7;AWA
MMO^_-&L+_/=7N9+J"2V]-UIV&_]5TC[H*V*4RZQ[4A"(--%YBU'NEAW:*.]+
M]N9Y>W?')%5?!1$NR)6J*94+F7=,^4*+==:ES(6FGB>;KJC+1&D,Z/U""+U;
M&("R;_6_ 5!+ P04    " "&A$M9;P(B(1 $  !"%0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970U,RYX;6S%6%USXC84_2L:M]/9G4EBRU] "LP ]K9IFPT3
MLNW#3A\4K( GMD4E =G^^DJRXV"C>,A6,WD!2[KW7%V=R\&ZPSVACVR-,0=/
M>5:PD;7F?'-IVVRYQCEB%V2#"['R0&B.N!C2E<TV%*-$.>69[3I.:.<H+:SQ
M4,W-Z7A(MCQ+"SRG@&WS'-%O4YR1_<B"UO/$;;I:<SEACX<;M,(+S+]LYE2,
M[!HE27-<L)04@.*'D36!ES'TI(.R^#/%>W;P#&0J]X0\RL%5,K(<N2.<X267
M$$A\[? ,9YE$$OOXIP*UZIC2\?#Y&?V32EXD<X\8GI'LKS3AZY'5MT""'] V
MX[=D_RNN$@HDWI)D3'V"?6G;&UA@N66<Y)6SV$&>%N4W>JH.XL!!X.@=W,K!
M;3OXKSAXE8-W:@2_<O!/C1!4#BIUN\Q='5R$.!H/*=D#*JT%FGQ0IZ^\Q7FE
MA2R4!:=B-15^?+RXNYG]#J:311R!V<WU//Z\F-Q=W7P&'R+,49HQ< X6:T2Q
MHB,!2Y*+&F5(LOQ1K'U91.##CQ^'-A>;D9#VL@H\+0.[KP3VP#4I^)J!N$AP
MHO&/NOW##G];'$)]$N[S24S=3L#?ML4%\)PSX#JNK]G/['1W3Y?._XL>?W?T
MQF%X=5EX"L][K2PDY>=31?D<?1/*P,&$4E2LL'P^ _&3+ .QBHH$S- FY2A+
M_\7)&9CD9"NLO_XA(,$5QSG[6U<=97Q?'U_*XR7;H"4>64+_&*8[;(U_^@&&
MSL\Z:DR"12;!8D-@#1+]FD2_"WU\1P0I0$C(\O'\^->K(Z7$"Q2>_(O9C7N.
MYP1#>W=XVL=6T M##S;-(HU9$,*V67QLYL(!#-W:K)%[4.<>=.:^$'\]:;%2
MY7F-Z"/F<E15+?AZC?-[3+6%V8G[UL(T"1:9!(L-@37("6MRPG=6E] DB2;!
M(I-@L2&P!HF]FL2>874I\<)#07##(W4YMNKUPWZ_)2['5K[3\[R6MF@B.N%@
MT--K2[_.O-^9^:TX2T27:U6=$=Z)M^V-JN%3Y*43^JV5:1(L,@D6&P)K\#.H
M^1F\L[P,3))H$BPR"18; FN0")V7FXEC6& JP,/?N^L$;8$YR2K26/D0.BV!
MT5B)=YQ KR_PX%(&.U/_!1>8BN1E?4X2<>U+&:=(7JE/TIAN]+?6IU&TR"A:
M; JMR9/[PI/[SDI3;< 4E2;1(J-HL2FT)I4O%U[8>17['K7QCFXN01#Z?EMN
M=&;]HQ<:C1F$T&W;Q3H[)PP"V-(<^Z GE&.Z4LTX)I(255?V >K9NN$W46VN
MUOP47LZ@9CZ2#4+5@WJ!+[N+XKZU2@L&,OP@0CD7/;%96C;LR@$G&]61NB><
MDUP]KC%*,)4&8OV!$/X\D 'JMNGX/U!+ P04    " "&A$M9>7G1G\H$  !/
M'   &0   'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6S%F6USXC80Q[^*QNVT
MR<Q=_ @D*7B&X-P<;9,PX7)]<=,7PE[ $]OB) %)/WTEV]@8'$UIU<D;L(WV
MO]+/VI46];>$/K,E $<O:9*Q@;'D?'5MFBQ<0HK9!5E!)GZ9$YIB+F[IPF0K
M"CC*C=+$="RK:Z8XS@R_GS^;4+]/UCR),YA0Q-9IBNGK#21D.S!L8_?@,5XL
MN7Q@^OT57L 4^--J0L6=6:E$<0H9BTF&*,P'QM"^#IS<(&_Q-88MV[M&<B@S
M0I[ES3@:&);L$200<BF!Q=<&1I D4DGTXWLI:E0^I>'^]4[]4SYX,9@99C B
MR1]QQ)<#X]) $<SQ.N&/9/L9R@%UI%Y($I9_HFW1MG=EH'#-.$E+8]&#-,Z*
M;_Q2@M@S$#KM!DYIX!P:>&\8N*6!^T\-O-+ R\D40\DY!)ACOT_)%E'96JC)
MBQQF;BV&'V?RO4\Y%;_&PH[[TR\/H]_0S7!Z&Z#1P]WD]GXZ_#)^N$=G 7 <
M)PS=8TJQ?#GGZ"-ZF@;H[,?SOLF%;ZE@AJ6?F\*/\X:?+KHC&5\R=)M%$#7M
M3='GJN/.KN,WCE+PUW5V@5SK W(LQVOISTAM'D HS.W<W&TQ#]3FPQ6]0$YA
M[BA&XU:OP<WUW+=>PQ)3^'@C)G"$1B054<UP'A=# 3];@(@TCF:O:+_=!+_F
MCX=;3"/T[7<AB<8<4O9GV^LI_'OM_F5VN68K',+ $.F# =V X?_T@]VU?FEC
MJU,LT"36X.Y5W#V5NO^PDI096@C*_'!>%N *@6XN(+/HQK?ZYF:?AM+%J30T
MB35H="H:'26-<<9I+%)ZB#8X60,B)1UX 1K&K)U/(=E1\%$Z/96/)K$&GV[%
MIZOD<R\"\BLP,5'0E)/P&>VFS[<[2&= 6P-/*7EJX.D4"S2)-5#V*I2]=TYX
M/9W<=8H%FL0:W"\K[I?**?R440C)(HO_$D##?? A8;R-X^51?#NVXW6\@R!7
MNCV5D":Q!J&KBM#5?R#T06QVY78ZSA:( TW;B*GU[0Y*\ZU0VSQ3FIY*49-8
M@Z)MU1M+2SG.1Y$H:1S6R?(IBSE#9X_3)W:NS)AJX5-#5ZM:H$NM"75OMVZ_
M<]HL.Z +ODZU0)=:$[Y3PW<TY\Y2L)$\>V[G('6JW9X,29-:$U)=R-C*_;HO
MPOMGY7ZZM%=MJ-4N3@;R?Q08=EUAV.H2HPC%61Z*C4D#+_(:6AEY1_/&LWJN
M>\A):^6A2ZW)J:X];'7Q\3!+X@66RP4G*&9,U!],HD-D+KF)-1,QN8ZT\NH<
MS:E>Q[TZQ*6U$-&EUL15ER*VNA;9E1Z?(8G4JZG6 D2K6J!+K<FPKD'L]RY"
M;*U5B%:U0)=:$WY=B-CJ2N1?_=E@'U<C1XN'UDI$EUH34EV+V.IB81@FF,H9
M>?M]'?-7-,Y",?GB#:!)@K/\WT=U\.LL*$9:U0)=:LV_C^OZQ+'>.?@=K76,
M5K5 EUH3?EW'.,JMNG^_EE-V?VF7E%FQ[K=&OEKP9)CVT8;![GB>TVTFDZ"M
MG=.QK#KI% #,O1.8%.@B/\EB8G#KC!>',=73ZK1LF)\1F77SXJCM#M.%R(LH
M@;DPM2YZ(MG1XO2JN.%DE9_GS CG),TOEX CH+*!^'U."-_=2 ?5&:+_-U!+
M P04    " "&A$M9F5'XVBL#  !.$@  #0   'AL+W-T>6QE<RYX;6S=6%U/
MVS 4_2N1&1-($VF;$9K15MHJ(4W:)B1XV!MR&Z>UY-B9X[*67X^OG:8?^"+&
MPU:6JL2^Q^?<8_L&1QW49B78S9PQ$RU+(>LAF1M3?8KC>CIG):W/5,6D10JE
M2VIL5\_BNM*,YC602A'W.ITT+BF79#20B_*J-'4T50MIAN2\#47^]C4?DF[Z
MD41>;JQR-B1W)^]_+92Y?!?Y^]&'HZ/.W>GE?OS$ :<D#HJ>OT#TK ,7*NUA
M+$'ZL@3/J6/2%[O2;OBQ%?+$8XS6#]!LE@T3.HX<-QLS&A1*;O8G(3Y@U6G)
MHGLJAF1,!9]H#JR"EERL?+@'@:D22D?&%H9-UX5(_>#AKN]!S30Z)9=*N]P^
M@_\[:8;O >L>&.1"M 9[Q =&@XH:P[2\LATWV 6?0%'3OEU5UN%,TU6W=TXV
M!'>S229*YTRW:;ID'1H-!"O CN:S.=R-JF( C5&E;>2<SI2DSL.:T32L[)0)
M<0,/U,]B1WM9;.U;!W9-MDUKJ&EZ&=\!_6TUK[TM^SK=J.+WRGQ9V.E(UX<"
M9=>:%7SI^LNB-8"I=W%U6E5B]5GPF2R9G_R+$XX&=,V+YDKS!YL-2F5J TR3
MZ)YIPZ?;D=^:5K=L:=;EM"QPS[TWZ/GOKO.,2::IV#9M:_^05_G5CIL3Z%]X
M=O]6]AT'3287A^^Q.74/W63Z%DR^B>WN'Z3)N#D;MP[@G>.WC4;PFC,D/^"E
M26R21I,%%X;+IC?G><[DDU/8RALZL2_+._IV?,X*NA#FM@6'9-/^SG*^*+-V
MU#4L1#-JT_X&T^NF[3N6S<5ESI8L'S==/9NX9F0;-FMS 6$?N7)7&,$X'@LC
M@&%Y, <8Q[.P//_3?/KH?#R&>>L'D3[*Z:,<SPHA8_?!\H0YF;W",\VR)$E3
M;$7'XZ"#,;9N:0K?L!KF#1A8'LCT9VN-[S9>(<_7 ;:GSU4(-E.\$K&9XFL-
M2'C=@)%EX=W&\@ #VP6L=B!_. _45)B3)+"KF#?L"<:1+,,0J,5PC:8ILCHI
M?,+[@STE29)E802PL(,DP1!X&G$$<P >,"1)W#FX=Q[%ZW,JWOR"-'H$4$L#
M!!0    ( (:$2UF7BKL<P    !,"   +    7W)E;',O+G)E;'.=DKENPS ,
M0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BD
MMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G
M<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^
M=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"
MR0_L?@!02P,$%     @ AH1+6=F5_H-Y!   *20   \   !X;"]W;W)K8F]O
M:RYX;6S%FEUOHS@40/^*E9?M/NPF?'5FJLE(E#@MVL1D,8G4IY&;.(TU!")#
MVMWY]6O(IFMKVJM]N9.G@$'D<(WOL2]\?JGUM\>Z_D;^VI=5,Q[LVO9P,QPV
MZYW<B^;W^B K<V1;Z[UHS:Y^&C8'+<6FV4G9[LNA/QI=#_="58,OG\_76NBA
MO5.W<MVJNC*-7<-*R9?FO^/=+GE6C7I4I6K_'@_Z[5(.R%Y5:J^^R\UX,!J0
M9E>_W-=:?:^K5I1\K>NR' ^\TX&5U*U:_]#,.\A"/#9]2RL><V% QH/KD;G@
M5NFF[<_HKR\,X[,T)Y_VCFT]564K]42T\D[7QX.JGKK+F+L86K?1Q^'\>PKB
MC?X_8:RW6[66DWI]W,NJ/<51R[(#K)J=.C0#4HF]' ^2^EGJ[G[,'Z2;T[VU
M!LJ*E+Y1YH!.-ST>)DJUD54C-^16E*):2]+'K['H?(#.OPP=N5H(+2L+,@ @
M@Y\%R3N"[NR&U%N2':0V9UN0(0 97@8RV8GJ2=K='0&0T84@1;,CT]*"O 8@
MKW$ABWM*DFR^B-D#B=F$W,8\Y22;DD5..646Y < \@,N)%_.YW'^T&'Q](ZE
MTS2)64'B),F6K$@MR(\ Y$=<R&F<YF05SY:4S&G,ESF=4U9P"^X3 /<)%RZG
M";4BQNY,_V;,;"<]I9V]1U#Z'F%CKBA;4AL'M FR3OARL9CU 8IG9)JRF"6I
MV4K9-,OGL1,U2"L>LE=FYG&C]H/F0?[PD 62FFBQN_1V1DG,.75&@ <YPT.6
M!K_/\H(4-)\3EA64]_DNR=B*YH7!M3$A:WC8VLCF\[3H<\>9L!NPU#Q[;B=#
MUO"0M<&++/GC/IM-:,Z_$OKG,BT>;#9(%AZR+1@MR"SCG"QH3OA]G--.'%U8
M,T:X,VHA77C(ONA#V/F63GH#4\;C(LULY7J0,3QD9?#E+3<=VVFCR\K../8A
M2?C(D@!G U]]&Q.2AX\L#W!FY6*":Q)D>;PS;2%79J59.E-I'[**CVP54,5N
M-"''^,B.^4%^YSC^:A-">O&1]0):T TD)!C_ H)Y,Y:0:?Q+FL:-)60:_T*F
M^3>>-B8D'!]9.'#"#.SR"*2? %D_,&9H8T+Z"2ZJG\C&A/03(.L'EKG3Z6!1
M#%D_[UIR(ENA[%I. .DG0-8/B.DDI !R4(#L(!C3Z73(00&V@\ YAX,)62A
MKXY!F$Y"@BP48%L(Q'02$F2A -E"IV+*>6 WA G=U;V?I3WK""$!A<@">F..
M>8;]C:3V:X00$E"(+" 0<WJT,2$!A<@" C"[KK<Q(0&%V.L?<-INYZ(0?"]S
MR1J;DXM"2$#A)6MLY,K&A 04_L1%T"^OBZ#7461C0@(*L07TYEKM=139F)"
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M_K+\/CEZ>R\X!_B3X/$+4$L#!!0    ( (:$2UDA7:<FS0$  "0@   3
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M4$L! A0#%     @ AH1+65'H-L6, @  ) <  !@              ("!&Q(
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( (:$2UF@H8&?
MT 8   H@   8              " @=T4  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " "&A$M9(2FL=00.  #AC@  &
M@('C&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ AH1+
M637]!)_@!P  8",  !@              ("!'2H  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( (:$2UGOG>G$X0\  )(K   8
M      " @3,R  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" "&A$M94(/&?/P-  #/(@  &               @(%*0@  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ AH1+6627!SVY!0  ?0T  !@
M             ("!?%   'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( (:$2UFJX@B0B0(  *L%   9              " @6M6  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ AH1+64C>2ED9 P
M^P8  !D              ("!*UD  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " "&A$M9M!JZZPT$  #_"   &0              @(%[
M7   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( (:$2UDT
M%7SM_@$  )<$   9              " @;]@  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ AH1+62Z^@>O4 P  <P@  !D
M     ("!]&(  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (:$2UF%AEB_AP@   <5   9              "
M@0F!  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ AH1+
M69P--QKA!   (0P  !D              ("!QXD  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " "&A$M9--,6*-4.  !(*0  &0
M        @('?C@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( (:$2UG!3H9G<@,  /((   9              " @>N=  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ AH1+60#2:$ -!   -PH
M !D              ("!E*$  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " "&A$M9 8;:P1T$  #>"0  &0              @('8I0
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( (:$2UDYJI^"
M @,  !D'   9              " @2RJ  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ AH1+6:=#TC'R @  ,P8  !D
M ("!9:T  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "&
MA$M9V!J7X[X#  !%"   &0              @(&.L   >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( (:$2UG#;;XTQ0,   H*   9
M          " @8.T  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#
M%     @ AH1+63,_2 LJ!   5 H  !D              ("!?[@  'AL+W=O
M<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "&A$M94N>6-L4#  ""
M$@  &0              @('@O   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM
M;%!+ 0(4 Q0    ( (:$2UDF*\\OBP0  !$>   9              " @=S
M  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ AH1+613N
M3>A4 @  < 4  !D              ("!GL4  'AL+W=O<FMS:&5E=',O<VAE
M970S,BYX;6Q02P$"% ,4    " "&A$M9("54R1P$  !'%0  &0
M    @($IR   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M (:$2UFE?3CE+ 0  - <   9              " @7S,  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ AH1+6?P]1V>Z P  .@X  !D
M             ("!W]   'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " "&A$M98)!*IKH#   (#P  &0              @('0U   >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( (:$2UE=_N"HN ,
M *81   9              " @<'8  !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ AH1+6<FSP]F! @  8 <  !D              ("!
ML-P  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "&A$M9
M.X#(7I,#   Y$   &0              @(%HWP  >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( (:$2UF4%O1H- (  )0%   9
M      " @3+C  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ AH1+698$O"D@ P  T@L  !D              ("!G>4  'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " "&A$M9AC+M!G8"  !:!@
M&0              @('TZ   >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    ( (:$2UF^#BZ/L0(  -\'   9              " @:'K  !X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ AH1+623H*>;W
M @  0P@  !D              ("!B>X  'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    " "&A$M9HF0)E)L+  "BFP  &0
M@(&W\0  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( (:$
M2UEBVB$_^P(  &X)   9              " @8G]  !X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ AH1+65H-\&2"!@  72,  !D
M         ("!NP ! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
M    " "&A$M9^B39A7,'  ">3P  &0              @(%T!P$ >&PO=V]R
M:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( (:$2UDO+T[WSP,  ,T,
M   9              " @1X/ 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL
M4$L! A0#%     @ AH1+6<.JDF!G P  7PX  !D              ("!)!,!
M 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " "&A$M9XQ)
M8/ #   $$0  &0              @('"%@$ >&PO=V]R:W-H965T<R]S:&5E
M=#4Q+GAM;%!+ 0(4 Q0    ( (:$2UG;??W\;0,  ,,*   9
M  " @>D: 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @
MAH1+66\"(B$0!   0A4  !D              ("!C1X! 'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6Q02P$"% ,4    " "&A$M9>7G1G\H$  !/'   &0
M            @('4(@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4
M Q0    ( (:$2UF94?C:*P,  $X2   -              "  =4G 0!X;"]S
M='EL97,N>&UL4$L! A0#%     @ AH1+69>*NQS     $P(   L
M     ( !*RL! %]R96QS+RYR96QS4$L! A0#%     @ AH1+6=F5_H-Y!
M*20   \              ( !%"P! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( (:$2UD/E%1(V@$  %D@   :              "  ;HP 0!X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( (:$2UDA7:<FS0$  "0@
M   3              "  <PR 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0   ^ #X Z1   ,HT 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>72
<FILENAME>0001683168-24-007103-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-24-007103-xbrl.zip
M4$L#!!0    ( (6$2UEHFN4.20(  .L%   3    86-L87)I;VY?97@R,S Q
M+FAT;;5436_;, R]!\A_('K(R8N;M(>A\0+DPVD-I$D0NQAZ9&PZT69+GB2C
MR;\?9;?!T*W#@+4&K ^*U'OB(QC<)??+<;<3W(63.<_@OB")DF4X#OQVYE/_
M^3B8KN>/$">/R_#+1:ZDO8'!964A$2496-$3;%6)TFL-'L2D17[!@1RZ>8DK
M4>^%O('+BW$P'8?'@]@)"\.K_B#PIXRZ>=N_)W>F&OWN\J]41G"^; 26CO83
M%F+/VY2D)=T0FJU7<;A*8+V :#4/-R$/O-V&MU&<A-MP#IN'Z3*:P60V6S^L
MDFAUV^TLHNW]G]G_-[5OM;$B/SENVT:+=T!@U[=0OA*D2AK.!U@%]D!0&P(A
M>2D,;&DOC-5HA9(06[14LF>WP[N%TB7$GP;^9 @JATE:H&8O#R*9]IU%U1HT
M54I;R#@P@P7M=(WZ!,-+C__A-:#,X!YU>H#AY];DP9.P!XXS%:5G2KF0*%.!
M!9@7#H8ANIU7J.BL,*>4RAUIN!HTEUYY#5"N='/9B;!92""94=:'-1/%.N.B
M?*8K9%K4&6<6V>=8%2C1*N9=H<:]QLKQ*S@G<N\(GCET.XY$3YL?M1IQ\$X4
MPIZ<"V>8O6MR!!'VRD6R+24M^Q\M<%M&+#,61KW66E-.FIB(,SC!<L&JUIR7
M-E<I5HWT/7Z2'87'BK0U[<;5B*E9NHU6C5BUZ3^7["^C;WRXPY,4!#TLJQ',
M5%FA/'WTJ]^Q<_P%)<;"PA*_$\Q8:0\>+!X^&G.=6N6*>] 6]_49SW?-NNW>
MKLG_!%!+ P04    " "%A$M9*2*(,_,"  !/"   $P   &%C;&%R:6]N7V5X
M,C,P,BYH=&W-5MU/VS 0?Z_4_^'$ ]JDT$**8*(=4FE3R!32J F:>'2=2^LM
ML3/;X6-__<X)L"\F38@'\I#8]^7?_>XN\N0BNXQ.^[W)13"=TQ?<,\G"+ I.
M)\/N2]KA@WIRMIQ?0YI=1\''G4))>P('^[6%3%1H(,9;6*F*2:\3>)"B%L4.
M.9)K\NA7,;T1\@3V=TXG9Z?!W5:LA05_-/ GPS,Z-?FW_:Y<FWK\M\G_0AG#
M4[ Q6+RS>ZP4&]IRE!9U"VBVC-,@SF"Y@#">!TE +]JN@O,PS8)5,(?DZBP*
M9S"=S997<1;&Y_W>(EQ=/H_^!=!>-<^=9S#]FOF7QEA1W(_A!;')E.)_1N!*
M&F(0K *[11"2EXT12M**!,) HHS="XH"N14W"-,*95XYCU@-P._WR'&%&V&L
M9M;YI999; UHLU"Z@G3O -XYZ]%HM.<?'QT=?G@/3.:@L23;'!*M3$WQ&P*J
M"E"-)E6MM(6\U7]J),*![X&_[X\\P#N.A+]0FC!8TK2*PWYOA3>H#1($Q;]"
M6I?">IW),3%PE211<$D-,8U@$<;3>!;2*HP7R]7E- N7L4= L&8B-RTZ17QH
MX(W6+AEF#-I.,>5<-P3KIU$IV%K0:8*H[O><O -V2,>CA4@9XI'LTBW3Z%*<
MJ:IJN2*@'L5V]-]N!=^V17!9 U&_P+5NF+X'_R%%#VZ%W1(Y+5V/-:.M;7DJ
MA&22"U:">2R"Z??HN"DOF:;B>!!*/G#GD7".'*LUH1IUT?TV(<>J"WJ/K%U(
MH'IC/H E584U.<W[0VW:5LG1<4(EJ4LFF54$MF::;32KMUU]A=P0T'[O=PR[
MVGQKU)B<6^+N72[4BF3=H,/'8*.<)\DX:CEXE8'JFOX5)_1IBEAIU)^CI+%
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M<W>?L+F[2]C<^@O9W$<+E,5MKN29#>8[T]0?K&37LZT4UVCU9I_+;UR8R?W
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MUT$*+BD.5$G!=9:"2R:"2@JNAQ1<4@"P8O2K9_1+<_)7C'Y]&?W2B:!B].O
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M9J^2=2'=/)9U(84M5-!EC2_JAL^J(N:*F!\BYL?+X?JB^PVAVT[_ZT 1Z_<
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MZ_F4.=G&@E7J\W!\W_535[BX#]CW)4VH0<1Y[]B) B^XCB]$U+YQ(O%E6#[
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M7=HH8ZAY<+<5$3 P'C(FI&KEDLG5]430'<*-3Q+T])(^=:5WRB)'B]HGT\7
MW^OC58J_TC6)?/H#W\O"G]DO"#WCM?>&%XP=IOIIW^YXKJ3S2/R9>I&NBG,2
MRQ=XV'^K;X/EJBDW9[5\@5]?T*\OLU]GU >L[+7GO<D-#<*4]@-F+L?/['I/
M7B_F^K&<M86_3H:Y%[=''[./^;&2F3QC\@$6U83S\>UWTB]BW1FTY-BH6B1@
MIL+Q$[-"2I+W3::VL#QRN Y")@7131M#,?A8Z;F"9D6U#O",%UCR)=^\F-Y
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M%91'MPBPK(5NS+_"%&RM,/7Q$CIN,9X&\B"\%IST"X=IC4D(R,*4&7?!'L1
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MMR/\MGUR='QI?SG^>GYY;$_8@OGF>\Z[5\;DDU4)]=/Q2"L@Z"]9EV5ZV[*
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ME-^)R(?O8(9&QAW4#WZ*80X1E!^/=2TAP\JHU!O@J]@X!(O\(HTME,U#I^[
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MQ#"2:@;VM6AR4@M5KW(';WJ&QL>?RGW@U%ASN2#7C'HW[4?%WW!]-:_85OO
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MPZ%J_?_9>]/FQI'L;/0[?@5B[CA>500D:ZW%/9X(E;K:UDQ75[E4[7Y]O]P
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MJ\RY>+BYI,[WM)FV=P@M -(K$ US$V'[AI9U.O^&O5JO/Q(I\)WXK#M1QO;
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MR$VE/&N$^Q;-4H2<FW&+W$EI7-M%6+A%8%(94E04I?&8$9"[+2O;&C0(TCW
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M-L3PE; $N8K]" 2EPCZ?DUL@.=,Z<Q2-804IU%Y:,V\#C3]$G7G%#SFOR 5
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M[PSK0Q#F5YFT$9>.)1I.=44<7RS:>-6T\Q$V7H8'\K1 %)>^U47-F]HQM@/
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M&%.L)R&EE)=C,I1!1[W=>[L7'U=8&Q9_SM.Q@6UI89TPE)/$[ZNRG$\Q3I"
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M?,\\;'(4QCI7?NH^64#DH>^^TT3<.WB=[.T?Z!/6?M:WR89$$ N0:6L)8$7
ME&_8#4L[^3H!%9$5U-$YWDJV(@*'Q>($N<P^Y[#3]WHY/21WM3_HP4%R<'"X
M[LS?YH+O[[^ !=\[ %WZ[F#=FB*<L+H0RUBP:[1>$L-9O6+/:ZD&\Q:8"8#K
MZ.#JF.IJT:2G7_4_&=(78:]R:?]0:YKMA7DIMFW"*97GM1='R>NW1V $O/LC
MRB!<S3.S:+A@"Y>32=W=$CZOY;OB!CR"Y=U;&6*]V;(&?M9SU:+KU_/H:"]Y
MNW=T$XO"+;IPX][L<A-^ O!L%E@2.'&2/.RT//<=  W]=O]HE4 '%QPM,B;0
M!Q<Y+8)U1MFF"_ 2?$*ND.8R[E2+G#UZ?MZ"^PTK/,3M>+O.(K6Z^49@;A#G
M@^3=F\/DZ.W>BKV,7+.UD>7_H9WD,EZ-!O25/S:*B]\C/;1E _I,Y2P8TF6K
M1E@)M".*-R)W@8!Q_[R[LW]PF$3DUSVW+0ZW8N@*#@7^N[9"XKJT'2>WL!U[
M;X[>)<S<^;QV0P+XKW?>6GZ/R[+"7KO3@62^; ,E1:5&0DQYK@ *$_P8;.?$
M?<8UZO3?;MK_PS];K,+_&;MV#:97'RPN]M*#;X_C#=9A!0\W6,$'P J^V6 %
M'^-!^F/ OR,+_/MR>O;W^*?CDZ^?OIR]-"X96!8_;;1S9U79]UK1]Y?L)DFV
MJ)MD^Y^UR2["X6%79<J#N#I3'-FEZT<F+R\3T&GGW%#-8MPX@3]<'-ZO_DXT
MMS9/J2HTI21;+9UB5B?9L)=[X:A5+94JLIUAXQ;LU9:L:JH<A>W[I&<?<51R
M8:F815Y5J6N+QFW3S81*A<F(HF=R;\&F2M73=AW9O9V1;NP&.VN:A(AJ,//(
MO\ZQ9I4@)I5EK5ER"3<N UE/Q*/#NR-X2&:S=,23WV8IB@GXF3 ,9;%J@D-^
MHGVII9QY(#\:X5O+H#X,4E.D?A.[[G)T5GJXE2>^K:,E\^J<"?8BY= H(RG6
M:C./DVE<__ J7603E%0$3=)F%Q=951:\,'B@J A:YTO49<9!3M5@Y?Q>UBA%
MT**L:_(DT,]W1?X1LZ]-,G@[W!3* /H/2.#;%3$6P5C<LX7+B>=@3M#F#7X-
M,Y7^:C'WD6%B2S*B>:%1O/DK2512"'.4<?^^H*J;Z.*H*AI^PX1_G>+H>+@X
MVB=@XH=)@78N!=J.-PZT9O8<M";?!<06P.==09"EA>P]E]NA+]V>.%.3(986
M3KA'+N&N'9D)W[T6*27NWC#J*U&QEN<P [6%;;&0XM<\B:1^J\]$ULX<4X-R
M2A)1G:A"\;5U52,/?P:ZJ=='Q['4YNFEX[@@:'0&-[+1UFK8211;0\'.$RO<
MVCVBIO/(A4'*D9G6RK8AWF30&'.]70><^)@%#+S^# GI""N'5V$'\[C^\6H-
MN-R4=,O%<$1$+:Y2Y?9E)EZ/ZMMB-:1#*;(ZR/78 Y&@J$EXJH?&7#]%.@#1
M8,&!,D;8@'#OL;!-)A<AT'*)[\!(\DOQ.8KZ )FAL X: Q336?]V>'?PBWA4
M,-Y[#%*'*"%/%-@XP1P\0EDZT\J/CC30 \I K"V?&W9GCP^IA+ 2+VJHUVNK
M6>?(=J?=B=\;O@N%I7U,="J\5#A3ZE#//UUC>4@<IWF+DV[,JK=*V)2(4-E*
MT!$3+"O4;F__&)SJ"?YZQ2G,.6DFK"9PBQ=LTI&JB#Q-FB#7,'8TN//;1A7J
M72MNZ_:P.0I+T2YU'7O*)&TB1^S>T,-IF?/L=\J H>S;OY.L/)>[)URCA2J4
M%:F1@86+;[IP;%+7)1U01$]7&460W.=R<))R>O@DRUOK>MD/1'#QP+1T(TWF
M>SUJTY++U9%X.BM>C/HKTL*G8^9O4F.&;DMW4R8^D9+06$\,]HU+T.J_0/"$
M$$U3I9'_DGR ZS4:6#6+F]1.?,:,RL@ ;8OG_)JJ_IJ3;QC\6F0T=MO;6>U4
M'4LU+RPUMU>. /]<.IGHPN?[5W34$0X,*D@+<UP"4H0>91@\61((C=N(;AXA
MU9<!E_?21_O+;WF.:78K'34>C>HB!EQ-(_>N[> FB@8N:K[80' Q)8;EA>XD
MP9?Q.C3?I T\;35_5:36+^$(Y&XL;7C7EHY$/OF6NUI7E(.($#X392I=#;3Z
MDEP6ZBJAM3QKEFUU:6VWF'2MB>:9K_;@@C</6@P4)IH+!9(T=ZN.0BUOS4+Z
MC&B_@9(26\BV<D:SU!,;-;#7F*]D'ZG2BU;,N[3W$^A*TBGK33-6-M<H.!XL
MLXJX^HF4&"BL56>*N>&PY+:66!:%T.1@#=<%:UN<-*],.EEJ@GMU@6HT=/Y7
MNP?KDZMTUF?IA-HA:"7TVJ)JE>LZ<D7BZZ7:M=F2#7OZ9_RKIQW30!SZYGH9
MW<"CI2B(=9(E=,?ZERUT5JQS;'2#IX2*3#)D=$?11#W#.7BR%PQO/49UZ5_;
M%,8RDRB(_/LY?#SR4F'/QD0JFML6\E-[7<?N.C%U5ID57O20NG>J*?(]ZVO)
MT>#1O*YO/80^I(##NNVY6E_LQ#_2PZ68Z"HB3;$=K0,:KA$?;4X,^!>_%:6K
M?'-WX0[F%59?O$_]0#Z79UP#\7"T03P\ .+A[0;Q\+0.4F8;#HZJ,IWX86^Y
M\]I:;>"H,(V+F'F%W[UJ]FMI8F:R7E(V1?3QW%E7^?(>'!T$=X2^ZEWGJ;@+
MC*4V=U&4%<NOG?34R/$I$@:W8%7:B&.6_B5+9;LNUZ\E]R%_->TJAX4BF'#6
M(.^.%A+[X$MZ6[@II2?/O[$9@O?F*L*)Q.>\QFR])6BP29AR@2VPV@)- '"/
M5B3O VB#)(PO9P2?B,IPO3/L@>C:C<HZ$M(63  RN%RP6Q9&;"2<)5HMV@W)
M*W)VL>:)P00/.A'XX-;6:$0KB15Z&\5!.C4 :0P\)10\\TQHEW3&C[L .3I6
MU,<1OL@&YS0%WXN0I]W5P.7B'HOD=TQARVK_!(H9[3PZAS+(2UQG?G/^%+MG
M-BFN4 89KYN=IS#<#0,?\6>Q(&6):F,I-P30$NSJU3$X!.M4S39N61(Y>=H^
M!ZO0)-9'A7LEI0"%#Y3Y2DOFOE1;7;;$&P)68II>P&% 2P%.=%O9<)(?17H&
M-F68_>?D)+ZFL$_D'#N[5<VZ&I5V)X''=8^[EPCG;PZ&Y!_T;CZ;7#10/MF\
MG<>C;"*GRFNTR'>N?(+.E\@AJN*]-S^H+^Q_1;3@,)D(^;^4':^E4R$!KC C
M3[/I>7#BNL$M5%&726Q<>U$B;(24*L59,EOCJKH6.TMB:L[ROMS+LM]7#%LM
M,+G+$<<VS<:8>UB"8=]@%(F5&>B<2/:!:S)D%W[^^23>DDN9_RY7ZRL;D5#Y
MZ4M-[+X!$E!C^U3-$7<D*>J(18KI)VEVOKOK982W<.ME/N_AVY])#K^X;]OI
M45-Q[*SJ#PV[S9>)C!_]V5'R9<4ZN?4??#;P,8GR#<SD&2CB3X5TL'^K&(Y+
M3Z;2&(OFP#80#$LTO$F_T!_M_I#8B<A)BZ*@J?")]E=-ZU7BA1\;%(*H-A2+
M:["[C3[D9U$D7UJX-X^.CG:WTE?8=7Y*4#UN-#O12R66*-:@;F+CI_MF8&%/
MA 1,C!IN9SZ?FTE&: 2KRT3QG;B^RG0^ NO$VAC#4[B7*,BMP[[O&E;.@6'9
M#]OX*NH+E: WP**[R-"DW7N["S= ;K!?>#Q)EZ"L,)1+$"8EFWG#PO_*M02B
MML3G:2":E%!PHM#Y:T2"VQ7!A>-W)"JSK J\,B$G[4U2D5;PR<X<J6^I_F[H
MT$9=\0+C?SKM:#GXC3VN_A&?JM=(Z]K!2Q-2Q^7JG="O$.CH]@3Z@43NN!DZ
MS1&&Q[F9<_^VF!NC6L9C*SC0C1I2#OXP[%:R[D7_LJQ3@JH1F8?GZ8-C%Z5M
M ZZ(F#KD)Y5I-6%8!T@#>YDEM38G*EGVDS J2-M,KI/K#B>N,$.;3<C#LH:_
MH6C**"6X&"(=;6:@_W5.OZ@(8B=T=/0$I0%GJ'&N/>9&:NG4'=/4Z%8@,'J%
M'+WTA,)L@X+?GF(D8VN/_GWT*J*.6_/T&UDAE$)R'YSB;2^?W'TE3W47COF&
M6#9^'D.[K&=..?D52YP59)#69>[#6GZ(K)DBSBSG]/JO35&6AI/(\IJ8BJ7V
M[C[EKOBI+!)X=UI1@;GY,L27F$A9Q+X]24*&'>39I!^:B89N"GRR9*UP,A6E
MABA* @?>K=? );?&1HP&[_,GK!S0=&K/X2?DA8YZQ]NWHM@@7VL8P?)?80]=
MSS;=B4Y9'O_9IA4\-%]*3WB_M?Q_D6E$ L7W#$=__M:"W!WL#N@J&0-!!JL-
M:2SFWDM>'^XG>V_>4#U-XD.4$GMW8DOY>KH<L-M&K[;V7B$T%;02Z@[$:/&[
MXQV&R73O2-H[J*^6O)7>B3J^BFR&-1"PMR)9 [J;[W@!V ;X9XLQHK3 TV;2
MW,(T=!ZD.)^P%%N,!+T>F ^CDNO3.;PW3]F5U"1M6IB<]<M,XENZ1*#NES7%
MANL6E'?!W &59R8P_BQ>N( <M1O%FBAG$<FP'/NL:PN8"FVG#CD\E>LPK0#+
MLW*%2=*;INT5IGD/XJU[RB[<TW="'TGV]_4F^_L V=]WF^SOK0KY4VLPOO)U
M[O"QO,.[ SM,O[OA9-;26DG>\NY5W'?.\ <T 2*!*8J-HU>[%WW8$ZM0*\3=
MK<KY0/P:>2KVMM>J-Y=10QMN!Z'G.7]?OJ8W?59'8AHD HQU9L34@JZ&G%!;
ML0,F"-:"?QK\@$8"R9;!9!V^GUCC;  .V1]LH1#WL%@B_-J$<:N]"*GFDQUY
MV).1417.6YGW=\HHIBG4V?!<U@;1F"EU?=#^Y/$<_MD28-[V;Q\*UWE W8$X
M<2W-Y^=<#5HW7'&G/H/G06/^WV70#-9QL-^&7I:;@M+4#D[EADZ<RMH=^<RW
M*EH/J]D>YK&G@TRFHOS8[6!!2OJ?DP)+^.BY)3KX9ULVXML4Q%\(UMLV[#\\
MMD73*G(?J)?PA#DZ5I+'6&3%[W$],P9+LGY=E(7X8$B1KLIX8!J7E'0=&:SS
M\J.Z'*4Z;_/4HZ8 N?UP$H65^EIZ2B\ BKJ0(!26+?@_<VGR4H,$$D]FU .I
M8:UT3;73EXLX&^G)Q2$2*G:(Y*D6_.%5JAX%&46AY_#>Q2O=QDI0;\Y2$P'+
M[M%H>._H4M+XMHC-"1:3Z\1M%IMO-P?Y\<$;%D'>!XK#;TI, "SEJ51A1QN9
MQN.T)JX, 8\0.<8RFF9,GM'!JA/;1(W ++HN8<(C*GI/D8@%0XE6G(A1/]Q.
M6Z?6%1E;O%09(MH887(8@X(P)N8_;,I@\&X.Y-U>YCW1A\7/0>!1&"Z,W7_B
MY>#YW2WZY;'JN1_#7 LKEV@-_4L/!.%SR# @B^(@Q#-@>:DK9:656D*LT@Z.
M;88OQ*JCAJE3(@&OQ<@[,I[@9[8ZTME<G9P2B!2/5\"E*0@R;S"61OS4"ER_
MUOK8%=)5R6M!!'"AD ZOY:O=.OI%B8POBE+CDH9BFDW(&05];N N+Y<&WY\P
M*O*AK("'-JVLK#V<B@*C),#48%VEI9B98/5MN6! A,4J9G=<O/-8)?N6'CL,
M*;/0P\11'^$/*#I(&(R(0P(4%RW",HE3()*0YUW#>A_MAMP]/FW]T_'63N%@
M,C\3(V&[7",'M&_4S<#!2QU'$A]\\PV9GI&;(2@J+-M1@PW.VIZFM!XB92W.
M2P:G(>=:D7BLQ<-8,[ECIVU%^L8JV3N'G5U+D.X0FGZMU@CZOP5"OZ0IFP+S
M/.A:,IA?XK\WXK&A+X;?%C0Q78B.V.Q&LQ'JCC\N'M0?U26ZRANN"@J4EMEY
MK67E6@:S#=T NOVS:NZXYK"P]-LB3\%:*BLLTJ_2\RI=S#0ES4F[&\U$$->#
MATISAI29YHQA[UQ*.AT68F$="L3/6^+"Y<Z-YO/)+Z4'(WCF@CWME*6&GH(P
M=+8*A&K:\0CB M4$5.!RS!)/Z(TF(:E45$8,P0'_3^"1;6'C#S[6%$L)"K Y
M#+DWY*O!+IH%IP$P<XAVU/6ZBNC_U&/#?1C;]&>Z1(:_23LV!+ PZ( 4!.Z
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M (_V-L"C!P >'6Z 1T_K(*TSU=V-.\<NW=4R.L'. (C:/CT]C4\^GL4G8!B
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MH'T&>I7YK'J)-&F!AX)E[SDF<8A6D@LRE!]-3C^JZCILU#:??!GV3=#LTP.
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M39-.T8)ARB$UGWSZ^=/L"Y":K =J3:5L:%W "I.%"6QWDK8#=V".J/A911,
MJ W"PSV5J_?F,35$))V($TX^F_QTX;5SDRO8)DV]N<1I!K_;^73UNCGUXF :
M="R9]ZP;B2\B?:U%19XVOXYONG8<CWR@?;;;I[6=.^I3WTR@SN"+4MF7*_F4
M?S8!-:H"":FFDH< E,+]Q:KRUG17))17S18!;V72"3L.%(7P<9@:!1*I>[$V
MM )/;B:NKI*>"J23"2<3%@P/EE."<S@$3!YA[3IZUGIP>7OI/-MQPY%*C)7O
M<-]T4*+>(#-AHAIV$C>N<;^XQN1\K*&4-JIH-KU-W.8,G< I*9O7K:LX><LV
MV$%Q6%_'RM5T/G.!+;X N*NN!KJVB)G0:Y2J*V0?J>##&_69Q&."*60:I[L4
M(][T>^JQ4>%VIH3E+8 JDCDTPVW3[O?D[9;!JQ,FU#=(2PYFM:T=*^HX'QE3
M5VEGR+#CS;8VU]<_;$@/BR50O]5X3X-O&HJ-<; HY4%67S%*?7E*HN[/@#[I
M$O*$<A\&!6M_4BCZ:@05K*+JW#2LWD5!6R&GBS%@V[),W+F<)#9\0LH?D\V7
MY- XDW\&T(AS!X97$@5=%\.L:5.0O:/P_>0>B*Q/ I!84%$IB@7321WALE*E
MD9FD@OON21K08"#/$<<OMK9,D2A+%5?B\%O&-JD;S*<U*PT6K5W'D2M]@RL5
MAW<-X8?OR"Y"*6#/.1'%(&598L$L'XO %Z8R0;+(L(E7I.=_;H>V3;W=HU!/
M2PF(0O-#V3WQBT)L 5W5.3=A;OKFQHZC:6">DX^ \G5A]ES%%]D-M[,J!PTB
M.F0W5,:E'<>%B+)R@$^>L<M"!N$GE\U3K;[[>^77&(5=)NS#CI'P41=AJ!L/
MB)_H,_\B2_,7PO[. IH_#]&SFJK9H1AW+$*OO\NYLB(\1QQ/+M"QIQ[')PO0
M+2J17UXC(< MW,U6_OKB.08U,4J)$8$X#7JJ"0@Q^KB%8"#YY!B4A83NV@F+
M18I^L&!T*#M',?,JV7,ZU/\$)TD\N0?DI'#B\F@ HD&K)=V??5U!+@;9CQ28
M4%SIW\E_3_?M=W_G>P)-*D<G@3$.V$6J4^/B'GZ K#&%(RX8"5"@D94(@F59
M]X(AE0?2>PHXT%TT5P^D]MW$ ^^=I=U"V$@F@V(%XF>+X=ZZOV7<8U!'4D[N
M$?*!+70/FFE^<9H+/V3OX\+,W#KM$OE[%=[?C5DMNC%W0M>CC@B3N3S4K0ES
MMR8]9.;@@"PEN2.Y5U-V"[^G5Q/B[OL)O9K5C_=J@KW\3^;5:#1O(VE1RUG7
M)BR[-AP5+4SN^_DV2P.I8^P'-,A+)0*<;^\'&0NEE F%V;9AO8V=WS/6P2_B
M4^G+2>)*3^/@J$(D7DO\7VFU?O@NV:7<XP%H@2\>T0*_ EK@#X]H@0]J(WT#
MPI$YS%++#>+Y<*D@<,7!T*(N0*)QCU<^UW0L;G+K-0=5;B9G%T^E2W"$DP[A
MZ).C+A$4_!W@2MR=0=52J34>.Z.4,+K&.?SP!)EY5VYA5$PD6Y.RLF5_ND'=
MZ$C7]T_AE7CD/S,I]P=$;/W[3S]$8FN.B R=[QHUC*VJ.KOJEQ9&HJ=/R?K2
MT^/N@*&])4%-ILFE'J/I=+E,V \<9R\<2MV#A^;AHZPTI4SE?+E#>>Q,M,M1
MJDUUW,Q$ 38-]9::A:/+#H0\#POZBW_@[]L89;H.,Y257^J7.YI&"4?L<MP6
MEY94V^VT'MAS+"VI#.JUD9@B*\_;:.J*E<MGY^ %CZ:+6KD&4_]0"=&_J%D<
M#NV5:RG>U]%_CO][QXD2TP18[5OB<$^K<Z"%?<NM9#6Z2"YW%'7QQ-%KLO5(
M8WK=[[?2:'53G^(VWO/W+G\X.$T6C\S=_DC:!XI36$Q<)!QGZEE0/]&O*JWU
MBK+1Y8YB!D*,YBO^RTC7A9U>!SKQ^ESN<)"L)IBB5\=.\EILS).+?X=L%5NH
M8T?DEI021/Z/DI$ IH&.U=;3#+UUN>.7/+AH[^4H3%6\[YY^\W3U%UE.A <_
MQCCDM:6?B5DAVJ]G?_S][RD03!H;!Z /*M4:_<N+U\\K57&M!\0_12AZV:LT
M.FS[?0,?KR%<TT;S^EX!1L6(XS?Y#RRG2O!>2K:,&FJG81[/?#^.^6[2\3[N
M1W(#]W'&.NY?1@3#<%=D3?NQ68B,6<!6Z2HXZ!'Q%*)BS6YMCU0^LB:P 3?Y
M 5*WTHF7[Z^+EK)Q.>JIP1Y"MK[HS;MJ^N29&ES!.0WUD#GZ=*E^:,?#!6O8
M? OL3R+<X.Q./8[]IK6V^#PO%!PM'Y8PU6^6:/[KB?$\3L^$=,U;3L^XJV27
M%UVGN?IOV:]\ 64(W^$BM33A#H"IT,P'O'Z67W'%;G &0&./%GHT*=ICVDEE
M$+8#,1D4WXURFV@>]OW(_#3".. Y5S*. B8L%OBBVRU!.I^<C@8.,N6AJ)8
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M&-JI>U;GY#V][Y_U*FMK!-H'-_61H;!W )JS3F(SI6 -1"$$17(#XC0;4@\
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MH,*%A)^F=6+,L7>7*K[93F.SWU48?::(VU$XR&57:N(87$T+L%+Z&96!6J(
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M##M'MDP+A4O"F.3,/@Y]YHP48Y=KUO>COWWZ[#^C$?JO<8K><_R_@90_CC&
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M3USYMS+42#^J$C9E"+6^1PX)TKL4MI1DN/QMIL/-N[O\7B8V7,^/6[8T<-=
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MF,RGX(?PC!IV9PKE WC_XZ#W R7.X2#&0_<)8#*CA(62*)(J[XP/  :F]U$
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M):_TG;3U*?VQZX-</((F+M'Q$;!L%/E,/DF@&R0#XH\($MV[KH?$F'8HN;]
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M.\^'1XQ<32HW:TXP[C2]EMP_AT128/@<F!&RM.",RO^<AL5?7US R7PI]WA
M7>GWCW6E7[ZN]/DGCW6E#VLCK?_K#7IU'(J0 9M3@\"0M=_HL)M.__D?ZPN
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MD/%V#NCMC$.]%\+!6Q>78^D0CBV>A>1D4,F:J[?5OZCQ>G%@YV\(L?#P0GE
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MJ.2L55Z%S:3N'ZGJY#M8-JX&NQ77!?V>I8>NY$RM@=WS7E]6FD@'_AEQ#:U
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M9GGD99:E:^\[8B0RMHTNDZ'[W0A6W.(>L]$/,OK2:<1S+*O8ZA(TYJJ5,Q-
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MPGREY"JAN4"Q"02"47J^+LZS0+,MBAI_4V4+ER5^6@"'<<YGM@8!*/]EZ.T
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M\;<3%:(Q1"RT-ABD&TRFN\C-V_RC1,)[\3Z\>^"'45GB\*KN;X0@-'H.2!Q
M"<2#)4#68BV?&/LU-[)VF)Q$7QLAW8:I@E.DN%[LJ@"%2@#EA6]TCCJ:HP+Q
MW9DB$ZFV[.]M;P2ZJ*8H!=7G4TCRQE^WQ @4\!(<HV"ZB[^"GCY$0(84"EMI
M"NX@^_G#&RD-,%"M"B2APHW'I'_D[O$@,*45 SD-UD;3@65%'/>XN8GX!Z%)
M'77?R%X[8ZL';3')VY+"86O43R[-QW+V\OY?F[ORC"T*Z$\?"NBW4$!_\5!
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M/LM/Y<PSME&TA>1!_="\UR54%$3:K,0+6">3-)P1?8CT 2,)Z/Z A "=?<"
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MP=$'P6'<KXC^T28Q)9<'N1/1RC26DC21 3,NXJFP?B3D9,2P9D3UWJ)(RZ+
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MP*$5L&7$$W9H0LGJ_IO=SQ449?(H8(7D?5U 5C'4W^WUZ(JR<SV&FGKHS[C
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MGE^3,K*0"08GP7($(TD.PH^O7PH=3E:+L"RF1.O\Q)LGOQ1K%]D0.Z4F7-$
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M @OU>T#16K3H(W4=[T#-\-]@7A$-X2)=GC"!O>D/[5KL7J?<+%MC9ZH_E-X
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M4^=(1['#I:</=3%EA$G3[/:KOH_9"3EQ"]?Z25Z=U-F9-VL)RMV%"U$5A5D
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MSQXJZS=?67]Z\%!9OU\'B?1M_3(2<(U:V5KB?8)-![0E9#S#Y0&<7'@SS 2
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M5R+$M6JX!%;GRZK-'9;##9HU GUS! G0N%J5JY6N>>'C\YP2M_Q:JF_5FP=
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MO[PT&DE2YKO,IOCGSO*Z3GZO=1!U6G/^ZRN8?.>P%1WL/H35O='CKWHP3QU
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M&!IHR-24M!B+.06%^PJ)"HT?X? B\F"E/(<7MU4F2<#<@<=FEO24/F;?;Z0
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M0M"R HY^^E_L&)@B+2A%.'Y:)-N3?'L<S\+>K)<APN\M_>0FR:Z3:E*CO@<
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MX&V&EHC+H/+,U+";XKA!%E]R?:_=R7X\B>F'F"]'A!#2"L=Y7H2TMR27T[Y
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M[C90@Q&_&24^/RU\2_-"+8. *' >)RY0RA%X0PK;A^UHO]VVGNI @35HN7*
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M"&3%82^47C\]4] ((XA-F;$LCQ)S)%1$I!&,=N!->W=O9_^=O7==N:K<Y!E
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M03"M#A5$N+J!8C!-F00*(+!Z23@$+0#P<U&<VP?>.;U8&KTMSU"IMR(&/D1
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MS R%,E:5Y2 @6I'O=K'"0>2M/&VD]P/P!R"9GC+,&D,5'V83;$M\1K#:"A)
M1RAHZG>>P147<IF:L%,%-D"R@N)UFQE4C[A/X4QA!W'D?PM4R,"P=+VWR=>A
MB:9/0!E-J_+=TMN&A3:7N_VGV%UYQS726D_NTUI?/JWU;.<^K76K-A(.&N4I
M $E/I*,921B?*(FZM:&)=K<2"<_3M?OU8P$?D:OG7"1YUI!!,,)#ZN:[]/]Z
M^.KI[HNCU7"0OHM%E$P6.IL"7:1_Y VQ_L\FS?+W_96_0S/TW*V?_+17\5P1
MXWF>ZC?Q$Q]\3V+@ A(0AZLB3)_S:_5[GNW]T0\Z\G2,O7&4CRCEGL4_VCEZ
M^O+IVL7_I"]>_?N:];V):!Z[,M=8T/_T"SYIG1Y\3_Y3%A<0111GZIHY&%37
M0]NPHNRP4)O,_<EB.LB;S>=D9O][4?H.K,C<DK*YJ#\40LR?P1'EQS+E"WDN
M3W<>/=\77^F&9.7ELY='KQ[>2EDA5_7/(RO.L>_QP5<<^7L]LKO[)Y(-Q&D\
M^&-]6 8$V:O2TS\P!I)>$;A)H\#-O3+:W?L3"9P+6.6.1%HB<W<W$70DS$6Y
MZ\^JY07,A<S(+-=R//'U4V>+2G#GQ?MUF1U))4[K.?^S77!GV+C@S8KJ+(H<
M= Z^]/U ]:*DIZ,==^TIM<$LC;NMJXIL#.5?*K1=LB_*L3!4BTKOMI;P8!PO
MYP#?H.!&MYPNY![C<); =TQC08OBQ:Q&Q9"VLN98N999JEN'N"GI$,#P6I*G
M?+1NELI6ZP%<?: D![AV)^R*:M1Z\KY6)5SBD9R B#Z#;@CR)MR,^P)S@,8Y
MX,&>38)>U"$SKO6]CXG17&]U9E:SBD,'!0I"DE8OH,PX(TNQ>3Z<#8M.:LE2
MBG):Z_%N_5 U T>CTI@Y>/#K19OXHC)\T#P_$_*JL QM@,9-P[J9U4%#QH !
M:+6^U%4:ABS=+B-W[HIE$R:(*Y;7[W ][\J7!I"U:LL+CZH:J3/60H\&:91:
M2L15KI)#B<HS5'+LNQ[DI!4G^=(*<F(AD1JCD<R4!?@EXREW0R)0.S=9XA/B
MFSLW'F=)1(-G7V*E=Y.E%=_A7YR^*D9!P9U5MODQ20-FFP<_PBOF-KFZ>WC0
MU:&S]$$SLS#[B]E<#W&] T'>P??'M%<G$UJ-!6WX$]1*(TNRE?Y4#HNJQ?-.
M\KE-1O*NR<'HWKR_(S0LOW*VCK.;J%V?#HPW VQ<;@9F,@-9,L?GHZBJX:9D
M2"RS@:,,!6YR,JBQ2S"1<K<^24HM&,-(QYZ5884]JK4H?LY5J0O)D+EEF=FR
MR,NV$X T3$N."IQGK5&D6DUK[OF@ZP&3*C"JAO[!/_0_WP_/49"$[<Y_+>1@
MG]=V9=+9/%S472V#LFZM?PVNL9-$B3-7M:XKJ)8F)]*S>UJ0939JLPB<Q B2
M)/PPQN*IP(;'D+1*=G5E:$G0'5BF2 ]]$[=-; M;&<RU*5A\H2!:2E)/E1:V
M0?5HTWB%H0@1G'8@U).DPW@1EQ\'$ZR+-L+1.%=N6X3>27[U \/5$@(0I=8@
M02T]8H /89(%S33232@*G/N)B@GZ^ENSSY<SQ0'HHZ35><,2M^8QG@(PX:L9
MBW\IA=.^^) /??LP?3B7^KT7B "T^*"H"G2<ALGIEU^8';+T8('\[Z3,@>>O
M\A'^]YSV<9;^F,]R9L@8E3FKKU,R-L[3@S$J*.Z ^GX3L',\8W*.AW&GQ)#H
M@[9)FD]E0VCF5: PCMS$-%[ >1#RBNB)T,,KX@KPWQ9G@IH:FQ"QP2 [^)"&
M3PM=E7D2.7/F"^\=X#\/OF=8K!#!J'>5]EZ_^QC_>?"]WX/FC/5=O?\*_WGP
M?99>=96-0<H]2=X3G[1&[4IN[TC;93LOIK1>9N"H;C#M@2I>0[)(Y3[<!08V
MJ"X>%594>E&8"M9RE7E)%@V)]K0F%0W*ZT1B&(IOMZB$(27*"@8.&_M@J[%?
M<*#B>:KM B(TU"F/7I%-&+ BX)CC4E2#/(/!"?Z921\&J']Y;,(WD-RA5U\U
M[6XIK[."%\5U'D5+!Q&\SF*K?!^;'#DXE\=;WW9-P:RLP2FTLI<CO9'(X<.$
M/LINMC4HE.[LLFXF(_BO68_FT,>[J0SUM9$[Z7&AAE-@#0@$TAN;@<T0*C5@
M.[>%*"MF:.'@@">_FN5+/W[LJH=_P7]7Q5RZ/)F6TK&/ C*< W=T3999TO-4
MH(ZF"VR@"@:4O81YX>:Y8*]K.4D%$4H7LBX$5$_?ZS%\@+ Z_MK@:_A0+UK2
M(CB%$^[J%CZ(G;V05N^_'NUD.SL[-#N'IZ^X530#D3#3,8=*S&S#40L)!!38
M[JBR,4, ?IDB4D?%.">/$'6!"T50^6>PQU5\F"'HPL_CF_&S&M0P2=%=)T12
MI9.\G:^N@\B O.&7[=-M)Q4!F1\"/_[M^F(+T>[M[#WFV:%_T,%HV&2RQ,$)
MW(@MM#1N'9,ZGA^:!^P:I07L4OG TYR*?C2H;H(F6"'VB4W1 I$EVB*,.(?=
M DDI(Y; ,YBD/!LPDXN;Z?O\)T F?2/HIZ?WZ*>O@'[:O4<_?8:-]#G:@Q[P
M >O\$\&G[V?KHQL)/.4Q;9.:3ZZ]O92MX)'S+TG_/DX1[/B8[TI'AACCNT_L
MNK,FMX#>DRN?H;SQ20]]$8XC#L]/)LX%=T,VWSNT8'I?X.($@+X[+*TSI<3I
M#=G,$L:Y7W7E-=VN=,#U.?YV=^)VWJA@].BUY$"27$<\:XXGY[KOEX+Z:XR
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M6#DG.9!N#$2C$9!["ZV'1NG)^Z*8Z1W->^ZXFPD3_[P4Y)HTXV!%.>)3BTQ
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MUD1F12*12W4J-;\2VP?NFQ:M[6+K.^(SE4BFK*BX8'/Q ==TO]0 (2(+B2W
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MH":C$^>^$.*!;F3TBF%-!\7OOT^4A*F=TXNXQX)0L 7*L_O>Q#^C'F@U&6-
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MI;T^GWPS)O4';>)U!/A P&+I4Y.W#I#Z[KQ;PJ!('GGYWB/ >7:?6L?RC\^
M0PO]<'3RUN/Z\AZ,*^TTE$ (8UY$"6ID6AJT27RT)(!!.3":\-Z3\G8D9P=-
MD;N!O'QY$(Q#-Q[@CNB2+2P:92LEJR%'#=2)D5?D<ZX<'C$HP,&P@\]HM Y)
MJ$9%I:";\>^%8DU*458Z:AH2@E,<\&JW4TR5LE$QM[;Q<..(\#LI"1#F(<K%
M-P3T#EE$A>;Z_]#F;%#\;,1I+>D!\M% >J" -91O3VHAP!X[)K(D)$J39T<A
M;JL<:P-4NB_EX=8^=16HA(VPX%E;*G.=LB_[>?@7KF1AD&JB(% PPS 7O@M/
MX[CEQ_CW<E&/U/3L/W[X?&\GM;J?#?8VN9%TV6IN?],]2Q)"KH7<F.>4U>]=
M *$=5^F/BXEMZIV]G2S>.4'<  Z3<-N/-!.WO<6L$2>Z*4_/N9N=0QEFOCC[
MLA \D/7JU'YHF.[<.%H48@7(3\PJ*QARC]'A\]^+/,-2M=N,["FM0 L/F^#Z
M.[!J=^4=UX%2/+V'4GP-*,7N/93BV]Q*T@X*N:.ZJ<J<-#39UB!1,35\,)S?
M2FOS(]^4N:#TX8G9;5F"MD'3H D3#,<?<[(*&CW3=AEVOD-&76W WY#DS#J/
M]+&T2HF<)Y-E_T9+:?NX6%&-&7Q$8,<=CW$"HGRXKTD>/JB'"T8J43T0I<^$
M@AFL#5&#%GK*01IU6+(DHKQL'L_W!,<RW;R0UDO%A]E$W4C?&2GB=S26^P!!
M()S:,^G"!8>0:SM]24+'FC?;\S:=QK3U!M\?6K\P.'6#V[7-CK575YD#G#$7
MUN>@]2C744I2T>K$Y4M=^\X!MZ*"-\8E4X40*H^Y8WB;AA2TVB+']PC-4FOH
MS%&'3,D!, (H_9%(#AH.1ER?29A09R@WP/7%A798=G$(H[&0!@WT)4-E>X:S
M%'SQC(18>EAHYS+YWLR!4B[)Z=.V 862G6HMG!%'VAU"Z*3]BZR''&_KJ$N8
M[[953D%FX  \S(E%#AJ-"JDZ9O*<(?#E"PKBIF'A8Z+E$5W3>IUB71.##W>%
MCM(W3 SS:*#"C:Z# ^Y">T_P)MY];KR60@*6I?_O5I,OLV1"RI1<J]=OCS.#
M_ERPBWQ1Z!<V^>Q\F6Z<'&U:X.O2K^+*"&C>^:,T=-0NJZ*!UX!NI*W.;_>=
M\SJQ=EH= 5<&BK&_A6M?6Z.>+%OMP6F.0H6G2HF!S1@?%-:,%N/UZQ/"M1U'
MEXU%@G2L> &6\I+GVJVA13(-I0+/Q7G!$0:-8UKS[6"5R6.J==1SA9, 2R7O
M=L]VMR:AS-ECZD:^7#CY0)C.-(M:U#%82O>LC#E)MH8YLY1P7V-7%2\+$!Y,
M5J]PKBU8((WT;H94OEDT2?!NP;)Q+6#8_-IO^I#C0B@R4N[S)?T.N8<,GG#&
M,9%&2N_!MGA6V11)+\/@E3RAW(F>30#?=Y7<3T1+W9N7:T8G.)P:)#.S-MC?
MCC<O:/'7.7%U'$I"*Q^7\$1ET1CQ<M=Q&23B0N>!8LBHG0/;U $\D#M,=#G.
MY,&WOUSR.6O$,XY,;3&V\3MHK7GQ(#R$HQ[!"1>L2Y=/;9/+\3L0"8_TE5JC
M5;>.ZM"O9"C*JV=-_9&*/2XR:5"(Y:/CTCT@.DHK07I9U24."&1 VL\*)+YB
M,K]P%O&*D?R!].*3WK3AW<LW!C)Y:<0U(G?:L4E.+'] 6F?5[^Y:-OJSR-&3
M1Y];CL*_UI\=\] C#W7%D?F1M@4WCDW.L\+A!2EH(1UD5U$SY\M1$V*TY,@$
M2IVIXYC*C.S5(&AKX%TA3B-W>3%ALY#3)$<_O3BQKCG@0X4%C\K&T"8,N(;I
M])LL [1X^)Z9U+RZ+Q.>-+8EZ?X3,TI) 1^I43IUA)^XTX-"YDS3K) XS==K
MR?VL0,T>UR##;)F5E4_@_T:C)M>F'TOTB=+X*0+X!Z[]R-$>?$#R!_;3W=H^
MKDF'0Z57DHPD#TZ*CW+)=3O!F,"P8V.#%.$(\*/S8LJ,&AY#.>'<.E^@?J47
M>^M09)7/8ER+4R)4Y+*??,FT[C-Q3BP#XRM1:O!D.TP];%]M8UASX$D:(N+W
M_UZ@+=D\EU^MQS1=4S;NI?BK2+&UUZP7<TB'MF&@!3\K&LG#&@"GQWSP(%SQ
MJ4L2VL%B[GK<P1^UED#2#,<_#FH\N(TE.LSUD5:%^',E=/H_)O/GCW?^@AW!
M.!*&X""TN6CE,DG,>HCRV?SYL\[U@ C#W!;._^Y7^\]TG\X[;0YGLGLV^3T'
M7HW@2SB&9,@C?S:JGSDJIF@8T6CO=HF/PDGUQTGGG.'&H]*>FXG#/S?4ZV[8
M:;#W_\3F?:\YXX01D;9[L_]/I."/#+C"EKW@VF-K>H[>($CMD%9K<+Q7=;5E
ME_XAD_7^4/^*:VZ'UF#)+>D&TMQ RG6O%@"G+/"(K7%3W$O![90" *@,,(W"
M%W8TI*_&*F&GT$'CDLB.VOV+E&9Q;]1Q@+=TU._^T6")FU@(/0P4&!<U"5VE
M[=;%)@/_.AM5^5CHO:R9'-H<3I!R^DU>V;I!(961GASUBS!45YA_X*%CM%6M
M-(/TBZ78=GT!,1=-5^"Q*\!]_?:T=Q-<6[:^\B[XLVX!3Y?'YY[DJ-G+!?.3
M^@$1$[J_/-*#DK]T+8;<54BLE)5OK2<90XX=?>28=1[U6N?Y7KB^>>&J26]5
M!F5 OSG. \] )S"1S''0J%N:* R7WC=4T-'A.\ 2."VH96>6K 90>[ P;A%1
MAX '+)D)E1_:2&\JN7QHP5?/G Q0=\TX;>>DTNBX_272W4R8Z'S5$-0C\=,A
MW=*&X2)V9J4;M+!TVC9">64^*ET,>%7V.;Y, Q)R7[P]PZ]9,^,]'JS5*<@,
MMHU[10K+Y N[Q-_<XZX#DWUV#Y/]&C#9O7N8[+>P00;?OYS.)O6R*-H;!.5]
MS09-;)"^&<YK %7W&,3Z,)/.&*/T">V(.<J7[:.S9%^*+>JI%%H4U1FMUT@Z
M)VMS1$%H,LB$Z6A\]XLLW0WOD/CEF9QGKJHIN%5.BOB52?" ,ZT&RR.R\U5
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M%8R0<N32B%$D65P4E? AN5Y:_[6[O;?_*!TH&RX=!AO#S31\FN0,BZD4V@\
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M%( L!\>A>R16+WGVF*XY:K9=^H(Y/;E)8NX2\*!+'!9(NN]LIW\3*'<^F]4
M;8Z"@*D#A$B^_C5S) N+&?,>%T.0E[GK7;++!_?YOH-94TY2W$7W[FU?5VU\
M=";V/CX3KVDF$ WO?.+ARS?*0N6FI*YH16=S*9("!1R^\^;&NG^]L;JP:G?
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M.@.] ]F!3'<R:XJM5T<'M YT.K-1%[BNL0$S7M"9KS[9)"=7X#Q8)/-PP0Q
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M,XIR"61M U>7G2BO8&HIMRLZ'^8;6C[1FE89EO5FTIV"-BX1]K-P-<M2=M^
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M)=JLT]=-9BLFLT0A.<=W-CN'F9 F1R)UF6-W[W>360=+WZ^RBN_]L)Z'Q?/
MNBI35(5AP)8TJD7[;3=]8VY^6*_^CA#R]-@[113PEMD\_#N/O8#EP5C]'QO
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M2JHFRH_:'*VM4#+I(OYM9WZZVRTY((V!-VN$D&E3@R09XEA846$,.'U!U7S
MMJ?:^39G_#(F:Z[1"AT;N<SLBMS,Y HW5V:UR-,JZGQN@A++9QA.0@5ER;8C
M2"?/2T(VQK! !W$L.!,KK;45V80+X=47A.G34#SE:Q@X*&*IMF]'1T$AHV)R
M\!KQX>05301/+ZL S?=_06Z)L?*9RWU)G/,J-<%T'7R9LH*8Y14-@] D82$^
M@DEZJ%JQ0><$!:X/I".J(2AH<T3C!)TG)#30 5#<%^CM%MEWI["&)3'I\U)%
MYL]6(^N,7;$E!XJD <?4,XVP446C*;_)-=D<5[3Q\-JA#=@!)MNC/3@5MQFE
M/..\-'Z-0^$D1)3A>V=$5=A6BH65'B32CU7+((R*7-DU"^:5$IM%:[-@80>E
MG@D/AG%6P'[&E>DY5=.&^YR1'*<"/;8.O KJYS4C2Y9$&Z2)'PA^"VJI&7J\
MP^S&!HUA#)T24Z?"XZ1EW<_CLT@S[<>!-S)0%&!4-6>?\M.8*$Z9#IR!9R#9
M'+8B$")H4.@L*NNZ:H9)K,T-3R,9 G7$FQF:(-4J$> :6!#O:%;>F/@6#G\/
M<$"^*.@,G_QG=8\]OP\O$GD\Z2*/:X@\]O>[R.-3/72#7R]N$O%D@V94C)>$
M?+,U%&C/\L*+ZP)4"+JW+F[PTDR-LP"1(E0%8BAD YS**C.T)4=(3D%/M2OI
M<SAMK%V(^I2(4T^AU,E^8@!71;H70L-*-+'R%"HT!>I;E%YYXT<C/;$+]HYY
M=B 2]8=47ZZ1'X[Q83Q<C#[O6XIN4*!#Y$[L?D*29?W6<Z1JLU3H3.%F]=,Z
MI?NBA(BS_FD<&U7]=NYL?4RGRD@Q<?2H?AI25A9!] A:/(/1BAE<@3IJF<.B
MSA6,WC1,T&F8H%GV-:K\]8J\&!VKHY$?@I84)$-0X&)52]M#E:S"B#:FA!Y<
MXLF8C>]@C%D<IN3&LOT>:$]%]-W<L"3GYXU40%!)K$8.$:(?6-VHY[_'! ]!
M;$X_GH.E!81"W9+Q8"O,[E29W<K7DP1N0N\'(N75[24KQAP%LZDEV/M5B6M/
M6/6O5#8)Q< 8^>+G9L_7/&^;;?NRV5 _IR7?L+ED=4D0PB(N+%IJ(%[00IF@
MD9?K5,3R:> 8DSCM@,:2S$+N>Y(]69F%[,=_8+E9$,H.$LH4QBT+M$?UH4<+
M!KLG##G=@,\LHOTRE&Z9G,FLY]C?UD<A+2*#-7I-*-0&:I2ICW\R^=^F<T!U
M/\J% $/"'Q $NKH"I+<LC4PH:EQA>&TIRZO-:=$%[CGG&:>6%E'NN;I]1E5X
M/$A@L*L/#7MD!Y*#)!Z:5Z;7Y;2NJ\HR(H,$;9/$#A)7-_\H.4B(2\97R5_V
MKB"^^!T87(Q(0'>74\3B2(1Y^!3*N;M1]"W?!NS!ZY#7J1=2N_1D$K5#Q0>O
MME%"')-4$U+;K"3-G*$?(QGO?!R21$=(-BMEPMIKM=I><# 1M_N^C7]^@?7?
MVV\0!\SLYW2#/"?=%K1[;J7RXAWW5['[KFR[HM^*>SGGXX0.;Q$!XRG2C-DQ
M7B\\!J!5@NQ%SHI5"X0\)PL:EW&)Z'JX=W#D[L"X+S*06_FNAP[,[X_/]H[W
MW1T&K+@.J117W&+2LNCO?ER@"G[ V+,NNL323,.B\%CLPYMIGR.S(-_@0 %]
MJ/C@'.8484=C'*_O,? T^Z9]CFOBFH\(02T.\6-D ?BB7LU\901::VY_2T<%
M*B0@S'PJ_G!*5V1Y4ZGZ%DCH48\2H"%E-Y@(<%O'DCQ)(D-W.)"F&KK5A6=3
M*L/H9Y)>^W'X7[X!R(T<CL/(3WF(3/R=NAAEV:B[6R,FK&8C]7VGW%:SP?#7
ML-:\R3XKI=MYIHF$F%,&Y\NP(<ILXK@!VKP1<J%@*)FO<AJ/YU"4 G@,GHZF
MIAT80[-0,P<,^F$2S(>RXT0^RY_ZAIE!IJ]J4Y55AIC]0R=6<ZDS1C3O ;K1
M ]9+D#OO$M.=*O"GF67T$P*\?EN"%YJ5C0G3TN(M5:C$E/>S-37=$6D'?Q<0
M1/MP7=&?3?\YB3NQW %:([!@67=;6;*IPS+D0Q6]\@CC*<8J=TI:SGZ\8J%+
MBL(-J2/6QIB4)DX$"TN(K4I#Z-DIVI*#5!E8CN)0DM7YCAP#26KI-/8\B21&
M_ "7<'B]D4V-\D+)K80'Z=XFTBH$AHX3AQI(L6CT!UG9N:0D>VLOO]0V)&%*
MTK>&,K J[YC&>C ;=4N8QE09:,*4%%?E\U3O? *;@<-3(JH=\:Q2Y5E)P-\G
M<AE6,PB==O)XV/61+E1N$F(E$-45A7:*U_C;B!%$**T($AT3UF7TQ&@Z 5F/
M6.G+A,4"U,6F(@K]ZVL,E^8S0I&L(SC/SVK7/[7NF6/V;/Z.9;H[DH?6<JQC
M[)C9,QPF:5 U6JNMNNO]AZQ@LR<#D<=D?CLBS/BD.90UOM(_1J789<PD+N$=
M,W/EU5E5_8F)4R+[S-,M;??FB1+*A"K+^>^T '].[/5VY+&1,.72G:H <<*L
MBJ-XITH@2G9\83L=S/S"OHA6O@7E^I5H\@WW)+& 282T O?:\#?@4J@4<PH-
M=Z_0J/V66\L3\(4J1J9?0\<$\4$! XD,,**"I'9D7)Q,B/I'B"\TOXS== 5"
M^"/#3=S?#?O",HZ$M .B]&E*C_ :DU/<4&-WSNBD9?<.HB(V!4P-GE) VHTT
MEBL]"%:[&R[ML$A4*E)(YEDI03*6[3_=_:?I1G"J8H(=,O=,@-UUN$I;GVO4
M<NN'F IL1%,H#S/.HYQ7:G>,PJ&*J@VGLQS)Y3A 0&J3[$BCT?-54+.2[YIV
M[5G)B>?WX452/4Z[5(]UI'KTNE2/)WKH&AV'<%\[ED-/(D]AJF\1404EY+F#
MB;Y<'6G_ONO6F]R98!7GT1I0IC(=OHH(A6%L!*'+Z'XZW#L[,UK"L_7*F7H?
MJ>?VR4.+ZKAV3#1Z['3= /VA7GY>J6QHOLDISS5K\#/?<:!0#!QGD"2?7\"8
MZ90K\B1HK%5],#4)4><:6_CB_]*M*O[Y@GNG?=*8@29AY6T\W$/5MC*")Q/B
M_\_>%^FG%DV=@2H]^(+M9K7?M*9HQ6U1=R8P' T11E5$_%,"CWY*T;-G9@6#
MO?ITX>EX(L91TE+KCD& HG%^H0+E_B]_#&+](ME#MYK@]%"*$+Z?$#Y:6>G&
M>34\:7C@Z;'V=[_^*RE@Q^C I^HVA&&PQ&DR=80-VUA%P]H27S6PN.?JS"71
M>9$Q&9T9<Z5!*DGC&9%2S=XVQ[RO0__H>\P+\O;ZY#Q<V:8\3D"8 H#FG)WS
M<?HHQ$@]1[N=Z"_/,1R()]]@EPH7QH&C^25E&W"F_[JP9Y5]]:/UN,$_:^+N
MW3L0!KU3]YT_\J<*I+/[ 918Y;E_) F(^Q3^U_M_N;W>T=GI2EL_KG5/X':C
MR^MRF"=HGO8YY*G34>BJZ>U[^X>'WDG_U)D76+)=*.3JGU U\IBC1+W#HUI-
M.[8T1M?<GMOSJFU=FWH"4^"W_,13WA&0%9=DAU]:CKLE)PNLN1]FA>D<PW3?
M%I,GS]V-'[B]8^_H[,0[/CT3AX;M :TPK7:'NCN@2.EB5/W)B@ IW7S^(+E5
M$O^WE;],E<,AM^Z$NV ]'WA'Q\?E'[A-FM5D=B9MP<%VP6?<C^7+A+MTPHI/
M/3";=D(8LW_L'9\</&1(G?-0'_/$PQ%QFM[123E)9Y$1]_?V]_?[3=/<"6]W
MW4,I:7S0+*4#KSVF V.>P9@P)(BA@Z/:J*(%@ZJ!6@*[0]^H04JL0GS"#>],
MX9RWX$2.3INF@3_MW +!CH"YCD JGLV?2MG'F.<B57P3O&?&I 0\C"R.1>J#
M_2?0-QK/T+RU6[>[=00QO#R,*-\,#QGM"K(QG<QZUHH.QF/T!EO*#F]4KOL0
MVBDMU<QYVLW,]O=*EI&)',.T^3J4V49<THBN=3(+T9M;/JU5E.H2G_(M]JDJ
M$<DC33D*E6P#2?(EF]61)CKX--O%8W_JV4AMD[GY),@5?G:#T5?,?]9IAT8[
M)+N1W?T\D;+(4W2/@8_)"Q*!QMH 7.EG>)(R"?1G:;+1E)))^#V[T9<5!W;K
MYA5=;V ;%652YVQ<@$-_<!_Q1\5T:@L8\SUDR(QUFC4, IUF8S%[,_VT.EV?
MD5,-+U;>K*VPGABF(1$>EB"&/\#YSC)V%&@D/:<2N%A*"'/-XN\M.81BR?$U
MO; E77"_WT<=A-0:'88VE*[G&7W4WA?*#C9I\J*_Z+PC3^?^4?%_9M0<8FGT
M4;&GT222%1.NYK'8#S04N(E/^T?N),ERSJRT=/<+5J^N.'[8F)II8MO?GY[L
M[1^6%T#IZYJ_&LDW<LI4H3+5$KYM;)ECSK>$U>5 3Z$J_WCRB-RS0DMAQ5Z1
MQZ#1RCTO"X2XSKH0USI"7/TNQ+7IA]5L\$#ZT(3!7[[+_KW?.\&312U:KEZ_
M>_?V_5_=J]<7OW]\^^E??[M\]^KUQY7Y*:P9Z76OVB/R!VK-[CN\HW>PM0J\
MRWT"I*)ERNKJ+MU+F"+JD"8HR7]L>W+41&%^&%?B2MK,G'1%!G/AU%JQ+@=3
M!-Z!@:TIE04V'_2U?:X]^'N.=)37 1/3/J'YD_4,X2J4%?YB??CCQW/"J4DE
M/LEUF/83><*+=ZQ/C@@\BS***)O6)M4>5MJ!S6QTU@JX#:$(8>F159DWNV2C
MQE9GZO&_'?HWO$$YN^@L$D0Y( TH)9S@#1^["2>LCQ59F0P*]. ,/LP*Q;[U
M3T$')3<6AYP5V+"N+L.!K<6P#\=J#/"GL_!9T-LPC[D%9IL/R PW&,ZN!(48
MI-OA*=-?U,1'/S$9;RXEFI43SPI,XV;L-H:L*A>@0XDC++++-))V1M'!&8\X
MZZ8SF9C"%W!-%^-8Z^._^5_"<3%VWQM#ZJI1/Y8"YTM</B*D50X?+.V#6;1V
M6)154B@_G!GY41T=26SM5TGJ9L)N/R^_--D,U(.7.N8@CQ@@L%I&,'LZ/Q;
M2;V#X,7!3K!+?5>*Z+I2UOSZPI*RU6)@9"$)>69MO$Y?@3],Q"=5UK;(X7&J
MAX?DDX!V\?A8CDO"C2"@F!=+ ,DY287U_ Z[5KOIW#J5H@OM-<7@,>6&L%"V
MI$68E>>N9B9:<:.Y!4F6;SZ)G9EC]U)Q92F)7RWM*P[">Y.BYUR05>[0KI]
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M*KHN\$K'#,^ &:0MW$!W:#&VLSCNYSN[M]F;]-8J@*5.2-.RS42])V(R<DI
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M+C[6.\(FF@T'L%HO,<(6NN@0!'WE6FD4?[WW:"\E> :01?TLB>& @(6#$E6
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MR=VV'>73;D,_<Q+H^P23!%M=1>O=IK/MVJ9O_YKSK7JZV=X_^__>WS^\KPO
MK#[U]R)6[L$^-R2G\SISBLVF^(MRA7%4--L2-1VWOUV[7J/YT7TKO%<;^G2#
MJ39(^JOPB_L;O'^C)>KL[GS=ABRP"X]L:BQY%XX?M@NE"O,P]66=&[1M]D5U
M@TX?N$&SFL8Z:;]M"F&5]F?WK? >I6 %!#U9;;N9E;CW]:9THW:C=J.N+'0V
M-U7E\&?0H$A]^@F'E^3FG]U_^E&!#W29+-^6R?+FQ5?ELG29+&N,GZ^TP'O!
M# _,22FC>G*Y-X9ZG'M#/>M9QS)IV#\\W#O!.? \VG-/N7CJ9>*G 56P:XQ=
MU&9_&:0__NK8YLGC3@[FL_3\:?PD_=_CO;,C/)R;B0&"%U+XZZ6&*&;,G/:8
M_=*NPJ^8Y]*OXZ\MGK;!&^Q*56<@/J<,?4[N#%>Y.Q9$P6X;"HIGJF"E$YI;
MA3E(C%O%<X>E<9_-&O>.JAGW@F*-!N>H8G 28D2.[54(-F)V"C&933MXM:,>
M<JLB*:81^&X_:P5_V=USWG)=C !A>^TX,0)@ZX[\,(VFGBYX-555NO*U/H2!
MY9V+EN$TD3@K(J8K5AB7M.7Z0RPE7H!:C'V(F7X$;8JU91:ZPR3%'@03K%F^
M5C%\((JF#I;33?*RX/OWF%B*SAM-YWP,2Q[ZZP)28;F@C]RZC_Y5,0 NB0E)
M\E52#'*GQ!6I ]B<"\X(<.5%!8X'UO-7PA:Y8&R1]2]K[1+M4[W6WAPIQSJ5
M)68JG,^)3ZTCLZP8<PF]7]D&AF";BX-TGE%[ID+#V:-+QNWK\NHFN> Y%2]+
MZW+L>=P04+C $J0(5D&XHU&2$5(\@B?43CLA6;DL*T&I)ZA?@K!HEJJ,.N%C
MKX7,8L\ V5-@;PBTH&3'N53YS8]][K#VOT$.PCV2,>X,%C4+;3+$",ZI&Y./
MC3JQF"Y0V3 -!S8EN9JY4;X&B;1D)[0)1I0.D$VDX)9:2*!](H*Q!)F Y0P1
MKD(7,A:QH%CGT[WEY3)O)N33O6+RI9^%?#V((M6)EE\_24WG+!<2BHE<OA,L
MHVT$AC+R?&P.QIZ+)<.UMT+NB,O],1#'(JGHLC/#-4JX@9^59;^DWNVY@O[@
MM^!XV4A?III<K#PM@RQK[_(6CBV=+#:!=BH7_JZS\^'B_/+E+I? 4__?2E,9
M&V*L"6I'?[$% .;WO:L]=Z0"5#YF.H$;T!73^]N9#QA3OH]/F+KZ"].WTPQ)
MBWJZ6'#S;040[4$Q)(1KS55.R_[@[1$ 6Q@:,^% D"/\0?E7X0H6U'>*[@E7
M0$BH(2WM(WZ)RN0'!'AD4 L47=LI?EKTI[L;13@:K0JY3XV@&1[!:.&XRR7
MDAXC**CB'4P"QOT?I3 1OHL,=W*%OL7;#NH6W-'B#I'8[I1I'0)CR:I079=5
MB9Z.C;/3V(]T1QX7VVY9*S!0+*1MZ I\LPV$262?,J>DENX43427_E,+?\YS
M!T5.:]2VPJ1()[B',(K(* 9\JXLI[L6!R''PB-,B"A^R;.(R^)]H1MTI(R#C
MA$&!Y///\FQ>:CXH8;>$T]"(GZ3)4 5%RF%"']5%-F[3,/N<M1X$T]ZA27^=
M?T@\^PBSQ:BGX BV&5YY@06(@E.1MNO6?,URU!<?!N)^'<#20)\LQTLNA*FH
M6^R'-U0U'"S=E NG(MU394R&E6I8%M_'3$E21LOOW_I1X>=F[$9CN,BD!SW<
MB]P&"ZBH>SQ);X[!U+K_/02(O%-@7R"28O43>!+055"VP"F] <US_P-MFBA4
MMR).C71 BB*-4$FW9.? *'G8(^PYGY^5^@;:OQK^^F/V8V,Q#$]B>2[;D\?T
MUSX(GGE-.W[E1[GSSO\,5Q+HW)[[>^[?K&DJ;]0@+;!-?%_283SIH^3@T>3T
M#H;#[9T0V"T(3=VV6EK(P#'^S4_AE_XI#_$<#[%V9F<JO64,0!3S=8V#!"+0
M%;26H9*DH^VGU7>_DG[MOGWE[A\>G6QF<'+3AULDA^&H2U=8;[I"OTM76/M1
M^88L RHCU>[5KZL^T&6HSD/+4%?IU=V^%(4U9B>L)#7A@9!EVYP0\:#<AY:\
MX,<R<C9")?RV_ 9IT&=IDOW>SVW9#OVOR'9PFK,=W'JVPXJ3'1I=(KO8H?QQ
MDQT<D^PP6S+>?]1,!Z<IT\'M,AT:\'@^JM)Q2)'A--5M8%M[G*Q^8H_1/:<Q
M^G\P/_H_ERQE>@)/7S>+X7]9Q+6]M4^C9>X#NFTY#:*!U7,K_&!>M9,"M"P0
M,EI^5?)B9PTI" <>1W/T13*8NJ_\[+^?_<AYF40YC(#-@[ =-6Q)05Y@MXC+
M/@>5V(A$P/3B:AV+/ W;S)TBRA9$\#^N"[0)N!-S/4/#45] _<VL_D0P.LBT
MTO.Q4-Z&1QZEP"V]4B><8K;GOM81'7$VF=PS"][%03KX0PF'Z;[@$Y5,(BZ3
MQ/ #;XL0T"T)^ 18F&5O)2L+[@>36?(XXOBQSFISHE6C)'/6E6A5^0(V*GM8
M"I5/X>UB7+ B)9K8<E*EG*]/E7*7GBKE?'6JU'9S\M:E0JV5)%T.5)<#]=1S
MH-I2G5JVP7GT5"=W3JJ3\XBI3FYKJI/SF*E.;GNJD[.&5*<6B>=L6:K3XYRT
MN8E+;E/BDK.NQ"773EQRUI>XU)S\XSQRXI+;F+CDK"%QZ5DG_JTU<6D&U?4I
MYBS5?!OK2E<J8A T<-F^@5_#P%\7NU$ ==EX_W/N!X()ZO6UHXGSHER=%R4>
MJ$/WHT)%7#$>E'L%&B](*'KBQ'.N?O_PX=WKWUZ__W3^#ELFG[^_> O_RVJ9
M[+D?T#L1!G8G1MW63QQ6^ >XE]-")"4_%(5LXH>X+OR9IW4(7U>Y^RZ!2_L#
M/':%15<.==JF%K,TS_9<KM+W)@M<EFS;D' <9V@Y4F+;EJ%%[@=8?<_=(:V'
MJ)/[G^DF1'V KS*YUD 7+(-(#_ [DL/R_V?O6YL:1Y)%O^M7Z'9TWZ4C"M:2
MW]VS$T'3]"Q[>H#3,+.QGV[(=AFT(TM>289A?_W-S*K2PY:,#7[(HD[$[&G
MKD>^*M\);]O\('A>[.S\B!BK2];8GC=_U=RCCD[$VF\B5E,G8FTZ=V/+)8Y)
M@[?B.1_;W#&7 =9-,\ &<UU-=W'W99V."V; K,#XJY]P-1&Q[@P8]3EYU&.4
M$>(\Q4#(BXE5^QL*R5,L8I[?9=45JW0::FWXPDZ195<!A"/I_^V=_6[UX^YF
MX9>/'UD=X/3V/7*4_+B<!R^QHEHEK*UI'@V+-^S,/[FEKWS!=D5GS8J$^1,7
M'*]@W4T-<MDQ).U-0U*HQJ^'X '<T]X/I:PI"Y9+DE(@KPS/%>%UI)*8/JZW
M]<H *M*LPKO!D=WL,?G?QQ)V&_&AG*C^280//-?GA9@[O;DYO[W9UE-5H _O
M[]U\Q6%>@[)_"F5X'3PM'N8LY[KY5$$05>HPVV6Q(J54ZKJ=SH="]&':;I+J
MC%&^!\<3^:*%AJ7]H5A:Y3]E%>[UOF1-J\18M5C#AO\Z_;+O%>ZRU"[?[?%;
M79OU&IT7'W\+S/V<V2(.@0G&H4LA>:2++?.1U6"-1J,B3/V2P^R>J1?/(S-E
M,/5AR(&)P:1FIL_C;8.KR>QN97#78^U%:5%)'BM1K)/8B*C;+XJ.K* )+Y5Q
MSRGEJ\)_G74D?NQ6FS6:"]12J,NO>HP#NK[5[[-NP]K ]7<I<.QUZ/<VB#'K
MIBX$:S&[UV?-19GR9D@6"98UN@LZS(Z)=D[25E>_K]1A]F?/+Y[K,O"/A]I6
M/ #5!+40K,R(G\@P1)MP*O+0=J!.LFYOP=>W)Y0U6;.U(/>J\RZOI5=>^+'C
MW[DRM9EC;F8&F0?Y,%F='NNLZ "OY<ML@ZEJ-[K5>IDWID/Z"^_%02/+ZC98
MJ]%^R]3:9.WV)MAU.T*VNFI I0ZS!5'Q3%2K6%+8)^U45JPF'^17UF40^AI5
MFWJ%BNV"6WC-591OA+7:?=;MME:ZQLN%1-6AT+=:\*P_:W"O! 4M*>HE*=:*
M(!<1Q_>+TR\7WR]N+\YOS-/+K^;-[=79__S]ZOO7\Q\W?S'/__>WB]M_F4=?
MS[]=G%W<?JP@4"MU&,U>!PK\C0;^,V49VJ-3>?] )E X=9XP2O@R,"V\]P40
MZG8:K-U<L'DVBZ]5#M+JV& IK^E7VIOW;6GETY:)NM?NLNYBMMV>6,RV.ZRU
MRX#NIGB,*M,D?Y&G#6NAL+P8.6_K+E3+;@,2%PR)O<G)GFU9^W_=5L/</YTP
M=#*OVM.V2;S79U9GRS*RNKC:%,-]Y:'[X% )X:XP9]D6:]IK!@CJ@[G-Y[Y\
M=S,MO*BUGVS*>L!^SV:3V?U-N.@/\O8E1%D9G^^R8,6+O)(%.3 %NML!8K+)
MK!YHAF\W$:;3Z[%.=]^Y6SH-IGI6]YI>$VSQ)GOC4MH]M:J\X_X0N\$=W7 N
MVUK8VW8__C10?P3#9.HY3Y\PYLHS4GNP4%V^)Z1O_JB:">O!A-6];Z4.LW=G
M<7;^R5\69BU4$&*5.LP.'C"7.J-^,H^%R;9*^HYXS (Y3L,\-M\W3AKP?Q;V
MD32Q3QW'G@]43X/_F<XLO@]"][_2M]FSVQCSIG^W^F!,M]IFA,V;HK2Q.[8$
MC9-AND=1\CPVMTTTO8K0RYJNH?UYK>%#* APQ(CCCHYQUH<S=<$4VC* 6I17
MQ-J+J8![PEC+8NU^AUF+A7_5L7'7<LR<+C9E/V!+[JC58G8/<+3HNUO1FELH
MJS^DVS?[K-EM,.O%J7@?MR9H5DKA$-Z5528X;9G-C[IVE_7[*\CG;9_$9C8\
MI?WVFD^6UL@/5*7;6AYEQE<I.A2OP65E4J3J^88ZZW);69>RM>#6VLNI/;?8
MP0[=<:?9P3MB0G@<E QZW&XS/77A[;?MTSN]9J?,'DO;JG9U6U7QC7VU56WI
MMJH'R6"[[J@ZF&NJVDN:JM[DYB9>)?/,=G&F;W)RRK^X$T;F.8Y871CAVF1%
M#5<WW-J\!OU;%SV<NG_K"PP:W;^U<EU'-]Z_%<5-@;19R9ND6[GJ5JZZE>L*
MSIIZM7+%D3'^[(65)MHGN.'87=H0= $S<^;.+KME=MNLU5APPQU&I\].@[5:
M+S_[[@-_A2_!61!1G4I83!,'%.3J8OW+0C3DS:2JMIG=W\3M]]06YMW/OX0X
MS&L:!F,W-H]P8OC6@WG-5>JEMGZ*%NNU5S^'#N#5Z[%>2ZLJXAOI?_+O<(HM
M]R-=D;VG('CYWC>.F@L^<<(_.")KRU#IMKNLL:A9[2LYJM^#TZR9JK4M7LMM
M^(-'G*8/TBA@T(&\@-H>;AD@O6Z3-9M5*2/$=ON8U;+#6OGUN:A$?_V%^S@,
M64R@'.$@Z"@.J2;T@)6Y)L.FV4WKS=80-H$:&ZQK;:+RK%KUKB+G)EAXLP\8
M6:"_@NW5:;]9:FVS=KL#U/IL/I'N<UA?O7 [ZGUI9]]A,.'22A9SG(-,&/I@
M.>E(R))^[Z4UMP>=I0URI&/!?R]UXV@/P?X/LQ.KY8H:1+E2"$@5XJ,V^RM?
M:T,]V3F&]Y3BMVWG8J<!Y^VM4"2P=3<G2+9&E[57Z:Z_O6J3U9!T=N_X=UB1
MZ)MCQY5EC1@E>92-HH2W8*'[T/9;M75:'; +UVR.MD4F/-#.4=\QU!#X5')*
MP]%3W&X;@T<X'K"S@JME^P72!]\\BM[!0Q]J<=1>I(8WH.VV[7WWU=G!3+2@
M4%$[8*P=-=NLV7]E%>EAWESH+PW[I>,\-J_45%?3KM1A=AWMRSMG1,&'D@&Q
M\^?6=<2C%NM;%FLNUC?N0>L'CNGT6'M19.Q2ZU_/JP8XPC24!S=R _^ )994
M\%9VK]?2-__FNE'*HN-+'B=Z1RZ7J@P"U2Y6+I=I*U<K'SH$2B7INA#0&DC=
M-9"O[H,[XOXH,ATY5@!T$'C3^)B'(<<OIBT>7@:N508PO,C!L(V#'+6L]FJM
MHG:G@A1(:-/QO&!(995Q8 XS;=:VCJH=J(PK':/+6KT6LZS=^(A?PEJ+6)N"
MA4\=[/:)O][)*A-TMXDZJW_26?#H[)?#_DFJ$[84A,6Q%EXV&@S&.>QDNPTR
MV"]RA\+![WHS^/:6WQ-,'>DUJM)XL(D]TA;K"%9[WC;7^R5=OVY]7C9\LZHO
MMTI'E)[NB"*^L:^.*&W=$>45M%V9A4IZAE 3D\S*QV-GXGI/GY:OG6^Y8J0M
M5Z@#R@Y.K-JN]).V*W"@?.>53)@^WVKZG-K5&4=?DW9U%6G,8JB^+&:VQKNF
M;;"VM,?N+G"0+6X6KS7?V+M=6@Q<60?*Y@]3K1X\&C3U!\W:O9(67VZA:?:R
MK"J?XQ7B,VLNM]C'9/6F0JOI(9GM43*"R#S=XGWJ )YC4"-.CVW\GR;^3TO#
M:QF\OC#SR[&U]4MMMH'5&T+3=1*0(/5=$[.&T@% Z;5,7] JJVIX6KT#W/JB
MF5SPATS$6P0.N4$U;#3A:,+1A%,+PJF&AKQ)%!3X)K9_('T'?0=]AWK=83W1
M^++\)1E/:&&L>GUQ_L7QL#B2+<2QRGPJF>:G&WT)5WS]EO9>??FCON*VW>*8
M^#/[RA3)%X!SLY<\6-2]UU@[0*SMB^$ZS&YU60<'.&KD'1#+88FT1MBA<9ME
MLU:SQ=J-AL;>0;&;99>%%K>.L=>KQ<ORPY.)][DDF.?R8I[W+QT/G(BC;3'!
M$G_JP[8I>Z7 1GDM*VQ6X=G$R31T-'0T=#1T-'0J YU=^*>V]29?YTM=S9$L
MB(6EGC"I5U.!YA$-'0T=#1T-G4.$SL$9R6>!#V?#ADI8N#77B8(.,5<RKVE!
M<XJ&SL]'SP4LUCS<QUK!IBPH\):!\JS/_6T#I\RO_1JH'+*E7/8P*XLYHH-(
MLUD_TF_T&=+0T=#1T-'0J1ET,@_WX1G1JK6C*R?*T"G@3],PF+A1%(1/IH\-
MK30Y:&;1T-'0T=#1T#E$Z!RR=7V1F2^5:SF*?<#4P"DZ3,@][ :&%O;%]17-
M-$JG4PV#*-;ON.8G#1T-'0T=#9V#A,[&8];K/[U%G0 TQC0]:^AHZ&CH:.@<
M!'1>Z[0NMX97?U#36<D::YJF-70T=#1T-'0.$#H'$_N]N+[2_F#- QHZ&CH:
M.AHZ-8#.(<=US__DX="-I'/9IR-C?C0F7&GC6#.*AHZ&CH:.ALYA0V<'0YI?
M\O@NC. N < ^NKQMDAS6V>OUY++U_GL:'1H=&AT:'1H=&AT:'8>'CD/VUY1.
M,BCK(#&_A7W2WA;)T=+F*)@-/+X#JBO?;O.$1WMM5Q)4%3%K-6W6.-',\I81
MHYFE>CC1S%)1Q-2>63**YLY3<]Z>"WG%Q=ZF?UT#1P-' T<#IR[ 6>MIU2_H
M_A&F@:.!HX&C@:.!4Q'@[+%E8'H<B:3,C\\C(/_=)<!]_H-%"^K#Z,,<\&&V
M44Z]#F_O):BYB2CZUD/_=0B='U8FPTOGS6I,:&ZH  XT-U0%$YH;]H\#S0W;
M<8Z^HN;AF8/I>>)OWH&AH:.AHZ&CH5,KZ&PS?WSY670K6$W:&CH:.AHZ&CJU
M@LXV@Y&KG^LZ#(:<CR)S' 83,W(\>FAO>.CRR#R='_9=(^Q:FNJ+X<(:FYH^
M7#O8:'FIH:.A<X#0V5GY\^J'_,%'?#*-Y3S0-_#@'FWHQ:W73/O-O;9U@HL6
MEAHZ&CH'")V-SPE[X<G.@LG$C2?<CZ6WV#P6_5W'KN_X0]>_TSC5%*^AHZ&C
MH:.A<XC0J:!)6S1D3+^[FOXU=#1T-'0T=&H!G:I8N*5Y4?#B\O_,W/C)]%R?
M:\1JLM?0T=#1T-'0.43H5-#,S?B6]<.K&4!#1T-'0T=#IV;0V:Z=NX6.*F>9
MMWANVK9Y3(?0K[/F$@T=#1T-'0V= X?.:XN'7EJ->^9$]QZ/(I-GAFA/0WX\
MAL7Y2(_/UG2NH:.AHZ&CH7/0T*E*E/<L\&'+2%8)/? HAD<VA/\7NL-8%0F9
M,]\%(S<.=(,,S0L:.AHZ&CH:.H</G8J&?A,?\[%\?:.IY\8F;6S.IAJ_FOHU
M=#1T-'0T= X1.CNS?%\2X[WDL>GZ8.5R\\@+HFB^YX'ZW@$TXUY*$W7HR*W1
MH=&AT:'1H=&AT:'1<=#HV(4G9O[D]LGS\XA+AZ@U5P3/*IN\D)QH:7,4S 8>
MWP%%E6^W>:*BO;;+Y55%S%HC=#1.-+.\9<1H9JD>3C2S5!0QM6>6O!+YU]B!
ML^.PMFEV"=!8&W"S6W?"(_.2/YH_@HGC,_$+1FURQY_-B1/>N7 ._&@C?[0A
M]V,>PN$&L"O^-SWL/10<]1;)%N\4Q/_/\;'YS>7>Z)-Y[=P!(]SP_\PX& 2P
M:+/_V?S=\6;X;_/X6%+?R'U8U2X36Q['P?23V4$&D+]07^B0%"$JAFMZGF2;
MO[UKO*.?@?"'ZN?\EF 2><XT@I.I?WTV']U1?(^P:'SX;&9X"8&#VY2:7'"^
M0MY,^5DNW6Q^2/&0YWCUB=:'8NQ].\Z"6@'YLWG[-(4CGH;.P!U^-B^="1>(
MN P0XIWLE_ZJOH5_*=N_^:%0EF4/C>)#R8Z?_@KH+$!LR)T_C@=\'(1PGBD1
MQFK(3 @S0VY9VLUNF+T;WIEH;!.TG6.5M<AK]2U7(\1W*UG[J^14Y,DN^^.Z
MWUT2-'O^@[LXS+S$V^]I-&CT:79\FM5JDE:M-]J=:QA$(/[V;^\Z\^_U2J[;
M1"=<MKV<\O#EV&;P/ZLZ*5]RK:U#R7ZWC'#V>UI]^=U<_ME@PTH0.85%< R*
MX]4#*F^:)"IX^57#5LL5V6I<9J>OU74RBNBF8!3101'H%J$D4\(/'D2;%NO7
MCCLZOO U2#(OW7 XF\P\)^:C>H"E>@+R%=*>%G_D:#'CA[S1ON^R#/*;-TV*
M2D8/E"PW#AQR)&O8:,+1A+-!Q<F9NG%=C+Z-0^<K'[M#-];0*=S^-M@RY>S;
M:-R6EK9:>L &#J3OH.^@[Z#O4+D[;#>+7:4R8!K'^@]1:3Y[V>AL%:U_T6ZO
MKY/(;+_+D@FY;;<X763IOFW6LVS6:_1?!-#-7O-@D;=6JN)F\+8\95%CK<HL
MUV&=1EMC[J#X[64/CL;7WO#59XUVB]FMLJ02C;@*B\@C4/-ZO0YK-#N[05]9
MWXR#Q=P>6.X(%4E 7*>Q%Z3MOS<I>?Z/!T[$T;R;3+D?.9C(LRF3\66G6LK#
M%>NUHZ&CH:.AHZ&SJ,XQ"]2!3KNGX:.IIX+4LX.FK%N8$)8F-(K&K2/WP85-
M1K#4$Q9:U8@$-(-HZ&CH:.AHZ%0).D<MJ\W:I=VI7NG$T9#9K:=D*S-,L^->
MIGE]A0Z1&?)24'%PT"3P7&SV#;.'%JO+%K,;+=9OE848WSQT-%P*%^LRJV&S
M5E?#1\N<EU*/W>MNU\=R8!Z6,OU%>5HB.HATM]18E]&\HZ'S4NAT+-9NMC1P
M"A<KRTMZZW!I,;L+RHS=T/#1(N?%U+,][CI8'XPS'(8ST&!<K.3B44RG@#]-
MPV#B1E$0/IE^$.MANV^&5S1TECH;.JS3W9 7MW; T:2S5+5CO7:;63KG15-/
M):GG,'->+J)HAC6%J,MDG2VFXX_,1R<,'3\67IF04V<B],I<7%\QT\=9B^K;
MPR"*M8[S5IA)0V>IJ&FV6=/22H[VT*P#EQYKMVW6;&KU1LN<%U-/:WO^O0UZ
M:-;72(IZB!TRNMX\,2< >',W7^X>8>V&=M%KGGF!6M6P64/3CJ:="M+.-C)5
M5M<AE!.C1@C3Y*RAHZ&CH;-[)[K=TRJ&IIRJ4<[+%8S-=#JYN+[2H9"W2=@:
M.AHZ&CK;@,Y1N]E@K8XNAM5T4QFZV4&.Q^I'._^3AT,WDH$2GTZ"93.8;ZJ]
M'F^-[#5TEBW69-UN61O&MPX;33D:.AHZAPB=K?L]7I)1>HEYH?XPF'#SR NB
MJ*R7\#X:"&^2&-;9Z_7$LO6FW!H=&AT:'1H=&AT:'1H=KT/'49<U.CW6[I<Y
MH;8YHT$C8^_(V*Z;</Z\]DG[61273HXKZV[UDDU>2$>TM#D*9@./[X"4RK?;
MO*2EO;8K:ZN*F+4FKFB<U))96GV+-4L;+VK$[(-9-#:JA(V6!8I)AUFE,Z(T
M6O:!EJ-FGS6[#6:U5U4:7X:7577XJJ)DUP^*S6R[S?JE71RVQBT[JWZL80QD
MQ<7>9H!( T<#1P-' T<#YRT 9U4U(J,MJ%4D;#,_/@^W_'>7P.3Y#Q8MJ ^C
M#Z,/LYG#: .CHB); T<#1P-' T<#1P.G^L#1F0>U]7WK*'?UXD0:)Q5E%IUY
M4#UFT=BH$C9TYD$ET:(S#RJ'DCHD';S0PKC!QLO' R?B(^S%/.5^Y,1NX-?*
M(-,5K!HZ&CH:.KN%3JO=T0V;->U4DG:VXT5<?@P]]N&M4[6&SK+%<(!=F<O\
MK<-&4XZ&CH;.(4)GWYV;K\-@R/DH,L=A,#$CQR/]XX:'+H_,4W,:\C$/0X[+
M!\,_-&(UV6OH:.AHZ&CH:.CLP00Z/*?'"\_W@X_X9(JAEIP^<JWUD3=)^1HZ
M&CH:.AHZ&CI5@L[1!A62S360VXQCY"R83-QXPOU8AF',8S%88NSZCC]T_;L:
M(5*3N8;.2Z%C6\RV=!A?D\X+[-ENFW6LOH:.IIW*T4ZEO"%%X[RU/O)625]#
M1T-'0V<;T.ET65NGI&K2J1[I;,LAXOHC[L>?S&,JV5&5/'C&3V;N5ZM/4\AX
M3G)YK*"P\/_,W/B)#N*Y/J\1^C5S:.B\V)2Q6%=;P9IT-'0T=&H$G1UX4+:D
MO2B5Q725WV481.AQH4,()48K,)I7-'0T=#1T7@>=([O18IU6=QM9!(<-&4TW
M^Z*; W*VE%8-:V_+FV4-#9UEB]F]-NLWRWH9O77HE#7=>NMPL5BK8[-^JZQ9
MW%N'CY8YJU#/0:>K;,/9XD3W'H\BD__)PZ$;D1HS#?GQ&(['1W0,E>]2(W+0
MS**A\^('FC7[^A'2E*.AHZ%3'^@<D,?E+/#A;)&L3'[@4<Q'9@C_+W2'L=19
MJ#C9G/EN')EQH-NY:9[1T)E;K,_Z39UIJ2E'0T=#IS[0.5 W3#;GY5AJ+]'4
M<V.33DCGF$TU'6@NT=#YN:O5%DTV&CH:.O6!S@[:K;Q$+[GDL>GZPV#"S2,O
MB*)59S8]O_+SZ"Z<HP0+FU'@N:,=S/\KV6OS4QFM;4\UT^C0Z-#HT.C0Z-#H
MT.A8,\VYQ?J6Q9K=UA8QHO6JRB+C@.;9KS6O=3MT=% CNO7L]!4OH>?95P\G
MNV:6GMUFK799_JQ&S#Z89>?SH#4VEFS5:K)V&_Y;[QW6:-DR6HY:+6;W+,!+
M6=:NGF>_CP?EJ&MW6;_?WB%2E"[_U]B!(_]L&,9/T^PWP5YHP(UNW0F/S$O^
M:/X()H[/Q"\8#4$9?S8G3GCGPO;XT48*M^G/&UEN8PMM^%P;72Z/QR'W8QZ^
M^_F&<_-T. PF@+$GP+UY&<2<\C>_B1:KCF?>Q$[,L;59M-6C[."V.]A"+%XY
M["=$_G^.CP&UW!M],J^=.Y A-_P_,PZV+2S:@CO][G@S_+=Y?"P%X,A]6-6W
M(+8\CH/I)[.#HD/^0GVA0U*8) $ S/.DP/G;N\8[^AGDQE#]G-\2K'O/F49P
M,O6OS^:C.XKO$1:-#Y_-C!1"X. VI=X#.%^A5$LEH5RZV?R0XB$O*]4G6A^*
MZ>#;<1;4"LB?S=NG*1SQ-'0&[O"S>>E,N$#$98 0[V:_]%?U+?Q+V?[-#X7/
M0/;0*(*5_/WIKX#. L2&W/GC>,#'00CGF1)AK(;,A# SY):EW>R&V;OAG8G&
M*B7 ?QK 6H--K5<B(08_GPX])W0#^/:%/SS9Q8[BQ79'?WOWQ_]KV 0R>J13
MV8Z)_5B::'[S@L=H%V?Z%H1F?,_-?W$GC,QS+'Y<]*\QT_%'^"][^T<2BZ\E
MGE8_P&J"[-U*CL_4J5FJBO77SPDI^4JB!L.!\;=_>V<GUR\$X]9/5(]+K.KE
M?A6R<Q]^Y/@XX+K>:,W4E)7!VIE_N4N5A8(CK8T)%!U"<M!)LM)CG6C%PE'6
M)X!Z8M/>*3;7B*=L"FUO :9V'5EA$WC8S5-52F ;I:5-T,H15G2"/C@J\ZOM
MD#A>%MM]!@K+O5=T9%*!QZ@"F^,PF)C!E(=.C)X19QB[#V[LKE[-^AP:"_2/
M%4ZXJ23;]19[Z<$T<+;""B4)R-*2Z'0^K$WXJ^8=RRWL#R\77_F5K/7/6A;*
M4"N6.$66"[_G\EQ>?MPW!\HN:W1ZK-TOT^8V!<JJS"NCHYV._CV+8N%+B0,S
MY,/ '[H>-_UYSL(_XR^'^-;,(CZ"/ZN')O#I&.EC\TD+5/W:5/.UR=?AHA-L
M;7[^RJ? *"X1/GGZG$D I_HO_:)&R+4Z-NMLH(BRGJ1OM9JL4VJG[I?V5T\H
M?04;W& 5^O' P;< @['<C^K& :UVAS4:EN: 8@Y@5J_#.NW7M^@]+/E_FA'W
M&($:\3$/0]2(<E-(:H3I5K\+>'Y]-\-Z\L&FBGX/]B4XNW?\.QZA13!VW-!\
MP'R,W ADU))&/'0?@&D>5FYP?P"X/^JT.JRY@:%PA4;W(4.FRERQO;?A,O"/
MR41VT7?-HQAL:@_=TV@_#T)W=,=-[)F\QACP \!UO\<ZO;(,3?T\5)<1=O(\
M_%.] J@? 2<XD>D#FPA7TIA2-D%E FOBKDXO0]=FO<[VS,/#!DZ5>6)[CT/6
M8G[@_B@(S:GS)+.4-6[?!.5;#9LU-C!__&!?@^]!%)E@.(_<:!I$CH=VPG@6
M^FX\"SD9"C@.:XI<42.T:Z98MEB3=7L;,J$.YC&X4 ;",.U3#CPQA-UC,^)Q
M[(D8FQ@.5R-D:U98[E2U^WW6;KQ^7N)N7X@WAB8=%:Z7=O\BCR>*9R<"62T<
MG)[K#%Q/9]N]*4JO;/[#3I1Y+,.=H6LGY$/N/F 54HVP>V2Q5G]#T=\ZN?:/
M+!NTE W9L%N?Z+P!,K\.^=1Q1T+,!_$]#\WA+ S!1)7ROT[(!7G1;NJ UB)@
M>EW6WE3"SSZ:QVU"SD^=IYH)>=MNL$[S]>.4ZZG@''4:368U*D?U6\SN&0Y#
MBE(EHKZ>>GVKU5O2J.W-T[UE-5FOM!C@P*7]2\I$%5\DB0V!;T[#8.)&41 ^
MB0( ?R2]F;&+_0A\[,M3 L&-UJG*;VRN9>WS!+7!EK52T#*K5*5^9;O:0E5,
M(Z)$'V@T6-=:J_ZXDAXMVG5Y6>E+Q,"EJ@$ZDD5 '],J(,WKJYI8#-,&^ZTR
M)[_F]QTBHP6(Z#-KJRR_"P7@C6EHVB]]F'[IES]7SP;4<<8W=CTXU5T/-+U7
MA=YWXI^[#H,AYR/9_R-R/)Y+JZH5IG7VR++LD:KF%K["8?<2,^7"CQW_CKP0
M,D)_;%X[<4&JK=:+2SU@_27Q#FVB[! 5=J/'>J65^(=BH.S>,^$F*F%I(RQ-
M<YK]JXX*N]$]&/:?>^??F/ZEC;2Z&FFO]T_(X13:/Z%)OTJDO[U,BB^Y<O?Z
M=D<Y:MI-UMQ4FZ ZI<Q5N1!@)WZY<RK>,CW7YS6F_RZV(=U0=R!-_H<N]O.^
M:)YR0(TP:[%6Q\:XL=9W#H[R]Q"0241_,,[DS!7FQQTRUFUFMQM;C4 <-GRJ
MS!6[>@]4;!(G3/'(/ 5^4.T3HS@8_E$C=&\W&'?8L*DR*^SD@?C!1WPR52U$
M$VZXKBTW'&V0';21<.B/PL7UE0C6U=8JUHDJRWUFG39K="I70[PCV2_;OM7<
M'M LL)0%J!'<MA[%0\K5REC'PV R"7RA_% ]F6HA38?)]-*%!X310)H1'\V&
MNOID4URYI0(GC8ZRS7JLW;99TRJ;HE#!BK/]IWC!H_G@XNSMP9/L( P+B1I4
MG>BU'OTU@?9:K-O<<<6C1DC99AUF];K,+AVK4D&!H).^=.;+?H"S]V=LA1?+
M]8<A=R)N'HVX^!=F)HN'C%HFX#\P3OK@>#7K!7[4:EOPMFRHF6F=W'X6:S0;
MS.YN;ZB2%N@5E5D:.'L3Z)LP0G#:.EL0VHQ$.3;&"=TA^BB&]+$!OW-]7QDG
MZ.[CH1N,M"J\:II-SV:]1IF0U+;)CA'2:MNLW=QF)<IN(EC/RP'[I+U92<#]
MT8MDP"H'>2'1T=+F*)@-/+ZQ(>QK[K2JK@3_=<JR[0I!MEU!H+&RMG#>&%9T
M^YSJJW$:.+M]T#;@J4A&\I6ZT#5*-;U71V#GSN?Z(]"]/IG'(BR=#U7;K^D#
M/.*#>"Y+2<6AZ21UGNMJV\QJZQ36LL7>8N+>"FR!+%'3LA^[S[K-#15Z:H:H
MU#.RB:363"*3REMZ$_._.UW6UJ4.!\@6VWLGK@ TKN]XZ1N1#+<\LMH?/B[R
M!1VB?KS1;+6859K=I9FCNLRQFW'(<KC($S("\@I/<F!Q6GB=3/!FD]G][<TU
M/6S@5)D1ME@&-)?Z[<94%B%(_TVH3E:WS3J6[B-P>%RQD^?AF^.&YH/CS?)&
M!4881SQT'YS8?>!91AF[810+QQ1\='C/Z\LZW9;-^CVM61T>ZVSO05F;7R(^
M#&1DOO8,8[6;K&=I._WP&*::;TU\[X9OA74Z#=8H'1&D6:>ZK+.]M^:KBS5H
M/HZ%ED$1&HF8-/"HF_VNR[F7+=:RVJQM;V^.<.6?CS.:_!G)CC9S;9WPN<C6
M=M<(\9HMEBUFMUFWW6+-[O9<'-5\'9:SPRAY.S1CO$W&:#&[:[.6O;UL@@-[
M,9RE Z9%<QR5<57:)J1&!*+99ZE!QGKM#FLUM^?^J^:SDHV8P(8\? QAJ_ O
M46'&R<7U58UPKCEB*4?T^\QN5;.>>"?/R5<>P4>=.%6YIHX[,OF?4^Y'/)+\
MH#L.OE'VZ+19J[%]^_ROL3/P^,^&\=,T^VU!T^:M.P%*O.2/YH]@XOA,_()1
M ]CQ9W/BA'<N' $_VH S#)*=!K##=!.KYMEJR%';>O?S#>?FZ1#4*KC0$TYK
MN41U"UE&CBUR//,FAF=E(CI4;.0H*1PWM)Q<Z/\<'\.QN3?Z9%X[=_PS?/H_
M,PXL#XNVK,_F[^CCAG^;Q\>21,$<4YL_5S(KMCR.@^DGLX-22OY"?:&#]/$3
M$0% U_.D8/O;N\8[^AE(9JA^SF\)LM)SIA&<3/WKL_GHCN)[A$7CPV<S0X4(
M'-RF5!;#^0H%:$KR<NEF\T.*ASQ3J$^T/A03S;?C+*@5D#^;MT]3..)IZ S<
MX6?STIEP@8C+ "'>RW[IK^I;^)>R_9L?"JL3LX=&[E.L]]-? 9T%B VY\\?Q
M@(^#$,XS)<)8#9D)86;(+4N[V0VS=\,[$XU5EU6V(TU ;IT./2>$EYB9%_[P
M9.OR"W84 ML=_>W='_^O85MX11+/2R69N8N3?0M",[[GYK^X$YKG/O:M^\J'
M?#+@H=FTF&DWT&^\I7/\>Q;%[OAIPP2TQST H)=7M^>F=6+>_OW</+OZ]?KT
M\E_FZ>57\\OIS<6->?7-O/YQ?G-^>7MZ>W%U60_(PJUO@83.Q M=CSOE902#
M]RV<\-![ N5C"(N-U.^/D'E0N[4;GR4 Z"?KLP&<)?^@%I-_^0AZONF8]]SQ
MXONA$W(XPO#>!W/D[LF4>@XPI1/#PPAO)TCJ",Y\YW-X1;%Y0^"3C1!-^3 .
M@V@83)_,([G5KS]NU"[4[,%PT%$U#5T>.^&3.7 !(.$?P-P@=()I[$[@R3:'
MGNOC VW&\ Y1FF,$!)RB%.SW2$  76#F-SX(9[B:W;#:#"_C^L,@G 8AV?;P
MB:]@YH/-ST6_B7LG,ER09W *D'%3V&<*F@NY"0:SR/5YA"N87\(@F(SQ?6*P
M,=AFSB@XV04E[8A'?KC1'R)EX3= 7Q@[KB\*F>O +UEJ 8*(9H-_ W4BE3T@
MZ<\BT(S4]6?9ZQOCD-2L&'@+E"VLPN"AZ)XJ6 &'3P!U()_!&P6?BF+B"*">
M$;"'%TR18$_,F]GPOFP3)%!O-@)Z',QB$SG.#X"[@/J%,XH1?:J?@RDP'8WF
MOG>C. B?&!T%V(_L=YH5$\!YPO2$+/FR,QPB/</%4;G&+P"]8]()?&;$P=P?
MD4H)Z_S!G[#="K"SSSW!K !\N%O2?AVT S@^?#]TIN[(O N#Q_@>.)/6#FF;
M>QYQ<6M&(%(XF !B8,U) +<09XWOX49T" *:B3<>PJ<"D&OFP(DXR(U^Z[/I
M3J8>'<% ,$8SNL]XYB%^_N3#6<SIJPGGXJ=(IA#$HAB%P-V37$QM-@:K(7@\
M%FYS;(H=R0_(;KFP#W6>"=,C13Q\<(?R5'06)X;%AW"MD"-BA7"9!#&F_W#S
M/S.@21 ?HQ2H),0 V4-0O@:(<_,.Y)8#%,:%?,U"[-'U//Q4>F,D.PEHO!K!
M&J6Z@&>4T-M.A-36Q=.%[Q*M7<\&'KPS5^,Q?!T3I>H@GJY\\Q2>'\^TA4YK
M"VX)^9U+%.M2Q$9JWL88D3P+ ?\")%,!DD"")'EL+ZZODB<=G\@1QX<>*)##
M)[%3!3\!-0&D!! C]8$'(HOOA2A3GR > F;'7Z(+,'LD(SG2IQVB8#7_@' ,
M9%T%JQ\IYSG(VKF- CN7#%KAW%UPVLF%[-8T;W//?Z[0 Y'[\J)+;>Q,7._I
MDWGS-!D$7H&' _;K-9?Z%)]U?*3\5[K],Z!<.-6C*%84](7OD6D= ST?=T]:
M73FH  .;7 8HHZGGTF.#]![,8J X,1(Y%\8\0I8!TQ3_?8/?^"C$<HD3?JES
M=8'HGG'&;N+SFSS;)I!Z8#0%.@UP.U"%!ZJ0 \]DM@P0E8R92L:=XL-(OQTY
M,9H>\&3ZTBA "L.$=HQXC%1K?)"N4>KQN'<>.+S!W,<G'DR;J9"1H'HX([R7
MB!R&?.R1<DD2?)&:47SC*44ONR@]A2;:-T2TCQQHS",)B"D;9)J>X3G&<)*8
MK,^+Q&S-O<WD@L._*S-6I'' _QN!R0S+^'"(9,TO3_"A2)/6&R(M:5F*GIEE
M;V:2\_"()@B83N'0C40BMD/3@82<!,O+C4CC[#18J]'+EUB;1TW6[7;43\X8
MC&/SSGW W<03+XH=."JU+?U"OU6*M%NLU6^S1J.U0)22=*2*-Y_L2<0YI&0W
M\4P#.369W>TSR^K.TZ+=:+%^JVVJVV^.H6@?.KJF=$WI2W51SZ-CJ)3,-%LY
M\!>,&#F[]@LSOQQ;^#\V/>5?CIO/,0+06K\'3&7WYYF@8[&V+4RI_%_6)UD\
MC";;-TFVV4SBC!?R+U%>=O/A#$ET/M>8O$US4OO(_6BV[ [K=D"'V+B$7A#0
M1[!5I]M\)1\0.QZY[L=478*/3F?A\!ZGTJC[;/PZXJCBK1R;><5M0U=CPJ 8
M<)^#Q8&&[C#-*4<G.6 05KT3PB:A!YD2:,ZF$M[IMTZ6)G75PSW;R;IGE6L>
MPRP>)TJ/(P.]I( TFV':7*/1,&<^!B2<&/3J>4\M+"H"C>];)\TVN2?PTR?F
MN3.\IW\B?$$#I[C/F)@H\+G4S>>'?AZEK?0-P%GCI-&QVU0?D/>(B&B'C!E(
MRI@C=]Q$DGR.XI=LGG6!B*V-=;8F:G0R'AIEDLP#*;?1^T[_I-,H7_;$_*;^
M9."?\# 8X%(Q+.G6%OC,)(5'YM0)T;DNPDK2-H(/N?"" [T#B7B!Z+@3B%'T
MY%Z28!IE@VN%5I>1!6H3U.-NNS'_DF?O:3>P 921_\226Y^2)) #7N$#^7QW
MZA<4(<\*MYC*\V7H10CYD+L/Y$:(4;(/.1^1?NY,X:<_W0G(!N_)>-\[Z1@@
MW3QU>>$_*RDN02^:4%Q"AYX.^-2E$XV<_XBCT0W@U</0?T1/9Y1D)YQ=7<HP
M!BV9^?4_Y>^9 >!(G'$UB'?598]5LDIMG56ZWZS2OLXJ/2BF*@G9TC,&\ILZ
M(<HF(QP$HPPOB!8D\LG+O71.X1.5>_:M;I/9H,JDSIK\VV\U6 _>^Y=HV.+=
M]XN>^_9)JV4>O>]U3QHMX9><!E%\G#YTPCOY,54:3HQ;"KID[YRM[\KH%4(>
M"'4 SWDUC /,*E4JGGB^,.D"7D<WI)28G!+8K<$[4Y!W(-29G)UC6 Q=:SVK
M7TH W39K-BSC%986H.P!$[$PF ;X&B4DG+$]SRG!!^GX[-YQ0[KTU_#$_ <L
M'O(G0'[HP"_AMP\\DF&](E:1"KNL=E*I#7!=+&]*S@B'G]!5*95&PD4D'B[1
M4@V1\Z3 Z$;F>^NDCW3<M%:G8]I%K4%A1P>0?OR$:=!XKGK27@FZ4+(9&4J@
M:JWNYTCPJ<I>-<]%X_P+'Y]#)))K#T^6YKG2Q_&72FT$ZW<(CV$V'^8*M-A!
M /1'"7S ]R 60D1!A/IO@';P2%D2J#2+V)QHP(EY6]*/7;"$$RG:DQ]-%=_D
M8.F=G5E\'X2RN:TSFK@^&H%S'S\Q3N.Y!9*K8(2;"[O&N;L+^1T&#?T99<[+
M0Y8P,Z6>#8.9-\)\,_F< !1G%!>'?Y!KDG0$8!D@91X917<12V F(_\3C0@P
MB<$<)I-8F3B6W<[^O)[_(I/$*4PE"M(;E.@4#4-W( 1 'F)UXIO^*GSC "WZ
M,^&2HZ). -=7YP'^<<G!.B5_<XAV[*7,]'IO221Q9W@/#.&;OSI/IM5<83-3
M;4;+-,4R:F,T>?_AX/6O865 9#UP@<"Q5X$-:F/*8R00 7_YS7?)>P9\#C [
MPQ31(/1=QSPV;X"%OF%S.&S^+OB8,ED$<.TF:%P]:L,((B@:/XF-@ W_!++_
MU?7@ 41GS;7S)+P4 SBZ$%8RV7ADX/E4ZO*?\+L(Q88'SQ@Z^!R0&>0FJ0&:
M?AK\3!+@A\S&R<B16N>/*G(KSK8KRDW*UHO,)]4EN:1 @.C1E"^#\/T49QG4
MAG9:]:6="Y1AH.A3+9U9H&89A,K[P!N1M8A>P >9M[1(0%C-$T3XL*"_FU*7
MU",,LNQ.*$@^)RH<H[S!0I_DYW'\Q%*Q.:8I&+0&/AZ@C(PX*K^N+PHP\L:!
M4+E@+Z1-G)@1\D0* WV:XUE(B?'B ECU@(42^36R-Z7<Z'\XOBPELELY'339
M$+20**D028"3.7X!D 18,I"(W#]!(_2-.?9K%;$? .C>Q=Q^'LT\:>0@+LC5
M2^*==L^J>D79%EDV98:RD)D\IS(]YN;Q"IM'!C2PY$'@.R17-U9>^ !U=!C(
M0R0M45&74($#=)&%[A\92Q^?QES3U-PAA#&44U$'H,[Z65]RAA@15L>)[YPL
M*Q7%O#R]^7KZO_B3PFN+Q&6K!G+J-!*9A$ 3RJB=%^ $6J5,&YD_,$"IA^I?
MJCA3$<DC&+8BHS91^1>ZKK%,0BV;3[ 5Y./)NCLLT5/VDH\9:J"#"$*)^*82
M;J75("&08;JH/._VQ+CPDX@-ENT\@6QPAC)^(UF&K*)',FD2V&3L(V<1_+G-
M*7^#&KO AV=39=;XW*&PZB,('6Y(V_^;D%1LCH_E0:@)"SJO1.0FZWX0WHH%
M!DY8:P5PNKZQ!!^E()Q'PU+2R_ZA!IR'TBD3BD/<)) Q(^[QC.C,,($AX961
M8( 31QCO0FR59)"3+P$#<KZPQ_%CZ!F*<%)Z484\?1)1\FFM&IJUH;5:W$25
MRY1%2H2OOV10;R[:,E!_@N=^ZCE/GTP?7M1W/TM/4$*X6; +I2T?URA*TEE(
M#H*[8'K#W][9[TJ^5QR4*0[E+-NRPB=;M9/5"MA;:7<98\N/9YX?CVX]"YC.
M?&BO-)JXROY%L,SPW/R5"HZ[RCZU +R]=<"+#B!;@'@M0&/OE1A?UL]./A6=
MSF*$O2B"?I:+.94X)8[Q0181ETAHO!9&-#O,MOOTX2[K8>:LU4Z:SQ>&ONVB
MJ/^25%+U[*UVE?<ENUK-Y[XO(_!6<P'AZYU@:=Y!Q2^/?;(W=?<M=##=("DG
MT4-)RSV[S5IM0<BMOL6:K3(R7@=]+\'9*GCJK?6E9719A=NT7WF;[<K2%0YS
MFJ8J8ECB&&,8SM2-X>=YJ5E%^+>:K-UNLF9_@?L/FJQ:\!CU.ZRQ*- /0I(M
M)ZJ\_*HD^ 55M1=URSI0E=7H;(BJ-M>RM2J9L ?I&LGY/XIP=S.\YZ.9QQ,_
MXH8\48J,5BW=6L8@J[LHGENQ0J=1VR]RSQIHGN]F_*Q)M]#_^)5>D9+NG-25
M<\'G^(HSOL#-L4S:[MA$W[2S8F7?1!7ON8;GH0J.AD4F_B>="@TPT>0RB9VF
MMA@CZ3@4<QY=;X:??DYG3FSI54WG-8UTJR0YO\?Z#?BOV5IB)*_M#]CQ'5!S
M:;-V9YFAOW-M>).44ZP8;_HY4Y9KN\-ZC05K?->/JSQ-LX>ZZ9JGV:Y\6-S[
MRP+2L$C."Z(HC7Q'U C2'<R$)CD7+E=I-&5B8CWH+A@!!8 ]:IRT%YP4BTM]
MW.()K)/%9Z_T!#MAT8TB<A-<NQ(<>R>]A6=UQYCLGW06 ES/HK(65B)HJU]$
M,M'8O$[JBU1 N0Y)#$YVBLGR?!R#1@2%,ON,^N]1TV_*W;OC/KQ[6#J-W8:G
MLNTPYB[+FG=LL^VE?9-_\ZDU,?4U(_">3N#@0R=I9/K+Z>FU2G^3"2,'#>RZ
M[+%*>6]3E_?F=-2=E_=:#5W?>XA<M>49(/:)>?/;K[^>_O@73OVXN?CE\N+;
MQ=GIY:UY>G9V]=OE[<7E+^;UU?>+LXOSFWJ\<7#UWR)R@9[#;["/18VF&X@'
MV5%%K87/MRA/0K^O&S\9HO*Z\&$N>,&?>ZMQ3((;TBB09$@ J,P3YP]N<@5N
MD30>1;.)JC*^=V+#D95^HG0[H#XAJFLOICE&$9=YX9X+,@YT;%<NA6G^H+3/
MDIQVN@EN7?8EL<U(=E!5:?H$*2,#*96N6G0>](/[,YYOG6*.9J'JQ"*^1""E
M/-D3\W08SZ@6 /.#(UD9.7*Q#9 J0PBB#)SJDA5;3(14?@;O^R1ISFQ0=K7L
M-RJ:D*9DA*46U'HJ1T7_GHWN,J-@)F"$F3C$DOKG^ME/BP1T),81-@: \\@\
M[PEBZ;_R)RQ5$-$0)"09JY09[KA?\G<D@5RQ0D'%?*;.(E\SDK;UPV_F2J7P
M&ED:,";.$R:8)ZG9#O!6@%T 9V$XE]2*A<P!HLQY<%P/'V5Q:$QE3VMCTZ+>
M#*!J0&H@UW_/8N\K?/5!]+NX\*,XG,G)BW40]>DDMM-4<M^@5]$)1Y'YA6J2
ME-WT[?3FB[*;C,+/GP4CT7 :B4A][?3F+*GUZUGMXU:#F3^Y/Z=@%73_=SZ"
MX]Y]@D5\FGQ"=3:.;Y[#+G%:I7_UJ&KS?_JK^S,SY,P2;!-XST5)EF]R^L"Q
MY_I_\!$)<EPQF9I"*>_B,\FTG?PN1;(&!*^J8J7-J%6V_**!)?VN'\W&V/Z.
MG@Q1<O]?R9PS7R9@J0*0P(0G)49/$)4CR1-FGLJ0J^=4%LI348AZ?I[24314
M+C%VW% 42('T"X/9W3T.$/)Q"HXHEUI\1K)3C+@02&A%Q]G;NRG%"Y$G*^9,
M5S:RR'X CYQY'G%ZC"S-,<?<B6=)X8O PQ-A83+@(PSYC5)ZP#9K8=DAE&A?
M@$UF9U'KDJYHI"N( 5ZN;,8&\CN@YB"P*%T\@2*!5X2JL;Z%?D<?FP.FZ(M
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M,S/#Q7D7&'.)5$+92(W4E/L/GJ1"G#M<$N-U%L I(T?17"%)Y370Q$X2OAW
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M_I;8PYDHZZ%?,%>2*XQYT@>DW2[B %DO/C,RE8+JU1=1QJ0M0=)U;'YN$*C
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MQ&E6QZ/@D5KK%9PE/89ZCI.!JZ- HHO&:(_$V%7/8]A 7@[U!<P1YP&U8;;
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MQ&^1<931OT2=B=1=Y5Y)[_U\NWVP:V,:*1.QHE,9N"N-?C2%QTTL(4XZ/P'
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MJ4'U!F$*^Q)?IP/ Z6L8] AD]UALRURH!1'-'"Y<^0.\,"*&C>U\@7-&"$P
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MK =,EU5=RH\D.M?G\GS$WNAX,U3N&JH^<ID$5J:"T3#) :$71:&G!B\ J ]
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M4]9V"0TX3-5?<1^PQ683H=>G2C(2Z11'BH8NY=,Z^*ZB <,Q4]OGCX['"(M
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MR>J_!&2(M?G6%F2 LJ?F)9&5E-8R:7E ;?9L/&/HAK8]^7@DER.[Z"[):%5
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M,E>=']W+K<W2P.K)*010(&2B&TA,0&_\D^9U G8N#QI-B=OE.2^7YZX")=^
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M'%YBR:.#R2PG-E_E]3CS"M^4T#WPN6&BZD@\B<CS;3?%>:S&<:8G@%)D593
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M',$]@A"K@9S!_[UQ"?"."O]O<$H)/?I"&_[O3<<^&X)RW^647=$UIX_0PZ%
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M#_?[QZ),5;Z6A.PB75.^JDJ36A#4QG^1Z.3KE$.AZ*Q3#H6BLXQ2]7:@;"Y
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M:V!J8&I@U@=,;#6$N-(],[?'3\IQ3_K\T)'77_18[YG)D.>1JEHXN*'HK.I
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M'Z"JD^*H#U#5V6SQ@K1S<';ZCDXDY)*%M/&S.5G(L^C[98C"5B *+[2!-I[
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M@N$+[C</3-N!C..7']*5<?3E8G\U(X/BP[\X-:8:@? ,Y] F^ CHX^0,+&/
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MAN!;17:IM?E*D<^GZINQ+/PJ><3F-W>7MLD@E);OE>:WYS^_SXMIO"Z92;Z
M V9?^F+$0C(EO97?S'6P_]!;16[I6\;R8C&?DN)6RKCBRKA%VV0EJ43:UW2%
M_@*&[L4',\Y^Z>VG^Q*^^0S;S*>A1$O62"P#IHDABZMQ$^<X-*ZQ-WZ]Y !/
M1[O2V[G9WS]T5]"VM$EKVJUUH%HP)T\-\QI-IF9_)%L)"3M"LZW5;./^=OQ8
M^[F+HNNU<BVOD8+&$Z<)I$OR[6B2?X<I,<D,LS7O.24_219&V-!J2U&<]"XO
M-J';(HN;7<7+TO?H2L3+,LC43#"!+B+C!C(U04VQ/5X62-8LW_X>S!]/'BTU
MPU:9&21K3MC1N-[,&=G]4=(U4R7X15QM2@Z6N@6#Q)?R(A9?ZT^=_ZC\:ZLW
MN8ICI6Z#+/!"*9DO8[,BV<],S;W(T?/W]P-\A/\@Q/2,;432/<VR3;5O(P7^
M@*5I\!>^)]M8LS24<,UWX[6O30%+G$D-U[*-&H,!@BQ/J!+P"1OS!FFCQDF]
MU\IP<,%FPD9EQ^&^*.Q 4!Y 99#LN)*1!X0/RZUVBQHI95?J%$2A*/ E8?4T
MAO\5R;5"\]X#9%@A_@J;MVVLE"J).KQEK+MO!-NNVNG.7YJ%]LG-:^_X:3N^
MB(3L$[;&+S!(PC5-=__D[SS70T-5UT&%AVPQ@B#OF'JV2#Q!6JA9K0&A $$\
M!'=;@ (VR O-2S =*K/V-N^>'>[Z0L7("TW=<UW@"Q61K^0S:P.2I#575@RM
MT9T?UZ6SBT?K5AG(&8_G7<K%Q*/BNGP,09^]I!R,?7]=E">O<8HQ[6DHT9#O
M-;_R1C@?J=$54H?CL16+<;Z40GX3R*1G8Y^W&A1-4;>:VL=4$@I\,86>GNA.
M/WT3^^:;\-</NO,WG$IF77%=9><V&ON+1W=<+^I.@_DL%]VT:-AMZ!DNI(,A
MN]:Y.^_SU##]DV?GRJ]>R[RZFO=;:>(4VZP3)1L'GY$[@A:SOC<>AYD0NNF\
M,,4-XOY%H<J7R^]L!-_&(%WARRCN[X1:[]1>*AB<7[4A,DMA0&AT;K?^U*J5
MDV+A+,T F,2Y3T$:[/F3?MUM,9K<!UR)AUI*VDL=IX9Q!M5-QQF\*V"NHKKT
MID>YR)>$39G8*@EY*JOF+Q@?V1K<L0X$6"7R!@@NGZDW/QE6[,>3Q^J/41J;
M.BN!>>H-P<3D&C/\<A]GZZ6#?DJB_M]*,,X0M*M(/'7V<;D@\M7*IM.[XSJN
M.23.>O>#WA H;%A!VI7GPOVLU'QLG^\ZR]@9-P':;:C 9A^)>#WXIB/>TO],
MAG%6(%U!M*4-)MM6^&*J^J8D212+*K'#O5:0Z_G]K^EUZ[5QA?:EQ5%41Z-]
MH=FDX$U)K6_7!N3= 7,5G:8W1<I\<3OY_S[9VL+04759 Q @9PR%4%Q!J_>&
M].?D619GDPQ[ER8C4&?#1*XB=P0,]T4H_OW//E+J6A!.2:[)NH=\%'+='**K
M:#9]TF@E2Z+]CPW]9+[E<O^=^!WQE#BX&W6,+*Z)7KAK8RSK//T%3TI;!E^Y
ML6QB*/W+P:/Y("4]8.)7!S-OT4GV:_013 @_^-9!B)/[?6,\D?499+:0SD=
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M:)E#65?G9% 7OD["M\D_:-&<A2%-_MD:N%?LW3#H'YIA34UT@_=UK$%E'3
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M,P0+=0QCG?KPAE6P\V@_/G\7LX7/^+;G?-&EG2\J)@G;Y2DHYTIQSI'B?IT
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M^$"8TW$9>C,E27 -DNB&ADD^@*'F0_?)U)Q 3>2_[PAZ]/\>%54]CEFJWRZ
MPCD!%#;N$!.NZZEZFAKP/W2Z<PXHA3:4INC'*N,4H,W^$CT JW^D")"E,C@Z
M#6,O"R2TJX._$9A%!N8K/VP!)1E0/>\IJ?JA "<5B),I46PADQC^C%2B3BLJ
MYGV0'D&>\?[5LY#Y#%Z!CPY0R<5;[\P,6CFG M.G8-+0AB-,_,*-1B?<:$80
M73\(QW2(3]9E;38'2PO+RDA5GD:47,,  Z=GX%^$@S;,3)LR:8^XI38K-5E=
M,R[*=/4S=8N]1NXQ;,\$5 SG2=YWF+BHD>D3$DXH3#6)I6@B?!97[,)QL&B
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M2I/91HAY2KZ,M0DLXQRMP:;MZ;UO8<4"[T0FY7CTT5"5]=1B$"7>QL-.?V2
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MZ/R$@<6^V_7 0,_9777,$!-=(U$SF))2+)5X,3X_DSCW@E033+S,A3&/#$?
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M@D1Q1PL11!;IO'Q1D#YLY%+<&O=-@(3-X^&XH'WO70GO! E#D<J$2)A!@:#
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M%]EVN58D_I3>*?X N-; H"R"4MO#H(1)@LM!<FI,S5UQG?+[Q!H T1I(D\5
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M$VOUS.K(5\B(IOKSUTI%"\CDJ'-]I?S\W?>KZO)5M+GD6ZV\"2K:&W"=':Y
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M6%4R,X6%85A&QAP%4:@*JNO:70/#_]'P^JQW1WK9Z@80XW\Z'_&!J![$XXI
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M$P?=B^$9JFF.A9YAHG=UQA'X8:2 #]IZUW?0HS0?_NBIVX?:17QY:!M 4^&
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MW :(5R7^5_^PG\%761M0THN4XN[+T'>)[C/E9AU=?=CMZ(@!HPT-,6;DN\T
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M,OZ=7K@WIM>/QU8&ZI6P0SXAFT.+6?J8Z?DE4,80Q.Y][8Y6 /4,B^IGS-V
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MN/:'.-!%O-:8 QJ<0[N$+LYU0T $V&GICV:0@QA23)KKG =II&$%,^?X=E>
MXM#CT"!_!C5PK)(["2N2TL8F!;A0!@(CR[+(."*6.3BI+D_<Y,=[0@N_H.7?
M0>TG)!*+)?0"US8U1/:-<MS5'UDI^OZXXS_E(,NEA)=F_;S@57C!^Y?<K( 9
MN%>KKHSA"\#PI4H#L=%&:5:&7Z]4Q$:S7 2[CT9=&[5J*87=RU51ELI;;K_
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MC.9V6Y:8+BNV++%@EEC-R1*WAON6H[Z&RT$<-3U?=T,X:IQ+%E&*N)PHT]0
M7@$#@13TS[(<[T\H!04)=$06/D(R23E>A2S5<)*C(G1T[U'7K7C;86!O,!S%
MT<?3YZ.\(.WDR8Y\068584#RKH33(M,K@M8$B)DYDAO*5(J8C; TII(UFWPE
MW$:I-#*RJ$$OFBG?)3+$;UH)17S8^IH0QKISE^J6NZP?=REB@L*K5EE2F(@<
M8R*(.=Q8+NV.?FY;N_'ZJZW>\38XPZH,L[7@#*F6VQOG#$J2,T1F>4\;X;TF
MJ+SE!\7P@U7M;RWX06IYYAOG!Y4D/[C2[PS7HPFP\0:+6\;P-AC#1L>1XHQA
M8EKL6V ,U7JU@1A#HI(;1JS@K3NZB9V;,*MAHB&1/:UU37![W1E$8U>JO 8&
M\:9\#$5D@+]J!E$O2QEAD1]]P]/Q[D]!7YBA=\N:X/*:,P2IO(O^?\L0UHLA
M%)&SO&D,04YE"%MK8LL;WI3;42DB^?95\X9&12XGK0G>Q3 Q4DGS*,[MD0Z%
MYZQ9E+)E%HLQ"VE7EE\#LWA+BH121%KJ)C&+F2.76V[QMKG%FU(MWGQZ9HQ;
MY(QF;GG$V^81;RG*J:QUMN4+\(A9(YQ;9O&VF<5;BGPJ;SMYLH+^K=3KA%DT
M'I*,XNBIVU>MNVTTH[#PID2[T:^*RC;5"5$JD F\[3Q)Q 1J]::TN,.RK0\]
MHC(H9.IL96G,HB!J7'-F(95W@5\LBUD4MLNU9Q:%J@QO.XLRR2U2/)83?!!;
M)O%6F<2;<E2^[8S*))-(<53F<4)LN<5;Y1;K[[(LCF'(2KH&];KX!9<,)2O,
MACBP+1?(&='[9W5L&20QZO]3!V@QI"6@%X_7W:.0O="ZD,L2=[C^,)P=7#\+
MEOWS]M9!9)]7)YIWB1=G ]0XF/-$ ?\(#8N^=:4_6P:R*TY/+Z&1C*8/=?1?
MB,<0A4*'1(E+OV,:7:'5[=J^Y1G6'4S,'01P6!G#>0&Z>$V4N/ZL-957%.5[
M1 Q ^=^T0_RS-#+EY/$!LLMMTQ1.]3L5_??I@;!C6%W3UQ#]&)907'PA,@*W
M7&6J 1VO@T]:!05(_?A^3?!R68V/YXD7_"/+_ZPP7C!M0]65.?L*4C0*-N[E
MRIZT8IJ=2(G&T_^OV=W_SDV1+J7&2_N1ECHBUM#R/-NQ=*R:"SLGC"N 2P]M
M7/5\1\=S']\+:X*56X*=B+!OFF*E<GV="'9^T8D.0KUH>#@@WOVQOM**XRT=
MSKTA='NOE Q3!D_#S\DOIYFDW%C<VPG_1^<Z+W]6[@>AHW8?[AQD%VHPF=EV
M_A4>H6(/?9$UKIG-UYW(A JUWIMP):E<*^W:I[(E_+I+1Q\9MN^:8V%N<[P'
M(R+W@GVE\NQ<4&(/T9NI%#3IC<"M",#-N?8!.K2*K"?#ZMG.@,0VNN@9]!D=
M?HN^]/J&*[#IHGW5%3K0'=?1-;4+00_HBZL.A[KJN +Z$CJ%R^4//^'_\+^E
M#_"QU]<%S7"[INV".H:T-E<=Z,*C[9L:>J&@PK>J-E+1XG<Z-*Z 7["@"W6I
MX,WH0*0/NC<TU:Z^M\BM%@?'B1WCEWN%)Y:&#NBAGZ"'$>AP. KNT$'70S1D
M!_T]&.J6JR(]>2P@P%GI<&.L<T'.R9CS<%$FG*7.=#[N=-X+QX:E6EU#-=$*
M" #XX&ZWKVN^J;M[,!"6;*3-/BM9MB>8X'1#&-NQ1SK"9O1?&)WM@>'!YQV]
MJ_JNCO&,IPI'_^,;#FFI@M#5U3UT$X[7AP<='4C(%>#UB!),=!\@%Q#<T8=N
MWWZT&.8&6RZUV99=>,Z"5BSD59Z]5P#D"KR$0E]%7\)-IP?#[ -Z\H\/\[71
M"YL2GE6/B4@S1FRY:;.%8[.A:UBS#04T+Y#C CNZ0E*@QB1R4H&>R&^B2&SJ
M/?R+N$A1E+]#0 --)I^H_)WN$CPYV>4!RD#Y0;@>#]$>6X[:,;H?A'/$;PFX
MSVV <(W_T3_L5_!-U@:4V 8<B()'=PV<A+&1__R#KB_E(AU=?=CMZ(A\T'Z&
M^/KY.=_DYM+Z//.8R+^</P><#^//^B']!FB+,8QH_IW;X)Q[]$GGXPEBE'@#
M4GUOVECSY>_FQM) :7I ]^4FME.L),T8WXT_-' 0";VP&J6+Y>%9)FI%$;!8
M/(,5=N$8Z$V6_>BH_+CEQ 7-Y?[845/]^'%4KQ2TW#52 WS (1?]"ND33J#B
M"B#^.V/R+<(PW?VW$)LE#8:% $Z:"+A"@&4+8,.)@N8[$!95+:2^(G2T<<P'
MG:S;1Z9$#P$3M"A714J>H#J@TL'3 U5#/U6%H>UZNSIZK(M'92(Y:&E86\16
M!M+1'#ZW*U FTZ%?"&63F05OBFI3;Y]3'>9_R604,O92D10=$#[][SOYW8RR
M(X:?- A)4-.QW2'",M\-[05$T&U /-LBAY7*B.'L*._)7\@.!KN JU=H=7&X
M4VHJ2I:;^15?QK)OP]%[)H(VL[>X"X'[Z2&3&',*?80M+]4Q7,Q6>DB1QC\(
MN01D= KT>M+Y@[!CDQ\-$']!SX ^/H'7 '>W>^\)UQ+1#I$":VB^:IIC;"J2
M':MW=V@UM(*(WCAT=!S^5H4>(F!XEX>L75KC1G_ &ZFA54J_3-_X'G3B>#2\
M/OK$ M:"GP5]_,Y&?XD85@BOD:+N8C-6T^F_T6M'MND/B ,G1%K,@Q&R[Q@$
M8)X-&]6 B3C"2#7]K!\0_P\8SOI35P?SNJ]ZE+$_JHPSPZ/OB:,)[4S31P8Y
M4<^Q!W@]TWZ$??:102(@@+-[TQ':#'!F[D!],@;^@*P+)W8P# ?J&*QYBC4D
MDX#" H^YX_ '^Q(%@!I^ FH&#->%70Q]Q_55(DZN?%,G=%21*SL=2N5&3TRY
M7_B3W*7+ 19..71@GEYX_Y:-<,P!IP3"?KD,(A C6Q03V!F#)<+3DA<FT(/Z
MZ@Y4L^N;!*3Q3.=C76=>/"*AZ$]#%$_'L4WD7<;>A/C&4@0*(*\#'BZ>RC$.
M(LP Q&2.4O#IP=UI<!5&Q\</ ED-0S<Z=;^&6)[!UA A1=:F6(96<OUN/[*5
MR6SFY5$@Y5)27ICZVX1;8ZF;GZ)IR^F:=G \92&<0RQ7!,9 ,,EWD S#_%K3
M$08,#(MIWJ:A=@P3YLYC$V6"YB(*NHI0!>-+ID1T^TCV ?O5H(B">595P4*Z
M; 9JXK[66& 1M$^1*-0?*V)&"L\$3! D$&R(^Y'J$8&#Q(2>L1\B8]'CB!(Z
MMH5$L:%Q+Z5B/0O7L\S)ZM^3>=8L3RFYGFK4_TZZZ@HV:-Z(*<,Y(.8A9B6W
MOV%>'7@ L0VL'$7H")DB UVU@%8F6<5 ZE2!XDB%F-2A/D:5-+08!!!]R[61
M(H?I"=$,9AN!0L%3X1H(A4F<<IV8?F4BGLS)Z(OE\Z  J*!=#F"":H33\IP9
MOR'#Z<5KSQ.<,6 .W:F.9NIN](V/L HX>W2O;VN"[Q+.[2)N$T=AIBO1C@ .
M4LH3:*XZ>B!*P*4$6,TTG^"'44H*R:6'6(W]"+OI(O/ MR PBT[ABI, \&@0
MJ:/B/0.X8]O$DHP]U46O0P*(1B+Q3O$^X;AQZ9;8]]:CM00Q4,UBU+/:)-/>
M-Y>?*R95RO.]O(6=6[II %MW(HXNA'S\7Q-I/:Z^A=9X-+I.;.U,NWH3;<N)
MMS?GC?4<71<8?XSX)C.N 5WQ4*5.2W2OH#+H2"GN3;E6]"AFN^A_'1V]BEWD
M>,*/)N?N;5G1JV9%4]!Y068$$;2A[3#M$LM?,,-FQW>:ZD9B12F>%K5C^]X4
MS#<\EY>Y:-F1H<U*0A] QF\>5QLM@ZN1NXXH6,2(-\#)3U4BZI@*;AI"@9,9
M4D+M6F**W-OE4//:S-6EVLPY[*(9;"*$2#@8F# S.&2#Q$"_<T\]N)QVHY0/
MJ/,L$7N8'F=0$?]1'8_8]SE<:(Q<<-"'T!4.,:3_%#/2,;;OK.B6]S&K"W\?
M;EUGFS?@K0B(D&(6_WE+S/"]!8>Q-($O]IS@O%8#'10'\ P,ZI[AN![144BH
M+W![6,B<W!,N*=,6A;[]J(_@RC!'L6SNS9B%8'LWVV_.W1EC2>P,DQWNX<LU
MN^OC3]&!;82*#HY?X2 <ADSD8\31L,:%,_<,B[*PHO<'MJ>(D[AML/8#NQ0'
M(E3B/$5O8$G')+G;A.BK83N!%1I< KIM?X@XL*[AX.+ UA"-8I()ER1A0-4-
M #/;N1[5F0$/R\,V0_@/$+@-]*@YCIV$A8:#$VV=6KD9>:UHI]:)Y=H]U0'T
MA)RX@67TF%8 +)WQ;>+;(>'^J1R<AH6'P/T].D=30_9IU[,=)%L1SS2ZD',$
M? EC/1*76.=$']J6&\>ZA)>+"[83A=$E7B+&11\-E\:'^>PP5GFA:N@'+%3.
M%)WA_VOORIH;19+P^_P*Q3[MKF96XA"(V=B-X- !DD!<$N)E D$A@;@/ ?KU
M"TAVN]VVV^V1/?:V_6 [[!"5E>>769E%'::^5%OO[*NA\?9>W#NGUI>SO*\Y
MUD"H78V(TX;B]DZ***R_5PUW0=D<1]\Y/FPXUGKF<WTK:3MZ?ZVY"QH(;8(&
MT?RKPU[.BX^W9FUT3,]P_%8\]PFX6;VE[J[L_GXGO+1AVJA:*[U@NKN8W&Y(
M!4':'JO7?+B4\B+#:1VF<2O*6TF>1R3NR_$!,5YV7E-GUJRP<Z_VRG:SU$TB
M8K2=/HV'<VX<4]/64#_T'RUS:_XE%\=]=B7/),5IYW*"<R/1ERZ$)^KSW^C/
MV8OG05M!_59MFCRFN7XD!=ZEFR!K(N6MUJ4@R[PSY5_1U_2]6&V!M@8TM;F<
M@T3]I$OHCFH6U.ZS<9EN36MJ.>8%LH-.G#<=&LV&]J 5[X-*6:]X#N,_KIHW
M5=-=6'NYX$Q]:WY.4*=ZAN7FULTJ-Z>#M7GDCSCTU\+^;]DC_!<L_)R9#_AS
MYN,M9C[PSYF/J[?;OZD176^QF^'K1RH$[:R#S$YX4E&ED7P>='AK$J[&Y\;I
M/L+K1Q=?WH-LES.*-A/^Y<F^W397:L_3'PC#34"U\CJG:.<,K?.9YU<M=_*7
M_"3H-%>0=N3?H)NYPW/9JD$$-167TN*W=:T+(,N;C+!=S,BS?9C4_LNZ[40T
MFV)&33&5A*%O-Z9T^Z^6@O,%9C5'#"O\M1->YH A*&L2H/:30HU<MG6R_$MS
M;\$UIA;/8GI]=7CN&F\RL76=,?XGN]^0*\] D?2<E%B!_[7#\O3C0U!WVI^^
MUV'W4,?>(WGKH\U2T--]4 ^&Z3N-5M?C$%7]_E22>Y^0,WSYHA9/;^-[F.@[
M3T<;S-%+>QTNW >=>9AL'6 >G.<6!\Y/>UKOGOVWZW'\_F9^J!KS3O=$[QU@
MWQER%\X)XIN/&SX.$%XQ+K\"X/G^AEX;UKTF)S_"DJUI.-9__A:%QA_]/O2W
MF[!Q/:CU/"SUI:AQAE,W58';]JV;0MX-5#*:\-^L_4M35;A4+ZSVU@WG<O^&
M=0T ]-$T]O]HI/U>7-W>CZL7FN#A(QGY=^Y8JY.IF[L(OS?#_B(<\!B]Z/T>
MCF?3JSB9][:TPB^FE:D-\ D8^F((?:V_O?38Y7N,^W%F-="/2AJ'R(,T??"*
MMV<>+SUOO3.*&96U]V[;S"\HIJW.,I?B]U6H^/,UV4LZ6Z>X-^_NB/[<B=Z/
M<^LM)?/W9>+4R#*JH>4WXGGX9N,K*_FS<\(7;W&9@*99.LA>I&YOL;>W<";O
MB9;7=6R/IX&OZ=R>3-%^;G_VU@*YX].^2*6Q_3NO5GB/+N[3#5S+#3QXF>9U
ME>Q+M*3WAI/4AGA]-/,D =\:]I_O/GJ!;0/;3D#54?:)4?,@>(D]_0RZ_IYH
M^=!V][,9&&,<':N.]H;W:5KOGY9/T_I IK5V/,\Q_,X:I."]Q:ZG=O6.]/T]
MT?)I>Q_(]LC:X"RC<S'!9Q>Z?C:=?D^T?-K7![(O.0/1'@0=!CA9:NX_[>O]
MT_)I7Q_)OLQ:/,T9FF-MC21[$_NZSCN-/DQWP=46?DG?[U^T[#^_?LU1^V$+
MF.&YD>7W<W>OYP3@H:..,\/^/[[?&M3/)/W[!R4?>>\UQ+^\D/,W)_AM;)C9
MU1[\ESJ&O]8K;6_7O\HDQO/&LI!_=X2HO<+L]\[<2+//*:T?FM*2GS6DM6KN
MQZXI_G9<"WK+<:U7>8O.%37U6E]?BR2[X7IIE?_NL$S[RQ_](?5'S440M(/9
M+2?:CP&N@M8@R^'31K7#69>$1XNBV(QB(/J&GO4ROYB6V8E->2@OYJ3M3J7#
M:+!B74,QP:3;SXAB;VTG5NE.//VP(<5RNBR[/9/I>@#'.(2K-BFE!MT)/?!U
M<J4''LOKY(B3!5)"V6C7S=*L ,-QP@7R(>"R*7RDQ!FY"!<G2+>'5BE9,*9O
M(F?2Y8CN)"-Z@ZR'1BB/@ZY4&#;P>XMNGRGV"XWDC444*H5O5EY5J922RZFT
M.DJ2R4TS?*S;(AWZ71HIYSA2$=ON >]YA.ET88++1:U<ZZ?-'/C%$0>6@!^P
M.6M:&JJ*"^3@RZ88;K?QBL-ZL*U+K":SR9$(U-@-J$0Q&+Y+48=2D@C9)W>Z
MZ>WSF!4+<:V>"MTRI/&P)]H;<I2NB(3H(4=U.DY&QH!E291:ZB1'362:'(PF
M<N&,O)DS6FN[P!GW4[[>BC/LSTT:)Y:,>^J/#=$QT:G @0-7SE)7HP<S:Q8(
M2L@/CXZ_0C([38?ZMB;.( 1\29O:7*;RD<,?%$--^I.L7+K'7>V,59\?34!^
M=*G5>CASIH;A%8[DF<%0-N43>9A3&<(%PMZBS)*6^K#A^%5&L'1&B?V^7\Q%
M+-ZL#^YF$YT8Y(C%1W/L,Z,^"(D1X[L\WR_44#5W+,0R4PN=E_Q:!Q0W7TIF
M[&CR,31%O7)%9Z/QO7[IB\3 ,I ]B,F5I_*G1;_P)7,YHX;^>LJ*" &O]^5>
MB<1X%H=K3A%/GNNQ'LZ>) K5)PCNS=V(.7K[<&KM2;#L;V#%(DL3#Q598GVB
M/V.*G>U:XE+B2P9 JL_*<CP*&%H \=(:1'/=S"%W8\O$1B,QBK%H;*^Q6U(>
MJ-3>WRK29-KW60,:CGV2S$IFRIAIXLQ68,PO4".TN3W;12UG927R5MBX4U2H
M])Z')4.S&$/EO.^$/+1;GOK+K05P \[5N4/2#,4@1G% *3]RH]TB1IF=A<#J
M2*U$;J&,?"F*D7I+K#;7]VLU7-!=@SWI..UC]JXL,7PK9<.9;H80LX=C25EE
M\DR(%$8C;<./J JV5HNINC9/ACDW2X16]HY!GD(K3X$RE=.QY@PGU,*Q A,*
MP\@S]D-86P<3/C&AF3Z070\N<!3OSY&=1I#\B,_68V$["?W^;)8P$!6K4WB!
MAY,<G;.0JPVVC"CGR]$>V12:W*LF?>5HS850KR*$R5R$Y[?,.K27Q_%:Q[ M
M0E.#_HP*8)F+#6LGNI'#22:+*)-C1!NN/''%<AN@YM%<#$,4=FI%RCU=LYE9
M2% >OU!%3!&\P8!)!CLN4CG #_K%8BWSP928X '=X^ #5@[F87I<!8J[3 6A
ML)U)/O=)^@CZOC+&#1V:83"R+#6*1Q&CM$-!'/ 3+-X91A+@$XF)CB(6!:0R
M/^*H9;D:BD(#,-64A)0$Q\'"X$2F:<5NS3&^,V@/YGD5WS*2GR6 ,D?;(6:(
MJ_'"'2N2LMR78S*A=5D?97&9FUYW+P3<RHNRV4E0)\ =KEP:. 48KXU-H4@>
MZ^!SB(&&*=959<0S1/84# )6P-4DF8YTKD+7O& 7Y58KY7C#*3K@C^,J/)*)
M>S+X:CC*#%5?995IZUTO[B;B.K6(/;-B:Q6=.\%BPMB][+1<&_!LX'<WF^$&
MF /17;%!%<(Y7<1QN*UE7K&TAS+3:>8:V&P5F/J:M>*(7&]JIXQR&VRY6X(=
M4^0 RV5OZ^4###$6FPK MGP:"E-D7B!*Y.B4E_ :WQUH>X19@0V5<\LNH%#^
M6(DQ5F)@'D&;E5(I.8GVHK$P!8)UVF&6#D'NK*@*GQGSVQC:3")7C<.1*J.A
MP$!3?[2$/%X,>5U,M50XI$O!I D&&=>B75%(!J\2+!5\6#\20VJ$;C.8-*%@
M4#+=#>%@]NJT6P6BYPT</#K.IQL_WME,'T.Q/53RY<'8LU6&2+VJ2R';*3CJ
M(NH1"'4ZV2Q4BEY*ZP<6:%K</^*ZCE;+S&#R0Z!DN$?[,^W Y4OO9 -Y:!]Q
M>$R,B6*)5UTB1@RT9W<Y_)1JFM"M>OC(PCGUA-.];M*%=PD![ZIRF*^=J9W3
M8]M&=IR5ABZM[>3I:#I8 M7?Q#E9@@,E](65*@]6Z3;BF#$[E%6UCVMZ#XXD
M49BF!$$1G#$F1^=HW]N&5M7\W&>^]]__ 5!+ P04    " "%A$M98QYE+<01
M  #NQ0  $0   &%C;VXM,C R-# V,S N>'-D[5WKD]LVDO]^5?<_X.:J;KUU
M)<_+X\03SVYI]'!4T4A:26,GG[8P)"1A30$*0,[C_OH#P/<;I,9G)$=_2#1$
M-]"-7P-H-!O$Q[\_[QWPB!C'E-R<G+\].P&(6-3&9'MS<K_J]5>#R>0$_/UO
M__YO0/S[^!^]'AACY-C78$BMWH1LZ$]@!O?H&GQ"!#'H4O83^ P=3SZA8^P@
M!@9T?W"0BT2!W](UN'I[<?D >CV->C\C8E-VOYQ$]>Y<]\"O3T^?GI[>$OH(
MGRC[RM]:=*]7X<J%KL>CVLZ>SX)_>NQWF%L1\W__0@_TA^<E_G6+R(_>Z.'7
MP]T<KH8>7+@O5U<7^+>OSX_[Y=7FR_[WQ<L_G,^_?+GZ@!?_>K(N/IW]2D=^
MDQ^YM4-[" 08A-^<2/T"]9XNWU*V/;TX.SL__?5NNE)T)S[A];.#R=<B\O,/
M'SZ<JM*0-$?Y_,"<L.K+4UG\ #F*:A:EN((>$^Y"8J7H;3=B2!)?G?J%*5)<
M2/K>)\4AJ8TR=!Q9;[?T\504"/J+=R&AQWM;" \1\0;R!U5I4) BYLS-$XJ'
M6:*>^W) O)#4+THQV"[+,*1Z312?RF+)<]$[N^Q=GH><_<%\%C%!RX%,C!!I
MS:K^L_>7<DPZ:(^(.Z9L/T0;Z#E"A=\]Z. -1O8)<"';(E>:)S] "]74%MHX
M)(2*H2#*@R?RV>& A:U'#\0C:1O7C#IH+>0'\H<8B\5-R,+3 17SR0G ]LV)
M_S-165B=C3:88-5T,/;.04^.-$^J*7XJSH^G6>)\31Y']IS\3?T^,,0%NU)I
M*AX$_ %)-:\%'<MS6K'&\E5Q!L_#CCRFAV^A(P??:H>0R_V>3C_2ZO$+T<UR
M*D11EQ,;$2$V""H#?FT="AHH+" 3.N^0BX4*!9"DR[7PN=3$![Q)5?[7#J]B
MO**^Y//-_"!=%5$<#)^2,BV<WI7B%-<*Z ;$]8(W]P1Z-G:1W:&E@=9@!\D6
M\0E9N=3ZNJ..+=S(T>\>=E_$:H@M[.91U.#10O=*$]V@/8 )2+;X%^"W"=X$
MK?ZU [\A^)#OQ@Y]*ABI<9$6E.]UH135 E5OAY6.N[<_0/+2)_8MY%B@LD@H
M'KJ!521:V/T@W4.Q\7(H]Q@2?ZQ_'H'!_&[1G_T&^K,AN.VO)BLP'X/%<K0:
MS=;]]60^ZS K&5_>?@_9RWRSPELB]A 6)&[?LJA'7+'Q7U!'S%0H''!ZM%HH
M_IA%<75_=]=?_B9Q6TT^S2;CR: _6X/^8#"_GZTGLT]@,9].!I/1JH.R&,HQ
MQ$S%(NX0E)VJ9C$?N>(B+: ^9($:]R=+\+D_O1^!NU%_=;\<W8E!UJ%2@LH2
M62@U3!@EXJ>5A*>&1@>G\[,L3LO18)090,OY3/P>=(!5 _:(B(="9/P_M" X
MST/P>32['W4]7;;V' Y^- LZ8TS$1A9#1\97V3[A,M12:6%SD5]O%HNI&@G]
M*1A/9OW98")^36;C^?*N<QDJ8)N*-21T"8+?6A!<9B&8BN6C6\[+NGDB="1;
M_."@/N=1="_W5*OKWV6[?B+,?O9I<CL=@?YJ->I6@](Y:D>9NT9L/Z,NXF+?
M(K:*CXBY$H$A>@C##7546BA=Y>:HG^?+-5B/EG=@-E^/5FI[,YC//H^6:X7=
M<'2[[I KW8WNL:L\*!\0Z5DA$F]GJ@BT\'J?Q4OL0N\F:^5=A5!)QVLTZ[8M
M51&>;%0N#._DGFNADHL/K-;SP2\_SZ?#T7+U7__YX\7Y#S^!T3_N)^O?.DB*
M(9DA=THY7R"VVD&&YALY5*@?/_7!J:30@BD7 )B-UF Z7ZW 8K04,U]_.9*Q
M #FDYC,?PPZNBA%T*QPQ6X;7$.%)[[FX3 NBW-9?H2#C:Z.ABKB-9JO.4Z[<
MX#QP]+LG5!T]QKO]W%,=,"YR^_O5_>U*3&-RCR^WF9T+=UR(LTVHLU'(\R(7
M'M />8(W85/=RX<V+Q_64#CB7.,51$"HA6<NI*#U(@*\\=OH@&P2QDX"6$6@
M!5PN$%$2TNZ@.C* ET1-DU8+P%PXHSZ8UV'9,-R4Q*ZD3 NK7% C%WKJH#DR
M!I4:9GJT6M#EXAM:\:@.SL8!CQ2 9:5:D#4(?G0X'1$%22*F0:>%78N(2(=A
MJ]!(;KR546CAIATFZ= Z9@\W1"[$#N\EDZF#5,LQH_O5P0F3/X^O1@?WRUQ$
M1G/_%T@@&,+L;2Z% %:0-[H18@ NY>@,Y1A#62*746BY^!$I*IG+P3A2 U[!
MK!,0:%"9EM'D@D#-C*8'$H* !RD)<'>BRWQQ )?R^,;333/'6,\,,IFB_XCT
M;21FT;*$MN&C</J(FNMP/BKP6PQX2UXMY'/QIR:!X [^HP*)\7QN>8P)*-5X
M7E/Q7&R:,4$1UWPSQ? !.]$+Z5>L3\M,<E&NTC!E8G$(I B7!@KL4!"U3FR$
M-.!1BB./-\@G3BA49T=M["C$5$P&03'ONQ&'AN'45*!E*;D86YVER.2[N%VP
M#QH&T$U82&<0;0PB,=Z_R"FZ.@>_BDL+^ER,KGZ2&.?F@*>@R0[QEB\ZPKX5
M7N$!8EO&7>>B8]E S,8RLS^1P/DZ56G91CX8J/&:))XA0@D )#:@4@9@^4(
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MB*D(R,:,F+!VC$1K(NOC\MMLK50J9#HJAZ<1Y7]2;O')_P%02P,$%     @
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M#?^B7?U\<?FDG9T)U/L5.29V'Z:#;;U+WU][OYR??__^_6<'O^C?L?O-^]G
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MT:'>GQN/G6WUK6-.ZYC3.N:TCCFM8T[KF-,ZYLASS-E=#-'?F&:'O*(J.^=
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MKK(G68;S[.SE0_!?*3'>.!Y2@M,;"\--Z]Q@L%?WSM#QF(4;#KR$4UX$:LI
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MR4:Q5!X&F>Q ZC:!Z^/=(0[J &TT,KVGVSP&LG;0X]HIN^<!JWETXHAW'G(
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M&%U;_#R[N>5>Z7QV=NN=4<VE0KX9GO(-<)RPL!!K5S6P#*<)0\:8UTGZ,*0
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MM197B#LO[\1JG"U/W+3!2<:O@Y7WFWG^!V[K79#AL,J5;=J@V[%0IYLP>ZF
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MNJ0)>/>"I$H:#+^,$!4I&3+4:)X@=GL$3>(X_<1S_K(7(L[3[5V^WL:H4@!
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M&] *SKG)_GI  8@'\W-(GQW!+ZIWM/UP7/C\[X+F:JO],;W&=+QD]_]&U&=
M7@OK#KE0+;[;<)#]A7Y;0L7VGR[IO^B?JS_1_X]E'J=_^7]02P,$%     @
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M/I4. :AJ3K@;G$PP(F>M"\"';!O3VZ3@NBZF]>M=]_<W&2VL^]*VS GM.WJ
M ###7_=S4:2UJ40DZ[ZZ*GIDX!',^+K"&LCHO>.10)+DLD:X4A7T@,).&*S%
M!9VY&=FE9X[)BJN>:G.<N 9Z-&%KO*E0,3 ZM)JO$Y+<2%D+/3[Q>$Y!<N+S
MVIHZE3Y&J:*_I'+4UT(/CVQO*0:@8^"T+ES\0V:TK )ZG&4[DUF-B8%$YH\"
M$,<827GT8,UV:%0B@GXXJC^ %]-&]#T[^05A?VRDO:C;0P_L[%BE@2)ZUG<?
MV09TYU-VO(SH<F,%QXVFI@U"AU-G]K#6-_6&F)[U<0\.8AO&,HV@I[,TDKT"
M*RJ7E/\_UW6>+)?$GFC9&RC\#VPB%'^1*YDD!RM?5PZ?EV[$M^0L=&3&*!BN
M5D1F@3UU/Z #L_M48/"!B</5USJX.QJK\*%G4O1O*TB>_3-^)HXGC1PN[[K/
MR':B$?5JLO?L0S>R&UK/WI\SXEPX@+M+>!/0<=)]WCB-TY@N0B?-:C[:Q\<R
M;4(240RN#:6H.]NI-M[*Q.9"D#JGZF A*N<B5/(DJPHEJ3N3:#LDJ>'IB*$[
MRZ'Q^YJ'U(1,A$,8HE8T8-/&H"QV9Q$]AL7C(.R(U]3EG,_Q@HE=BT_=1J \
M=F?H/(;'9I"=+%^J%G/PZE#.NK,FMK."PF#JB*T)==:LSVZ<E#US^;_ZH$69
M9AO@)#=&\M8(L!KR3IT=DF?9L;P7)NN-%3A!;*O>-[[O9R%+Y/>]-STNH>L'
M$27L'XN?A[W!Y&':'__6ZX]O>S?]^6C>F]SUIK/A?#A>]!>CR1@G.^2$KBTO
M344Q\+W =QW;2E-&Y27=IZFPW$.J2[6"U%+S. KB49T_#( %&W$WKO1FJ/TO
M(>>J;'58E;32KF@Q8+&91]NM15\FJ[FS]IR5LV3[6QI6RM\#89(N\U<?A57G
MA_*J,__\\-"?_<;7F?GHTWAT-QKTQXM>?S"8?!XO1N-/O>GD?C08#><X2T]5
M,$!*2$D=I!1V,J8 4Q]:'WE"J\DJYZG3PL6 N;=7ZAZ(Q6?0MF ^+TRU'\M3
M[:X_FO5^Z=]_'O8>AOWYY]GP@6WK2/-J+\BABX"9):^%,[?J*!EYNTAS=]5L
M!GFF0>@KS;5&.!DPY7C>E<+R0'V/_;B4S+VK[\IS;S8<#$O;VHRI&Y_' \Q)
M>!!J$%M?N8%H2*E/!SZE9,G1T]KN(*U@N;5\$3'(>IOV>Y\=(R[CL$/9S@5M
MC^VT;LSF"1\,%<>8]E V8N8_$2\B]5/\JCK%?QF./P]Q9G+:5>X R;2-F*-?
MG7 SB(+0WQ*JGL3@!K "BJ3= \Q1> O(\U"3RDJ,D1Y0!DRS>;1C*P!?)2QW
MKPR/O)5/MV+[U=5U59.<3N_CW;1_W[L;C?OCP8C]-!K?368/%^.5D<:K//4W
MELM-YO,-(6'N5 G13K5:><5&IR9P&K  W'-'0\%)^EUYFM\SU;6A,4AP2W)H
M/NF(9,[Q\N+B.'/HG@0!(?O4/4FG +-&50]KGL@QKAWW, @,&.G"Q"N%,?^^
M/.9';$\;?QK=W ][_?E\B*4N?O)]^XOCNFRE*@MRZ*YZQ])L!BNGH*AG@*D%
MJHR\#S4BLY)2$ R2 9-OOO%IN"!T&\?><X74]YX(#7G_"TYGA<GXH7+._'DR
M6_06P]E#;SQ9#.?Q92E;LWX9SA;Q%+T=WBQP)BB70F<FBLICO;&4[PU@F@DK
M($\M.0V5IY"D4ALP;PZN?^FDX7LL\827?%<?RU-F,'EX&"UB0V<V6[@-=#C&
MN]>3"*4S@S2;08I*@'02,-]TVT&>AHTH+@<A-(+.@$DK?KRY.%<K;D#SQ63P
MCY\G][?#V?R___3#]=7W?^T-__EYM/@-9Z(FG5?/Q'(Y4][,YH<-K5FFT03R
M!*NG1OFRM@(1 R;/F(3\[94IH;&S>WUVM,(TJOBUC(>+WOUD/N]-AS-V9.S/
MAMS%A6^$DW$RQY"FDT4]MH3M90-,+&$-G"E6[@]@2DFJ8$\A!1VER:24W8#)
M$\\2\=N/A6E3\5&)9P9W/1W>QLZHP_$<T71_Z%J\!.R%2?V!8S?\F(='+FZ6
M-@*@=QW9+I)^!NWU3;[7$#WNV(:Q];U6ADE9+VP';1,6A.@Q(/^.6'/#)Z'+
MS'7%96;^^6;.#I[<;8;?K&,9/<N]5\]N<0VL2[9B?T W:L(JR'--14?E1DPA
MNQ'S ^)/+?6KOJYXH\#]JGM_SIK^"[87VCF[6'_F*:*&0>ALV?(LR>50+F>,
MUQ?09;I>3O2D>H>XUF2FO(#LQ^(ZX$<A3>%%#0 Z1[F(Y)R?#Y,JBL\N2;?%
M= &K@]/NF\*<%BSH).;&V8SL^!/1WIJ_&I[]-DU^)N$1W@(X.9PI5.J"@\YF
MFD>GG H,NH("JX.#@DWA40L6=!(/+\/"F9/5 =+56889;;K4 !C 4>R7RQ_Y
M9H=\CJ0&5<JJ0,8Z2S?3@#$@'!UE1KAWV+2VV4J<OI<W(X$?T67L%O+)YS$0
MOK<D%$ 2;ZYQ:T#>.DLP ^?M*#$-F8,B,QI\NX,V .2ULX0S^AN>'C3H5&9/
M6P\V%EUKJ7SR>D#B.LLZT^#$"0&BHU5TN"5TS?KZB?I?PDV:A(1[JT< 1N('
M5#0: &OD^-SHBF:,*5*:1V81'[#J[8^5:!Q0-IG>GY,VD0R/KS@R1S!AY\L-
ML2.77RDEP9@+/_')V'\X)D0U;?6;>8U!-\V0Z'1!/G1G1D+J6]S<0.*I/*/L
MQ$V#Y*6"^<YUPD"3Z@8M8AM13T![8YP-6.UKDXG(5OE*,)8@I0CRNOX*<XO<
M.]:CX\9O2J1DV1-V4%]&E+(S1CSR='*,Z#5WQKE&FN"&KMP >\\6L;'OT:(P
MJC5=#R#()[ 7^>Z&!QQ@]"%SV)#Z01!M=W&V#OXL#71 @!O OEYK0+<F. ;L
MS*J4"+)-NA(]JDZ,<-'#C,V0L+?O<&M<:G=U_D-XQW>68S,1)N&&T 9!JL>W
M_!J5NM; ,6]C2,Q7V:/33(0TLWAN$VRP6S1H%?O$T&D*CA;P-FO0M#%$VAD0
MG9TI3C8@FM*/G:="=MZH!,A7LE4@'R^^IK05A]'&1JH3,@7GB52ZJS^%-1I[
M!6DMC@#1F*7;E_7]+@HY"EONH):L>L-G?OU+=$=&.U_!/@^T.6;:Q-V C4"5
M,T6V,5320( RIR!O%N>=0N6P<AU\3G.NQ%IKOJH%[* [G20KNKB8,/,J<?.R
MN::1Q@%Y@IU9/H?]P*G/8Y ][S2A,V>]T9QAVDUB!ZN#\CT<BY@!<T^6_T$V
M"QMD@<">C6>?#N(PWLH]X_<U2_[DH>-&89.;$,T&L6>G7BJ)(W$S1M&9K/I>
MZ-B\KVQ3G_/+NMBVDCQ<3^PD$_9V%V4FG ;Y0[KX%K;2TWBXM VW >M]?<H2
MV4H/3ER"K<Y<,IC4G^;VF3/RO8_'P22Y'\Y"]?2WC>9M8ZM47>0Q:0]S@[:<
ML1\_+TKL&?M?ZBS93[$<GSTG/&+D-&H6>R/I>-0< ;5! R8/#$?DSJ>5Y#U]
MKABMTTLE-^Y1O(/6SYL8UYN7J6MY^@/MI-W!OMWK>( B4&O D4D:*7)+0LMQ
M@S?Y-RA2_WA^/HS=HFO/5>\J6:" <23I%UF%])N]@'^TMTR^VN.#HA?P[UY\
MG(SS<9JL5@$)X\>Z#U=K$EGKBZN6F<K4.3M7 H'@^< W,PADBPN)WUJ'DYBK
M8@B1LD&I("8GS'YS0R-GP;:>P(K?[UNPS_2?'0DMM87/CY!:,7('870F;OVM
MY7@@'K*B9K @&4UB#C(1#OIKFT%O;%GEOXQ/%0]D^TAH#:Z\9%U!;.U).";R
MX69B"3N*(YRR$R@0T[J2V"=^&*AB&=$5Q]Q]4QSK(%XHJB6QO;)59X&:%Q;J
M1,UQP"1(O+'O$_&%'8U[^43HHQ^0N*P!_,4J7C *@NB@6TEI+%; 7I^.H+-.
M\M?%ZB0*@]#R;(:.!K6%6MA+Y='\UF!PUB3W;3O.1V6Y4\NQ1UX:_"'F5U@!
M.WNA+K4*R5MFU4B#526:OQ+,7V^VJJ1?UC-;O>GE/MQ[Y%_NA1O22W,)] +^
M_<1\=8G1,\]^5<SU(;&_E\J9H=%U&OQ2DAC?5+7O$<!&55?6#,[J1YP(?*/,
M42./+<GDT+?T+D1NEI)6.B-*I'*@VZ<$O5/9JA35S* ',.Q@7'5NRP+9L8RR
M88'&3<F>=5I;%LR.990-2Q_4>CG1;5F_$N[G3>P^.\M::S*.>._2J^^\]AB[
MG8I7&<UFL)^I$1XS2JM,(W3.6L$62)QZ&VL85K0;PEXGCQT4*HC.>EC4>J&+
MR1<4QUZUP11+Q7U51*:C%D[EO@*V :TQF261OP++V9A'=7'K5;U]K&EZX,RM
M:]_\Q?IEG/7KXKUU\=XRSD!V\=ZZ>&]=O+?.P7OK<+?&_R:UT=07Q=;J0,Y&
M,BG1+3350/W*O:?LD@10^<Q\DC0 ,2 4 _9^,.R@7LGPKO..L"FG]=?QH#!_
MNMJQ'<XL30;A PDWOCU*XN'(W-HGV;AYJ1;.BJGNI%O]BAF[G/8C2NV"@'^B
M/W0QUW/ L5Y5SPQZNY@8P@%1#P2^7E#;0[EV(*GR=1-KB(*1Z]'8VK(?-30.
M2%W32!8,W#)C ,F.U$R.=YR83H2*2W:=>RB";M8&C[.R1T193'3-Y;581TZP
M\LF,*M<7H\KK,JKP*QN7));J:?3(#L%,!2;\$1NI@45=#7OM AE;H-)WY'"4
M_SR/?N'I"#*/#C#\HHI  MX;0X < ?0=9& %&[Z(/K$5EM_AA .+TA<V5%1Q
M=XIZV/Y'( VP'-L#PL((RCY[CA<_U]7?<E5?SE.E,+;)N#$[ K'1*3GD9N*]
M%+-1+H?NKM.$B'IAT3G@>86^\)7VSJ>W?O08KB(W>X-F1I:$36NI)1!:'_L(
MT(@S/7#PN;3_%05ADIO<%\3EQ0]02>B$-X%]IFC&J"Y$!MS4U#ZX>X@]++PS
MZ;/?$[IE*.QK35;9VT$O];<WE:?_A._SY@(/TZ]F88=^S\X^',<@KMC7>T_\
M\SU_%?_&S3IQ>=[WA,_[?O;\QX#0>)T:>;LH9'_VO26K=4A6"Y"^M2^9H7MW
M_#8P# K\"Y\69:JLNYT.IGO3+I>ZFI+=#<)[DZZE]G+=O.SWJH%K!8'<-*NH
M]G4.C7HLT*^I6H2A+*'*!'R"3QLVU&33J+LE101.-\;J]$68_2>E-E)186R3
MSLEF1=[.*D>N(_/VX04M&&.2\D#2/KPJTI3XH5L?<JO/_L>?'4)9ES8O]^2)
MN.#=7%K?L+7V9-NZ%!3T*]E:(T6UR^"]&M:,86,!-/)%#,,DQG9:V?<L'LA!
M+-V5RHU%6@G;FM]HY(I(%*-BSOJ<Z^-U$^:N3;G6[XJYZS-@[ET3YMZ9X@_0
M%7/O3&5N3,(XB*1BBI<05U,'V3^@2X.AB%TA<J;?S%0Q"OKAOD;]5<P'W:L8
M5B3WG=XV_5#/"G-7,)<;%W.,5Y<;E\N-R^7&Q:BMZ'+C<KEQN=RX7&Y<+C<N
MEQN7RXW+$3<NW9OH+C<NM2O\S\1>Y[&IT3,EB[2T]E=H<0"@V3@WWXX-*M^>
MAQ8-CTFW*)CRP^?DY5*>=\QZ\5<K_A!R2 +V#X':R:LI:[VB-5LX"$! F#;O
MDP?0TS=R1][^]Y_8DG;O!\$58/8#VGA%RS]X$0!#:\YHZ&P7^/W:H+L>,S8"
M#DDK6\'0LY$3M4J-V+DH@O00*WC+Z*-^$,%=)4;@2_J)B\':'-W_8K"^&*PO
M!FNC-K"+P?IBL+X8K"\&ZXO!^F*P/D>#=?U*$= PMTJP?QU6"/:/WV>Q9:9^
ML6=_S_W9L)G6T:)>E+D;_V\()<))E740.I$ZIJ6(5SV665<[<;)6@/G@>,XV
MVLK@+!5!BX,IPU4!LU86E%7CP7I6HEHL D3U(P*J=;*@FQ_C_%Q3ZBQEZ:)S
M9;Z>"Z4J,F:0]6@%Q.;)UH@7I+!3/O"XX>_FY5!D:KWP7_6_6-3>P]8/@F@;
MV\:#X?..\'Q&"T*WDIN&+K_YB@YGH-'4*75FC,X;M8@W.B+^XKNL&7Z(G5FA
M:HWJ^N-?T4W:"<E\70-WY@1_W%'", \)&Q[A"8=M_:>_HJN_DQ'9D<_7G>O[
M-'UDSEN+3F6\:&U)8\+".G;TD,!D0%31/-KMW'BT6>[^P<"1M_+I-FX_NT"=
M4K*S'#OH>W:<LF[ T.'C,7ZLJ/Z6]OOJ0SW3Z7U\,]N_[]V-QOWQ8,1^&HWO
M)K.'TG.:;WK9%WN69_=\_LW>,OEHSXJ_>GEHT[B'-O<]43WI4RIGAA6MRZ<U
MRQ+CW[:*GPZ6\'5OVDUG_8@3@7]OTBWCC>7R=*_S#2'A/?\"!TYZP2BN<49D
MB(5 OQ2LZYKJ-D]6QPQ65.,,P$_'[VMN?!IRZ\ MV?F!$\J?(!"6QK;/J$=/
MX;E-N="=Q6DD3H/9:Q,#/U# +:V!K:WI00X0OB/8T[/LB&?&YQV^Y<=H*>S2
M&MA)R?1@!PA_(MBU$-<$^WLSP3XES@-6TEE:KGI1D54 XOVC47A+1.\6\RR,
MY(XH7NZ1E(=NG(;LG$K)NT4\-G] H"X4A&)LR%8IEK4C<.,O'9ZYD(]E46$H
MR(9LC'*9T2\:]O.,VZ9)9OA++'ZI^4^L%H$J8[] );2 E%0B#23.R*2;/2Y3
MCC@L&'%_.,Z(FWVCMTL^<K'97FRV%YOMQ69[L=F>%1D7F^U7:[,]_J&XXC%#
ME4I64/Q\C+MR.3I5H@:4V Y_$M56HLW+BXN?EUU7)3:Z)E4:"TKE253^7/0E
MN;R-DQ@\$?KH!P0YA8&&>D4C8F?:8L[+J%[3^O%H38M_+N<MXQZ^>%&[+FK7
M1>VZJ%T7M>NLR+BH75^MVB4XX:>[/#M8,:%<Z>F^ONCYZ%%B&3K5H=)/WOA>
M)+^$JBMX7GJ36-2NO(_X87CO"B]W.ZHM>EZ.+S)QNQV]_8@IQ.SK]V1MN>FU
M%6@T2RN>ER<,'(INN<@B<B#PE\N>ER^,5."NEVN+%L*H8$NWH-*9.<3 ,.C2
M<2/M02&22N6_(:YS9KXR( 1,L$&6.BBQ3-6:)"'5S\A""4?CS V6]\1B6UYJ
M*1SS9$L\SWRM$?+]=V4CY/VP/Q_FG@#;UV]F4A0=#/>?3#HKL?W%!RMA<9RY
M-=D1#HJWCKN3'C(D=LOZXEAS1XYH[?21"FR "Q0[@EC>VGET2>*DE=GDR[^O
MGP17Y4DP&B_ZXT^CF_MAKS^?#XM/XAW:Q(U+_>3[]A?'==E"5A%_+XS:J*[9
M#))!=KDA=N22V+SLA.2>+4B5[JH,ZQIMF&&=:L1PV;ZK(36^X5W2Q\H.7Y-H
M$U3;#&[U1W0Y<29(6'Q3OJ2?-R\/UK]\"LFTJ]/(ZR>X*C/Z_8"DMX>^CJTM
M46;+U6W(#+H;#',XW_6"=W/C,&4:%;^S]9BRM%3;$<7%L6\>&H[(0E2, @MT
M)3_68"O2*3SNI)6P;S2.9 TBHB'<223]1/V@V6Z8UL3.@ZEQC(.O@@543*:O
MOUQ&V\AEBX?=W_HT3/UF&A$J;,O@Y?4(CA70F<SZF,C>\5'40\_=V F;.4C.
MW*8J,C#=12'7P>N&:L'$=*UE8DI:[5FY9B]&)M05/<=$:OT<LQ$T\UW6@?7B
M"W&?R(/OA9MFN[9.\\A;>QLVJ5:!-GE+J)$FE>0W8M'%%[^MT5)N%?MP</I1
M4H_K&0\.U@'9RWA'MHM]WL =('ELSW>(W/F11,L_LEEL.P#J ,DC>\;C(W?K
MW^;XB)O%SN:,.S[R_A38XZ/6UB551L4UL/UMVV!5A8>Y[@H*7YUW&CKDD6X[
M%[U1Q],NMU9,5B*7DQH7.T6]5Z#IP: Q8$;NL[.._3#V#1SXWA-A?6>=O26/
M86;OX7^6Y4]Z_[X2U?OS9+;H+8:SA]YXLAC.>_WQ;6\P&?\RG"WBJ7L[O%GD
MC3_\$\CIDV*)-::IJ#S.?(PI+)%4[7.Q%/)<DP->FE1U\G7D[/W92VV0Q.;=
MBX/\V>3($NON8UWB-)CINYYU*QYOK&%;V*8,&#5'"&@.@;>$.D^% \@Q%.9;
MPS8W=$1B%3 3:!P%0<3#&?@_VB"RV!ZV8: C*NM ,X',A1]:;ALLI@UAZ^T=
MT5> R0R5/+]-*S, B6M@J^1:1Q.5X.=STE?HXA^./.9CZ^?G?<+GO1EYK \1
M(*%.;6$SG$:UYE:M'/@N^\5NW:N]](45S.%$,+:DA-R;Y'1_[WOK,'YKYC%<
ML._(O>OK2Y\;'?52H#O&E[NE\G\7E3>##MG 4O#1\9M2Q'/\PM%#_JB4L#BV
M?B,?+X47I10B=Z2^S)G22X(;#:B%Y;'/MCI8*X3N%.R!)MBUY;&SN>B"+1$:
M7<'C_9^L<D\WRS=807$SEG3X#BL0(V>\0[J ._2(*W1CW[,.OUFPGP)VJF:8
M*B-CM!LR@T'I:"S?R.F*V,UVG3WFU%]3DG1&NJR)BT.O!SHS+3<<?/GU3@5&
M-\M=0,/<Y&+_.DPL]H_?!]S@1BC#('SA\5:"%8X5K2]IQM0 +&Y""7(GO=/!
M/B.[B++A$!Q&0[EW0@V"U=>HCDR0$/8*.QHR=9>$DV><YVYB3R1@U=2Y]03E
M\98K/2"KBY02!/1#6>Z%78C50U#\;-8MN1BY>QQ#V% 9/H05S&!$.KI4G'2[
M/GWV K*,V.P<Q\G9L]N,6'^2+E20BM 5J[,;0\5 *EX90H% 7ZQRW>.*\?Y"
M2NFWI*QH@"N3Y#Z@-%. ,*#3593JSEKRF,](=J,KKF&"1Q.<(97DAE'S8(41
M=<*76RL$WPD6ZYC@J]24GCKIT0F:4G])B!W<,4GGV?H,6>J4%;%M]7I4 7'H
MR)+,^SJASMKQ+)<[.Y',J69*Z))X-+36(K<_6%43/(L 9, %,F3Z%.7*DFW/
MV P?KE9DR9U(DFX+&*R%1]D,]M7,,:L@$"-T9O?'5=Y],7.E8D!F/IK!3*V,
MZ,CGE^+,\W.R O(!JHQ]V]9\:U+@@<^=]1+;R.]\&K_Q,"=AF+S/)S'V2"L!
MN?K!$*[4\AO#T605RY;SK09P5%L)^V6,9AQ)Y$?GJ!B;E[DBQJ<@2K9.M)7<
MDZJK@I5<,P@#@X%.6^;_'@\FI5]Y?6GT]TYT3W=BD5O.*W;ZHWUB 0N<O<62
M7[!DR,PW#,TX-H785_*SO4X[Z)?F^J=[?9@,F*F*;B>&M&-XW;> _H1.RXR6
MH.G()C(C_";!\=:3* Q"R[/9C^E;0)/5E#K>TME9:0!\K%$*#"0-VD&_5M$P
MES2&J2/:[OT@F'B9UTRR70N8J2\*!1_;NB&6 '_S$Z4/SPV'TOMP4\NQ!30I
M:T$9P[9Z@(0Q9'_J,$_"E2%V#85]_?Q.C)_80ASP)8'$BP)_DBER@@W'0K@.
MIG4!5:'L&F() 8-QYLF'!_YVZX29ARD[+7%)"5MCH*^\?2Q'JPXF#P^CQ<-P
MO-@'JBY&XT_#\6#4XN-O+3A)B 77"%[5; ;[B:N![S(9_ 3YJGOQ4O#GO*\Q
M^"FL]KYEAI=6HQ$C?#*K/73PXW1;D*6R'M=-M3:_8L:8ZFYF5IRAV@2OHRCD
MKR)LH'O*55$'+0<L7Z(.SB[J8$;6R1728D,^>TYL*PM?V(BT7&?E4\^QI+Z]
M\.IH_HC'AB3H(M21.>K!\9QMM.U[7F2Y,__%<L.7] )0P(VT!K+_;A?GA#QI
M +30+2-IMY0/.Y?+87OV=LF=0&0A8R?/ZQ3ZRS\VOLL0#H;_CK@3;)JS-6>U
MKF1=+*C)WU>2.BTF@W_\/+F_'<[F_VWM_."OO>$_/X\6O^7SM>::[WU)VT?2
MEQ.YU0IQN1RVQAO?W]VP38!I;%L^L-(9<QC -R^',NEJT6=@VV!%]^A/F'$P
MK6=8J, >+36^WJH4020!0%MMHVTSQD7K<ZD2T78\4OAIL1(QE9&AI6)?!\,E
MH='S9C67\B")9T]=RX.\.MW-U\P8.;6C7G=^-Y*_&\4X/<3-0^K\0:;46<I3
M(HF+8Q_7NQSB>95+!5A'>G'ULU>:1%V9DI0-CZDK)*JN-:FZ-B6G&QY5UT*J
M3''.J?;YG2;-[TS))H='\SND&?E>DZKWFE1U%CJ!1]5[)*H^:%+U0?=$\@J/
M)!^0N/JHR=5'7:Y>X:'DXTFXBBVZ27AV?3('7JI<"/GVI#UK52$A:BT2Z-<D
M^;"+>%Q,"8U_I]"SZZL8KXUI4Z>6V1 B!ZX5!)-5.M$G=.:L-V'N7D/B[Z.L
MB9U.I3-:H:"AL]L8@>'SSJ%Q87DVG=8^8+R:?]02T!X%)E^W*ER1?Y#>L?[I
MA^NK[ZN7K-A^R&=VKQH]!H[M6/1E0I,>/9!PXZ=Y.PF96_$M B>0#;M*X:R8
MZFJUU:^882F'W:ZV*K@!%ZS[+N9Z7EG09 .@OIX9E'8Q&80#HAX('$?<69Q1
M7.A]F_OSZR>J*"^.ARW_OM#4D'70D'<%BGC58]G2^P"-P$Q]"&5PEHJ@:2%E
MN"I@ULK2C<Z@0M5Z5J):+()V7E>C6B<+"JH+?OR=K$9,)WQR[,ARQ6NRH.A7
ML3X+9._F;1E=RGYUPLV,N#'BP<;9+?RA%W*51Q(3H=T(_IHO':HRKE2B=?6&
M#%E&7"L<;"R';BU/\82,H#1:WM(F2%9MPPH4\*U/=:=CQ<L,XBJO?RU48]#-
MNS0ZE!YZQ&^.)JM< ('2T0Y0US22!0.WS!A LDX.RQK,C:83U1MHN2+8F6;A
MXZQ$145,]%4PUW.U_W%M8=,F16<K7ZWTZ,_9:"QQQJYHDD$HYJ!C7]Z-$Y)[
M]IED?'"KV3X05.Z8 :B(G==7N5Q!!3%D$>/)-7POGMS)G78_8G.?.O\YW!K5
M)U\15L+VU@"9OBM9&I0HF,34U*(3.F>0$OL7RXT /AJ@RNC>&D=2IX(%G<)I
MYC.L.=]4]=#],9H0!P/#,,[T9QZT/KJ?Q/$<&C__*LL\S!]*6@O[B9QV]CLC
M?9PJ[B@SPO.!D*3?.]>1N&V *J/'M33A3@,6 \-5IFEJF-AI4J 'E,J@FRRT
M6*H1P*3Y-",VUT/L"1U8KDOLVXBR.<]6:L=/%FW%E +41P\C:CRKP.#@<YDS
MHT5<H4Q#R%.7Y)&7TU-AAEMU*]BJ=S->&P!E$KM0'WQA#?1(L2-9,].[/M?!
M@>\Q 4GBT3LC2^(\L15$>P)"FD%_@.=8,N%8H3.<>Y+KD-!N'QH >Y:LOB)^
M0& C50^&!SIOA[BJPO:=+/IC\B7^D^RB&E@?_;V=YL<<,#KH9-:_89C37F5V
M%V55_&C/9C87("9GGB%_3$+^#D"V]1=$S-( WEB!L^Q[]JWC1B&Q2U7V0!2B
M57XL1ZN,AXO>_60^[TV'L][\Y_YLV)O<Q>GT)^,DE"6?&C#^9,_R[)Z=?+3G
MD;#'&@MZ.T)[ ?\P5DB+1?F+/GOY <$MPAIH\WWEQ!Q*)_:^#/)=DPKPZLPM
M2==51#SA<8O$[K.9;*U)4?$I//C$QG+=6V7Q):9F(]BW1U RFLAFR'8X\I8T
MOD2VW'0Q3&Y-PI ZCU'('3 6?C7H,)<]0.(CU$+;V/=0FO.Q/3C11X;6@!8/
M LUFL.^L-/EN!)*IU*9''HU[+.V&L*^VVJ%7!90!@=>0HVXLAO-$YOSY=B=T
M<EI:_GC[X;OCCK?99WK!_CN7T^S1R;#[7NC8%0*'STLW8J.$:W(\AT"4C*;)
MJBP(."-V.]\QP[-1<_:W#0)^$/>1<E3L"#5)D5O[@AE#IIL)5TZJW!IH!B3/
M/DZ6FY?Z!A2IN+O\Z&4@MH,C>J[P^LY!\GZK:YHQ2$XP^4 CYF39O0-(6L9
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MHL'_AT=IL]_\?U!+ 0(4 Q0    ( (6$2UEHFN4.20(  .L%   3
M      "  0    !A8VQA<FEO;E]E>#(S,#$N:'1M4$L! A0#%     @ A81+
M62DBB#/S @  3P@  !,              ( !>@(  &%C;&%R:6]N7V5X,C,P
M,BYH=&U02P$"% ,4    " "%A$M9FZPF:=OZ! #J=R@ $P
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2      @ "  . @  Y.,%

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>aclarion_posam2_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ACON="http://aclarion.com/20240630"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="acon-20240630.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-04-012024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PreferredStockSeriesAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PreferredStockSeriesA1A2A3A4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesA1A2A3A4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PreferredStockSeriesBB1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesBB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PreferredStockSeriesB2B3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesB2B3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_PreferredStockSeriesAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_PreferredStockSeriesA1A2A3A4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesA1A2A3A4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_PreferredStockSeriesBB1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesBB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_PreferredStockSeriesB2B3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesB2B3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PreferredStockSeriesAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PreferredStockSeriesA1A2A3A4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesA1A2A3A4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PreferredStockSeriesBB1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesBB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PreferredStockSeriesB2B3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesB2B3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_PreferredStockSeriesAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_PreferredStockSeriesA1A2A3A4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesA1A2A3A4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_PreferredStockSeriesBB1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesBB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_PreferredStockSeriesB2B3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesB2B3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_PreferredStockSeriesAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_PreferredStockSeriesA1A2A3A4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesA1A2A3A4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_PreferredStockSeriesBB1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesBB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_PreferredStockSeriesB2B3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesB2B3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_PreferredStockSeriesAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_PreferredStockSeriesA1A2A3A4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesA1A2A3A4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_PreferredStockSeriesBB1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesBB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_PreferredStockSeriesB2B3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesB2B3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_PreferredStockSeriesA1A2A3A4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesA1A2A3A4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_PreferredStockSeriesBB1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesBB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_PreferredStockSeriesB2B3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesB2B3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_custom_PreferredStockSeriesAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_custom_PreferredStockSeriesA1A2A3A4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesA1A2A3A4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_custom_PreferredStockSeriesBB1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesBB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_custom_PreferredStockSeriesB2B3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesB2B3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_PreferredStockSeriesAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_PreferredStockSeriesA1A2A3A4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesA1A2A3A4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_PreferredStockSeriesBB1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesBB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_PreferredStockSeriesB2B3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesB2B3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_PreferredStockSeriesAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_PreferredStockSeriesA1A2A3A4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesA1A2A3A4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_PreferredStockSeriesBB1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesBB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_PreferredStockSeriesB2B3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ACON:PreferredStockSeriesB2B3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-01-31_custom_StockSplit2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ACON:StockSplit2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_Pre2024SplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ACON:Pre2024SplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_Post2024SplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ACON:Post2024SplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PreSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ACON:PreSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PostSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ACON:PostSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-02-012024-02-29_us-gaap_IPOMember_custom_CompletionOfPublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ACON:CompletionOfPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_IPOMember_custom_CompletionOfIssuanceOfSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ACON:CompletionOfIssuanceOfSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_WarrantLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_custom_WarrantLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_custom_WarrantLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_DerivativeLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:DerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_custom_DerivativeLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:DerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_custom_DerivativeLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:DerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_custom_DerivativeLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:DerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_WarrantLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_DerivativeLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:DerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_WarrantLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_DerivativeLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:DerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_WarrantLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_WarrantLiabilityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_WarrantLiabilityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ACON:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_ShortTermDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:ShortTermDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ShortTermDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:ShortTermDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_DeferredOfferingCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:DeferredOfferingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_DeferredOfferingCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:DeferredOfferingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_PrepaidInsuranceDAndOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:PrepaidInsuranceDAndOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PrepaidInsuranceDAndOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:PrepaidInsuranceDAndOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_PrepaidInsuranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:PrepaidInsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PrepaidInsuranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:PrepaidInsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_PrepaidClinicalCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:PrepaidClinicalCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PrepaidClinicalCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:PrepaidClinicalCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_PrepaidExchangeFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:PrepaidExchangeFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PrepaidExchangeFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:PrepaidExchangeFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_PrepaidOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:PrepaidOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PrepaidOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:PrepaidOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_OtherReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_OtherReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AccountsPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AccountsPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_CreditCardsPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:CreditCardsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CreditCardsPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:CreditCardsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_AccruedPayrollMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:AccruedPayrollMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AccruedPayrollMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:AccruedPayrollMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_AccruedBonusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:AccruedBonusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AccruedBonusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:AccruedBonusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_DAndOFinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:DAndOFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_DAndOFinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:DAndOFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_AccruedAuditAndLegalExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:AccruedAuditAndLegalExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AccruedAuditAndLegalExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:AccruedAuditAndLegalExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_AccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:AccruedInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:AccruedInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_AccruedBoardCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:AccruedBoardCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AccruedBoardCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:AccruedBoardCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_OtherAccruedLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:OtherAccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_OtherAccruedLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ACON:OtherAccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_PatentsAndLicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ACON:PatentsAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PatentsAndLicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ACON:PatentsAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-05-31_custom_SeniorNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ACON:SeniorNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="From2023-05-012023-05-31_custom_SeniorNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ACON:SeniorNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_SeriesBNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ACON:SeriesBNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-09-012023-09-30_custom_SeriesBNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ACON:SeriesBNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-30_custom_SeriesCNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ACON:SeriesCNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="From2023-11-012023-11-30_custom_SeriesCNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ACON:SeriesCNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="From2023-11-012023-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_custom_SeniorNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ACON:SeniorNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_SeniorNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ACON:SeniorNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-222024-01-29_custom_ExchangeAgreementsMember_custom_AccreditedInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ACON:AccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ACON:ExchangeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-22</startDate>
            <endDate>2024-01-29</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-01-31_custom_ExchangeAgreementsMember_custom_AccreditedInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ACON:AccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ACON:ExchangeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2024-03-052024-03-06_custom_UnsecuredNonConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">ACON:UnsecuredNonConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-05</startDate>
            <endDate>2024-03-06</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-06_custom_UnsecuredNonConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">ACON:UnsecuredNonConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-06</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_UnsecuredNonConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">ACON:UnsecuredNonConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_RegentsOfTheUniversityOfCaliforniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ACON:RegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_custom_RegentsOfTheUniversityOfCaliforniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ACON:RegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_RegentsOfTheUniversityOfCaliforniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ACON:RegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_RegentsOfTheUniversityOfCaliforniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ACON:RegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_RegentsOfTheUniversityOfCaliforniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ACON:RegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-03-232024-03-24_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-23</startDate>
            <endDate>2024-03-24</endDate>
        </period>
    </context>
    <context id="From2024-03-232024-03-24_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-23</startDate>
            <endDate>2024-03-24</endDate>
        </period>
    </context>
    <context id="From2023-02-012023-02-28_custom_ExecutiveChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ACON:ExecutiveChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="From2024-02-262024-02-27_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-26</startDate>
            <endDate>2024-02-27</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-27_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-27</instant>
        </period>
    </context>
    <context id="From2023-10-082023-10-09_custom_WhiteLionEquityLineAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ACON:WhiteLionEquityLineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-08</startDate>
            <endDate>2023-10-09</endDate>
        </period>
    </context>
    <context id="From2024-04-242024-04-26_custom_WhiteLionEquityLineAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ACON:WhiteLionEquityLineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-24</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_WhiteLionEquityLineAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ACON:WhiteLionEquityLineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_WarrantStrikePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_WarrantStrikePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_WarrantStrikePrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_WarrantStrikePrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_WarrantStrikePrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_WarrantStrikePrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_WarrantStrikePrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_WarrantStrikePrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_WarrantStrikePrice4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_WarrantStrikePrice4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_WarrantStrikePrice5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_WarrantStrikePrice5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_WarrantStrikePrice6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePrice6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_WarrantStrikePrice6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:WarrantStrikePrice6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ACON:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ACON:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_RestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ACON:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_RestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ACON:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ACON:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ACON:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-21_custom_AclarionEquityIncentivePlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ACON:AclarionEquityIncentivePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-21</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AclarionEquityIncentivePlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ACON:AclarionEquityIncentivePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_OptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_NonVestedStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:NonVestedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_NonVestedStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ACON:NonVestedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentDescription contextRef="From2024-01-01to2024-06-30" id="Fact000003">Updated S-1</dei:AmendmentDescription>
    <dei:DocumentFiscalYearFocus contextRef="From2024-01-01to2024-06-30" id="Fact000004">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-01-01to2024-06-30" id="Fact000005">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-06-30" id="Fact000006">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-06-30" id="Fact000007">0001635077</dei:EntityCentralIndexKey>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesA1A2A3A4Member"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesBB1Member"
      id="xdx2ixbrl0281"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesB2B3Member"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:ProceedsFromSaleOfSeriesPreferredStock
      contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesA1A2A3A4Member"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:ProceedsFromSaleOfSeriesPreferredStock
      contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesBB1Member"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:ProceedsFromSaleOfSeriesPreferredStock
      contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesB2B3Member"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:RedemptionOfSeriesPreferredStock
      contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesA1A2A3A4Member"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:RedemptionOfSeriesPreferredStock
      contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesBB1Member"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:RedemptionOfSeriesPreferredStock
      contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesB2B3Member"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesA1A2A3A4Member"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesBB1Member"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesB2B3Member"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesA1A2A3A4Member"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesBB1Member"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesB2B3Member"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:CommitmentSharesNoteFinancing
      contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:CommitmentSharesNoteFinancing
      contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesA1A2A3A4Member"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:CommitmentSharesNoteFinancing
      contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesBB1Member"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:CommitmentSharesNoteFinancing
      contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesB2B3Member"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:CommitmentSharesNoteFinancingShares
      contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0326"
      unitRef="Shares"
      xsi:nil="true"/>
    <ACON:IssuanceOfWarrantsNoteFinancing
      contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfWarrantsNoteFinancing
      contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesA1A2A3A4Member"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfWarrantsNoteFinancing
      contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesBB1Member"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfWarrantsNoteFinancing
      contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesB2B3Member"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesA1A2A3A4Member"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesBB1Member"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_custom_PreferredStockSeriesB2B3Member"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesA1A2A3A4Member"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesBB1Member"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesB2B3Member"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0369"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesA1A2A3A4Member"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesBB1Member"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesB2B3Member"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0374"
      unitRef="Shares"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommonSharesEquityLineOfCredit
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommonSharesEquityLineOfCredit
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesA1A2A3A4Member"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommonSharesEquityLineOfCredit
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesBB1Member"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommonSharesEquityLineOfCredit
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesB2B3Member"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommonSharesEquityLineOfCreditShares
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0381"
      unitRef="Shares"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommitmentSharesNoteFinancing
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommitmentSharesNoteFinancing
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesA1A2A3A4Member"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommitmentSharesNoteFinancing
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesBB1Member"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommitmentSharesNoteFinancing
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesB2B3Member"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommitmentSharesNoteFinancingShares
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0388"
      unitRef="Shares"
      xsi:nil="true"/>
    <ACON:CashlessExerciseOfPrefundedWarrant
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:CashlessExerciseOfPrefundedWarrant
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesA1A2A3A4Member"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:CashlessExerciseOfPrefundedWarrant
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesBB1Member"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:CashlessExerciseOfPrefundedWarrant
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesB2B3Member"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:CashlessExerciseOfPrefundedWarrantsShares
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0395"
      unitRef="Shares"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesA1A2A3A4Member"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesBB1Member"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesB2B3Member"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0402"
      unitRef="Shares"
      xsi:nil="true"/>
    <ACON:PublicOfferingAndLineOfCreditIssuanceCosts
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:PublicOfferingAndLineOfCreditIssuanceCosts
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesA1A2A3A4Member"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:PublicOfferingAndLineOfCreditIssuanceCosts
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesBB1Member"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:PublicOfferingAndLineOfCreditIssuanceCosts
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesB2B3Member"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommonSharesDebtForEquityExchange
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommonSharesDebtForEquityExchange
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesA1A2A3A4Member"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommonSharesDebtForEquityExchange
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesBB1Member"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommonSharesDebtForEquityExchange
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesB2B3Member"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommonSharesDebtForEquityExchangeShares
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0414"
      unitRef="Shares"
      xsi:nil="true"/>
    <ACON:RoundUpConversionRelatedToReverseStockSplit
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:RoundUpConversionRelatedToReverseStockSplit
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesA1A2A3A4Member"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:RoundUpConversionRelatedToReverseStockSplit
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesBB1Member"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:RoundUpConversionRelatedToReverseStockSplit
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesB2B3Member"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:RoundUpConventionRelatedToReverseStockSplitShares
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0421"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesA1A2A3A4Member"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesBB1Member"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_custom_PreferredStockSeriesB2B3Member"
      id="xdx2ixbrl0426"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0441"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesA1A2A3A4Member"
      id="xdx2ixbrl0442"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesBB1Member"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesB2B3Member"
      id="xdx2ixbrl0444"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesA1A2A3A4Member"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesBB1Member"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesB2B3Member"
      id="xdx2ixbrl0449"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommonSharesEquityLineOfCredit
      contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommonSharesEquityLineOfCredit
      contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesA1A2A3A4Member"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommonSharesEquityLineOfCredit
      contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesBB1Member"
      id="xdx2ixbrl0453"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommonSharesEquityLineOfCredit
      contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesB2B3Member"
      id="xdx2ixbrl0454"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesAMember"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesA1A2A3A4Member"
      id="xdx2ixbrl0457"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesBB1Member"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_custom_PreferredStockSeriesB2B3Member"
      id="xdx2ixbrl0459"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0481"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:ProceedsFromSaleOfSeriesPreferredStock
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0486"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:ProceedsFromSaleOfSeriesPreferredStock
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:ProceedsFromSaleOfSeriesPreferredStock
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0488"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:RedemptionOfSeriesPreferredStock
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:RedemptionOfSeriesPreferredStock
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0492"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:RedemptionOfSeriesPreferredStock
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0508"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0510"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:CommitmentSharesNoteFinancing
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0513"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:CommitmentSharesNoteFinancing
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfWarrantsNoteFinancing
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0520"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfWarrantsNoteFinancing
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0522"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0525"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0526"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0544"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0546"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0549"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0550"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0551"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0552"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommonSharesEquityLineOfCredit
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommitmentSharesNoteFinancing
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0563"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommitmentSharesNoteFinancing
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0565"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:CashlessExerciseOfPrefundedWarrant
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0570"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:CashlessExerciseOfPrefundedWarrant
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:CashlessExerciseOfPrefundedWarrant
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0572"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:CashlessExerciseOfPrefundedWarrant
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0573"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0579"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:PublicOfferingAndLineOfCreditIssuanceCosts
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0584"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:PublicOfferingAndLineOfCreditIssuanceCosts
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0586"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommonSharesDebtForEquityExchange
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0591"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:RoundUpConversionRelatedToReverseStockSplit
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0596"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:RoundUpConversionRelatedToReverseStockSplit
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0597"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:RoundUpConversionRelatedToReverseStockSplit
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0598"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:RoundUpConversionRelatedToReverseStockSplit
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0599"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0603"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0604"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0615"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0617"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0620"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0621"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0622"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-012024-06-30"
      id="xdx2ixbrl0623"
      unitRef="USD"
      xsi:nil="true"/>
    <ACON:IssuanceOfCommonSharesEquityLineOfCredit
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0629"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0634"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0635"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-01-01to2024-06-30" id="Fact000013">POS AM</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-06-30" id="Fact000014">Aclarion, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-06-30" id="Fact000015">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-06-30" id="Fact000016">47-3324725</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-06-30" id="Fact000017">8181 Arista Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-01-01to2024-06-30" id="Fact000018">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-06-30" id="Fact000019">Broomfield</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-06-30" id="Fact000020">CO</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-06-30" id="Fact000021">80021</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-06-30" id="Fact000022">833</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-06-30" id="Fact000023">275-2266</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-06-30" id="Fact000024">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-06-30" id="Fact000025">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-06-30" id="Fact000026">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2024-01-01to2024-06-30" id="Fact000027">false</dei:EntityExTransitionPeriod>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000035"
      unitRef="USD">1172687</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000036"
      unitRef="USD">1021069</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000038"
      unitRef="USD">10000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000039"
      unitRef="USD">10000</us-gaap:RestrictedCash>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000041"
      unitRef="USD">19713</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000042"
      unitRef="USD">13270</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000044"
      unitRef="USD">649357</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000045"
      unitRef="USD">245030</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000047"
      unitRef="USD">1851757</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000048"
      unitRef="USD">1289369</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000053"
      unitRef="USD">1189</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000054"
      unitRef="USD">1782</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000056"
      unitRef="USD">1235875</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000057"
      unitRef="USD">1168623</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000059"
      unitRef="USD">1237064</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000060"
      unitRef="USD">1170405</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000062"
      unitRef="USD">3088821</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000063"
      unitRef="USD">2459774</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000071"
      unitRef="USD">179123</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000072"
      unitRef="USD">760535</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000074"
      unitRef="USD">447972</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000075"
      unitRef="USD">857722</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OtherNotesPayableCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000077"
      unitRef="USD">777087</us-gaap:OtherNotesPayableCurrent>
    <us-gaap:OtherNotesPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000078"
      unitRef="USD">1125724</us-gaap:OtherNotesPayableCurrent>
    <ACON:WarrantLiabilityCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000080"
      unitRef="USD">23861</ACON:WarrantLiabilityCurrent>
    <ACON:WarrantLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000081"
      unitRef="USD">289165</ACON:WarrantLiabilityCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000083"
      unitRef="USD">18601</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000084"
      unitRef="USD">121326</us-gaap:DerivativeLiabilitiesCurrent>
    <ACON:LiabilityToIssueEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000086"
      unitRef="USD">0</ACON:LiabilityToIssueEquity>
    <ACON:LiabilityToIssueEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000087"
      unitRef="USD">33297</ACON:LiabilityToIssueEquity>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000089"
      unitRef="USD">1446644</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000090"
      unitRef="USD">3187769</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000092"
      unitRef="USD">1446644</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000093"
      unitRef="USD">3187769</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000101"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000103"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000105"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000107"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000109"
      unitRef="Shares">8210671</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000111"
      unitRef="Shares">8210671</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000113"
      unitRef="Shares">825459</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000115"
      unitRef="Shares">825459</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000098"
      unitRef="USD">82</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000099"
      unitRef="USD">8</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000117"
      unitRef="USD">49560800</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000118"
      unitRef="USD">43553523</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000120"
      unitRef="USD">-47918705</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000121"
      unitRef="USD">-44281526</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000123"
      unitRef="USD">1642177</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000124"
      unitRef="USD">-727995</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000126"
      unitRef="USD">3088821</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000127"
      unitRef="USD">2459774</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000134"
      unitRef="USD">10971</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000135"
      unitRef="USD">17072</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000136"
      unitRef="USD">21085</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000137"
      unitRef="USD">42542</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000139"
      unitRef="USD">23294</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000140"
      unitRef="USD">19301</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000141"
      unitRef="USD">42770</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000142"
      unitRef="USD">36754</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000144"
      unitRef="USD">-12323</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000145"
      unitRef="USD">-2229</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000146"
      unitRef="USD">-21685</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000147"
      unitRef="USD">5788</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000154"
      unitRef="USD">225037</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000155"
      unitRef="USD">207790</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000156"
      unitRef="USD">406094</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000157"
      unitRef="USD">385074</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000159"
      unitRef="USD">202102</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000160"
      unitRef="USD">250006</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000161"
      unitRef="USD">441143</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000162"
      unitRef="USD">454405</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000164"
      unitRef="USD">696099</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000165"
      unitRef="USD">946175</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000166"
      unitRef="USD">1541947</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000167"
      unitRef="USD">1753774</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000169"
      unitRef="USD">1123238</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000170"
      unitRef="USD">1403971</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000171"
      unitRef="USD">2389184</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000172"
      unitRef="USD">2593253</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000174"
      unitRef="USD">-1135561</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000175"
      unitRef="USD">-1406200</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000176"
      unitRef="USD">-2410869</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000177"
      unitRef="USD">-2587465</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseOther
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000184"
      unitRef="USD">127848</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000185"
      unitRef="USD">47139</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000186"
      unitRef="USD">463672</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000187"
      unitRef="USD">48519</us-gaap:InterestExpenseOther>
    <ACON:LossOnExchangeOfDebt
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000189"
      unitRef="USD">-0</ACON:LossOnExchangeOfDebt>
    <ACON:LossOnExchangeOfDebt
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000190"
      unitRef="USD">-0</ACON:LossOnExchangeOfDebt>
    <ACON:LossOnExchangeOfDebt
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000191"
      unitRef="USD">1066732</ACON:LossOnExchangeOfDebt>
    <ACON:LossOnExchangeOfDebt
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000192"
      unitRef="USD">-0</ACON:LossOnExchangeOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000194"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000195"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000196"
      unitRef="USD">-111928</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000197"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000199"
      unitRef="USD">25357</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000200"
      unitRef="USD">-11800</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000201"
      unitRef="USD">323041</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000202"
      unitRef="USD">-11800</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000204"
      unitRef="USD">-25</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000205"
      unitRef="USD">583</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000206"
      unitRef="USD">92980</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000207"
      unitRef="USD">-234</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000209"
      unitRef="USD">-102516</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000210"
      unitRef="USD">-58356</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000211"
      unitRef="USD">-1226311</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000212"
      unitRef="USD">-60552</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000214"
      unitRef="USD">-1238077</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000215"
      unitRef="USD">-1464557</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000216"
      unitRef="USD">-3637180</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000217"
      unitRef="USD">-2648017</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000219"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000220"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000221"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000222"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000224"
      unitRef="USD">-1238077</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000225"
      unitRef="USD">-1464557</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000226"
      unitRef="USD">-3637180</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000227"
      unitRef="USD">-2648017</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000229"
      unitRef="USD">-1238077</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000230"
      unitRef="USD">-1464557</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000231"
      unitRef="USD">-3637180</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000232"
      unitRef="USD">-2648017</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000234"
      unitRef="USDPShares">-0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000236"
      unitRef="USDPShares">-0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      id="Fact000238"
      unitRef="USDPShares">-2.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      id="Fact000240"
      unitRef="USDPShares">-2.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact000242"
      unitRef="USDPShares">-0.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact000244"
      unitRef="USDPShares">-0.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact000246"
      unitRef="USDPShares">-5.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact000248"
      unitRef="USDPShares">-5.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000250"
      unitRef="Shares">8217024</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000252"
      unitRef="Shares">8217024</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      id="Fact000254"
      unitRef="Shares">517979</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      id="Fact000256"
      unitRef="Shares">517979</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact000258"
      unitRef="Shares">6829825</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact000260"
      unitRef="Shares">6829825</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact000262"
      unitRef="Shares">507499</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact000264"
      unitRef="Shares">507499</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_custom_PreferredStockSeriesAMember"
      decimals="INF"
      id="Fact000271"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_PreferredStockSeriesAMember"
      decimals="0"
      id="Fact000266"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_custom_PreferredStockSeriesA1A2A3A4Member"
      decimals="INF"
      id="Fact000273"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_PreferredStockSeriesA1A2A3A4Member"
      decimals="0"
      id="Fact000267"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_custom_PreferredStockSeriesBB1Member"
      decimals="INF"
      id="Fact000275"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_PreferredStockSeriesBB1Member"
      decimals="0"
      id="Fact000268"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_custom_PreferredStockSeriesB2B3Member"
      decimals="INF"
      id="Fact000277"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_PreferredStockSeriesB2B3Member"
      decimals="0"
      id="Fact000269"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <ACON:PreferredStockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesAMember"
      decimals="INF"
      id="Fact000289"
      unitRef="Shares">1</ACON:PreferredStockIssuedDuringPeriodSharesNewIssues>
    <ACON:ProceedsFromSaleOfSeriesPreferredStock
      contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesAMember"
      decimals="0"
      id="Fact000284"
      unitRef="USD">1000</ACON:ProceedsFromSaleOfSeriesPreferredStock>
    <ACON:RedemptionOfSeriesPreferredStockShares
      contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesAMember"
      decimals="INF"
      id="Fact000296"
      unitRef="Shares">1</ACON:RedemptionOfSeriesPreferredStockShares>
    <ACON:RedemptionOfSeriesPreferredStock
      contextRef="From2023-01-012023-03-31_custom_PreferredStockSeriesAMember"
      decimals="0"
      id="Fact000291"
      unitRef="USD">-1000</ACON:RedemptionOfSeriesPreferredStock>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_custom_PreferredStockSeriesAMember"
      decimals="INF"
      id="Fact000308"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_custom_PreferredStockSeriesAMember"
      decimals="0"
      id="Fact000303"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_custom_PreferredStockSeriesA1A2A3A4Member"
      decimals="INF"
      id="Fact000310"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_custom_PreferredStockSeriesA1A2A3A4Member"
      decimals="0"
      id="Fact000304"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_custom_PreferredStockSeriesBB1Member"
      decimals="INF"
      id="Fact000312"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_custom_PreferredStockSeriesBB1Member"
      decimals="0"
      id="Fact000305"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_custom_PreferredStockSeriesB2B3Member"
      decimals="INF"
      id="Fact000314"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_custom_PreferredStockSeriesB2B3Member"
      decimals="0"
      id="Fact000306"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_custom_PreferredStockSeriesAMember"
      decimals="INF"
      id="Fact000343"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_custom_PreferredStockSeriesAMember"
      decimals="0"
      id="Fact000338"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_custom_PreferredStockSeriesA1A2A3A4Member"
      decimals="INF"
      id="Fact000345"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_custom_PreferredStockSeriesA1A2A3A4Member"
      decimals="0"
      id="Fact000339"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_custom_PreferredStockSeriesBB1Member"
      decimals="INF"
      id="Fact000347"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_custom_PreferredStockSeriesBB1Member"
      decimals="0"
      id="Fact000340"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_custom_PreferredStockSeriesB2B3Member"
      decimals="INF"
      id="Fact000349"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_custom_PreferredStockSeriesB2B3Member"
      decimals="0"
      id="Fact000341"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_custom_PreferredStockSeriesAMember"
      decimals="INF"
      id="Fact000356"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_PreferredStockSeriesAMember"
      decimals="0"
      id="Fact000351"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_custom_PreferredStockSeriesA1A2A3A4Member"
      decimals="INF"
      id="Fact000358"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_PreferredStockSeriesA1A2A3A4Member"
      decimals="0"
      id="Fact000352"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_custom_PreferredStockSeriesBB1Member"
      decimals="INF"
      id="Fact000360"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_PreferredStockSeriesBB1Member"
      decimals="0"
      id="Fact000353"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_custom_PreferredStockSeriesB2B3Member"
      decimals="INF"
      id="Fact000362"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_PreferredStockSeriesB2B3Member"
      decimals="0"
      id="Fact000354"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_custom_PreferredStockSeriesAMember"
      decimals="INF"
      id="Fact000433"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_custom_PreferredStockSeriesAMember"
      decimals="0"
      id="Fact000428"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_custom_PreferredStockSeriesA1A2A3A4Member"
      decimals="INF"
      id="Fact000435"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_custom_PreferredStockSeriesA1A2A3A4Member"
      decimals="0"
      id="Fact000429"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_custom_PreferredStockSeriesBB1Member"
      decimals="INF"
      id="Fact000437"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_custom_PreferredStockSeriesBB1Member"
      decimals="0"
      id="Fact000430"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_custom_PreferredStockSeriesB2B3Member"
      decimals="INF"
      id="Fact000439"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_custom_PreferredStockSeriesB2B3Member"
      decimals="0"
      id="Fact000431"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_custom_PreferredStockSeriesAMember"
      decimals="INF"
      id="Fact000466"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_custom_PreferredStockSeriesAMember"
      decimals="0"
      id="Fact000461"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_custom_PreferredStockSeriesA1A2A3A4Member"
      decimals="INF"
      id="Fact000468"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_custom_PreferredStockSeriesA1A2A3A4Member"
      decimals="0"
      id="Fact000462"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_custom_PreferredStockSeriesBB1Member"
      decimals="INF"
      id="Fact000470"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_custom_PreferredStockSeriesBB1Member"
      decimals="0"
      id="Fact000463"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_custom_PreferredStockSeriesB2B3Member"
      decimals="INF"
      id="Fact000472"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_custom_PreferredStockSeriesB2B3Member"
      decimals="0"
      id="Fact000464"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000479"
      unitRef="Shares">491345</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000474"
      unitRef="USD">5</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000475"
      unitRef="USD">41596106</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000476"
      unitRef="USD">-39370153</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000477"
      unitRef="USD">2225958</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000482"
      unitRef="USD">82531</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000484"
      unitRef="USD">82531</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ACON:ProceedsFromSaleOfSeriesPreferredStock
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000489"
      unitRef="USD">1000</ACON:ProceedsFromSaleOfSeriesPreferredStock>
    <ACON:RedemptionOfSeriesPreferredStock
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000494"
      unitRef="USD">-1000</ACON:RedemptionOfSeriesPreferredStock>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000498"
      unitRef="USD">-1183460</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000499"
      unitRef="USD">-1183460</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000506"
      unitRef="Shares">491345</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000501"
      unitRef="USD">5</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000502"
      unitRef="USD">41678637</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000503"
      unitRef="USD">-40553613</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000504"
      unitRef="USD">1125029</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000509"
      unitRef="USD">136631</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000511"
      unitRef="USD">136631</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ACON:CommitmentSharesNoteFinancingShares
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000518"
      unitRef="Shares">21210</ACON:CommitmentSharesNoteFinancingShares>
    <ACON:CommitmentSharesNoteFinancing
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000514"
      unitRef="USD">175619</ACON:CommitmentSharesNoteFinancing>
    <ACON:CommitmentSharesNoteFinancing
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000516"
      unitRef="USD">175619</ACON:CommitmentSharesNoteFinancing>
    <ACON:IssuanceOfWarrantsNoteFinancing
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000521"
      unitRef="USD">37500</ACON:IssuanceOfWarrantsNoteFinancing>
    <ACON:IssuanceOfWarrantsNoteFinancing
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000523"
      unitRef="USD">37500</ACON:IssuanceOfWarrantsNoteFinancing>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000527"
      unitRef="USD">-1464557</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000528"
      unitRef="USD">-1464557</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000535"
      unitRef="Shares">512555</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000530"
      unitRef="USD">5</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000531"
      unitRef="USD">42028387</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000532"
      unitRef="USD">-42018169</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000533"
      unitRef="USD">10223</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000542"
      unitRef="Shares">825459</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000537"
      unitRef="USD">8</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000538"
      unitRef="USD">43553524</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000539"
      unitRef="USD">-44281526</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000540"
      unitRef="USD">-727995</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000545"
      unitRef="USD">85827</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000547"
      unitRef="USD">85827</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000554"
      unitRef="Shares">4261</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <ACON:IssuanceOfCommonSharesEquityLineOfCreditShares
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000561"
      unitRef="Shares">452343</ACON:IssuanceOfCommonSharesEquityLineOfCreditShares>
    <ACON:IssuanceOfCommonSharesEquityLineOfCredit
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000556"
      unitRef="USD">5</ACON:IssuanceOfCommonSharesEquityLineOfCredit>
    <ACON:IssuanceOfCommonSharesEquityLineOfCredit
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000557"
      unitRef="USD">1449527</ACON:IssuanceOfCommonSharesEquityLineOfCredit>
    <ACON:IssuanceOfCommonSharesEquityLineOfCredit
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000559"
      unitRef="USD">1449532</ACON:IssuanceOfCommonSharesEquityLineOfCredit>
    <ACON:IssuanceOfCommitmentSharesNoteFinancingShares
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000568"
      unitRef="Shares">9312</ACON:IssuanceOfCommitmentSharesNoteFinancingShares>
    <ACON:IssuanceOfCommitmentSharesNoteFinancing
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000564"
      unitRef="USD">33297</ACON:IssuanceOfCommitmentSharesNoteFinancing>
    <ACON:IssuanceOfCommitmentSharesNoteFinancing
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000566"
      unitRef="USD">33297</ACON:IssuanceOfCommitmentSharesNoteFinancing>
    <ACON:CashlessExerciseOfPrefundedWarrantsShares
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000575"
      unitRef="Shares">2915</ACON:CashlessExerciseOfPrefundedWarrantsShares>
    <ACON:IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000582"
      unitRef="Shares">5175000</ACON:IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares>
    <ACON:IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000577"
      unitRef="USD">52</ACON:IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts>
    <ACON:IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000578"
      unitRef="USD">2691339</ACON:IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts>
    <ACON:IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000580"
      unitRef="USD">2691391</ACON:IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts>
    <ACON:PublicOfferingAndLineOfCreditIssuanceCosts
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000585"
      unitRef="USD">-399106</ACON:PublicOfferingAndLineOfCreditIssuanceCosts>
    <ACON:PublicOfferingAndLineOfCreditIssuanceCosts
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000587"
      unitRef="USD">-399106</ACON:PublicOfferingAndLineOfCreditIssuanceCosts>
    <ACON:IssuanceOfCommonSharesDebtForEquityExchangeShares
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000594"
      unitRef="Shares">644142</ACON:IssuanceOfCommonSharesDebtForEquityExchangeShares>
    <ACON:IssuanceOfCommonSharesDebtForEquityExchange
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000589"
      unitRef="USD">6</ACON:IssuanceOfCommonSharesDebtForEquityExchange>
    <ACON:IssuanceOfCommonSharesDebtForEquityExchange
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000590"
      unitRef="USD">1771600</ACON:IssuanceOfCommonSharesDebtForEquityExchange>
    <ACON:IssuanceOfCommonSharesDebtForEquityExchange
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000592"
      unitRef="USD">1771606</ACON:IssuanceOfCommonSharesDebtForEquityExchange>
    <ACON:RoundUpConventionRelatedToReverseStockSplitShares
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000601"
      unitRef="Shares">40068</ACON:RoundUpConventionRelatedToReverseStockSplitShares>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000605"
      unitRef="USD">-2399102</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000606"
      unitRef="USD">-2399102</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000613"
      unitRef="Shares">7153500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000608"
      unitRef="USD">72</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000609"
      unitRef="USD">49186006</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000610"
      unitRef="USD">-46680628</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000611"
      unitRef="USD">2505449</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000616"
      unitRef="USD">70305</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000618"
      unitRef="USD">70305</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000625"
      unitRef="Shares">7171</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <ACON:IssuanceOfCommonSharesEquityLineOfCreditShares
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000632"
      unitRef="Shares">1050000</ACON:IssuanceOfCommonSharesEquityLineOfCreditShares>
    <ACON:IssuanceOfCommonSharesEquityLineOfCredit
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000627"
      unitRef="USD">10</ACON:IssuanceOfCommonSharesEquityLineOfCredit>
    <ACON:IssuanceOfCommonSharesEquityLineOfCredit
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000628"
      unitRef="USD">304490</ACON:IssuanceOfCommonSharesEquityLineOfCredit>
    <ACON:IssuanceOfCommonSharesEquityLineOfCredit
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000630"
      unitRef="USD">304500</ACON:IssuanceOfCommonSharesEquityLineOfCredit>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000636"
      unitRef="USD">-1238077</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000637"
      unitRef="USD">-1238077</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000644"
      unitRef="Shares">8210671</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000639"
      unitRef="USD">82</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000640"
      unitRef="USD">49560800</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000641"
      unitRef="USD">-47918705</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000642"
      unitRef="USD">1642177</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000649"
      unitRef="USD">-3637180</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000650"
      unitRef="USD">-2648017</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000655"
      unitRef="USD">90864</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000656"
      unitRef="USD">79809</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000658"
      unitRef="USD">156131</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000659"
      unitRef="USD">219162</us-gaap:ShareBasedCompensation>
    <ACON:GainLossOnExchangeOfDebt
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000661"
      unitRef="USD">1066732</ACON:GainLossOnExchangeOfDebt>
    <ACON:GainLossOnExchangeOfDebt
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000662"
      unitRef="USD">0</ACON:GainLossOnExchangeOfDebt>
    <ACON:GainsLossesOnExtinguishmentOfDebts
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000664"
      unitRef="USD">111928</ACON:GainsLossesOnExtinguishmentOfDebts>
    <ACON:GainsLossesOnExtinguishmentOfDebts
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000665"
      unitRef="USD">0</ACON:GainsLossesOnExtinguishmentOfDebts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000667"
      unitRef="USD">442289</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000668"
      unitRef="USD">28520</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000670"
      unitRef="USD">-323041</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000671"
      unitRef="USD">11800</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <ACON:NoncashInterestRelatedToBridgeFunding
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000673"
      unitRef="USD">49116</ACON:NoncashInterestRelatedToBridgeFunding>
    <ACON:NoncashInterestRelatedToBridgeFunding
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000674"
      unitRef="USD">14346</ACON:NoncashInterestRelatedToBridgeFunding>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000679"
      unitRef="USD">5115</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000680"
      unitRef="USD">-1414</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000682"
      unitRef="USD">405657</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000683"
      unitRef="USD">-33287</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000685"
      unitRef="USD">-540710</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000686"
      unitRef="USD">57914</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000688"
      unitRef="USD">-267325</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000689"
      unitRef="USD">241110</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <ACON:IncreaseDecreaseInNotePayableNetOfDiscount
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000691"
      unitRef="USD">-31129</ACON:IncreaseDecreaseInNotePayableNetOfDiscount>
    <ACON:IncreaseDecreaseInNotePayableNetOfDiscount
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000692"
      unitRef="USD">0</ACON:IncreaseDecreaseInNotePayableNetOfDiscount>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000694"
      unitRef="USD">-3293096</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000695"
      unitRef="USD">-1960653</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000700"
      unitRef="USD">157523</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000701"
      unitRef="USD">72634</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000703"
      unitRef="USD">-157523</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000704"
      unitRef="USD">-72634</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000709"
      unitRef="USD">2691391</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000710"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000712"
      unitRef="USD">1754032</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000713"
      unitRef="USD">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000715"
      unitRef="USD">300973</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000716"
      unitRef="USD">-0</us-gaap:RepaymentsOfNotesPayable>
    <ACON:EquityLineOfCreditIssuanceCosts
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000718"
      unitRef="USD">262744</ACON:EquityLineOfCreditIssuanceCosts>
    <ACON:EquityLineOfCreditIssuanceCosts
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000719"
      unitRef="USD">-0</ACON:EquityLineOfCreditIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000721"
      unitRef="USD">256094</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000722"
      unitRef="USD">-0</us-gaap:PaymentsOfStockIssuanceCosts>
    <ACON:BridgeFundingIssuanceCosts
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000724"
      unitRef="USD">23375</ACON:BridgeFundingIssuanceCosts>
    <ACON:BridgeFundingIssuanceCosts
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000725"
      unitRef="USD">85000</ACON:BridgeFundingIssuanceCosts>
    <ACON:ProceedsFromBridgeFunding
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000727"
      unitRef="USD">0</ACON:ProceedsFromBridgeFunding>
    <ACON:ProceedsFromBridgeFunding
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000728"
      unitRef="USD">1250000</ACON:ProceedsFromBridgeFunding>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000730"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000731"
      unitRef="USD">1000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000733"
      unitRef="USD">-0</us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000734"
      unitRef="USD">1000</us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000736"
      unitRef="USD">3602237</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000737"
      unitRef="USD">1165000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000739"
      unitRef="USD">151618</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000740"
      unitRef="USD">-868287</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000742"
      unitRef="USD">1031069</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000743"
      unitRef="USD">1482806</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000745"
      unitRef="USD">1182687</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000746"
      unitRef="USD">614518</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <ACON:IssuanceOfCommonSharesInExchangeForDebt
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000751"
      unitRef="USD">1519779</ACON:IssuanceOfCommonSharesInExchangeForDebt>
    <ACON:IssuanceOfCommonSharesInExchangeForDebt
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000752"
      unitRef="USD">0</ACON:IssuanceOfCommonSharesInExchangeForDebt>
    <ACON:IssuanceOfBridgeFundCommitmentShares
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000754"
      unitRef="USD">33297</ACON:IssuanceOfBridgeFundCommitmentShares>
    <ACON:IssuanceOfBridgeFundCommitmentShares
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000755"
      unitRef="USD">175619</ACON:IssuanceOfBridgeFundCommitmentShares>
    <ACON:FairValueOfWarrantsAndDerivativeRelatedToBridgeFunding
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000757"
      unitRef="USD">0</ACON:FairValueOfWarrantsAndDerivativeRelatedToBridgeFunding>
    <ACON:FairValueOfWarrantsAndDerivativeRelatedToBridgeFunding
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000758"
      unitRef="USD">742988</ACON:FairValueOfWarrantsAndDerivativeRelatedToBridgeFunding>
    <ACON:AccruedDebtIssuanceCostsRelatedToBridgeFunding
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000760"
      unitRef="USD">0</ACON:AccruedDebtIssuanceCostsRelatedToBridgeFunding>
    <ACON:AccruedDebtIssuanceCostsRelatedToBridgeFunding
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000761"
      unitRef="USD">118575</ACON:AccruedDebtIssuanceCostsRelatedToBridgeFunding>
    <ACON:IssuanceOfWarrantsRelatedToBridgeFunding
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000763"
      unitRef="USD">0</ACON:IssuanceOfWarrantsRelatedToBridgeFunding>
    <ACON:IssuanceOfWarrantsRelatedToBridgeFunding
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000764"
      unitRef="USD">37500</ACON:IssuanceOfWarrantsRelatedToBridgeFunding>
    <ACON:OriginalIssueDiscount15RelatedToBridgeFunding
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000766"
      unitRef="USD">0</ACON:OriginalIssueDiscount15RelatedToBridgeFunding>
    <ACON:OriginalIssueDiscount15RelatedToBridgeFunding
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000767"
      unitRef="USD">187500</ACON:OriginalIssueDiscount15RelatedToBridgeFunding>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000769">&lt;p id="xdx_804_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zMtdWvT9gXrj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&lt;/b&gt;&#160; &lt;b&gt;1. &lt;span id="xdx_822_zka55zb6zZBd"&gt;THE COMPANY AND BASIS
OF PRESENTATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;The Company&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Aclarion, Inc., formerly Nocimed, Inc., (the &#x201c;Company&#x201d;
or &#x201c;Aclarion&#x201d;) is a healthcare technology company that leverages magnetic resonance spectroscopy (&#x201c;MRS&#x201d;), and
a proprietary biomarker to optimize clinical treatments. The Company was formed in February 2015, is incorporated in Delaware, and has
its principal place of business in Broomfield, Colorado.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying condensed financial statements
have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;) and
pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial information.
Accordingly, they do not include all of the information required by U.S. GAAP for complete financial statements. The interim condensed
financial statements reflect all adjustments that are of a normal recurring nature and that are considered necessary for a fair representation
of the results for the periods presented and should be read in conjunction with the audited financial statements and notes thereto for
the year ended December 31, 2023, which include a complete set of footnote disclosures, including our significant accounting policies.
The December 31, 2023, condensed balance sheet was derived from the December 31, 2023, audited financial statements. They should be read
in conjunction with the financial statements and notes thereto included in our Annual report on Form 10-K, filed with the SEC on March
28, 2024. The results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or
for any other future period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Risks and Uncertainties&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is subject to various risks and uncertainties
frequently encountered by companies in the early stages of development. Such risks and uncertainties include, but are not limited to,
its limited operating history, competition from other companies, limited access to additional funds, dependence on key personnel, and
management of potential rapid growth. To address these risks, the Company must, among other things, develop its customer base&#x37e; implement
and successfully execute its business and marketing strategy&#x37e; develop follow-on products&#x37e; provide superior customer service&#x37e;
and attract, retain, and motivate qualified personnel. There can be no guarantee that the Company will be successful in addressing these
or other such risks.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;2024 Reverse Stock Split&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In March 2023 the Company&#x2019;s stockholders
approved a reverse stock split proposal at a ratio in the range of one-for-five to one-for-fifty, with the final ratio to be determined
by the Company's board in its discretion without further approval from the Company's stockholders. In January 2024, the Company's board
subsequently approved the final reverse stock split ratio of &lt;span id="xdx_90A_eus-gaap--StockholdersEquityReverseStockSplit_c20240101__20240131__us-gaap--TransactionTypeAxis__custom--StockSplit2024Member_zKdEPfaEeWA1" title="Reverse stock split"&gt;one-for-sixteen&lt;/span&gt; (the &#x201c;2024 Stock Split&#x201d;), which resulted in a
reduction in the number of outstanding shares of common stock, warrants, stock options and restricted share units and a proportionate
increase in the value of each share or strike price of the warrants and stock options. The common stock began trading on a reverse split-adjusted
basis on the NASDAQ on January 4, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As a result of the 2024 Stock Split, unless described
otherwise, all references to common stock, share data, per share data and related information contained in these financial statements
have been retrospectively adjusted to reflect the effect of the stock splits for all periods presented. In addition, any fractional shares
that would otherwise be issued as a result of the stock splits were rounded up to the nearest whole share. Further, the number of shares
issuable and exercise prices of stock options and warrants have been retrospectively adjusted in these financial statements for all periods
presented to reflect the 2024 Stock Split.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following tables present selected share information
reflecting on a retroactive basis the reverse stock splits as of and for the year ended December 31, 2023:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfChangesToEquityStatementTableTextBlock_zZRvytdP8TH3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details - Balance sheet changes from split)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B1_z5fsJdtzTOkc" style="display: none"&gt;Schedule of equity statement information&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_zx70AX1o1z2a" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CommonStockValue_iI_pp0p0_hus-gaap--TransactionTypeAxis__custom--Pre2024SplitMember_z00mAK4ij0Y3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 83%; text-align: left"&gt;Common shares issued and outstanding - pre-2024 split, &lt;span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_c20231231__us-gaap--TransactionTypeAxis__custom--Pre2024SplitMember_zzbiaUSo59Pd" title="Common stock shares issued"&gt;&lt;span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--TransactionTypeAxis__custom--Pre2024SplitMember_zRXG7S1lnhA3" title="Common stock shares outstanding"&gt;13,206,229&lt;/span&gt;&lt;/span&gt; shares&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;132&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CommonStockValue_iI_pp0p0_hus-gaap--TransactionTypeAxis__custom--Post2024SplitMember_zFLz567u1sZ2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common shares issued and outstanding - post-2024 split, &lt;span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20231231__us-gaap--TransactionTypeAxis__custom--Post2024SplitMember_zq5ZhNpBA2Yl" title="Common stock shares issued"&gt;&lt;span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--TransactionTypeAxis__custom--Post2024SplitMember_zWAI9cspabM6" title="Common stock shares outstanding"&gt;825,459&lt;/span&gt;&lt;/span&gt; shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_hus-gaap--TransactionTypeAxis__custom--Pre2024SplitMember_z36SUXsfVLUi" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Additional paid-in capital - pre-2024 split&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;43,553,399&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_hus-gaap--TransactionTypeAxis__custom--Post2024SplitMember_z03MNEEJTmcj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Additional paid-in capital - post-2024 split&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;43,553,523&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zo2yVaKiuuzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfRetroactiveBasisRreverseStockSplitsTableTextBlock_zhBkya5ufew7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details- Retroactive basis the reverse stock splits)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B9_zVL8x49ZagWc" style="display: none"&gt;Schedule of share information reflecting on a retroactive basis the reverse stock splits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 83%; text-align: left"&gt;Weighted average shares outstanding, basic and diluted - pre-2024 split&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PreSplitMember_zRCKpWECLsDk" title="Weighted average shares outstanding, basic"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PreSplitMember_ziZ01LCrKPSd" title="Weighted average shares outstanding, diluted"&gt;8,908,934&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted average shares outstanding, basic and diluted - post-2024 split&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PostSplitMember_zNy0pB4jkdD" title="Weighted average shares outstanding, basic"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PostSplitMember_zyspSxsF3Cdd" title="Weighted average shares outstanding, diluted"&gt;556,808&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Basic and diluted net loss per shares attributable to common stockholders - pre-2024 split&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PreSplitMember_z9bzbcgtXBe2" title="Basic net loss per shares attributable to common stockholders"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PreSplitMember_z9zldA0n5aS8" title="Diluted net loss per shares attributable to common stockholders"&gt;(0.55&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Basic and diluted net loss per shares attributable to common stockholders - post-2024 split&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareBasic_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PostSplitMember_zbqirK9pCUt3" title="Basic net loss per shares attributable to common stockholders"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PostSplitMember_zqys2puH9Qhd" title="Diluted net loss per shares attributable to common stockholders"&gt;(8.82&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zveFxll1R1M5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Nasdaq notice regarding &lt;span style="background-color: white"&gt;compliance
with the $1.00 Minimum Bid Price requirement&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="background-color: white"&gt;&lt;/span&gt;&lt;/b&gt;On April 8, 2024, Aclarion, Inc. (the &#x201c;Company&#x201d;) received a written
notice (the &#x201c;Notice&#x201d;) from the Listing Qualifications Department of The Nasdaq Stock Market (&#x201c;Nasdaq&#x201d;) indicating
that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued
listing on The Nasdaq Capital Market (the &#x201c;Bid Price Requirement&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Notice does not result in the immediate delisting
of the Company&#x2019;s common stock from The Nasdaq Capital Market.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Nasdaq Listing Rules require listed securities to maintain
a minimum bid price of $1.00 per share and, based upon the closing bid price of the Company&#x2019;s common stock for the 30 consecutive
business days for the period ending April 5, 2024, the Company no longer meets this requirement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Notice indicated that the
Company will be provided 180 calendar days (or until October 7, 2024) in which to regain compliance. If at any time during this 180 calendar
day period the bid price of the Company&#x2019;s common stock closes at or above $1.00 per share for a minimum of ten consecutive business
days, the Nasdaq staff (the &#x201c;Staff&#x201d;) will provide the Company with a written confirmation of compliance and the matter will
be closed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Alternatively, if the Company fails to regain compliance with Rule 5550(a)(2) prior to the expiration of the initial
180 calendar day period, the Company may be eligible for an additional 180 calendar day compliance period, provided (i) it meets the
continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The
Nasdaq Capital Market (except for the Bid Price Requirement) and (ii) it provides written notice to Nasdaq of its intention to cure this
deficiency during the second compliance period by effecting a reverse stock split, if necessary. In the event the Company does not regain
compliance with Rule 5550(a)(2) prior to the expiration of the initial 180 calendar day period, and if it appears to the Staff that the
Company will not be able to cure the deficiency, or if the Company is not otherwise eligible, the Staff will provide the Company with
written notification that its securities are subject to delisting from The Nasdaq Capital Market. At that time, the Company may appeal
the delisting determination to a Hearings Panel.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company intends to monitor the closing bid price of its common stock and
is considering its options to regain compliance with the Bid Price Requirement. The Company&#x2019;s receipt of the Notice does not affect
the Company&#x2019;s business, operations or reporting requirements with the Securities and Exchange Commission.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Nasdaq Stockholder Equity Notice&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 3, 2023, the Company received a written notice (the &#x201c;Stockholder Equity Notice&#x201d;) from Nasdaq indicating that it
is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Stock Market to maintain a minimum
of $2,500,000 in stockholders&#x2019; equity for continued listing. In its annual report on Form 10-K filed on February 27, 2023 for the
period ended December 31, 2022, the Company reported stockholders&#x2019; equity of $1,787,751, and, as a result, does not currently satisfy
Listing Rule 5550(b)(1).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Stockholder Equity Notice also indicated that the Company had a period of 45 calendar days
from the date of the Stockholder Equity Notice, or until April 17, 2023, to submit a plan to regain compliance with the stockholders&#x2019;
equity requirement under Nasdaq Listing Rule 5550(b)(1). The Company submitted such a plan to Nasdaq on April 12, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April
20, 2023, the Company received a letter (the &#x201c;Extension Notice&#x201d;) from Nasdaq notifying the Company that it has been granted
an additional 180-day period, or until August 30, 2023, to regain compliance with Nasdaq Listing Rule 5550(b)(1).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 31,
2023, the Nasdaq staff notified the Company that it had not met the terms of the Extension Notice. Accordingly, the Nasdaq staff had
determined to delist the Company&#x2019;s common stock from Nasdaq, unless the Company timely requests an appeal of the staff&#x2019;s
determination to a hearings panel (the &#x201c;Panel&#x201d;), pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company requested a hearing before a hearings panel (the &#x201c;Panel&#x201d;) to appeal the delisting notice from the staff.
The Company's hearing with the Panel occurred on October 19, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 7, 2023, we were notified by the Panel that the
Company&#x2019;s request for continued listing on Nasdaq was granted, subject to the Company demonstrating compliance with the stockholders&#x2019;
equity requirement and bid price requirement on or before January 31, 2024. The Panel subsequently extended this compliance date to February
27, 2024. On February 27, 2024, the Company completed a public offering of 5,175,000 units (&#x201c;Units&#x201d;) at a price of $0.58
per Unit, for gross proceeds of approximately $3.0 million, before deducting offering expenses. Each Unit was comprised of (i) one share
of common stock or, in lieu of common stock, one prefunded warrant to purchase a share of common stock, and (ii) two common warrants,
each common warrant to purchase a share of common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 15, 2024, the Company filed a Quarterly Report on Form 10-Q for
the three months ending March 31, 2024, and reported stockholders&#x2019; equity of $2,505,450.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of June 30, 2024, the Company had Stockholders&#x2019;
Equity of $1,642,177.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2024-01-012024-01-31_custom_StockSplit2024Member"
      id="Fact000771">one-for-sixteen</us-gaap:StockholdersEquityReverseStockSplit>
    <ACON:ScheduleOfChangesToEquityStatementTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000777">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfChangesToEquityStatementTableTextBlock_zZRvytdP8TH3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details - Balance sheet changes from split)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B1_z5fsJdtzTOkc" style="display: none"&gt;Schedule of equity statement information&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_zx70AX1o1z2a" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CommonStockValue_iI_pp0p0_hus-gaap--TransactionTypeAxis__custom--Pre2024SplitMember_z00mAK4ij0Y3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 83%; text-align: left"&gt;Common shares issued and outstanding - pre-2024 split, &lt;span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_c20231231__us-gaap--TransactionTypeAxis__custom--Pre2024SplitMember_zzbiaUSo59Pd" title="Common stock shares issued"&gt;&lt;span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--TransactionTypeAxis__custom--Pre2024SplitMember_zRXG7S1lnhA3" title="Common stock shares outstanding"&gt;13,206,229&lt;/span&gt;&lt;/span&gt; shares&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;132&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CommonStockValue_iI_pp0p0_hus-gaap--TransactionTypeAxis__custom--Post2024SplitMember_zFLz567u1sZ2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common shares issued and outstanding - post-2024 split, &lt;span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20231231__us-gaap--TransactionTypeAxis__custom--Post2024SplitMember_zq5ZhNpBA2Yl" title="Common stock shares issued"&gt;&lt;span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--TransactionTypeAxis__custom--Post2024SplitMember_zWAI9cspabM6" title="Common stock shares outstanding"&gt;825,459&lt;/span&gt;&lt;/span&gt; shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_hus-gaap--TransactionTypeAxis__custom--Pre2024SplitMember_z36SUXsfVLUi" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Additional paid-in capital - pre-2024 split&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;43,553,399&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_hus-gaap--TransactionTypeAxis__custom--Post2024SplitMember_z03MNEEJTmcj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Additional paid-in capital - post-2024 split&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;43,553,523&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ACON:ScheduleOfChangesToEquityStatementTableTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31_custom_Pre2024SplitMember"
      decimals="INF"
      id="Fact000781"
      unitRef="Shares">13206229</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_Pre2024SplitMember"
      decimals="INF"
      id="Fact000783"
      unitRef="Shares">13206229</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31_custom_Pre2024SplitMember"
      decimals="0"
      id="Fact000779"
      unitRef="USD">132</us-gaap:CommonStockValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31_custom_Post2024SplitMember"
      decimals="INF"
      id="Fact000787"
      unitRef="Shares">825459</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_Post2024SplitMember"
      decimals="INF"
      id="Fact000789"
      unitRef="Shares">825459</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31_custom_Post2024SplitMember"
      decimals="0"
      id="Fact000785"
      unitRef="USD">8</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31_custom_Pre2024SplitMember"
      decimals="0"
      id="Fact000791"
      unitRef="USD">43553399</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31_custom_Post2024SplitMember"
      decimals="0"
      id="Fact000793"
      unitRef="USD">43553523</us-gaap:AdditionalPaidInCapital>
    <ACON:ScheduleOfRetroactiveBasisRreverseStockSplitsTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000795">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfRetroactiveBasisRreverseStockSplitsTableTextBlock_zhBkya5ufew7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details- Retroactive basis the reverse stock splits)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B9_zVL8x49ZagWc" style="display: none"&gt;Schedule of share information reflecting on a retroactive basis the reverse stock splits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 83%; text-align: left"&gt;Weighted average shares outstanding, basic and diluted - pre-2024 split&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PreSplitMember_zRCKpWECLsDk" title="Weighted average shares outstanding, basic"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PreSplitMember_ziZ01LCrKPSd" title="Weighted average shares outstanding, diluted"&gt;8,908,934&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted average shares outstanding, basic and diluted - post-2024 split&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PostSplitMember_zNy0pB4jkdD" title="Weighted average shares outstanding, basic"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PostSplitMember_zyspSxsF3Cdd" title="Weighted average shares outstanding, diluted"&gt;556,808&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Basic and diluted net loss per shares attributable to common stockholders - pre-2024 split&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PreSplitMember_z9bzbcgtXBe2" title="Basic net loss per shares attributable to common stockholders"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PreSplitMember_z9zldA0n5aS8" title="Diluted net loss per shares attributable to common stockholders"&gt;(0.55&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Basic and diluted net loss per shares attributable to common stockholders - post-2024 split&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareBasic_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PostSplitMember_zbqirK9pCUt3" title="Basic net loss per shares attributable to common stockholders"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PostSplitMember_zqys2puH9Qhd" title="Diluted net loss per shares attributable to common stockholders"&gt;(8.82&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ACON:ScheduleOfRetroactiveBasisRreverseStockSplitsTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31_custom_PreSplitMember"
      decimals="INF"
      id="Fact000797"
      unitRef="Shares">8908934</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31_custom_PreSplitMember"
      decimals="INF"
      id="Fact000799"
      unitRef="Shares">8908934</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31_custom_PostSplitMember"
      decimals="INF"
      id="Fact000801"
      unitRef="Shares">556808</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31_custom_PostSplitMember"
      decimals="INF"
      id="Fact000803"
      unitRef="Shares">556808</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31_custom_PreSplitMember"
      decimals="INF"
      id="Fact000805"
      unitRef="USDPShares">-0.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31_custom_PreSplitMember"
      decimals="INF"
      id="Fact000807"
      unitRef="USDPShares">-0.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31_custom_PostSplitMember"
      decimals="INF"
      id="Fact000809"
      unitRef="USDPShares">-8.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31_custom_PostSplitMember"
      decimals="INF"
      id="Fact000811"
      unitRef="USDPShares">-8.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000816">&lt;p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_z7gDNj0vRmL6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&lt;/b&gt;  &lt;b&gt;2. &lt;span id="xdx_821_zZssDNNZtoL6"&gt;SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--UseOfEstimates_ziG9kpLZ5Bff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_867_zn4BPLb1gMOa"&gt;Use of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The financial statements include some amounts
that are based on management's best estimates and judgments. The most significant estimates relate to depreciation, amortization, and
valuation of warrants, warrant and derivative liabilities, and options to purchase shares of the Company's common stock. These estimates
may be adjusted as more current information becomes available, and any adjustment could be significant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;





&lt;p id="xdx_84B_eus-gaap--DerivativesPolicyTextBlock_zQFUWdhps961" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86B_zvGU9YFgC5dg"&gt;Valuation of Derivative Instruments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial Accounting Standards Board (&#x201c;FASB&#x201d;)
Accounting Standards Codification (&#x201c;ASC&#x201d;) 815-40, &lt;i&gt;Derivatives and Hedging: Contracts on an Entity&#x2019;s Own Equity&lt;/i&gt;,
addresses whether an equity-linked contract qualifies as equity in the entity&#x2019;s financial statements. Agreements where an entity
has insufficient authorized and unissued shares to settle the contract generally are accounted for as a liability and marked to fair value
through earnings each reporting period. The Company evaluates its financial instruments to determine if such instruments are liabilities
or contain features that qualify as embedded derivatives. For financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then revalued at each reporting date, with changes in the fair value reported
as charges or credits to income.&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zRpqL0aSezma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_862_zO4Tn9Q11Wl1"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;ASC 820, Fair Value Measurements, provides guidance
on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price,
representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market
participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions
that market participants would use in pricing an asset or a liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accounting guidance classifies fair value
measurements in one of the following three categories for disclosure purposes:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;Level 1&lt;/i&gt; - Unadjusted quoted prices
in active markets for identical instruments that are accessible by the Company on the measurement date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;Level 2&lt;/i&gt; - Quoted prices in markets
that are not active or inputs which are either directly or indirectly observable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;Level 3&lt;/i&gt; - Unobservable inputs
for the instrument requiring the development of assumptions by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company analyzes all financial instruments
with features of both liabilities and equity under the Financial Accounting Standard Board&#x2019;s (&#x201c;FASB&#x201d;) accounting standard
for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level
of input that is significant to the fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The carrying values of the Company&#x2019;s financial
instruments including cash equivalents, restricted cash, accounts receivable, and accounts payable are approximately equal to their respective
fair values due to the relatively short-term nature of these instruments. The Company&#x2019;s warrant liabilities and derivative liabilities
are estimated using level 3 inputs (see Note 3).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--DerivativesReportingOfDerivativeActivity_zVoH8tcJ5E1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_864_z3ko8Qu0N10l"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has derivative financial instruments
that are not hedges and do not qualify for hedge accounting. Changes in the fair value of these instruments are recorded in other income
(expenses), on a net basis in the Consolidated Statements of Operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zk0RdMwL3mnk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_864_zVRDtCC2yNvc"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers all highly liquid
instruments purchased with an original maturity of three months or less to be cash equivalents. The Company had &lt;span id="xdx_90F_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20240630_zJosY1pNcA8e" title="Cash equivalents"&gt;&lt;span id="xdx_90F_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20231231_zQ3wey1WdzB5" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt;
cash equivalents at June 30, 2024 and December 31, 2023. The Company maintains cash deposits at several financial institutions,
which are insured by the FDIC up to $250,000. The Company&#x2019;s cash balance may at times exceed these limits. On June 30, 2024,
and December 31, 2023, the Company had $&lt;span id="xdx_90A_eus-gaap--CashUninsuredAmount_pp0p0_c20240630_zvmXQ04QcOR4" title="Cash uninsured amount"&gt;818,591 &lt;/span&gt;and
$&lt;span id="xdx_905_eus-gaap--CashUninsuredAmount_iI_pp0p0_c20231231_zF4ZgR3wsS2i" title="Cash uninsured amount"&gt;761,800&lt;/span&gt;,
respectively, in excess of federally insured limits. The Company continually monitors its positions with, and the credit quality of,
the financial institutions with which it invests. The Company maintains no international bank accounts. As of June 30, 2024, $&lt;span id="xdx_90A_eus-gaap--RestrictedCash_pp0p0_c20240630_zjS4vKHk3vag" title="Restricted cash"&gt;10,000&lt;/span&gt;
of the Company&#x2019;s cash was restricted as collateral related to the credit card program offered by our bank.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ReceivablesPolicyTextBlock_zerACPyV9j7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86F_zcsnM77PyZQa"&gt;Accounts Receivable, Less Allowance for Doubtful
Accounts&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company estimates an allowance for doubtful
accounts based upon an evaluation of the current status of receivables, historical experience, and other factors as necessary. It is reasonably
possible that the Company&#x2019;s estimate of the allowance for doubtful accounts will change. The allowance for doubtful accounts was
$&lt;span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_c20240630_za2m8ElG0ibl" title="Allowance for doubtful accounts"&gt;&lt;span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_c20231231_zSjpkmAhEE6k" title="Allowance for doubtful accounts"&gt;0&lt;/span&gt;&lt;/span&gt; on June 30, 2024, and December 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p id="xdx_84D_eus-gaap--RevenueRecognitionPolicyTextBlock_zsEL0fBsDPzh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_zqmMPrW88aq3"&gt;Revenue Recognition&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Revenues are recognized when a contract with a
customer exists, and at that point in time when we have delivered a Nociscan report to our customer. Revenue is recognized in the amount
that reflects the negotiated consideration expected to be received in exchange for those reports. Following the delivery of the report,
the company has no ongoing obligations or services to provide to the customer. Customers pay no other upfront, licensing, or other fees.
To date, our reports are not reimbursable under any third-party payment arrangements, The Company invoices its customers based on the
billing schedules in its sales arrangements. Payment terms range generally from 30 to 90 days from the date of invoice.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_ecustom--LiquidityCapitalResourcesAndGoingConcernPolicyTextBlock_z5a6J8nqvx05" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86F_zj66HsO4f93g"&gt;Liquidity, Capital Resources and Going Concern&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company believes that the net proceeds from
the February 2024 initial public offering, and subsequent funding from the April 2024 equity line agreement described in Note 11, will
be sufficient to fund current operating plans into the third quarter of 2024, approaching our final maturity repayment of our unsecured
non-convertible note, which is due in September 2024. The Company has based these estimates, however, on assumptions that may prove to
be wrong, and could spend available financial resources much faster than we currently expect. The Company will need to raise additional
funds to continue funding our technology development. Management plans to secure such additional funding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As a result of the Company&#x2019;s recurring
losses from operations and the need for additional financing to fund its operating and capital requirements, there is uncertainty regarding
the Company&#x2019;s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to
the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zYhjdlqc7Rki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86A_zVMECq7BR5Ci"&gt;Share-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for stock-based awards in
accordance with provisions of ASC Topic 718, Compensation&#x2014;Stock Compensation, under which the Company recognizes the grant-date
fair value of stock-based awards issued to employees and nonemployee board members as compensation expense on a straight-line basis over
the vesting period of the award, while awards containing a performance condition are recognized as expense when the achievement of the
performance criteria is achieved. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock
options. The Company records expense for forfeitures in the periods they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The exercise or strike price of each option is
not less than 100% of the fair market value of the Common Stock subject to the option on the date the option is granted.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company issues restricted stock unit awards
to non-employee consultants who are providing various services. The awards are valued at the market price on the date of the grant. The
awards vest over the contract life and based on achievement of targeted performance milestones.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On occasion, the Company grants common stock to
compensate vendors for services rendered.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--DeferredChargesPolicyTextBlock_zhAbqLlDwUt5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_zvEaGPLTAznc"&gt;Deferred Financing Costs&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company capitalizes certain legal, accounting,
and other fees and costs that are directly attributable to in-process equity financings as deferred offering costs until such financings
are completed. Upon the completion of an equity financing, these costs are recorded as a reduction of additional paid-in capital of the
related offering. Upon the completion of the public offering in February 2024, approximately $&lt;span id="xdx_905_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20240201__20240229__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TransactionTypeAxis__custom--CompletionOfPublicOfferingMember_zE4lWkkHSuXd" title="Adjustment to additional paid in capital"&gt;566,200&lt;/span&gt; of offering costs related to the
public offering were reclassified to additional paid-in capital ($310,105 deducted from proceeds, and $256,094 paid or accrued). Upon
the completion of the issuance of shares pursuant to the equity line in the first quarter of 2024, $&lt;span id="xdx_909_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20240101__20240331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TransactionTypeAxis__custom--CompletionOfIssuanceOfSharesMember_zZUikbr0Sf4k"&gt;133,000&lt;/span&gt; of offering costs were reclassified
to additional paid-in capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p id="xdx_84D_ecustom--EmergingGrowthCompanyStatusPolicyTextBlock_zJUuI0JP9rFb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_zEi2eT73N822"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is an emerging growth company, as
defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies
can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those
standards apply to private companies. The Company has elected to use this extended transition period to comply with certain new or revised
accounting standards that have different effective dates for public and private companies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-06-30" id="Fact000818">&lt;p id="xdx_849_eus-gaap--UseOfEstimates_ziG9kpLZ5Bff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_867_zn4BPLb1gMOa"&gt;Use of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The financial statements include some amounts
that are based on management's best estimates and judgments. The most significant estimates relate to depreciation, amortization, and
valuation of warrants, warrant and derivative liabilities, and options to purchase shares of the Company's common stock. These estimates
may be adjusted as more current information becomes available, and any adjustment could be significant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;





</us-gaap:UseOfEstimates>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000823">&lt;p id="xdx_84B_eus-gaap--DerivativesPolicyTextBlock_zQFUWdhps961" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86B_zvGU9YFgC5dg"&gt;Valuation of Derivative Instruments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial Accounting Standards Board (&#x201c;FASB&#x201d;)
Accounting Standards Codification (&#x201c;ASC&#x201d;) 815-40, &lt;i&gt;Derivatives and Hedging: Contracts on an Entity&#x2019;s Own Equity&lt;/i&gt;,
addresses whether an equity-linked contract qualifies as equity in the entity&#x2019;s financial statements. Agreements where an entity
has insufficient authorized and unissued shares to settle the contract generally are accounted for as a liability and marked to fair value
through earnings each reporting period. The Company evaluates its financial instruments to determine if such instruments are liabilities
or contain features that qualify as embedded derivatives. For financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then revalued at each reporting date, with changes in the fair value reported
as charges or credits to income.&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2024-01-01to2024-06-30" id="Fact000825">&lt;p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zRpqL0aSezma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_862_zO4Tn9Q11Wl1"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;ASC 820, Fair Value Measurements, provides guidance
on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price,
representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market
participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions
that market participants would use in pricing an asset or a liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accounting guidance classifies fair value
measurements in one of the following three categories for disclosure purposes:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;Level 1&lt;/i&gt; - Unadjusted quoted prices
in active markets for identical instruments that are accessible by the Company on the measurement date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;Level 2&lt;/i&gt; - Quoted prices in markets
that are not active or inputs which are either directly or indirectly observable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;Level 3&lt;/i&gt; - Unobservable inputs
for the instrument requiring the development of assumptions by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company analyzes all financial instruments
with features of both liabilities and equity under the Financial Accounting Standard Board&#x2019;s (&#x201c;FASB&#x201d;) accounting standard
for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level
of input that is significant to the fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The carrying values of the Company&#x2019;s financial
instruments including cash equivalents, restricted cash, accounts receivable, and accounts payable are approximately equal to their respective
fair values due to the relatively short-term nature of these instruments. The Company&#x2019;s warrant liabilities and derivative liabilities
are estimated using level 3 inputs (see Note 3).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:DerivativesReportingOfDerivativeActivity contextRef="From2024-01-01to2024-06-30" id="Fact000827">&lt;p id="xdx_841_eus-gaap--DerivativesReportingOfDerivativeActivity_zVoH8tcJ5E1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_864_z3ko8Qu0N10l"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has derivative financial instruments
that are not hedges and do not qualify for hedge accounting. Changes in the fair value of these instruments are recorded in other income
(expenses), on a net basis in the Consolidated Statements of Operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:DerivativesReportingOfDerivativeActivity>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000829">&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zk0RdMwL3mnk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_864_zVRDtCC2yNvc"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers all highly liquid
instruments purchased with an original maturity of three months or less to be cash equivalents. The Company had &lt;span id="xdx_90F_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20240630_zJosY1pNcA8e" title="Cash equivalents"&gt;&lt;span id="xdx_90F_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20231231_zQ3wey1WdzB5" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt;
cash equivalents at June 30, 2024 and December 31, 2023. The Company maintains cash deposits at several financial institutions,
which are insured by the FDIC up to $250,000. The Company&#x2019;s cash balance may at times exceed these limits. On June 30, 2024,
and December 31, 2023, the Company had $&lt;span id="xdx_90A_eus-gaap--CashUninsuredAmount_pp0p0_c20240630_zvmXQ04QcOR4" title="Cash uninsured amount"&gt;818,591 &lt;/span&gt;and
$&lt;span id="xdx_905_eus-gaap--CashUninsuredAmount_iI_pp0p0_c20231231_zF4ZgR3wsS2i" title="Cash uninsured amount"&gt;761,800&lt;/span&gt;,
respectively, in excess of federally insured limits. The Company continually monitors its positions with, and the credit quality of,
the financial institutions with which it invests. The Company maintains no international bank accounts. As of June 30, 2024, $&lt;span id="xdx_90A_eus-gaap--RestrictedCash_pp0p0_c20240630_zjS4vKHk3vag" title="Restricted cash"&gt;10,000&lt;/span&gt;
of the Company&#x2019;s cash was restricted as collateral related to the credit card program offered by our bank.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000831"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000833"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000835"
      unitRef="USD">818591</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000837"
      unitRef="USD">761800</us-gaap:CashUninsuredAmount>
    <us-gaap:RestrictedCash
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000839"
      unitRef="USD">10000</us-gaap:RestrictedCash>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000841">&lt;p id="xdx_84E_eus-gaap--ReceivablesPolicyTextBlock_zerACPyV9j7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86F_zcsnM77PyZQa"&gt;Accounts Receivable, Less Allowance for Doubtful
Accounts&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company estimates an allowance for doubtful
accounts based upon an evaluation of the current status of receivables, historical experience, and other factors as necessary. It is reasonably
possible that the Company&#x2019;s estimate of the allowance for doubtful accounts will change. The allowance for doubtful accounts was
$&lt;span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_c20240630_za2m8ElG0ibl" title="Allowance for doubtful accounts"&gt;&lt;span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_c20231231_zSjpkmAhEE6k" title="Allowance for doubtful accounts"&gt;0&lt;/span&gt;&lt;/span&gt; on June 30, 2024, and December 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000843"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000845"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000851">&lt;p id="xdx_84D_eus-gaap--RevenueRecognitionPolicyTextBlock_zsEL0fBsDPzh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_zqmMPrW88aq3"&gt;Revenue Recognition&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Revenues are recognized when a contract with a
customer exists, and at that point in time when we have delivered a Nociscan report to our customer. Revenue is recognized in the amount
that reflects the negotiated consideration expected to be received in exchange for those reports. Following the delivery of the report,
the company has no ongoing obligations or services to provide to the customer. Customers pay no other upfront, licensing, or other fees.
To date, our reports are not reimbursable under any third-party payment arrangements, The Company invoices its customers based on the
billing schedules in its sales arrangements. Payment terms range generally from 30 to 90 days from the date of invoice.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <ACON:LiquidityCapitalResourcesAndGoingConcernPolicyTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000853">&lt;p id="xdx_84C_ecustom--LiquidityCapitalResourcesAndGoingConcernPolicyTextBlock_z5a6J8nqvx05" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86F_zj66HsO4f93g"&gt;Liquidity, Capital Resources and Going Concern&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company believes that the net proceeds from
the February 2024 initial public offering, and subsequent funding from the April 2024 equity line agreement described in Note 11, will
be sufficient to fund current operating plans into the third quarter of 2024, approaching our final maturity repayment of our unsecured
non-convertible note, which is due in September 2024. The Company has based these estimates, however, on assumptions that may prove to
be wrong, and could spend available financial resources much faster than we currently expect. The Company will need to raise additional
funds to continue funding our technology development. Management plans to secure such additional funding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As a result of the Company&#x2019;s recurring
losses from operations and the need for additional financing to fund its operating and capital requirements, there is uncertainty regarding
the Company&#x2019;s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to
the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</ACON:LiquidityCapitalResourcesAndGoingConcernPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000855">&lt;p id="xdx_843_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zYhjdlqc7Rki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86A_zVMECq7BR5Ci"&gt;Share-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for stock-based awards in
accordance with provisions of ASC Topic 718, Compensation&#x2014;Stock Compensation, under which the Company recognizes the grant-date
fair value of stock-based awards issued to employees and nonemployee board members as compensation expense on a straight-line basis over
the vesting period of the award, while awards containing a performance condition are recognized as expense when the achievement of the
performance criteria is achieved. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock
options. The Company records expense for forfeitures in the periods they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The exercise or strike price of each option is
not less than 100% of the fair market value of the Common Stock subject to the option on the date the option is granted.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company issues restricted stock unit awards
to non-employee consultants who are providing various services. The awards are valued at the market price on the date of the grant. The
awards vest over the contract life and based on achievement of targeted performance milestones.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On occasion, the Company grants common stock to
compensate vendors for services rendered.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000857">&lt;p id="xdx_84B_eus-gaap--DeferredChargesPolicyTextBlock_zhAbqLlDwUt5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_zvEaGPLTAznc"&gt;Deferred Financing Costs&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company capitalizes certain legal, accounting,
and other fees and costs that are directly attributable to in-process equity financings as deferred offering costs until such financings
are completed. Upon the completion of an equity financing, these costs are recorded as a reduction of additional paid-in capital of the
related offering. Upon the completion of the public offering in February 2024, approximately $&lt;span id="xdx_905_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20240201__20240229__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TransactionTypeAxis__custom--CompletionOfPublicOfferingMember_zE4lWkkHSuXd" title="Adjustment to additional paid in capital"&gt;566,200&lt;/span&gt; of offering costs related to the
public offering were reclassified to additional paid-in capital ($310,105 deducted from proceeds, and $256,094 paid or accrued). Upon
the completion of the issuance of shares pursuant to the equity line in the first quarter of 2024, $&lt;span id="xdx_909_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20240101__20240331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TransactionTypeAxis__custom--CompletionOfIssuanceOfSharesMember_zZUikbr0Sf4k"&gt;133,000&lt;/span&gt; of offering costs were reclassified
to additional paid-in capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2024-02-012024-02-29_us-gaap_IPOMember_custom_CompletionOfPublicOfferingMember"
      decimals="0"
      id="Fact000859"
      unitRef="USD">566200</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2024-01-012024-03-31_us-gaap_IPOMember_custom_CompletionOfIssuanceOfSharesMember"
      decimals="0"
      id="Fact000860"
      unitRef="USD">133000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <ACON:EmergingGrowthCompanyStatusPolicyTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000866">&lt;p id="xdx_84D_ecustom--EmergingGrowthCompanyStatusPolicyTextBlock_zJUuI0JP9rFb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_zEi2eT73N822"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is an emerging growth company, as
defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies
can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those
standards apply to private companies. The Company has elected to use this extended transition period to comply with certain new or revised
accounting standards that have different effective dates for public and private companies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</ACON:EmergingGrowthCompanyStatusPolicyTextBlock>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000868">&lt;p id="xdx_803_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zgrmGCl64dOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 3: &lt;span id="xdx_822_zVDsykCc31lf"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with ASC 820 (Fair Value Measurements
and Disclosures), the Company uses various inputs to measure the outstanding warrants, certain embedded redemption features associated
with the senior note to Aclarion, Inc. on a recurring basis to determine the fair value of the liability.&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_z5DHIjUGoj67" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details- Recurring basis to determine the fair value of the liability)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B8_zWsBf9xJ1UB8" style="display: none"&gt;Schedule of recurring basis to determine the fair value of the liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair value measured as of June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Fair value on&lt;br/&gt; June 30,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Quoted prices&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;in active&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;markets&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;other&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;observable&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;inputs&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Significant unobservable&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;inputs&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Warrant liability&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_c20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zA998PkcuyZk" style="width: 12%; text-align: right" title="Total Fair value"&gt;23,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zoLgDjODusAg" style="width: 12%; text-align: right" title="Total Fair value"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zBYKvutvi8Ng" style="width: 12%; text-align: right" title="Total Fair value"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueNetAssetLiability_pp0p0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zLaohb2EEvqf" style="width: 12%; text-align: right" title="Total Fair value"&gt;23,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Derivative Liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_c20240630__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_zlfWBvMfTNoh" style="border-bottom: Black 1pt solid; text-align: right" title="Total Fair value"&gt;18,601&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_zfXnrkd37Wvl" style="border-bottom: Black 1pt solid; text-align: right" title="Total Fair value"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_z7h2kPtKhmVg" style="border-bottom: Black 1pt solid; text-align: right" title="Total Fair value"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueNetAssetLiability_pp0p0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_z0SijhPWVEma" style="border-bottom: Black 1pt solid; text-align: right" title="Total Fair value"&gt;18,601&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total Fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueNetAssetLiability_pp0p0_c20240630_z43pQYhHON8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Fair value"&gt;42,462&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z6bJ5xowjKLc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Fair value"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zwzpmUh6TWbi" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Fair value"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueNetAssetLiability_pp0p0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zM04iHzAvbXk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Fair value"&gt;42,462&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AF_z3ybJzpQPRKk" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;There were no transfers between Level 1, 2, and
3 during the six months ended June 30, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table presents changes in Level
3 liabilities measures at fair value for the six months ended June 30, 2024. Both observable and unobservable inputs were used to determine
the fair value positions that the Company has classified within the Level 3 category.&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_ziPQmesJtQ7c" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Liabilities measures at fair value)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B0_zoX9EIuMPvmi" style="display: none"&gt;Schedule of liabilities measures at fair value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zG0wTBSIxWt2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_zgv8BPVxntkh" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20240630_z0lU2wVoFOj5" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Warrant&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Liability&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Derivative&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Liability&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FairValueHedgeLiabilitiesAtFairValue_iS_d0_zLtUPk9WPLzj" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 49%"&gt;Balance &#x2013; December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;289,165&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;121,326&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;410,491&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--ExchangeAndPayoffOfNotesPayable_d0_zaS5H20uttU1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 9pt"&gt;Exchange and Payoff of Notes Payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(44,988&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(44,988&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_zoD7OVLvy4Nc" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 9pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(265,304&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(57,737&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(323,041&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FairValueHedgeLiabilitiesAtFairValue_iE_zBA4hafI9HUk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance &#x2013; June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;23,861&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;18,601&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;42,462&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AB_z6dYD8CMFBy3" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of the embedded derivative liabilities
associated with the Senior Notes Payable was estimated using a probability weighted discounted cash flow model to measure the fair value.
This involves significant Level 3 inputs and assumptions including an (i) estimated probability and timing of certain financing events
and event of default, and (ii) the Company&#x2019;s risk-adjusted discount rate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of the warrants to purchase shares
of common stock was estimated using a Monte Carlo simulation using the following assumptions.&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zmUoad8QJIye" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details- Fair value of the warrants)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B8_zFEAOSKhbGl7" style="display: none"&gt;Schedule of assumptions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Dec 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrant Liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrant Liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%"&gt;Strike Price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharePrice_iI_c20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zOAACiCYM3Mc" title="Strike Price"&gt;4.32&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharePrice_c20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zxP9Y65jeFVg" title="Strike Price"&gt;0.29&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Contractual term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zaz2aQfE56f2" title="Contractual term (years)"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zhS3Y0k1tA9a" title="Contractual term (years)"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Volatility (annual)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230101__20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zIpabLWtGOf3" title="Volatility (annual)"&gt;80.0&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zjcBHjV81VK6" title="Volatility (annual)"&gt;80.0&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230101__20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zHhsZBfMcWsc" title="Risk-free rate"&gt;3.89&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember__srt--RangeAxis__srt--MinimumMember_zLS5YTh5Wju3" title="Risk-free rate"&gt;4.39&lt;/span&gt;-&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember__srt--RangeAxis__srt--MaximumMember_z6hRSb9ZgVR2" title="Risk-free rate"&gt;4.44&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Floor Financing price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--FloorFinancingPrice_iI_c20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zchQoQsnIuza" title="Floor Financing price"&gt;2.24&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--FloorFinancingPrice_c20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zySMHJETMa5f" title="Floor Financing price"&gt;0.14&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A9_zo7snNywcdEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000870">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_z5DHIjUGoj67" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details- Recurring basis to determine the fair value of the liability)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B8_zWsBf9xJ1UB8" style="display: none"&gt;Schedule of recurring basis to determine the fair value of the liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair value measured as of June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Fair value on&lt;br/&gt; June 30,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Quoted prices&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;in active&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;markets&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;other&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;observable&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;inputs&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Significant unobservable&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;inputs&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Warrant liability&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_c20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zA998PkcuyZk" style="width: 12%; text-align: right" title="Total Fair value"&gt;23,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zoLgDjODusAg" style="width: 12%; text-align: right" title="Total Fair value"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zBYKvutvi8Ng" style="width: 12%; text-align: right" title="Total Fair value"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueNetAssetLiability_pp0p0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zLaohb2EEvqf" style="width: 12%; text-align: right" title="Total Fair value"&gt;23,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Derivative Liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_c20240630__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_zlfWBvMfTNoh" style="border-bottom: Black 1pt solid; text-align: right" title="Total Fair value"&gt;18,601&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_zfXnrkd37Wvl" style="border-bottom: Black 1pt solid; text-align: right" title="Total Fair value"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_z7h2kPtKhmVg" style="border-bottom: Black 1pt solid; text-align: right" title="Total Fair value"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueNetAssetLiability_pp0p0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_z0SijhPWVEma" style="border-bottom: Black 1pt solid; text-align: right" title="Total Fair value"&gt;18,601&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total Fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueNetAssetLiability_pp0p0_c20240630_z43pQYhHON8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Fair value"&gt;42,462&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z6bJ5xowjKLc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Fair value"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zwzpmUh6TWbi" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Fair value"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueNetAssetLiability_pp0p0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zM04iHzAvbXk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Fair value"&gt;42,462&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-06-30_custom_WarrantLiabilityMember"
      decimals="0"
      id="Fact000872"
      unitRef="USD">23861</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_custom_WarrantLiabilityMember"
      decimals="0"
      id="Fact000874"
      unitRef="USD">0</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_custom_WarrantLiabilityMember"
      decimals="0"
      id="Fact000876"
      unitRef="USD">0</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilityMember"
      decimals="0"
      id="Fact000878"
      unitRef="USD">23861</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-06-30_custom_DerivativeLiabilityMember"
      decimals="0"
      id="Fact000880"
      unitRef="USD">18601</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member_custom_DerivativeLiabilityMember"
      decimals="0"
      id="Fact000882"
      unitRef="USD">0</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member_custom_DerivativeLiabilityMember"
      decimals="0"
      id="Fact000884"
      unitRef="USD">0</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member_custom_DerivativeLiabilityMember"
      decimals="0"
      id="Fact000886"
      unitRef="USD">18601</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000888"
      unitRef="USD">42462</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000890"
      unitRef="USD">0</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="Fact000892"
      unitRef="USD">0</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000894"
      unitRef="USD">42462</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000896">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_ziPQmesJtQ7c" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Liabilities measures at fair value)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B0_zoX9EIuMPvmi" style="display: none"&gt;Schedule of liabilities measures at fair value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zG0wTBSIxWt2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_zgv8BPVxntkh" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20240630_z0lU2wVoFOj5" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Warrant&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Liability&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Derivative&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Liability&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FairValueHedgeLiabilitiesAtFairValue_iS_d0_zLtUPk9WPLzj" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 49%"&gt;Balance &#x2013; December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;289,165&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;121,326&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;410,491&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--ExchangeAndPayoffOfNotesPayable_d0_zaS5H20uttU1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 9pt"&gt;Exchange and Payoff of Notes Payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(44,988&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(44,988&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_zoD7OVLvy4Nc" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 9pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(265,304&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(57,737&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(323,041&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FairValueHedgeLiabilitiesAtFairValue_iE_zBA4hafI9HUk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance &#x2013; June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;23,861&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;18,601&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;42,462&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:FairValueHedgeLiabilitiesAtFairValue
      contextRef="AsOf2023-12-31_custom_WarrantLiabilityMember"
      decimals="0"
      id="Fact000898"
      unitRef="USD">289165</us-gaap:FairValueHedgeLiabilitiesAtFairValue>
    <us-gaap:FairValueHedgeLiabilitiesAtFairValue
      contextRef="AsOf2023-12-31_custom_DerivativeLiabilityMember"
      decimals="0"
      id="Fact000899"
      unitRef="USD">121326</us-gaap:FairValueHedgeLiabilitiesAtFairValue>
    <us-gaap:FairValueHedgeLiabilitiesAtFairValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000900"
      unitRef="USD">410491</us-gaap:FairValueHedgeLiabilitiesAtFairValue>
    <ACON:ExchangeAndPayoffOfNotesPayable
      contextRef="From2024-01-012024-06-30_custom_WarrantLiabilityMember"
      decimals="0"
      id="Fact000902"
      unitRef="USD">0</ACON:ExchangeAndPayoffOfNotesPayable>
    <ACON:ExchangeAndPayoffOfNotesPayable
      contextRef="From2024-01-012024-06-30_custom_DerivativeLiabilityMember"
      decimals="0"
      id="Fact000903"
      unitRef="USD">-44988</ACON:ExchangeAndPayoffOfNotesPayable>
    <ACON:ExchangeAndPayoffOfNotesPayable
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000904"
      unitRef="USD">-44988</ACON:ExchangeAndPayoffOfNotesPayable>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="From2024-01-012024-06-30_custom_WarrantLiabilityMember"
      decimals="0"
      id="Fact000906"
      unitRef="USD">-265304</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="From2024-01-012024-06-30_custom_DerivativeLiabilityMember"
      decimals="0"
      id="Fact000907"
      unitRef="USD">-57737</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000908"
      unitRef="USD">-323041</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueHedgeLiabilitiesAtFairValue
      contextRef="AsOf2024-06-30_custom_WarrantLiabilityMember"
      decimals="0"
      id="Fact000910"
      unitRef="USD">23861</us-gaap:FairValueHedgeLiabilitiesAtFairValue>
    <us-gaap:FairValueHedgeLiabilitiesAtFairValue
      contextRef="AsOf2024-06-30_custom_DerivativeLiabilityMember"
      decimals="0"
      id="Fact000911"
      unitRef="USD">18601</us-gaap:FairValueHedgeLiabilitiesAtFairValue>
    <us-gaap:FairValueHedgeLiabilitiesAtFairValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000912"
      unitRef="USD">42462</us-gaap:FairValueHedgeLiabilitiesAtFairValue>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000918">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zmUoad8QJIye" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details- Fair value of the warrants)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B8_zFEAOSKhbGl7" style="display: none"&gt;Schedule of assumptions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Dec 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrant Liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrant Liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%"&gt;Strike Price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharePrice_iI_c20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zOAACiCYM3Mc" title="Strike Price"&gt;4.32&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharePrice_c20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zxP9Y65jeFVg" title="Strike Price"&gt;0.29&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Contractual term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zaz2aQfE56f2" title="Contractual term (years)"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zhS3Y0k1tA9a" title="Contractual term (years)"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Volatility (annual)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230101__20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zIpabLWtGOf3" title="Volatility (annual)"&gt;80.0&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zjcBHjV81VK6" title="Volatility (annual)"&gt;80.0&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230101__20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zHhsZBfMcWsc" title="Risk-free rate"&gt;3.89&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember__srt--RangeAxis__srt--MinimumMember_zLS5YTh5Wju3" title="Risk-free rate"&gt;4.39&lt;/span&gt;-&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember__srt--RangeAxis__srt--MaximumMember_z6hRSb9ZgVR2" title="Risk-free rate"&gt;4.44&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Floor Financing price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--FloorFinancingPrice_iI_c20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zchQoQsnIuza" title="Floor Financing price"&gt;2.24&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--FloorFinancingPrice_c20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zySMHJETMa5f" title="Floor Financing price"&gt;0.14&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_custom_WarrantLiabilityMember"
      decimals="INF"
      id="Fact000920"
      unitRef="USDPShares">4.32</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2024-06-30_custom_WarrantLiabilityMember"
      decimals="INF"
      id="Fact000922"
      unitRef="USDPShares">0.29</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-12-31_custom_WarrantLiabilityMember"
      id="Fact000924">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-06-30_custom_WarrantLiabilityMember"
      id="Fact000926">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-12-31_custom_WarrantLiabilityMember"
      decimals="INF"
      id="Fact000928"
      unitRef="Pure">0.800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-06-30_custom_WarrantLiabilityMember"
      decimals="INF"
      id="Fact000930"
      unitRef="Pure">0.800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-12-31_custom_WarrantLiabilityMember"
      decimals="INF"
      id="Fact000932"
      unitRef="Pure">0.0389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-06-30_custom_WarrantLiabilityMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000934"
      unitRef="Pure">0.0439</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-06-30_custom_WarrantLiabilityMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000936"
      unitRef="Pure">0.0444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <ACON:FloorFinancingPrice
      contextRef="AsOf2023-12-31_custom_WarrantLiabilityMember"
      decimals="INF"
      id="Fact000938"
      unitRef="USDPShares">2.24</ACON:FloorFinancingPrice>
    <ACON:FloorFinancingPrice
      contextRef="AsOf2024-06-30_custom_WarrantLiabilityMember"
      decimals="INF"
      id="Fact000940"
      unitRef="USDPShares">0.14</ACON:FloorFinancingPrice>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000942">&lt;p id="xdx_808_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zSdY292RwJ19" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&lt;/b&gt;&#160; &lt;b&gt;4. &lt;span id="xdx_828_zrzMnZQQ0LQg"&gt;RECENT ACCOUNTING PRONOUNCEMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;To date, there have been no recent accounting
pronouncements not yet effective that have significance, or potential significance, to our Consolidated Financial Statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000944">&lt;p id="xdx_808_eus-gaap--RevenueFromContractWithCustomerTextBlock_zmRrrjg9Kjx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&lt;/b&gt;&#160; &lt;b&gt;5. &lt;span id="xdx_826_z9TbXXEUwy4a"&gt;REVENUE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Contract Balances&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The timing of revenue recognition, billings, and
cash collections may result in trade, unbilled receivables, and deferred revenues on the balance sheets. At times, revenue recognition
may occur before the billing, resulting in an unbilled receivable, which would represent a contract asset. The contract asset would be
a component of accounts receivable and other assets for the current and non-current portions, respectively. In the event the Company receives
advances or deposits from customers before revenue is recognized, this would result in a contract liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000946">&lt;p id="xdx_802_eus-gaap--SupplementalBalanceSheetDisclosuresTextBlock_z38Paqrdbrtl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 6. &lt;span id="xdx_825_zc4ACJqUwL85"&gt;SUPPLEMENTAL FINANCIAL INFORMATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Balance Sheets&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Prepaids and other current assets:&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zeNyOudskBJ1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Prepaids and other current assets)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B5_zK2pEwT8cpR" style="display: none"&gt;Schedule of prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Short term deposits&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--ShortTermDepositsMember_zb4aN5R8jCqg" style="width: 13%; text-align: right" title="Prepaids and other current assets"&gt;50,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--ShortTermDepositsMember_pp0p0" style="width: 13%; text-align: right" title="Prepaids and other current assets"&gt;50,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred offering costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--DeferredOfferingCostsMember_zktWUjLur0Vi" style="text-align: right" title="Prepaids and other current assets"&gt;74,648&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--DeferredOfferingCostsMember_pp0p0" style="text-align: right" title="Prepaids and other current assets"&gt;100,588&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance D&amp;amp;O&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidInsuranceDAndOMember_z0Dq6pWKqSPf" style="text-align: right" title="Prepaids and other current assets"&gt;241,445&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidInsuranceDAndOMember_pp0p0" style="text-align: right" title="Prepaids and other current assets"&gt;34,769&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance, other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidInsuranceMember_zQnE22F9Hp2a" style="text-align: right" title="Prepaids and other current assets"&gt;5,010&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidInsuranceMember_pp0p0" style="text-align: right" title="Prepaids and other current assets"&gt;17,884&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid clinical costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidClinicalCostsMember_z4NdHg9Wvrwj" style="text-align: right" title="Prepaids and other current assets"&gt;165,417&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_d0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidClinicalCostsMember_zWatJ1Hu44N1" style="text-align: right" title="Prepaids and other current assets"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid exchange fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidExchangeFeesMember_zJM5gk9Evs19" style="text-align: right" title="Prepaids and other current assets"&gt;53,720&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_d0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidExchangeFeesMember_zMfMHNbAAo04" style="text-align: right" title="Prepaids and other current assets"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidOtherMember_zRBV1TXD6WMb" style="text-align: right" title="Prepaids and other current assets"&gt;59,117&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidOtherMember_pp0p0" style="text-align: right" title="Prepaids and other current assets"&gt;41,635&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other receivables&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_d0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--OtherReceivablesMember_z5XNvq0Z7use" style="border-bottom: Black 1pt solid; text-align: right" title="Prepaids and other current assets"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--OtherReceivablesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Prepaids and other current assets"&gt;154&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_pp0p0_c20240630_zkKJiSoOyZwe" style="border-bottom: Black 2.5pt double; text-align: right" title="Prepaids and other current assets"&gt;649,357&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Prepaids and other current assets"&gt;245,030&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_z7C8U8F1Mml8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Accounts payable&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zTvrYeDxelCb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accounts payable)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B5_zSyxO9ISdGC9" style="display: none"&gt;Schedule of accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableMember_zdUfHxMTEIEa" style="width: 13%; text-align: right" title="Accounts payable, current"&gt;177,610&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20231231__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableMember_zJoexTeiy02g" style="width: 13%; text-align: right" title="Accounts payable, current"&gt;758,821&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Credit cards payable&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--CreditCardsPayableMember_zVaRZmq7fgMi" style="border-bottom: Black 1pt solid; text-align: right" title="Accounts payable, current"&gt;1,513&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--CreditCardsPayableMember_zVNBgm4lGbQ1" style="border-bottom: Black 1pt solid; text-align: right" title="Accounts payable, current"&gt;1,714&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20240630_zF97TVRPQL9a" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts payable, current"&gt;179,123&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20231231_zI3iZs4JGxhk" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts payable, current"&gt;760,535&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zfLnjLm6PRz2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Accrued and other liabilities:&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zrTml1alRrec" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accrued and other liabilities)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B0_z8XLJzLqEuCe" style="display: none"&gt;Schedule of accrued and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Accrued payroll&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_d0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedPayrollMember_zuUB5QnUo5Gj" style="width: 13%; text-align: right" title="Accrued liabilities and other liabilities"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedPayrollMember_pp0p0" style="width: 13%; text-align: right" title="Accrued liabilities and other liabilities"&gt;162,887&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued bonus&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedBonusMember_zMsVY1gUUsR1" style="text-align: right" title="Accrued liabilities and other liabilities"&gt;127,875&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedBonusMember_pp0p0" style="text-align: right" title="Accrued liabilities and other liabilities"&gt;262,580&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;D&amp;amp;O financing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--DAndOFinancingMember_zjLLjX2IFC2" style="text-align: right" title="Accrued liabilities and other liabilities"&gt;126,605&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_d0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--DAndOFinancingMember_zFBb4u5EQxIj" style="text-align: right" title="Accrued liabilities and other liabilities"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued audit and legal expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedAuditAndLegalExpensesMember_zuRK6HTESlkl" style="text-align: right" title="Accrued liabilities and other liabilities"&gt;40,226&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedAuditAndLegalExpensesMember_pp0p0" style="text-align: right" title="Accrued liabilities and other liabilities"&gt;89,082&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Accrued interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedInterestMember_z7lMRjF6iPde" style="text-align: right" title="Accrued liabilities and other liabilities"&gt;58,666&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedInterestMember_pp0p0" style="text-align: right" title="Accrued liabilities and other liabilities"&gt;98,685&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued board compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedBoardCompensationMember_zexcHQEREEye" style="text-align: right" title="Accrued liabilities and other liabilities"&gt;46,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedBoardCompensationMember_pp0p0" style="text-align: right" title="Accrued liabilities and other liabilities"&gt;92,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--OtherAccruedLiabilitiesMember_zS0PkkCzetue" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued liabilities and other liabilities"&gt;48,350&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--OtherAccruedLiabilitiesMember_z8nqfOTF3aL6" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued liabilities and other liabilities"&gt;151,988&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_pp0p0_c20240630_zvVXBovpmAfi" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued liabilities and other liabilities"&gt;447,972&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued liabilities and other liabilities"&gt;857,722&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zjCBivLPC25h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&#160;&lt;/p&gt;

</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000948">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zeNyOudskBJ1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Prepaids and other current assets)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B5_zK2pEwT8cpR" style="display: none"&gt;Schedule of prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Short term deposits&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--ShortTermDepositsMember_zb4aN5R8jCqg" style="width: 13%; text-align: right" title="Prepaids and other current assets"&gt;50,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--ShortTermDepositsMember_pp0p0" style="width: 13%; text-align: right" title="Prepaids and other current assets"&gt;50,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred offering costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--DeferredOfferingCostsMember_zktWUjLur0Vi" style="text-align: right" title="Prepaids and other current assets"&gt;74,648&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--DeferredOfferingCostsMember_pp0p0" style="text-align: right" title="Prepaids and other current assets"&gt;100,588&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance D&amp;amp;O&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidInsuranceDAndOMember_z0Dq6pWKqSPf" style="text-align: right" title="Prepaids and other current assets"&gt;241,445&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidInsuranceDAndOMember_pp0p0" style="text-align: right" title="Prepaids and other current assets"&gt;34,769&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance, other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidInsuranceMember_zQnE22F9Hp2a" style="text-align: right" title="Prepaids and other current assets"&gt;5,010&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidInsuranceMember_pp0p0" style="text-align: right" title="Prepaids and other current assets"&gt;17,884&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid clinical costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidClinicalCostsMember_z4NdHg9Wvrwj" style="text-align: right" title="Prepaids and other current assets"&gt;165,417&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_d0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidClinicalCostsMember_zWatJ1Hu44N1" style="text-align: right" title="Prepaids and other current assets"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid exchange fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidExchangeFeesMember_zJM5gk9Evs19" style="text-align: right" title="Prepaids and other current assets"&gt;53,720&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_d0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidExchangeFeesMember_zMfMHNbAAo04" style="text-align: right" title="Prepaids and other current assets"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidOtherMember_zRBV1TXD6WMb" style="text-align: right" title="Prepaids and other current assets"&gt;59,117&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidOtherMember_pp0p0" style="text-align: right" title="Prepaids and other current assets"&gt;41,635&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other receivables&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_d0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--OtherReceivablesMember_z5XNvq0Z7use" style="border-bottom: Black 1pt solid; text-align: right" title="Prepaids and other current assets"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--OtherReceivablesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Prepaids and other current assets"&gt;154&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_pp0p0_c20240630_zkKJiSoOyZwe" style="border-bottom: Black 2.5pt double; text-align: right" title="Prepaids and other current assets"&gt;649,357&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Prepaids and other current assets"&gt;245,030&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-06-30_custom_ShortTermDepositsMember"
      decimals="0"
      id="Fact000950"
      unitRef="USD">50000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31_custom_ShortTermDepositsMember"
      decimals="0"
      id="Fact000952"
      unitRef="USD">50000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-06-30_custom_DeferredOfferingCostsMember"
      decimals="0"
      id="Fact000954"
      unitRef="USD">74648</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31_custom_DeferredOfferingCostsMember"
      decimals="0"
      id="Fact000956"
      unitRef="USD">100588</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-06-30_custom_PrepaidInsuranceDAndOMember"
      decimals="0"
      id="Fact000958"
      unitRef="USD">241445</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31_custom_PrepaidInsuranceDAndOMember"
      decimals="0"
      id="Fact000960"
      unitRef="USD">34769</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-06-30_custom_PrepaidInsuranceMember"
      decimals="0"
      id="Fact000962"
      unitRef="USD">5010</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31_custom_PrepaidInsuranceMember"
      decimals="0"
      id="Fact000964"
      unitRef="USD">17884</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-06-30_custom_PrepaidClinicalCostsMember"
      decimals="0"
      id="Fact000966"
      unitRef="USD">165417</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31_custom_PrepaidClinicalCostsMember"
      decimals="0"
      id="Fact000968"
      unitRef="USD">0</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-06-30_custom_PrepaidExchangeFeesMember"
      decimals="0"
      id="Fact000970"
      unitRef="USD">53720</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31_custom_PrepaidExchangeFeesMember"
      decimals="0"
      id="Fact000972"
      unitRef="USD">0</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-06-30_custom_PrepaidOtherMember"
      decimals="0"
      id="Fact000974"
      unitRef="USD">59117</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31_custom_PrepaidOtherMember"
      decimals="0"
      id="Fact000976"
      unitRef="USD">41635</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-06-30_custom_OtherReceivablesMember"
      decimals="0"
      id="Fact000978"
      unitRef="USD">0</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31_custom_OtherReceivablesMember"
      decimals="0"
      id="Fact000980"
      unitRef="USD">154</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000982"
      unitRef="USD">649357</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000984"
      unitRef="USD">245030</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000990">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zTvrYeDxelCb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accounts payable)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B5_zSyxO9ISdGC9" style="display: none"&gt;Schedule of accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableMember_zdUfHxMTEIEa" style="width: 13%; text-align: right" title="Accounts payable, current"&gt;177,610&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20231231__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableMember_zJoexTeiy02g" style="width: 13%; text-align: right" title="Accounts payable, current"&gt;758,821&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Credit cards payable&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--CreditCardsPayableMember_zVaRZmq7fgMi" style="border-bottom: Black 1pt solid; text-align: right" title="Accounts payable, current"&gt;1,513&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--CreditCardsPayableMember_zVNBgm4lGbQ1" style="border-bottom: Black 1pt solid; text-align: right" title="Accounts payable, current"&gt;1,714&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20240630_zF97TVRPQL9a" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts payable, current"&gt;179,123&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20231231_zI3iZs4JGxhk" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts payable, current"&gt;760,535&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-06-30_us-gaap_AccountsPayableMember"
      decimals="0"
      id="Fact000992"
      unitRef="USD">177610</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31_us-gaap_AccountsPayableMember"
      decimals="0"
      id="Fact000994"
      unitRef="USD">758821</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-06-30_custom_CreditCardsPayableMember"
      decimals="0"
      id="Fact000996"
      unitRef="USD">1513</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31_custom_CreditCardsPayableMember"
      decimals="0"
      id="Fact000998"
      unitRef="USD">1714</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001000"
      unitRef="USD">179123</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001002"
      unitRef="USD">760535</us-gaap:AccountsPayableCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001004">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zrTml1alRrec" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accrued and other liabilities)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B0_z8XLJzLqEuCe" style="display: none"&gt;Schedule of accrued and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Accrued payroll&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_d0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedPayrollMember_zuUB5QnUo5Gj" style="width: 13%; text-align: right" title="Accrued liabilities and other liabilities"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedPayrollMember_pp0p0" style="width: 13%; text-align: right" title="Accrued liabilities and other liabilities"&gt;162,887&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued bonus&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedBonusMember_zMsVY1gUUsR1" style="text-align: right" title="Accrued liabilities and other liabilities"&gt;127,875&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedBonusMember_pp0p0" style="text-align: right" title="Accrued liabilities and other liabilities"&gt;262,580&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;D&amp;amp;O financing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--DAndOFinancingMember_zjLLjX2IFC2" style="text-align: right" title="Accrued liabilities and other liabilities"&gt;126,605&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_d0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--DAndOFinancingMember_zFBb4u5EQxIj" style="text-align: right" title="Accrued liabilities and other liabilities"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued audit and legal expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedAuditAndLegalExpensesMember_zuRK6HTESlkl" style="text-align: right" title="Accrued liabilities and other liabilities"&gt;40,226&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedAuditAndLegalExpensesMember_pp0p0" style="text-align: right" title="Accrued liabilities and other liabilities"&gt;89,082&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Accrued interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedInterestMember_z7lMRjF6iPde" style="text-align: right" title="Accrued liabilities and other liabilities"&gt;58,666&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedInterestMember_pp0p0" style="text-align: right" title="Accrued liabilities and other liabilities"&gt;98,685&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued board compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedBoardCompensationMember_zexcHQEREEye" style="text-align: right" title="Accrued liabilities and other liabilities"&gt;46,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedBoardCompensationMember_pp0p0" style="text-align: right" title="Accrued liabilities and other liabilities"&gt;92,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--OtherAccruedLiabilitiesMember_zS0PkkCzetue" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued liabilities and other liabilities"&gt;48,350&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--OtherAccruedLiabilitiesMember_z8nqfOTF3aL6" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued liabilities and other liabilities"&gt;151,988&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_pp0p0_c20240630_zvVXBovpmAfi" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued liabilities and other liabilities"&gt;447,972&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued liabilities and other liabilities"&gt;857,722&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2024-06-30_custom_AccruedPayrollMember"
      decimals="0"
      id="Fact001006"
      unitRef="USD">0</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2023-12-31_custom_AccruedPayrollMember"
      decimals="0"
      id="Fact001008"
      unitRef="USD">162887</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2024-06-30_custom_AccruedBonusMember"
      decimals="0"
      id="Fact001010"
      unitRef="USD">127875</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2023-12-31_custom_AccruedBonusMember"
      decimals="0"
      id="Fact001012"
      unitRef="USD">262580</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2024-06-30_custom_DAndOFinancingMember"
      decimals="0"
      id="Fact001014"
      unitRef="USD">126605</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2023-12-31_custom_DAndOFinancingMember"
      decimals="0"
      id="Fact001016"
      unitRef="USD">0</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2024-06-30_custom_AccruedAuditAndLegalExpensesMember"
      decimals="0"
      id="Fact001018"
      unitRef="USD">40226</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2023-12-31_custom_AccruedAuditAndLegalExpensesMember"
      decimals="0"
      id="Fact001020"
      unitRef="USD">89082</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2024-06-30_custom_AccruedInterestMember"
      decimals="0"
      id="Fact001022"
      unitRef="USD">58666</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2023-12-31_custom_AccruedInterestMember"
      decimals="0"
      id="Fact001024"
      unitRef="USD">98685</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2024-06-30_custom_AccruedBoardCompensationMember"
      decimals="0"
      id="Fact001026"
      unitRef="USD">46250</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2023-12-31_custom_AccruedBoardCompensationMember"
      decimals="0"
      id="Fact001028"
      unitRef="USD">92500</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2024-06-30_custom_OtherAccruedLiabilitiesMember"
      decimals="0"
      id="Fact001030"
      unitRef="USD">48350</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2023-12-31_custom_OtherAccruedLiabilitiesMember"
      decimals="0"
      id="Fact001032"
      unitRef="USD">151988</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001034"
      unitRef="USD">447972</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001036"
      unitRef="USD">857722</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001038">&lt;p id="xdx_804_eus-gaap--LesseeOperatingLeasesTextBlock_zGC3EjGPHWg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 7. &lt;span id="xdx_825_zTY09N13LGe1"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company had &lt;span id="xdx_905_eus-gaap--OperatingLeaseExpense_do_c20240101__20240630_zX8zSUxV5Z67" title="Office lease"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseExpense_do_c20230101__20231231_zh4rWwxUDzig" title="Office lease"&gt;no&lt;/span&gt;&lt;/span&gt; office lease for the quarter
ended June 30, 2024, and the year ended December 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact001040"
      unitRef="USD">0</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001042"
      unitRef="USD">0</us-gaap:OperatingLeaseExpense>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001044">&lt;p id="xdx_800_eus-gaap--IntangibleAssetsDisclosureTextBlock_z91wxPjcXXOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 8. &lt;span id="xdx_828_zKoSPnqWrXM"&gt;INTANGIBLE ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s intangible assets are as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zhB6FjHufG38" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS (Details - Intangible assets)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B1_zYNZ7On6vOw9" style="display: none"&gt;Schedule of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Patents and licenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember_zfZNiqzh3foj" style="width: 13%; text-align: right" title="Intangible assets gross"&gt;2,424,773&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember_z31PDMbOROfb" style="width: 13%; text-align: right" title="Intangible assets gross"&gt;2,267,251&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zXtlrxNqIsrc" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible assets gross"&gt;5,017&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zpYXKnkgRmdd" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible assets gross"&gt;5,017&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20240630_znK4725Bxe74" style="text-align: right" title="Intangible assets gross"&gt;2,429,790&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231_zGmbyoCwOype" style="text-align: right" title="Intangible assets gross"&gt;2,272,268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_pp0p0_c20240630_zW4Ue8YHjAAd" style="border-bottom: Black 1pt solid; text-align: right" title="Less: accumulated amortization"&gt;(1,193,915&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20231231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Less: accumulated amortization"&gt;(1,103,645&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_pp0p0_c20240630_zZgNolLTo23b" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net"&gt;1,235,875&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_c20231231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net"&gt;1,168,623&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8AC_z1Zqnm8VB3Wf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Patents and licenses costs are accounted for as
intangible assets and amortized over the life of the patent or license agreement and charged to research and development.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Amortization expense related to purchased intangible
assets was $&lt;span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20240401__20240630_zdW8DImGUUy" title="Amortization of intangible assets"&gt;45,458&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20230401__20230630_zissSmIK4bOd" title="Amortization of intangible assets"&gt;39,940&lt;/span&gt; for the three months ended June 30, 2024, and 2023, respectively. Amortization expense related to purchased
intangible assets was $&lt;span id="xdx_90A_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20240101__20240630_zawle9A08a0i" title="Amortization of intangible assets"&gt;90,270&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20230101__20230630_zYUnuCsn9CQj" title="Amortization of intangible assets"&gt;78,805&lt;/span&gt; for the six months ended June 30, 2024, and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Patents and trademarks are reviewed at least annually
for impairment. No impairment was recorded through June 30, 2024, and December 31, 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Future amortization of intangible assets is as
follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zVjC7kro9EO5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS (Details - Future amortization)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B9_zeB5K09APzF1" style="display: none"&gt;Schedule of future amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240630_zEz3tmZnbFS7" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 83%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;96,015&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;192,030&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;192,030&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;192,030&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;2028 and beyond&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;563,770&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OtherIntangibleAssetsNet_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,235,875&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8AF_zJmZzSpOfYo2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001046">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zhB6FjHufG38" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS (Details - Intangible assets)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B1_zYNZ7On6vOw9" style="display: none"&gt;Schedule of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Patents and licenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember_zfZNiqzh3foj" style="width: 13%; text-align: right" title="Intangible assets gross"&gt;2,424,773&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember_z31PDMbOROfb" style="width: 13%; text-align: right" title="Intangible assets gross"&gt;2,267,251&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zXtlrxNqIsrc" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible assets gross"&gt;5,017&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zpYXKnkgRmdd" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible assets gross"&gt;5,017&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20240630_znK4725Bxe74" style="text-align: right" title="Intangible assets gross"&gt;2,429,790&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231_zGmbyoCwOype" style="text-align: right" title="Intangible assets gross"&gt;2,272,268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_pp0p0_c20240630_zW4Ue8YHjAAd" style="border-bottom: Black 1pt solid; text-align: right" title="Less: accumulated amortization"&gt;(1,193,915&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20231231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Less: accumulated amortization"&gt;(1,103,645&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_pp0p0_c20240630_zZgNolLTo23b" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net"&gt;1,235,875&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_c20231231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net"&gt;1,168,623&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-06-30_custom_PatentsAndLicensesMember"
      decimals="0"
      id="Fact001048"
      unitRef="USD">2424773</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_custom_PatentsAndLicensesMember"
      decimals="0"
      id="Fact001050"
      unitRef="USD">2267251</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-06-30_us-gaap_OtherIntangibleAssetsMember"
      decimals="0"
      id="Fact001052"
      unitRef="USD">5017</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_us-gaap_OtherIntangibleAssetsMember"
      decimals="0"
      id="Fact001054"
      unitRef="USD">5017</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001056"
      unitRef="USD">2429790</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001058"
      unitRef="USD">2272268</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001060"
      unitRef="USD">-1193915</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001062"
      unitRef="USD">-1103645</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001064"
      unitRef="USD">1235875</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001066"
      unitRef="USD">1168623</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact001068"
      unitRef="USD">45458</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact001070"
      unitRef="USD">39940</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact001072"
      unitRef="USD">90270</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact001074"
      unitRef="USD">78805</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001080">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zVjC7kro9EO5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS (Details - Future amortization)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B9_zeB5K09APzF1" style="display: none"&gt;Schedule of future amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240630_zEz3tmZnbFS7" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 83%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;96,015&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;192,030&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;192,030&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;192,030&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;2028 and beyond&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;563,770&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OtherIntangibleAssetsNet_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,235,875&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001082"
      unitRef="USD">96015</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001084"
      unitRef="USD">192030</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001086"
      unitRef="USD">192030</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001088"
      unitRef="USD">192030</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001090"
      unitRef="USD">563770</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001092"
      unitRef="USD">1235875</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001094">&lt;p id="xdx_801_eus-gaap--DebtDisclosureTextBlock_zlJk15fg5pm4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&lt;/b&gt;&#160; &lt;b&gt;9. &lt;span id="xdx_827_ziIBCsPkvEGi"&gt;SHORT TERM NOTES AND CONVERTIBLE
DEBT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Convertible Notes:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2023, there were &lt;span id="xdx_90D_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_do_c20231231_znzzovgCIuZ9" title="Convertible notes payable outstanding"&gt;no&lt;/span&gt; Convertible
Notes payable and outstanding. There was &lt;span id="xdx_90C_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_do_c20240630_zfvyuEhxsTpe" title="Convertible notes payable outstanding"&gt;no&lt;/span&gt; convertible note activity in the three months ended June 30, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Senior Notes Payable&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In May 2023, the Company issued $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20230531__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesPayableMember_ziQJNjOL2sqf" title="Debt instrument face amount"&gt;1,437,500&lt;/span&gt;
unsecured senior notes with a maturity date of &lt;span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20230501__20230531__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesPayableMember_zAgQmBQ6t3C4" title="Maturity date"&gt;May
16, 2024&lt;/span&gt; (&#x201c;the Senior Notes Payable&#x201d;), for cash proceeds of $&lt;span id="xdx_90D_eus-gaap--ProceedsFromSecuredNotesPayable_c20230501__20230531__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesPayableMember_zzJOqzc4uGwi" title="Proceeds from secured notes payable"&gt;1,250,000&lt;/span&gt;.
The Senior Notes Payable contained an original issue discount of &lt;span id="xdx_908_ecustom--DebtOriginalIssueDiscountPercenrtage_iI_dp_c20230531__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesPayableMember_z50hrDNBIGNe" title="Original issue discount, percentage"&gt;15.0&lt;/span&gt;%
and accrue interest at an annual rate of &lt;span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20230531__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesPayableMember_zqodwGe3Med4" title="Annual rate percentage"&gt;8.0&lt;/span&gt;%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In September 2023, as agreed to during the
issuance of the Senior Notes Payable, the Company exercised their right to an additional financing, issuing $&lt;span id="xdx_909_eus-gaap--UnsecuredDebt_iI_c20230930__us-gaap--LongtermDebtTypeAxis__custom--SeriesBNotesPayableMember_zZWI74uySrV9" title="Issuing unsecured senior notes"&gt;862,500&lt;/span&gt;
unsecured senior notes that mature on &lt;span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20230901__20230930__us-gaap--LongtermDebtTypeAxis__custom--SeriesBNotesPayableMember_zX76nbvmzQRd" title="Maturity date"&gt;September
1, 2024&lt;/span&gt; ("the Series B Notes Payable) for cash proceeds of $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfUnsecuredDebt_c20230901__20230930__us-gaap--LongtermDebtTypeAxis__custom--SeriesBNotesPayableMember_zK65V3n7jW16" title="Cash proceeds"&gt;750,000&lt;/span&gt;.
The Series B Notes Payable contained an original issue discount of &lt;span id="xdx_908_ecustom--DebtOriginalIssueDiscountPercenrtage_iI_dp_c20230930__us-gaap--LongtermDebtTypeAxis__custom--SeriesBNotesPayableMember_zutrWpABSzq" title="Original issue discount, percentage"&gt;15.0&lt;/span&gt;%
and accrue interest at an annual rate of &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20230930__us-gaap--LongtermDebtTypeAxis__custom--SeriesBNotesPayableMember_zA3ejm5fWkI5" title="Annual rate percentage"&gt;8.0&lt;/span&gt;%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In November 2023, the Company issued $&lt;span id="xdx_90E_eus-gaap--UnsecuredDebt_iI_c20231130__us-gaap--LongtermDebtTypeAxis__custom--SeriesCNotesPayableMember_zWZAD6h7ABXd" title="Issuing unsecured senior notes"&gt;294,118&lt;/span&gt;
unsecured senior notes with a maturity date of &lt;span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20231101__20231130__us-gaap--LongtermDebtTypeAxis__custom--SeriesCNotesPayableMember_zsMJjmFikEol" title="Maturity date"&gt;April
19, 2024&lt;/span&gt; (&#x201c;the Series C Notes Payable&#x201d;), for cash proceeds of $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfUnsecuredDebt_c20231101__20231130__us-gaap--LongtermDebtTypeAxis__custom--SeriesCNotesPayableMember_zhMisB3KpCIk" title="Cash proceeds"&gt;250,000&lt;/span&gt;.
The Senior Notes Payable contained an original issue discount of &lt;span id="xdx_90F_ecustom--DebtOriginalIssueDiscountPercenrtage_dp_c20231130__us-gaap--LongtermDebtTypeAxis__custom--SeriesCNotesPayableMember_zCRSv78cDYD" title="Original issue discount, percentage"&gt;15.0&lt;/span&gt;%
and accrue interest at an annual rate of &lt;span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20231130__us-gaap--LongtermDebtTypeAxis__custom--SeriesCNotesPayableMember_zU1uK2SzJKna" title="Annual rate percentage"&gt;8.0&lt;/span&gt;%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company incurred issuance costs, recorded
as deferred financing costs, of $&lt;span id="xdx_909_eus-gaap--PaymentsForLegalSettlements_c20231101__20231130_zgu0H6Rz1zJb" title="Diligence and legal costs"&gt;296,313&lt;/span&gt; relating to due diligence and legal costs associated with the issuance of the notes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluated the embedded redemption
and contingent interest features in the notes to determine if such features were required to be bifurcated as an embedded derivative liability.
In accordance with ASC 815-40, Derivatives and Hedging Activities, the embedded redemption features and contingent interest feature were
accounted for as derivative liabilities at the date of issuance and shall be adjusted to fair value at each reporting date. The Company
fair valued such derivative liabilities and recorded a debt discount at issuance of the notes of $&lt;span id="xdx_906_eus-gaap--PaymentsOfDebtIssuanceCosts_c20231101__20231130_zrh02kXYPJf1" title="Issuance of debt discount"&gt;320,561&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company issued warrants to purchase 77,010
and 46,556 shares of common stock (1,232,156 and 744,890 shares before giving effect to the 2024 Stock Split) to the holders of the Senior
Notes Payable and Series C Notes Payable (collectively the &#x201c;Senior Notes Warrants&#x201d;) with an exercise price of $10.02 and $4.58
per share ($0.6262 and $0.2856 pre-2024 split), respectively. The Company accounted for the warrants in accordance with the guidance contained
in ASC 815 &#x201c;Derivatives and Hedging&#x201d; whereby under that provision these warrants did not meet the criteria for equity treatment
and were recorded as a liability. As such, these warrants are recorded at fair value as of each reporting date with the change in fair
value reported within other income in the accompanying consolidated statements of operations as &#x201c;Change in fair value of warrant
liability&#x201d; until the warrants are exercised, expired or other facts and circumstances lead the warrant liability to be reclassified
to stockholders&#x2019; equity. The fair value of the Senior Notes Warrants at issuance was $736,249 and was recorded as a debt discount.
The Company incurred issuance costs of $72,862 relating to the Senior Notes Warrants which was recorded as a day 1 expense due to the
liability classification of such warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the issuance of the Senior
Notes Payable and Series C Notes Payable, the Company paid a commitment fee in the form of 21,210 and 9,311 shares (339,360 and 148,978
shares before giving effect to the 2024 Stock Split) of unregistered common stock to the holders, respectively. The aggregate commitment
fees had a fair value at issuance of $208,916 and are recorded as a deferred financing cost.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The resulting debt discounts from the derivative
liabilities, warrant liabilities and deferred financing costs were presented as a direct deduction from the carrying amount of that debt
liability and amortized to interest expense using the effective interest rate method. For the three months ended June 30, 2024, the Company
recognized $&lt;span id="xdx_901_eus-gaap--AmortizationOfDebtDiscountPremium_c20240401__20240630__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesPayableMember_zMPibOHoNAAk" title="Amortization of debt discounts"&gt;&lt;span id="xdx_900_eus-gaap--DeferredCostsCurrent_iI_c20240630__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesPayableMember_zaj5CN0Rsyh8" title="Deferred financing costs"&gt;106,937&lt;/span&gt;&lt;/span&gt; in amortization of debt discounts and deferred financing costs which is recorded in interest expense.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Between January 22 and January 29, 2024, the Company
entered into a series of exchange agreements (the &#x201c;Exchange Agreements&#x201d;) with the accredited investors to exchange principal
and accrued interest on these notes for shares of common stock. Pursuant to the Exchange Agreements, the Company issued an aggregate of
&lt;span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240122__20240129__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementsMember__srt--CounterpartyNameAxis__custom--AccreditedInvestorsMember_zQucwyyeJxkb" title="Number of common shares issued on exchange"&gt;644,142&lt;/span&gt; post-split shares of common stock in exchange for $&lt;span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20240122__20240129__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementsMember__srt--CounterpartyNameAxis__custom--AccreditedInvestorsMember_zjLwfPWqBZvi" title="Exchange of principal and accrued interest"&gt;1,519,779&lt;/span&gt; principal and accrued interest on the notes. Following these exchanges,
the remaining outstanding balance of principal and interest on the notes was $&lt;span id="xdx_90C_ecustom--RemainingOutstandingBalanceOfPrincipalAndInterest_c20240122__20240129__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementsMember__srt--CounterpartyNameAxis__custom--AccreditedInvestorsMember_zBot47Kz0uXd" title="Remaining outstanding balance of principal and interest"&gt;1,145,037&lt;/span&gt;. This transaction accelerated the recognition
of the related note discounts and resulted in a $&lt;span id="xdx_901_ecustom--LossOnExchangeOfDebt_c20240101__20240131__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementsMember__srt--CounterpartyNameAxis__custom--AccreditedInvestorsMember_z2DU0vT0YRSd" title="Exchange of principal and accrued interest"&gt;1,066,732&lt;/span&gt; charge.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 6, 2024, the Company paid $&lt;span id="xdx_904_ecustom--PrincipalAndAccruedInterestPaid_c20240305__20240306__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredNonConvertibleNotesMember_zCw1GaMARoF5" title="Principal and accrued interest paid"&gt;300,974&lt;/span&gt; of
principal and accrued interest on certain unsecured non-convertible notes. Following this payment, the remaining outstanding balance of
principal and interest on the notes was $&lt;span id="xdx_901_eus-gaap--NotesPayable_iI_c20240306__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredNonConvertibleNotesMember_ztB4KyasF758" title="Outstanding balance"&gt;898,380&lt;/span&gt;. This transaction accelerated the recognition of the related note discounts and resulted
in a $&lt;span id="xdx_90D_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20240101__20240630__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredNonConvertibleNotesMember_zNx7AWSMcmg3" title="Principal and accrued interest paid"&gt;111,928&lt;/span&gt; charge.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table reconciles the aggregate amount
for the Senior Notes Payable, Series B Notes Payable, and Series C Notes Payable as well as the unamortized deferred financing costs and
debt discounts relating to the derivative liabilities and warrant liabilities.&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfDerivativeInstrumentsTextBlock_z4DHNowa9Azk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT (Details - Note payable)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BA_zxLYHvNf4Ulc" style="display: none"&gt;Schedule of derivative liabilities and warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;June 30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Note Payable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--NotesPayable_pp0p0_c20240630_zqz3p393tW25" style="width: 14%; text-align: right" title="Note Payable"&gt;862,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--NotesPayable_c20231231_pp0p0" style="width: 14%; text-align: right" title="Note Payable"&gt;2,594,118&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: Unamortized Discounts and Deferred Financing Costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-indent: 9pt"&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsWarrants_iI_pp0p0_d0_c20240630_zTX1z2WgTctb" style="text-align: right" title="Warrants"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsWarrants_c20231231_pp0p0" style="text-align: right" title="Warrants"&gt;(557,582&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 9pt"&gt;Derivative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsDerivative_iI_pp0p0_c20240630_zfU2xKExR65a" style="text-align: right" title="Derivative"&gt;(34,475&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsDerivative_c20231231_pp0p0" style="text-align: right" title="Derivative"&gt;(235,628&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left; text-indent: 9pt"&gt;Deferred financing costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost_iI_pp0p0_c20240630_zzOeVpNyJTNk" style="border-bottom: Black 1pt solid; text-align: right" title="Deferred financing costs"&gt;(50,938&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost_c20231231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Deferred financing costs"&gt;(675,184&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsTotal_iI_pp0p0_d0_c20240630_z5De3Php7MDe" style="border-bottom: Black 1pt solid; text-align: right" title="Total notes payable discount"&gt;(85,413&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsTotal_c20231231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total notes payable discount"&gt;(1,468,394&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OtherNotesPayableCurrent_pp0p0_c20240630_zEMiVbduCHde" style="border-bottom: Black 2.5pt double; text-align: right" title="Note payable, net of discount"&gt;777,087&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OtherNotesPayableCurrent_c20231231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Note payable, net of discount"&gt;1,125,724&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001096"
      unitRef="USD">0</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001098"
      unitRef="USD">0</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-05-31_custom_SeniorNotesPayableMember"
      decimals="0"
      id="Fact001100"
      unitRef="USD">1437500</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2023-05-012023-05-31_custom_SeniorNotesPayableMember"
      id="Fact001102">2024-05-16</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ProceedsFromSecuredNotesPayable
      contextRef="From2023-05-012023-05-31_custom_SeniorNotesPayableMember"
      decimals="0"
      id="Fact001104"
      unitRef="USD">1250000</us-gaap:ProceedsFromSecuredNotesPayable>
    <ACON:DebtOriginalIssueDiscountPercenrtage
      contextRef="AsOf2023-05-31_custom_SeniorNotesPayableMember"
      decimals="INF"
      id="Fact001106"
      unitRef="Pure">0.150</ACON:DebtOriginalIssueDiscountPercenrtage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2023-05-31_custom_SeniorNotesPayableMember"
      decimals="INF"
      id="Fact001108"
      unitRef="Pure">0.080</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:UnsecuredDebt
      contextRef="AsOf2023-09-30_custom_SeriesBNotesPayableMember"
      decimals="0"
      id="Fact001110"
      unitRef="USD">862500</us-gaap:UnsecuredDebt>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2023-09-012023-09-30_custom_SeriesBNotesPayableMember"
      id="Fact001112">2024-09-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ProceedsFromIssuanceOfUnsecuredDebt
      contextRef="From2023-09-012023-09-30_custom_SeriesBNotesPayableMember"
      decimals="0"
      id="Fact001114"
      unitRef="USD">750000</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
    <ACON:DebtOriginalIssueDiscountPercenrtage
      contextRef="AsOf2023-09-30_custom_SeriesBNotesPayableMember"
      decimals="INF"
      id="Fact001116"
      unitRef="Pure">0.150</ACON:DebtOriginalIssueDiscountPercenrtage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2023-09-30_custom_SeriesBNotesPayableMember"
      decimals="INF"
      id="Fact001118"
      unitRef="Pure">0.080</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:UnsecuredDebt
      contextRef="AsOf2023-11-30_custom_SeriesCNotesPayableMember"
      decimals="0"
      id="Fact001120"
      unitRef="USD">294118</us-gaap:UnsecuredDebt>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2023-11-012023-11-30_custom_SeriesCNotesPayableMember"
      id="Fact001122">2024-04-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ProceedsFromIssuanceOfUnsecuredDebt
      contextRef="From2023-11-012023-11-30_custom_SeriesCNotesPayableMember"
      decimals="0"
      id="Fact001124"
      unitRef="USD">250000</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
    <ACON:DebtOriginalIssueDiscountPercenrtage
      contextRef="AsOf2023-11-30_custom_SeriesCNotesPayableMember"
      decimals="INF"
      id="Fact001126"
      unitRef="Pure">0.150</ACON:DebtOriginalIssueDiscountPercenrtage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2023-11-30_custom_SeriesCNotesPayableMember"
      decimals="INF"
      id="Fact001128"
      unitRef="Pure">0.080</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="From2023-11-012023-11-30"
      decimals="0"
      id="Fact001130"
      unitRef="USD">296313</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2023-11-012023-11-30"
      decimals="0"
      id="Fact001132"
      unitRef="USD">320561</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2024-04-012024-06-30_custom_SeniorNotesPayableMember"
      decimals="0"
      id="Fact001137"
      unitRef="USD">106937</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DeferredCostsCurrent
      contextRef="AsOf2024-06-30_custom_SeniorNotesPayableMember"
      decimals="0"
      id="Fact001139"
      unitRef="USD">106937</us-gaap:DeferredCostsCurrent>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2024-01-222024-01-29_custom_ExchangeAgreementsMember_custom_AccreditedInvestorsMember"
      decimals="INF"
      id="Fact001141"
      unitRef="Shares">644142</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2024-01-222024-01-29_custom_ExchangeAgreementsMember_custom_AccreditedInvestorsMember"
      decimals="0"
      id="Fact001143"
      unitRef="USD">1519779</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <ACON:RemainingOutstandingBalanceOfPrincipalAndInterest
      contextRef="From2024-01-222024-01-29_custom_ExchangeAgreementsMember_custom_AccreditedInvestorsMember"
      decimals="0"
      id="Fact001145"
      unitRef="USD">1145037</ACON:RemainingOutstandingBalanceOfPrincipalAndInterest>
    <ACON:LossOnExchangeOfDebt
      contextRef="From2024-01-012024-01-31_custom_ExchangeAgreementsMember_custom_AccreditedInvestorsMember"
      decimals="0"
      id="Fact001147"
      unitRef="USD">1066732</ACON:LossOnExchangeOfDebt>
    <ACON:PrincipalAndAccruedInterestPaid
      contextRef="From2024-03-052024-03-06_custom_UnsecuredNonConvertibleNotesMember"
      decimals="0"
      id="Fact001149"
      unitRef="USD">300974</ACON:PrincipalAndAccruedInterestPaid>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-03-06_custom_UnsecuredNonConvertibleNotesMember"
      decimals="0"
      id="Fact001151"
      unitRef="USD">898380</us-gaap:NotesPayable>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-012024-06-30_custom_UnsecuredNonConvertibleNotesMember"
      decimals="0"
      id="Fact001153"
      unitRef="USD">111928</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001155">&lt;table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfDerivativeInstrumentsTextBlock_z4DHNowa9Azk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT (Details - Note payable)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BA_zxLYHvNf4Ulc" style="display: none"&gt;Schedule of derivative liabilities and warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;June 30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Note Payable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--NotesPayable_pp0p0_c20240630_zqz3p393tW25" style="width: 14%; text-align: right" title="Note Payable"&gt;862,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--NotesPayable_c20231231_pp0p0" style="width: 14%; text-align: right" title="Note Payable"&gt;2,594,118&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: Unamortized Discounts and Deferred Financing Costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-indent: 9pt"&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsWarrants_iI_pp0p0_d0_c20240630_zTX1z2WgTctb" style="text-align: right" title="Warrants"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsWarrants_c20231231_pp0p0" style="text-align: right" title="Warrants"&gt;(557,582&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 9pt"&gt;Derivative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsDerivative_iI_pp0p0_c20240630_zfU2xKExR65a" style="text-align: right" title="Derivative"&gt;(34,475&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsDerivative_c20231231_pp0p0" style="text-align: right" title="Derivative"&gt;(235,628&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left; text-indent: 9pt"&gt;Deferred financing costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost_iI_pp0p0_c20240630_zzOeVpNyJTNk" style="border-bottom: Black 1pt solid; text-align: right" title="Deferred financing costs"&gt;(50,938&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost_c20231231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Deferred financing costs"&gt;(675,184&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsTotal_iI_pp0p0_d0_c20240630_z5De3Php7MDe" style="border-bottom: Black 1pt solid; text-align: right" title="Total notes payable discount"&gt;(85,413&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsTotal_c20231231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total notes payable discount"&gt;(1,468,394&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OtherNotesPayableCurrent_pp0p0_c20240630_zEMiVbduCHde" style="border-bottom: Black 2.5pt double; text-align: right" title="Note payable, net of discount"&gt;777,087&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OtherNotesPayableCurrent_c20231231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Note payable, net of discount"&gt;1,125,724&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001157"
      unitRef="USD">862500</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001159"
      unitRef="USD">2594118</us-gaap:NotesPayable>
    <ACON:UnamortizedDiscountsAndDeferredFinancingCostsWarrants
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001161"
      unitRef="USD">0</ACON:UnamortizedDiscountsAndDeferredFinancingCostsWarrants>
    <ACON:UnamortizedDiscountsAndDeferredFinancingCostsWarrants
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001163"
      unitRef="USD">-557582</ACON:UnamortizedDiscountsAndDeferredFinancingCostsWarrants>
    <ACON:UnamortizedDiscountsAndDeferredFinancingCostsDerivative
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001165"
      unitRef="USD">-34475</ACON:UnamortizedDiscountsAndDeferredFinancingCostsDerivative>
    <ACON:UnamortizedDiscountsAndDeferredFinancingCostsDerivative
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001167"
      unitRef="USD">-235628</ACON:UnamortizedDiscountsAndDeferredFinancingCostsDerivative>
    <ACON:UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001169"
      unitRef="USD">-50938</ACON:UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost>
    <ACON:UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001171"
      unitRef="USD">-675184</ACON:UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost>
    <ACON:UnamortizedDiscountsAndDeferredFinancingCostsTotal
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001173"
      unitRef="USD">-85413</ACON:UnamortizedDiscountsAndDeferredFinancingCostsTotal>
    <ACON:UnamortizedDiscountsAndDeferredFinancingCostsTotal
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001175"
      unitRef="USD">-1468394</ACON:UnamortizedDiscountsAndDeferredFinancingCostsTotal>
    <us-gaap:OtherNotesPayableCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001177"
      unitRef="USD">777087</us-gaap:OtherNotesPayableCurrent>
    <us-gaap:OtherNotesPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001179"
      unitRef="USD">1125724</us-gaap:OtherNotesPayableCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001181">&lt;p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zsZtOZEebdj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 10. &lt;span id="xdx_82F_zp5jn8mqS7zc"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Royalty Agreement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has an exclusive license agreement
with the Regents of the University of California to make, use, sell and otherwise distribute products under certain of the Regents of
the University of California&#x2019;s patents anywhere in the world. The Company is obligated to pay a minimum annual royalty of $&lt;span id="xdx_901_ecustom--MinimumAnnualRoyaltyPayment_iI_c20240630__srt--CounterpartyNameAxis__custom--RegentsOfTheUniversityOfCaliforniaMember_z40fsnAJo1za" title="Minimum annual royalty payment"&gt;50,000&lt;/span&gt;,
and an earned royalty of 4% of net sales. The minimum annual royalty will be applied against the earned royalty due for the calendar year
in which the minimum payment was made. The license agreements expire upon expiration of the patents and may be terminated earlier if the
Company so elects. The U.S. licensed patents that are currently issued expire between 2026 and 2029, without considering any possible
patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees.
The Company recorded royalty costs of $&lt;span id="xdx_909_eus-gaap--RoyaltyExpense_c20240401__20240630__srt--CounterpartyNameAxis__custom--RegentsOfTheUniversityOfCaliforniaMember_z1308vfk3yNg" title="Royalty expense"&gt;&lt;span id="xdx_908_eus-gaap--RoyaltyExpense_c20230401__20230630__srt--CounterpartyNameAxis__custom--RegentsOfTheUniversityOfCaliforniaMember_zk6I9VOeHRjf" title="Royalty expense"&gt;12,500&lt;/span&gt;&lt;/span&gt; for the three months ended June 30, 2024, and 2023, respectively, and $&lt;span id="xdx_906_eus-gaap--RoyaltyExpense_c20240101__20240630__srt--CounterpartyNameAxis__custom--RegentsOfTheUniversityOfCaliforniaMember_zkHrqG9SKkpg" title="Royalty expense"&gt;&lt;span id="xdx_90C_eus-gaap--RoyaltyExpense_c20230101__20230630__srt--CounterpartyNameAxis__custom--RegentsOfTheUniversityOfCaliforniaMember_zxzBnbHfeXr2" title="Royalty expense"&gt;25,000&lt;/span&gt;&lt;/span&gt; for the six
months ended June 30, 2024, and 2023, respectively, as Cost of Revenue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Litigation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;To date, the Company has not been involved in
legal proceedings arising in the ordinary course of its business. If any legal proceeding occurs, the Company will record a provision
for a loss when it believes that it is both probable that a loss has been incurred and the amount can be reasonably estimated, although
litigation is inherently unpredictable and is subject to significant uncertainties, some of which are beyond the Company&#x2019;s control.
Should any of these estimates and assumptions change or prove to have been incorrect, the Company could incur significant charges related
to legal matters that could have a material impact on its results of operations, financial position and cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ACON:MinimumAnnualRoyaltyPayment
      contextRef="AsOf2024-06-30_custom_RegentsOfTheUniversityOfCaliforniaMember"
      decimals="0"
      id="Fact001183"
      unitRef="USD">50000</ACON:MinimumAnnualRoyaltyPayment>
    <us-gaap:RoyaltyExpense
      contextRef="From2024-04-012024-06-30_custom_RegentsOfTheUniversityOfCaliforniaMember"
      decimals="0"
      id="Fact001185"
      unitRef="USD">12500</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2023-04-012023-06-30_custom_RegentsOfTheUniversityOfCaliforniaMember"
      decimals="0"
      id="Fact001187"
      unitRef="USD">12500</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2024-01-012024-06-30_custom_RegentsOfTheUniversityOfCaliforniaMember"
      decimals="0"
      id="Fact001189"
      unitRef="USD">25000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2023-01-012023-06-30_custom_RegentsOfTheUniversityOfCaliforniaMember"
      decimals="0"
      id="Fact001191"
      unitRef="USD">25000</us-gaap:RoyaltyExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001197">&lt;p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zmMgODpX1cmc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 11. &lt;span id="xdx_824_zHd6p14jyvC6"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company filed an Amended and Restated Certificate
of Incorporation on April 21, 2022, as part of the Company&#x2019;s initial public offering. The Company was authorized to issue two classes
of stock to be designated, respectively, &#x201c;common stock&#x201d; and &#x201c;preferred stock.&#x201d; The total number of shares which
the Company was authorized to issue was two hundred twenty million (220,000,000) shares. Two hundred million (&lt;span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20240630_zsbPAzQb1jK" title="Common stock, shares authorized"&gt;200,000,000&lt;/span&gt;) shares were authorized
to be common stock, having a par value per share of $&lt;span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240630_zFhX2FEZluEl" title="Common stock, par value"&gt;0.00001&lt;/span&gt;. Twenty million (&lt;span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20240630_znqavJoGlk19" title="Preferred stock, shares authorized"&gt;20,000,000&lt;/span&gt;) shares were authorized to be preferred stock,
having a par value per share of $&lt;span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240630_zdZL7ncqlh5l" title="Preferred stock, par value"&gt;0.00001&lt;/span&gt;. As of June 30, 2024, the Company had &lt;span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20240630_zuLXKsSe7bja" title="Common stock, shares outstanding"&gt;8,210,671&lt;/span&gt; common shares outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Stockholders&#x2019; Vote &#x2013; Reverse stock
split&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company held a special meeting of stockholders
on March 24, 2023. At the special meeting, our stockholders approved one proposal, which was to grant discretionary authority to our board
of directors to (i) amend our certificate of incorporation to combine outstanding shares of our common stock into a lesser number of outstanding
shares, or a &#x201c;reverse stock split,&#x201d; at a specific ratio within a range of &lt;span id="xdx_906_eus-gaap--StockholdersEquityReverseStockSplit_c20240323__20240324__srt--RangeAxis__srt--MinimumMember_z3nH5C4xGxg8" title="Stockholders equity, reverse stock Split"&gt;one-for-five&lt;/span&gt; (1-for-5) to a maximum of a &lt;span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20240323__20240324__srt--RangeAxis__srt--MaximumMember_zPYs1eWBSEX8" title="Stockholders equity, reverse stock Split"&gt;one-for-fifty&lt;/span&gt;
(1-for-50) split, with the exact ratio to be determined by our board of directors in its sole discretion; and (ii) effect the reverse
stock split, if at all, within one year of the date the proposal was approved by stockholders.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In January 2024, the Company's board subsequently
approved the final reverse stock split ratio of one-for-sixteen (the &#x201c;2024 Stock Split&#x201d;), which resulted in a reduction in
the number of outstanding shares of common stock, warrants, stock options and restricted share units and a proportionate increase in the
value of each share or strike price of the warrants and stock options. The common stock began trading on a reverse split-adjusted basis
on the NASDAQ on January 4, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Series A Preferred Stock&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In February 2023 the Company sold one (1) share
of the Company&#x2019;s newly designated Series A preferred stock to Jeffrey Thramann, the Company&#x2019;s Executive Chairman, for a purchase
price of $&lt;span id="xdx_909_ecustom--PurchasePrice_c20230201__20230228__srt--TitleOfIndividualAxis__custom--ExecutiveChairmanMember_zL0NtzklOwHd" title="Purchase price"&gt;1,000&lt;/span&gt;. The share of Series A preferred stock had proportional voting rights that were limited to the proposal to approve a reverse
stock split of the Company&#x2019;s common stock. Following the March 24, 2023, special meeting, the Company redeemed the one outstanding
share of Series A preferred stock on March 28, 2023, in accordance with its terms. The redemption price was $&lt;span id="xdx_907_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_c20240101__20240630_zl1w3LDReM4b" title="Redemption price"&gt;1,000&lt;/span&gt;. No Series A preferred
stock remains outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Public Offering&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 27, 2024, the Company completed a
public offering of &lt;span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240226__20240227__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zY6NX13D0WK1" title="Issued units"&gt;5,175,000&lt;/span&gt; units (&#x201c;Units&#x201d;) at a price of $&lt;span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20240227__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zkoFuLPx90j2" title="Price per unit"&gt;0.58&lt;/span&gt; per Unit, for gross proceeds of approximately $&lt;span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn6n6_c20240226__20240227__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z56C0JMPRZok" title="Gross proceeds"&gt;3&lt;/span&gt;.0 million,
before deducting offering expenses. Each Unit was comprised of (i) one share of common stock or, in lieu of common stock, one prefunded
warrant to purchase a share of common stock, and (ii) two common warrants, each common warrant to purchase a share of common stock. The
prefunded warrants were immediately exercisable at a price of $0.00001 per share of common stock and only expire when such prefunded warrants
are fully exercised. The common warrants were immediately exercisable at a price of $0.58 per share of common stock and will expire five
years from the date of issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;White Lion Equity Line Agreement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 9, 2023, the Company entered into an
equity line common stock purchase agreement (the &#x201c;Equity Line Purchase Agreement&#x201d;) and a related registration rights agreement
with White Lion Capital, LLC (&#x201c;White Lion&#x201d;). Pursuant to the Equity Line Agreement, the Company has the right, but not the
obligation to require White Lion to purchase, from time to time, up to $&lt;span id="xdx_90C_eus-gaap--PaymentsForRepurchaseOfWarrants_c20231008__20231009__us-gaap--TransactionTypeAxis__custom--WhiteLionEquityLineAgreementMember_z5JWvqdnTuFd" title="Aggregate gross purchase price"&gt;10,000,000&lt;/span&gt; in aggregate gross purchase price of newly issued shares
of the Company&#x2019;s common stock, subject to certain limitations and conditions set forth in the Equity Line Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the Equity Line Purchase Agreement,
the Company issued to White Lion &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240424__20240426__us-gaap--TransactionTypeAxis__custom--WhiteLionEquityLineAgreementMember_zb1Wp5ZAAnTl" title="Issued shares"&gt;1,050,000&lt;/span&gt; newly issued common shares for proceeds of $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240424__20240426__us-gaap--TransactionTypeAxis__custom--WhiteLionEquityLineAgreementMember_zTjpZkz2rA0c" title="Proceeds from issuance of common shares"&gt;304,500&lt;/span&gt; on April 26, 2024. Through June 30, 2024,
the Company has issued &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240630__us-gaap--TransactionTypeAxis__custom--WhiteLionEquityLineAgreementMember_zrvCiCidW0Y7" title="Issued shares"&gt;1,800,000&lt;/span&gt; shares to White Lion for total proceeds of $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20240630__us-gaap--TransactionTypeAxis__custom--WhiteLionEquityLineAgreementMember_zsczwgdCYrga" title="Proceeds from issuance of common shares"&gt;3,216,981&lt;/span&gt;.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes the
Company&#x2019;s outstanding warrants as of June 30, 2024. The warrants and related strike prices have been adjusted to reflect
the 2024 Stock Split.&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zeO8GMHB4xni" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details - Outstanding warrants)"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&lt;span id="xdx_8BC_zDYQiP0cRYif" style="display: none"&gt;Schedule of warrants and related strike prices&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="border: black 1pt solid; width: 36%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Issue Date&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 16%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Strike price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 21%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 25%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Expiration&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(238,238,238)"&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePriceMember_fKDEp_zQTeExaR3F09" title="Issue date"&gt;April 21, 2022&lt;/span&gt; (1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePriceMember_fKDEp_z6lUJG3j11mb" title="Strike price"&gt;69.60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePriceMember_fKDEp_z9AvwNC0r9fe" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;155,610&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePriceMember_fKDEp_zJ7zgL2ZelT8" title="Expiration"&gt;April 21, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice1Member_z9pJvj90xyok" title="Issue date"&gt;April 21, 2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice1Member_zVRoDsbB8YYh" title="Strike price"&gt;87.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice1Member_zrK5fyXYQTMf" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,825&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice1Member_zXp7Xrmz7z28" title="Expiration"&gt;April 21, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(238,238,238)"&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice2Member_zAL3HNZT5cwe" title="Issue date"&gt;April 21, 2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice2Member_z6GuYgYlJZv9" title="Strike price"&gt;69.60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice2Member_zCJWWiqdmGZj" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;26,673&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice2Member_zEbTR3XZhu5a" title="Expiration"&gt;April 21, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice3Member_fKDIp_zKn3cxuZlpj2"&gt;May 16, 2023&lt;/span&gt; (2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice3Member_fKDIp_zaa23c02Ypni" title="Strike price"&gt;0.29&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice3Member_fKDIp_zfbPTWn3ixq8" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;77,010&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice3Member_fKDIp_zt5B26Xna7zd" title="Expiration"&gt;May 16, 2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(238,238,238)"&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice4Member_fKDIp_zZKYEOaU9Dl2"&gt;November 21, 2023&lt;/span&gt; (2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice4Member_fKDIp_za5OwvRfkRjb" title="Strike price"&gt;0.29&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice4Member_fKDIp_zetOjQH87aHk" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;46,556&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice4Member_fKDIp_zVMslzSfPg94" title="Expiration"&gt;November 21, 2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice5Member_zyVIuNupPfab" title="Issue date"&gt;November 21, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice5Member_ze9lEuppAHH1" title="Strike price"&gt;0.00001&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice5Member_zWcXOoFlmoq4" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,576&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice5Member_zAVvgOlrmmtd" title="Expiration"&gt;November 21, 2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(238,238,238)"&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice6Member_z0r4BBtZVwTb" title="Issue date"&gt;February 27, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice6Member_zGxVNyRQ7IYe" title="Strike price"&gt;0.58&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice6Member_zc5Qv22unfrg" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,350,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice6Member_zQtn98pTlbZ3" title="Expiration"&gt;February 27, 2029&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 5%; text-align: justify"&gt;&lt;span id="xdx_F03_znuzUtQP6ula" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 95%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F1C_zH4hCCWyNCSl"&gt;These
    warrants were issued as part of the Company&#x2019;s initial public offering completed April 2022, and trade on Nasdaq under the
    ticker symbol &#x201c;ACONW.&#x201d;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F02_zXPSiiQZe8N1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F11_zom5hNjrTiyc"&gt;The per share exercise price of these warrants is subject to a &#x201c;ratchet&#x201d; adjustment if the Company issues securities at an effective per share price lower than the then effective warrant exercise price. The strike price of $0.29 is current through the equity line activity closed April 26, 2024.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A9_ziLpPF7lpbv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact001199"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact001201"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact001203"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact001205"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact001207"
      unitRef="Shares">8210671</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2024-03-232024-03-24_srt_MinimumMember"
      id="Fact001209">one-for-five</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2024-03-232024-03-24_srt_MaximumMember"
      id="Fact001211">one-for-fifty</us-gaap:StockholdersEquityReverseStockSplit>
    <ACON:PurchasePrice
      contextRef="From2023-02-012023-02-28_custom_ExecutiveChairmanMember"
      decimals="0"
      id="Fact001213"
      unitRef="USD">1000</ACON:PurchasePrice>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact001215"
      unitRef="USD">1000</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-02-262024-02-27_us-gaap_IPOMember"
      decimals="INF"
      id="Fact001217"
      unitRef="Shares">5175000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-02-27_us-gaap_IPOMember"
      decimals="INF"
      id="Fact001219"
      unitRef="USDPShares">0.58</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-02-262024-02-27_us-gaap_IPOMember"
      decimals="-6"
      id="Fact001221"
      unitRef="USD">3000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="From2023-10-082023-10-09_custom_WhiteLionEquityLineAgreementMember"
      decimals="0"
      id="Fact001226"
      unitRef="USD">10000000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-04-242024-04-26_custom_WhiteLionEquityLineAgreementMember"
      decimals="INF"
      id="Fact001228"
      unitRef="Shares">1050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-04-242024-04-26_custom_WhiteLionEquityLineAgreementMember"
      decimals="0"
      id="Fact001230"
      unitRef="USD">304500</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-06-30_custom_WhiteLionEquityLineAgreementMember"
      decimals="INF"
      id="Fact001232"
      unitRef="Shares">1800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-06-30_custom_WhiteLionEquityLineAgreementMember"
      decimals="0"
      id="Fact001234"
      unitRef="USD">3216981</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001236">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zeO8GMHB4xni" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details - Outstanding warrants)"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&lt;span id="xdx_8BC_zDYQiP0cRYif" style="display: none"&gt;Schedule of warrants and related strike prices&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="border: black 1pt solid; width: 36%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Issue Date&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 16%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Strike price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 21%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 25%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Expiration&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(238,238,238)"&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePriceMember_fKDEp_zQTeExaR3F09" title="Issue date"&gt;April 21, 2022&lt;/span&gt; (1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePriceMember_fKDEp_z6lUJG3j11mb" title="Strike price"&gt;69.60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePriceMember_fKDEp_z9AvwNC0r9fe" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;155,610&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePriceMember_fKDEp_zJ7zgL2ZelT8" title="Expiration"&gt;April 21, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice1Member_z9pJvj90xyok" title="Issue date"&gt;April 21, 2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice1Member_zVRoDsbB8YYh" title="Strike price"&gt;87.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice1Member_zrK5fyXYQTMf" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,825&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice1Member_zXp7Xrmz7z28" title="Expiration"&gt;April 21, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(238,238,238)"&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice2Member_zAL3HNZT5cwe" title="Issue date"&gt;April 21, 2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice2Member_z6GuYgYlJZv9" title="Strike price"&gt;69.60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice2Member_zCJWWiqdmGZj" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;26,673&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice2Member_zEbTR3XZhu5a" title="Expiration"&gt;April 21, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice3Member_fKDIp_zKn3cxuZlpj2"&gt;May 16, 2023&lt;/span&gt; (2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice3Member_fKDIp_zaa23c02Ypni" title="Strike price"&gt;0.29&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice3Member_fKDIp_zfbPTWn3ixq8" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;77,010&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice3Member_fKDIp_zt5B26Xna7zd" title="Expiration"&gt;May 16, 2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(238,238,238)"&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice4Member_fKDIp_zZKYEOaU9Dl2"&gt;November 21, 2023&lt;/span&gt; (2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice4Member_fKDIp_za5OwvRfkRjb" title="Strike price"&gt;0.29&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice4Member_fKDIp_zetOjQH87aHk" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;46,556&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice4Member_fKDIp_zVMslzSfPg94" title="Expiration"&gt;November 21, 2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice5Member_zyVIuNupPfab" title="Issue date"&gt;November 21, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice5Member_ze9lEuppAHH1" title="Strike price"&gt;0.00001&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice5Member_zWcXOoFlmoq4" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,576&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice5Member_zAVvgOlrmmtd" title="Expiration"&gt;November 21, 2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(238,238,238)"&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice6Member_z0r4BBtZVwTb" title="Issue date"&gt;February 27, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice6Member_zGxVNyRQ7IYe" title="Strike price"&gt;0.58&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice6Member_zc5Qv22unfrg" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,350,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice6Member_zQtn98pTlbZ3" title="Expiration"&gt;February 27, 2029&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 5%; text-align: justify"&gt;&lt;span id="xdx_F03_znuzUtQP6ula" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 95%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F1C_zH4hCCWyNCSl"&gt;These
    warrants were issued as part of the Company&#x2019;s initial public offering completed April 2022, and trade on Nasdaq under the
    ticker symbol &#x201c;ACONW.&#x201d;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F02_zXPSiiQZe8N1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F11_zom5hNjrTiyc"&gt;The per share exercise price of these warrants is subject to a &#x201c;ratchet&#x201d; adjustment if the Company issues securities at an effective per share price lower than the then effective warrant exercise price. The strike price of $0.29 is current through the equity line activity closed April 26, 2024.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <ACON:StockIssueDate
      contextRef="From2024-01-012024-06-30_custom_WarrantStrikePriceMember"
      id="Fact001238">2022-04-21</ACON:StockIssueDate>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-06-30_custom_WarrantStrikePriceMember"
      decimals="INF"
      id="Fact001240"
      unitRef="USDPShares">69.60</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-06-30_custom_WarrantStrikePriceMember"
      decimals="INF"
      id="Fact001242"
      unitRef="Shares">155610</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2024-01-012024-06-30_custom_WarrantStrikePriceMember"
      id="Fact001244">2027-04-21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <ACON:StockIssueDate
      contextRef="From2024-01-012024-06-30_custom_WarrantStrikePrice1Member"
      id="Fact001246">2022-04-21</ACON:StockIssueDate>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-06-30_custom_WarrantStrikePrice1Member"
      decimals="INF"
      id="Fact001248"
      unitRef="USDPShares">87.04</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-06-30_custom_WarrantStrikePrice1Member"
      decimals="INF"
      id="Fact001250"
      unitRef="Shares">10825</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2024-01-012024-06-30_custom_WarrantStrikePrice1Member"
      id="Fact001252">2027-04-21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <ACON:StockIssueDate
      contextRef="From2024-01-012024-06-30_custom_WarrantStrikePrice2Member"
      id="Fact001254">2022-04-21</ACON:StockIssueDate>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-06-30_custom_WarrantStrikePrice2Member"
      decimals="INF"
      id="Fact001256"
      unitRef="USDPShares">69.60</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-06-30_custom_WarrantStrikePrice2Member"
      decimals="INF"
      id="Fact001258"
      unitRef="Shares">26673</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2024-01-012024-06-30_custom_WarrantStrikePrice2Member"
      id="Fact001260">2027-04-21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <ACON:StockIssueDate
      contextRef="From2024-01-012024-06-30_custom_WarrantStrikePrice3Member"
      id="Fact001261">2023-05-16</ACON:StockIssueDate>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-06-30_custom_WarrantStrikePrice3Member"
      decimals="INF"
      id="Fact001263"
      unitRef="USDPShares">0.29</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-06-30_custom_WarrantStrikePrice3Member"
      decimals="INF"
      id="Fact001265"
      unitRef="Shares">77010</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2024-01-012024-06-30_custom_WarrantStrikePrice3Member"
      id="Fact001267">2028-05-16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <ACON:StockIssueDate
      contextRef="From2024-01-012024-06-30_custom_WarrantStrikePrice4Member"
      id="Fact001268">2023-11-21</ACON:StockIssueDate>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-06-30_custom_WarrantStrikePrice4Member"
      decimals="INF"
      id="Fact001270"
      unitRef="USDPShares">0.29</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-06-30_custom_WarrantStrikePrice4Member"
      decimals="INF"
      id="Fact001272"
      unitRef="Shares">46556</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2024-01-012024-06-30_custom_WarrantStrikePrice4Member"
      id="Fact001274">2028-11-21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <ACON:StockIssueDate
      contextRef="From2024-01-012024-06-30_custom_WarrantStrikePrice5Member"
      id="Fact001276">2023-11-21</ACON:StockIssueDate>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-06-30_custom_WarrantStrikePrice5Member"
      decimals="INF"
      id="Fact001278"
      unitRef="USDPShares">0.00001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-06-30_custom_WarrantStrikePrice5Member"
      decimals="INF"
      id="Fact001280"
      unitRef="Shares">1576</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2024-01-012024-06-30_custom_WarrantStrikePrice5Member"
      id="Fact001282">2028-11-21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <ACON:StockIssueDate
      contextRef="From2024-01-012024-06-30_custom_WarrantStrikePrice6Member"
      id="Fact001284">2024-02-27</ACON:StockIssueDate>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-06-30_custom_WarrantStrikePrice6Member"
      decimals="INF"
      id="Fact001286"
      unitRef="USDPShares">0.58</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-06-30_custom_WarrantStrikePrice6Member"
      decimals="INF"
      id="Fact001288"
      unitRef="Shares">10350000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2024-01-012024-06-30_custom_WarrantStrikePrice6Member"
      id="Fact001290">2029-02-27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001294">&lt;p id="xdx_800_eus-gaap--EarningsPerShareTextBlock_zy0JXDs1fVDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 12. &lt;span id="xdx_82F_zes4OZvugAGk"&gt;NET LOSS PER SHARE OF COMMON STOCK&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic and diluted net loss per share is computed
by dividing net loss attributable to stockholders by the weighted average number shares of common stock outstanding during the period
and shares issuable for vested restricted stock units. Potentially dilutive outstanding shares of common stock equivalents were excluded
from the computation of diluted net loss per share for loss periods presented because including them would have been antidilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A reconciliation of the numerator and denominator
used in the calculation of basic and diluted net loss per share attributable to stockholders follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zOBicJRIU8Q6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Basic and diluted net loss per share)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BD_z4534VW0VB3b" style="display: none"&gt;Schedule of reconciliation of basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ProfitLoss_c20240401__20240630_zRqXvkIA5F5g" style="width: 13%; text-align: right" title="Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share"&gt;(1,238,077&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ProfitLoss_c20230401__20230630_zluZTpibBKI" style="width: 13%; text-align: right" title="Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share"&gt;(1,464,557&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Weighted average shares outstanding used to compute basic and dilutive loss per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--WeightedAverageNumberOfSharesOutstandingBasic1_c20240401__20240630_zvbTvMv46EO1" style="text-align: right" title="Weighted average shares outstanding used to compute basic and dilutive loss per share"&gt;8,208,281&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--WeightedAverageNumberOfSharesOutstandingBasic1_c20230401__20230630_zHC2O3Vhjsf2" style="text-align: right" title="Weighted average shares outstanding used to compute basic and dilutive loss per share"&gt;505,485&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Weighted average shares issuable for vested restricted stock units&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c20240401__20240630_z7cyP1rhrlYj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average shares issuable for vested restricted stock units"&gt;8,743&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c20230401__20230630_zxg6eTNXwjHg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average shares issuable for vested restricted stock units"&gt;12,494&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_zHkoSbbSqQVl" title="Weighted average shares of common stock outstanding, basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zttpRmKIGWJb" title="Weighted average shares of common stock outstanding, diluted"&gt;8,217,024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630_zL11xWBCdfef" title="Weighted average shares of common stock outstanding, basic"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630_zEanN7LkPm0i" title="Weighted average shares of common stock outstanding, diluted"&gt;517,979&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&lt;/p&gt;





&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Dilutive securities)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Six Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ProfitLoss_c20240101__20240630_zQezW8C3z1I8" style="width: 13%; text-align: right" title="Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share"&gt;(3,637,180&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ProfitLoss_c20230101__20230630_ziLnBC20sjWj" style="width: 13%; text-align: right" title="Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share"&gt;(2,648,017&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Weighted average shares outstanding used to compute basic and dilutive loss per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--WeightedAverageNumberOfSharesOutstandingBasic1_c20240101__20240630_z8wEh4n4P4o6" style="text-align: right" title="Weighted average shares outstanding used to compute basic and dilutive loss per share"&gt;6,817,419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--WeightedAverageNumberOfSharesOutstandingBasic1_c20230101__20230630_zvbL6WdrpmAg" style="text-align: right" title="Weighted average shares outstanding used to compute basic and dilutive loss per share"&gt;498,415&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Weighted average shares issuable for vested restricted stock units&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c20240101__20240630_zS2qQxKYUMik" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average shares issuable for vested restricted stock units"&gt;12,406&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c20230101__20230630_z2vkQKGEftQe" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average shares issuable for vested restricted stock units"&gt;9,084&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_zDW2ANguK92g" title="Weighted average shares of common stock outstanding, basic"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zjvrwv6h73y2" title="Weighted average shares of common stock outstanding, diluted"&gt;6,829,825&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630_zNxkDGSoU7q9" title="Weighted average shares of common stock outstanding, basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630_zuNTUzpSSISb" title="Weighted average shares of common stock outstanding, diluted"&gt;507,499&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_z1G6C1gFphj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following outstanding potentially dilutive
securities were excluded from the weighted average calculation of dilutive loss per share attributable to common stockholders because
their impact would have been antidilutive for the period presented:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMLYqGufMkN6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Dilutive securities)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BC_zIU952YOod9a" style="display: none"&gt;Schedule of anti-dilutive securities excluded from computation of earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;June 30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;June 30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%"&gt;Warrants&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_z6O5fIgId0sg" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;10,666,674&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zVoXztMvdzk7" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;219,910&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zUdurxZWOqm5" style="text-align: right" title="Antidilutive shares"&gt;4,853&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zp1OkIoaM1R4" style="text-align: right" title="Antidilutive shares"&gt;43,276&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Stock options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zqXA7perEKUd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares"&gt;169,458&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zn1xY5JHgPaj" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares"&gt;171,176&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630_zwDiURYaUSil" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares"&gt;10,840,985&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630_zr5181425Buk" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares"&gt;434,362&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001296">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zOBicJRIU8Q6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Basic and diluted net loss per share)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BD_z4534VW0VB3b" style="display: none"&gt;Schedule of reconciliation of basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ProfitLoss_c20240401__20240630_zRqXvkIA5F5g" style="width: 13%; text-align: right" title="Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share"&gt;(1,238,077&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ProfitLoss_c20230401__20230630_zluZTpibBKI" style="width: 13%; text-align: right" title="Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share"&gt;(1,464,557&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Weighted average shares outstanding used to compute basic and dilutive loss per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--WeightedAverageNumberOfSharesOutstandingBasic1_c20240401__20240630_zvbTvMv46EO1" style="text-align: right" title="Weighted average shares outstanding used to compute basic and dilutive loss per share"&gt;8,208,281&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--WeightedAverageNumberOfSharesOutstandingBasic1_c20230401__20230630_zHC2O3Vhjsf2" style="text-align: right" title="Weighted average shares outstanding used to compute basic and dilutive loss per share"&gt;505,485&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Weighted average shares issuable for vested restricted stock units&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c20240401__20240630_z7cyP1rhrlYj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average shares issuable for vested restricted stock units"&gt;8,743&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c20230401__20230630_zxg6eTNXwjHg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average shares issuable for vested restricted stock units"&gt;12,494&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_zHkoSbbSqQVl" title="Weighted average shares of common stock outstanding, basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zttpRmKIGWJb" title="Weighted average shares of common stock outstanding, diluted"&gt;8,217,024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630_zL11xWBCdfef" title="Weighted average shares of common stock outstanding, basic"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630_zEanN7LkPm0i" title="Weighted average shares of common stock outstanding, diluted"&gt;517,979&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&lt;/p&gt;





&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Dilutive securities)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Six Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ProfitLoss_c20240101__20240630_zQezW8C3z1I8" style="width: 13%; text-align: right" title="Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share"&gt;(3,637,180&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ProfitLoss_c20230101__20230630_ziLnBC20sjWj" style="width: 13%; text-align: right" title="Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share"&gt;(2,648,017&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Weighted average shares outstanding used to compute basic and dilutive loss per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--WeightedAverageNumberOfSharesOutstandingBasic1_c20240101__20240630_z8wEh4n4P4o6" style="text-align: right" title="Weighted average shares outstanding used to compute basic and dilutive loss per share"&gt;6,817,419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--WeightedAverageNumberOfSharesOutstandingBasic1_c20230101__20230630_zvbL6WdrpmAg" style="text-align: right" title="Weighted average shares outstanding used to compute basic and dilutive loss per share"&gt;498,415&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Weighted average shares issuable for vested restricted stock units&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c20240101__20240630_zS2qQxKYUMik" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average shares issuable for vested restricted stock units"&gt;12,406&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c20230101__20230630_z2vkQKGEftQe" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average shares issuable for vested restricted stock units"&gt;9,084&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_zDW2ANguK92g" title="Weighted average shares of common stock outstanding, basic"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zjvrwv6h73y2" title="Weighted average shares of common stock outstanding, diluted"&gt;6,829,825&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630_zNxkDGSoU7q9" title="Weighted average shares of common stock outstanding, basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630_zuNTUzpSSISb" title="Weighted average shares of common stock outstanding, diluted"&gt;507,499&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact001298"
      unitRef="USD">-1238077</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact001300"
      unitRef="USD">-1464557</us-gaap:ProfitLoss>
    <ACON:WeightedAverageNumberOfSharesOutstandingBasic1
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact001302"
      unitRef="Shares">8208281</ACON:WeightedAverageNumberOfSharesOutstandingBasic1>
    <ACON:WeightedAverageNumberOfSharesOutstandingBasic1
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      id="Fact001304"
      unitRef="Shares">505485</ACON:WeightedAverageNumberOfSharesOutstandingBasic1>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact001306"
      unitRef="Shares">8743</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      id="Fact001308"
      unitRef="Shares">12494</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact001310"
      unitRef="Shares">8217024</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact001312"
      unitRef="Shares">8217024</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      id="Fact001314"
      unitRef="Shares">517979</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      id="Fact001316"
      unitRef="Shares">517979</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact001320"
      unitRef="USD">-3637180</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact001322"
      unitRef="USD">-2648017</us-gaap:ProfitLoss>
    <ACON:WeightedAverageNumberOfSharesOutstandingBasic1
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact001324"
      unitRef="Shares">6817419</ACON:WeightedAverageNumberOfSharesOutstandingBasic1>
    <ACON:WeightedAverageNumberOfSharesOutstandingBasic1
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact001326"
      unitRef="Shares">498415</ACON:WeightedAverageNumberOfSharesOutstandingBasic1>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact001328"
      unitRef="Shares">12406</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact001330"
      unitRef="Shares">9084</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact001332"
      unitRef="Shares">6829825</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact001334"
      unitRef="Shares">6829825</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact001336"
      unitRef="Shares">507499</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact001338"
      unitRef="Shares">507499</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001340">&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMLYqGufMkN6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Dilutive securities)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BC_zIU952YOod9a" style="display: none"&gt;Schedule of anti-dilutive securities excluded from computation of earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;June 30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;June 30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%"&gt;Warrants&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_z6O5fIgId0sg" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;10,666,674&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zVoXztMvdzk7" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;219,910&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zUdurxZWOqm5" style="text-align: right" title="Antidilutive shares"&gt;4,853&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zp1OkIoaM1R4" style="text-align: right" title="Antidilutive shares"&gt;43,276&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Stock options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zqXA7perEKUd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares"&gt;169,458&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zn1xY5JHgPaj" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares"&gt;171,176&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630_zwDiURYaUSil" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares"&gt;10,840,985&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630_zr5181425Buk" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares"&gt;434,362&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-06-30_custom_WarrantsMember"
      decimals="INF"
      id="Fact001342"
      unitRef="Shares">10666674</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-06-30_custom_WarrantsMember"
      decimals="INF"
      id="Fact001344"
      unitRef="Shares">219910</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-06-30_custom_RestrictedStockUnitsMember"
      decimals="INF"
      id="Fact001346"
      unitRef="Shares">4853</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-06-30_custom_RestrictedStockUnitsMember"
      decimals="INF"
      id="Fact001348"
      unitRef="Shares">43276</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001350"
      unitRef="Shares">169458</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001352"
      unitRef="Shares">171176</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact001354"
      unitRef="Shares">10840985</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact001356"
      unitRef="Shares">434362</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001358">&lt;p id="xdx_801_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zzg2XxwG8CNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 13. &lt;span id="xdx_820_zBeXq9ZaQ4bf"&gt;STOCK BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;2022 Aclarion Equity Incentive Plan&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 21, 2022, in connection with the IPO,
the Company&#x2019;s 2022 Aclarion Equity Incentive Plan, or &#x201c;2022 Plan&#x201d;, went into effect. Our board of directors has appointed
the compensation committee of our board of directors as the committee under the 2022 Plan with the authority to administer the 2022 Plan.
The aggregate number of our shares of common stock that may be issued or used for reference purposes under the 2022 Plan is &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20220421__us-gaap--PlanNameAxis__custom--AclarionEquityIncentivePlan2022Member_zqcgf0zFWDnf" title="Number of common shares issued"&gt;125,000&lt;/span&gt; shares
(2,000,000 prior to the 2024 Stock Split), with an automatic increase on January 1st of each year, for a period of not more than ten years,
commencing on January 1st of the year following the year in which the initial public offering date (April 2022) occurs and ending on (and
including) January 1, 2032, in an amount equal to 5% of the total number of shares of Capital Stock outstanding on December 31st of the
preceding calendar year. Notwithstanding the foregoing, the Board may act prior to January 1st of a given year to provide that there will
be no January 1st increase in shares for such year or that the increase in shares for such year will be a lesser number of shares of Common
Stock than would otherwise occur pursuant to the preceding sentence.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of the year ended December 31, 2023, the aggregate
number of our shares of common stock that may be issued or used for reference purposes under the 2022 Plan was &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20231231__us-gaap--PlanNameAxis__custom--AclarionEquityIncentivePlan2022Member_zEy7ijCE1GK" title="Number of common shares issued"&gt;154,426&lt;/span&gt; (2,470,814 pre-split).
On January 1, 2024, the 2022 Plan had an automatic increase of 41,270 (660,311 pre-split) shares which was 5% of the total number of shares
of Capital Stock outstanding on December 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Options granted under the 2022 Plan may be incentive
stock options or non-statutory stock options, as determined by the administrator at the time of grant of an option. Restricted stock may
also be granted under the 2022 Plan. The options vest in accordance with the grant terms and are exercisable for a period of up to 10
years from grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20240101__20240630_z2uwhkqSJq7l" title="Options granted"&gt;No&lt;/span&gt; options were granted in the six months ended
June 30, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Nocimed, Inc. 2015 Stock Plan&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company maintains the Nocimed, Inc. 2015 Stock
Plan, or the &#x201c;Existing Plan&#x201d;, under which the Company could grant 152,558 shares (after giving effect to the 2024 Stock Split)
or options of the Company to our employees, consultants, and other service providers. The Company suspended the Existing Plan in connection
with the April 2022, initial public offering. The Company did not grant any stock options under the Existing Plan for the twelve months
ended December 31, 2022, and thereafter. No further awards will be granted under the Existing Plan, but awards granted prior to the suspension date will
continue in accordance with their terms and the terms of the Existing Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Determining Fair Value of Stock Options&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of each grant of stock options
was determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires
significant judgment to determine.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Valuation and Amortization Method &lt;/i&gt;&#x2014;The
Company estimates the fair value of its stock options using the Black-Scholes-Merton option-pricing model. This fair value is then amortized
over the requisite service periods of the awards.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Expected Term&lt;/i&gt;&#x2014;The Company estimates
the expected term of stock option by taking the average of the vesting term and the contractual term of the option, as illustrated by
the simplified method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Expected Volatility&lt;/i&gt;&#x2014;The expected
volatility is derived from the Company&#x2019;s expectations of future market volatility over the expected term of the options.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Risk-Free Interest Rate&lt;/i&gt;&#x2014;The risk-free
interest rate is based on the 10-year U.S. Treasury yield curve on the date of grant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Dividend Yield&lt;/i&gt;&#x2014;The dividend yield
assumption is based on the Company&#x2019;s history and expectation of no dividend payouts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Stock Award Activity &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of option activity under the Company&#x2019;s
incentive plans is as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z0YRy0CouXe1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK BASED COMPENSATION (Details - Option activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BF_z5ndK5Ip9mLc" style="display: none"&gt;Schedule of option activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Life (In Years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 49%"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240630_ziEbKKlajOQ4" style="width: 13%; text-align: right" title="Number of share options outstanding, Beginning"&gt;169,456&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630_ztzwJh2DJBsj" style="width: 13%; text-align: right" title="Weighted average exercise price, Beginning"&gt;31.15&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zhb47Tevujcl" title="Weighted average remaining contractual life"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20240101__20240630_zrSY25AjPoAg" style="text-align: right" title="Options granted"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20240101__20240630_zKsW4n8Ypfw6" style="text-align: right" title="Weighted average exercise price, Options granted"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_d0_c20240101__20240630_zwdp07jOO9Gf" style="text-align: right" title="Options exercised"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20240101__20240630_z3gf1yCre7jj" style="text-align: right" title="Weighted average exercise price, Options exercised"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Options forfeited/expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d0_c20240101__20240630_zRKrgkTLHmOi" style="border-bottom: Black 1pt solid; text-align: right" title="Options forfeited or expired"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20240101__20240630_zM9MSTKUhKPa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Options forfeited or expired"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240630_zgGpyxoeCIuj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of share options outstanding, Ending"&gt;169,456&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630_zmLnIcsg8aY8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Ending"&gt;31.15&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630_zpAxW2DRAvvf" title="Weighted average remaining contractual life"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Exercisable at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231_zRQKl506Bqbd" style="text-align: right" title="Options exercisable"&gt;147,977&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231_z9oGo4nj6li1" style="text-align: right" title="Weighted average exercise price, Option exercisable"&gt;30.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_z139Zn2yr4Mg" title="weighted average remaining contractual life, Options exercisable"&gt;7.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercisable at June 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630_z0DZmV1BTCSi" style="text-align: right" title="Options exercisable"&gt;154,971&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240630_zXshqrmyo0W8" style="text-align: right" title="Weighted average exercise price, Option exercisable"&gt;30.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240630_ztmuQ0k80rK" title="Weighted average remaining contractual life, Options exercisable"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The aggregate intrinsic value of options outstanding
at June 30, 2024 is $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20240101__20240630_zv709ybiOnD2" title="Intrinsic value options outstanding"&gt;0&lt;/span&gt;. The aggregate intrinsic value of vested and exercisable options at June 30, 2024 is $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240630__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zOdKuSwKZLd" title="Intrinsic value options exercised"&gt;0&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of June 30, 2024, there was approximately $&lt;span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20240630__us-gaap--AwardTypeAxis__custom--NonVestedStockOptionsMember_zCdAcK1Q1gKl" title="Unrecognized compensation cost"&gt;212,454&lt;/span&gt;
of total unrecognized compensation cost related to non-vested stock options, which is expected to be recognized over the next &lt;span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtM_c20240101__20240630__us-gaap--AwardTypeAxis__custom--NonVestedStockOptionsMember_zmtrVpzYoTUj" title="Unrecognized compensation cost, remaining term"&gt;15&lt;/span&gt; months.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Restricted Stock Units&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In the six months ended June 30, 2024, the Company
had &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_do_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z10gADxGBbPl" title="RSU's granted"&gt;no&lt;/span&gt; new grants of RSUs under the 2022 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Post-split RSU activity under the 2022 Plan was
as follows for the six months ended June 30, 2024:&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_znkXrAaqdKi2" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCK BASED COMPENSATION (Details - RSU activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B8_zlry3kkdAuRd" style="display: none"&gt;Schedule of RSU activity&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;RSU&#x2019;s&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted-Average Grant-Date Fair value per Unit&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nonvested as of December 31, 2023&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zePX4Qyrfiej" style="width: 14%; text-align: right" title="Number of Rsu shares outstanding, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15,749&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjpfSHqj9crd" style="width: 14%; text-align: right" title="Weighted average grant date fair value per unit, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.72&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zahTZfqSkZq5" style="text-align: right" title="RSU's granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ziHveFgJQBjj" style="text-align: right" title="RSU's granted, weighted-average grant date fair value per unit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vested&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zcmCPBhYXQZ" style="text-align: right" title="RSU's vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3,953&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNdV89pR7yXl" style="text-align: right" title="RSU's vested, weighted-average grant date fair value per unit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.30&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7U6sSahi0vf" style="border-bottom: black 1pt solid; text-align: right" title="RSU's forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(6,942&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMI4bZqbrpT1" style="border-bottom: black 1pt solid; text-align: right" title="RSU's forfeited, weighted-average grant date fair value per unit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13.42&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nonvested as of June 30, 2024&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zc83dXAXOWx3" style="border-bottom: black 2.25pt double; text-align: right" title="Number of Rsu shares outstanding, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,854&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvS4oeiGAyV8" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average grant date fair value per unit, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.20&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The grant date fair value for a RSU is the market
price of the common stock on the date of grant. The total share-based compensation expense related to RSUs recognized during the six months
ended June 30, 2024, was $&lt;span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxBXymiIEGRk" title="Share-based compensation expense"&gt;40,733&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of June 30, 2024, there was approximately $&lt;span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKOzNcOti995" title="Unrecognized compensation cost"&gt;2,735&lt;/span&gt;
total unrecognized compensation cost related to non-vested RSUs which is expected to be recognized over the next three months.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of June 30, 2024, the Company is obligated
to issue &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCZYvGt9SpF7" title="Obligated to issue share of common stock"&gt;7,539&lt;/span&gt; post-split shares of common stock associated with vested Restricted Stock Units.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Stock-based Compensation Expense&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes the total stock-based
compensation expense included in the Company&#x2019;s statements of operations for the periods presented:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zJu4tEMlReM2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK BASED COMPENSATION (Details - Share based compensation)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BC_zYuwJnv8gwP5" style="display: none"&gt;Schedule of stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three months ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Six months ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Sales and marketing&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zLOfSKVm9H6" style="width: 12%; text-align: right" title="Total stock-based compensation"&gt;12,605&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_z3jc3MI7sEhi" style="width: 12%; text-align: right" title="Total stock-based compensation"&gt;78,688&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zRB0FsyZiys4" style="width: 12%; text-align: right" title="Total stock-based compensation"&gt;40,733&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_z7yWBeNbyZm2" style="width: 12%; text-align: right" title="Total stock-based compensation"&gt;106,997&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zkdWfugvBio9" style="text-align: right" title="Total stock-based compensation"&gt;2,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zQ8KKpLlNz12" style="text-align: right" title="Total stock-based compensation"&gt;2,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z38BJhvIHmqi" style="text-align: right" title="Total stock-based compensation"&gt;4,110&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zV23PCvbPxqd" style="text-align: right" title="Total stock-based compensation"&gt;5,615&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zogvgu0lPfM" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation"&gt;55,644&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zf4C6vqufR21" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation"&gt;55,888&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zagqkI9NH7j8" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation"&gt;111,288&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zfZPA7ZVraN4" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation"&gt;106,551&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: white; text-align: left; padding-bottom: 2.5pt"&gt;Total share based compensation&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630_zrS0WUsqZy2l" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;70,305&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630_z4AHE4AehdS2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;136,631&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240630_z8II90fIOkr2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;156,131&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230630_zZMVK0sXPuyk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;219,162&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2022-04-21_custom_AclarionEquityIncentivePlan2022Member"
      decimals="INF"
      id="Fact001360"
      unitRef="Shares">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2023-12-31_custom_AclarionEquityIncentivePlan2022Member"
      decimals="INF"
      id="Fact001362"
      unitRef="Shares">154426</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact001364"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001369">&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z0YRy0CouXe1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK BASED COMPENSATION (Details - Option activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BF_z5ndK5Ip9mLc" style="display: none"&gt;Schedule of option activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Life (In Years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 49%"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240630_ziEbKKlajOQ4" style="width: 13%; text-align: right" title="Number of share options outstanding, Beginning"&gt;169,456&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630_ztzwJh2DJBsj" style="width: 13%; text-align: right" title="Weighted average exercise price, Beginning"&gt;31.15&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zhb47Tevujcl" title="Weighted average remaining contractual life"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20240101__20240630_zrSY25AjPoAg" style="text-align: right" title="Options granted"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20240101__20240630_zKsW4n8Ypfw6" style="text-align: right" title="Weighted average exercise price, Options granted"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_d0_c20240101__20240630_zwdp07jOO9Gf" style="text-align: right" title="Options exercised"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20240101__20240630_z3gf1yCre7jj" style="text-align: right" title="Weighted average exercise price, Options exercised"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Options forfeited/expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d0_c20240101__20240630_zRKrgkTLHmOi" style="border-bottom: Black 1pt solid; text-align: right" title="Options forfeited or expired"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20240101__20240630_zM9MSTKUhKPa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Options forfeited or expired"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240630_zgGpyxoeCIuj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of share options outstanding, Ending"&gt;169,456&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630_zmLnIcsg8aY8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Ending"&gt;31.15&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630_zpAxW2DRAvvf" title="Weighted average remaining contractual life"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Exercisable at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231_zRQKl506Bqbd" style="text-align: right" title="Options exercisable"&gt;147,977&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231_z9oGo4nj6li1" style="text-align: right" title="Weighted average exercise price, Option exercisable"&gt;30.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_z139Zn2yr4Mg" title="weighted average remaining contractual life, Options exercisable"&gt;7.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercisable at June 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630_z0DZmV1BTCSi" style="text-align: right" title="Options exercisable"&gt;154,971&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240630_zXshqrmyo0W8" style="text-align: right" title="Weighted average exercise price, Option exercisable"&gt;30.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240630_ztmuQ0k80rK" title="Weighted average remaining contractual life, Options exercisable"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001371"
      unitRef="Shares">169456</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001373"
      unitRef="USDPShares">31.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-012023-12-31" id="Fact001375">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact001377"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact001379"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact001381"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact001383"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact001385"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact001387"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact001389"
      unitRef="Shares">169456</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact001391"
      unitRef="USDPShares">31.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2024-01-01to2024-06-30" id="Fact001393">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001395"
      unitRef="Shares">147977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001397"
      unitRef="USDPShares">30.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-01-012023-12-31" id="Fact001399">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact001401"
      unitRef="Shares">154971</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact001403"
      unitRef="USDPShares">30.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2024-01-01to2024-06-30" id="Fact001405">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact001410"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2024-01-012024-06-30_us-gaap_OptionMember"
      decimals="0"
      id="Fact001412"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2024-06-30_custom_NonVestedStockOptionsMember"
      decimals="0"
      id="Fact001414"
      unitRef="USD">212454</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2024-01-012024-06-30_custom_NonVestedStockOptionsMember"
      id="Fact001416">P15M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001418"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001420">&lt;table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_znkXrAaqdKi2" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCK BASED COMPENSATION (Details - RSU activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B8_zlry3kkdAuRd" style="display: none"&gt;Schedule of RSU activity&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;RSU&#x2019;s&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted-Average Grant-Date Fair value per Unit&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nonvested as of December 31, 2023&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zePX4Qyrfiej" style="width: 14%; text-align: right" title="Number of Rsu shares outstanding, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15,749&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjpfSHqj9crd" style="width: 14%; text-align: right" title="Weighted average grant date fair value per unit, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.72&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zahTZfqSkZq5" style="text-align: right" title="RSU's granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ziHveFgJQBjj" style="text-align: right" title="RSU's granted, weighted-average grant date fair value per unit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vested&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zcmCPBhYXQZ" style="text-align: right" title="RSU's vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3,953&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNdV89pR7yXl" style="text-align: right" title="RSU's vested, weighted-average grant date fair value per unit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.30&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7U6sSahi0vf" style="border-bottom: black 1pt solid; text-align: right" title="RSU's forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(6,942&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMI4bZqbrpT1" style="border-bottom: black 1pt solid; text-align: right" title="RSU's forfeited, weighted-average grant date fair value per unit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13.42&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nonvested as of June 30, 2024&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zc83dXAXOWx3" style="border-bottom: black 2.25pt double; text-align: right" title="Number of Rsu shares outstanding, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,854&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvS4oeiGAyV8" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average grant date fair value per unit, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.20&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001422"
      unitRef="Shares">15749</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001424"
      unitRef="USDPShares">10.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001426"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001428"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001430"
      unitRef="Shares">3953</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001432"
      unitRef="USDPShares">10.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001434"
      unitRef="Shares">6942</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001436"
      unitRef="USDPShares">13.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001438"
      unitRef="Shares">4854</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001440"
      unitRef="USDPShares">7.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact001442"
      unitRef="USD">40733</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact001444"
      unitRef="USD">2735</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001446"
      unitRef="Shares">7539</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001448">&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zJu4tEMlReM2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK BASED COMPENSATION (Details - Share based compensation)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BC_zYuwJnv8gwP5" style="display: none"&gt;Schedule of stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three months ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Six months ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Sales and marketing&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zLOfSKVm9H6" style="width: 12%; text-align: right" title="Total stock-based compensation"&gt;12,605&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_z3jc3MI7sEhi" style="width: 12%; text-align: right" title="Total stock-based compensation"&gt;78,688&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zRB0FsyZiys4" style="width: 12%; text-align: right" title="Total stock-based compensation"&gt;40,733&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_z7yWBeNbyZm2" style="width: 12%; text-align: right" title="Total stock-based compensation"&gt;106,997&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zkdWfugvBio9" style="text-align: right" title="Total stock-based compensation"&gt;2,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zQ8KKpLlNz12" style="text-align: right" title="Total stock-based compensation"&gt;2,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z38BJhvIHmqi" style="text-align: right" title="Total stock-based compensation"&gt;4,110&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zV23PCvbPxqd" style="text-align: right" title="Total stock-based compensation"&gt;5,615&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zogvgu0lPfM" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation"&gt;55,644&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zf4C6vqufR21" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation"&gt;55,888&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zagqkI9NH7j8" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation"&gt;111,288&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zfZPA7ZVraN4" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation"&gt;106,551&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: white; text-align: left; padding-bottom: 2.5pt"&gt;Total share based compensation&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630_zrS0WUsqZy2l" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;70,305&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630_z4AHE4AehdS2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;136,631&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240630_z8II90fIOkr2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;156,131&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230630_zZMVK0sXPuyk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;219,162&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_SellingAndMarketingExpenseMember"
      decimals="0"
      id="Fact001450"
      unitRef="USD">12605</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-04-012023-06-30_us-gaap_SellingAndMarketingExpenseMember"
      decimals="0"
      id="Fact001452"
      unitRef="USD">78688</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-06-30_us-gaap_SellingAndMarketingExpenseMember"
      decimals="0"
      id="Fact001454"
      unitRef="USD">40733</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-06-30_us-gaap_SellingAndMarketingExpenseMember"
      decimals="0"
      id="Fact001456"
      unitRef="USD">106997</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001458"
      unitRef="USD">2055</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-04-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001460"
      unitRef="USD">2055</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001462"
      unitRef="USD">4110</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001464"
      unitRef="USD">5615</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001466"
      unitRef="USD">55644</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-04-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001468"
      unitRef="USD">55888</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001470"
      unitRef="USD">111288</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001472"
      unitRef="USD">106551</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact001474"
      unitRef="USD">70305</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact001476"
      unitRef="USD">136631</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact001478"
      unitRef="USD">156131</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact001480"
      unitRef="USD">219162</us-gaap:ShareBasedCompensation>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact001482">&lt;p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_z3VOft7VDVoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 14. &lt;span id="xdx_82F_zUyUP3ABlnAa"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Common Stock Subscription Agreement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 12, 2024, we entered into a subscription
agreement with an institutional investor, pursuant to which the Company agreed to issue and sell to the investor 400,000 shares of Common
Stock of the Company at a price of $0.29 per share for gross proceeds to the Company of $116,000.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The shares were issued pursuant to the Company&#x2019;s
Form 1-A Offering Statement initially filed by the Company with the Securities and Exchange Commission under the Securities Act of 1933,
as amended on June 11, 2024 and qualified on June 24, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Exchange Agreements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In May, September and November 2023 the Company
issued $2,594,118 aggregate principal amount of unsecured non-convertible notes to certain accredited investors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Between January 22 and January 29, 2024, the Company
entered into a series of exchange agreements (the &#x201c;Exchange Agreements&#x201d;) with the accredited investors to exchange principal
and accrued interest on these notes for shares of common stock. Pursuant to the Exchange Agreements, the Company issued an aggregate of
644,142 post-split shares of common stock in exchange for $1,519,779 principal and accrued interest on the notes. Following these exchanges,
the remaining outstanding balance of principal and interest on the notes was $1,145,037.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On March 6, 2024, the
Company paid $300,973 of principal and accrued interest on certain unsecured non-convertible notes. Following this payment, the remaining
outstanding balance of principal and interest on the notes was $898,380.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 14, 2024, the Company entered into an
additional exchange agreement with the accredited investors to exchange $930,052 principal and accrued interest on these notes for newly
issued shares of Series B convertible preferred stock. Following this exchange, there was no remaining outstanding balance of principal
and interest on the notes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact001238"
          xlink:label="Fact001238"
          xlink:type="locator"/>
        <link:footnote id="Footnote001291" xlink:label="Footnote001291" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">These
    warrants were issued as part of the Company&#x2019;s initial public offering completed April 2022, and trade on Nasdaq under the
    ticker symbol &#x201c;ACONW.&#x201d;</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001238"
          xlink:to="Footnote001291"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001240"
          xlink:label="Fact001240"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001240"
          xlink:to="Footnote001291"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001242"
          xlink:label="Fact001242"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001242"
          xlink:to="Footnote001291"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001244"
          xlink:label="Fact001244"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001244"
          xlink:to="Footnote001291"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001261"
          xlink:label="Fact001261"
          xlink:type="locator"/>
        <link:footnote id="Footnote001292" xlink:label="Footnote001292" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The per share exercise price of these warrants is subject to a &#x201c;ratchet&#x201d; adjustment if the Company issues securities at an effective per share price lower than the then effective warrant exercise price. The strike price of $0.29 is current through the equity line activity closed April 26, 2024.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001261"
          xlink:to="Footnote001292"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001263"
          xlink:label="Fact001263"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001263"
          xlink:to="Footnote001292"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001265"
          xlink:label="Fact001265"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001265"
          xlink:to="Footnote001292"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001267"
          xlink:label="Fact001267"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001267"
          xlink:to="Footnote001292"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001268"
          xlink:label="Fact001268"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001268"
          xlink:to="Footnote001292"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001270"
          xlink:label="Fact001270"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001270"
          xlink:to="Footnote001292"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001272"
          xlink:label="Fact001272"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001272"
          xlink:to="Footnote001292"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001274"
          xlink:label="Fact001274"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001274"
          xlink:to="Footnote001292"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807656117264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">POS AM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">Updated S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Aclarion,
Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001635077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3324725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8181 Arista Place<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite
100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Broomfield<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">80021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">275-2266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807644844368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,172,687<span></span>
</td>
<td class="nump">$ 1,021,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">19,713<span></span>
</td>
<td class="nump">13,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaids and other current assets</a></td>
<td class="nump">649,357<span></span>
</td>
<td class="nump">245,030<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,851,757<span></span>
</td>
<td class="nump">1,289,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,189<span></span>
</td>
<td class="nump">1,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">1,235,875<span></span>
</td>
<td class="nump">1,168,623<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">1,237,064<span></span>
</td>
<td class="nump">1,170,405<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">3,088,821<span></span>
</td>
<td class="nump">2,459,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">179,123<span></span>
</td>
<td class="nump">760,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">447,972<span></span>
</td>
<td class="nump">857,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNotesPayableCurrent', window );">Note payable, net of discount</a></td>
<td class="nump">777,087<span></span>
</td>
<td class="nump">1,125,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_WarrantLiabilityCurrent', window );">Warrant liability</a></td>
<td class="nump">23,861<span></span>
</td>
<td class="nump">289,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability</a></td>
<td class="nump">18,601<span></span>
</td>
<td class="nump">121,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_LiabilityToIssueEquity', window );">Liability to issue equity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,297<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,446,644<span></span>
</td>
<td class="nump">3,187,769<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,446,644<span></span>
</td>
<td class="nump">3,187,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $0.00001 par value, 200,000,000 authorized and 8,210,671 and 825,459 shares issued and outstanding (see Note 11)</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">49,560,800<span></span>
</td>
<td class="nump">43,553,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(47,918,705)<span></span>
</td>
<td class="num">(44,281,526)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">1,642,177<span></span>
</td>
<td class="num">(727,995)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">$ 3,088,821<span></span>
</td>
<td class="nump">$ 2,459,774<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_LiabilityToIssueEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_LiabilityToIssueEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_WarrantLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_WarrantLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807647150944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">8,210,671<span></span>
</td>
<td class="nump">825,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">8,210,671<span></span>
</td>
<td class="nump">825,459<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807640411280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 10,971<span></span>
</td>
<td class="nump">$ 17,072<span></span>
</td>
<td class="nump">$ 21,085<span></span>
</td>
<td class="nump">$ 42,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">23,294<span></span>
</td>
<td class="nump">19,301<span></span>
</td>
<td class="nump">42,770<span></span>
</td>
<td class="nump">36,754<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit (loss)</a></td>
<td class="num">(12,323)<span></span>
</td>
<td class="num">(2,229)<span></span>
</td>
<td class="num">(21,685)<span></span>
</td>
<td class="nump">5,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">225,037<span></span>
</td>
<td class="nump">207,790<span></span>
</td>
<td class="nump">406,094<span></span>
</td>
<td class="nump">385,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">202,102<span></span>
</td>
<td class="nump">250,006<span></span>
</td>
<td class="nump">441,143<span></span>
</td>
<td class="nump">454,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">696,099<span></span>
</td>
<td class="nump">946,175<span></span>
</td>
<td class="nump">1,541,947<span></span>
</td>
<td class="nump">1,753,774<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,123,238<span></span>
</td>
<td class="nump">1,403,971<span></span>
</td>
<td class="nump">2,389,184<span></span>
</td>
<td class="nump">2,593,253<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) from operations</a></td>
<td class="num">(1,135,561)<span></span>
</td>
<td class="num">(1,406,200)<span></span>
</td>
<td class="num">(2,410,869)<span></span>
</td>
<td class="num">(2,587,465)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expense</a></td>
<td class="num">(127,848)<span></span>
</td>
<td class="num">(47,139)<span></span>
</td>
<td class="num">(463,672)<span></span>
</td>
<td class="num">(48,519)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_LossOnExchangeOfDebt', window );">Loss on exchange of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,066,732)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(111,928)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Changes in fair value of warrant and derivative liabilities</a></td>
<td class="nump">25,357<span></span>
</td>
<td class="num">(11,800)<span></span>
</td>
<td class="nump">323,041<span></span>
</td>
<td class="num">(11,800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(25)<span></span>
</td>
<td class="nump">583<span></span>
</td>
<td class="nump">92,980<span></span>
</td>
<td class="num">(234)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(102,516)<span></span>
</td>
<td class="num">(58,356)<span></span>
</td>
<td class="num">(1,226,311)<span></span>
</td>
<td class="num">(60,552)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="num">(1,238,077)<span></span>
</td>
<td class="num">(1,464,557)<span></span>
</td>
<td class="num">(3,637,180)<span></span>
</td>
<td class="num">(2,648,017)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(1,238,077)<span></span>
</td>
<td class="num">(1,464,557)<span></span>
</td>
<td class="num">(3,637,180)<span></span>
</td>
<td class="num">(2,648,017)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) allocable to common stockholders</a></td>
<td class="num">$ (1,238,077)<span></span>
</td>
<td class="num">$ (1,464,557)<span></span>
</td>
<td class="num">$ (3,637,180)<span></span>
</td>
<td class="num">$ (2,648,017)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share allocable to common shareholders, basic</a></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (2.83)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (5.22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share allocable to common shareholders, diluted</a></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (2.83)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (5.22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding, basic</a></td>
<td class="nump">8,217,024<span></span>
</td>
<td class="nump">517,979<span></span>
</td>
<td class="nump">6,829,825<span></span>
</td>
<td class="nump">507,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding, diluted</a></td>
<td class="nump">8,217,024<span></span>
</td>
<td class="nump">517,979<span></span>
</td>
<td class="nump">6,829,825<span></span>
</td>
<td class="nump">507,499<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_LossOnExchangeOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_LossOnExchangeOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807638646736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Preferred Stock Series A [Member]</div></th>
<th class="th"><div>Preferred Stock Series A 1 A 2 A 3 A 4 [Member]</div></th>
<th class="th"><div>Preferred Stock Series B B 1 [Member]</div></th>
<th class="th"><div>Preferred Stock Series B 2 B 3 [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 41,596,106<span></span>
</td>
<td class="num">$ (39,370,153)<span></span>
</td>
<td class="nump">$ 2,225,958<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">491,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">82,531<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">82,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_ProceedsFromSaleOfSeriesPreferredStock', window );">Proceeds from sale of Series A preferred stock</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_PreferredStockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from sale of Series A preferred stock, shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_RedemptionOfSeriesPreferredStock', window );">Redemption of Series A Preferred stock</a></td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_RedemptionOfSeriesPreferredStockShares', window );">Redemption of Series A Preferred stock, shares</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,183,460)<span></span>
</td>
<td class="num">(1,183,460)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">41,678,637<span></span>
</td>
<td class="num">(40,553,613)<span></span>
</td>
<td class="nump">1,125,029<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">491,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">41,596,106<span></span>
</td>
<td class="num">(39,370,153)<span></span>
</td>
<td class="nump">2,225,958<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">491,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,648,017)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2023</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">42,028,387<span></span>
</td>
<td class="num">(42,018,169)<span></span>
</td>
<td class="nump">10,223<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">512,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">41,678,637<span></span>
</td>
<td class="num">(40,553,613)<span></span>
</td>
<td class="nump">1,125,029<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">491,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">136,631<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">136,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_CommitmentSharesNoteFinancing', window );">Commitment shares - note financing</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">175,619<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">175,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_CommitmentSharesNoteFinancingShares', window );">Commitment shares - note financing, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_IssuanceOfWarrantsNoteFinancing', window );">Issuance of warrants - note financing</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">37,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,464,557)<span></span>
</td>
<td class="num">(1,464,557)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2023</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">42,028,387<span></span>
</td>
<td class="num">(42,018,169)<span></span>
</td>
<td class="nump">10,223<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">512,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">43,553,524<span></span>
</td>
<td class="num">(44,281,526)<span></span>
</td>
<td class="num">(727,995)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">825,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">85,827<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">85,827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common shares related to restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common shares related to restricted stock units, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_IssuanceOfCommonSharesEquityLineOfCredit', window );">Issuance of common shares - equity line of credit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">1,449,527<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,449,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_IssuanceOfCommonSharesEquityLineOfCreditShares', window );">Issuance of common shares - equity line of credit, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">452,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_IssuanceOfCommitmentSharesNoteFinancing', window );">Issuance of commitment shares - note financing</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">33,297<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">33,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_IssuanceOfCommitmentSharesNoteFinancingShares', window );">Issuance of commitment shares - note financing, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_CashlessExerciseOfPrefundedWarrant', window );">Cashless exercise of pre-funded warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_CashlessExerciseOfPrefundedWarrantsShares', window );">Cashless exercise of pre-funded warrants, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts', window );">Issuance of common stock and warrants related to public offering, net issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">2,691,339<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,691,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares', window );">Issuance of common stock and warrants related to public offering, net issuance costs, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_PublicOfferingAndLineOfCreditIssuanceCosts', window );">Public offering and line of credit issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(399,106)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(399,106)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_IssuanceOfCommonSharesDebtForEquityExchange', window );">Issuance of common shares - debt for equity exchange</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">1,771,600<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,771,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_IssuanceOfCommonSharesDebtForEquityExchangeShares', window );">Issuance of common shares - debt for equity exchange, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_RoundUpConversionRelatedToReverseStockSplit', window );">Round up conversion related to reverse stock split</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_RoundUpConventionRelatedToReverseStockSplitShares', window );">Round up convention related to reverse stock split, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,399,102)<span></span>
</td>
<td class="num">(2,399,102)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2024</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">49,186,006<span></span>
</td>
<td class="num">(46,680,628)<span></span>
</td>
<td class="nump">2,505,449<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,153,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">43,553,524<span></span>
</td>
<td class="num">(44,281,526)<span></span>
</td>
<td class="num">(727,995)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">825,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,637,180)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2024</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">49,560,800<span></span>
</td>
<td class="num">(47,918,705)<span></span>
</td>
<td class="nump">1,642,177<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,210,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2024</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">49,186,006<span></span>
</td>
<td class="num">(46,680,628)<span></span>
</td>
<td class="nump">2,505,449<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,153,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">70,305<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">70,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common shares related to restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common shares related to restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_IssuanceOfCommonSharesEquityLineOfCredit', window );">Issuance of common shares - equity line of credit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">304,490<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">304,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_IssuanceOfCommonSharesEquityLineOfCreditShares', window );">Issuance of common shares - equity line of credit, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,238,077)<span></span>
</td>
<td class="num">(1,238,077)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2024</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">$ 49,560,800<span></span>
</td>
<td class="num">$ (47,918,705)<span></span>
</td>
<td class="nump">$ 1,642,177<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,210,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_CashlessExerciseOfPrefundedWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_CashlessExerciseOfPrefundedWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_CashlessExerciseOfPrefundedWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_CashlessExerciseOfPrefundedWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_CommitmentSharesNoteFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_CommitmentSharesNoteFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_CommitmentSharesNoteFinancingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_CommitmentSharesNoteFinancingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_IssuanceOfCommitmentSharesNoteFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_IssuanceOfCommitmentSharesNoteFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_IssuanceOfCommitmentSharesNoteFinancingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_IssuanceOfCommitmentSharesNoteFinancingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_IssuanceOfCommonSharesDebtForEquityExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_IssuanceOfCommonSharesDebtForEquityExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_IssuanceOfCommonSharesDebtForEquityExchangeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_IssuanceOfCommonSharesDebtForEquityExchangeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_IssuanceOfCommonSharesEquityLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_IssuanceOfCommonSharesEquityLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_IssuanceOfCommonSharesEquityLineOfCreditShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_IssuanceOfCommonSharesEquityLineOfCreditShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_IssuanceOfWarrantsNoteFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_IssuanceOfWarrantsNoteFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_PreferredStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_PreferredStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_ProceedsFromSaleOfSeriesPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_ProceedsFromSaleOfSeriesPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_PublicOfferingAndLineOfCreditIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_PublicOfferingAndLineOfCreditIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_RedemptionOfSeriesPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_RedemptionOfSeriesPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_RedemptionOfSeriesPreferredStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_RedemptionOfSeriesPreferredStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_RoundUpConventionRelatedToReverseStockSplitShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_RoundUpConventionRelatedToReverseStockSplitShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_RoundUpConversionRelatedToReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_RoundUpConversionRelatedToReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807637136512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (3,637,180)<span></span>
</td>
<td class="num">$ (2,648,017)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">90,864<span></span>
</td>
<td class="nump">79,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">156,131<span></span>
</td>
<td class="nump">219,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_GainLossOnExchangeOfDebt', window );">Loss on exchange of debt</a></td>
<td class="nump">1,066,732<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_GainsLossesOnExtinguishmentOfDebts', window );">Loss on extinguishment of debt</a></td>
<td class="nump">111,928<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred issuance costs</a></td>
<td class="nump">442,289<span></span>
</td>
<td class="nump">28,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value related to warrants and derivative</a></td>
<td class="num">(323,041)<span></span>
</td>
<td class="nump">11,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_NoncashInterestRelatedToBridgeFunding', window );">Non-cash interest related to bridge funding</a></td>
<td class="nump">49,116<span></span>
</td>
<td class="nump">14,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(5,115)<span></span>
</td>
<td class="nump">1,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaids and other current assets</a></td>
<td class="num">(405,657)<span></span>
</td>
<td class="nump">33,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(540,710)<span></span>
</td>
<td class="nump">57,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="num">(267,325)<span></span>
</td>
<td class="nump">241,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_IncreaseDecreaseInNotePayableNetOfDiscount', window );">Note payable, net of discount</a></td>
<td class="num">(31,129)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) operations</a></td>
<td class="num">(3,293,096)<span></span>
</td>
<td class="num">(1,960,653)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Intangible assets - Patents</a></td>
<td class="num">(157,523)<span></span>
</td>
<td class="num">(72,634)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) investing activities</a></td>
<td class="num">(157,523)<span></span>
</td>
<td class="num">(72,634)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock and warrants related to public offering, net deductions</a></td>
<td class="nump">2,691,391<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from equity line</a></td>
<td class="nump">1,754,032<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of promissory notes</a></td>
<td class="num">(300,973)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_EquityLineOfCreditIssuanceCosts', window );">Equity line cash issuance costs</a></td>
<td class="num">(262,744)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Public offering cash issuance costs</a></td>
<td class="num">(256,094)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_BridgeFundingIssuanceCosts', window );">Bridge fund cash issuance costs</a></td>
<td class="num">(23,375)<span></span>
</td>
<td class="num">(85,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_ProceedsFromBridgeFunding', window );">Proceeds from bridge funding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from sale of Series A preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock', window );">Redemption of Series A Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">3,602,237<span></span>
</td>
<td class="nump">1,165,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">151,618<span></span>
</td>
<td class="num">(868,287)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">1,031,069<span></span>
</td>
<td class="nump">1,482,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">1,182,687<span></span>
</td>
<td class="nump">614,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_IssuanceOfCommonSharesInExchangeForDebt', window );">Issuance of common shares in exchange for debt</a></td>
<td class="nump">1,519,779<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_IssuanceOfBridgeFundCommitmentShares', window );">Issuance of bridge fund commitment shares</a></td>
<td class="nump">33,297<span></span>
</td>
<td class="nump">175,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_FairValueOfWarrantsAndDerivativeRelatedToBridgeFunding', window );">Fair value of warrants and derivative related to bridge funding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">742,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_AccruedDebtIssuanceCostsRelatedToBridgeFunding', window );">Accrued debt issuance costs related to bridge funding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">118,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_IssuanceOfWarrantsRelatedToBridgeFunding', window );">Issuance of warrants related to bridge funding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_OriginalIssueDiscount15RelatedToBridgeFunding', window );">Original issue discount (15%) related to bridge funding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 187,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_AccruedDebtIssuanceCostsRelatedToBridgeFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_AccruedDebtIssuanceCostsRelatedToBridgeFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_BridgeFundingIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_BridgeFundingIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_EquityLineOfCreditIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_EquityLineOfCreditIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_FairValueOfWarrantsAndDerivativeRelatedToBridgeFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_FairValueOfWarrantsAndDerivativeRelatedToBridgeFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_GainLossOnExchangeOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_GainLossOnExchangeOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_GainsLossesOnExtinguishmentOfDebts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_GainsLossesOnExtinguishmentOfDebts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_IncreaseDecreaseInNotePayableNetOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_IncreaseDecreaseInNotePayableNetOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_IssuanceOfBridgeFundCommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_IssuanceOfBridgeFundCommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_IssuanceOfCommonSharesInExchangeForDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_IssuanceOfCommonSharesInExchangeForDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_IssuanceOfWarrantsRelatedToBridgeFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_IssuanceOfWarrantsRelatedToBridgeFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_NoncashInterestRelatedToBridgeFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_NoncashInterestRelatedToBridgeFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_OriginalIssueDiscount15RelatedToBridgeFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_OriginalIssueDiscount15RelatedToBridgeFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_ProceedsFromBridgeFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_ProceedsFromBridgeFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire preferred stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807640842176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">THE COMPANY AND BASIS OF PRESENTATION</a></td>
<td class="text"><p id="xdx_804_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zMtdWvT9gXrj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE</b>&#160; <b>1. <span id="xdx_822_zka55zb6zZBd">THE COMPANY AND BASIS
OF PRESENTATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aclarion, Inc., formerly Nocimed, Inc., (the &#8220;Company&#8221;
or &#8220;Aclarion&#8221;) is a healthcare technology company that leverages magnetic resonance spectroscopy (&#8220;MRS&#8221;), and
a proprietary biomarker to optimize clinical treatments. The Company was formed in February 2015, is incorporated in Delaware, and has
its principal place of business in Broomfield, Colorado.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying condensed financial statements
have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) and
pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information.
Accordingly, they do not include all of the information required by U.S. GAAP for complete financial statements. The interim condensed
financial statements reflect all adjustments that are of a normal recurring nature and that are considered necessary for a fair representation
of the results for the periods presented and should be read in conjunction with the audited financial statements and notes thereto for
the year ended December 31, 2023, which include a complete set of footnote disclosures, including our significant accounting policies.
The December 31, 2023, condensed balance sheet was derived from the December 31, 2023, audited financial statements. They should be read
in conjunction with the financial statements and notes thereto included in our Annual report on Form 10-K, filed with the SEC on March
28, 2024. The results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or
for any other future period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks and Uncertainties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to various risks and uncertainties
frequently encountered by companies in the early stages of development. Such risks and uncertainties include, but are not limited to,
its limited operating history, competition from other companies, limited access to additional funds, dependence on key personnel, and
management of potential rapid growth. To address these risks, the Company must, among other things, develop its customer base&#894; implement
and successfully execute its business and marketing strategy&#894; develop follow-on products&#894; provide superior customer service&#894;
and attract, retain, and motivate qualified personnel. There can be no guarantee that the Company will be successful in addressing these
or other such risks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2024 Reverse Stock Split</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2023 the Company&#8217;s stockholders
approved a reverse stock split proposal at a ratio in the range of one-for-five to one-for-fifty, with the final ratio to be determined
by the Company's board in its discretion without further approval from the Company's stockholders. In January 2024, the Company's board
subsequently approved the final reverse stock split ratio of <span id="xdx_90A_eus-gaap--StockholdersEquityReverseStockSplit_c20240101__20240131__us-gaap--TransactionTypeAxis__custom--StockSplit2024Member_zKdEPfaEeWA1" title="Reverse stock split">one-for-sixteen</span> (the &#8220;2024 Stock Split&#8221;), which resulted in a
reduction in the number of outstanding shares of common stock, warrants, stock options and restricted share units and a proportionate
increase in the value of each share or strike price of the warrants and stock options. The common stock began trading on a reverse split-adjusted
basis on the NASDAQ on January 4, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the 2024 Stock Split, unless described
otherwise, all references to common stock, share data, per share data and related information contained in these financial statements
have been retrospectively adjusted to reflect the effect of the stock splits for all periods presented. In addition, any fractional shares
that would otherwise be issued as a result of the stock splits were rounded up to the nearest whole share. Further, the number of shares
issuable and exercise prices of stock options and warrants have been retrospectively adjusted in these financial statements for all periods
presented to reflect the 2024 Stock Split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables present selected share information
reflecting on a retroactive basis the reverse stock splits as of and for the year ended December 31, 2023:</p>

<table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfChangesToEquityStatementTableTextBlock_zZRvytdP8TH3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details - Balance sheet changes from split)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B1_z5fsJdtzTOkc" style="display: none">Schedule of equity statement information</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_zx70AX1o1z2a" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CommonStockValue_iI_pp0p0_hus-gaap--TransactionTypeAxis__custom--Pre2024SplitMember_z00mAK4ij0Y3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: left">Common shares issued and outstanding - pre-2024 split, <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_c20231231__us-gaap--TransactionTypeAxis__custom--Pre2024SplitMember_zzbiaUSo59Pd" title="Common stock shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--TransactionTypeAxis__custom--Pre2024SplitMember_zRXG7S1lnhA3" title="Common stock shares outstanding">13,206,229</span></span> shares</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">132</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CommonStockValue_iI_pp0p0_hus-gaap--TransactionTypeAxis__custom--Post2024SplitMember_zFLz567u1sZ2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common shares issued and outstanding - post-2024 split, <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20231231__us-gaap--TransactionTypeAxis__custom--Post2024SplitMember_zq5ZhNpBA2Yl" title="Common stock shares issued"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--TransactionTypeAxis__custom--Post2024SplitMember_zWAI9cspabM6" title="Common stock shares outstanding">825,459</span></span> shares</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_hus-gaap--TransactionTypeAxis__custom--Pre2024SplitMember_z36SUXsfVLUi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Additional paid-in capital - pre-2024 split</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">43,553,399</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_hus-gaap--TransactionTypeAxis__custom--Post2024SplitMember_z03MNEEJTmcj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additional paid-in capital - post-2024 split</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">43,553,523</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zo2yVaKiuuzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfRetroactiveBasisRreverseStockSplitsTableTextBlock_zhBkya5ufew7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details- Retroactive basis the reverse stock splits)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B9_zVL8x49ZagWc" style="display: none">Schedule of share information reflecting on a retroactive basis the reverse stock splits</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: left">Weighted average shares outstanding, basic and diluted - pre-2024 split</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PreSplitMember_zRCKpWECLsDk" title="Weighted average shares outstanding, basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PreSplitMember_ziZ01LCrKPSd" title="Weighted average shares outstanding, diluted">8,908,934</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average shares outstanding, basic and diluted - post-2024 split</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PostSplitMember_zNy0pB4jkdD" title="Weighted average shares outstanding, basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PostSplitMember_zyspSxsF3Cdd" title="Weighted average shares outstanding, diluted">556,808</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Basic and diluted net loss per shares attributable to common stockholders - pre-2024 split</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PreSplitMember_z9bzbcgtXBe2" title="Basic net loss per shares attributable to common stockholders"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PreSplitMember_z9zldA0n5aS8" title="Diluted net loss per shares attributable to common stockholders">(0.55</span></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Basic and diluted net loss per shares attributable to common stockholders - post-2024 split</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PostSplitMember_zbqirK9pCUt3" title="Basic net loss per shares attributable to common stockholders"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PostSplitMember_zqys2puH9Qhd" title="Diluted net loss per shares attributable to common stockholders">(8.82</span></span></td><td style="text-align: left">)</td></tr>
  </table>

<p id="xdx_8AF_zveFxll1R1M5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Nasdaq notice regarding <span style="background-color: white">compliance
with the $1.00 Minimum Bid Price requirement</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="background-color: white">&#160;</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="background-color: white"></span></b>On April 8, 2024, Aclarion, Inc. (the &#8220;Company&#8221;) received a written
notice (the &#8220;Notice&#8221;) from the Listing Qualifications Department of The Nasdaq Stock Market (&#8220;Nasdaq&#8221;) indicating
that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued
listing on The Nasdaq Capital Market (the &#8220;Bid Price Requirement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Notice does not result in the immediate delisting
of the Company&#8217;s common stock from The Nasdaq Capital Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Nasdaq Listing Rules require listed securities to maintain
a minimum bid price of $1.00 per share and, based upon the closing bid price of the Company&#8217;s common stock for the 30 consecutive
business days for the period ending April 5, 2024, the Company no longer meets this requirement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Notice indicated that the
Company will be provided 180 calendar days (or until October 7, 2024) in which to regain compliance. If at any time during this 180 calendar
day period the bid price of the Company&#8217;s common stock closes at or above $1.00 per share for a minimum of ten consecutive business
days, the Nasdaq staff (the &#8220;Staff&#8221;) will provide the Company with a written confirmation of compliance and the matter will
be closed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alternatively, if the Company fails to regain compliance with Rule 5550(a)(2) prior to the expiration of the initial
180 calendar day period, the Company may be eligible for an additional 180 calendar day compliance period, provided (i) it meets the
continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The
Nasdaq Capital Market (except for the Bid Price Requirement) and (ii) it provides written notice to Nasdaq of its intention to cure this
deficiency during the second compliance period by effecting a reverse stock split, if necessary. In the event the Company does not regain
compliance with Rule 5550(a)(2) prior to the expiration of the initial 180 calendar day period, and if it appears to the Staff that the
Company will not be able to cure the deficiency, or if the Company is not otherwise eligible, the Staff will provide the Company with
written notification that its securities are subject to delisting from The Nasdaq Capital Market. At that time, the Company may appeal
the delisting determination to a Hearings Panel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company intends to monitor the closing bid price of its common stock and
is considering its options to regain compliance with the Bid Price Requirement. The Company&#8217;s receipt of the Notice does not affect
the Company&#8217;s business, operations or reporting requirements with the Securities and Exchange Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nasdaq Stockholder Equity Notice</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 3, 2023, the Company received a written notice (the &#8220;Stockholder Equity Notice&#8221;) from Nasdaq indicating that it
is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Stock Market to maintain a minimum
of $2,500,000 in stockholders&#8217; equity for continued listing. In its annual report on Form 10-K filed on February 27, 2023 for the
period ended December 31, 2022, the Company reported stockholders&#8217; equity of $1,787,751, and, as a result, does not currently satisfy
Listing Rule 5550(b)(1).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Stockholder Equity Notice also indicated that the Company had a period of 45 calendar days
from the date of the Stockholder Equity Notice, or until April 17, 2023, to submit a plan to regain compliance with the stockholders&#8217;
equity requirement under Nasdaq Listing Rule 5550(b)(1). The Company submitted such a plan to Nasdaq on April 12, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April
20, 2023, the Company received a letter (the &#8220;Extension Notice&#8221;) from Nasdaq notifying the Company that it has been granted
an additional 180-day period, or until August 30, 2023, to regain compliance with Nasdaq Listing Rule 5550(b)(1).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31,
2023, the Nasdaq staff notified the Company that it had not met the terms of the Extension Notice. Accordingly, the Nasdaq staff had
determined to delist the Company&#8217;s common stock from Nasdaq, unless the Company timely requests an appeal of the staff&#8217;s
determination to a hearings panel (the &#8220;Panel&#8221;), pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company requested a hearing before a hearings panel (the &#8220;Panel&#8221;) to appeal the delisting notice from the staff.
The Company's hearing with the Panel occurred on October 19, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 7, 2023, we were notified by the Panel that the
Company&#8217;s request for continued listing on Nasdaq was granted, subject to the Company demonstrating compliance with the stockholders&#8217;
equity requirement and bid price requirement on or before January 31, 2024. The Panel subsequently extended this compliance date to February
27, 2024. On February 27, 2024, the Company completed a public offering of 5,175,000 units (&#8220;Units&#8221;) at a price of $0.58
per Unit, for gross proceeds of approximately $3.0 million, before deducting offering expenses. Each Unit was comprised of (i) one share
of common stock or, in lieu of common stock, one prefunded warrant to purchase a share of common stock, and (ii) two common warrants,
each common warrant to purchase a share of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 15, 2024, the Company filed a Quarterly Report on Form 10-Q for
the three months ending March 31, 2024, and reported stockholders&#8217; equity of $2,505,450.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2024, the Company had Stockholders&#8217;
Equity of $1,642,177.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807647125216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_z7gDNj0vRmL6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE</b>  <b>2. <span id="xdx_821_zZssDNNZtoL6">SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_849_eus-gaap--UseOfEstimates_ziG9kpLZ5Bff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_867_zn4BPLb1gMOa">Use of Estimates</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements include some amounts
that are based on management's best estimates and judgments. The most significant estimates relate to depreciation, amortization, and
valuation of warrants, warrant and derivative liabilities, and options to purchase shares of the Company's common stock. These estimates
may be adjusted as more current information becomes available, and any adjustment could be significant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>





<p id="xdx_84B_eus-gaap--DerivativesPolicyTextBlock_zQFUWdhps961" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86B_zvGU9YFgC5dg">Valuation of Derivative Instruments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial Accounting Standards Board (&#8220;FASB&#8221;)
Accounting Standards Codification (&#8220;ASC&#8221;) 815-40, <i>Derivatives and Hedging: Contracts on an Entity&#8217;s Own Equity</i>,
addresses whether an equity-linked contract qualifies as equity in the entity&#8217;s financial statements. Agreements where an entity
has insufficient authorized and unissued shares to settle the contract generally are accounted for as a liability and marked to fair value
through earnings each reporting period. The Company evaluates its financial instruments to determine if such instruments are liabilities
or contain features that qualify as embedded derivatives. For financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then revalued at each reporting date, with changes in the fair value reported
as charges or credits to income.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zRpqL0aSezma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_862_zO4Tn9Q11Wl1">Fair Value of Financial Instruments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820, Fair Value Measurements, provides guidance
on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price,
representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market
participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions
that market participants would use in pricing an asset or a liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accounting guidance classifies fair value
measurements in one of the following three categories for disclosure purposes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Level 1</i> - Unadjusted quoted prices
in active markets for identical instruments that are accessible by the Company on the measurement date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Level 2</i> - Quoted prices in markets
that are not active or inputs which are either directly or indirectly observable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Level 3</i> - Unobservable inputs
for the instrument requiring the development of assumptions by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company analyzes all financial instruments
with features of both liabilities and equity under the Financial Accounting Standard Board&#8217;s (&#8220;FASB&#8221;) accounting standard
for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level
of input that is significant to the fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying values of the Company&#8217;s financial
instruments including cash equivalents, restricted cash, accounts receivable, and accounts payable are approximately equal to their respective
fair values due to the relatively short-term nature of these instruments. The Company&#8217;s warrant liabilities and derivative liabilities
are estimated using level 3 inputs (see Note 3).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p id="xdx_841_eus-gaap--DerivativesReportingOfDerivativeActivity_zVoH8tcJ5E1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_864_z3ko8Qu0N10l">Derivative Financial Instruments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has derivative financial instruments
that are not hedges and do not qualify for hedge accounting. Changes in the fair value of these instruments are recorded in other income
(expenses), on a net basis in the Consolidated Statements of Operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zk0RdMwL3mnk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_864_zVRDtCC2yNvc">Cash and Cash Equivalents</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid
instruments purchased with an original maturity of three months or less to be cash equivalents. The Company had <span id="xdx_90F_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20240630_zJosY1pNcA8e" title="Cash equivalents"><span id="xdx_90F_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20231231_zQ3wey1WdzB5" title="Cash equivalents">no</span></span>
cash equivalents at June 30, 2024 and December 31, 2023. The Company maintains cash deposits at several financial institutions,
which are insured by the FDIC up to $250,000. The Company&#8217;s cash balance may at times exceed these limits. On June 30, 2024,
and December 31, 2023, the Company had $<span id="xdx_90A_eus-gaap--CashUninsuredAmount_pp0p0_c20240630_zvmXQ04QcOR4" title="Cash uninsured amount">818,591 </span>and
$<span id="xdx_905_eus-gaap--CashUninsuredAmount_iI_pp0p0_c20231231_zF4ZgR3wsS2i" title="Cash uninsured amount">761,800</span>,
respectively, in excess of federally insured limits. The Company continually monitors its positions with, and the credit quality of,
the financial institutions with which it invests. The Company maintains no international bank accounts. As of June 30, 2024, $<span id="xdx_90A_eus-gaap--RestrictedCash_pp0p0_c20240630_zjS4vKHk3vag" title="Restricted cash">10,000</span>
of the Company&#8217;s cash was restricted as collateral related to the credit card program offered by our bank.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84E_eus-gaap--ReceivablesPolicyTextBlock_zerACPyV9j7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86F_zcsnM77PyZQa">Accounts Receivable, Less Allowance for Doubtful
Accounts</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company estimates an allowance for doubtful
accounts based upon an evaluation of the current status of receivables, historical experience, and other factors as necessary. It is reasonably
possible that the Company&#8217;s estimate of the allowance for doubtful accounts will change. The allowance for doubtful accounts was
$<span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_c20240630_za2m8ElG0ibl" title="Allowance for doubtful accounts"><span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_c20231231_zSjpkmAhEE6k" title="Allowance for doubtful accounts">0</span></span> on June 30, 2024, and December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p id="xdx_84D_eus-gaap--RevenueRecognitionPolicyTextBlock_zsEL0fBsDPzh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_865_zqmMPrW88aq3">Revenue Recognition</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues are recognized when a contract with a
customer exists, and at that point in time when we have delivered a Nociscan report to our customer. Revenue is recognized in the amount
that reflects the negotiated consideration expected to be received in exchange for those reports. Following the delivery of the report,
the company has no ongoing obligations or services to provide to the customer. Customers pay no other upfront, licensing, or other fees.
To date, our reports are not reimbursable under any third-party payment arrangements, The Company invoices its customers based on the
billing schedules in its sales arrangements. Payment terms range generally from 30 to 90 days from the date of invoice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84C_ecustom--LiquidityCapitalResourcesAndGoingConcernPolicyTextBlock_z5a6J8nqvx05" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86F_zj66HsO4f93g">Liquidity, Capital Resources and Going Concern</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company believes that the net proceeds from
the February 2024 initial public offering, and subsequent funding from the April 2024 equity line agreement described in Note 11, will
be sufficient to fund current operating plans into the third quarter of 2024, approaching our final maturity repayment of our unsecured
non-convertible note, which is due in September 2024. The Company has based these estimates, however, on assumptions that may prove to
be wrong, and could spend available financial resources much faster than we currently expect. The Company will need to raise additional
funds to continue funding our technology development. Management plans to secure such additional funding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the Company&#8217;s recurring
losses from operations and the need for additional financing to fund its operating and capital requirements, there is uncertainty regarding
the Company&#8217;s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to
the Company&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_843_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zYhjdlqc7Rki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86A_zVMECq7BR5Ci">Share-Based Compensation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock-based awards in
accordance with provisions of ASC Topic 718, Compensation&#8212;Stock Compensation, under which the Company recognizes the grant-date
fair value of stock-based awards issued to employees and nonemployee board members as compensation expense on a straight-line basis over
the vesting period of the award, while awards containing a performance condition are recognized as expense when the achievement of the
performance criteria is achieved. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock
options. The Company records expense for forfeitures in the periods they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The exercise or strike price of each option is
not less than 100% of the fair market value of the Common Stock subject to the option on the date the option is granted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issues restricted stock unit awards
to non-employee consultants who are providing various services. The awards are valued at the market price on the date of the grant. The
awards vest over the contract life and based on achievement of targeted performance milestones.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On occasion, the Company grants common stock to
compensate vendors for services rendered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84B_eus-gaap--DeferredChargesPolicyTextBlock_zhAbqLlDwUt5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_865_zvEaGPLTAznc">Deferred Financing Costs</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company capitalizes certain legal, accounting,
and other fees and costs that are directly attributable to in-process equity financings as deferred offering costs until such financings
are completed. Upon the completion of an equity financing, these costs are recorded as a reduction of additional paid-in capital of the
related offering. Upon the completion of the public offering in February 2024, approximately $<span id="xdx_905_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20240201__20240229__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TransactionTypeAxis__custom--CompletionOfPublicOfferingMember_zE4lWkkHSuXd" title="Adjustment to additional paid in capital">566,200</span> of offering costs related to the
public offering were reclassified to additional paid-in capital ($310,105 deducted from proceeds, and $256,094 paid or accrued). Upon
the completion of the issuance of shares pursuant to the equity line in the first quarter of 2024, $<span id="xdx_909_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20240101__20240331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TransactionTypeAxis__custom--CompletionOfIssuanceOfSharesMember_zZUikbr0Sf4k">133,000</span> of offering costs were reclassified
to additional paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p id="xdx_84D_ecustom--EmergingGrowthCompanyStatusPolicyTextBlock_zJUuI0JP9rFb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_865_zEi2eT73N822">Emerging Growth Company Status</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is an emerging growth company, as
defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies
can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those
standards apply to private companies. The Company has elected to use this extended transition period to comply with certain new or revised
accounting standards that have different effective dates for public and private companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807647207952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p id="xdx_803_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zgrmGCl64dOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3: <span id="xdx_822_zVDsykCc31lf">FAIR VALUE MEASUREMENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 820 (Fair Value Measurements
and Disclosures), the Company uses various inputs to measure the outstanding warrants, certain embedded redemption features associated
with the senior note to Aclarion, Inc. on a recurring basis to determine the fair value of the liability.</p>

<table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_z5DHIjUGoj67" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details- Recurring basis to determine the fair value of the liability)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B8_zWsBf9xJ1UB8" style="display: none">Schedule of recurring basis to determine the fair value of the liability</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value measured as of June 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fair value on<br/> June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Quoted prices</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>in active</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>markets</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Level 1)</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Significant</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>other</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>observable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>inputs</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Level 2)</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Significant unobservable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>inputs</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Level 3)</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 40%; text-align: justify">Warrant liability</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_c20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zA998PkcuyZk" style="width: 12%; text-align: right" title="Total Fair value">23,861</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zoLgDjODusAg" style="width: 12%; text-align: right" title="Total Fair value">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zBYKvutvi8Ng" style="width: 12%; text-align: right" title="Total Fair value">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueNetAssetLiability_pp0p0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zLaohb2EEvqf" style="width: 12%; text-align: right" title="Total Fair value">23,861</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Derivative Liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_c20240630__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_zlfWBvMfTNoh" style="border-bottom: Black 1pt solid; text-align: right" title="Total Fair value">18,601</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_zfXnrkd37Wvl" style="border-bottom: Black 1pt solid; text-align: right" title="Total Fair value">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_z7h2kPtKhmVg" style="border-bottom: Black 1pt solid; text-align: right" title="Total Fair value">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueNetAssetLiability_pp0p0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_z0SijhPWVEma" style="border-bottom: Black 1pt solid; text-align: right" title="Total Fair value">18,601</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total Fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueNetAssetLiability_pp0p0_c20240630_z43pQYhHON8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Fair value">42,462</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z6bJ5xowjKLc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Fair value">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zwzpmUh6TWbi" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Fair value">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueNetAssetLiability_pp0p0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zM04iHzAvbXk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Fair value">42,462</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8AF_z3ybJzpQPRKk" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no transfers between Level 1, 2, and
3 during the six months ended June 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents changes in Level
3 liabilities measures at fair value for the six months ended June 30, 2024. Both observable and unobservable inputs were used to determine
the fair value positions that the Company has classified within the Level 3 category.</p>

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_ziPQmesJtQ7c" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Liabilities measures at fair value)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B0_zoX9EIuMPvmi" style="display: none">Schedule of liabilities measures at fair value</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zG0wTBSIxWt2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_zgv8BPVxntkh" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20240630_z0lU2wVoFOj5" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrant</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Liability</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Derivative</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Liability</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueHedgeLiabilitiesAtFairValue_iS_d0_zLtUPk9WPLzj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 49%">Balance &#8211; December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">289,165</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">121,326</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">410,491</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ExchangeAndPayoffOfNotesPayable_d0_zaS5H20uttU1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 9pt">Exchange and Payoff of Notes Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(44,988</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(44,988</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_zoD7OVLvy4Nc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 9pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(265,304</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(57,737</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(323,041</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--FairValueHedgeLiabilitiesAtFairValue_iE_zBA4hafI9HUk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance &#8211; June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">23,861</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,601</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">42,462</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8AB_z6dYD8CMFBy3" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the embedded derivative liabilities
associated with the Senior Notes Payable was estimated using a probability weighted discounted cash flow model to measure the fair value.
This involves significant Level 3 inputs and assumptions including an (i) estimated probability and timing of certain financing events
and event of default, and (ii) the Company&#8217;s risk-adjusted discount rate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the warrants to purchase shares
of common stock was estimated using a Monte Carlo simulation using the following assumptions.&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zmUoad8QJIye" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details- Fair value of the warrants)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B8_zFEAOSKhbGl7" style="display: none">Schedule of assumptions</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b><b>As of</b></b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b>Dec 31, 2023</b></p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b><b>As of</b></b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b>June 30, 2024</b></p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrant Liability</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrant Liability</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%">Strike Price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_905_eus-gaap--SharePrice_iI_c20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zOAACiCYM3Mc" title="Strike Price">4.32</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_909_eus-gaap--SharePrice_c20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zxP9Y65jeFVg" title="Strike Price">0.29</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Contractual term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zaz2aQfE56f2" title="Contractual term (years)">5.0</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zhS3Y0k1tA9a" title="Contractual term (years)">5.0</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Volatility (annual)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230101__20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zIpabLWtGOf3" title="Volatility (annual)">80.0</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zjcBHjV81VK6" title="Volatility (annual)">80.0</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230101__20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zHhsZBfMcWsc" title="Risk-free rate">3.89</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember__srt--RangeAxis__srt--MinimumMember_zLS5YTh5Wju3" title="Risk-free rate">4.39</span>-<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember__srt--RangeAxis__srt--MaximumMember_z6hRSb9ZgVR2" title="Risk-free rate">4.44</span>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Floor Financing price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_ecustom--FloorFinancingPrice_iI_c20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zchQoQsnIuza" title="Floor Financing price">2.24</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_ecustom--FloorFinancingPrice_c20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zySMHJETMa5f" title="Floor Financing price">0.14</span></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A9_zo7snNywcdEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/820/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807647154912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECENT ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">RECENT ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text"><p id="xdx_808_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zSdY292RwJ19" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE</b>&#160; <b>4. <span id="xdx_828_zrzMnZQQ0LQg">RECENT ACCOUNTING PRONOUNCEMENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, there have been no recent accounting
pronouncements not yet effective that have significance, or potential significance, to our Consolidated Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807647265856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE</a></td>
<td class="text"><p id="xdx_808_eus-gaap--RevenueFromContractWithCustomerTextBlock_zmRrrjg9Kjx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE</b>&#160; <b>5. <span id="xdx_826_z9TbXXEUwy4a">REVENUE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Contract Balances</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The timing of revenue recognition, billings, and
cash collections may result in trade, unbilled receivables, and deferred revenues on the balance sheets. At times, revenue recognition
may occur before the billing, resulting in an unbilled receivable, which would represent a contract asset. The contract asset would be
a component of accounts receivable and other assets for the current and non-current portions, respectively. In the event the Company receives
advances or deposits from customers before revenue is recognized, this would result in a contract liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807640757184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL FINANCIAL INFORMATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">SUPPLEMENTAL FINANCIAL INFORMATION</a></td>
<td class="text"><p id="xdx_802_eus-gaap--SupplementalBalanceSheetDisclosuresTextBlock_z38Paqrdbrtl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6. <span id="xdx_825_zc4ACJqUwL85">SUPPLEMENTAL FINANCIAL INFORMATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Balance Sheets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Prepaids and other current assets:</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zeNyOudskBJ1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Prepaids and other current assets)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B5_zK2pEwT8cpR" style="display: none">Schedule of prepaid and other current assets</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Short term deposits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--ShortTermDepositsMember_zb4aN5R8jCqg" style="width: 13%; text-align: right" title="Prepaids and other current assets">50,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--ShortTermDepositsMember_pp0p0" style="width: 13%; text-align: right" title="Prepaids and other current assets">50,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--DeferredOfferingCostsMember_zktWUjLur0Vi" style="text-align: right" title="Prepaids and other current assets">74,648</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--DeferredOfferingCostsMember_pp0p0" style="text-align: right" title="Prepaids and other current assets">100,588</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Prepaid insurance D&amp;O</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidInsuranceDAndOMember_z0Dq6pWKqSPf" style="text-align: right" title="Prepaids and other current assets">241,445</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidInsuranceDAndOMember_pp0p0" style="text-align: right" title="Prepaids and other current assets">34,769</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid insurance, other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidInsuranceMember_zQnE22F9Hp2a" style="text-align: right" title="Prepaids and other current assets">5,010</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidInsuranceMember_pp0p0" style="text-align: right" title="Prepaids and other current assets">17,884</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Prepaid clinical costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidClinicalCostsMember_z4NdHg9Wvrwj" style="text-align: right" title="Prepaids and other current assets">165,417</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_d0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidClinicalCostsMember_zWatJ1Hu44N1" style="text-align: right" title="Prepaids and other current assets">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid exchange fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidExchangeFeesMember_zJM5gk9Evs19" style="text-align: right" title="Prepaids and other current assets">53,720</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_d0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidExchangeFeesMember_zMfMHNbAAo04" style="text-align: right" title="Prepaids and other current assets">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Prepaid other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidOtherMember_zRBV1TXD6WMb" style="text-align: right" title="Prepaids and other current assets">59,117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidOtherMember_pp0p0" style="text-align: right" title="Prepaids and other current assets">41,635</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other receivables</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_d0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--OtherReceivablesMember_z5XNvq0Z7use" style="border-bottom: Black 1pt solid; text-align: right" title="Prepaids and other current assets">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--OtherReceivablesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Prepaids and other current assets">154</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_pp0p0_c20240630_zkKJiSoOyZwe" style="border-bottom: Black 2.5pt double; text-align: right" title="Prepaids and other current assets">649,357</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Prepaids and other current assets">245,030</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_z7C8U8F1Mml8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b>&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Accounts payable&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zTvrYeDxelCb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accounts payable)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B5_zSyxO9ISdGC9" style="display: none">Schedule of accounts payable</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Accounts payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableMember_zdUfHxMTEIEa" style="width: 13%; text-align: right" title="Accounts payable, current">177,610</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20231231__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableMember_zJoexTeiy02g" style="width: 13%; text-align: right" title="Accounts payable, current">758,821</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Credit cards payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--CreditCardsPayableMember_zVaRZmq7fgMi" style="border-bottom: Black 1pt solid; text-align: right" title="Accounts payable, current">1,513</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--CreditCardsPayableMember_zVNBgm4lGbQ1" style="border-bottom: Black 1pt solid; text-align: right" title="Accounts payable, current">1,714</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20240630_zF97TVRPQL9a" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts payable, current">179,123</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20231231_zI3iZs4JGxhk" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts payable, current">760,535</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zfLnjLm6PRz2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Accrued and other liabilities:</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zrTml1alRrec" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accrued and other liabilities)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B0_z8XLJzLqEuCe" style="display: none">Schedule of accrued and other liabilities</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Accrued payroll</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_d0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedPayrollMember_zuUB5QnUo5Gj" style="width: 13%; text-align: right" title="Accrued liabilities and other liabilities">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedPayrollMember_pp0p0" style="width: 13%; text-align: right" title="Accrued liabilities and other liabilities">162,887</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued bonus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedBonusMember_zMsVY1gUUsR1" style="text-align: right" title="Accrued liabilities and other liabilities">127,875</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedBonusMember_pp0p0" style="text-align: right" title="Accrued liabilities and other liabilities">262,580</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">D&amp;O financing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--DAndOFinancingMember_zjLLjX2IFC2" style="text-align: right" title="Accrued liabilities and other liabilities">126,605</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_d0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--DAndOFinancingMember_zFBb4u5EQxIj" style="text-align: right" title="Accrued liabilities and other liabilities">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued audit and legal expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedAuditAndLegalExpensesMember_zuRK6HTESlkl" style="text-align: right" title="Accrued liabilities and other liabilities">40,226</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedAuditAndLegalExpensesMember_pp0p0" style="text-align: right" title="Accrued liabilities and other liabilities">89,082</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedInterestMember_z7lMRjF6iPde" style="text-align: right" title="Accrued liabilities and other liabilities">58,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedInterestMember_pp0p0" style="text-align: right" title="Accrued liabilities and other liabilities">98,685</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued board compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedBoardCompensationMember_zexcHQEREEye" style="text-align: right" title="Accrued liabilities and other liabilities">46,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedBoardCompensationMember_pp0p0" style="text-align: right" title="Accrued liabilities and other liabilities">92,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--OtherAccruedLiabilitiesMember_zS0PkkCzetue" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued liabilities and other liabilities">48,350</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--OtherAccruedLiabilitiesMember_z8nqfOTF3aL6" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued liabilities and other liabilities">151,988</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_pp0p0_c20240630_zvVXBovpmAfi" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued liabilities and other liabilities">447,972</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued liabilities and other liabilities">857,722</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zjCBivLPC25h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b>&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807640843168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_804_eus-gaap--LesseeOperatingLeasesTextBlock_zGC3EjGPHWg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7. <span id="xdx_825_zTY09N13LGe1">LEASES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had <span id="xdx_905_eus-gaap--OperatingLeaseExpense_do_c20240101__20240630_zX8zSUxV5Z67" title="Office lease"><span id="xdx_909_eus-gaap--OperatingLeaseExpense_do_c20230101__20231231_zh4rWwxUDzig" title="Office lease">no</span></span> office lease for the quarter
ended June 30, 2024, and the year ended December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807640774128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_800_eus-gaap--IntangibleAssetsDisclosureTextBlock_z91wxPjcXXOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8. <span id="xdx_828_zKoSPnqWrXM">INTANGIBLE ASSETS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s intangible assets are as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zhB6FjHufG38" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS (Details - Intangible assets)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B1_zYNZ7On6vOw9" style="display: none">Schedule of intangible assets</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Patents and licenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember_zfZNiqzh3foj" style="width: 13%; text-align: right" title="Intangible assets gross">2,424,773</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember_z31PDMbOROfb" style="width: 13%; text-align: right" title="Intangible assets gross">2,267,251</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zXtlrxNqIsrc" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible assets gross">5,017</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zpYXKnkgRmdd" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible assets gross">5,017</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20240630_znK4725Bxe74" style="text-align: right" title="Intangible assets gross">2,429,790</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231_zGmbyoCwOype" style="text-align: right" title="Intangible assets gross">2,272,268</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: accumulated amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_pp0p0_c20240630_zW4Ue8YHjAAd" style="border-bottom: Black 1pt solid; text-align: right" title="Less: accumulated amortization">(1,193,915</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20231231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Less: accumulated amortization">(1,103,645</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Intangible assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_pp0p0_c20240630_zZgNolLTo23b" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">1,235,875</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_c20231231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">1,168,623</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8AC_z1Zqnm8VB3Wf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patents and licenses costs are accounted for as
intangible assets and amortized over the life of the patent or license agreement and charged to research and development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amortization expense related to purchased intangible
assets was $<span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20240401__20240630_zdW8DImGUUy" title="Amortization of intangible assets">45,458</span> and $<span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20230401__20230630_zissSmIK4bOd" title="Amortization of intangible assets">39,940</span> for the three months ended June 30, 2024, and 2023, respectively. Amortization expense related to purchased
intangible assets was $<span id="xdx_90A_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20240101__20240630_zawle9A08a0i" title="Amortization of intangible assets">90,270</span> and $<span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20230101__20230630_zYUnuCsn9CQj" title="Amortization of intangible assets">78,805</span> for the six months ended June 30, 2024, and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patents and trademarks are reviewed at least annually
for impairment. No impairment was recorded through June 30, 2024, and December 31, 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Future amortization of intangible assets is as
follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zVjC7kro9EO5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS (Details - Future amortization)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B9_zeB5K09APzF1" style="display: none">Schedule of future amortization of intangible assets</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20240630_zEz3tmZnbFS7" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">96,015</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">192,030</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">192,030</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">192,030</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">2028 and beyond</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">563,770</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherIntangibleAssetsNet_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,235,875</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8AF_zJmZzSpOfYo2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807647186480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHORT TERM NOTES AND CONVERTIBLE DEBT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">SHORT TERM NOTES AND CONVERTIBLE DEBT</a></td>
<td class="text"><p id="xdx_801_eus-gaap--DebtDisclosureTextBlock_zlJk15fg5pm4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE</b>&#160; <b>9. <span id="xdx_827_ziIBCsPkvEGi">SHORT TERM NOTES AND CONVERTIBLE
DEBT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Convertible Notes:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, there were <span id="xdx_90D_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_do_c20231231_znzzovgCIuZ9" title="Convertible notes payable outstanding">no</span> Convertible
Notes payable and outstanding. There was <span id="xdx_90C_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_do_c20240630_zfvyuEhxsTpe" title="Convertible notes payable outstanding">no</span> convertible note activity in the three months ended June 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Senior Notes Payable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2023, the Company issued $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20230531__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesPayableMember_ziQJNjOL2sqf" title="Debt instrument face amount">1,437,500</span>
unsecured senior notes with a maturity date of <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20230501__20230531__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesPayableMember_zAgQmBQ6t3C4" title="Maturity date">May
16, 2024</span> (&#8220;the Senior Notes Payable&#8221;), for cash proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromSecuredNotesPayable_c20230501__20230531__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesPayableMember_zzJOqzc4uGwi" title="Proceeds from secured notes payable">1,250,000</span>.
The Senior Notes Payable contained an original issue discount of <span id="xdx_908_ecustom--DebtOriginalIssueDiscountPercenrtage_iI_dp_c20230531__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesPayableMember_z50hrDNBIGNe" title="Original issue discount, percentage">15.0</span>%
and accrue interest at an annual rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20230531__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesPayableMember_zqodwGe3Med4" title="Annual rate percentage">8.0</span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2023, as agreed to during the
issuance of the Senior Notes Payable, the Company exercised their right to an additional financing, issuing $<span id="xdx_909_eus-gaap--UnsecuredDebt_iI_c20230930__us-gaap--LongtermDebtTypeAxis__custom--SeriesBNotesPayableMember_zZWI74uySrV9" title="Issuing unsecured senior notes">862,500</span>
unsecured senior notes that mature on <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20230901__20230930__us-gaap--LongtermDebtTypeAxis__custom--SeriesBNotesPayableMember_zX76nbvmzQRd" title="Maturity date">September
1, 2024</span> ("the Series B Notes Payable) for cash proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfUnsecuredDebt_c20230901__20230930__us-gaap--LongtermDebtTypeAxis__custom--SeriesBNotesPayableMember_zK65V3n7jW16" title="Cash proceeds">750,000</span>.
The Series B Notes Payable contained an original issue discount of <span id="xdx_908_ecustom--DebtOriginalIssueDiscountPercenrtage_iI_dp_c20230930__us-gaap--LongtermDebtTypeAxis__custom--SeriesBNotesPayableMember_zutrWpABSzq" title="Original issue discount, percentage">15.0</span>%
and accrue interest at an annual rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20230930__us-gaap--LongtermDebtTypeAxis__custom--SeriesBNotesPayableMember_zA3ejm5fWkI5" title="Annual rate percentage">8.0</span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2023, the Company issued $<span id="xdx_90E_eus-gaap--UnsecuredDebt_iI_c20231130__us-gaap--LongtermDebtTypeAxis__custom--SeriesCNotesPayableMember_zWZAD6h7ABXd" title="Issuing unsecured senior notes">294,118</span>
unsecured senior notes with a maturity date of <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20231101__20231130__us-gaap--LongtermDebtTypeAxis__custom--SeriesCNotesPayableMember_zsMJjmFikEol" title="Maturity date">April
19, 2024</span> (&#8220;the Series C Notes Payable&#8221;), for cash proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfUnsecuredDebt_c20231101__20231130__us-gaap--LongtermDebtTypeAxis__custom--SeriesCNotesPayableMember_zhMisB3KpCIk" title="Cash proceeds">250,000</span>.
The Senior Notes Payable contained an original issue discount of <span id="xdx_90F_ecustom--DebtOriginalIssueDiscountPercenrtage_dp_c20231130__us-gaap--LongtermDebtTypeAxis__custom--SeriesCNotesPayableMember_zCRSv78cDYD" title="Original issue discount, percentage">15.0</span>%
and accrue interest at an annual rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20231130__us-gaap--LongtermDebtTypeAxis__custom--SeriesCNotesPayableMember_zU1uK2SzJKna" title="Annual rate percentage">8.0</span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company incurred issuance costs, recorded
as deferred financing costs, of $<span id="xdx_909_eus-gaap--PaymentsForLegalSettlements_c20231101__20231130_zgu0H6Rz1zJb" title="Diligence and legal costs">296,313</span> relating to due diligence and legal costs associated with the issuance of the notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluated the embedded redemption
and contingent interest features in the notes to determine if such features were required to be bifurcated as an embedded derivative liability.
In accordance with ASC 815-40, Derivatives and Hedging Activities, the embedded redemption features and contingent interest feature were
accounted for as derivative liabilities at the date of issuance and shall be adjusted to fair value at each reporting date. The Company
fair valued such derivative liabilities and recorded a debt discount at issuance of the notes of $<span id="xdx_906_eus-gaap--PaymentsOfDebtIssuanceCosts_c20231101__20231130_zrh02kXYPJf1" title="Issuance of debt discount">320,561</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issued warrants to purchase 77,010
and 46,556 shares of common stock (1,232,156 and 744,890 shares before giving effect to the 2024 Stock Split) to the holders of the Senior
Notes Payable and Series C Notes Payable (collectively the &#8220;Senior Notes Warrants&#8221;) with an exercise price of $10.02 and $4.58
per share ($0.6262 and $0.2856 pre-2024 split), respectively. The Company accounted for the warrants in accordance with the guidance contained
in ASC 815 &#8220;Derivatives and Hedging&#8221; whereby under that provision these warrants did not meet the criteria for equity treatment
and were recorded as a liability. As such, these warrants are recorded at fair value as of each reporting date with the change in fair
value reported within other income in the accompanying consolidated statements of operations as &#8220;Change in fair value of warrant
liability&#8221; until the warrants are exercised, expired or other facts and circumstances lead the warrant liability to be reclassified
to stockholders&#8217; equity. The fair value of the Senior Notes Warrants at issuance was $736,249 and was recorded as a debt discount.
The Company incurred issuance costs of $72,862 relating to the Senior Notes Warrants which was recorded as a day 1 expense due to the
liability classification of such warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the issuance of the Senior
Notes Payable and Series C Notes Payable, the Company paid a commitment fee in the form of 21,210 and 9,311 shares (339,360 and 148,978
shares before giving effect to the 2024 Stock Split) of unregistered common stock to the holders, respectively. The aggregate commitment
fees had a fair value at issuance of $208,916 and are recorded as a deferred financing cost.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The resulting debt discounts from the derivative
liabilities, warrant liabilities and deferred financing costs were presented as a direct deduction from the carrying amount of that debt
liability and amortized to interest expense using the effective interest rate method. For the three months ended June 30, 2024, the Company
recognized $<span id="xdx_901_eus-gaap--AmortizationOfDebtDiscountPremium_c20240401__20240630__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesPayableMember_zMPibOHoNAAk" title="Amortization of debt discounts"><span id="xdx_900_eus-gaap--DeferredCostsCurrent_iI_c20240630__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesPayableMember_zaj5CN0Rsyh8" title="Deferred financing costs">106,937</span></span> in amortization of debt discounts and deferred financing costs which is recorded in interest expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Between January 22 and January 29, 2024, the Company
entered into a series of exchange agreements (the &#8220;Exchange Agreements&#8221;) with the accredited investors to exchange principal
and accrued interest on these notes for shares of common stock. Pursuant to the Exchange Agreements, the Company issued an aggregate of
<span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240122__20240129__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementsMember__srt--CounterpartyNameAxis__custom--AccreditedInvestorsMember_zQucwyyeJxkb" title="Number of common shares issued on exchange">644,142</span> post-split shares of common stock in exchange for $<span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20240122__20240129__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementsMember__srt--CounterpartyNameAxis__custom--AccreditedInvestorsMember_zjLwfPWqBZvi" title="Exchange of principal and accrued interest">1,519,779</span> principal and accrued interest on the notes. Following these exchanges,
the remaining outstanding balance of principal and interest on the notes was $<span id="xdx_90C_ecustom--RemainingOutstandingBalanceOfPrincipalAndInterest_c20240122__20240129__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementsMember__srt--CounterpartyNameAxis__custom--AccreditedInvestorsMember_zBot47Kz0uXd" title="Remaining outstanding balance of principal and interest">1,145,037</span>. This transaction accelerated the recognition
of the related note discounts and resulted in a $<span id="xdx_901_ecustom--LossOnExchangeOfDebt_c20240101__20240131__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementsMember__srt--CounterpartyNameAxis__custom--AccreditedInvestorsMember_z2DU0vT0YRSd" title="Exchange of principal and accrued interest">1,066,732</span> charge.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 6, 2024, the Company paid $<span id="xdx_904_ecustom--PrincipalAndAccruedInterestPaid_c20240305__20240306__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredNonConvertibleNotesMember_zCw1GaMARoF5" title="Principal and accrued interest paid">300,974</span> of
principal and accrued interest on certain unsecured non-convertible notes. Following this payment, the remaining outstanding balance of
principal and interest on the notes was $<span id="xdx_901_eus-gaap--NotesPayable_iI_c20240306__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredNonConvertibleNotesMember_ztB4KyasF758" title="Outstanding balance">898,380</span>. This transaction accelerated the recognition of the related note discounts and resulted
in a $<span id="xdx_90D_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20240101__20240630__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredNonConvertibleNotesMember_zNx7AWSMcmg3" title="Principal and accrued interest paid">111,928</span> charge.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table reconciles the aggregate amount
for the Senior Notes Payable, Series B Notes Payable, and Series C Notes Payable as well as the unamortized deferred financing costs and
debt discounts relating to the derivative liabilities and warrant liabilities.</p>

<table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfDerivativeInstrumentsTextBlock_z4DHNowa9Azk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT (Details - Note payable)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BA_zxLYHvNf4Ulc" style="display: none">Schedule of derivative liabilities and warrant liabilities</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Note Payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--NotesPayable_pp0p0_c20240630_zqz3p393tW25" style="width: 14%; text-align: right" title="Note Payable">862,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--NotesPayable_c20231231_pp0p0" style="width: 14%; text-align: right" title="Note Payable">2,594,118</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: Unamortized Discounts and Deferred Financing Costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: 9pt">Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsWarrants_iI_pp0p0_d0_c20240630_zTX1z2WgTctb" style="text-align: right" title="Warrants">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsWarrants_c20231231_pp0p0" style="text-align: right" title="Warrants">(557,582</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 9pt">Derivative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsDerivative_iI_pp0p0_c20240630_zfU2xKExR65a" style="text-align: right" title="Derivative">(34,475</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsDerivative_c20231231_pp0p0" style="text-align: right" title="Derivative">(235,628</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; text-align: left; text-indent: 9pt">Deferred financing costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost_iI_pp0p0_c20240630_zzOeVpNyJTNk" style="border-bottom: Black 1pt solid; text-align: right" title="Deferred financing costs">(50,938</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost_c20231231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Deferred financing costs">(675,184</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsTotal_iI_pp0p0_d0_c20240630_z5De3Php7MDe" style="border-bottom: Black 1pt solid; text-align: right" title="Total notes payable discount">(85,413</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsTotal_c20231231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total notes payable discount">(1,468,394</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt; text-indent: 9pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--OtherNotesPayableCurrent_pp0p0_c20240630_zEMiVbduCHde" style="border-bottom: Black 2.5pt double; text-align: right" title="Note payable, net of discount">777,087</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--OtherNotesPayableCurrent_c20231231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Note payable, net of discount">1,125,724</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807640687504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zsZtOZEebdj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10. <span id="xdx_82F_zp5jn8mqS7zc">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Royalty Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has an exclusive license agreement
with the Regents of the University of California to make, use, sell and otherwise distribute products under certain of the Regents of
the University of California&#8217;s patents anywhere in the world. The Company is obligated to pay a minimum annual royalty of $<span id="xdx_901_ecustom--MinimumAnnualRoyaltyPayment_iI_c20240630__srt--CounterpartyNameAxis__custom--RegentsOfTheUniversityOfCaliforniaMember_z40fsnAJo1za" title="Minimum annual royalty payment">50,000</span>,
and an earned royalty of 4% of net sales. The minimum annual royalty will be applied against the earned royalty due for the calendar year
in which the minimum payment was made. The license agreements expire upon expiration of the patents and may be terminated earlier if the
Company so elects. The U.S. licensed patents that are currently issued expire between 2026 and 2029, without considering any possible
patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees.
The Company recorded royalty costs of $<span id="xdx_909_eus-gaap--RoyaltyExpense_c20240401__20240630__srt--CounterpartyNameAxis__custom--RegentsOfTheUniversityOfCaliforniaMember_z1308vfk3yNg" title="Royalty expense"><span id="xdx_908_eus-gaap--RoyaltyExpense_c20230401__20230630__srt--CounterpartyNameAxis__custom--RegentsOfTheUniversityOfCaliforniaMember_zk6I9VOeHRjf" title="Royalty expense">12,500</span></span> for the three months ended June 30, 2024, and 2023, respectively, and $<span id="xdx_906_eus-gaap--RoyaltyExpense_c20240101__20240630__srt--CounterpartyNameAxis__custom--RegentsOfTheUniversityOfCaliforniaMember_zkHrqG9SKkpg" title="Royalty expense"><span id="xdx_90C_eus-gaap--RoyaltyExpense_c20230101__20230630__srt--CounterpartyNameAxis__custom--RegentsOfTheUniversityOfCaliforniaMember_zxzBnbHfeXr2" title="Royalty expense">25,000</span></span> for the six
months ended June 30, 2024, and 2023, respectively, as Cost of Revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Litigation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, the Company has not been involved in
legal proceedings arising in the ordinary course of its business. If any legal proceeding occurs, the Company will record a provision
for a loss when it believes that it is both probable that a loss has been incurred and the amount can be reasonably estimated, although
litigation is inherently unpredictable and is subject to significant uncertainties, some of which are beyond the Company&#8217;s control.
Should any of these estimates and assumptions change or prove to have been incorrect, the Company could incur significant charges related
to legal matters that could have a material impact on its results of operations, financial position and cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807647253136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zmMgODpX1cmc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11. <span id="xdx_824_zHd6p14jyvC6">STOCKHOLDERS&#8217; EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company filed an Amended and Restated Certificate
of Incorporation on April 21, 2022, as part of the Company&#8217;s initial public offering. The Company was authorized to issue two classes
of stock to be designated, respectively, &#8220;common stock&#8221; and &#8220;preferred stock.&#8221; The total number of shares which
the Company was authorized to issue was two hundred twenty million (220,000,000) shares. Two hundred million (<span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20240630_zsbPAzQb1jK" title="Common stock, shares authorized">200,000,000</span>) shares were authorized
to be common stock, having a par value per share of $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240630_zFhX2FEZluEl" title="Common stock, par value">0.00001</span>. Twenty million (<span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20240630_znqavJoGlk19" title="Preferred stock, shares authorized">20,000,000</span>) shares were authorized to be preferred stock,
having a par value per share of $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240630_zdZL7ncqlh5l" title="Preferred stock, par value">0.00001</span>. As of June 30, 2024, the Company had <span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20240630_zuLXKsSe7bja" title="Common stock, shares outstanding">8,210,671</span> common shares outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stockholders&#8217; Vote &#8211; Reverse stock
split</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company held a special meeting of stockholders
on March 24, 2023. At the special meeting, our stockholders approved one proposal, which was to grant discretionary authority to our board
of directors to (i) amend our certificate of incorporation to combine outstanding shares of our common stock into a lesser number of outstanding
shares, or a &#8220;reverse stock split,&#8221; at a specific ratio within a range of <span id="xdx_906_eus-gaap--StockholdersEquityReverseStockSplit_c20240323__20240324__srt--RangeAxis__srt--MinimumMember_z3nH5C4xGxg8" title="Stockholders equity, reverse stock Split">one-for-five</span> (1-for-5) to a maximum of a <span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20240323__20240324__srt--RangeAxis__srt--MaximumMember_zPYs1eWBSEX8" title="Stockholders equity, reverse stock Split">one-for-fifty</span>
(1-for-50) split, with the exact ratio to be determined by our board of directors in its sole discretion; and (ii) effect the reverse
stock split, if at all, within one year of the date the proposal was approved by stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2024, the Company's board subsequently
approved the final reverse stock split ratio of one-for-sixteen (the &#8220;2024 Stock Split&#8221;), which resulted in a reduction in
the number of outstanding shares of common stock, warrants, stock options and restricted share units and a proportionate increase in the
value of each share or strike price of the warrants and stock options. The common stock began trading on a reverse split-adjusted basis
on the NASDAQ on January 4, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Series A Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2023 the Company sold one (1) share
of the Company&#8217;s newly designated Series A preferred stock to Jeffrey Thramann, the Company&#8217;s Executive Chairman, for a purchase
price of $<span id="xdx_909_ecustom--PurchasePrice_c20230201__20230228__srt--TitleOfIndividualAxis__custom--ExecutiveChairmanMember_zL0NtzklOwHd" title="Purchase price">1,000</span>. The share of Series A preferred stock had proportional voting rights that were limited to the proposal to approve a reverse
stock split of the Company&#8217;s common stock. Following the March 24, 2023, special meeting, the Company redeemed the one outstanding
share of Series A preferred stock on March 28, 2023, in accordance with its terms. The redemption price was $<span id="xdx_907_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_c20240101__20240630_zl1w3LDReM4b" title="Redemption price">1,000</span>. No Series A preferred
stock remains outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Public Offering</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 27, 2024, the Company completed a
public offering of <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240226__20240227__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zY6NX13D0WK1" title="Issued units">5,175,000</span> units (&#8220;Units&#8221;) at a price of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20240227__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zkoFuLPx90j2" title="Price per unit">0.58</span> per Unit, for gross proceeds of approximately $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn6n6_c20240226__20240227__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z56C0JMPRZok" title="Gross proceeds">3</span>.0 million,
before deducting offering expenses. Each Unit was comprised of (i) one share of common stock or, in lieu of common stock, one prefunded
warrant to purchase a share of common stock, and (ii) two common warrants, each common warrant to purchase a share of common stock. The
prefunded warrants were immediately exercisable at a price of $0.00001 per share of common stock and only expire when such prefunded warrants
are fully exercised. The common warrants were immediately exercisable at a price of $0.58 per share of common stock and will expire five
years from the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>White Lion Equity Line Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 9, 2023, the Company entered into an
equity line common stock purchase agreement (the &#8220;Equity Line Purchase Agreement&#8221;) and a related registration rights agreement
with White Lion Capital, LLC (&#8220;White Lion&#8221;). Pursuant to the Equity Line Agreement, the Company has the right, but not the
obligation to require White Lion to purchase, from time to time, up to $<span id="xdx_90C_eus-gaap--PaymentsForRepurchaseOfWarrants_c20231008__20231009__us-gaap--TransactionTypeAxis__custom--WhiteLionEquityLineAgreementMember_z5JWvqdnTuFd" title="Aggregate gross purchase price">10,000,000</span> in aggregate gross purchase price of newly issued shares
of the Company&#8217;s common stock, subject to certain limitations and conditions set forth in the Equity Line Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Equity Line Purchase Agreement,
the Company issued to White Lion <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240424__20240426__us-gaap--TransactionTypeAxis__custom--WhiteLionEquityLineAgreementMember_zb1Wp5ZAAnTl" title="Issued shares">1,050,000</span> newly issued common shares for proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240424__20240426__us-gaap--TransactionTypeAxis__custom--WhiteLionEquityLineAgreementMember_zTjpZkz2rA0c" title="Proceeds from issuance of common shares">304,500</span> on April 26, 2024. Through June 30, 2024,
the Company has issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240630__us-gaap--TransactionTypeAxis__custom--WhiteLionEquityLineAgreementMember_zrvCiCidW0Y7" title="Issued shares">1,800,000</span> shares to White Lion for total proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20240630__us-gaap--TransactionTypeAxis__custom--WhiteLionEquityLineAgreementMember_zsczwgdCYrga" title="Proceeds from issuance of common shares">3,216,981</span>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the
Company&#8217;s outstanding warrants as of June 30, 2024. The warrants and related strike prices have been adjusted to reflect
the 2024 Stock Split.</p>

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zeO8GMHB4xni" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details - Outstanding warrants)">
  <tr style="vertical-align: top">
    <td><span id="xdx_8BC_zDYQiP0cRYif" style="display: none">Schedule of warrants and related strike prices</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; width: 36%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issue Date</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 16%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Strike price</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 21%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number outstanding</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePriceMember_fKDEp_zQTeExaR3F09" title="Issue date">April 21, 2022</span> (1)</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePriceMember_fKDEp_z6lUJG3j11mb" title="Strike price">69.60</span></span></td>
    <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePriceMember_fKDEp_z9AvwNC0r9fe" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">155,610</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePriceMember_fKDEp_zJ7zgL2ZelT8" title="Expiration">April 21, 2027</span></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice1Member_z9pJvj90xyok" title="Issue date">April 21, 2022</span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice1Member_zVRoDsbB8YYh" title="Strike price">87.04</span></span></td>
    <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice1Member_zrK5fyXYQTMf" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,825</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice1Member_zXp7Xrmz7z28" title="Expiration">April 21, 2027</span></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice2Member_zAL3HNZT5cwe" title="Issue date">April 21, 2022</span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice2Member_z6GuYgYlJZv9" title="Strike price">69.60</span></span></td>
    <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice2Member_zCJWWiqdmGZj" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,673</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice2Member_zEbTR3XZhu5a" title="Expiration">April 21, 2027</span></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice3Member_fKDIp_zKn3cxuZlpj2">May 16, 2023</span> (2)</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice3Member_fKDIp_zaa23c02Ypni" title="Strike price">0.29</span></span></td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice3Member_fKDIp_zfbPTWn3ixq8" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77,010</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice3Member_fKDIp_zt5B26Xna7zd" title="Expiration">May 16, 2028</span></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice4Member_fKDIp_zZKYEOaU9Dl2">November 21, 2023</span> (2)</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice4Member_fKDIp_za5OwvRfkRjb" title="Strike price">0.29</span></span></td>
    <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice4Member_fKDIp_zetOjQH87aHk" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,556</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice4Member_fKDIp_zVMslzSfPg94" title="Expiration">November 21, 2028</span></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice5Member_zyVIuNupPfab" title="Issue date">November 21, 2023</span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice5Member_ze9lEuppAHH1" title="Strike price">0.00001</span></span></td>
    <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice5Member_zWcXOoFlmoq4" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,576</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice5Member_zAVvgOlrmmtd" title="Expiration">November 21, 2028</span></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice6Member_z0r4BBtZVwTb" title="Issue date">February 27, 2024</span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice6Member_zGxVNyRQ7IYe" title="Strike price">0.58</span></span></td>
    <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice6Member_zc5Qv22unfrg" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,350,000</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice6Member_zQtn98pTlbZ3" title="Expiration">February 27, 2029</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; text-align: justify"><span id="xdx_F03_znuzUtQP6ula" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F1C_zH4hCCWyNCSl">These
    warrants were issued as part of the Company&#8217;s initial public offering completed April 2022, and trade on Nasdaq under the
    ticker symbol &#8220;ACONW.&#8221;</i></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span id="xdx_F02_zXPSiiQZe8N1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F11_zom5hNjrTiyc">The per share exercise price of these warrants is subject to a &#8220;ratchet&#8221; adjustment if the Company issues securities at an effective per share price lower than the then effective warrant exercise price. The strike price of $0.29 is current through the equity line activity closed April 26, 2024.</i></span></td></tr>
  </table>
<p id="xdx_8A9_ziLpPF7lpbv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807653343120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE OF COMMON STOCK<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE OF COMMON STOCK</a></td>
<td class="text"><p id="xdx_800_eus-gaap--EarningsPerShareTextBlock_zy0JXDs1fVDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 12. <span id="xdx_82F_zes4OZvugAGk">NET LOSS PER SHARE OF COMMON STOCK</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic and diluted net loss per share is computed
by dividing net loss attributable to stockholders by the weighted average number shares of common stock outstanding during the period
and shares issuable for vested restricted stock units. Potentially dilutive outstanding shares of common stock equivalents were excluded
from the computation of diluted net loss per share for loss periods presented because including them would have been antidilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reconciliation of the numerator and denominator
used in the calculation of basic and diluted net loss per share attributable to stockholders follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zOBicJRIU8Q6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Basic and diluted net loss per share)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BD_z4534VW0VB3b" style="display: none">Schedule of reconciliation of basic and diluted net loss per share</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left; text-indent: -10pt; padding-left: 10pt">Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ProfitLoss_c20240401__20240630_zRqXvkIA5F5g" style="width: 13%; text-align: right" title="Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share">(1,238,077</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ProfitLoss_c20230401__20230630_zluZTpibBKI" style="width: 13%; text-align: right" title="Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share">(1,464,557</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Weighted average shares outstanding used to compute basic and dilutive loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--WeightedAverageNumberOfSharesOutstandingBasic1_c20240401__20240630_zvbTvMv46EO1" style="text-align: right" title="Weighted average shares outstanding used to compute basic and dilutive loss per share">8,208,281</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--WeightedAverageNumberOfSharesOutstandingBasic1_c20230401__20230630_zHC2O3Vhjsf2" style="text-align: right" title="Weighted average shares outstanding used to compute basic and dilutive loss per share">505,485</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Weighted average shares issuable for vested restricted stock units</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c20240401__20240630_z7cyP1rhrlYj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average shares issuable for vested restricted stock units">8,743</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c20230401__20230630_zxg6eTNXwjHg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average shares issuable for vested restricted stock units">12,494</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_zHkoSbbSqQVl" title="Weighted average shares of common stock outstanding, basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zttpRmKIGWJb" title="Weighted average shares of common stock outstanding, diluted">8,217,024</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630_zL11xWBCdfef" title="Weighted average shares of common stock outstanding, basic"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630_zEanN7LkPm0i" title="Weighted average shares of common stock outstanding, diluted">517,979</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>


<p style="margin: 0">&#160;</p>



<p style="margin: 0"></p>





<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Dilutive securities)">
  <tr style="vertical-align: bottom">
    <td><span></span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left; text-indent: -10pt; padding-left: 10pt">Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ProfitLoss_c20240101__20240630_zQezW8C3z1I8" style="width: 13%; text-align: right" title="Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share">(3,637,180</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ProfitLoss_c20230101__20230630_ziLnBC20sjWj" style="width: 13%; text-align: right" title="Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share">(2,648,017</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Weighted average shares outstanding used to compute basic and dilutive loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--WeightedAverageNumberOfSharesOutstandingBasic1_c20240101__20240630_z8wEh4n4P4o6" style="text-align: right" title="Weighted average shares outstanding used to compute basic and dilutive loss per share">6,817,419</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--WeightedAverageNumberOfSharesOutstandingBasic1_c20230101__20230630_zvbL6WdrpmAg" style="text-align: right" title="Weighted average shares outstanding used to compute basic and dilutive loss per share">498,415</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Weighted average shares issuable for vested restricted stock units</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c20240101__20240630_zS2qQxKYUMik" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average shares issuable for vested restricted stock units">12,406</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c20230101__20230630_z2vkQKGEftQe" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average shares issuable for vested restricted stock units">9,084</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_zDW2ANguK92g" title="Weighted average shares of common stock outstanding, basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zjvrwv6h73y2" title="Weighted average shares of common stock outstanding, diluted">6,829,825</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630_zNxkDGSoU7q9" title="Weighted average shares of common stock outstanding, basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630_zuNTUzpSSISb" title="Weighted average shares of common stock outstanding, diluted">507,499</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_z1G6C1gFphj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following outstanding potentially dilutive
securities were excluded from the weighted average calculation of dilutive loss per share attributable to common stockholders because
their impact would have been antidilutive for the period presented:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMLYqGufMkN6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Dilutive securities)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BC_zIU952YOod9a" style="display: none">Schedule of anti-dilutive securities excluded from computation of earnings per share</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%">Warrants</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_z6O5fIgId0sg" style="width: 13%; text-align: right" title="Antidilutive shares">10,666,674</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zVoXztMvdzk7" style="width: 13%; text-align: right" title="Antidilutive shares">219,910</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zUdurxZWOqm5" style="text-align: right" title="Antidilutive shares">4,853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zp1OkIoaM1R4" style="text-align: right" title="Antidilutive shares">43,276</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Stock options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zqXA7perEKUd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">169,458</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zn1xY5JHgPaj" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">171,176</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630_zwDiURYaUSil" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">10,840,985</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630_zr5181425Buk" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">434,362</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807647117872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_801_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zzg2XxwG8CNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 13. <span id="xdx_820_zBeXq9ZaQ4bf">STOCK BASED COMPENSATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2022 Aclarion Equity Incentive Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 21, 2022, in connection with the IPO,
the Company&#8217;s 2022 Aclarion Equity Incentive Plan, or &#8220;2022 Plan&#8221;, went into effect. Our board of directors has appointed
the compensation committee of our board of directors as the committee under the 2022 Plan with the authority to administer the 2022 Plan.
The aggregate number of our shares of common stock that may be issued or used for reference purposes under the 2022 Plan is <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20220421__us-gaap--PlanNameAxis__custom--AclarionEquityIncentivePlan2022Member_zqcgf0zFWDnf" title="Number of common shares issued">125,000</span> shares
(2,000,000 prior to the 2024 Stock Split), with an automatic increase on January 1st of each year, for a period of not more than ten years,
commencing on January 1st of the year following the year in which the initial public offering date (April 2022) occurs and ending on (and
including) January 1, 2032, in an amount equal to 5% of the total number of shares of Capital Stock outstanding on December 31st of the
preceding calendar year. Notwithstanding the foregoing, the Board may act prior to January 1st of a given year to provide that there will
be no January 1st increase in shares for such year or that the increase in shares for such year will be a lesser number of shares of Common
Stock than would otherwise occur pursuant to the preceding sentence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the year ended December 31, 2023, the aggregate
number of our shares of common stock that may be issued or used for reference purposes under the 2022 Plan was <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20231231__us-gaap--PlanNameAxis__custom--AclarionEquityIncentivePlan2022Member_zEy7ijCE1GK" title="Number of common shares issued">154,426</span> (2,470,814 pre-split).
On January 1, 2024, the 2022 Plan had an automatic increase of 41,270 (660,311 pre-split) shares which was 5% of the total number of shares
of Capital Stock outstanding on December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options granted under the 2022 Plan may be incentive
stock options or non-statutory stock options, as determined by the administrator at the time of grant of an option. Restricted stock may
also be granted under the 2022 Plan. The options vest in accordance with the grant terms and are exercisable for a period of up to 10
years from grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20240101__20240630_z2uwhkqSJq7l" title="Options granted">No</span> options were granted in the six months ended
June 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Nocimed, Inc. 2015 Stock Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains the Nocimed, Inc. 2015 Stock
Plan, or the &#8220;Existing Plan&#8221;, under which the Company could grant 152,558 shares (after giving effect to the 2024 Stock Split)
or options of the Company to our employees, consultants, and other service providers. The Company suspended the Existing Plan in connection
with the April 2022, initial public offering. The Company did not grant any stock options under the Existing Plan for the twelve months
ended December 31, 2022, and thereafter. No further awards will be granted under the Existing Plan, but awards granted prior to the suspension date will
continue in accordance with their terms and the terms of the Existing Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Determining Fair Value of Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of each grant of stock options
was determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires
significant judgment to determine.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Valuation and Amortization Method </i>&#8212;The
Company estimates the fair value of its stock options using the Black-Scholes-Merton option-pricing model. This fair value is then amortized
over the requisite service periods of the awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Expected Term</i>&#8212;The Company estimates
the expected term of stock option by taking the average of the vesting term and the contractual term of the option, as illustrated by
the simplified method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Expected Volatility</i>&#8212;The expected
volatility is derived from the Company&#8217;s expectations of future market volatility over the expected term of the options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Risk-Free Interest Rate</i>&#8212;The risk-free
interest rate is based on the 10-year U.S. Treasury yield curve on the date of grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dividend Yield</i>&#8212;The dividend yield
assumption is based on the Company&#8217;s history and expectation of no dividend payouts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock Award Activity </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of option activity under the Company&#8217;s
incentive plans is as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z0YRy0CouXe1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK BASED COMPENSATION (Details - Option activity)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BF_z5ndK5Ip9mLc" style="display: none">Schedule of option activity</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Options</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Outstanding</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (In Years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 49%">Balance at December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240630_ziEbKKlajOQ4" style="width: 13%; text-align: right" title="Number of share options outstanding, Beginning">169,456</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630_ztzwJh2DJBsj" style="width: 13%; text-align: right" title="Weighted average exercise price, Beginning">31.15</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zhb47Tevujcl" title="Weighted average remaining contractual life">7.5</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20240101__20240630_zrSY25AjPoAg" style="text-align: right" title="Options granted">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20240101__20240630_zKsW4n8Ypfw6" style="text-align: right" title="Weighted average exercise price, Options granted">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_d0_c20240101__20240630_zwdp07jOO9Gf" style="text-align: right" title="Options exercised">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20240101__20240630_z3gf1yCre7jj" style="text-align: right" title="Weighted average exercise price, Options exercised">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Options forfeited/expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d0_c20240101__20240630_zRKrgkTLHmOi" style="border-bottom: Black 1pt solid; text-align: right" title="Options forfeited or expired">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20240101__20240630_zM9MSTKUhKPa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Options forfeited or expired">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Balance at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240630_zgGpyxoeCIuj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of share options outstanding, Ending">169,456</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630_zmLnIcsg8aY8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Ending">31.15</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630_zpAxW2DRAvvf" title="Weighted average remaining contractual life">7.0</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Exercisable at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231_zRQKl506Bqbd" style="text-align: right" title="Options exercisable">147,977</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231_z9oGo4nj6li1" style="text-align: right" title="Weighted average exercise price, Option exercisable">30.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_z139Zn2yr4Mg" title="weighted average remaining contractual life, Options exercisable">7.4</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercisable at June 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630_z0DZmV1BTCSi" style="text-align: right" title="Options exercisable">154,971</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240630_zXshqrmyo0W8" style="text-align: right" title="Weighted average exercise price, Option exercisable">30.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240630_ztmuQ0k80rK" title="Weighted average remaining contractual life, Options exercisable">6.9</span></td><td style="text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value of options outstanding
at June 30, 2024 is $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20240101__20240630_zv709ybiOnD2" title="Intrinsic value options outstanding">0</span>. The aggregate intrinsic value of vested and exercisable options at June 30, 2024 is $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240630__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zOdKuSwKZLd" title="Intrinsic value options exercised">0</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2024, there was approximately $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20240630__us-gaap--AwardTypeAxis__custom--NonVestedStockOptionsMember_zCdAcK1Q1gKl" title="Unrecognized compensation cost">212,454</span>
of total unrecognized compensation cost related to non-vested stock options, which is expected to be recognized over the next <span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtM_c20240101__20240630__us-gaap--AwardTypeAxis__custom--NonVestedStockOptionsMember_zmtrVpzYoTUj" title="Unrecognized compensation cost, remaining term">15</span> months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Restricted Stock Units</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the six months ended June 30, 2024, the Company
had <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_do_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z10gADxGBbPl" title="RSU's granted">no</span> new grants of RSUs under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Post-split RSU activity under the 2022 Plan was
as follows for the six months ended June 30, 2024:</p>


<table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_znkXrAaqdKi2" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCK BASED COMPENSATION (Details - RSU activity)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B8_zlry3kkdAuRd" style="display: none">Schedule of RSU activity</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>RSU&#8217;s</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Outstanding</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-Average Grant-Date Fair value per Unit</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonvested as of December 31, 2023</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zePX4Qyrfiej" style="width: 14%; text-align: right" title="Number of Rsu shares outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,749</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjpfSHqj9crd" style="width: 14%; text-align: right" title="Weighted average grant date fair value per unit, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.72</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zahTZfqSkZq5" style="text-align: right" title="RSU's granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ziHveFgJQBjj" style="text-align: right" title="RSU's granted, weighted-average grant date fair value per unit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zcmCPBhYXQZ" style="text-align: right" title="RSU's vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,953</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNdV89pR7yXl" style="text-align: right" title="RSU's vested, weighted-average grant date fair value per unit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7U6sSahi0vf" style="border-bottom: black 1pt solid; text-align: right" title="RSU's forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,942</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)&#160;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMI4bZqbrpT1" style="border-bottom: black 1pt solid; text-align: right" title="RSU's forfeited, weighted-average grant date fair value per unit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.42</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonvested as of June 30, 2024</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zc83dXAXOWx3" style="border-bottom: black 2.25pt double; text-align: right" title="Number of Rsu shares outstanding, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,854</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvS4oeiGAyV8" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average grant date fair value per unit, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.20</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The grant date fair value for a RSU is the market
price of the common stock on the date of grant. The total share-based compensation expense related to RSUs recognized during the six months
ended June 30, 2024, was $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxBXymiIEGRk" title="Share-based compensation expense">40,733</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2024, there was approximately $<span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKOzNcOti995" title="Unrecognized compensation cost">2,735</span>
total unrecognized compensation cost related to non-vested RSUs which is expected to be recognized over the next three months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2024, the Company is obligated
to issue <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCZYvGt9SpF7" title="Obligated to issue share of common stock">7,539</span> post-split shares of common stock associated with vested Restricted Stock Units.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-based Compensation Expense</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the total stock-based
compensation expense included in the Company&#8217;s statements of operations for the periods presented:</p>

<table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zJu4tEMlReM2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK BASED COMPENSATION (Details - Share based compensation)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BC_zYuwJnv8gwP5" style="display: none">Schedule of stock-based compensation expense</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 36%; text-align: left">Sales and marketing</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zLOfSKVm9H6" style="width: 12%; text-align: right" title="Total stock-based compensation">12,605</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_z3jc3MI7sEhi" style="width: 12%; text-align: right" title="Total stock-based compensation">78,688</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zRB0FsyZiys4" style="width: 12%; text-align: right" title="Total stock-based compensation">40,733</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_z7yWBeNbyZm2" style="width: 12%; text-align: right" title="Total stock-based compensation">106,997</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zkdWfugvBio9" style="text-align: right" title="Total stock-based compensation">2,055</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zQ8KKpLlNz12" style="text-align: right" title="Total stock-based compensation">2,055</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z38BJhvIHmqi" style="text-align: right" title="Total stock-based compensation">4,110</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zV23PCvbPxqd" style="text-align: right" title="Total stock-based compensation">5,615</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zogvgu0lPfM" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">55,644</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zf4C6vqufR21" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">55,888</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zagqkI9NH7j8" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">111,288</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zfZPA7ZVraN4" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">106,551</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: white; text-align: left; padding-bottom: 2.5pt">Total share based compensation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630_zrS0WUsqZy2l" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">70,305</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630_z4AHE4AehdS2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">136,631</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240630_z8II90fIOkr2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">156,131</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230630_zZMVK0sXPuyk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">219,162</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807647253136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_z3VOft7VDVoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 14. <span id="xdx_82F_zUyUP3ABlnAa">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Stock Subscription Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 12, 2024, we entered into a subscription
agreement with an institutional investor, pursuant to which the Company agreed to issue and sell to the investor 400,000 shares of Common
Stock of the Company at a price of $0.29 per share for gross proceeds to the Company of $116,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares were issued pursuant to the Company&#8217;s
Form 1-A Offering Statement initially filed by the Company with the Securities and Exchange Commission under the Securities Act of 1933,
as amended on June 11, 2024 and qualified on June 24, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Exchange Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May, September and November 2023 the Company
issued $2,594,118 aggregate principal amount of unsecured non-convertible notes to certain accredited investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Between January 22 and January 29, 2024, the Company
entered into a series of exchange agreements (the &#8220;Exchange Agreements&#8221;) with the accredited investors to exchange principal
and accrued interest on these notes for shares of common stock. Pursuant to the Exchange Agreements, the Company issued an aggregate of
644,142 post-split shares of common stock in exchange for $1,519,779 principal and accrued interest on the notes. Following these exchanges,
the remaining outstanding balance of principal and interest on the notes was $1,145,037.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On March 6, 2024, the
Company paid $300,973 of principal and accrued interest on certain unsecured non-convertible notes. Following this payment, the remaining
outstanding balance of principal and interest on the notes was $898,380.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 14, 2024, the Company entered into an
additional exchange agreement with the accredited investors to exchange $930,052 principal and accrued interest on these notes for newly
issued shares of Series B convertible preferred stock. Following this exchange, there was no remaining outstanding balance of principal
and interest on the notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807640006736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_849_eus-gaap--UseOfEstimates_ziG9kpLZ5Bff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_867_zn4BPLb1gMOa">Use of Estimates</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements include some amounts
that are based on management's best estimates and judgments. The most significant estimates relate to depreciation, amortization, and
valuation of warrants, warrant and derivative liabilities, and options to purchase shares of the Company's common stock. These estimates
may be adjusted as more current information becomes available, and any adjustment could be significant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>





<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Valuation of Derivative Instruments</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--DerivativesPolicyTextBlock_zQFUWdhps961" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86B_zvGU9YFgC5dg">Valuation of Derivative Instruments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial Accounting Standards Board (&#8220;FASB&#8221;)
Accounting Standards Codification (&#8220;ASC&#8221;) 815-40, <i>Derivatives and Hedging: Contracts on an Entity&#8217;s Own Equity</i>,
addresses whether an equity-linked contract qualifies as equity in the entity&#8217;s financial statements. Agreements where an entity
has insufficient authorized and unissued shares to settle the contract generally are accounted for as a liability and marked to fair value
through earnings each reporting period. The Company evaluates its financial instruments to determine if such instruments are liabilities
or contain features that qualify as embedded derivatives. For financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then revalued at each reporting date, with changes in the fair value reported
as charges or credits to income.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zRpqL0aSezma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_862_zO4Tn9Q11Wl1">Fair Value of Financial Instruments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820, Fair Value Measurements, provides guidance
on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price,
representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market
participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions
that market participants would use in pricing an asset or a liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accounting guidance classifies fair value
measurements in one of the following three categories for disclosure purposes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Level 1</i> - Unadjusted quoted prices
in active markets for identical instruments that are accessible by the Company on the measurement date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Level 2</i> - Quoted prices in markets
that are not active or inputs which are either directly or indirectly observable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Level 3</i> - Unobservable inputs
for the instrument requiring the development of assumptions by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company analyzes all financial instruments
with features of both liabilities and equity under the Financial Accounting Standard Board&#8217;s (&#8220;FASB&#8221;) accounting standard
for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level
of input that is significant to the fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying values of the Company&#8217;s financial
instruments including cash equivalents, restricted cash, accounts receivable, and accounts payable are approximately equal to their respective
fair values due to the relatively short-term nature of these instruments. The Company&#8217;s warrant liabilities and derivative liabilities
are estimated using level 3 inputs (see Note 3).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesReportingOfDerivativeActivity', window );">Derivative Financial Instruments</a></td>
<td class="text"><p id="xdx_841_eus-gaap--DerivativesReportingOfDerivativeActivity_zVoH8tcJ5E1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_864_z3ko8Qu0N10l">Derivative Financial Instruments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has derivative financial instruments
that are not hedges and do not qualify for hedge accounting. Changes in the fair value of these instruments are recorded in other income
(expenses), on a net basis in the Consolidated Statements of Operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zk0RdMwL3mnk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_864_zVRDtCC2yNvc">Cash and Cash Equivalents</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid
instruments purchased with an original maturity of three months or less to be cash equivalents. The Company had <span id="xdx_90F_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20240630_zJosY1pNcA8e" title="Cash equivalents"><span id="xdx_90F_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20231231_zQ3wey1WdzB5" title="Cash equivalents">no</span></span>
cash equivalents at June 30, 2024 and December 31, 2023. The Company maintains cash deposits at several financial institutions,
which are insured by the FDIC up to $250,000. The Company&#8217;s cash balance may at times exceed these limits. On June 30, 2024,
and December 31, 2023, the Company had $<span id="xdx_90A_eus-gaap--CashUninsuredAmount_pp0p0_c20240630_zvmXQ04QcOR4" title="Cash uninsured amount">818,591 </span>and
$<span id="xdx_905_eus-gaap--CashUninsuredAmount_iI_pp0p0_c20231231_zF4ZgR3wsS2i" title="Cash uninsured amount">761,800</span>,
respectively, in excess of federally insured limits. The Company continually monitors its positions with, and the credit quality of,
the financial institutions with which it invests. The Company maintains no international bank accounts. As of June 30, 2024, $<span id="xdx_90A_eus-gaap--RestrictedCash_pp0p0_c20240630_zjS4vKHk3vag" title="Restricted cash">10,000</span>
of the Company&#8217;s cash was restricted as collateral related to the credit card program offered by our bank.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable, Less Allowance for Doubtful Accounts</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--ReceivablesPolicyTextBlock_zerACPyV9j7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86F_zcsnM77PyZQa">Accounts Receivable, Less Allowance for Doubtful
Accounts</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company estimates an allowance for doubtful
accounts based upon an evaluation of the current status of receivables, historical experience, and other factors as necessary. It is reasonably
possible that the Company&#8217;s estimate of the allowance for doubtful accounts will change. The allowance for doubtful accounts was
$<span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_c20240630_za2m8ElG0ibl" title="Allowance for doubtful accounts"><span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_c20231231_zSjpkmAhEE6k" title="Allowance for doubtful accounts">0</span></span> on June 30, 2024, and December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--RevenueRecognitionPolicyTextBlock_zsEL0fBsDPzh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_865_zqmMPrW88aq3">Revenue Recognition</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues are recognized when a contract with a
customer exists, and at that point in time when we have delivered a Nociscan report to our customer. Revenue is recognized in the amount
that reflects the negotiated consideration expected to be received in exchange for those reports. Following the delivery of the report,
the company has no ongoing obligations or services to provide to the customer. Customers pay no other upfront, licensing, or other fees.
To date, our reports are not reimbursable under any third-party payment arrangements, The Company invoices its customers based on the
billing schedules in its sales arrangements. Payment terms range generally from 30 to 90 days from the date of invoice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_LiquidityCapitalResourcesAndGoingConcernPolicyTextBlock', window );">Liquidity, Capital Resources and Going Concern</a></td>
<td class="text"><p id="xdx_84C_ecustom--LiquidityCapitalResourcesAndGoingConcernPolicyTextBlock_z5a6J8nqvx05" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86F_zj66HsO4f93g">Liquidity, Capital Resources and Going Concern</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company believes that the net proceeds from
the February 2024 initial public offering, and subsequent funding from the April 2024 equity line agreement described in Note 11, will
be sufficient to fund current operating plans into the third quarter of 2024, approaching our final maturity repayment of our unsecured
non-convertible note, which is due in September 2024. The Company has based these estimates, however, on assumptions that may prove to
be wrong, and could spend available financial resources much faster than we currently expect. The Company will need to raise additional
funds to continue funding our technology development. Management plans to secure such additional funding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the Company&#8217;s recurring
losses from operations and the need for additional financing to fund its operating and capital requirements, there is uncertainty regarding
the Company&#8217;s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to
the Company&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><p id="xdx_843_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zYhjdlqc7Rki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86A_zVMECq7BR5Ci">Share-Based Compensation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock-based awards in
accordance with provisions of ASC Topic 718, Compensation&#8212;Stock Compensation, under which the Company recognizes the grant-date
fair value of stock-based awards issued to employees and nonemployee board members as compensation expense on a straight-line basis over
the vesting period of the award, while awards containing a performance condition are recognized as expense when the achievement of the
performance criteria is achieved. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock
options. The Company records expense for forfeitures in the periods they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The exercise or strike price of each option is
not less than 100% of the fair market value of the Common Stock subject to the option on the date the option is granted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issues restricted stock unit awards
to non-employee consultants who are providing various services. The awards are valued at the market price on the date of the grant. The
awards vest over the contract life and based on achievement of targeted performance milestones.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On occasion, the Company grants common stock to
compensate vendors for services rendered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Financing Costs</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--DeferredChargesPolicyTextBlock_zhAbqLlDwUt5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_865_zvEaGPLTAznc">Deferred Financing Costs</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company capitalizes certain legal, accounting,
and other fees and costs that are directly attributable to in-process equity financings as deferred offering costs until such financings
are completed. Upon the completion of an equity financing, these costs are recorded as a reduction of additional paid-in capital of the
related offering. Upon the completion of the public offering in February 2024, approximately $<span id="xdx_905_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20240201__20240229__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TransactionTypeAxis__custom--CompletionOfPublicOfferingMember_zE4lWkkHSuXd" title="Adjustment to additional paid in capital">566,200</span> of offering costs related to the
public offering were reclassified to additional paid-in capital ($310,105 deducted from proceeds, and $256,094 paid or accrued). Upon
the completion of the issuance of shares pursuant to the equity line in the first quarter of 2024, $<span id="xdx_909_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20240101__20240331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TransactionTypeAxis__custom--CompletionOfIssuanceOfSharesMember_zZUikbr0Sf4k">133,000</span> of offering costs were reclassified
to additional paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p id="xdx_84D_ecustom--EmergingGrowthCompanyStatusPolicyTextBlock_zJUuI0JP9rFb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_865_zEi2eT73N822">Emerging Growth Company Status</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is an emerging growth company, as
defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies
can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those
standards apply to private companies. The Company has elected to use this extended transition period to comply with certain new or revised
accounting standards that have different effective dates for public and private companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_LiquidityCapitalResourcesAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_LiquidityCapitalResourcesAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesReportingOfDerivativeActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesReportingOfDerivativeActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807641629536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND BASIS OF PRESENTATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_ScheduleOfChangesToEquityStatementTableTextBlock', window );">Schedule of equity statement information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfChangesToEquityStatementTableTextBlock_zZRvytdP8TH3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details - Balance sheet changes from split)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B1_z5fsJdtzTOkc" style="display: none">Schedule of equity statement information</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_zx70AX1o1z2a" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CommonStockValue_iI_pp0p0_hus-gaap--TransactionTypeAxis__custom--Pre2024SplitMember_z00mAK4ij0Y3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: left">Common shares issued and outstanding - pre-2024 split, <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_c20231231__us-gaap--TransactionTypeAxis__custom--Pre2024SplitMember_zzbiaUSo59Pd" title="Common stock shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--TransactionTypeAxis__custom--Pre2024SplitMember_zRXG7S1lnhA3" title="Common stock shares outstanding">13,206,229</span></span> shares</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">132</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CommonStockValue_iI_pp0p0_hus-gaap--TransactionTypeAxis__custom--Post2024SplitMember_zFLz567u1sZ2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common shares issued and outstanding - post-2024 split, <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20231231__us-gaap--TransactionTypeAxis__custom--Post2024SplitMember_zq5ZhNpBA2Yl" title="Common stock shares issued"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--TransactionTypeAxis__custom--Post2024SplitMember_zWAI9cspabM6" title="Common stock shares outstanding">825,459</span></span> shares</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_hus-gaap--TransactionTypeAxis__custom--Pre2024SplitMember_z36SUXsfVLUi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Additional paid-in capital - pre-2024 split</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">43,553,399</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_hus-gaap--TransactionTypeAxis__custom--Post2024SplitMember_z03MNEEJTmcj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additional paid-in capital - post-2024 split</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">43,553,523</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_ScheduleOfRetroactiveBasisRreverseStockSplitsTableTextBlock', window );">Schedule of share information reflecting on a retroactive basis the reverse stock splits</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfRetroactiveBasisRreverseStockSplitsTableTextBlock_zhBkya5ufew7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details- Retroactive basis the reverse stock splits)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B9_zVL8x49ZagWc" style="display: none">Schedule of share information reflecting on a retroactive basis the reverse stock splits</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: left">Weighted average shares outstanding, basic and diluted - pre-2024 split</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PreSplitMember_zRCKpWECLsDk" title="Weighted average shares outstanding, basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PreSplitMember_ziZ01LCrKPSd" title="Weighted average shares outstanding, diluted">8,908,934</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average shares outstanding, basic and diluted - post-2024 split</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PostSplitMember_zNy0pB4jkdD" title="Weighted average shares outstanding, basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PostSplitMember_zyspSxsF3Cdd" title="Weighted average shares outstanding, diluted">556,808</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Basic and diluted net loss per shares attributable to common stockholders - pre-2024 split</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PreSplitMember_z9bzbcgtXBe2" title="Basic net loss per shares attributable to common stockholders"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PreSplitMember_z9zldA0n5aS8" title="Diluted net loss per shares attributable to common stockholders">(0.55</span></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Basic and diluted net loss per shares attributable to common stockholders - post-2024 split</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PostSplitMember_zbqirK9pCUt3" title="Basic net loss per shares attributable to common stockholders"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--PostSplitMember_zqys2puH9Qhd" title="Diluted net loss per shares attributable to common stockholders">(8.82</span></span></td><td style="text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_ScheduleOfChangesToEquityStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_ScheduleOfChangesToEquityStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_ScheduleOfRetroactiveBasisRreverseStockSplitsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_ScheduleOfRetroactiveBasisRreverseStockSplitsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807645322704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of recurring basis to determine the fair value of the liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_z5DHIjUGoj67" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details- Recurring basis to determine the fair value of the liability)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B8_zWsBf9xJ1UB8" style="display: none">Schedule of recurring basis to determine the fair value of the liability</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value measured as of June 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fair value on<br/> June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Quoted prices</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>in active</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>markets</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Level 1)</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Significant</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>other</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>observable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>inputs</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Level 2)</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Significant unobservable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>inputs</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Level 3)</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 40%; text-align: justify">Warrant liability</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_c20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zA998PkcuyZk" style="width: 12%; text-align: right" title="Total Fair value">23,861</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zoLgDjODusAg" style="width: 12%; text-align: right" title="Total Fair value">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zBYKvutvi8Ng" style="width: 12%; text-align: right" title="Total Fair value">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueNetAssetLiability_pp0p0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zLaohb2EEvqf" style="width: 12%; text-align: right" title="Total Fair value">23,861</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Derivative Liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_c20240630__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_zlfWBvMfTNoh" style="border-bottom: Black 1pt solid; text-align: right" title="Total Fair value">18,601</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_zfXnrkd37Wvl" style="border-bottom: Black 1pt solid; text-align: right" title="Total Fair value">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_z7h2kPtKhmVg" style="border-bottom: Black 1pt solid; text-align: right" title="Total Fair value">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueNetAssetLiability_pp0p0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_z0SijhPWVEma" style="border-bottom: Black 1pt solid; text-align: right" title="Total Fair value">18,601</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total Fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueNetAssetLiability_pp0p0_c20240630_z43pQYhHON8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Fair value">42,462</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z6bJ5xowjKLc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Fair value">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_d0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zwzpmUh6TWbi" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Fair value">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueNetAssetLiability_pp0p0_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zM04iHzAvbXk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Fair value">42,462</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of liabilities measures at fair value</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_ziPQmesJtQ7c" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Liabilities measures at fair value)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B0_zoX9EIuMPvmi" style="display: none">Schedule of liabilities measures at fair value</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zG0wTBSIxWt2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_zgv8BPVxntkh" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20240630_z0lU2wVoFOj5" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrant</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Liability</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Derivative</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Liability</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueHedgeLiabilitiesAtFairValue_iS_d0_zLtUPk9WPLzj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 49%">Balance &#8211; December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">289,165</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">121,326</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">410,491</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ExchangeAndPayoffOfNotesPayable_d0_zaS5H20uttU1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 9pt">Exchange and Payoff of Notes Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(44,988</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(44,988</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_zoD7OVLvy4Nc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 9pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(265,304</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(57,737</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(323,041</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--FairValueHedgeLiabilitiesAtFairValue_iE_zBA4hafI9HUk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance &#8211; June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">23,861</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,601</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">42,462</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Schedule of assumptions</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zmUoad8QJIye" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details- Fair value of the warrants)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B8_zFEAOSKhbGl7" style="display: none">Schedule of assumptions</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b><b>As of</b></b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b>Dec 31, 2023</b></p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b><b>As of</b></b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b>June 30, 2024</b></p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrant Liability</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrant Liability</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%">Strike Price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_905_eus-gaap--SharePrice_iI_c20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zOAACiCYM3Mc" title="Strike Price">4.32</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_909_eus-gaap--SharePrice_c20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zxP9Y65jeFVg" title="Strike Price">0.29</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Contractual term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zaz2aQfE56f2" title="Contractual term (years)">5.0</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zhS3Y0k1tA9a" title="Contractual term (years)">5.0</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Volatility (annual)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230101__20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zIpabLWtGOf3" title="Volatility (annual)">80.0</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zjcBHjV81VK6" title="Volatility (annual)">80.0</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230101__20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zHhsZBfMcWsc" title="Risk-free rate">3.89</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember__srt--RangeAxis__srt--MinimumMember_zLS5YTh5Wju3" title="Risk-free rate">4.39</span>-<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240101__20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember__srt--RangeAxis__srt--MaximumMember_z6hRSb9ZgVR2" title="Risk-free rate">4.44</span>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Floor Financing price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_ecustom--FloorFinancingPrice_iI_c20231231__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zchQoQsnIuza" title="Floor Financing price">2.24</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_ecustom--FloorFinancingPrice_c20240630__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zySMHJETMa5f" title="Floor Financing price">0.14</span></td><td style="text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807656021520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL FINANCIAL INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of prepaid and other current assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zeNyOudskBJ1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Prepaids and other current assets)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B5_zK2pEwT8cpR" style="display: none">Schedule of prepaid and other current assets</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Short term deposits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--ShortTermDepositsMember_zb4aN5R8jCqg" style="width: 13%; text-align: right" title="Prepaids and other current assets">50,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--ShortTermDepositsMember_pp0p0" style="width: 13%; text-align: right" title="Prepaids and other current assets">50,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--DeferredOfferingCostsMember_zktWUjLur0Vi" style="text-align: right" title="Prepaids and other current assets">74,648</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--DeferredOfferingCostsMember_pp0p0" style="text-align: right" title="Prepaids and other current assets">100,588</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Prepaid insurance D&amp;O</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidInsuranceDAndOMember_z0Dq6pWKqSPf" style="text-align: right" title="Prepaids and other current assets">241,445</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidInsuranceDAndOMember_pp0p0" style="text-align: right" title="Prepaids and other current assets">34,769</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid insurance, other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidInsuranceMember_zQnE22F9Hp2a" style="text-align: right" title="Prepaids and other current assets">5,010</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidInsuranceMember_pp0p0" style="text-align: right" title="Prepaids and other current assets">17,884</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Prepaid clinical costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidClinicalCostsMember_z4NdHg9Wvrwj" style="text-align: right" title="Prepaids and other current assets">165,417</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_d0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidClinicalCostsMember_zWatJ1Hu44N1" style="text-align: right" title="Prepaids and other current assets">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid exchange fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidExchangeFeesMember_zJM5gk9Evs19" style="text-align: right" title="Prepaids and other current assets">53,720</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_d0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidExchangeFeesMember_zMfMHNbAAo04" style="text-align: right" title="Prepaids and other current assets">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Prepaid other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--PrepaidOtherMember_zRBV1TXD6WMb" style="text-align: right" title="Prepaids and other current assets">59,117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidOtherMember_pp0p0" style="text-align: right" title="Prepaids and other current assets">41,635</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other receivables</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0_d0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--OtherReceivablesMember_z5XNvq0Z7use" style="border-bottom: Black 1pt solid; text-align: right" title="Prepaids and other current assets">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231__us-gaap--BalanceSheetLocationAxis__custom--OtherReceivablesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Prepaids and other current assets">154</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_pp0p0_c20240630_zkKJiSoOyZwe" style="border-bottom: Black 2.5pt double; text-align: right" title="Prepaids and other current assets">649,357</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_c20231231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Prepaids and other current assets">245,030</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accounts payable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zTvrYeDxelCb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accounts payable)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B5_zSyxO9ISdGC9" style="display: none">Schedule of accounts payable</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Accounts payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableMember_zdUfHxMTEIEa" style="width: 13%; text-align: right" title="Accounts payable, current">177,610</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20231231__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableMember_zJoexTeiy02g" style="width: 13%; text-align: right" title="Accounts payable, current">758,821</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Credit cards payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--CreditCardsPayableMember_zVaRZmq7fgMi" style="border-bottom: Black 1pt solid; text-align: right" title="Accounts payable, current">1,513</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--CreditCardsPayableMember_zVNBgm4lGbQ1" style="border-bottom: Black 1pt solid; text-align: right" title="Accounts payable, current">1,714</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20240630_zF97TVRPQL9a" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts payable, current">179,123</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20231231_zI3iZs4JGxhk" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts payable, current">760,535</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued and other liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zrTml1alRrec" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accrued and other liabilities)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B0_z8XLJzLqEuCe" style="display: none">Schedule of accrued and other liabilities</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Accrued payroll</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_d0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedPayrollMember_zuUB5QnUo5Gj" style="width: 13%; text-align: right" title="Accrued liabilities and other liabilities">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedPayrollMember_pp0p0" style="width: 13%; text-align: right" title="Accrued liabilities and other liabilities">162,887</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued bonus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedBonusMember_zMsVY1gUUsR1" style="text-align: right" title="Accrued liabilities and other liabilities">127,875</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedBonusMember_pp0p0" style="text-align: right" title="Accrued liabilities and other liabilities">262,580</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">D&amp;O financing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--DAndOFinancingMember_zjLLjX2IFC2" style="text-align: right" title="Accrued liabilities and other liabilities">126,605</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_d0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--DAndOFinancingMember_zFBb4u5EQxIj" style="text-align: right" title="Accrued liabilities and other liabilities">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued audit and legal expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedAuditAndLegalExpensesMember_zuRK6HTESlkl" style="text-align: right" title="Accrued liabilities and other liabilities">40,226</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedAuditAndLegalExpensesMember_pp0p0" style="text-align: right" title="Accrued liabilities and other liabilities">89,082</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedInterestMember_z7lMRjF6iPde" style="text-align: right" title="Accrued liabilities and other liabilities">58,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedInterestMember_pp0p0" style="text-align: right" title="Accrued liabilities and other liabilities">98,685</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued board compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--AccruedBoardCompensationMember_zexcHQEREEye" style="text-align: right" title="Accrued liabilities and other liabilities">46,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231__us-gaap--BalanceSheetLocationAxis__custom--AccruedBoardCompensationMember_pp0p0" style="text-align: right" title="Accrued liabilities and other liabilities">92,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20240630__us-gaap--BalanceSheetLocationAxis__custom--OtherAccruedLiabilitiesMember_zS0PkkCzetue" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued liabilities and other liabilities">48,350</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_pp0p0_c20231231__us-gaap--BalanceSheetLocationAxis__custom--OtherAccruedLiabilitiesMember_z8nqfOTF3aL6" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued liabilities and other liabilities">151,988</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_pp0p0_c20240630_zvVXBovpmAfi" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued liabilities and other liabilities">447,972</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_c20231231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued liabilities and other liabilities">857,722</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807647230992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zhB6FjHufG38" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS (Details - Intangible assets)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B1_zYNZ7On6vOw9" style="display: none">Schedule of intangible assets</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Patents and licenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember_zfZNiqzh3foj" style="width: 13%; text-align: right" title="Intangible assets gross">2,424,773</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember_z31PDMbOROfb" style="width: 13%; text-align: right" title="Intangible assets gross">2,267,251</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zXtlrxNqIsrc" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible assets gross">5,017</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zpYXKnkgRmdd" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible assets gross">5,017</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20240630_znK4725Bxe74" style="text-align: right" title="Intangible assets gross">2,429,790</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231_zGmbyoCwOype" style="text-align: right" title="Intangible assets gross">2,272,268</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: accumulated amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_pp0p0_c20240630_zW4Ue8YHjAAd" style="border-bottom: Black 1pt solid; text-align: right" title="Less: accumulated amortization">(1,193,915</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20231231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Less: accumulated amortization">(1,103,645</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Intangible assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_pp0p0_c20240630_zZgNolLTo23b" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">1,235,875</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_c20231231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">1,168,623</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of future amortization of intangible assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zVjC7kro9EO5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS (Details - Future amortization)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B9_zeB5K09APzF1" style="display: none">Schedule of future amortization of intangible assets</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20240630_zEz3tmZnbFS7" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">96,015</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">192,030</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">192,030</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">192,030</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">2028 and beyond</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">563,770</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherIntangibleAssetsNet_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,235,875</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807647134688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHORT TERM NOTES AND CONVERTIBLE DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Schedule of derivative liabilities and warrant liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfDerivativeInstrumentsTextBlock_z4DHNowa9Azk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT (Details - Note payable)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BA_zxLYHvNf4Ulc" style="display: none">Schedule of derivative liabilities and warrant liabilities</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Note Payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--NotesPayable_pp0p0_c20240630_zqz3p393tW25" style="width: 14%; text-align: right" title="Note Payable">862,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--NotesPayable_c20231231_pp0p0" style="width: 14%; text-align: right" title="Note Payable">2,594,118</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: Unamortized Discounts and Deferred Financing Costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: 9pt">Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsWarrants_iI_pp0p0_d0_c20240630_zTX1z2WgTctb" style="text-align: right" title="Warrants">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsWarrants_c20231231_pp0p0" style="text-align: right" title="Warrants">(557,582</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 9pt">Derivative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsDerivative_iI_pp0p0_c20240630_zfU2xKExR65a" style="text-align: right" title="Derivative">(34,475</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsDerivative_c20231231_pp0p0" style="text-align: right" title="Derivative">(235,628</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; text-align: left; text-indent: 9pt">Deferred financing costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost_iI_pp0p0_c20240630_zzOeVpNyJTNk" style="border-bottom: Black 1pt solid; text-align: right" title="Deferred financing costs">(50,938</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost_c20231231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Deferred financing costs">(675,184</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsTotal_iI_pp0p0_d0_c20240630_z5De3Php7MDe" style="border-bottom: Black 1pt solid; text-align: right" title="Total notes payable discount">(85,413</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--UnamortizedDiscountsAndDeferredFinancingCostsTotal_c20231231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total notes payable discount">(1,468,394</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt; text-indent: 9pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--OtherNotesPayableCurrent_pp0p0_c20240630_zEMiVbduCHde" style="border-bottom: Black 2.5pt double; text-align: right" title="Note payable, net of discount">777,087</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--OtherNotesPayableCurrent_c20231231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Note payable, net of discount">1,125,724</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807647270624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants and related strike prices</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zeO8GMHB4xni" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details - Outstanding warrants)">
  <tr style="vertical-align: top">
    <td><span id="xdx_8BC_zDYQiP0cRYif" style="display: none">Schedule of warrants and related strike prices</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; width: 36%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issue Date</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 16%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Strike price</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 21%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number outstanding</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePriceMember_fKDEp_zQTeExaR3F09" title="Issue date">April 21, 2022</span> (1)</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePriceMember_fKDEp_z6lUJG3j11mb" title="Strike price">69.60</span></span></td>
    <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePriceMember_fKDEp_z9AvwNC0r9fe" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">155,610</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePriceMember_fKDEp_zJ7zgL2ZelT8" title="Expiration">April 21, 2027</span></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice1Member_z9pJvj90xyok" title="Issue date">April 21, 2022</span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice1Member_zVRoDsbB8YYh" title="Strike price">87.04</span></span></td>
    <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice1Member_zrK5fyXYQTMf" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,825</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice1Member_zXp7Xrmz7z28" title="Expiration">April 21, 2027</span></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice2Member_zAL3HNZT5cwe" title="Issue date">April 21, 2022</span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice2Member_z6GuYgYlJZv9" title="Strike price">69.60</span></span></td>
    <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice2Member_zCJWWiqdmGZj" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,673</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice2Member_zEbTR3XZhu5a" title="Expiration">April 21, 2027</span></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice3Member_fKDIp_zKn3cxuZlpj2">May 16, 2023</span> (2)</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice3Member_fKDIp_zaa23c02Ypni" title="Strike price">0.29</span></span></td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice3Member_fKDIp_zfbPTWn3ixq8" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77,010</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice3Member_fKDIp_zt5B26Xna7zd" title="Expiration">May 16, 2028</span></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice4Member_fKDIp_zZKYEOaU9Dl2">November 21, 2023</span> (2)</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice4Member_fKDIp_za5OwvRfkRjb" title="Strike price">0.29</span></span></td>
    <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice4Member_fKDIp_zetOjQH87aHk" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,556</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice4Member_fKDIp_zVMslzSfPg94" title="Expiration">November 21, 2028</span></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice5Member_zyVIuNupPfab" title="Issue date">November 21, 2023</span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice5Member_ze9lEuppAHH1" title="Strike price">0.00001</span></span></td>
    <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice5Member_zWcXOoFlmoq4" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,576</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice5Member_zAVvgOlrmmtd" title="Expiration">November 21, 2028</span></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--StockIssueDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice6Member_z0r4BBtZVwTb" title="Issue date">February 27, 2024</span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice6Member_zGxVNyRQ7IYe" title="Strike price">0.58</span></span></td>
    <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice6Member_zc5Qv22unfrg" style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,350,000</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--WarrantStrikePrice6Member_zQtn98pTlbZ3" title="Expiration">February 27, 2029</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; text-align: justify"><span id="xdx_F03_znuzUtQP6ula" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F1C_zH4hCCWyNCSl">These
    warrants were issued as part of the Company&#8217;s initial public offering completed April 2022, and trade on Nasdaq under the
    ticker symbol &#8220;ACONW.&#8221;</i></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span id="xdx_F02_zXPSiiQZe8N1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F11_zom5hNjrTiyc">The per share exercise price of these warrants is subject to a &#8220;ratchet&#8221; adjustment if the Company issues securities at an effective per share price lower than the then effective warrant exercise price. The strike price of $0.29 is current through the equity line activity closed April 26, 2024.</i></span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807647168048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE OF COMMON STOCK (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of reconciliation of basic and diluted net loss per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zOBicJRIU8Q6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Basic and diluted net loss per share)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BD_z4534VW0VB3b" style="display: none">Schedule of reconciliation of basic and diluted net loss per share</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left; text-indent: -10pt; padding-left: 10pt">Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ProfitLoss_c20240401__20240630_zRqXvkIA5F5g" style="width: 13%; text-align: right" title="Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share">(1,238,077</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ProfitLoss_c20230401__20230630_zluZTpibBKI" style="width: 13%; text-align: right" title="Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share">(1,464,557</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Weighted average shares outstanding used to compute basic and dilutive loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--WeightedAverageNumberOfSharesOutstandingBasic1_c20240401__20240630_zvbTvMv46EO1" style="text-align: right" title="Weighted average shares outstanding used to compute basic and dilutive loss per share">8,208,281</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--WeightedAverageNumberOfSharesOutstandingBasic1_c20230401__20230630_zHC2O3Vhjsf2" style="text-align: right" title="Weighted average shares outstanding used to compute basic and dilutive loss per share">505,485</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Weighted average shares issuable for vested restricted stock units</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c20240401__20240630_z7cyP1rhrlYj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average shares issuable for vested restricted stock units">8,743</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c20230401__20230630_zxg6eTNXwjHg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average shares issuable for vested restricted stock units">12,494</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_zHkoSbbSqQVl" title="Weighted average shares of common stock outstanding, basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zttpRmKIGWJb" title="Weighted average shares of common stock outstanding, diluted">8,217,024</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630_zL11xWBCdfef" title="Weighted average shares of common stock outstanding, basic"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630_zEanN7LkPm0i" title="Weighted average shares of common stock outstanding, diluted">517,979</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>


<p style="margin: 0">&#160;</p>



<p style="margin: 0"></p>





<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Dilutive securities)">
  <tr style="vertical-align: bottom">
    <td><span></span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left; text-indent: -10pt; padding-left: 10pt">Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ProfitLoss_c20240101__20240630_zQezW8C3z1I8" style="width: 13%; text-align: right" title="Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share">(3,637,180</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ProfitLoss_c20230101__20230630_ziLnBC20sjWj" style="width: 13%; text-align: right" title="Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share">(2,648,017</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Weighted average shares outstanding used to compute basic and dilutive loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--WeightedAverageNumberOfSharesOutstandingBasic1_c20240101__20240630_z8wEh4n4P4o6" style="text-align: right" title="Weighted average shares outstanding used to compute basic and dilutive loss per share">6,817,419</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--WeightedAverageNumberOfSharesOutstandingBasic1_c20230101__20230630_zvbL6WdrpmAg" style="text-align: right" title="Weighted average shares outstanding used to compute basic and dilutive loss per share">498,415</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Weighted average shares issuable for vested restricted stock units</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c20240101__20240630_zS2qQxKYUMik" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average shares issuable for vested restricted stock units">12,406</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c20230101__20230630_z2vkQKGEftQe" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average shares issuable for vested restricted stock units">9,084</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_zDW2ANguK92g" title="Weighted average shares of common stock outstanding, basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zjvrwv6h73y2" title="Weighted average shares of common stock outstanding, diluted">6,829,825</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630_zNxkDGSoU7q9" title="Weighted average shares of common stock outstanding, basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630_zuNTUzpSSISb" title="Weighted average shares of common stock outstanding, diluted">507,499</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti-dilutive securities excluded from computation of earnings per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMLYqGufMkN6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Dilutive securities)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BC_zIU952YOod9a" style="display: none">Schedule of anti-dilutive securities excluded from computation of earnings per share</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%">Warrants</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_z6O5fIgId0sg" style="width: 13%; text-align: right" title="Antidilutive shares">10,666,674</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zVoXztMvdzk7" style="width: 13%; text-align: right" title="Antidilutive shares">219,910</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zUdurxZWOqm5" style="text-align: right" title="Antidilutive shares">4,853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zp1OkIoaM1R4" style="text-align: right" title="Antidilutive shares">43,276</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Stock options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zqXA7perEKUd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">169,458</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zn1xY5JHgPaj" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">171,176</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630_zwDiURYaUSil" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">10,840,985</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630_zr5181425Buk" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">434,362</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807647253392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z0YRy0CouXe1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK BASED COMPENSATION (Details - Option activity)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BF_z5ndK5Ip9mLc" style="display: none">Schedule of option activity</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Options</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Outstanding</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (In Years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 49%">Balance at December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240630_ziEbKKlajOQ4" style="width: 13%; text-align: right" title="Number of share options outstanding, Beginning">169,456</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630_ztzwJh2DJBsj" style="width: 13%; text-align: right" title="Weighted average exercise price, Beginning">31.15</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zhb47Tevujcl" title="Weighted average remaining contractual life">7.5</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20240101__20240630_zrSY25AjPoAg" style="text-align: right" title="Options granted">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20240101__20240630_zKsW4n8Ypfw6" style="text-align: right" title="Weighted average exercise price, Options granted">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_d0_c20240101__20240630_zwdp07jOO9Gf" style="text-align: right" title="Options exercised">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20240101__20240630_z3gf1yCre7jj" style="text-align: right" title="Weighted average exercise price, Options exercised">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Options forfeited/expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d0_c20240101__20240630_zRKrgkTLHmOi" style="border-bottom: Black 1pt solid; text-align: right" title="Options forfeited or expired">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20240101__20240630_zM9MSTKUhKPa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Options forfeited or expired">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Balance at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240630_zgGpyxoeCIuj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of share options outstanding, Ending">169,456</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630_zmLnIcsg8aY8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Ending">31.15</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630_zpAxW2DRAvvf" title="Weighted average remaining contractual life">7.0</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Exercisable at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231_zRQKl506Bqbd" style="text-align: right" title="Options exercisable">147,977</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231_z9oGo4nj6li1" style="text-align: right" title="Weighted average exercise price, Option exercisable">30.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_z139Zn2yr4Mg" title="weighted average remaining contractual life, Options exercisable">7.4</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercisable at June 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630_z0DZmV1BTCSi" style="text-align: right" title="Options exercisable">154,971</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240630_zXshqrmyo0W8" style="text-align: right" title="Weighted average exercise price, Option exercisable">30.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240630_ztmuQ0k80rK" title="Weighted average remaining contractual life, Options exercisable">6.9</span></td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of RSU activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_znkXrAaqdKi2" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCK BASED COMPENSATION (Details - RSU activity)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B8_zlry3kkdAuRd" style="display: none">Schedule of RSU activity</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>RSU&#8217;s</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Outstanding</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-Average Grant-Date Fair value per Unit</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonvested as of December 31, 2023</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zePX4Qyrfiej" style="width: 14%; text-align: right" title="Number of Rsu shares outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,749</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjpfSHqj9crd" style="width: 14%; text-align: right" title="Weighted average grant date fair value per unit, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.72</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zahTZfqSkZq5" style="text-align: right" title="RSU's granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ziHveFgJQBjj" style="text-align: right" title="RSU's granted, weighted-average grant date fair value per unit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zcmCPBhYXQZ" style="text-align: right" title="RSU's vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,953</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNdV89pR7yXl" style="text-align: right" title="RSU's vested, weighted-average grant date fair value per unit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7U6sSahi0vf" style="border-bottom: black 1pt solid; text-align: right" title="RSU's forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,942</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)&#160;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMI4bZqbrpT1" style="border-bottom: black 1pt solid; text-align: right" title="RSU's forfeited, weighted-average grant date fair value per unit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.42</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonvested as of June 30, 2024</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zc83dXAXOWx3" style="border-bottom: black 2.25pt double; text-align: right" title="Number of Rsu shares outstanding, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,854</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvS4oeiGAyV8" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average grant date fair value per unit, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.20</span></td>
    <td>&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zJu4tEMlReM2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK BASED COMPENSATION (Details - Share based compensation)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BC_zYuwJnv8gwP5" style="display: none">Schedule of stock-based compensation expense</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 36%; text-align: left">Sales and marketing</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zLOfSKVm9H6" style="width: 12%; text-align: right" title="Total stock-based compensation">12,605</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_z3jc3MI7sEhi" style="width: 12%; text-align: right" title="Total stock-based compensation">78,688</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zRB0FsyZiys4" style="width: 12%; text-align: right" title="Total stock-based compensation">40,733</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_z7yWBeNbyZm2" style="width: 12%; text-align: right" title="Total stock-based compensation">106,997</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zkdWfugvBio9" style="text-align: right" title="Total stock-based compensation">2,055</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zQ8KKpLlNz12" style="text-align: right" title="Total stock-based compensation">2,055</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z38BJhvIHmqi" style="text-align: right" title="Total stock-based compensation">4,110</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zV23PCvbPxqd" style="text-align: right" title="Total stock-based compensation">5,615</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zogvgu0lPfM" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">55,644</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zf4C6vqufR21" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">55,888</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zagqkI9NH7j8" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">111,288</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zfZPA7ZVraN4" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">106,551</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: white; text-align: left; padding-bottom: 2.5pt">Total share based compensation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630_zrS0WUsqZy2l" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">70,305</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630_z4AHE4AehdS2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">136,631</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240630_z8II90fIOkr2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">156,131</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230630_zZMVK0sXPuyk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">219,162</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807645096944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>THE COMPANY AND BASIS OF PRESENTATION (Details - Balance sheet changes from split) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares issued and outstanding - post-2024 split, 825,459 shares</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">8,210,671<span></span>
</td>
<td class="nump">825,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="nump">8,210,671<span></span>
</td>
<td class="nump">825,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital - post-2024 split</a></td>
<td class="nump">$ 49,560,800<span></span>
</td>
<td class="nump">$ 43,553,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=ACON_Pre2024SplitMember', window );">Pre 2024 Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares issued and outstanding - post-2024 split, 825,459 shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,206,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,206,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital - post-2024 split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,553,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=ACON_Post2024SplitMember', window );">Post 2024 Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares issued and outstanding - post-2024 split, 825,459 shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital - post-2024 split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,553,523<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=ACON_Pre2024SplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=ACON_Pre2024SplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=ACON_Post2024SplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=ACON_Post2024SplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807640392592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND BASIS OF PRESENTATION (Details- Retroactive basis the reverse stock splits) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="nump">8,217,024<span></span>
</td>
<td class="nump">517,979<span></span>
</td>
<td class="nump">6,829,825<span></span>
</td>
<td class="nump">507,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="nump">8,217,024<span></span>
</td>
<td class="nump">517,979<span></span>
</td>
<td class="nump">6,829,825<span></span>
</td>
<td class="nump">507,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per shares attributable to common stockholders</a></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (2.83)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (5.22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per shares attributable to common stockholders</a></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (2.83)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (5.22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ACON_PreSplitMember', window );">Pre Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,908,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,908,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per shares attributable to common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per shares attributable to common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.55)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ACON_PostSplitMember', window );">Post Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per shares attributable to common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8.82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per shares attributable to common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8.82)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ACON_PreSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ACON_PreSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ACON_PostSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ACON_PostSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807644809360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND BASIS OF PRESENTATION (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=ACON_StockSplit2024Member', window );">Stock Split 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">one-for-sixteen<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=ACON_StockSplit2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=ACON_StockSplit2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807641689904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash uninsured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">818,591<span></span>
</td>
<td class="nump">761,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Completion Of Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Adjustment to additional paid in capital</a></td>
<td class="nump">$ 566,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Completion Of Issuance Of Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Adjustment to additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=ACON_CompletionOfPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=ACON_CompletionOfPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=ACON_CompletionOfIssuanceOfSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=ACON_CompletionOfIssuanceOfSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807639825744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details- Recurring basis to determine the fair value of the liability)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total Fair value</a></td>
<td class="nump">$ 42,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total Fair value</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total Fair value</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total Fair value</a></td>
<td class="nump">42,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=ACON_WarrantLiabilityMember', window );">Warrant Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total Fair value</a></td>
<td class="nump">23,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=ACON_WarrantLiabilityMember', window );">Warrant Liability [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total Fair value</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=ACON_WarrantLiabilityMember', window );">Warrant Liability [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total Fair value</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=ACON_WarrantLiabilityMember', window );">Warrant Liability [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total Fair value</a></td>
<td class="nump">23,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=ACON_DerivativeLiabilityMember', window );">Derivative Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total Fair value</a></td>
<td class="nump">18,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=ACON_DerivativeLiabilityMember', window );">Derivative Liability [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total Fair value</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=ACON_DerivativeLiabilityMember', window );">Derivative Liability [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total Fair value</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=ACON_DerivativeLiabilityMember', window );">Derivative Liability [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total Fair value</a></td>
<td class="nump">$ 18,601<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=ACON_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=ACON_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=ACON_DerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=ACON_DerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807637123312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details - Liabilities measures at fair value)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueHedgeLiabilitiesAtFairValue', window );">Balance &#8211; December 31, 2023</a></td>
<td class="nump">$ 410,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_ExchangeAndPayoffOfNotesPayable', window );">Exchange and Payoff of Notes Payable</a></td>
<td class="num">(44,988)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Change in fair value</a></td>
<td class="num">(323,041)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueHedgeLiabilitiesAtFairValue', window );">Balance &#8211; June 30, 2024</a></td>
<td class="nump">42,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=ACON_WarrantLiabilityMember', window );">Warrant Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueHedgeLiabilitiesAtFairValue', window );">Balance &#8211; December 31, 2023</a></td>
<td class="nump">289,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_ExchangeAndPayoffOfNotesPayable', window );">Exchange and Payoff of Notes Payable</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Change in fair value</a></td>
<td class="num">(265,304)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueHedgeLiabilitiesAtFairValue', window );">Balance &#8211; June 30, 2024</a></td>
<td class="nump">23,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=ACON_DerivativeLiabilityMember', window );">Derivative Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueHedgeLiabilitiesAtFairValue', window );">Balance &#8211; December 31, 2023</a></td>
<td class="nump">121,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_ExchangeAndPayoffOfNotesPayable', window );">Exchange and Payoff of Notes Payable</a></td>
<td class="num">(44,988)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Change in fair value</a></td>
<td class="num">(57,737)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueHedgeLiabilitiesAtFairValue', window );">Balance &#8211; June 30, 2024</a></td>
<td class="nump">$ 18,601<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_ExchangeAndPayoffOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_ExchangeAndPayoffOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueHedgeLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of all derivative liabilities designated as fair value hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueHedgeLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=ACON_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=ACON_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=ACON_DerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=ACON_DerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807656093392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details- Fair value of the warrants) - Warrant Liability [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Strike Price</a></td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 4.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual term (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility (annual)</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.89%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_FloorFinancingPrice', window );">Floor Financing price</a></td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="nump">$ 2.24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=ACON_WarrantLiabilityMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">4.39%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=ACON_WarrantLiabilityMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">4.44%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_FloorFinancingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_FloorFinancingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=ACON_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=ACON_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807644977216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTAL FINANCIAL INFORMATION (Details - Prepaids and other current assets) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaids and other current assets</a></td>
<td class="nump">$ 649,357<span></span>
</td>
<td class="nump">$ 245,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ACON_ShortTermDepositsMember', window );">Short Term Deposits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaids and other current assets</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ACON_DeferredOfferingCostsMember', window );">Deferred Offering Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaids and other current assets</a></td>
<td class="nump">74,648<span></span>
</td>
<td class="nump">100,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ACON_PrepaidInsuranceDAndOMember', window );">Prepaid Insurance D&amp;O [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaids and other current assets</a></td>
<td class="nump">241,445<span></span>
</td>
<td class="nump">34,769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ACON_PrepaidInsuranceMember', window );">Prepaid Insurance, Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaids and other current assets</a></td>
<td class="nump">5,010<span></span>
</td>
<td class="nump">17,884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ACON_PrepaidClinicalCostsMember', window );">Prepaid Clinical Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaids and other current assets</a></td>
<td class="nump">165,417<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ACON_PrepaidExchangeFeesMember', window );">Prepaid Exchange Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaids and other current assets</a></td>
<td class="nump">53,720<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ACON_PrepaidOtherMember', window );">Prepaid Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaids and other current assets</a></td>
<td class="nump">59,117<span></span>
</td>
<td class="nump">41,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ACON_OtherReceivablesMember', window );">Other Receivables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaids and other current assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ACON_ShortTermDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ACON_ShortTermDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ACON_DeferredOfferingCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ACON_DeferredOfferingCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ACON_PrepaidInsuranceDAndOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ACON_PrepaidInsuranceDAndOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ACON_PrepaidInsuranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ACON_PrepaidInsuranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ACON_PrepaidClinicalCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ACON_PrepaidClinicalCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ACON_PrepaidExchangeFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ACON_PrepaidExchangeFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ACON_PrepaidOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ACON_PrepaidOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ACON_OtherReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ACON_OtherReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807647236624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accounts payable) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable, current</a></td>
<td class="nump">$ 179,123<span></span>
</td>
<td class="nump">$ 760,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember', window );">Accounts Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable, current</a></td>
<td class="nump">177,610<span></span>
</td>
<td class="nump">758,821<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ACON_CreditCardsPayableMember', window );">Credit Cards Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable, current</a></td>
<td class="nump">$ 1,513<span></span>
</td>
<td class="nump">$ 1,714<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ACON_CreditCardsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ACON_CreditCardsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807637100704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accrued and other liabilities) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued liabilities and other liabilities</a></td>
<td class="nump">$ 447,972<span></span>
</td>
<td class="nump">$ 857,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ACON_AccruedPayrollMember', window );">Accrued Payroll [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued liabilities and other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">162,887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ACON_AccruedBonusMember', window );">Accrued Bonus [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued liabilities and other liabilities</a></td>
<td class="nump">127,875<span></span>
</td>
<td class="nump">262,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ACON_DAndOFinancingMember', window );">D&amp;O Financing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued liabilities and other liabilities</a></td>
<td class="nump">126,605<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ACON_AccruedAuditAndLegalExpensesMember', window );">Accrued Audit And Legal Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued liabilities and other liabilities</a></td>
<td class="nump">40,226<span></span>
</td>
<td class="nump">89,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ACON_AccruedInterestMember', window );">Accrued Interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued liabilities and other liabilities</a></td>
<td class="nump">58,666<span></span>
</td>
<td class="nump">98,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ACON_AccruedBoardCompensationMember', window );">Accrued Board Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued liabilities and other liabilities</a></td>
<td class="nump">46,250<span></span>
</td>
<td class="nump">92,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ACON_OtherAccruedLiabilitiesMember', window );">Other Accrued Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued liabilities and other liabilities</a></td>
<td class="nump">$ 48,350<span></span>
</td>
<td class="nump">$ 151,988<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ACON_AccruedPayrollMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ACON_AccruedPayrollMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ACON_AccruedBonusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ACON_AccruedBonusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ACON_DAndOFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ACON_DAndOFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ACON_AccruedAuditAndLegalExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ACON_AccruedAuditAndLegalExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ACON_AccruedInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ACON_AccruedInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ACON_AccruedBoardCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ACON_AccruedBoardCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ACON_OtherAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ACON_OtherAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807637136096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Office lease</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807640570640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details - Intangible assets) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets gross</a></td>
<td class="nump">$ 2,429,790<span></span>
</td>
<td class="nump">$ 2,272,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="num">(1,193,915)<span></span>
</td>
<td class="num">(1,103,645)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">1,235,875<span></span>
</td>
<td class="nump">1,168,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ACON_PatentsAndLicensesMember', window );">Patents And Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets gross</a></td>
<td class="nump">2,424,773<span></span>
</td>
<td class="nump">2,267,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets gross</a></td>
<td class="nump">$ 5,017<span></span>
</td>
<td class="nump">$ 5,017<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ACON_PatentsAndLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ACON_PatentsAndLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807640742576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details - Future amortization)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths', window );">2024</a></td>
<td class="nump">$ 96,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo', window );">2025</a></td>
<td class="nump">192,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree', window );">2026</a></td>
<td class="nump">192,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour', window );">2027</a></td>
<td class="nump">192,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive', window );">2028 and beyond</a></td>
<td class="nump">563,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 1,235,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807637119856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 45,458<span></span>
</td>
<td class="nump">$ 39,940<span></span>
</td>
<td class="nump">$ 90,270<span></span>
</td>
<td class="nump">$ 78,805<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807646723840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SHORT TERM NOTES AND CONVERTIBLE DEBT (Details - Note payable) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Note Payable</a></td>
<td class="nump">$ 862,500<span></span>
</td>
<td class="nump">$ 2,594,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_UnamortizedDiscountsAndDeferredFinancingCostsWarrants', window );">Warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(557,582)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_UnamortizedDiscountsAndDeferredFinancingCostsDerivative', window );">Derivative</a></td>
<td class="num">(34,475)<span></span>
</td>
<td class="num">(235,628)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost', window );">Deferred financing costs</a></td>
<td class="num">(50,938)<span></span>
</td>
<td class="num">(675,184)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_UnamortizedDiscountsAndDeferredFinancingCostsTotal', window );">Total notes payable discount</a></td>
<td class="num">(85,413)<span></span>
</td>
<td class="num">(1,468,394)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNotesPayableCurrent', window );">Note payable, net of discount</a></td>
<td class="nump">$ 777,087<span></span>
</td>
<td class="nump">$ 1,125,724<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_UnamortizedDiscountsAndDeferredFinancingCostsDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_UnamortizedDiscountsAndDeferredFinancingCostsDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_UnamortizedDiscountsAndDeferredFinancingCostsTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_UnamortizedDiscountsAndDeferredFinancingCostsTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_UnamortizedDiscountsAndDeferredFinancingCostsWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_UnamortizedDiscountsAndDeferredFinancingCostsWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807638966256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHORT TERM NOTES AND CONVERTIBLE DEBT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 06, 2024</div></th>
<th class="th"><div>Jan. 29, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes payable outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Diligence and legal costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 296,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Issuance of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_LossOnExchangeOfDebt', window );">Exchange of principal and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
<td class="nump">$ (0)<span></span>
</td>
<td class="nump">1,066,732<span></span>
</td>
<td class="nump">$ (0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">862,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">862,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,594,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Principal and accrued interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(111,928)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=ACON_UnsecuredNonConvertibleNotesMember', window );">Unsecured Non Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_PrincipalAndAccruedInterestPaid', window );">Principal and accrued interest paid</a></td>
<td class="nump">$ 300,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Outstanding balance</a></td>
<td class="nump">$ 898,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Principal and accrued interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ACON_ExchangeAgreementsMember', window );">Exchange Agreements [Member] | Accredited Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of common shares issued on exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Exchange of principal and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,519,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_RemainingOutstandingBalanceOfPrincipalAndInterest', window );">Remaining outstanding balance of principal and interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,145,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_LossOnExchangeOfDebt', window );">Exchange of principal and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,066,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ACON_SeniorNotesPayableMember', window );">Senior Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,437,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 16,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSecuredNotesPayable', window );">Proceeds from secured notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_DebtOriginalIssueDiscountPercenrtage', window );">Original issue discount, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Annual rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ACON_SeriesBNotesPayableMember', window );">Series B Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_DebtOriginalIssueDiscountPercenrtage', window );">Original issue discount, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Annual rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Issuing unsecured senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 862,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt', window );">Cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ACON_SeriesCNotesPayableMember', window );">Series C Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 19,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_DebtOriginalIssueDiscountPercenrtage', window );">Original issue discount, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Annual rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Issuing unsecured senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 294,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt', window );">Cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_DebtOriginalIssueDiscountPercenrtage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_DebtOriginalIssueDiscountPercenrtage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_LossOnExchangeOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_LossOnExchangeOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_PrincipalAndAccruedInterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_PrincipalAndAccruedInterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_RemainingOutstandingBalanceOfPrincipalAndInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_RemainingOutstandingBalanceOfPrincipalAndInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSecuredNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings supported by a written promise to pay an obligation that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSecuredNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=ACON_UnsecuredNonConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=ACON_UnsecuredNonConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ACON_ExchangeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ACON_ExchangeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ACON_AccreditedInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ACON_AccreditedInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ACON_SeniorNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ACON_SeniorNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ACON_SeriesBNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ACON_SeriesBNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ACON_SeriesCNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ACON_SeriesCNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807638228560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - Regents Of The University Of California [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_MinimumAnnualRoyaltyPayment', window );">Minimum annual royalty payment</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_MinimumAnnualRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_MinimumAnnualRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ACON_RegentsOfTheUniversityOfCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ACON_RegentsOfTheUniversityOfCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807639017648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details - Outstanding warrants)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Jun. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ACON_WarrantStrikePriceMember', window );">Strike Price 69.60 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_StockIssueDate', window );">Issue date</a></td>
<td class="text">Apr. 21,  2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Strike price | $ / shares</a></td>
<td class="nump">$ 69.60<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares outstanding | shares</a></td>
<td class="nump">155,610<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration</a></td>
<td class="text">Apr. 21,  2027<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ACON_WarrantStrikePrice1Member', window );">Strike Price 87.04 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_StockIssueDate', window );">Issue date</a></td>
<td class="text">Apr. 21,  2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Strike price | $ / shares</a></td>
<td class="nump">$ 87.04<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares outstanding | shares</a></td>
<td class="nump">10,825<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration</a></td>
<td class="text">Apr. 21,  2027<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ACON_WarrantStrikePrice2Member', window );">Strike Price 69.60 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_StockIssueDate', window );">Issue date</a></td>
<td class="text">Apr. 21,  2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Strike price | $ / shares</a></td>
<td class="nump">$ 69.60<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares outstanding | shares</a></td>
<td class="nump">26,673<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration</a></td>
<td class="text">Apr. 21,  2027<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ACON_WarrantStrikePrice3Member', window );">Strike Price 0.29 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_StockIssueDate', window );">Issue date</a></td>
<td class="text">May 16,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Strike price | $ / shares</a></td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares outstanding | shares</a></td>
<td class="nump">77,010<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration</a></td>
<td class="text">May 16,  2028<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ACON_WarrantStrikePrice4Member', window );">Strike Price 0.29 (1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_StockIssueDate', window );">Issue date</a></td>
<td class="text">Nov. 21,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Strike price | $ / shares</a></td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares outstanding | shares</a></td>
<td class="nump">46,556<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration</a></td>
<td class="text">Nov. 21,  2028<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ACON_WarrantStrikePrice5Member', window );">Strike Price 0.00001 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_StockIssueDate', window );">Issue date</a></td>
<td class="text">Nov. 21,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Strike price | $ / shares</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares outstanding | shares</a></td>
<td class="nump">1,576<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration</a></td>
<td class="text">Nov. 21,  2028<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ACON_WarrantStrikePrice6Member', window );">Strike Price 0.58 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_StockIssueDate', window );">Issue date</a></td>
<td class="text">Feb. 27,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Strike price | $ / shares</a></td>
<td class="nump">$ 0.58<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares outstanding | shares</a></td>
<td class="nump">10,350,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration</a></td>
<td class="text">Feb. 27,  2029<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">These
    warrants were issued as part of the Company&#8217;s initial public offering completed April 2022, and trade on Nasdaq under the
    ticker symbol &#8220;ACONW.&#8221;</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The per share exercise price of these warrants is subject to a &#8220;ratchet&#8221; adjustment if the Company issues securities at an effective per share price lower than the then effective warrant exercise price. The strike price of $0.29 is current through the equity line activity closed April 26, 2024.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_StockIssueDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_StockIssueDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ACON_WarrantStrikePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ACON_WarrantStrikePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ACON_WarrantStrikePrice1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ACON_WarrantStrikePrice1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ACON_WarrantStrikePrice2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ACON_WarrantStrikePrice2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ACON_WarrantStrikePrice3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ACON_WarrantStrikePrice3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ACON_WarrantStrikePrice4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ACON_WarrantStrikePrice4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ACON_WarrantStrikePrice5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ACON_WarrantStrikePrice5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ACON_WarrantStrikePrice6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ACON_WarrantStrikePrice6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807635969344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Mar. 24, 2024</div></th>
<th class="th"><div>Feb. 27, 2024</div></th>
<th class="th"><div>Oct. 09, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,210,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Redemption price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,691,391<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=ACON_WhiteLionEquityLineAgreementMember', window );">White Lion Equity Line Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Aggregate gross purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares</a></td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares</a></td>
<td class="nump">$ 304,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,216,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ACON_ExecutiveChairmanMember', window );">Executive Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_PurchasePrice', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders equity, reverse stock Split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-five<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders equity, reverse stock Split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-fifty<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_PurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_PurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=ACON_WhiteLionEquityLineAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=ACON_WhiteLionEquityLineAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ACON_ExecutiveChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ACON_ExecutiveChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807646425232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE OF COMMON STOCK (Details - Basic and diluted net loss per share) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share</a></td>
<td class="num">$ (1,238,077)<span></span>
</td>
<td class="num">$ (1,464,557)<span></span>
</td>
<td class="num">$ (3,637,180)<span></span>
</td>
<td class="num">$ (2,648,017)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ACON_WeightedAverageNumberOfSharesOutstandingBasic1', window );">Weighted average shares outstanding used to compute basic and dilutive loss per share</a></td>
<td class="nump">8,208,281<span></span>
</td>
<td class="nump">505,485<span></span>
</td>
<td class="nump">6,817,419<span></span>
</td>
<td class="nump">498,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Weighted average shares issuable for vested restricted stock units</a></td>
<td class="nump">8,743<span></span>
</td>
<td class="nump">12,494<span></span>
</td>
<td class="nump">12,406<span></span>
</td>
<td class="nump">9,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding, basic</a></td>
<td class="nump">8,217,024<span></span>
</td>
<td class="nump">517,979<span></span>
</td>
<td class="nump">6,829,825<span></span>
</td>
<td class="nump">507,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding, diluted</a></td>
<td class="nump">8,217,024<span></span>
</td>
<td class="nump">517,979<span></span>
</td>
<td class="nump">6,829,825<span></span>
</td>
<td class="nump">507,499<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ACON_WeightedAverageNumberOfSharesOutstandingBasic1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ACON_WeightedAverageNumberOfSharesOutstandingBasic1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ACON_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807639770560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE OF COMMON STOCK (Details - Dilutive securities) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="nump">10,840,985<span></span>
</td>
<td class="nump">434,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ACON_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="nump">10,666,674<span></span>
</td>
<td class="nump">219,910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ACON_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="nump">4,853<span></span>
</td>
<td class="nump">43,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ACON_StockOptionsMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="nump">169,458<span></span>
</td>
<td class="nump">171,176<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ACON_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ACON_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ACON_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ACON_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ACON_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ACON_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807644960768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK BASED COMPENSATION (Details - Option activity) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of share options outstanding, Beginning</a></td>
<td class="nump">169,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Beginning</a></td>
<td class="nump">$ 31.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Options granted</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options forfeited or expired</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Options forfeited or expired</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of share options outstanding, Ending</a></td>
<td class="nump">169,456<span></span>
</td>
<td class="nump">169,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Ending</a></td>
<td class="nump">$ 31.15<span></span>
</td>
<td class="nump">$ 31.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable</a></td>
<td class="nump">154,971<span></span>
</td>
<td class="nump">147,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Option exercisable</a></td>
<td class="nump">$ 30.80<span></span>
</td>
<td class="nump">$ 30.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, Options exercisable</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807656100128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK BASED COMPENSATION (Details - RSU activity) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Rsu shares outstanding, Beginning | shares</a></td>
<td class="nump">15,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per unit, Beginning | $ / shares</a></td>
<td class="nump">$ 10.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSU's granted | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSU's granted, weighted-average grant date fair value per unit | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSU's vested | shares</a></td>
<td class="num">(3,953)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">RSU's vested, weighted-average grant date fair value per unit | $ / shares</a></td>
<td class="nump">$ 10.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSU's forfeited | shares</a></td>
<td class="num">(6,942)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">RSU's forfeited, weighted-average grant date fair value per unit | $ / shares</a></td>
<td class="nump">$ 13.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Rsu shares outstanding, Ending | shares</a></td>
<td class="nump">4,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per unit, Ending | $ / shares</a></td>
<td class="nump">$ 7.20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807646695152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK BASED COMPENSATION (Details - Share based compensation) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">$ 70,305<span></span>
</td>
<td class="nump">$ 136,631<span></span>
</td>
<td class="nump">$ 156,131<span></span>
</td>
<td class="nump">$ 219,162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Selling and Marketing Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">12,605<span></span>
</td>
<td class="nump">78,688<span></span>
</td>
<td class="nump">40,733<span></span>
</td>
<td class="nump">106,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">2,055<span></span>
</td>
<td class="nump">2,055<span></span>
</td>
<td class="nump">4,110<span></span>
</td>
<td class="nump">5,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">$ 55,644<span></span>
</td>
<td class="nump">$ 55,888<span></span>
</td>
<td class="nump">$ 111,288<span></span>
</td>
<td class="nump">$ 106,551<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45807637131392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK BASED COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 21, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value options exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ACON_NonVestedStockOptionsMember', window );">Non Vested Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 212,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, remaining term</a></td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 2,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSU's granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 40,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Obligated to issue share of common stock</a></td>
<td class="nump">7,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember', window );">Options Held [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value options exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ACON_AclarionEquityIncentivePlan2022Member', window );">Aclarion Equity Incentive Plan 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of common shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,426<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ACON_NonVestedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ACON_NonVestedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ACON_AclarionEquityIncentivePlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ACON_AclarionEquityIncentivePlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>213</ContextCount>
  <ElementCount>259</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/BalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Statements of Changes in Stockholders' Equity (Deficit) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit</Role>
      <ShortName>Condensed Statements of Changes in Stockholders' Equity (Deficit) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/CompanyAndBasisOfPresentation</Role>
      <ShortName>THE COMPANY AND BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/RecentAccountingPronouncements</Role>
      <ShortName>RECENT ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - REVENUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/Revenue</Role>
      <ShortName>REVENUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/SupplementalFinancialInformation</Role>
      <ShortName>SUPPLEMENTAL FINANCIAL INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/IntangibleAssets</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aclarion.com/role/ShortTermNotesAndConvertibleDebt</Role>
      <ShortName>SHORT TERM NOTES AND CONVERTIBLE DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/NetLossPerShareOfCommonStock</Role>
      <ShortName>NET LOSS PER SHARE OF COMMON STOCK</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - STOCK BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/StockBasedCompensation</Role>
      <ShortName>STOCK BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/CompanyAndBasisOfPresentationTables</Role>
      <ShortName>THE COMPANY AND BASIS OF PRESENTATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aclarion.com/role/CompanyAndBasisOfPresentation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/FairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aclarion.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/SupplementalFinancialInformationTables</Role>
      <ShortName>SUPPLEMENTAL FINANCIAL INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aclarion.com/role/SupplementalFinancialInformation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/IntangibleAssetsTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aclarion.com/role/IntangibleAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aclarion.com/role/ShortTermNotesAndConvertibleDebtTables</Role>
      <ShortName>SHORT TERM NOTES AND CONVERTIBLE DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aclarion.com/role/ShortTermNotesAndConvertibleDebt</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aclarion.com/role/StockholdersEquity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/NetLossPerShareOfCommonStockTables</Role>
      <ShortName>NET LOSS PER SHARE OF COMMON STOCK (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aclarion.com/role/NetLossPerShareOfCommonStock</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - STOCK BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/StockBasedCompensationTables</Role>
      <ShortName>STOCK BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aclarion.com/role/StockBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details - Balance sheet changes from split)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-BalanceSheetChangesFromSplit</Role>
      <ShortName>THE COMPANY AND BASIS OF PRESENTATION (Details - Balance sheet changes from split)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aclarion.com/role/CompanyAndBasisOfPresentationTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details- Retroactive basis the reverse stock splits)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-RetroactiveBasisReverseStockSplits</Role>
      <ShortName>THE COMPANY AND BASIS OF PRESENTATION (Details- Retroactive basis the reverse stock splits)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aclarion.com/role/CompanyAndBasisOfPresentationTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/CompanyAndBasisOfPresentationDetailsNarrative</Role>
      <ShortName>THE COMPANY AND BASIS OF PRESENTATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aclarion.com/role/CompanyAndBasisOfPresentationTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - FAIR VALUE MEASUREMENTS (Details- Recurring basis to determine the fair value of the liability)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details- Recurring basis to determine the fair value of the liability)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aclarion.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Liabilities measures at fair value)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/FairValueMeasurementsDetails-LiabilitiesMeasuresAtFairValue</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details - Liabilities measures at fair value)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aclarion.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - FAIR VALUE MEASUREMENTS (Details- Fair value of the warrants)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/FairValueMeasurementsDetails-FairValueOfWarrants</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details- Fair value of the warrants)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aclarion.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Prepaids and other current assets)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets</Role>
      <ShortName>SUPPLEMENTAL FINANCIAL INFORMATION (Details - Prepaids and other current assets)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aclarion.com/role/SupplementalFinancialInformationTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accounts payable)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/SupplementalFinancialInformationDetails-AccountsPayable</Role>
      <ShortName>SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accounts payable)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aclarion.com/role/SupplementalFinancialInformationTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accrued and other liabilities)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities</Role>
      <ShortName>SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accrued and other liabilities)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aclarion.com/role/SupplementalFinancialInformationTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aclarion.com/role/Leases</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - INTANGIBLE ASSETS (Details - Intangible assets)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/IntangibleAssetsDetails-IntangibleAssets</Role>
      <ShortName>INTANGIBLE ASSETS (Details - Intangible assets)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aclarion.com/role/IntangibleAssetsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - INTANGIBLE ASSETS (Details - Future amortization)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/IntangibleAssetsDetails-FutureAmortization</Role>
      <ShortName>INTANGIBLE ASSETS (Details - Future amortization)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aclarion.com/role/IntangibleAssetsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aclarion.com/role/IntangibleAssetsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT (Details - Note payable)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetails-NotePayable</Role>
      <ShortName>SHORT TERM NOTES AND CONVERTIBLE DEBT (Details - Note payable)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aclarion.com/role/ShortTermNotesAndConvertibleDebtTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative</Role>
      <ShortName>SHORT TERM NOTES AND CONVERTIBLE DEBT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aclarion.com/role/ShortTermNotesAndConvertibleDebtTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aclarion.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - STOCKHOLDERS' EQUITY (Details - Outstanding warrants)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/StockholdersEquityDetails-OutstandingWarrants</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details - Outstanding warrants)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aclarion.com/role/StockholdersEquityTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Basic and diluted net loss per share)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-BasicAndDilutedNetLossPerShare</Role>
      <ShortName>NET LOSS PER SHARE OF COMMON STOCK (Details - Basic and diluted net loss per share)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aclarion.com/role/NetLossPerShareOfCommonStockTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Dilutive securities)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-DilutiveSecurities</Role>
      <ShortName>NET LOSS PER SHARE OF COMMON STOCK (Details - Dilutive securities)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aclarion.com/role/NetLossPerShareOfCommonStockTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - STOCK BASED COMPENSATION (Details - Option activity)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/StockBasedCompensationDetails-OptionActivity</Role>
      <ShortName>STOCK BASED COMPENSATION (Details - Option activity)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aclarion.com/role/StockBasedCompensationTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - STOCK BASED COMPENSATION (Details - RSU activity)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/StockBasedCompensationDetails-RsuActivity</Role>
      <ShortName>STOCK BASED COMPENSATION (Details - RSU activity)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aclarion.com/role/StockBasedCompensationTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - STOCK BASED COMPENSATION (Details - Share based compensation)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/StockBasedCompensationDetails-ShareBasedCompensation</Role>
      <ShortName>STOCK BASED COMPENSATION (Details - Share based compensation)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aclarion.com/role/StockBasedCompensationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="aclarion_posam2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - STOCK BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aclarion.com/role/StockBasedCompensationDetailsNarrative</Role>
      <ShortName>STOCK BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aclarion.com/role/StockBasedCompensationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="POS AM" isDefinitelyFs="true" isUsgaap="true" original="aclarion_posam2.htm">aclarion_posam2.htm</File>
    <File>acon-20240630.xsd</File>
    <File>acon-20240630_cal.xml</File>
    <File>acon-20240630_def.xml</File>
    <File>acon-20240630_lab.xml</File>
    <File>acon-20240630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="639">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="20">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>132
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "aclarion_posam2.htm": {
   "nsprefix": "ACON",
   "nsuri": "http://aclarion.com/20240630",
   "dts": {
    "inline": {
     "local": [
      "aclarion_posam2.htm"
     ]
    },
    "schema": {
     "local": [
      "acon-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "acon-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "acon-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "acon-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "acon-20240630_pre.xml"
     ]
    }
   },
   "keyStandard": 206,
   "keyCustom": 53,
   "axisStandard": 18,
   "axisCustom": 0,
   "memberStandard": 16,
   "memberCustom": 51,
   "hidden": {
    "total": 149,
    "http://fasb.org/us-gaap/2024": 65,
    "http://aclarion.com/20240630": 79,
    "http://xbrl.sec.gov/dei/2024": 5
   },
   "contextCount": 213,
   "entityCount": 1,
   "segmentCount": 67,
   "elementCount": 453,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 639,
    "http://xbrl.sec.gov/dei/2024": 20
   },
   "report": {
    "R1": {
     "role": "http://aclarion.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://aclarion.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Condensed Balance Sheets",
     "shortName": "Condensed Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://aclarion.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Condensed Balance Sheets (Parenthetical)",
     "shortName": "Condensed Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://aclarion.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Condensed Statements of Operations (Unaudited)",
     "shortName": "Condensed Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit",
     "longName": "00000005 - Statement - Condensed Statements of Changes in Stockholders' Equity (Deficit) (Unaudited)",
     "shortName": "Condensed Statements of Changes in Stockholders' Equity (Deficit) (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_custom_PreferredStockSeriesAMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://aclarion.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://aclarion.com/role/CompanyAndBasisOfPresentation",
     "longName": "00000007 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION",
     "shortName": "THE COMPANY AND BASIS OF PRESENTATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://aclarion.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://aclarion.com/role/FairValueMeasurements",
     "longName": "00000009 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://aclarion.com/role/RecentAccountingPronouncements",
     "longName": "00000010 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS",
     "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://aclarion.com/role/Revenue",
     "longName": "00000011 - Disclosure - REVENUE",
     "shortName": "REVENUE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://aclarion.com/role/SupplementalFinancialInformation",
     "longName": "00000012 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION",
     "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://aclarion.com/role/Leases",
     "longName": "00000013 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://aclarion.com/role/IntangibleAssets",
     "longName": "00000014 - Disclosure - INTANGIBLE ASSETS",
     "shortName": "INTANGIBLE ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://aclarion.com/role/ShortTermNotesAndConvertibleDebt",
     "longName": "00000015 - Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT",
     "shortName": "SHORT TERM NOTES AND CONVERTIBLE DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://aclarion.com/role/CommitmentsAndContingencies",
     "longName": "00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://aclarion.com/role/StockholdersEquity",
     "longName": "00000017 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://aclarion.com/role/NetLossPerShareOfCommonStock",
     "longName": "00000018 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK",
     "shortName": "NET LOSS PER SHARE OF COMMON STOCK",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://aclarion.com/role/StockBasedCompensation",
     "longName": "00000019 - Disclosure - STOCK BASED COMPENSATION",
     "shortName": "STOCK BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://aclarion.com/role/SubsequentEvents",
     "longName": "00000020 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://aclarion.com/role/CompanyAndBasisOfPresentationTables",
     "longName": "00000022 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Tables)",
     "shortName": "THE COMPANY AND BASIS OF PRESENTATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "ACON:ScheduleOfChangesToEquityStatementTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "ACON:ScheduleOfChangesToEquityStatementTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://aclarion.com/role/FairValueMeasurementsTables",
     "longName": "00000023 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://aclarion.com/role/SupplementalFinancialInformationTables",
     "longName": "00000024 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Tables)",
     "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://aclarion.com/role/IntangibleAssetsTables",
     "longName": "00000025 - Disclosure - INTANGIBLE ASSETS (Tables)",
     "shortName": "INTANGIBLE ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtTables",
     "longName": "00000026 - Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT (Tables)",
     "shortName": "SHORT TERM NOTES AND CONVERTIBLE DEBT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://aclarion.com/role/StockholdersEquityTables",
     "longName": "00000027 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://aclarion.com/role/NetLossPerShareOfCommonStockTables",
     "longName": "00000028 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Tables)",
     "shortName": "NET LOSS PER SHARE OF COMMON STOCK (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://aclarion.com/role/StockBasedCompensationTables",
     "longName": "00000029 - Disclosure - STOCK BASED COMPENSATION (Tables)",
     "shortName": "STOCK BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-BalanceSheetChangesFromSplit",
     "longName": "00000030 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details - Balance sheet changes from split)",
     "shortName": "THE COMPANY AND BASIS OF PRESENTATION (Details - Balance sheet changes from split)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:CommonStockValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_Pre2024SplitMember",
      "name": "us-gaap:CommonStockValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ACON:ScheduleOfChangesToEquityStatementTableTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-RetroactiveBasisReverseStockSplits",
     "longName": "00000031 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details- Retroactive basis the reverse stock splits)",
     "shortName": "THE COMPANY AND BASIS OF PRESENTATION (Details- Retroactive basis the reverse stock splits)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_PreSplitMember",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "ACON:ScheduleOfRetroactiveBasisRreverseStockSplitsTableTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://aclarion.com/role/CompanyAndBasisOfPresentationDetailsNarrative",
     "longName": "00000032 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details Narrative)",
     "shortName": "THE COMPANY AND BASIS OF PRESENTATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-01-31_custom_StockSplit2024Member",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-01-31_custom_StockSplit2024Member",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "00000033 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://aclarion.com/role/FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability",
     "longName": "00000034 - Disclosure - FAIR VALUE MEASUREMENTS (Details- Recurring basis to determine the fair value of the liability)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details- Recurring basis to determine the fair value of the liability)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:FairValueNetAssetLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:FairValueNetAssetLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://aclarion.com/role/FairValueMeasurementsDetails-LiabilitiesMeasuresAtFairValue",
     "longName": "00000035 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Liabilities measures at fair value)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details - Liabilities measures at fair value)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FairValueHedgeLiabilitiesAtFairValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FairValueHedgeLiabilitiesAtFairValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://aclarion.com/role/FairValueMeasurementsDetails-FairValueOfWarrants",
     "longName": "00000036 - Disclosure - FAIR VALUE MEASUREMENTS (Details- Fair value of the warrants)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details- Fair value of the warrants)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_custom_WarrantLiabilityMember",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_custom_WarrantLiabilityMember",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://aclarion.com/role/SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets",
     "longName": "00000037 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Prepaids and other current assets)",
     "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION (Details - Prepaids and other current assets)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_custom_ShortTermDepositsMember",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://aclarion.com/role/SupplementalFinancialInformationDetails-AccountsPayable",
     "longName": "00000038 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accounts payable)",
     "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accounts payable)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_us-gaap_AccountsPayableMember",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://aclarion.com/role/SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities",
     "longName": "00000039 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accrued and other liabilities)",
     "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION (Details - Accrued and other liabilities)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:AccruedLiabilitiesAndOtherLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_custom_AccruedPayrollMember",
      "name": "us-gaap:AccruedLiabilitiesAndOtherLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://aclarion.com/role/LeasesDetailsNarrative",
     "longName": "00000040 - Disclosure - LEASES (Details Narrative)",
     "shortName": "LEASES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://aclarion.com/role/IntangibleAssetsDetails-IntangibleAssets",
     "longName": "00000041 - Disclosure - INTANGIBLE ASSETS (Details - Intangible assets)",
     "shortName": "INTANGIBLE ASSETS (Details - Intangible assets)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://aclarion.com/role/IntangibleAssetsDetails-FutureAmortization",
     "longName": "00000042 - Disclosure - INTANGIBLE ASSETS (Details - Future amortization)",
     "shortName": "INTANGIBLE ASSETS (Details - Future amortization)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://aclarion.com/role/IntangibleAssetsDetailsNarrative",
     "longName": "00000043 - Disclosure - INTANGIBLE ASSETS (Details Narrative)",
     "shortName": "INTANGIBLE ASSETS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetails-NotePayable",
     "longName": "00000044 - Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT (Details - Note payable)",
     "shortName": "SHORT TERM NOTES AND CONVERTIBLE DEBT (Details - Note payable)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:NotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "ACON:UnamortizedDiscountsAndDeferredFinancingCostsWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative",
     "longName": "00000045 - Disclosure - SHORT TERM NOTES AND CONVERTIBLE DEBT (Details Narrative)",
     "shortName": "SHORT TERM NOTES AND CONVERTIBLE DEBT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:ConvertibleLongTermNotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ConvertibleLongTermNotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://aclarion.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "00000046 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_custom_RegentsOfTheUniversityOfCaliforniaMember",
      "name": "ACON:MinimumAnnualRoyaltyPayment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012024-06-30_custom_RegentsOfTheUniversityOfCaliforniaMember",
      "name": "us-gaap:RoyaltyExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://aclarion.com/role/StockholdersEquityDetails-OutstandingWarrants",
     "longName": "00000047 - Disclosure - STOCKHOLDERS' EQUITY (Details - Outstanding warrants)",
     "shortName": "STOCKHOLDERS' EQUITY (Details - Outstanding warrants)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_WarrantStrikePriceMember",
      "name": "ACON:StockIssueDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_WarrantStrikePriceMember",
      "name": "ACON:StockIssueDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://aclarion.com/role/StockholdersEquityDetailsNarrative",
     "longName": "00000048 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-BasicAndDilutedNetLossPerShare",
     "longName": "00000049 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Basic and diluted net loss per share)",
     "shortName": "NET LOSS PER SHARE OF COMMON STOCK (Details - Basic and diluted net loss per share)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-DilutiveSecurities",
     "longName": "00000050 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Details - Dilutive securities)",
     "shortName": "NET LOSS PER SHARE OF COMMON STOCK (Details - Dilutive securities)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://aclarion.com/role/StockBasedCompensationDetails-OptionActivity",
     "longName": "00000051 - Disclosure - STOCK BASED COMPENSATION (Details - Option activity)",
     "shortName": "STOCK BASED COMPENSATION (Details - Option activity)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://aclarion.com/role/StockBasedCompensationDetails-RsuActivity",
     "longName": "00000052 - Disclosure - STOCK BASED COMPENSATION (Details - RSU activity)",
     "shortName": "STOCK BASED COMPENSATION (Details - RSU activity)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://aclarion.com/role/StockBasedCompensationDetails-ShareBasedCompensation",
     "longName": "00000053 - Disclosure - STOCK BASED COMPENSATION (Details - Share based compensation)",
     "shortName": "STOCK BASED COMPENSATION (Details - Share based compensation)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012024-06-30_us-gaap_SellingAndMarketingExpenseMember",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://aclarion.com/role/StockBasedCompensationDetailsNarrative",
     "longName": "00000054 - Disclosure - STOCK BASED COMPENSATION (Details Narrative)",
     "shortName": "STOCK BASED COMPENSATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aclarion_posam2.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/BalanceSheets",
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-AccountsPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "verboseLabel": "Accounts payable, current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r648"
     ]
    },
    "us-gaap_AccountsPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableMember",
     "presentation": [
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-AccountsPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable [Member]",
        "documentation": "Obligations incurred and payable to vendors for goods and services received."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "ACON_AccreditedInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "AccreditedInvestorsMember",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accredited Investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_AccruedAuditAndLegalExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "AccruedAuditAndLegalExpensesMember",
     "presentation": [
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Audit And Legal Expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_AccruedBoardCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "AccruedBoardCompensationMember",
     "presentation": [
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Board Compensation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_AccruedBonusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "AccruedBonusMember",
     "presentation": [
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Bonus [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_AccruedDebtIssuanceCostsRelatedToBridgeFunding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "AccruedDebtIssuanceCostsRelatedToBridgeFunding",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued debt issuance costs related to bridge funding"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_AccruedInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "AccruedInterestMember",
     "presentation": [
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Interest [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/BalanceSheets",
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued and other liabilities",
        "verboseLabel": "Accrued liabilities and other liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "ACON_AccruedPayrollMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "AccruedPayrollMember",
     "presentation": [
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Payroll [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_AclarionEquityIncentivePlan2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "AclarionEquityIncentivePlan2022Member",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aclarion Equity Incentive Plan 2022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/BalanceSheets",
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-BalanceSheetChangesFromSplit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "verboseLabel": "Additional paid-in capital - post-2024 split",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r648",
      "r799"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r699",
      "r700",
      "r701",
      "r702",
      "r766",
      "r800"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to additional paid in capital",
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r355"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net income (loss) to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r390"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for doubtful accounts",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r202",
      "r239",
      "r242",
      "r243",
      "r794"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt discounts",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r72",
      "r313",
      "r777"
     ]
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of deferred issuance costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r313",
      "r695",
      "r777"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of intangible assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r253",
      "r259",
      "r621"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-DilutiveSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive shares",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-DilutiveSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-DilutiveSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-DilutiveSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aclarion.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r106",
      "r123",
      "r142",
      "r184",
      "r186",
      "r192",
      "r193",
      "r234",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r409",
      "r413",
      "r445",
      "r508",
      "r562",
      "r617",
      "r618",
      "r648",
      "r661",
      "r735",
      "r736",
      "r781"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://aclarion.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r126",
      "r142",
      "r234",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r409",
      "r413",
      "r445",
      "r648",
      "r735",
      "r736",
      "r781"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://aclarion.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r234",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r409",
      "r413",
      "r445",
      "r735",
      "r736",
      "r781"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://aclarion.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-RsuActivity",
      "http://aclarion.com/role/StockBasedCompensationDetailsNarrative",
      "http://aclarion.com/role/StockholdersEquityDetails-OutstandingWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-AccountsPayable",
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities",
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r795",
      "r796"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-AccountsPayable",
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities",
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r39",
      "r272",
      "r795",
      "r796"
     ]
    },
    "ACON_BridgeFundingIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "BridgeFundingIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Bridge fund cash issuance costs",
        "label": "BridgeFundingIssuanceCosts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r120",
      "r609"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r77",
      "r138"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r77"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r793"
     ]
    },
    "us-gaap_CashUninsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashUninsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash uninsured amount",
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "ACON_CashlessExerciseOfPrefundedWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "CashlessExerciseOfPrefundedWarrant",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cashless exercise of pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_CashlessExerciseOfPrefundedWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "CashlessExerciseOfPrefundedWarrantsShares",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cashless exercise of pre-funded warrants, shares"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetails-OutstandingWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://aclarion.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "ACON_CommitmentSharesNoteFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "CommitmentSharesNoteFinancing",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares - note financing"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_CommitmentSharesNoteFinancingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "CommitmentSharesNoteFinancingShares",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares - note financing, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://aclarion.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r274",
      "r275",
      "r603",
      "r729",
      "r734"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r651",
      "r652",
      "r653",
      "r655",
      "r656",
      "r657",
      "r658",
      "r699",
      "r700",
      "r702",
      "r766",
      "r798",
      "r800"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://aclarion.com/role/BalanceSheetsParenthetical",
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://aclarion.com/role/BalanceSheetsParenthetical",
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r550"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://aclarion.com/role/BalanceSheetsParenthetical",
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-BalanceSheetChangesFromSplit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "verboseLabel": "Common stock shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://aclarion.com/role/BalanceSheetsParenthetical",
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-BalanceSheetChangesFromSplit",
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "verboseLabel": "Common stock shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r57",
      "r550",
      "r568",
      "r800",
      "r801"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/BalanceSheets",
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-BalanceSheetChangesFromSplit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock - $0.00001 par value, 200,000,000 authorized and 8,210,671 and 825,459 shares issued and outstanding (see Note 11)",
        "verboseLabel": "Common shares issued and outstanding - post-2024 split, 825,459 shares",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r509",
      "r648"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r92"
     ]
    },
    "ACON_CompletionOfIssuanceOfSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "CompletionOfIssuanceOfSharesMember",
     "presentation": [
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Completion Of Issuance Of Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_CompletionOfPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "CompletionOfPublicOfferingMember",
     "presentation": [
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Completion Of Public Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes payable outstanding",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r142",
      "r234",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r445",
      "r617",
      "r735"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://aclarion.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r295",
      "r322",
      "r462",
      "r481",
      "r507",
      "r610",
      "r612"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "ACON_CreditCardsPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "CreditCardsPayableMember",
     "presentation": [
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-AccountsPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Cards Payable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ACON_DAndOFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "DAndOFinancingMember",
     "presentation": [
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "D&amp;O Financing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange of principal and accrued interest",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of common shares issued on exchange",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHORT TERM NOTES AND CONVERTIBLE DEBT",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r140",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r280",
      "r281",
      "r291",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r307",
      "r314",
      "r315",
      "r317",
      "r452"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument face amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r452",
      "r453",
      "r623",
      "r624",
      "r647"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual rate percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r318",
      "r452",
      "r453",
      "r647"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r316",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r647",
      "r697",
      "r776",
      "r778"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r622",
      "r771",
      "r772"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r26",
      "r27",
      "r45",
      "r85",
      "r86",
      "r146",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r316",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r647",
      "r697",
      "r776",
      "r778"
     ]
    },
    "ACON_DebtOriginalIssueDiscountPercenrtage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "DebtOriginalIssueDiscountPercenrtage",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Original issue discount, percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Financing Costs",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://aclarion.com/role/SupplementalFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of prepaid and other current assets",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred financing costs",
        "label": "Deferred Costs, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "ACON_DeferredOfferingCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "DeferredOfferingCostsMember",
     "presentation": [
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r184",
      "r189",
      "r193",
      "r617",
      "r618"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in fair value of warrant and derivative liabilities",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ACON_DerivativeLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "DerivativeLiabilityMember",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsDetails-LiabilitiesMeasuresAtFairValue",
      "http://aclarion.com/role/FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation of Derivative Instruments",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r33",
      "r34",
      "r36",
      "r42",
      "r145",
      "r164"
     ]
    },
    "us-gaap_DerivativesReportingOfDerivativeActivity": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesReportingOfDerivativeActivity",
     "presentation": [
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Instruments",
        "documentation": "Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ACON_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK BASED COMPENSATION",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r358",
      "r386",
      "r387",
      "r389",
      "r632"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r673",
      "r675",
      "r676"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-RetroactiveBasisReverseStockSplits",
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net income (loss) per share allocable to common shareholders, basic",
        "verboseLabel": "Basic net loss per shares attributable to common stockholders",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r168",
      "r171",
      "r177",
      "r178",
      "r179",
      "r183",
      "r403",
      "r406",
      "r426",
      "r427",
      "r504",
      "r518",
      "r614"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-RetroactiveBasisReverseStockSplits",
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net income (loss) per share allocable to common shareholders, diluted",
        "verboseLabel": "Diluted net loss per shares attributable to common stockholders",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r171",
      "r177",
      "r178",
      "r179",
      "r183",
      "r403",
      "r406",
      "r426",
      "r427",
      "r504",
      "r518",
      "r614"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://aclarion.com/role/NetLossPerShareOfCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER SHARE OF COMMON STOCK",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r180",
      "r181",
      "r182"
     ]
    },
    "ACON_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "presentation": [
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Emerging Growth Company Status"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation cost, remaining term",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation cost",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r115",
      "r130",
      "r131",
      "r132",
      "r147",
      "r148",
      "r149",
      "r153",
      "r160",
      "r162",
      "r164",
      "r185",
      "r235",
      "r238",
      "r265",
      "r334",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r404",
      "r405",
      "r406",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r425",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r454",
      "r456",
      "r459",
      "r516",
      "r524",
      "r525",
      "r526",
      "r539",
      "r588"
     ]
    },
    "ACON_EquityLineOfCreditIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "EquityLineOfCreditIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity line cash issuance costs",
        "label": "EquityLineOfCreditIssuanceCosts"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_ExchangeAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "ExchangeAgreementsMember",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_ExchangeAndPayoffOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "ExchangeAndPayoffOfNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsDetails-LiabilitiesMeasuresAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange and Payoff of Notes Payable"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_ExecutiveChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "ExecutiveChairmanMember",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Chairman [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r428",
      "r430",
      "r431",
      "r432",
      "r433",
      "r440",
      "r441",
      "r443",
      "r468",
      "r469",
      "r470",
      "r623",
      "r624",
      "r628",
      "r629",
      "r630",
      "r637",
      "r640"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsDetails-FairValueOfWarrants",
      "http://aclarion.com/role/FairValueMeasurementsDetails-LiabilitiesMeasuresAtFairValue",
      "http://aclarion.com/role/FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r442"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueHedgeLiabilitiesAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueHedgeLiabilitiesAtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsDetails-LiabilitiesMeasuresAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance \u2013 December 31, 2023",
        "periodEndLabel": "Balance \u2013 June 30, 2024",
        "label": "Fair Value Hedge Liabilities",
        "documentation": "Fair value of all derivative liabilities designated as fair value hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r345",
      "r350",
      "r430",
      "r441",
      "r468",
      "r628",
      "r629",
      "r630",
      "r637"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r345",
      "r350",
      "r430",
      "r431",
      "r441",
      "r469",
      "r623",
      "r624",
      "r628",
      "r629",
      "r630",
      "r637"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r430",
      "r431",
      "r432",
      "r433",
      "r441",
      "r470",
      "r623",
      "r624",
      "r628",
      "r629",
      "r630",
      "r637",
      "r640"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of liabilities measures at fair value",
        "documentation": "Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of recurring basis to determine the fair value of the liability",
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset."
       }
      }
     },
     "auth_ref": [
      "r768",
      "r769"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsDetails-FairValueOfWarrants",
      "http://aclarion.com/role/FairValueMeasurementsDetails-LiabilitiesMeasuresAtFairValue",
      "http://aclarion.com/role/FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r442"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsDetails-FairValueOfWarrants",
      "http://aclarion.com/role/FairValueMeasurementsDetails-LiabilitiesMeasuresAtFairValue",
      "http://aclarion.com/role/FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsDetails-FairValueOfWarrants",
      "http://aclarion.com/role/FairValueMeasurementsDetails-LiabilitiesMeasuresAtFairValue",
      "http://aclarion.com/role/FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r442"
     ]
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENTS",
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r428",
      "r430",
      "r431",
      "r432",
      "r433",
      "r440",
      "r441",
      "r443",
      "r468",
      "r469",
      "r470",
      "r623",
      "r624",
      "r628",
      "r629",
      "r630",
      "r637",
      "r640"
     ]
    },
    "us-gaap_FairValueNetAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetAssetLiability",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fair value",
        "documentation": "Fair value of asset after deduction of liability."
       }
      }
     },
     "auth_ref": [
      "r768",
      "r769"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ACON_FairValueOfWarrantsAndDerivativeRelatedToBridgeFunding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "FairValueOfWarrantsAndDerivativeRelatedToBridgeFunding",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants and derivative related to bridge funding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOptionChangesInFairValueGainLoss1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOptionChangesInFairValueGainLoss1",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsDetails-LiabilitiesMeasuresAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value",
        "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r240",
      "r241",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r316",
      "r332",
      "r422",
      "r444",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r517",
      "r620",
      "r637",
      "r638",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r649",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r712",
      "r713",
      "r714",
      "r715",
      "r767",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/IntangibleAssetsDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less: accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r250",
      "r258",
      "r621"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/IntangibleAssetsDetails-FutureAmortization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/IntangibleAssetsDetails-FutureAmortization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028 and beyond",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/IntangibleAssetsDetails-FutureAmortization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/IntangibleAssetsDetails-FutureAmortization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/IntangibleAssetsDetails-FutureAmortization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://aclarion.com/role/IntangibleAssetsDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r499",
      "r503",
      "r607"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/IntangibleAssetsDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r258",
      "r503",
      "r621"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://aclarion.com/role/IntangibleAssetsDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r258",
      "r260",
      "r261",
      "r263",
      "r499",
      "r607",
      "r621"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://aclarion.com/role/IntangibleAssetsDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r607"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/IntangibleAssetsDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets, net",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r499",
      "r724"
     ]
    },
    "ACON_FloorFinancingPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "FloorFinancingPrice",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsDetails-FairValueOfWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Floor Financing price"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_GainLossOnExchangeOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "GainLossOnExchangeOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on exchange of debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative",
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on extinguishment of debt",
        "verboseLabel": "Principal and accrued interest paid",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r24",
      "r25"
     ]
    },
    "ACON_GainsLossesOnExtinguishmentOfDebts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "GainsLossesOnExtinguishmentOfDebts",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Loss on extinguishment of debt",
        "label": "GainsLossesOnExtinguishmentOfDebts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r572"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit (loss)",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r67",
      "r105",
      "r142",
      "r234",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r445",
      "r616",
      "r617",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r735"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative",
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r101",
      "r105",
      "r505",
      "r513",
      "r616",
      "r617",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-RetroactiveBasisReverseStockSplits",
      "http://aclarion.com/role/StockBasedCompensationDetails-ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r272",
      "r273",
      "r435",
      "r439",
      "r442",
      "r521",
      "r523",
      "r573",
      "r607",
      "r639",
      "r797"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-RetroactiveBasisReverseStockSplits",
      "http://aclarion.com/role/StockBasedCompensationDetails-ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r435",
      "r439",
      "r442",
      "r521",
      "r523",
      "r573",
      "r607",
      "r639",
      "r797"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax provision",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r112",
      "r163",
      "r164",
      "r184",
      "r190",
      "r193",
      "r393",
      "r394",
      "r397",
      "r519",
      "r634"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value related to warrants and derivative",
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer)."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "ACON_IncreaseDecreaseInNotePayableNetOfDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "IncreaseDecreaseInNotePayableNetOfDiscount",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Note payable, net of discount",
        "label": "IncreaseDecreaseInNotePayableNetOfDiscount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaids and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "presentation": [
      "http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-BasicAndDilutedNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares issuable for vested restricted stock units",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r179",
      "r357"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://aclarion.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r262",
      "r264",
      "r606",
      "r607"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r724",
      "r726"
     ]
    },
    "us-gaap_InterestExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Other",
        "documentation": "Amount of interest expense classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "ACON_IssuanceOfBridgeFundCommitmentShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "IssuanceOfBridgeFundCommitmentShares",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of bridge fund commitment shares"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_IssuanceOfCommitmentSharesNoteFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "IssuanceOfCommitmentSharesNoteFinancing",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of commitment shares - note financing"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_IssuanceOfCommitmentSharesNoteFinancingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "IssuanceOfCommitmentSharesNoteFinancingShares",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of commitment shares - note financing, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_IssuanceOfCommonSharesDebtForEquityExchange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "IssuanceOfCommonSharesDebtForEquityExchange",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares - debt for equity exchange"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_IssuanceOfCommonSharesDebtForEquityExchangeShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "IssuanceOfCommonSharesDebtForEquityExchangeShares",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares - debt for equity exchange, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_IssuanceOfCommonSharesEquityLineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "IssuanceOfCommonSharesEquityLineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares - equity line of credit"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_IssuanceOfCommonSharesEquityLineOfCreditShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "IssuanceOfCommonSharesEquityLineOfCreditShares",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares - equity line of credit, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_IssuanceOfCommonSharesInExchangeForDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "IssuanceOfCommonSharesInExchangeForDebt",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares in exchange for debt"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants related to public offering, net issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCostsShares",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants related to public offering, net issuance costs, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_IssuanceOfWarrantsNoteFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "IssuanceOfWarrantsNoteFinancing",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of warrants - note financing"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_IssuanceOfWarrantsRelatedToBridgeFunding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "IssuanceOfWarrantsRelatedToBridgeFunding",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of warrants related to bridge funding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://aclarion.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r48",
      "r49",
      "r50",
      "r52",
      "r53",
      "r54",
      "r55",
      "r142",
      "r234",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r410",
      "r413",
      "r414",
      "r445",
      "r549",
      "r615",
      "r661",
      "r735",
      "r781",
      "r782"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aclarion.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity (deficit)",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r100",
      "r511",
      "r648",
      "r698",
      "r716",
      "r775"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://aclarion.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r119",
      "r142",
      "r234",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r410",
      "r413",
      "r414",
      "r445",
      "r648",
      "r735",
      "r781",
      "r782"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://aclarion.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_LiabilityToIssueEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "LiabilityToIssueEquity",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability to issue equity"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_LiquidityCapitalResourcesAndGoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "LiquidityCapitalResourcesAndGoingConcernPolicyTextBlock",
     "presentation": [
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity, Capital Resources and Going Concern"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r730",
      "r731",
      "r732"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r23",
      "r730",
      "r731",
      "r732"
     ]
    },
    "ACON_LossOnExchangeOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "LossOnExchangeOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative",
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on exchange of debt",
        "verboseLabel": "Exchange of principal and accrued interest",
        "label": "LossOnExchangeOfDebt"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsDetails-FairValueOfWarrants",
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r352",
      "r391",
      "r433",
      "r497",
      "r520",
      "r522",
      "r532",
      "r541",
      "r542",
      "r593",
      "r594",
      "r595",
      "r596",
      "r600",
      "r604",
      "r605",
      "r619",
      "r627",
      "r631",
      "r640",
      "r641",
      "r645",
      "r646",
      "r650",
      "r737",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ]
    },
    "ACON_MinimumAnnualRoyaltyPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "MinimumAnnualRoyaltyPayment",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum annual royalty payment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsDetails-FairValueOfWarrants",
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r352",
      "r391",
      "r433",
      "r497",
      "r520",
      "r522",
      "r532",
      "r541",
      "r542",
      "r593",
      "r594",
      "r595",
      "r596",
      "r600",
      "r604",
      "r605",
      "r619",
      "r627",
      "r631",
      "r640",
      "r641",
      "r645",
      "r650",
      "r737",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) operations",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r79"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows",
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss)",
        "label": "Net income (loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r79",
      "r102",
      "r117",
      "r128",
      "r129",
      "r132",
      "r142",
      "r152",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r163",
      "r164",
      "r175",
      "r234",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r403",
      "r406",
      "r427",
      "r445",
      "r515",
      "r570",
      "r586",
      "r587",
      "r659",
      "r735"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) allocable to common stockholders",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r156",
      "r157",
      "r158",
      "r159",
      "r168",
      "r169",
      "r176",
      "r179",
      "r406"
     ]
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://aclarion.com/role/RecentAccountingPronouncements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RECENT ACCOUNTING PRONOUNCEMENTS",
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r116",
      "r150",
      "r151",
      "r154",
      "r155",
      "r165",
      "r166",
      "r197",
      "r236",
      "r237",
      "r401",
      "r402",
      "r404",
      "r406",
      "r420",
      "r424",
      "r458",
      "r460",
      "r461",
      "r500",
      "r501",
      "r502",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ACON_NonVestedStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "NonVestedStockOptionsMember",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Vested Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_NoncashInterestRelatedToBridgeFunding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "NoncashInterestRelatedToBridgeFunding",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash interest related to bridge funding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense)",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetails-NotePayable",
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable",
        "verboseLabel": "Outstanding balance",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r99",
      "r791",
      "r792"
     ]
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OffsettingAssetsLineItems",
     "presentation": [
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-BalanceSheetChangesFromSplit",
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffsettingAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OffsettingAssetsTable",
     "presentation": [
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-BalanceSheetChangesFromSplit",
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Table]",
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss) from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r616",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office lease",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_OptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionMember",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Held [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received)."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r558",
      "r563",
      "r576",
      "r582",
      "r597",
      "r598",
      "r599",
      "r651",
      "r652"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://aclarion.com/role/CompanyAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "THE COMPANY AND BASIS OF PRESENTATION",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r94",
      "r533",
      "r534"
     ]
    },
    "ACON_OriginalIssueDiscount15RelatedToBridgeFunding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "OriginalIssueDiscount15RelatedToBridgeFunding",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Original issue discount (15%) related to bridge funding"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_OtherAccruedLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "OtherAccruedLiabilitiesMember",
     "presentation": [
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIntangibleAssetsMember",
     "presentation": [
      "http://aclarion.com/role/IntangibleAssetsDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Intangible Assets [Member]",
        "documentation": "Intangible assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r724",
      "r726",
      "r727",
      "r728"
     ]
    },
    "us-gaap_OtherIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/IntangibleAssetsDetails-FutureAmortization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_OtherNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/BalanceSheets",
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetails-NotePayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note payable, net of discount",
        "documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ACON_OtherReceivablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "OtherReceivablesMember",
     "presentation": [
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "ACON_PatentsAndLicensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "PatentsAndLicensesMember",
     "presentation": [
      "http://aclarion.com/role/IntangibleAssetsDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents And Licenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForLegalSettlements",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diligence and legal costs",
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfPreferredStockAndPreferenceStock",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Redemption of Series A Preferred stock",
        "label": "Payments for Repurchase of Preferred Stock and Preference Stock",
        "documentation": "The cash outflow to reacquire preferred stock during the period."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate gross purchase price",
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of debt discount",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Public offering cash issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangible assets - Patents",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763"
     ]
    },
    "ACON_Post2024SplitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "Post2024SplitMember",
     "presentation": [
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-BalanceSheetChangesFromSplit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post 2024 Split [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_PostSplitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "PostSplitMember",
     "presentation": [
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-RetroactiveBasisReverseStockSplits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post Split [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_Pre2024SplitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "Pre2024SplitMember",
     "presentation": [
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-BalanceSheetChangesFromSplit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre 2024 Split [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "ACON_PreSplitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "PreSplitMember",
     "presentation": [
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-RetroactiveBasisReverseStockSplits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Split [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_PreferredStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "PreferredStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of Series A preferred stock, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r320"
     ]
    },
    "ACON_PreferredStockSeriesA1A2A3A4Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "PreferredStockSeriesA1A2A3A4Member",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Series A 1 A 2 A 3 A 4 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_PreferredStockSeriesAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "PreferredStockSeriesAMember",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Series A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_PreferredStockSeriesB2B3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "PreferredStockSeriesB2B3Member",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Series B 2 B 3 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_PreferredStockSeriesBB1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "PreferredStockSeriesBB1Member",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Series B B 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r550"
     ]
    },
    "ACON_PrepaidClinicalCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "PrepaidClinicalCostsMember",
     "presentation": [
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Clinical Costs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_PrepaidExchangeFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "PrepaidExchangeFeesMember",
     "presentation": [
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Exchange Fees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/BalanceSheets",
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaids and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "ACON_PrepaidInsuranceDAndOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "PrepaidInsuranceDAndOMember",
     "presentation": [
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Insurance D&amp;O [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_PrepaidInsuranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "PrepaidInsuranceMember",
     "presentation": [
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Insurance, Other [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_PrepaidOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "PrepaidOtherMember",
     "presentation": [
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Other [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_PrincipalAndAccruedInterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "PrincipalAndAccruedInterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal and accrued interest paid"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_ProceedsFromBridgeFunding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "ProceedsFromBridgeFunding",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from bridge funding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows",
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants related to public offering, net deductions",
        "verboseLabel": "Proceeds from issuance of common shares",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from sale of Series A preferred stock",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfUnsecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfUnsecuredDebt",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash proceeds",
        "documentation": "The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from equity line",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r697"
     ]
    },
    "ACON_ProceedsFromSaleOfSeriesPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "ProceedsFromSaleOfSeriesPreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of Series A preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSecuredNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSecuredNotesPayable",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from secured notes payable",
        "documentation": "The cash inflow from borrowings supported by a written promise to pay an obligation that is collateralized (backed by pledge, mortgage or other lien in the entity's assets)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-BasicAndDilutedNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net (loss) allocable to common stockholders used to compute basic and diluted loss per common share",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r128",
      "r129",
      "r136",
      "r142",
      "r152",
      "r160",
      "r163",
      "r164",
      "r234",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r403",
      "r406",
      "r408",
      "r411",
      "r412",
      "r427",
      "r445",
      "r505",
      "r514",
      "r538",
      "r570",
      "r586",
      "r587",
      "r635",
      "r636",
      "r660",
      "r693",
      "r735"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r457",
      "r506",
      "r512",
      "r648"
     ]
    },
    "ACON_PublicOfferingAndLineOfCreditIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "PublicOfferingAndLineOfCreditIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public offering and line of credit issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_PurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "PurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsDetails-FairValueOfWarrants",
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r344",
      "r352",
      "r381",
      "r382",
      "r383",
      "r391",
      "r433",
      "r471",
      "r480",
      "r497",
      "r520",
      "r522",
      "r532",
      "r541",
      "r542",
      "r593",
      "r594",
      "r595",
      "r596",
      "r600",
      "r604",
      "r605",
      "r619",
      "r627",
      "r631",
      "r640",
      "r641",
      "r645",
      "r646",
      "r650",
      "r653",
      "r733",
      "r737",
      "r771",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsDetails-FairValueOfWarrants",
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r344",
      "r352",
      "r381",
      "r382",
      "r383",
      "r391",
      "r433",
      "r471",
      "r480",
      "r497",
      "r520",
      "r522",
      "r532",
      "r541",
      "r542",
      "r593",
      "r594",
      "r595",
      "r596",
      "r600",
      "r604",
      "r605",
      "r619",
      "r627",
      "r631",
      "r640",
      "r641",
      "r645",
      "r646",
      "r650",
      "r653",
      "r733",
      "r737",
      "r771",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Less Allowance for Doubtful Accounts",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r203",
      "r711"
     ]
    },
    "ACON_RedemptionOfSeriesPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "RedemptionOfSeriesPreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption of Series A Preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_RedemptionOfSeriesPreferredStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "RedemptionOfSeriesPreferredStockShares",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Redemption of Series A Preferred stock, shares",
        "label": "RedemptionOfSeriesPreferredStockShares"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_RegentsOfTheUniversityOfCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "RegentsOfTheUniversityOfCaliforniaMember",
     "presentation": [
      "http://aclarion.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regents Of The University Of California [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_RemainingOutstandingBalanceOfPrincipalAndInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "RemainingOutstandingBalanceOfPrincipalAndInterest",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining outstanding balance of principal and interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of promissory notes",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://aclarion.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "auth_ref": [
      "r143",
      "r144",
      "r295",
      "r322",
      "r462",
      "r481",
      "r507",
      "r611",
      "r612"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r607",
      "r617",
      "r789"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/BalanceSheets",
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r696",
      "r790",
      "r793"
     ]
    },
    "ACON_RestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "RestrictedStockUnitsMember",
     "presentation": [
      "http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-DilutiveSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-RsuActivity",
      "http://aclarion.com/role/StockBasedCompensationDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r87",
      "r510",
      "r527",
      "r531",
      "r537",
      "r551",
      "r648"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r147",
      "r148",
      "r149",
      "r153",
      "r160",
      "r162",
      "r164",
      "r235",
      "r238",
      "r265",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r404",
      "r405",
      "r406",
      "r415",
      "r417",
      "r418",
      "r421",
      "r425",
      "r454",
      "r456",
      "r524",
      "r526",
      "r539",
      "r800"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://aclarion.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUE",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r608",
      "r613"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r133",
      "r142",
      "r184",
      "r187",
      "r188",
      "r191",
      "r193",
      "r194",
      "r195",
      "r196",
      "r234",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r445",
      "r505",
      "r617",
      "r735"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_RoundUpConventionRelatedToReverseStockSplitShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "RoundUpConventionRelatedToReverseStockSplitShares",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Round up convention related to reverse stock split, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_RoundUpConversionRelatedToReverseStockSplit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "RoundUpConversionRelatedToReverseStockSplit",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Round up conversion related to reverse stock split"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty expense",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative",
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued units",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Price per unit",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://aclarion.com/role/SupplementalFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of accounts payable",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://aclarion.com/role/SupplementalFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of accrued and other liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-DilutiveSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://aclarion.com/role/NetLossPerShareOfCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of anti-dilutive securities excluded from computation of earnings per share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of assumptions",
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "ACON_ScheduleOfChangesToEquityStatementTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "ScheduleOfChangesToEquityStatementTableTextBlock",
     "presentation": [
      "http://aclarion.com/role/CompanyAndBasisOfPresentationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of equity statement information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://aclarion.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of stock-based compensation expense",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of derivative liabilities and warrant liabilities",
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r33",
      "r34",
      "r35",
      "r36",
      "r38",
      "r40",
      "r41",
      "r43"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://aclarion.com/role/NetLossPerShareOfCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation of basic and diluted net loss per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://aclarion.com/role/IntangibleAssetsDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r258",
      "r260",
      "r261",
      "r263",
      "r499",
      "r607",
      "r621"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://aclarion.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of intangible assets",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r723"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of RSU activity",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "ACON_ScheduleOfRetroactiveBasisRreverseStockSplitsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "ScheduleOfRetroactiveBasisRreverseStockSplitsTableTextBlock",
     "presentation": [
      "http://aclarion.com/role/CompanyAndBasisOfPresentationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of share information reflecting on a retroactive basis the reverse stock splits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-RsuActivity",
      "http://aclarion.com/role/StockBasedCompensationDetailsNarrative",
      "http://aclarion.com/role/StockholdersEquityDetails-OutstandingWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r356",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r90"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrants and related strike prices",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://aclarion.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of future amortization of intangible assets",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r725"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales and marketing",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpenseMember",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and Marketing Expense [Member]",
        "documentation": "Primary financial statement caption encompassing selling and marketing expense."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ACON_SeniorNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "SeniorNotesPayableMember",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Notes Payable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_SeriesBNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "SeriesBNotesPayableMember",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Notes Payable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_SeriesCNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "SeriesCNotesPayableMember",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Notes Payable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://aclarion.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/StatementsOfCashFlows",
      "http://aclarion.com/role/StockBasedCompensationDetails-ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation",
        "label": "Total stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-RsuActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "RSU's forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-RsuActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RSU's forfeited, weighted-average grant date fair value per unit",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-RsuActivity",
      "http://aclarion.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RSU's granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-RsuActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RSU's granted, weighted-average grant date fair value per unit",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-RsuActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Rsu shares outstanding, Beginning",
        "periodEndLabel": "Number of Rsu shares outstanding, Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-RsuActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average grant date fair value per unit, Beginning",
        "periodEndLabel": "Weighted average grant date fair value per unit, Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-RsuActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "RSU's vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-RsuActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RSU's vested, weighted-average grant date fair value per unit",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetails-OutstandingWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration",
        "documentation": "Date the equity-based award expires, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsDetails-FairValueOfWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility (annual)",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsDetails-FairValueOfWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-RsuActivity",
      "http://aclarion.com/role/StockBasedCompensationDetailsNarrative",
      "http://aclarion.com/role/StockholdersEquityDetails-OutstandingWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r356",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of common shares issued",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Option exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intrinsic value options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options forfeited or expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of share options outstanding, Beginning",
        "periodEndLabel": "Number of share options outstanding, Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, Beginning",
        "periodEndLabel": "Weighted average exercise price, Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obligated to issue share of common stock",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-RsuActivity",
      "http://aclarion.com/role/StockBasedCompensationDetailsNarrative",
      "http://aclarion.com/role/StockholdersEquityDetails-OutstandingWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Options exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Options forfeited or expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Options granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsDetails-FairValueOfWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Strike Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsDetails-FairValueOfWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual term (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life, Options exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetails-OutstandingWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Strike price",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r730",
      "r731",
      "r732"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r730",
      "r731",
      "r732"
     ]
    },
    "ACON_ShortTermDepositsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "ShortTermDepositsMember",
     "presentation": [
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short Term Deposits [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://aclarion.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r139"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r57",
      "r60",
      "r61",
      "r115",
      "r130",
      "r131",
      "r132",
      "r147",
      "r148",
      "r149",
      "r153",
      "r160",
      "r162",
      "r164",
      "r185",
      "r235",
      "r238",
      "r265",
      "r334",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r404",
      "r405",
      "r406",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r425",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r454",
      "r456",
      "r459",
      "r516",
      "r524",
      "r525",
      "r526",
      "r539",
      "r588"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-RetroactiveBasisReverseStockSplits",
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-AccountsPayable",
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities",
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r185",
      "r456",
      "r498",
      "r535",
      "r540",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r550",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r569",
      "r571",
      "r572",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r588",
      "r654"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-RetroactiveBasisReverseStockSplits",
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-AccountsPayable",
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-AccruedAndOtherLiabilities",
      "http://aclarion.com/role/SupplementalFinancialInformationDetails-PrepaidsAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r185",
      "r198",
      "r456",
      "r498",
      "r535",
      "r540",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r550",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r569",
      "r571",
      "r572",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r588",
      "r654"
     ]
    },
    "ACON_StockIssueDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "StockIssueDate",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetails-OutstandingWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r56",
      "r57",
      "r87",
      "r536",
      "r588",
      "r601"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares related to restricted stock units, shares",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r87"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares related to restricted stock units",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r56",
      "r57",
      "r87"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r57",
      "r60",
      "r61",
      "r87"
     ]
    },
    "ACON_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-DilutiveSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRedeemedOrCalledDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption price",
        "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ACON_StockSplit2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "StockSplit2024Member",
     "presentation": [
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Split 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/BalanceSheets",
      "http://aclarion.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity (deficit)",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r60",
      "r61",
      "r81",
      "r552",
      "r568",
      "r589",
      "r590",
      "r648",
      "r661",
      "r698",
      "r716",
      "r775",
      "r800"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://aclarion.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity (deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r141",
      "r319",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r423",
      "r591",
      "r592",
      "r602"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetailsNarrative",
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split",
        "verboseLabel": "Stockholders equity, reverse stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://aclarion.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r464"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative",
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative",
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative",
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://aclarion.com/role/SupplementalFinancialInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL FINANCIAL INFORMATION",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r780"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransactionDomain",
     "presentation": [
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-BalanceSheetChangesFromSplit",
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetailsNarrative",
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative",
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "us-gaap_TransactionTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransactionTypeAxis",
     "presentation": [
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-BalanceSheetChangesFromSplit",
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetailsNarrative",
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative",
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Type [Axis]",
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://aclarion.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r316",
      "r332",
      "r422",
      "r444",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r517",
      "r637",
      "r638",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r649",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r712",
      "r713",
      "r714",
      "r715",
      "r767",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "ACON_UnamortizedDiscountsAndDeferredFinancingCostsDerivative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "UnamortizedDiscountsAndDeferredFinancingCostsDerivative",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetails-NotePayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetails-NotePayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred financing costs"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_UnamortizedDiscountsAndDeferredFinancingCostsTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "UnamortizedDiscountsAndDeferredFinancingCostsTotal",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetails-NotePayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total notes payable discount"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_UnamortizedDiscountsAndDeferredFinancingCostsWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "UnamortizedDiscountsAndDeferredFinancingCostsWarrants",
     "crdr": "debit",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetails-NotePayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnsecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnsecuredDebt",
     "crdr": "credit",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuing unsecured senior notes",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r99",
      "r791"
     ]
    },
    "ACON_UnsecuredNonConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "UnsecuredNonConvertibleNotesMember",
     "presentation": [
      "http://aclarion.com/role/ShortTermNotesAndConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured Non Convertible Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://aclarion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r108",
      "r109",
      "r110",
      "r111"
     ]
    },
    "ACON_WarrantLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "WarrantLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aclarion.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aclarion.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_WarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "WarrantLiabilityMember",
     "presentation": [
      "http://aclarion.com/role/FairValueMeasurementsDetails-FairValueOfWarrants",
      "http://aclarion.com/role/FairValueMeasurementsDetails-LiabilitiesMeasuresAtFairValue",
      "http://aclarion.com/role/FairValueMeasurementsDetails-RecurringBasisToDetermineFairValueOfLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liability [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_WarrantStrikePrice1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "WarrantStrikePrice1Member",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetails-OutstandingWarrants",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Strike Price 87.04 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_WarrantStrikePrice2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "WarrantStrikePrice2Member",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetails-OutstandingWarrants",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Strike Price 69.60 [Member]",
        "label": "Strike Price 69.60 [Member] [Default Label]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_WarrantStrikePrice3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "WarrantStrikePrice3Member",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetails-OutstandingWarrants",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Strike Price 0.29 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_WarrantStrikePrice4Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "WarrantStrikePrice4Member",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetails-OutstandingWarrants",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Strike Price 0.29 (1) [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_WarrantStrikePrice5Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "WarrantStrikePrice5Member",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetails-OutstandingWarrants",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Strike Price 0.00001 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_WarrantStrikePrice6Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "WarrantStrikePrice6Member",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetails-OutstandingWarrants",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Strike Price 0.58 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_WarrantStrikePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "WarrantStrikePriceMember",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetails-OutstandingWarrants",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Strike Price 69.60 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "WarrantsMember",
     "presentation": [
      "http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-DilutiveSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-RetroactiveBasisReverseStockSplits",
      "http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-BasicAndDilutedNetLossPerShare",
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares of common stock outstanding, diluted",
        "verboseLabel": "Weighted average shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r179"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://aclarion.com/role/CompanyAndBasisOfPresentationDetails-RetroactiveBasisReverseStockSplits",
      "http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-BasicAndDilutedNetLossPerShare",
      "http://aclarion.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares of common stock outstanding, basic",
        "verboseLabel": "Weighted average shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r179"
     ]
    },
    "ACON_WeightedAverageNumberOfSharesOutstandingBasic1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic1",
     "presentation": [
      "http://aclarion.com/role/NetLossPerShareOfCommonStockDetails-BasicAndDilutedNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding used to compute basic and dilutive loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "ACON_WhiteLionEquityLineAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aclarion.com/20240630",
     "localname": "WhiteLionEquityLineAgreementMember",
     "presentation": [
      "http://aclarion.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "White Lion Equity Line Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://aclarion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-4"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "83",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480647/815-10-15-83"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/820/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
